nct_id,nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at
NCT04244591,"ClinicalTrials.gov processed this data on October 30, 2020",2020-01-23,NA,NA,2020-06-13,2020-01-25,2020-01-28,Actual,NA,NA,NA,NA,NA,NA,2020-06-13,2020-06-16,Actual,"January 26, 2020",Actual,2020-01-26,February 2020,2020-02-29,"April 13, 2020",Actual,2020-04-13,"April 13, 2020",Actual,2020-04-13,NA,Interventional,NA,,Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure,"Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by COVID-19: a Prospective, Randomized Controlled Trial",Completed,NA,Phase 2/Phase 3,80,Actual,Peking Union Medical College Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:19:59Z,2020-11-01T12:19:59Z
NCT04252118,"ClinicalTrials.gov processed this data on October 30, 2020",2020-01-27,NA,NA,2020-04-13,2020-01-30,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"January 27, 2020",Actual,2020-01-27,April 2020,2020-04-30,December 2021,Anticipated,2021-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19,Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With COVID-19,Recruiting,NA,Phase 1,20,Anticipated,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:19:01Z,2020-11-01T12:19:01Z
NCT04251871,"ClinicalTrials.gov processed this data on October 30, 2020",2020-01-28,NA,NA,2020-05-04,2020-01-30,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-04,2020-05-05,Actual,"January 22, 2020",Actual,2020-01-22,May 2020,2020-05-31,"January 22, 2021",Anticipated,2021-01-22,"January 22, 2021",Anticipated,2021-01-22,NA,Interventional,NA,,Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection,"Effects of Traditional Chinese Medicines (TCMs) on Patients With COVID-19 Infection: A Perspective, Open-labeled, Randomized, Controlled Trial",Recruiting,NA,N/A,150,Anticipated,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:19:03Z,2020-11-01T12:19:03Z
NCT04252274,"ClinicalTrials.gov processed this data on October 30, 2020",2020-01-29,NA,NA,2020-04-09,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"January 30, 2020",Actual,2020-01-30,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,DC-COVID-19,,Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19,Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19,Recruiting,NA,Phase 3,30,Anticipated,Shanghai Public Health Clinical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:19:00Z,2020-11-01T12:19:00Z
NCT04252885,"ClinicalTrials.gov processed this data on October 30, 2020",2020-01-30,NA,NA,2020-06-29,2020-01-31,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-06-29,2020-07-01,Actual,"January 28, 2020",Actual,2020-01-28,June 2020,2020-06-30,"May 31, 2020",Actual,2020-05-31,"April 30, 2020",Actual,2020-04-30,NA,Interventional,ELACOI,,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,"A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection",Completed,NA,Phase 4,86,Actual,Guangzhou 8th People's Hospital,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:18:56Z,2020-11-01T12:18:56Z
NCT04257656,"ClinicalTrials.gov processed this data on October 30, 2020",2020-01-31,NA,NA,2020-04-13,2020-02-03,2020-02-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"February 6, 2020",Actual,2020-02-06,April 2020,2020-04-30,"April 10, 2020",Actual,2020-04-10,"March 30, 2020",Actual,2020-03-30,NA,Interventional,NA,,A Trial of Remdesivir in Adults With Severe COVID-19,"A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe COVID-19.",Terminated,NA,Phase 3,237,Actual,Capital Medical University,,2,NA,"The epidemic of COVID-19 has been controlled well in China, no eligible patients can be
    enrolled at present.",FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:18:18Z,2020-11-01T12:18:18Z
NCT04263402,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-02,NA,NA,2020-03-14,2020-02-07,2020-02-10,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia,"An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia",Recruiting,NA,Phase 4,100,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:17:32Z,2020-11-01T12:17:32Z
NCT04255017,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-02,NA,NA,2020-03-14,2020-02-02,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia.",Recruiting,NA,Phase 4,400,Anticipated,Tongji Hospital,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:18:40Z,2020-11-01T12:18:40Z
NCT04254874,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-02,NA,NA,2020-03-14,2020-02-02,2020-02-05,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Two Therapeutic Schemes(Abidol Hydrochloride,Abidol Hydrochloride Combined With Interferon Atomization)in the Treatment of 2019-nCoV Pneumonia.",Recruiting,NA,Phase 4,100,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:18:41Z,2020-11-01T12:18:41Z
NCT04264533,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-04,NA,NA,2020-10-08,2020-02-08,2020-02-11,Actual,NA,NA,NA,NA,NA,NA,2020-10-08,2020-10-12,Actual,"February 14, 2020",Actual,2020-02-14,October 2020,2020-10-31,"March 29, 2020",Actual,2020-03-29,"March 2, 2020",Actual,2020-03-02,NA,Interventional,NA,,Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia,Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia: a Prospective Randomized Clinical Trial,Terminated,NA,Phase 2,56,Actual,Zhongnan Hospital,,2,NA,"the study was started in the second half of the outbreak, and the number of qualifying COVID-19
    patients decreased with the control of the epidemic so that we had to stop our trial before
    reaching the predefined sample size.",FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:17:20Z,2020-11-01T12:17:20Z
NCT04261270,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-04,NA,NA,2020-03-14,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 1, 2020",Actual,2020-02-01,March 2020,2020-03-31,"July 1, 2020",Anticipated,2020-07-01,"May 1, 2020",Anticipated,2020-05-01,NA,Interventional,NA,,"A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia","A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09/Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia",Recruiting,NA,Phase 3,60,Anticipated,Tongji Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:17:49Z,2020-11-01T12:17:49Z
NCT04331613,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-06,NA,NA,2020-03-31,2020-03-31,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-03-31,2020-04-02,Actual,"January 27, 2020",Actual,2020-01-27,January 2020,2020-01-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS,Safety and Efficacy Study of Human Embryonic Stem Cells Derived M Cells (CAStem) for the Treatment of Severe COVID-19 Associated With or Without Acute Respiratory Distress Syndrome (ARDS),Recruiting,NA,Phase 1/Phase 2,9,Anticipated,Chinese Academy of Sciences,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:08:12Z,2020-11-01T12:08:12Z
NCT04275245,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-06,NA,NA,2020-02-16,2020-02-16,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-02-16,2020-02-19,Actual,"February 3, 2020",Actual,2020-02-03,February 2020,2020-02-29,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia,"Single Center, Single Arm, Open Clinical Study to Access Safety and Initial Efficacy of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia",Recruiting,NA,Phase 1/Phase 2,20,Anticipated,Tang-Du Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:15:39Z,2020-11-01T12:15:39Z
NCT04261517,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-06,NA,NA,2020-04-09,2020-02-06,2020-02-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"February 6, 2020",Actual,2020-02-06,April 2020,2020-04-30,"February 25, 2020",Actual,2020-02-25,"February 25, 2020",Actual,2020-02-25,NA,Interventional,NA,,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Completed,NA,Phase 3,30,Actual,Shanghai Public Health Clinical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:17:47Z,2020-11-01T12:17:47Z
NCT04269525,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-07,NA,NA,2020-06-29,2020-02-12,2020-02-13,Actual,NA,NA,NA,NA,NA,NA,2020-06-29,2020-07-01,Actual,"February 6, 2020",Actual,2020-02-06,June 2020,2020-06-30,"December 30, 2020",Anticipated,2020-12-30,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,NA,,Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia,Clinical Research Regarding the Availability and Safety of UC-MSCs Treatment for Serious Pneumonia and Critical Pneumonia Caused by the 2019-nCOV Infection,Recruiting,NA,Phase 2,16,Anticipated,Zhongnan Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:16:30Z,2020-11-01T12:16:30Z
NCT04282902,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-10,NA,NA,2020-02-21,2020-02-21,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-02-21,2020-02-25,Actual,"February 4, 2020",Actual,2020-02-04,February 2020,2020-02-29,"June 1, 2020",Anticipated,2020-06-01,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection,"A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection",Recruiting,NA,Phase 3,294,Anticipated,Tongji Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:14:43Z,2020-11-01T12:14:43Z
NCT04276688,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-11,NA,NA,2020-04-13,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"February 10, 2020",Actual,2020-02-10,April 2020,2020-04-30,"March 31, 2020",Actual,2020-03-31,"March 30, 2020",Actual,2020-03-30,NA,Interventional,NA,,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment","An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection",Completed,NA,Phase 2,127,Actual,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:15:30Z,2020-11-01T12:15:30Z
NCT04280224,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-13,NA,NA,2020-04-11,2020-02-20,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-11,2020-04-14,Actual,"February 15, 2020",Actual,2020-02-15,February 2020,2020-02-29,"December 30, 2020",Anticipated,2020-12-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,NK Cells Treatment for COVID-19,Clinical Investigation of Natural Killer Cells Treatment in Pneumonia Patients Infected With 2019 Novel Coronavirus,Recruiting,NA,Phase 1,30,Anticipated,Xinxiang medical university,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:15:05Z,2020-11-01T12:15:05Z
NCT04304313,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-14,NA,NA,2020-03-14,2020-03-10,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-03-14,2020-03-17,Actual,"February 9, 2020",Actual,2020-02-09,March 2020,2020-03-31,"November 9, 2020",Anticipated,2020-11-09,"March 1, 2020",Actual,2020-03-01,NA,Interventional,NA,,A Pilot Study of Sildenafil in COVID-19,A Pilot Study of Sildenafi in the Treatment of COVID-19,Recruiting,NA,Phase 3,10,Anticipated,Tongji Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:11:47Z,2020-11-01T12:11:47Z
NCT04275414,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-14,NA,NA,2020-09-10,2020-02-16,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-09-10,2020-09-14,Actual,"February 15, 2020",Actual,2020-02-15,February 2020,2020-02-29,"May 2, 2020",Actual,2020-05-02,"April 5, 2020",Actual,2020-04-05,NA,Interventional,BEST-CP,,Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,Effecacy and Safety of Bevacizumab in Severe Patients With Covid-19: a Pilot Study (BEST-CP),Completed,NA,Phase 2,27,Actual,Qilu Hospital of Shandong University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:15:38Z,2020-11-01T12:15:38Z
NCT04273763,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-14,NA,NA,2020-04-29,2020-02-14,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-05-01,Actual,"February 16, 2020",Actual,2020-02-16,April 2020,2020-04-30,"June 1, 2020",Anticipated,2020-06-01,"May 10, 2020",Anticipated,2020-05-10,NA,Interventional,NA,,Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),"Active, not recruiting",NA,N/A,18,Actual,Second Affiliated Hospital of Wenzhou Medical University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:15:51Z,2020-11-01T12:15:51Z
NCT04279197,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-15,NA,NA,2020-09-21,2020-02-19,2020-02-21,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-23,Actual,"April 23, 2020",Actual,2020-04-23,September 2020,2020-09-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,,Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu,The Efficacy of Treating Pulmonary Fibrosis and Pulmonary Function Injury in COVID-19 With the Fuzheng Huayu Tablets: a Multicenter Randomized Controlled Trial,Recruiting,NA,Phase 2,160,Anticipated,ShuGuang Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:15:13Z,2020-11-01T12:15:13Z
NCT04273321,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-15,NA,NA,2020-05-08,2020-02-17,2020-02-18,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-11,Actual,"February 14, 2020",Actual,2020-02-14,April 2020,2020-04-30,"April 15, 2020",Actual,2020-04-15,"April 15, 2020",Actual,2020-04-15,NA,Interventional,NA,,Efficacy and Safety of Corticosteroids in COVID-19,Efficacy and Safety of Corticosteroids in COVID-19: A Prospective Randomized Controlled Trails,Completed,NA,N/A,86,Actual,Beijing Chao Yang Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-11-01T12:15:56Z,2020-11-01T12:15:56Z
NCT04276987,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-16,NA,NA,2020-09-03,2020-02-18,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-09-03,2020-09-07,Actual,"February 15, 2020",Actual,2020-02-15,September 2020,2020-09-30,"July 31, 2020",Actual,2020-07-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,,A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia,Completed,NA,Phase 1,24,Actual,Ruijin Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,Starting 6 months after publication,NA,NA,Yes,all IPD that underlie results in a publication,2020-11-01T12:15:27Z,2020-11-01T12:15:27Z
NCT04276896,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-17,NA,NA,2020-03-17,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-03-17,2020-03-19,Actual,"March 24, 2020",Anticipated,2020-03-24,March 2020,2020-03-31,"December 31, 2024",Anticipated,2024-12-31,"July 31, 2023",Anticipated,2023-07-31,NA,Interventional,NA,,Immunity and Safety of Covid-19 Synthetic Minigene Vaccine,Phase I/II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus,Recruiting,NA,Phase 1/Phase 2,100,Anticipated,Shenzhen Geno-Immune Medical Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:15:28Z,2020-11-01T12:15:28Z
NCT04343794,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-20,NA,NA,2020-04-13,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"January 31, 2022",Anticipated,2022-01-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,,Using BiovitalsÂ® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19,Using BiovitalsÂ® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19,Recruiting,NA,N/A,200,Anticipated,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:06:29Z,2020-11-01T12:06:29Z
NCT04280705,"ClinicalTrials.gov processed this data on November 06, 2020",2020-02-20,2020-09-16,NA,2020-11-01,2020-02-20,2020-02-21,Actual,2020-09-22,2020-09-25,Actual,NA,NA,NA,2020-11-01,2020-11-03,Actual,"February 21, 2020",Actual,2020-02-21,April 2020,2020-04-30,"May 21, 2020",Actual,2020-05-21,"May 21, 2020",Actual,2020-05-21,NA,Interventional,NA,,Adaptive COVID-19 Treatment Trial (ACTT),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults",Completed,NA,Phase 3,1062,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-07T11:27:08Z,2020-11-07T11:27:08Z
NCT04283461,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-21,NA,NA,2020-07-16,2020-02-21,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-17,Actual,"March 16, 2020",Actual,2020-03-16,"May 26, 2020",2020-05-26,"November 22, 2021",Anticipated,2021-11-22,"November 22, 2021",Anticipated,2021-11-22,NA,Interventional,NA,,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19),"Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults","Active, not recruiting",NA,Phase 1,120,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,13,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:14:40Z,2020-11-01T12:14:40Z
NCT04303299,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-24,NA,NA,2020-08-30,2020-03-08,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-08-30,2020-09-01,Actual,"August 19, 2020",Actual,2020-08-19,August 2020,2020-08-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,FIGHT-COVID-19,,"Favipiravir, Protease Inhibitors, Oseltamivir -Gpo, Hydroxychloroquine for Treatment of COVID-19","A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir/ Ritonavir Plus Oseltamivir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir/ Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19",Recruiting,NA,Phase 3,320,Anticipated,Rajavithi Hospital,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:11:56Z,2020-11-01T12:11:56Z
NCT04288102,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-24,NA,NA,2020-08-18,2020-02-25,2020-02-28,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"March 5, 2020",Actual,2020-03-05,August 2020,2020-08-31,"July 9, 2020",Actual,2020-07-09,"May 12, 2020",Actual,2020-05-12,NA,Interventional,NA,,Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19),"A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Severe COVID-19 Patients",Completed,NA,Phase 2,100,Actual,Beijing 302 Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"After approval from the steering committee and the Human Genetic Resources Administration of China, this trial data can be shared with qualifying researchers who submit a proposal with a valuable research question. A contract should be signed.",2020-11-01T12:14:07Z,2020-11-01T12:14:07Z
NCT04291729,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-27,NA,NA,2020-04-09,2020-02-28,2020-03-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"February 17, 2020",Actual,2020-02-17,March 2020,2020-03-31,"March 19, 2020",Actual,2020-03-19,"March 19, 2020",Actual,2020-03-19,NA,Interventional,NA,,Evaluation of Ganovo ï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,An Open Clinical Trial to Evaluate Ganovoï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,NA,Phase 4,11,Actual,The Ninth Hospital of Nanchang,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:13:37Z,2020-11-01T12:13:37Z
NCT04292899,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-28,NA,NA,2020-07-23,2020-02-28,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-07-23,2020-07-27,Actual,"March 6, 2020",Actual,2020-03-06,July 2020,2020-07-31,"June 30, 2020",Actual,2020-06-30,"April 9, 2020",Actual,2020-04-09,NA,Interventional,NA,,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19),A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe COVID-19,Completed,NA,Phase 3,4891,Actual,Gilead Sciences,,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:13:28Z,2020-11-01T12:13:28Z
NCT04292730,"ClinicalTrials.gov processed this data on October 30, 2020",2020-02-28,NA,NA,2020-07-23,2020-02-28,2020-03-03,Actual,NA,NA,NA,NA,NA,NA,2020-07-23,2020-07-27,Actual,"March 15, 2020",Actual,2020-03-15,July 2020,2020-07-31,"June 26, 2020",Actual,2020-06-26,"April 29, 2020",Actual,2020-04-29,NA,Interventional,NA,,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment,Completed,NA,Phase 3,1113,Actual,Gilead Sciences,,4,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:13:30Z,2020-11-01T12:13:30Z
NCT04308317,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-04,NA,NA,2020-03-13,2020-03-13,2020-03-16,Actual,NA,NA,NA,NA,NA,NA,2020-03-13,2020-03-16,Actual,"March 5, 2020",Anticipated,2020-03-05,March 2020,2020-03-31,"May 1, 2021",Anticipated,2021-05-01,"March 1, 2021",Anticipated,2021-03-01,NA,Interventional,TT-NPC,,Tetrandrine Tablets Used in the Treatment of COVID-19,Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19,Enrolling by invitation,NA,Phase 4,60,Anticipated,Henan Provincial People's Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:11:18Z,2020-11-01T12:11:18Z
NCT04304053,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-05,NA,NA,2020-06-26,2020-03-07,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-26,2020-06-30,Actual,"March 18, 2020",Actual,2020-03-18,June 2020,2020-06-30,"June 15, 2020",Actual,2020-06-15,"June 15, 2020",Actual,2020-06-15,NA,Interventional,HCQ4COV19,,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study),Completed,NA,Phase 3,2300,Actual,Fundacio Lluita Contra la SIDA,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,30 days after start of treatment,Open access for everybody,http://www.estudicovid19.org,Yes,Open access,2020-11-01T12:11:49Z,2020-11-01T12:11:49Z
NCT04299724,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-05,NA,NA,2020-03-06,2020-03-06,2020-03-09,Actual,NA,NA,NA,NA,NA,NA,2020-03-06,2020-03-09,Actual,"February 15, 2020",Actual,2020-02-15,March 2020,2020-03-31,"December 31, 2024",Anticipated,2024-12-31,"July 31, 2023",Anticipated,2023-07-31,NA,Interventional,NA,,Safety and Immunity of Covid-19 aAPC Vaccine,Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine,Recruiting,NA,Phase 1,100,Anticipated,Shenzhen Geno-Immune Medical Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:12:33Z,2020-11-01T12:12:33Z
NCT04303507,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-06,NA,NA,2020-10-01,2020-03-10,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-10-01,2020-10-05,Actual,"April 29, 2020",Actual,2020-04-29,March 2020,2020-03-31,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,COPCOV,,Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting,"Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)",Recruiting,NA,N/A,40000,Anticipated,University of Oxford,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.tropmedres.ac/units/moru-bangkok/bioethics-engagement/data-sharing,Yes,"With participant's consent, suitably anonymised clinical data and results from blood analyses stored in the database may be shared according to the terms defined in the MORU data sharing policy with other researchers to use in the future.",2020-11-01T12:11:54Z,2020-11-01T12:11:54Z
NCT04306055,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-08,NA,NA,2020-04-09,2020-03-10,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"March 13, 2020",Actual,2020-03-13,April 2020,2020-04-30,"April 3, 2020",Actual,2020-04-03,"March 13, 2020",Actual,2020-03-13,NA,Interventional,NA,,Blood Donor Recruitment During Epidemic of COVID-19,"Blood Donor Recruitment During Epidemic of COVID-19 in Guangzhou, China",Completed,NA,N/A,19491,Actual,Guangzhou Blood Center,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:11:34Z,2020-11-01T12:11:34Z
NCT04310228,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-09,NA,NA,2020-04-08,2020-03-14,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-10,Actual,"March 8, 2020",Actual,2020-03-08,April 2020,2020-04-30,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,"Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study",Recruiting,NA,N/A,150,Anticipated,Peking University First Hospital,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:11:01Z,2020-11-01T12:11:01Z
NCT04305457,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-09,NA,NA,2020-10-19,2020-03-11,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-22,Actual,"March 21, 2020",Actual,2020-03-21,October 2020,2020-10-31,"April 1, 2022",Anticipated,2022-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NoCovid,,Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19,Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID-19: a Randomized Clinical Trial,"Active, not recruiting",NA,Phase 2,66,Actual,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:11:38Z,2020-11-01T12:11:38Z
NCT04305106,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-09,NA,NA,2020-03-24,2020-03-09,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"March 17, 2020",Actual,2020-03-17,March 2020,2020-03-31,"July 31, 2020",Anticipated,2020-07-31,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,BEST-RCT,,Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT,The Efficacy and Safety of Bevacizumab in Severe or Critical Patients With COVID-19--a Multicenter Randomized Controlled Clinical Trial,Recruiting,NA,N/A,140,Anticipated,Qilu Hospital of Shandong University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:11:41Z,2020-11-01T12:11:41Z
NCT04304690,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-09,NA,NA,2020-04-10,2020-03-09,2020-03-11,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-13,Actual,"March 16, 2020",Actual,2020-03-16,April 2020,2020-04-30,"October 16, 2020",Anticipated,2020-10-16,"July 16, 2020",Anticipated,2020-07-16,NA,Interventional,SEROCOV,,"COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic","COVID-19 Seroconversion Among Medical and Paramedical Staff in Emergency, ICU and Infectious Disease Services During the 2020 Epidemic",Recruiting,NA,N/A,1000,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:11:44Z,2020-11-01T12:11:44Z
NCT04307693,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-10,NA,NA,2020-05-25,2020-03-12,2020-03-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-25,2020-05-27,Actual,"March 11, 2020",Actual,2020-03-11,May 2020,2020-05-31,"April 30, 2020",Actual,2020-04-30,"April 30, 2020",Actual,2020-04-30,NA,Interventional,NA,,Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Terminated,NA,Phase 2,65,Actual,Asan Medical Center,,3,NA,Terminated early because no patients were further enrolled since mid-Apr 2020.,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:11:22Z,2020-11-01T12:11:22Z
NCT04306393,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-10,NA,NA,2020-07-10,2020-03-10,2020-03-12,Actual,NA,NA,NA,NA,NA,NA,2020-07-10,2020-07-14,Actual,"March 21, 2020",Actual,2020-03-21,July 2020,2020-07-31,"March 21, 2022",Anticipated,2022-03-21,"March 21, 2021",Anticipated,2021-03-21,NA,Interventional,NOSARSCOVID,,Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19,Nitric Oxide Gas Inhalation Therapy for Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome Caused by SARS-CoV2: a Randomized Clinical Trial.,Recruiting,NA,Phase 2,200,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:11:31Z,2020-11-01T12:11:31Z
NCT04308668,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-11,NA,NA,2020-07-15,2020-03-11,2020-03-16,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-17,Actual,"March 17, 2020",Actual,2020-03-17,July 2020,2020-07-31,"May 20, 2020",Actual,2020-05-20,"May 20, 2020",Actual,2020-05-20,NA,Interventional,COVID-19 PEP,,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,Completed,NA,Phase 3,1309,Actual,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,at time of publication,To be publicly provided,http://covidpep.umn.edu,Yes,De-identified dataset will be available within 1 month of publication.,2020-11-01T12:11:15Z,2020-11-01T12:11:15Z
NCT04316377,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-13,NA,NA,2020-06-04,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-05,Actual,"March 25, 2020",Actual,2020-03-25,June 2020,2020-06-30,"March 3, 2025",Anticipated,2025-03-03,"May 25, 2020",Actual,2020-05-25,NA,Interventional,NO COVID-19,,Norwegian Coronavirus Disease 2019 Study,Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection,"Active, not recruiting",NA,Phase 4,53,Actual,"University Hospital, Akershus",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:10:13Z,2020-11-01T12:10:13Z
NCT04315948,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-13,NA,NA,2020-07-20,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-07-20,2020-07-22,Actual,"March 22, 2020",Actual,2020-03-22,March 2020,2020-03-31,March 2023,Anticipated,2023-03-31,March 2023,Anticipated,2023-03-31,NA,Interventional,DisCoVeRy,,Trial of Treatments for COVID-19 in Hospitalized Adults,"Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults",Recruiting,NA,Phase 3,3100,Anticipated,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,"Study protocol and statistical analysis plan will be available from September 2020 with no time limit.
Other data will be available upon request after first publication of the results for at least 5 years",Study protocol and statistical analysis plan will be published. All requests for the trial's data will be considered by the French DisCoVeRy Trial Management Team that can be contacted via the principal investigator: florence.ader@chu-lyon.fr,NA,Yes,"Study protocol and statistical analysis plan will be available. Systematic individual patient data sharing is not intended, but all requests for the trial's data will be considered by the French DisCoVeRy Trial Management Team.",2020-11-01T12:10:16Z,2020-11-01T12:10:16Z
NCT04312009,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-13,NA,NA,2020-07-17,2020-03-13,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-17,2020-07-21,Actual,"April 13, 2020",Actual,2020-04-13,July 2020,2020-07-31,"April 1, 2021",Anticipated,2021-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NA,,Losartan for Patients With COVID-19 Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization,Recruiting,NA,Phase 2,200,Anticipated,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:10:45Z,2020-11-01T12:10:45Z
NCT04311177,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-13,NA,NA,2020-06-11,2020-03-13,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-06-11,2020-06-16,Actual,"April 9, 2020",Actual,2020-04-09,June 2020,2020-06-30,"April 1, 2021",Anticipated,2021-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NA,,Losartan for Patients With COVID-19 Not Requiring Hospitalization,Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization,Recruiting,NA,Phase 2,580,Anticipated,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:10:50Z,2020-11-01T12:10:50Z
NCT04315480,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-14,NA,NA,2020-04-09,2020-03-18,2020-03-19,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"March 12, 2020",Actual,2020-03-12,April 2020,2020-04-30,May 2020,Anticipated,2020-05-31,"April 9, 2020",Anticipated,2020-04-09,NA,Interventional,NA,,Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis,Tocilizumab (RoActemra) as Early Treatment of Patients Affected by SARS-CoV2 (COVID-19) Infection With Severe Multifocal Interstitial Pneumonia,"Active, not recruiting",NA,Phase 2,38,Actual,UniversitÃ  Politecnica delle Marche,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:10:20Z,2020-11-01T12:10:20Z
NCT04311697,"ClinicalTrials.gov processed this data on November 02, 2020",2020-03-14,NA,NA,2020-10-29,2020-03-14,2020-03-17,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-10-30,Actual,"May 15, 2020",Actual,2020-05-15,July 2020,2020-07-31,"February 28, 2021",Anticipated,2021-02-28,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,COVID-AIV,,Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure,Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure,Recruiting,NA,Phase 2,144,Anticipated,"NeuroRx, Inc.",,2,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Currently available,NA,NA,Yes,NeuroRx will share study protocol and statistical analysis plan upon request by qualified researchers,2020-11-03T10:52:35Z,2020-11-03T10:52:35Z
NCT04315298,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-15,NA,NA,2020-09-30,2020-03-17,2020-03-19,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-01,Actual,"March 18, 2020",Actual,2020-03-18,September 2020,2020-09-30,"September 2, 2020",Actual,2020-09-02,"July 24, 2020",Actual,2020-07-24,NA,Interventional,NA,,Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19,"An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19",Completed,NA,Phase 2/Phase 3,1912,Actual,Regeneron Pharmaceuticals,,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, EMA, PMDA, etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://vivli.org/,Yes,All IPD that underlie publicly available results will be considered for sharing,2020-11-01T12:10:22Z,2020-11-01T12:10:22Z
NCT04313322,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-15,NA,NA,2020-03-15,2020-03-15,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-03-15,2020-03-18,Actual,"March 16, 2020",Anticipated,2020-03-16,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,Recruiting,NA,Phase 1,5,Anticipated,Stem Cells Arabia,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:10:35Z,2020-11-01T12:10:35Z
NCT04313127,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-15,NA,NA,2020-05-16,2020-03-17,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-05-16,2020-05-19,Actual,"March 16, 2020",Actual,2020-03-16,May 2020,2020-05-31,"December 20, 2022",Anticipated,2022-12-20,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,CTCOVID-19,,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,"A Single-center,Open-labelï¼ŒDose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old","Active, not recruiting",NA,Phase 1,108,Actual,CanSino Biologics Inc.,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Data will be available beginning 3 months and ending one year following article publication,"Data access requests will be reviewed by the sponsorï¼Œinvestigator and collaborators on the basis of scientific merit. To gain access, data requestors will need to sign a data access agreement.",http://www.jshealth.com/,Yes,"We support data sharing of the individual participant data. The individual participant data that underlie the results reported in this article, after deidentiï¬cation (text, tables, figures, and appendixes) will be shared. Individual participant data will be available beginning 3 months and ending one year following article publication. Supporting clinical documents including study protocol, statistical analysis plan (SAP), and the informed consent form (ICF) will be available immediately following publication for at least one year. Supporting clinical documents access information will be available at http://www.jshealth.com/. Researchers who provide a scientifically sound proposal will be allowed to access to the individual participant data. Proposals should be directed to jszfc@vip.sina.com or cw0226@foxmail.com.",2020-11-01T12:10:37Z,2020-11-01T12:10:37Z
NCT04312243,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-15,NA,NA,2020-06-14,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-06-14,2020-06-16,Actual,"April 7, 2020",Actual,2020-04-07,June 2020,2020-06-30,"April 7, 2022",Anticipated,2022-04-07,"April 7, 2021",Anticipated,2021-04-07,NA,Interventional,NOpreventCOVID,,NO Prevention of COVID-19 for Healthcare Providers,Nitric Oxide Gas Inhalation for Prevention of COVID-19 in Healthcare Providers,Recruiting,NA,Phase 2,470,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:10:43Z,2020-11-01T12:10:43Z
NCT04313023,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-16,NA,NA,2020-10-16,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-19,Actual,"June 9, 2020",Actual,2020-06-09,October 2020,2020-10-31,March 2021,Anticipated,2021-03-31,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2,A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2,Recruiting,NA,Phase 2,200,Anticipated,"Pulmotect, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:10:38Z,2020-11-01T12:10:38Z
NCT04312997,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-16,NA,NA,2020-10-16,2020-03-16,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-19,Actual,"June 16, 2020",Actual,2020-06-16,October 2020,2020-10-31,March 2021,Anticipated,2021-03-31,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,Recruiting,NA,Phase 2,100,Anticipated,"Pulmotect, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:10:38Z,2020-11-01T12:10:38Z
NCT04323514,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-18,NA,NA,2020-03-24,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-03-24,2020-03-26,Actual,"March 13, 2020",Actual,2020-03-13,March 2020,2020-03-31,"March 13, 2021",Anticipated,2021-03-13,"March 13, 2021",Anticipated,2021-03-13,NA,Interventional,NA,,Use of Ascorbic Acid in Patients With COVID 19,Use of Ascorbic Acid in Patients With COVID 19,Recruiting,NA,N/A,500,Anticipated,University of Palermo,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:09:18Z,2020-11-01T12:09:18Z
NCT04321174,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-18,NA,NA,2020-04-17,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-21,Actual,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,"March 31, 2022",Anticipated,2022-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,CORIPREV-LR,,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,Recruiting,NA,Phase 3,1220,Anticipated,"St. Michael's Hospital, Toronto",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,TBA,2020-11-01T12:09:36Z,2020-11-01T12:09:36Z
NCT04315896,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-18,NA,NA,2020-07-24,2020-03-18,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-07-24,2020-07-27,Actual,"April 14, 2020",Actual,2020-04-14,July 2020,2020-07-31,"August 15, 2020",Anticipated,2020-08-15,"July 1, 2020",Actual,2020-07-01,NA,Interventional,HYDRA,,Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial),Hydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease: Randomised Clinical Trial (HYDRA Trial),"Active, not recruiting",NA,Phase 3,500,Anticipated,"National Institute of Respiratory Diseases, Mexico",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,As requested by other investigators.,2020-11-01T12:10:16Z,2020-11-01T12:10:16Z
NCT04323527,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-19,NA,NA,2020-07-02,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-07-02,2020-07-07,Actual,"March 23, 2020",Actual,2020-03-23,July 2020,2020-07-31,"June 7, 2020",Actual,2020-06-07,"May 7, 2020",Actual,2020-05-07,NA,Interventional,CloroCOVID19,,Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2,"Efficacy and Safety of Chloroquine Diphosphate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV2: a Phase IIb, Double-blind, Randomized Adaptive Clinical Trial",Completed,NA,Phase 2,278,Actual,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,after study publication,upon request to researchers,NA,Yes,all patient data will be shared after study publication,2020-11-01T12:09:18Z,2020-11-01T12:09:18Z
NCT04320056,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-19,NA,NA,2020-04-20,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-20,2020-04-21,Actual,"April 20, 2020",Actual,2020-04-20,April 2020,2020-04-30,"October 31, 2021",Anticipated,2021-10-31,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,,Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During SARS-CoV-2 Pneumonia (COVID-19),Automated Oxygen Titration - Monitoring and Weaning in Patients With Infectious Pneumonia Requiring Oxygen - Impact on the Number of Interventions for Healthcare Workers. An Innovative Device to Manage Patients With COVID-19 Pneumonia COVID Study (Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decreaseduring Pneumonia),Recruiting,NA,N/A,216,Anticipated,Laval University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No There is not plan to share individual participant data. All data if shared with be de-identified. Data will be stored on a secure server with access only by study personal.,2020-11-01T12:09:45Z,2020-11-01T12:09:45Z
NCT04318015,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-19,NA,NA,2020-04-15,2020-03-19,2020-03-23,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,PHYDRA,,Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial),Chemoprophylaxis With Hydroxychloroquine in Healthcare Personnel in Contact With COVID-19 Patients: A Randomized Controlled Trial (PHYDRA Trial),Recruiting,NA,Phase 3,400,Anticipated,"National Institute of Respiratory Diseases, Mexico",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:10:01Z,2020-11-01T12:10:01Z
NCT04317092,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-19,NA,NA,2020-10-19,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-22,Actual,"March 19, 2020",Actual,2020-03-19,October 2020,2020-10-31,"December 19, 2022",Anticipated,2022-12-19,"December 19, 2020",Anticipated,2020-12-19,NA,Interventional,TOCIVID-19,,Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),Multicenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 Pneumonia,"Active, not recruiting",NA,Phase 2,400,Anticipated,"National Cancer Institute, Naples",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,"After peer-reviewed publication of the primary results, with no time limits",Motivated requests to access to IPD are to be sent by email to the Principal Investigator (f.perrone@istitutotumori.na.it),NA,Yes,"Data will be shared upon reasonable request to the Principal Investigator of the study
The following IPD will be available for sharing:
Baseline characteristics of patients
Treatment data
Safety data
Follow-up data",2020-11-01T12:10:08Z,2020-11-01T12:10:08Z
NCT04317040,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-19,NA,NA,2020-09-24,2020-03-19,2020-03-20,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-25,Actual,"April 8, 2020",Actual,2020-04-08,September 2020,2020-09-30,December 2020,Anticipated,2020-12-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,SAC-COVID,,CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment,"A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment","Active, not recruiting",NA,Phase 3,241,Actual,"OncoImmune, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:10:09Z,2020-11-01T12:10:09Z
NCT04321928,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-20,NA,NA,2020-06-05,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"April 1, 2020",Actual,2020-04-01,June 2020,2020-06-30,"August 21, 2021",Anticipated,2021-08-21,"April 21, 2021",Anticipated,2021-04-21,NA,Interventional,PROACTIVE-19,,Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary,Personalized Health Education Against the Health Damage of COVID-19 Epidemic in Hungary (PROACTIVE-19),Recruiting,NA,N/A,7576,Anticipated,University of Pecs,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:09:30Z,2020-11-01T12:09:30Z
NCT04319900,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-20,NA,NA,2020-03-22,2020-03-22,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-22,2020-03-24,Actual,"March 5, 2020",Actual,2020-03-05,March 2020,2020-03-31,"June 25, 2020",Anticipated,2020-06-25,"April 30, 2020",Anticipated,2020-04-30,NA,Interventional,NA,,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,Recruiting,NA,Phase 2/Phase 3,150,Anticipated,Beijing Chao Yang Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:09:46Z,2020-11-01T12:09:46Z
NCT04319445,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-20,NA,NA,2020-04-22,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"March 22, 2020",Actual,2020-03-22,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Mindfulness During COVID-19,Mindfulness During COVID-19 - Remote Mindfulness Sessions,Recruiting,NA,N/A,200,Anticipated,Wake Forest University Health Sciences,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:09:48Z,2020-11-01T12:09:48Z
NCT04318444,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-20,NA,NA,2020-04-23,2020-03-20,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-27,Actual,"March 29, 2020",Actual,2020-03-29,April 2020,2020-04-30,March 2022,Anticipated,2022-03-31,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,,Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19),Hydroxychloroquine Post Exposure Prophylaxis (PEP) for Household Contacts of COVID-19 Patients: A NYC Community-Based Randomized Clinical Trial,Recruiting,NA,Phase 2/Phase 3,1600,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T12:09:58Z,2020-11-01T12:09:58Z
NCT04318431,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-20,NA,NA,2020-07-08,2020-03-23,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-08,2020-07-09,Actual,"April 14, 2020",Actual,2020-04-14,July 2020,2020-07-31,"June 1, 2020",Actual,2020-06-01,"May 12, 2020",Actual,2020-05-12,NA,Interventional,COVILLE,,Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children,"Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children, a Cross-sectional, Prospective, Multicentre, Observational Study in Primary Care.",Completed,NA,N/A,605,Actual,Centre Hospitalier Intercommunal Creteil,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:09:58Z,2020-11-01T12:09:58Z
NCT04324606,"ClinicalTrials.gov processed this data on November 02, 2020",2020-03-20,NA,NA,2020-10-29,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-10-30,Actual,"April 23, 2020",Actual,2020-04-23,September 2020,2020-09-30,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,,A Study of a Candidate COVID-19 Vaccine (COV001),"A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers","Active, not recruiting",NA,Phase 1/Phase 2,1090,Actual,University of Oxford,,14,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-03T10:52:30Z,2020-11-03T10:52:30Z
NCT04325867,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-21,NA,NA,2020-03-30,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-04-01,Actual,"March 31, 2020",Actual,2020-03-31,March 2020,2020-03-31,"October 1, 2020",Anticipated,2020-10-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,eCardioCovid19,,Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19,"Integrated Distance Management Strategy for Patients With Cardiovascular Disease (Ischaemic Coronary Artery Disease, High Blood Pressure, Heart Failure) in the Context of the COVID-19 Pandemic",Recruiting,NA,N/A,200,Anticipated,Grigore T. Popa University of Medicine and Pharmacy,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"If this platform will be functional, we are willing to provide the system and protocols and know-how to other centers in Romania.",2020-11-01T12:08:59Z,2020-11-01T12:08:59Z
NCT04320953,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-21,NA,NA,2020-04-15,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"March 16, 2020",Actual,2020-03-16,April 2020,2020-04-30,"April 9, 2020",Actual,2020-04-09,"March 26, 2020",Actual,2020-03-26,NA,Interventional,NA,,Non-contact Endoscopy at Covid-19 Outbreak,Non-contact Endoscopy at Covid-19 Outbreak,Completed,NA,N/A,5,Actual,Changhai Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:09:38Z,2020-11-01T12:09:38Z
NCT04320238,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-21,NA,NA,2020-03-30,2020-03-21,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"January 21, 2020",Actual,2020-01-21,March 2020,2020-03-31,June 2020,Anticipated,2020-06-30,May 2020,Anticipated,2020-05-31,NA,Interventional,NA,,Experimental Trial of rhIFNÎ± Nasal Drops to Prevent 2019-nCOV in Medical Staff,An Clinic Trial of Recombinant Human Interferon Alpha Nasal Drops to Prevent Coronavirus Disease 2019 in Medical Staff in Epidemic Area,Recruiting,NA,Phase 3,2944,Anticipated,Shanghai Jiao Tong University School of Medicine,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:09:43Z,2020-11-01T12:09:43Z
NCT04319731,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-22,NA,NA,2020-04-15,2020-03-22,2020-03-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"March 20, 2020",Actual,2020-03-20,April 2020,2020-04-30,"March 20, 2021",Anticipated,2021-03-20,"March 20, 2021",Anticipated,2021-03-20,NA,Interventional,NA,,A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure,A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure,Recruiting,NA,Early Phase 1,10,Anticipated,University of Utah,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:09:47Z,2020-11-01T12:09:47Z
NCT04328129,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-23,NA,NA,2020-09-21,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-23,Actual,"March 23, 2020",Actual,2020-03-23,September 2020,2020-09-30,"March 23, 2022",Anticipated,2022-03-23,"March 23, 2022",Anticipated,2022-03-23,NA,Interventional,EPI-COVID-19,,Household Transmission Investigation Study for COVID-19 in Tropical Regions,Household Transmission Investigation Study for Coronavirus Disease 2019 (COVID-19) in Tropical Regions,Recruiting,NA,N/A,1300,Anticipated,Institut Pasteur,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:08:39Z,2020-11-01T12:08:39Z
NCT04323345,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-23,NA,NA,2020-04-18,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-04-18,2020-04-21,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"January 15, 2021",Anticipated,2021-01-15,"December 15, 2020",Anticipated,2020-12-15,NA,Interventional,NA,,Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus,"The Efficacy of Natural Honey in Patients Infected With Novel Coronavirus (COVID-19) : A Randomized, Controlled ,Single Masked , Investigator Initiated, Multi-center Trial",Recruiting,NA,Phase 3,1000,Anticipated,Misr University for Science and Technology,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:09:19Z,2020-11-01T12:09:19Z
NCT04323228,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-23,NA,NA,2020-09-18,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-09-18,2020-09-22,Actual,"September 1, 2020",Actual,2020-09-01,September 2020,2020-09-30,"December 30, 2020",Anticipated,2020-12-30,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,ONSCOVID19,,Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19,Anti-inflammatory/Antioxidant Oral Nutrition Supplementation on the Cytokine Storm and Progression of COVID-19: A Randomized Controlled Trial,Recruiting,NA,Phase 2/Phase 3,40,Anticipated,King Saud University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,starting 6 months after publication.,Access will be available for any researcher interested in this type of research on considerable consent.,NA,Yes,all IPD that underlie results in a publication will be shared,2020-11-01T12:09:20Z,2020-11-01T12:09:20Z
NCT04322682,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-23,NA,NA,2020-10-13,2020-03-25,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-14,Actual,"March 23, 2020",Actual,2020-03-23,October 2020,2020-10-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,COVID-19,,Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Recruiting,NA,Phase 3,6000,Anticipated,Montreal Heart Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:09:23Z,2020-11-01T12:09:23Z
NCT04322396,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-23,NA,NA,2020-05-07,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-11,Actual,"April 6, 2020",Actual,2020-04-06,May 2020,2020-05-31,"March 31, 2021",Anticipated,2021-03-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,ProPAC-COVID,,Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,"Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19",Recruiting,NA,Phase 2,226,Anticipated,"Chronic Obstructive Pulmonary Disease Trial Network, Denmark",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:09:27Z,2020-11-01T12:09:27Z
NCT04322344,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-23,NA,NA,2020-09-11,2020-03-23,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-09-11,2020-09-16,Actual,"March 23, 2020",Actual,2020-03-23,September 2020,2020-09-30,"December 30, 2020",Anticipated,2020-12-30,"June 30, 2020",Actual,2020-06-30,NA,Interventional,add-on-COV2,,Escin in Patients With Covid-19 Infection,Efficacy and Safety of Escin as add-on Treatment in Covid-19 Infected Patients,Recruiting,NA,Phase 2/Phase 3,120,Anticipated,University of Catanzaro,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:09:28Z,2020-11-01T12:09:28Z
NCT04321616,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-23,NA,NA,2020-04-10,2020-03-24,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"March 28, 2020",Actual,2020-03-28,April 2020,2020-04-30,November 2020,Anticipated,2020-11-30,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients,The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients,Recruiting,NA,Phase 2/Phase 3,700,Anticipated,Oslo University Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,The study will end according the requirements to WHO,WHO COVID 19 investigators,NA,Yes,All patients included in this study will automatically be included in the WHO COVID 19 protocol,2020-11-01T12:09:32Z,2020-11-01T12:09:32Z
NCT04321421,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-23,NA,NA,2020-05-27,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-28,Actual,"March 17, 2020",Actual,2020-03-17,May 2020,2020-05-31,"May 7, 2020",Actual,2020-05-07,"April 28, 2020",Actual,2020-04-28,NA,Interventional,COV19-PLASMA,,Hyperimmune Plasma for Critical Patients With COVID-19,Plasma From Donors Recovered From New Coronavirus 2019 As Therapy For Critical Patients With Covid-19,Completed,NA,N/A,49,Actual,Foundation IRCCS San Matteo Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,will be decided,2020-11-01T12:09:33Z,2020-11-01T12:09:33Z
NCT04321278,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-23,NA,NA,2020-07-01,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-07-01,2020-07-02,Actual,"March 28, 2020",Actual,2020-03-28,March 2020,2020-03-31,"June 14, 2020",Actual,2020-06-14,"June 14, 2020",Actual,2020-06-14,NA,Interventional,NA,,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - SEVERE - Patients,Completed,NA,Phase 3,440,Actual,Hospital Israelita Albert Einstein,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:09:35Z,2020-11-01T12:09:35Z
NCT04321096,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-23,NA,NA,2020-04-28,2020-03-24,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-30,Actual,"April 4, 2020",Actual,2020-04-04,March 2020,2020-03-31,"May 1, 2021",Anticipated,2021-05-01,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,CamoCO-19,,The Impact of Camostat Mesilate on COVID-19 Infection,"The Impact of Camostat Mesilate on COVID-19 Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial",Recruiting,NA,Phase 1/Phase 2,580,Anticipated,University of Aarhus,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,Access to the data sharing will be given to researchers who provide a methodologically sound proposal for any type of analysis and requires IRB/Ethics committee approval (if applicable). Proposals should be addressed to olesoega@rm.dk.,NA,Yes,"Data sharing plan: Individual deidentified participant data (including data dictionaries) will be shared following the publication of the primary and secondary endpoints as outlined in this protocol. Data to be shared includes deidentified data points in published, peer-reviewed articles. Additional, related documents will also be available (study protocol, informed consent form, statistical analysis plan). Data will become available following publication with no planned end date.",2020-11-01T12:09:36Z,2020-11-01T12:09:36Z
NCT04320615,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-23,NA,NA,2020-09-23,2020-03-23,2020-03-25,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-25,Actual,"April 3, 2020",Actual,2020-04-03,September 2020,2020-09-30,"July 28, 2020",Actual,2020-07-28,"June 24, 2020",Actual,2020-06-24,NA,Interventional,COVACTA,,A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia",Completed,NA,Phase 3,450,Actual,Hoffmann-La Roche,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform https://vivli.org.
Further details on Roche's criteria for eligible studies are available here: https://vivli.org.
For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here: (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm",2020-11-01T12:09:40Z,2020-11-01T12:09:40Z
NCT04328961,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-23,NA,NA,2020-10-27,2020-03-29,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-29,Actual,"March 31, 2020",Actual,2020-03-31,October 2020,2020-10-31,"October 8, 2020",Actual,2020-10-08,"September 24, 2020",Actual,2020-09-24,NA,Interventional,NA,,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),"Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study",Completed,NA,Phase 2/Phase 3,829,Actual,University of Washington,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,Within 3 months of publication of primary results.,De-identified data from the study will be made available in accordance with the funder's open access policy.,https://www.gatesfoundation.org/how-we-work/general-information/open-access-policy,Yes,De-identified data from the study will be made available in accordance with the funder's open access policy.,2020-11-02T10:30:32Z,2020-11-02T10:30:32Z
NCT04330690,"ClinicalTrials.gov processed this data on November 13, 2020",2020-03-23,NA,NA,2020-11-09,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"March 18, 2020",Actual,2020-03-18,November 2020,2020-11-30,"May 18, 2022",Anticipated,2022-05-18,"March 18, 2022",Anticipated,2022-03-18,NA,Interventional,CATCO,,Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,"A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)",Recruiting,NA,Phase 2,2900,Anticipated,Sunnybrook Health Sciences Centre,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Unknown and variable,NA,NA,Yes,"As per World Health Organization policies on data sharing in a Public Health Emergency, any clinical trial outcome data will be shared at the earliest possible opportunity. In addition, given the nature of this protocol, being performed across regions, the DSMB may access other regions trials, and possibly recommend alterations in study design based on accumulating data, through a centralized data repository being built under the auspices of the World Health Organization.
Data Sharing for Secondary Research Data from this study may be used for secondary research. All of the individual subject data collected during the trial will be made available after de-identification through expert determination. The SAP and Analytic Code will also be made available. This data will be available immediately following publication, with no end date, as part of data sharing requirements from journals and funding agencies.",2020-11-15T11:00:03Z,2020-11-15T11:00:03Z
NCT04327349,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-24,NA,NA,2020-03-30,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-03-30,2020-03-31,Actual,"March 28, 2020",Anticipated,2020-03-28,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"May 20, 2020",Anticipated,2020-05-20,NA,Interventional,NA,,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,Enrolling by invitation,NA,N/A,30,Anticipated,Mazandaran University of Medical Sciences,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:08:44Z,2020-11-01T12:08:44Z
NCT04326920,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-24,NA,NA,2020-04-23,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-24,Actual,"March 24, 2020",Actual,2020-03-24,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,SARPAC,,Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC),"A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (LeukineÂ®) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure.",Recruiting,NA,Phase 4,80,Anticipated,"University Hospital, Ghent",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T12:08:48Z,2020-11-01T12:08:48Z
NCT04322773,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-24,NA,NA,2020-10-08,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-10-08,2020-10-09,Actual,"April 5, 2020",Actual,2020-04-05,October 2020,2020-10-31,"October 8, 2020",Actual,2020-10-08,"October 8, 2020",Actual,2020-10-08,NA,Interventional,TOCIVID,,Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure,"Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients With Severe SARS-CoV-2 Pneumonia: An Open-Label, Multicenter Sequential and Cluster Randomized Trial",Terminated,NA,Phase 2,20,Actual,Frederiksberg University Hospital,,4,NA,The study has been terminated due to changed clinical conditions and too few patients available,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,NA,2020-11-01T12:09:23Z,2020-11-01T12:09:23Z
NCT04322565,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-24,NA,NA,2020-07-09,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-07-09,2020-07-10,Actual,"April 20, 2020",Actual,2020-04-20,July 2020,2020-07-31,"December 21, 2020",Anticipated,2020-12-21,"December 20, 2020",Anticipated,2020-12-20,NA,Interventional,ColCOVID-19,,Colchicine Counteracting Inflammation in COVID-19 Pneumonia,Colchicine to Counteract Inflammatory Response in COVID-19 Pneumonia,Recruiting,NA,Phase 2,310,Anticipated,Azienda Ospedaliero-Universitaria di Parma,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,Data will be avaliable from July 2020 and documentation will be shared for 10 years,The sponsor recognizes the importance of communicating study data and will disclose and publish the results in a suitable form regardless of outcome. The sponsor will publish the results of this study in scientific journals,NA,Yes,NA,2020-11-01T12:09:25Z,2020-11-01T12:09:25Z
NCT04322123,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-24,NA,NA,2020-05-28,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"April 1, 2020",Actual,2020-04-01,May 2020,2020-05-31,"August 30, 2020",Anticipated,2020-08-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,Coalition-I,,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),"An Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azithromycin for COVID-19 Infection on Hospitalized, Noncritical Patients","Active, not recruiting",NA,Phase 3,630,Anticipated,Hospital do Coracao,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:09:29Z,2020-11-01T12:09:29Z
NCT04321993,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-24,NA,NA,2020-07-22,2020-03-24,2020-03-26,Actual,NA,NA,NA,NA,NA,NA,2020-07-22,2020-07-24,Actual,"April 17, 2020",Actual,2020-04-17,July 2020,2020-07-31,March 2022,Anticipated,2022-03-31,February 2022,Anticipated,2022-02-28,NA,Interventional,NA,,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,Recruiting,NA,Phase 2,800,Anticipated,Nova Scotia Health Authority,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:09:30Z,2020-11-01T12:09:30Z
NCT04323800,"ClinicalTrials.gov processed this data on November 13, 2020",2020-03-24,NA,NA,2020-11-06,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"June 10, 2020",Actual,2020-06-10,October 2020,2020-10-31,January 2023,Anticipated,2023-01-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,CSSC-001,,Convalescent Plasma to Stem Coronavirus (CSSC-001),"Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19",Recruiting,NA,Phase 2,500,Anticipated,Johns Hopkins University,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,Sharing is governed by Johns Hopkins University Institutional Guidelines,2020-11-14T10:44:03Z,2020-11-14T10:44:03Z
NCT04371601,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-25,NA,NA,2020-04-30,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-01,Actual,"March 1, 2020",Actual,2020-03-01,March 2020,2020-03-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,,Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019,Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019,"Active, not recruiting",NA,Early Phase 1,60,Actual,Fuzhou General Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:02:51Z,2020-11-01T12:02:51Z
NCT04353271,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-25,NA,NA,2020-08-18,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-20,Actual,"April 17, 2020",Actual,2020-04-17,August 2020,2020-08-31,"July 8, 2020",Actual,2020-07-08,"July 8, 2020",Actual,2020-07-08,NA,Interventional,THICK,,Trial of Hydroxychloroquine In Covid-19 Kinetics,A Randomized Phase 2/3 Trial of Hydroxychloroquine In Covid-19 Kinetics,Terminated,NA,Phase 2/Phase 3,58,Actual,University of South Alabama,,2,NA,"FDA recommendations to not use outside of the hospital setting or in a clinical trial due to
    the risk of cardiac arrhythmias",FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:15Z,2020-11-01T12:05:15Z
NCT04336462,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-25,NA,NA,2020-04-03,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-03,2020-04-07,Actual,"February 15, 2020",Actual,2020-02-15,April 2020,2020-04-30,"August 1, 2020",Anticipated,2020-08-01,"February 21, 2020",Actual,2020-02-21,NA,Interventional,COVID-19,,Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19,"A Multi-center, Randomized, Parallel-Controlled Clinical Trial of the Application of A Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19",Recruiting,NA,N/A,100,Anticipated,Shanghai Asclepius Meditec Inc.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:07:28Z,2020-11-01T12:07:28Z
NCT04328285,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-25,NA,NA,2020-06-22,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-06-22,2020-06-23,Actual,"April 14, 2020",Actual,2020-04-14,May 2020,2020-05-31,"November 30, 2020",Anticipated,2020-11-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,COVIDAXIS,,Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers,Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers : A Randomized Double-blind Placebo-controlled Clinical Trial,"Active, not recruiting",NA,Phase 3,1200,Anticipated,Centre Hospitalier Universitaire de Saint Etienne,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:08:38Z,2020-11-01T12:08:38Z
NCT04327505,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-25,NA,NA,2020-06-03,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-05,Actual,"June 3, 2020",Actual,2020-06-03,June 2020,2020-06-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,COVID-19-HBO,,Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19,"A Randomized, Controlled, Open Label, Multicentre Clinical Trial to Explore Safety and Efficacy of Hyperbaric Oxygen for Preventing ICU Admission, Morbidity and Mortality in Adult Patients With COVID-19",Recruiting,NA,Phase 2/Phase 3,200,Anticipated,Karolinska Institutet,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:08:43Z,2020-11-01T12:08:43Z
NCT04327206,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-25,NA,NA,2020-10-19,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-22,Actual,"March 30, 2020",Actual,2020-03-30,October 2020,2020-10-31,"March 30, 2022",Anticipated,2022-03-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,BRACE,,BCG Vaccination to Protect Healthcare Workers Against COVID-19,BCG Vaccination to Reduce the Impact of COVID-19 in Healthcare Workers (BRACE) Trial,Recruiting,NA,Phase 3,10078,Anticipated,Murdoch Childrens Research Institute,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,"Beginning 6 months following analysis and article publications, for long-term use","Researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept MCRI's conditions, under a collaborator agreement",NA,Yes,"Beginning 6 months following analysis and article publications, the following may be made available long-term for use by future researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept MCRI's conditions, under a collaborator agreement, for accessing:
Individual participant data that underlie the results reported in our articles after de-identification (text, tables, figures and appendices)
Study protocol, Statistical Analysis Plan, Participant Informed Consent Form (PICF)",2020-11-01T12:08:45Z,2020-11-01T12:08:45Z
NCT04326452,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-25,NA,NA,2020-10-05,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-06,Actual,"March 27, 2020",Actual,2020-03-27,March 2020,2020-03-31,"March 27, 2021",Anticipated,2021-03-27,"March 27, 2021",Anticipated,2021-03-27,NA,Interventional,NA,,Treating COVID-19 With a Bidirectional Oxygenation Valve,The Use of a Bidirectional Oxygenation Valve in the Management of Respiratory Failure Due to COVID-19 Infection,Recruiting,NA,N/A,30,Anticipated,TMC HealthCare,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:08:53Z,2020-11-01T12:08:53Z
NCT04325893,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-25,NA,NA,2020-10-02,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-10-02,2020-10-06,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"June 18, 2020",Actual,2020-06-18,"June 18, 2020",Actual,2020-06-18,NA,Interventional,HYCOVID,,Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease,"Hydroxychloroquine Versus Placebo in Patients Presenting COVID-19 Infection and at Risk of Secondary Complication: a Prospective, Multicentre, Randomised, Double-blind Study",Terminated,NA,Phase 3,259,Actual,"University Hospital, Angers",,2,NA,decrease in number of eligible patients,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:08:59Z,2020-11-01T12:08:59Z
NCT04324996,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-25,NA,NA,2020-03-25,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-25,2020-03-27,Actual,"March 21, 2020",Actual,2020-03-21,March 2020,2020-03-31,"September 30, 2020",Anticipated,2020-09-30,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19,A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19,Recruiting,NA,Phase 1/Phase 2,90,Anticipated,Chongqing Public Health Medical Center,,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:09:06Z,2020-11-01T12:09:06Z
NCT04324528,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-25,NA,NA,2020-03-27,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-03-27,2020-03-31,Actual,"March 27, 2020",Actual,2020-03-27,March 2020,2020-03-31,"November 26, 2020",Anticipated,2020-11-26,"September 26, 2020",Anticipated,2020-09-26,NA,Interventional,CYCOV,,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Recruiting,NA,N/A,30,Anticipated,University Hospital Freiburg,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:09:09Z,2020-11-01T12:09:09Z
NCT04324489,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-25,NA,NA,2020-05-01,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-01,2020-05-05,Actual,"March 6, 2020",Actual,2020-03-06,May 2020,2020-05-31,"April 30, 2020",Actual,2020-04-30,"April 16, 2020",Actual,2020-04-16,NA,Interventional,NA,,DAS181 for Severe COVID-19: Compassionate Use,DAS181 for Severe COVID-19: Compassionate Use,Completed,NA,N/A,4,Actual,Renmin Hospital of Wuhan University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T12:09:09Z,2020-11-01T12:09:09Z
NCT04324463,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-25,NA,NA,2020-10-06,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"April 21, 2020",Actual,2020-04-21,October 2020,2020-10-31,"June 30, 2021",Anticipated,2021-06-30,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,ACTCOVID19,,Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial,"Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial",Recruiting,NA,Phase 3,4000,Anticipated,Population Health Research Institute,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:09:09Z,2020-11-01T12:09:09Z
NCT04324073,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-25,NA,NA,2020-04-14,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"March 27, 2020",Actual,2020-03-27,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"March 27, 2021",Anticipated,2021-03-27,NA,Interventional,CORIMUNO-SARI,,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,"Active, not recruiting",NA,Phase 2/Phase 3,239,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-11-01T12:09:12Z,2020-11-01T12:09:12Z
NCT04324021,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-25,NA,NA,2020-10-20,2020-03-25,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-20,2020-10-22,Actual,"April 2, 2020",Actual,2020-04-02,October 2020,2020-10-31,December 2020,Anticipated,2020-12-31,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,,Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.,"A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNÎ³) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection.",Recruiting,NA,Phase 2/Phase 3,54,Anticipated,Swedish Orphan Biovitrum,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:09:13Z,2020-11-01T12:09:13Z
NCT04355962,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-26,NA,NA,2020-09-09,2020-04-19,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-09-09,2020-09-11,Actual,"April 23, 2020",Actual,2020-04-23,September 2020,2020-09-30,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,NA,,Sevoflurane in COVID-19 ARDS (SevCov),Sevoflurane Sedation in COVID-19 ARDS Patients to Reduce Lung Injury: a Randomized Controlled Trial,Recruiting,NA,Phase 3,64,Anticipated,University of Zurich,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:04:55Z,2020-11-01T12:04:55Z
NCT04327401,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-26,NA,NA,2020-08-05,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-08-05,2020-08-07,Actual,"April 13, 2020",Actual,2020-04-13,August 2020,2020-08-31,"July 22, 2020",Actual,2020-07-22,"July 22, 2020",Actual,2020-07-22,NA,Interventional,CoDEX,,COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III,"COVID-19-associated ARDS Treated With DEXamethasone: an Open-label, Randomized, Controlled Trial: CoDEX (Alliance Covid-19 Brasil III)",Terminated,NA,Phase 3,299,Actual,Hospital Sirio-Libanes,,2,NA,"The Data Monitoring Committee recommended to stop the trial based on the Recovery Trial
    results, which was accepted by the CoDEX Steering Committee.",FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:08:44Z,2020-11-01T12:08:44Z
NCT04327388,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-26,NA,NA,2020-09-28,2020-03-26,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-29,Actual,"March 28, 2020",Actual,2020-03-28,September 2020,2020-09-30,"September 2, 2020",Actual,2020-09-02,"July 30, 2020",Actual,2020-07-30,NA,Interventional,NA,,Sarilumab COVID-19,"An Adaptive Phase 3, Randomized, Double-blind, Placebo-controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19",Completed,NA,Phase 3,420,Actual,Sanofi,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2020-11-01T12:08:44Z,2020-11-01T12:08:44Z
NCT04326790,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-26,NA,NA,2020-05-06,2020-03-26,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-08,Actual,"April 3, 2020",Actual,2020-04-03,May 2020,2020-05-31,"September 30, 2020",Anticipated,2020-09-30,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,GRECCO-19,,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,Recruiting,NA,Phase 2,180,Anticipated,National and Kapodistrian University of Athens,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:08:49Z,2020-11-01T12:08:49Z
NCT04326426,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-26,NA,NA,2020-04-16,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-20,Actual,"April 13, 2020",Actual,2020-04-13,April 2020,2020-04-30,"August 31, 2020",Anticipated,2020-08-31,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,NA,,ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection,"ODYSSEY: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection",Enrolling by invitation,NA,Phase 3,300,Anticipated,Vanda Pharmaceuticals,,2,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:08:53Z,2020-11-01T12:08:53Z
NCT04326036,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-26,NA,NA,2020-10-08,2020-03-26,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-10-08,2020-10-12,Actual,"March 25, 2020",Actual,2020-03-25,October 2020,2020-10-31,"December 31, 2021",Anticipated,2021-12-31,"November 1, 2021",Anticipated,2021-11-01,NA,Interventional,GARM-COVID19,,Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection,Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection,Recruiting,NA,Early Phase 1,10,Anticipated,"Black Tie Medical, Inc.",,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,In discussion phase,2020-11-01T12:08:57Z,2020-11-01T12:08:57Z
NCT04325906,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-26,NA,NA,2020-10-05,2020-03-27,2020-03-30,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-06,Actual,"April 2, 2020",Actual,2020-04-02,October 2020,2020-10-31,"December 31, 2020",Anticipated,2020-12-31,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,NA,,Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS,Early Prone Positioning Combined With High-Flow Nasal Cannula Versus High-Flow Nasal Cannula in COVID-19 Induced Moderate to Severe ARDS,Recruiting,NA,N/A,346,Anticipated,Rush University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:08:59Z,2020-11-01T12:08:59Z
NCT04324190,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-26,NA,NA,2020-04-11,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-04-11,2020-04-14,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,December 2021,Anticipated,2021-12-31,June 2020,Anticipated,2020-06-30,NA,Interventional,DISPOSE,,DIgital Online SuPport for COVID-19 StrEss,Online Support for Psychosocial Stress in the Context of the COVID-19 Pandemic,Recruiting,NA,N/A,600,Anticipated,International Psychoanalytic University Berlin,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:09:11Z,2020-11-01T12:09:11Z
NCT04329533,"ClinicalTrials.gov processed this data on November 13, 2020",2020-03-26,NA,NA,2020-11-11,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Estimate,"April 13, 2020",Actual,2020-04-13,November 2020,2020-11-30,"November 1, 2020",Actual,2020-11-01,"November 1, 2020",Actual,2020-11-01,NA,Interventional,NA,,Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic,Effects of a Mobile Meditation App on Stress During COVID-19 Pandemic in Outpatient Obstetrics and Gynecology Patients; a Randomized Controlled Trial,Completed,NA,N/A,101,Actual,University of Arizona,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-15T11:00:08Z,2020-11-15T11:00:08Z
NCT04331899,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-27,NA,NA,2020-09-24,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-28,Actual,"April 24, 2020",Actual,2020-04-24,September 2020,2020-09-30,May 2021,Anticipated,2021-05-31,"August 14, 2020",Actual,2020-08-14,NA,Interventional,COVID-Lambda,,Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19,"A Phase 2 Randomized, Single-Blind Study of a Single Dose of Peginterferon Lambda-1a (Lambda) Compared With Placebo in Outpatients With Mild COVID-19","Active, not recruiting",NA,Phase 2,120,Actual,Stanford University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No current plan to share the data.,2020-11-01T12:08:09Z,2020-11-01T12:08:09Z
NCT04328493,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-27,NA,NA,2020-05-27,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-29,Actual,"April 7, 2020",Actual,2020-04-07,May 2020,2020-05-31,"April 1, 2022",Anticipated,2022-04-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,VICO,,The Vietnam Chloroquine Treatment on COVID-19,A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam,Recruiting,NA,Phase 2,250,Anticipated,"Oxford University Clinical Research Unit, Vietnam",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:08:36Z,2020-11-01T12:08:36Z
NCT04328467,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-27,NA,NA,2020-05-26,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-27,Actual,"April 6, 2020",Actual,2020-04-06,May 2020,2020-05-31,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,Pre-exposure Prophylaxis for SARS-Coronavirus-2,Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial,"Active, not recruiting",NA,Phase 3,1500,Actual,University of Minnesota,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:08:36Z,2020-11-01T12:08:36Z
NCT04328441,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-27,NA,NA,2020-08-15,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-08-15,2020-08-19,Actual,"March 25, 2020",Actual,2020-03-25,August 2020,2020-08-31,"April 30, 2021",Anticipated,2021-04-30,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,BCG-CORONA,,Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine,"Reducing Health Care Workers Absenteeism in COVID-19 Pandemic by Enhanced Trained Immune Responses Through Bacillus Calmette-GuÃ©rin Vaccination, a Randomized Controlled Trial.","Active, not recruiting",NA,Phase 3,1500,Anticipated,UMC Utrecht,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,"The content of the study protocol is published. The statistical analysis plan is attached. The informed consent form (in Dutch) could be obtained by sending a mail to one of the contact persons.
The clinical study report and analytic code could be obtained by sending a mail to one of the contact persons after publication of the study in a peer-reviewed journal.",NA,NA,Yes,The results of this study will be disclosed unreservedly at the end of the study.,2020-11-01T12:08:36Z,2020-11-01T12:08:36Z
NCT04328012,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-27,NA,NA,2020-08-18,2020-03-27,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-20,Actual,"April 6, 2020",Actual,2020-04-06,August 2020,2020-08-31,"April 1, 2021",Anticipated,2021-04-01,"January 1, 2021",Anticipated,2021-01-01,NA,Interventional,COVIDMED,,COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2,Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial),Recruiting,NA,Phase 2/Phase 3,4000,Anticipated,Bassett Healthcare,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T12:08:40Z,2020-11-01T12:08:40Z
NCT04336254,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-28,NA,NA,2020-04-03,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-03,2020-04-07,Actual,"April 6, 2020",Anticipated,2020-04-06,April 2020,2020-04-30,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients,"Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19ï¼ša Single-center, Prospective, Randomised Clinical Trial",Recruiting,NA,Phase 1/Phase 2,20,Anticipated,Renmin Hospital of Wuhan University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:07:30Z,2020-11-01T12:07:30Z
NCT04329195,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-28,NA,NA,2020-06-02,2020-03-28,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"August 9, 2020",Anticipated,2020-08-09,"May 9, 2020",Actual,2020-05-09,NA,Interventional,ACORES-2,,ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemic,ACE Inhibitors or ARBs Discontinuation for Clinical Outcome Risk Reduction in Patients Hospitalized for the Endemic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection: the Randomized ACORES-2 Study,Recruiting,NA,Phase 3,554,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:08:32Z,2020-11-01T12:08:32Z
NCT04333368,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-29,NA,NA,2020-08-17,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-08-17,2020-08-18,Actual,"April 6, 2020",Actual,2020-04-06,August 2020,2020-08-31,"April 6, 2022",Anticipated,2022-04-06,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,STROMA-CoV2,,Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS,Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS,Recruiting,NA,Phase 1/Phase 2,40,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:07:54Z,2020-11-01T12:07:54Z
NCT04331054,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-29,NA,NA,2020-09-14,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-09-14,2020-09-16,Actual,"April 13, 2020",Actual,2020-04-13,September 2020,2020-09-30,"January 13, 2022",Anticipated,2022-01-13,"January 13, 2022",Anticipated,2022-01-13,NA,Interventional,INHASCO,,Protective Role of Inhaled Steroids for Covid-19 Infection,Protective Role of Inhaled Steroids for Covid-19 Infection,Recruiting,NA,Phase 3,436,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:08:19Z,2020-11-01T12:08:19Z
NCT04329611,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-29,NA,NA,2020-07-29,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-07-31,Actual,"April 13, 2020",Actual,2020-04-13,July 2020,2020-07-31,"July 20, 2020",Actual,2020-07-20,"July 20, 2020",Actual,2020-07-20,NA,Interventional,NA,,ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease,"A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Oral Hydroxychloroquine for the Treatment of SARS-CoV-2 Positive Patients for the Prevention of Severe COVID-19 Disease.",Terminated,NA,Phase 3,148,Actual,University of Calgary,,2,NA,"Enrolment was suspended on 22may2020, after Mehra et al (Lancet 2020) then stopped due to lack
    of Covid19 cases.",FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,24 months after study close out.,pending.,NA,Yes,NA,2020-11-01T12:08:29Z,2020-11-01T12:08:29Z
NCT04348370,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-30,NA,NA,2020-05-24,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-05-24,2020-05-27,Actual,"April 20, 2020",Actual,2020-04-20,May 2020,2020-05-31,November 2021,Anticipated,2021-11-30,May 2021,Anticipated,2021-05-31,NA,Interventional,BADAS,,BCG Vaccine for Health Care Workers as Defense Against COVID 19,Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2: A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses,Recruiting,NA,Phase 4,1800,Anticipated,Texas A&M University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,There is not a plan to make IPD available.,2020-11-01T12:05:54Z,2020-11-01T12:05:54Z
NCT04332380,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-30,NA,NA,2020-08-12,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-08-12,2020-08-17,Actual,"May 1, 2020",Actual,2020-05-01,August 2020,2020-08-31,"July 28, 2020",Actual,2020-07-28,"July 28, 2020",Actual,2020-07-28,NA,Interventional,CP-COVID-19,,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Completed,NA,Phase 2,10,Actual,Universidad del Rosario,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:08:04Z,2020-11-01T12:08:04Z
NCT04332081,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-30,NA,NA,2020-06-01,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-04,Actual,"April 6, 2020",Actual,2020-04-06,June 2020,2020-06-30,"May 29, 2020",Actual,2020-05-29,"May 29, 2020",Actual,2020-05-29,NA,Interventional,NA,,Hyperbaric Oxygen for COVID-19 Patients,Open Label Single-Center Study of Emergency Hyperbaric Oxygen for Respiratory Distress in Patients With COVID-19,Terminated,NA,N/A,20,Actual,NYU Langone Health,,2,NA,"The IRB has determined that the design of this trial should be changed to a randomized
    controlled trial. A new record will be created for the redesigned study.",FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,,Immediately following publication. No end date.,"Requests should be directed to David.Lee@nyulangone.org and Scott.Gorenstein@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be made available immediately following publication, upon reasonable request by an investigator who proposes to use the data.",2020-11-01T12:08:08Z,2020-11-01T12:08:08Z
NCT04331600,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-30,NA,NA,2020-05-21,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-05-21,2020-05-22,Actual,"April 16, 2020",Actual,2020-04-16,May 2020,2020-05-31,"December 31, 2020",Anticipated,2020-12-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,Chloroquine as Antiviral Treatment in Coronavirus Infection 2020,"Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Efficacy and Safety of Chloroquine Phosphate in Combination With Telemedicine Care in the Risk Reduction of COVID-19 Related Hospitalization or Death, in Ambulatory Patients With COVID-19 Being at Risk of Serious Complications",Recruiting,NA,Phase 4,400,Anticipated,Wroclaw Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:08:12Z,2020-11-01T12:08:12Z
NCT04331470,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-30,NA,NA,2020-04-09,2020-03-31,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-13,Actual,"April 4, 2020",Actual,2020-04-04,April 2020,2020-04-30,"May 20, 2020",Anticipated,2020-05-20,"April 20, 2020",Anticipated,2020-04-20,NA,Interventional,NA,,Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19,Evaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the Disease,Recruiting,NA,Phase 2/Phase 3,30,Anticipated,Fasa University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,between 1 to 2 months after analyzing the raw data.,Results will be available in Journals.,http://journal.fums.ac.ir/en,Yes,All IPD that underlie results in a publication and is comply with ethics will be revealed.,2020-11-01T12:08:13Z,2020-11-01T12:08:13Z
NCT04329923,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-30,NA,NA,2020-04-27,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-28,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"December 1, 2021",Anticipated,2021-12-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,PATCH,,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Recruiting,NA,Phase 2,400,Anticipated,University of Pennsylvania,,6,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,One year after study completion,Open access,NA,Yes,We will publish our results in a peer-reviewed journal and make available de-identified data for additional analysis,2020-11-01T12:08:27Z,2020-11-01T12:08:27Z
NCT04329832,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-30,NA,NA,2020-08-31,2020-03-30,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-02,Actual,"March 30, 2020",Actual,2020-03-30,August 2020,2020-08-31,"December 31, 2021",Anticipated,2021-12-31,"December 18, 2020",Anticipated,2020-12-18,NA,Interventional,HAHPS,,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS): A Prospective Pragmatic Trial,"Active, not recruiting",NA,Phase 2,85,Actual,"Intermountain Health Care, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"In order to protect patient privacy and comply with relevant regulations, identified data are unavailable. Requests for deidentified data from qualified researchers with appropriate ethics board approvals and relevant data use agreements will be processed by the Intermountain Office of Research, officeofresearch@imail.org.",2020-11-01T12:08:28Z,2020-11-01T12:08:28Z
NCT04328480,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-30,NA,NA,2020-04-28,2020-03-30,2020-03-31,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-30,Actual,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,"August 30, 2020",Anticipated,2020-08-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,COLCOVID,,The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.,The ECLA PHRI COLCOVID Trial,Recruiting,NA,Phase 3,2500,Anticipated,Estudios ClÃ­nicos Latino AmÃ©rica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:08:36Z,2020-11-01T12:08:36Z
NCT04332107,"ClinicalTrials.gov processed this data on November 06, 2020",2020-03-30,NA,NA,2020-11-02,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"May 22, 2020",Actual,2020-05-22,November 2020,2020-11-30,"December 30, 2021",Anticipated,2021-12-30,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,ACTION,,Azithromycin for COVID-19 Treatment in Outpatients Nationwide,Azithromycin for Prevention of Disease Progression in Patients With Mild or Moderate COVID-19,Recruiting,NA,Phase 3,2271,Anticipated,"University of California, San Francisco",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,NA,2020-11-07T11:25:47Z,2020-11-07T11:25:47Z
NCT04352348,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-31,NA,NA,2020-08-17,2020-04-14,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-08-17,2020-08-19,Actual,"March 31, 2020",Actual,2020-03-31,March 2020,2020-03-31,"March 31, 2022",Anticipated,2022-03-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,COVIDeF,,Cohort of Patients Infected With SARS-CoV2 (COVID-19) or Suspected of Being,Cohort of Patients Infected With SARS-CoV2 or Suspected of Being (COVID-19 in Ile-de-France),Recruiting,NA,N/A,2000,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:05:22Z,2020-11-01T12:05:22Z
NCT04347174,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-31,NA,NA,2020-06-09,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-09,2020-06-11,Actual,"April 30, 2020",Actual,2020-04-30,April 2020,2020-04-30,"July 30, 2020",Anticipated,2020-07-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients,A Clinical Trial to Evaluate the Safety and Efficacy of Mycobacterium W in Critically Ill Patients Suffering From COVID 19 Infection,Recruiting,NA,N/A,40,Anticipated,Cadila Pharnmaceuticals,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:03Z,2020-11-01T12:06:03Z
NCT04343651,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-31,NA,NA,2020-08-19,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-08-19,2020-08-20,Actual,"April 1, 2020",Actual,2020-04-01,August 2020,2020-08-31,"August 31, 2020",Anticipated,2020-08-31,"July 21, 2020",Actual,2020-07-21,NA,Interventional,NA,,Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19,"A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)","Active, not recruiting",NA,Phase 2,86,Actual,"CytoDyn, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:06:29Z,2020-11-01T12:06:29Z
NCT04342182,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-31,NA,NA,2020-05-15,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-05-15,2020-05-18,Actual,"April 8, 2020",Actual,2020-04-08,May 2020,2020-05-31,"July 1, 2020",Anticipated,2020-07-01,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,ConCoVid-19,,Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study),Convalescent Plasma Therapy From Recovered Covid-19 Patients as Therapy for Hospitalized Patients With Covid-19,Recruiting,NA,Phase 2/Phase 3,426,Anticipated,Erasmus Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:06:40Z,2020-11-01T12:06:40Z
NCT04336332,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-31,NA,NA,2020-05-06,2020-04-02,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-08,Actual,"April 1, 2020",Actual,2020-04-01,May 2020,2020-05-31,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,Recruiting,NA,Phase 2,160,Anticipated,"Rutgers, The State University of New Jersey",,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:07:30Z,2020-11-01T12:07:30Z
NCT04335305,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-31,NA,NA,2020-10-06,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"April 9, 2020",Actual,2020-04-09,October 2020,2020-10-31,"June 30, 2021",Anticipated,2021-06-30,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,COPERNICO,,Checkpoint Blockade in COVID-19 Pandemic,"A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined With Pembrolizumab (MK-3475) in Patients With Coronavirus Disease 2019 (COVID-19)-Pneumonia",Recruiting,NA,Phase 2,24,Anticipated,MedSIR,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:07:36Z,2020-11-01T12:07:36Z
NCT04334980,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-31,NA,NA,2020-10-24,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-10-24,2020-10-27,Actual,October 2020,Anticipated,2020-10-31,September 2020,2020-09-30,"February 28, 2022",Anticipated,2022-02-28,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NA,,"Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19","A Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Immunogenicity of the bacTRL-Spike Oral Candidate Vaccine for the Prevention of COVID-19 in Healthy Adults",Recruiting,NA,Phase 1,12,Anticipated,Symvivo Corporation,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:07:38Z,2020-11-01T12:07:38Z
NCT04333732,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-31,NA,NA,2020-09-07,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-09-07,2020-09-09,Actual,"September 4, 2020",Actual,2020-09-04,September 2020,2020-09-30,August 2021,Anticipated,2021-08-31,August 2021,Anticipated,2021-08-31,NA,Interventional,CROWN CORONA,,CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION,"An International, Multi-site, Bayesian Platform Adaptive, Randomized, Placebo-controlled Trial Assessing the Effectiveness of Candidate Agents in Mitigating COVID-19 Disease in Healthcare Workers",Recruiting,NA,Phase 3,30000,Anticipated,Washington University School of Medicine,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,From 3 months after the last patient last visit onward.,Investigators whose proposed use of the data has been approved by a review committee identified for this purpose.,NA,Yes,"Individual participant data that underlie the results reported in the main publication may be shared, after de-identification.",2020-11-01T12:07:50Z,2020-11-01T12:07:50Z
NCT04333355,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-31,NA,NA,2020-07-27,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-07-27,2020-07-28,Actual,"May 8, 2020",Actual,2020-05-08,July 2020,2020-07-31,"April 30, 2021",Anticipated,2021-04-30,"December 20, 2020",Anticipated,2020-12-20,NA,Interventional,NA,,Safety in Convalescent Plasma Transfusion to COVID-19,Phase 1 Study to Evaluate the Safety of Convalescent Plasma as an Adjuvant Therapy in Patients With SARS-CoV-2 Infection,Recruiting,NA,Phase 1,20,Anticipated,Hospital San Jose Tec de Monterrey,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:07:54Z,2020-11-01T12:07:54Z
NCT04332991,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-31,NA,NA,2020-09-01,2020-03-31,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-09-01,2020-09-02,Actual,"April 2, 2020",Actual,2020-04-02,September 2020,2020-09-30,"July 23, 2020",Actual,2020-07-23,"June 19, 2020",Actual,2020-06-19,NA,Interventional,ORCHID,,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Completed,NA,Phase 3,479,Actual,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:07:58Z,2020-11-01T12:07:58Z
NCT04332835,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-31,NA,NA,2020-08-31,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-02,Actual,"August 8, 2020",Actual,2020-08-08,August 2020,2020-08-31,"October 31, 2020",Anticipated,2020-10-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,CP-COVID-19,,"Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study","Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study",Recruiting,NA,Phase 2/Phase 3,90,Anticipated,Universidad del Rosario,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:07:59Z,2020-11-01T12:07:59Z
NCT04332094,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-31,NA,NA,2020-04-05,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-05,2020-04-07,Actual,"April 2, 2020",Actual,2020-04-02,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,September 2020,Anticipated,2020-09-30,NA,Interventional,TOCOVID,,"Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19","Pilot, Randomized, Multicenter, Open-label Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of SARS-CoV-2 Infection (COVID-19)",Recruiting,NA,Phase 2,276,Anticipated,FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:08:08Z,2020-11-01T12:08:08Z
NCT04331808,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-31,NA,NA,2020-04-26,2020-03-31,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-04-26,2020-04-28,Actual,"March 30, 2020",Actual,2020-03-30,March 2020,2020-03-31,"December 31, 2021",Anticipated,2021-12-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,CORIMUNO-TOC,,CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI),"Active, not recruiting",NA,Phase 2,228,Actual,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:08:09Z,2020-11-01T12:08:09Z
NCT04331366,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-31,NA,NA,2020-10-13,2020-03-31,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-19,Actual,"April 8, 2020",Actual,2020-04-08,October 2020,2020-10-31,"August 31, 2020",Actual,2020-08-31,"August 31, 2020",Actual,2020-08-31,NA,Interventional,GO2 PEEP,,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,GO2 PEEP Study: The Use of a Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Completed,NA,N/A,2,Actual,Emory University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:08:14Z,2020-11-01T12:08:14Z
NCT04330586,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-31,NA,NA,2020-09-14,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-09-14,2020-09-16,Actual,"April 1, 2020",Actual,2020-04-01,September 2020,2020-09-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19,A Trial of Ciclesonide to Assess The Antiviral Effect for Adults With Mild-to-moderate COVID-19,Recruiting,NA,Phase 2,94,Anticipated,Korea University Guro Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:08:23Z,2020-11-01T12:08:23Z
NCT04329650,"ClinicalTrials.gov processed this data on October 30, 2020",2020-03-31,NA,NA,2020-04-16,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Actual,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,"May 20, 2020",Anticipated,2020-05-20,"May 20, 2020",Anticipated,2020-05-20,NA,Interventional,NA,,Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia,"Phase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia",Recruiting,NA,Phase 2,200,Anticipated,Fundacion Clinic per a la Recerca BiomÃ©dica,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:08:29Z,2020-11-01T12:08:29Z
NCT04376515,"ClinicalTrials.gov processed this data on November 06, 2020",2020-03-31,NA,NA,2020-11-02,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"March 20, 2020",Actual,2020-03-20,November 2020,2020-11-30,"September 1, 2021",Anticipated,2021-09-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,,Harnessing Online Peer Education Online Support Intervention for COVID-19 (HOPE COVID-19),HOPE Intervention for COVID-19,"Active, not recruiting",NA,N/A,300,Actual,"University of California, Irvine",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-07T11:24:24Z,2020-11-07T11:24:24Z
NCT04335123,"ClinicalTrials.gov processed this data on November 06, 2020",2020-03-31,NA,NA,2020-11-02,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"April 4, 2020",Actual,2020-04-04,November 2020,2020-11-30,"August 17, 2020",Actual,2020-08-17,"June 21, 2020",Actual,2020-06-21,NA,Interventional,NA,,Study of Open Label Losartan in COVID-19,An Open Label Phase 1 Trial of Losartan for Worsening Respiratory Illness in COVID-19,Completed,NA,Phase 1,34,Actual,University of Kansas Medical Center,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-07T11:25:43Z,2020-11-07T11:25:43Z
NCT04330638,"ClinicalTrials.gov processed this data on November 06, 2020",2020-03-31,NA,NA,2020-11-03,2020-03-31,2020-04-01,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-04,Actual,"April 3, 2020",Actual,2020-04-03,November 2020,2020-11-30,March 2021,Anticipated,2021-03-31,February 2021,Anticipated,2021-02-28,NA,Interventional,COV-AID,,Treatment of COVID-19 Patients With Anti-interleukin Drugs,"A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome",Recruiting,NA,Phase 3,342,Anticipated,"University Hospital, Ghent",,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-08T11:36:33Z,2020-11-08T11:36:33Z
NCT04339712,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-01,NA,NA,2020-04-21,2020-04-06,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-22,Actual,"April 2, 2020",Actual,2020-04-02,April 2020,2020-04-30,"April 1, 2022",Anticipated,2022-04-01,"April 1, 2022",Anticipated,2022-04-01,NA,Interventional,ESCAPE,,Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Efficiency in Management of Organ Dysfunction Associated With Infection by the Novel SARS-CoV-2 Virus (COVID-19) Through a Personalized Immunotherapy Approach: the ESCAPE Clinical Trial,Recruiting,NA,Phase 2,40,Anticipated,Hellenic Institute for the Study of Sepsis,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:07:04Z,2020-11-01T12:07:04Z
NCT04338009,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-01,NA,NA,2020-04-22,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"March 31, 2020",Actual,2020-03-31,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,REPLACECOVID,,Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019,The Randomized Elimination or Prolongation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Coronavirus Disease 2019,Enrolling by invitation,NA,N/A,152,Anticipated,University of Pennsylvania,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Not making it available,2020-11-01T12:07:17Z,2020-11-01T12:07:17Z
NCT04337996,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-01,NA,NA,2020-09-22,2020-04-03,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-25,Actual,"July 13, 2020",Actual,2020-07-13,September 2020,2020-09-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,TRODVID-19,,Dynamic Evaluation of COVID-19 Diagnostic Tests,Dynamic Evaluation of COVID-19 Diagnostic Tests,Recruiting,NA,N/A,165,Anticipated,Tourcoing Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:07:17Z,2020-11-01T12:07:17Z
NCT04335279,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-01,NA,NA,2020-08-31,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-01,Actual,"April 9, 2020",Actual,2020-04-09,August 2020,2020-08-31,"July 24, 2020",Actual,2020-07-24,"June 3, 2020",Actual,2020-06-03,NA,Interventional,SPIN-CHAT,,Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program,A Partially Nested RCT to Evaluate the Effectiveness of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Program to Reduce Anxiety Among At-Risk Scleroderma Patients,Completed,NA,N/A,172,Actual,Lady Davis Institute,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,12 months after the collection of the primary outcome,Approval of proposed purpose for data access,NA,Yes,Upon request,2020-11-01T12:07:36Z,2020-11-01T12:07:36Z
NCT04335136,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-01,NA,NA,2020-10-05,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-06,Actual,"April 30, 2020",Actual,2020-04-30,May 2020,2020-05-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,APN01-COVID-19,,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Recruiting,NA,Phase 2,200,Anticipated,Apeiron Biologics,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:07:37Z,2020-11-01T12:07:37Z
NCT04335097,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-01,NA,NA,2020-05-11,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-13,Actual,"April 22, 2020",Actual,2020-04-22,May 2020,2020-05-31,"December 20, 2025",Anticipated,2025-12-20,"April 8, 2021",Anticipated,2021-04-08,NA,Interventional,HSC19,,Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation,"Sensor Based Vital Signs Monitoring of Patients With Clinical Manifestation of Covid 19 Disease During Home Isolation, a Randomized Feasibility Study",Recruiting,NA,N/A,214,Anticipated,Oslo University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:07:38Z,2020-11-01T12:07:38Z
NCT04334265,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-01,NA,NA,2020-04-22,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"December 1, 2020",Anticipated,2020-12-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019,"Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019-A Multicenter, Open, Randomized Controlled Study",Recruiting,NA,N/A,750,Anticipated,Peking University First Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:07:46Z,2020-11-01T12:07:46Z
NCT04334044,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-01,NA,NA,2020-04-16,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Actual,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,"June 1, 2020",Anticipated,2020-06-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,Treatment of SARS Caused by COVID-19 With Ruxolitinib,Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19 With Ruxolitinib,Recruiting,NA,Phase 1/Phase 2,20,Anticipated,Grupo Cooperativo de HemopatÃ­as Malignas,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:07:48Z,2020-11-01T12:07:48Z
NCT04333654,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-01,NA,NA,2020-07-10,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-07-10,2020-07-14,Actual,"April 12, 2020",Actual,2020-04-12,July 2020,2020-07-31,"May 26, 2020",Actual,2020-05-26,"May 26, 2020",Actual,2020-05-26,NA,Interventional,NA,,Hydroxychloroquine in Outpatient Adults With COVID-19,"A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study of Hydroxychloroquine in Outpatient Adults With COVID-19",Terminated,NA,Phase 1,8,Actual,Sanofi,,2,NA,Rate of enrollment too slow to allow completion in a reasonable timeframe,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2020-11-01T12:07:51Z,2020-11-01T12:07:51Z
NCT04333628,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-01,NA,NA,2020-10-13,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-14,Actual,"June 1, 2020",Actual,2020-06-01,October 2020,2020-10-31,"September 1, 2020",Actual,2020-09-01,"September 1, 2020",Actual,2020-09-01,NA,Interventional,NA,,Chloroquine for Mild Symptomatic and Asymptomatic COVID-19,"Chloroquine for Mild Symptomatic and Asymptomatic COVID-19 in A Two Staged, Multicenter, Open Label and Randomized Trial",Terminated,NA,Phase 2/Phase 3,5,Actual,"HaEmek Medical Center, Israel",,3,NA,Teminated due to changes in treatment guidelines .,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:07:51Z,2020-11-01T12:07:51Z
NCT04333589,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-01,NA,NA,2020-04-22,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"September 15, 2020",Anticipated,2020-09-15,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,NA,,Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive,"The Mechanism, Clinical Outcome and Therapeutic Intervention of Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive",Recruiting,NA,N/A,210,Anticipated,Peking University First Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:07:52Z,2020-11-01T12:07:52Z
NCT04333550,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-01,NA,NA,2020-04-30,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-04,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,March 2021,Anticipated,2021-03-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Application of Desferal to Treat COVID-19,Application of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 Manifestations,Recruiting,NA,Phase 1/Phase 2,50,Anticipated,Kermanshah University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:07:52Z,2020-11-01T12:07:52Z
NCT04333407,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-01,NA,NA,2020-04-08,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-09,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,"March 30, 2021",Anticipated,2021-03-30,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,C-19-ACS,,Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.,Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.,Recruiting,NA,N/A,3170,Anticipated,Imperial College London,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No individual participant data will be shared with other researchers or organisations. Anonymised data might be shared with other research organisations,2020-11-01T12:07:53Z,2020-11-01T12:07:53Z
NCT04333225,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-01,NA,NA,2020-05-04,2020-04-02,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-05-04,2020-05-05,Actual,"April 3, 2020",Actual,2020-04-03,May 2020,2020-05-31,"July 30, 2020",Anticipated,2020-07-30,"July 30, 2020",Anticipated,2020-07-30,NA,Interventional,NA,,Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers,A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk Exposures,"Active, not recruiting",NA,Phase 2,228,Actual,Baylor Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:07:56Z,2020-11-01T12:07:56Z
NCT04331795,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-01,NA,NA,2020-07-30,2020-04-01,2020-04-02,Actual,NA,NA,NA,NA,NA,NA,2020-07-30,2020-08-03,Actual,"April 4, 2020",Actual,2020-04-04,June 2020,2020-06-30,"June 5, 2020",Actual,2020-06-05,"June 5, 2020",Actual,2020-06-05,NA,Interventional,COVIDOSE,,"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",Early Institution of Tocilizumab Titration in Non-Critical Hospitalized COVID-19 Pneumonitis,Completed,NA,Phase 2,32,Actual,University of Chicago,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:08:09Z,2020-11-01T12:08:09Z
NCT04333420,"ClinicalTrials.gov processed this data on November 06, 2020",2020-04-01,NA,NA,2020-11-02,2020-04-01,2020-04-03,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"March 31, 2020",Actual,2020-03-31,September 2020,2020-09-30,"August 31, 2021",Anticipated,2021-08-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,PANAMO,,"Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia","A Pragmatic Adaptive Randomized, Controlled Phase II/III Multicenter Study of IFX-1 in Patients With Severe COVID-19 Pneumonia",Recruiting,NA,Phase 2/Phase 3,390,Anticipated,InflaRx GmbH,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-07T11:25:46Z,2020-11-07T11:25:46Z
NCT04347226,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-02,NA,NA,2020-10-06,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"April 16, 2020",Actual,2020-04-16,October 2020,2020-10-31,September 2022,Anticipated,2022-09-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,,Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19,A Randomized Phase 2 Study of Anti-IL-8 Therapy Versus Standard of Care in the Treatment of Hospitalized Patients With Severe COVID-19,Recruiting,NA,Phase 2,138,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:06:03Z,2020-11-01T12:06:03Z
NCT04345523,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-02,NA,NA,2020-04-14,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-15,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,ConPlas-19,,Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients,"Multi-center, Randomized Clinical Trial of Convalescent Plasma Therapy Versus Standard of Care for the Treatment of COVID-19 in Hospitalized Patients",Recruiting,NA,Phase 2,278,Anticipated,Puerta de Hierro University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:15Z,2020-11-01T12:06:15Z
NCT04340349,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-02,NA,NA,2020-05-11,2020-04-08,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-13,Actual,"May 11, 2020",Actual,2020-05-11,May 2020,2020-05-31,"August 20, 2020",Anticipated,2020-08-20,"July 20, 2020",Anticipated,2020-07-20,NA,Interventional,ELEVATE,,Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals,Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial),Enrolling by invitation,NA,Early Phase 1,140,Anticipated,Instituto Nacional de Rehabilitacion,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,"Under Mexican Law, we are not able to provide IPD",2020-11-01T12:06:52Z,2020-11-01T12:06:52Z
NCT04339660,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-02,NA,NA,2020-04-05,2020-04-05,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-04-05,2020-04-09,Actual,"February 1, 2020",Actual,2020-02-01,April 2020,2020-04-30,"June 30, 2020",Anticipated,2020-06-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia,Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia,Recruiting,NA,Phase 1/Phase 2,30,Anticipated,Puren Hospital Affiliated to Wuhan University of Science and Technology,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:07:05Z,2020-11-01T12:07:05Z
NCT04337541,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-02,NA,NA,2020-07-29,2020-04-05,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-08-03,Actual,"April 2, 2020",Actual,2020-04-02,July 2020,2020-07-31,"June 2, 2020",Actual,2020-06-02,"June 2, 2020",Actual,2020-06-02,NA,Interventional,NA,,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Completed,NA,N/A,6000,Actual,"Rigshospitalet, Denmark",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:07:21Z,2020-11-01T12:07:21Z
NCT04335851,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-02,NA,NA,2020-06-04,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-09,Actual,"April 6, 2020",Actual,2020-04-06,June 2020,2020-06-30,"June 3, 2020",Actual,2020-06-03,"May 15, 2020",Actual,2020-05-15,NA,Interventional,NA,,Video-Based Exercises and Well-Being During Social Isolation,Effectiveness of Video-Based Exercises on Physical and Emotional Well-Being During COVID-19 Induced Social Isolation,Completed,NA,N/A,68,Actual,Biruni University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:07:33Z,2020-11-01T12:07:33Z
NCT04335786,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-02,NA,NA,2020-06-08,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-09,Actual,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,December 2021,Anticipated,2021-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease,"PRAETORIAN-COVID: A Double-blind, Placebo-controlled Randomized Clinical Trial With Valsartan for PRevention of Acute rEspiraTORy dIstress Syndrome in hospitAlized patieNts With SARS-COV-2 (COVID-19) Infection Disease",Recruiting,NA,Phase 4,651,Anticipated,Radboud University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:07:33Z,2020-11-01T12:07:33Z
NCT04335084,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-02,NA,NA,2020-07-16,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-20,Actual,"June 22, 2020",Actual,2020-06-22,July 2020,2020-07-31,September 2021,Anticipated,2021-09-30,June 2021,Anticipated,2021-06-30,NA,Interventional,HELPCOVID-19,,"A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection","A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection",Recruiting,NA,Phase 2,600,Anticipated,ProgenaBiome,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:07:38Z,2020-11-01T12:07:38Z
NCT04335071,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-02,NA,NA,2020-10-12,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-10-12,2020-10-14,Actual,"April 26, 2020",Actual,2020-04-26,October 2020,2020-10-31,"September 27, 2020",Actual,2020-09-27,"September 27, 2020",Actual,2020-09-27,NA,Interventional,CORON-ACT,,Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),"CORON-ACT - a Multicenter, Double-blind, Randomized Controlled Phase II Trial on the Efficacy and Safety of Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)",Terminated,NA,Phase 2,5,Actual,"University Hospital Inselspital, Berne",,2,NA,"1.) Not possible to recruit the planned number of patients during the planned study period; 2.)
    ""Dexamethason"" was included in the standard of care for the study population during the course
    of the study and inclusion criteria could no longer be met.",FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:07:38Z,2020-11-01T12:07:38Z
NCT04334928,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-02,NA,NA,2020-08-24,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-08-24,2020-08-25,Actual,"April 15, 2020",Actual,2020-04-15,August 2020,2020-08-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,EPICOS,,Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel,Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo,Recruiting,NA,Phase 3,4000,Anticipated,Plan Nacional sobre el Sida (PNS),,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:07:41Z,2020-11-01T12:07:41Z
NCT04334850,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-02,NA,NA,2020-05-25,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-25,2020-05-27,Actual,"April 20, 2020",Actual,2020-04-20,May 2020,2020-05-31,August 2020,Anticipated,2020-08-31,July 2020,Anticipated,2020-07-31,NA,Interventional,MultiCov,,Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia,"Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia : a Multicenter, Parallel-group, Open-label, Randomized Controlled Trial",Recruiting,NA,N/A,194,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:07:42Z,2020-11-01T12:07:42Z
NCT04334629,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-02,NA,NA,2020-10-22,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-10-22,2020-10-23,Actual,"May 26, 2020",Actual,2020-05-26,May 2020,2020-05-31,"September 25, 2021",Anticipated,2021-09-25,"May 25, 2021",Anticipated,2021-05-25,NA,Interventional,LIBERATE,,LIBERATE Trial in COVID-19,"Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial",Recruiting,NA,Phase 4,230,Anticipated,King's College London,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:07:44Z,2020-11-01T12:07:44Z
NCT04334512,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-02,NA,NA,2020-07-16,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-20,Actual,"June 22, 2020",Actual,2020-06-22,July 2020,2020-07-31,September 2021,Anticipated,2021-09-30,June 2021,Anticipated,2021-06-30,NA,Interventional,HAZDpaC,,A Study of Quintuple Therapy to Treat COVID-19 Infection,"A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of Quintuple Therapy to Treat COVID-19 Infection",Recruiting,NA,Phase 2,600,Anticipated,ProgenaBiome,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:07:44Z,2020-11-01T12:07:44Z
NCT04334382,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-02,NA,NA,2020-04-07,2020-04-02,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-09,Actual,"April 2, 2020",Actual,2020-04-02,April 2020,2020-04-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,HyAzOUT,,Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19,Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 (HyAzOUT): A Prospective Pragmatic Trial,Recruiting,NA,Phase 3,1550,Anticipated,"Intermountain Health Care, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"In order to protect patient privacy and comply with relevant regulations, identified data are unavailable. Requests for deidentified data from qualified researchers with appropriate ethics board approvals and relevant data use agreements will be processed by the Intermountain Office of Research, officeofresearch@imail.org.",2020-11-01T12:07:45Z,2020-11-01T12:07:45Z
NCT04334460,"ClinicalTrials.gov processed this data on November 02, 2020",2020-04-02,NA,NA,2020-10-29,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-10-30,Actual,"May 4, 2020",Actual,2020-05-04,July 2020,2020-07-31,"November 30, 2020",Anticipated,2020-11-30,"October 9, 2020",Actual,2020-10-09,NA,Interventional,NA,,Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,"Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Antiviral Activity of BLD-2660 in Hospitalized Subjects With Recently Diagnosed COVID-19 Compared to Standard of Care Treatment","Active, not recruiting",NA,Phase 2,120,Actual,Blade Therapeutics,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-03T10:52:27Z,2020-11-03T10:52:27Z
NCT04348409,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-03,NA,NA,2020-06-08,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-09,Actual,"May 25, 2020",Actual,2020-05-25,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,NA,,Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19,"Proof of Concept, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Safety and Efficacy of Nitazoxanide 600 mg Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Moderate Condition.",Recruiting,NA,N/A,50,Anticipated,Azidus Brasil,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"It is believed that after the data analysis and presentation to the National Commission on Research Ethics, all data of the study will become public.",2020-11-01T12:05:53Z,2020-11-01T12:05:53Z
NCT04343053,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-03,NA,NA,2020-06-09,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-06-09,2020-06-11,Actual,"April 8, 2020",Actual,2020-04-08,June 2020,2020-06-30,"June 9, 2021",Anticipated,2021-06-09,"June 9, 2020",Actual,2020-06-09,NA,Interventional,ATTAC-Co,,Pro-thrombotic Status in Patients With SARS-Cov-2 Infection,"Patterns and Changes in Platelet Reactivity, Thrombotic Status and Endothelial Function in Hospitalized Patients With SARS-Cov-2 Infection","Active, not recruiting",NA,N/A,54,Actual,University Hospital of Ferrara,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,After specific request to study PIs,2020-11-01T12:06:34Z,2020-11-01T12:06:34Z
NCT04337008,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-03,NA,NA,2020-04-21,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"June 3, 2020",Anticipated,2020-06-03,NA,Interventional,SRA-COV,,Renin Angiotensin System - CoronaVirus,Renin Angiotensin System - CoronaVirus,Recruiting,NA,N/A,50,Anticipated,Assistance Publique Hopitaux De Marseille,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:07:24Z,2020-11-01T12:07:24Z
NCT04336904,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-03,NA,NA,2020-04-07,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-04-07,2020-04-08,Actual,"March 25, 2020",Actual,2020-03-25,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Patients With COVID-19-Moderate Type","Active, not recruiting",NA,Phase 3,100,Anticipated,ASST Fatebenefratelli Sacco,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:07:25Z,2020-11-01T12:07:25Z
NCT04336410,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-03,NA,NA,2020-09-18,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-09-18,2020-09-21,Actual,"April 3, 2020",Actual,2020-04-03,September 2020,2020-09-30,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Interventional,NA,,"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers","Active, not recruiting",NA,Phase 1,120,Actual,Inovio Pharmaceuticals,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,TRUE,NA,NA,NA,,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 10 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.,2020-11-01T12:07:28Z,2020-11-01T12:07:28Z
NCT04335552,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-03,NA,NA,2020-07-29,2020-04-03,2020-04-06,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-07-31,Actual,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,"June 26, 2020",Actual,2020-06-26,"June 17, 2020",Actual,2020-06-17,NA,Interventional,NA,,"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection","Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",Terminated,NA,Phase 2,11,Actual,Duke University,,4,NA,"Poor recruitment, strong evidence from larger trials of no therapeutic benefit",FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:07:35Z,2020-11-01T12:07:35Z
NCT04340544,"ClinicalTrials.gov processed this data on November 05, 2020",2020-04-03,NA,NA,2020-10-29,2020-04-08,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-11-02,Actual,"April 22, 2020",Actual,2020-04-22,April 2020,2020-04-30,"October 12, 2020",Actual,2020-10-12,"October 12, 2020",Actual,2020-10-12,NA,Interventional,COMIHY,,Hydroxychloroquine for the Treatment of Mild COVID-19 Disease,Hydroxychloroquine for the Treatment of Mild COVID-19 Disease,Terminated,NA,Phase 2,17,Actual,University Hospital Tuebingen,,2,NA,"It appeared to be impossible for the study centres to recruit the targeted number of patients,
    due to reduced incidence and reduced acceptance to IMP",FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-06T12:47:16Z,2020-11-06T12:47:16Z
NCT04342650,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-04,NA,NA,2020-07-02,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-07-02,2020-07-07,Actual,"April 8, 2020",Actual,2020-04-08,July 2020,2020-07-31,"June 8, 2020",Actual,2020-06-08,"May 14, 2020",Actual,2020-05-14,NA,Interventional,CloroCOVID19II,,Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection,"Phase IIb Study to Evaluate the Efficacy and Safety of Chloroquine Diphosphate in the Treatment of Patients With Comorbidities, Without Severe Acute Respiratory Syndrome, Under the New Coronavirus (SARS-CoV2): a Double-blind, Randomized, Placebo-controlled Clinical Trial",Completed,NA,Phase 2,152,Actual,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,after study publication,Upon formal request to researchers.,NA,Yes,all patient data will be shared after study publication,2020-11-01T12:06:37Z,2020-11-01T12:06:37Z
NCT04338698,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-04,NA,NA,2020-07-12,2020-04-04,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-07-12,2020-07-15,Actual,"April 22, 2020",Actual,2020-04-22,July 2020,2020-07-31,"November 30, 2020",Anticipated,2020-11-30,"September 1, 2020",Anticipated,2020-09-01,NA,Interventional,PROTECT,,"Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT",Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment,Recruiting,NA,Phase 3,500,Anticipated,University of Health Sciences Lahore,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"On completion of study, investigators are open to participation in planned IPD projects with a prospective registration, subject to appropriate approvals",2020-11-01T12:07:12Z,2020-11-01T12:07:12Z
NCT04338568,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-04,NA,NA,2020-08-14,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-08-14,2020-08-17,Actual,"April 16, 2020",Actual,2020-04-16,August 2020,2020-08-31,"December 30, 2020",Anticipated,2020-12-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,SCOUT,,Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study,Accuracy and Inter-observer Variability of Lung Ultrasound in COVID-19 Pneumonia,Recruiting,NA,N/A,50,Anticipated,Hasselt University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,no plan,2020-11-01T12:07:13Z,2020-11-01T12:07:13Z
NCT04341116,"ClinicalTrials.gov processed this data on November 05, 2020",2020-04-04,NA,NA,2020-10-29,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-11-02,Actual,"April 11, 2020",Actual,2020-04-11,October 2020,2020-10-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,,Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19),"A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,Phase 2/Phase 3,384,Anticipated,I-Mab Biopharma Co. Ltd.,,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-06T12:47:12Z,2020-11-06T12:47:12Z
NCT04345861,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-05,NA,NA,2020-06-08,2020-04-09,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-11,Actual,"April 11, 2020",Actual,2020-04-11,June 2020,2020-06-30,"June 8, 2020",Actual,2020-06-08,"June 8, 2020",Actual,2020-06-08,NA,Interventional,COVIDOC,,Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial),Randomized Trial Assessing Efficacy and Safety of Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for Hospitalized Adults With COVID-19 Pneumonia,Terminated,NA,Phase 2/Phase 3,7,Actual,"University Hospital, Montpellier",,2,NA,halted prematurely.,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:12Z,2020-11-01T12:06:12Z
NCT04341675,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-05,NA,NA,2020-05-18,2020-04-08,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-20,Actual,"April 24, 2020",Actual,2020-04-24,May 2020,2020-05-31,September 2020,Anticipated,2020-09-30,July 2020,Anticipated,2020-07-31,NA,Interventional,SCOPE,,Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia,Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia (The SCOPE Trial),Recruiting,NA,Phase 2,30,Anticipated,University of Cincinnati,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,De-identified aggregate data will be made available to other researchers on a case-by-case basis.,2020-11-01T12:06:43Z,2020-11-01T12:06:43Z
NCT04338841,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-05,NA,NA,2020-09-22,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-23,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"June 17, 2020",Actual,2020-06-17,"June 17, 2020",Actual,2020-06-17,NA,Interventional,HOME-CoV,,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With Confirmed or Probable SARS-CoV-2 Infection. A Before and After Implementation of a Consensus Help-decision Making Rule Study,Completed,NA,N/A,3133,Actual,"University Hospital, Angers",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:07:11Z,2020-11-01T12:07:11Z
NCT04338828,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-05,NA,NA,2020-05-18,2020-04-05,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-20,Actual,"April 18, 2020",Actual,2020-04-18,May 2020,2020-05-31,April 2022,Anticipated,2022-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NO COV-ED,,Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED,Nitric Oxide Inhalation Therapy for COVID-19 Infections in the Emergency Department,Recruiting,NA,Phase 2,260,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:07:11Z,2020-11-01T12:07:11Z
NCT04343092,"ClinicalTrials.gov processed this data on November 06, 2020",2020-04-05,2020-06-11,NA,2020-11-02,2020-04-08,2020-04-13,Actual,2020-11-02,2020-11-04,Actual,NA,NA,NA,2020-11-02,2020-11-04,Actual,"April 18, 2020",Actual,2020-04-18,November 2020,2020-11-30,"June 1, 2020",Actual,2020-06-01,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (An Externally Controlled Pilot Trial),Completed,NA,Phase 1,16,Actual,University of Baghdad,"small sample size; single center design, and short time for the study",1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-08T11:36:16Z,2020-11-08T11:36:16Z
NCT04349631,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-06,NA,NA,2020-10-21,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-23,Actual,"April 22, 2020",Actual,2020-04-22,October 2020,2020-10-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19,"A Phase II, Open Label, Single-Center, Clinical Trial to Assess Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus Disease","Active, not recruiting",NA,Phase 2,56,Anticipated,Hope Biosciences,,1,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:43Z,2020-11-01T12:05:43Z
NCT04346797,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-06,NA,NA,2020-04-23,2020-04-10,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-27,Actual,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,CORIMUNO19-ECU,,"CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort","CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort",Recruiting,NA,Phase 2,120,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:06:06Z,2020-11-01T12:06:06Z
NCT04344951,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-06,NA,NA,2020-05-29,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"April 6, 2020",Actual,2020-04-06,May 2020,2020-05-31,"April 30, 2021",Anticipated,2021-04-30,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,HOPE,,"Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial","Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial",Recruiting,NA,Phase 2,60,Anticipated,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:06:19Z,2020-11-01T12:06:19Z
NCT04340557,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-06,NA,NA,2020-05-29,2020-04-08,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"March 27, 2020",Actual,2020-03-27,May 2020,2020-05-31,"December 31, 2020",Anticipated,2020-12-31,"October 6, 2020",Anticipated,2020-10-06,NA,Interventional,NA,,Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection,Randomized Open Label Study of Standard of Care Plus an Angiotensin II Receptor Blocker Compared to Standard of Care Alone to Minimize the Progression to Respiratory Failure in SARS-CoV-2 Infection,Recruiting,NA,Phase 4,200,Anticipated,Sharp HealthCare,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:50Z,2020-11-01T12:06:50Z
NCT04338074,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-06,NA,NA,2020-06-10,2020-04-06,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-06-10,2020-06-12,Actual,"June 1, 2020",Actual,2020-06-01,June 2020,2020-06-30,"December 31, 2020",Anticipated,2020-12-31,"December 15, 2020",Anticipated,2020-12-15,NA,Interventional,TCOutpatient,,TXA and Corona Virus 2019 (COVID19) in Outpatients,Exploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in Outpatients,Recruiting,NA,Phase 2,100,Anticipated,University of Alabama at Birmingham,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:07:16Z,2020-11-01T12:07:16Z
NCT04337918,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-06,NA,NA,2020-06-23,2020-04-06,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-06-23,2020-06-25,Actual,"May 8, 2020",Actual,2020-05-08,June 2020,2020-06-30,"September 30, 2020",Anticipated,2020-09-30,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,NOCOVID,,Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection,"Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection",Recruiting,NA,Phase 2,200,Anticipated,Sanotize Research and Development corp.,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:07:17Z,2020-11-01T12:07:17Z
NCT04339816,"ClinicalTrials.gov processed this data on November 09, 2020",2020-04-06,NA,NA,2020-11-05,2020-04-06,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-05,2020-11-06,Actual,"May 13, 2020",Actual,2020-05-13,November 2020,2020-11-30,"November 4, 2020",Actual,2020-11-04,"November 4, 2020",Actual,2020-11-04,NA,Interventional,AZIQUINE-ICU,,Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial,Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled Trial,Terminated,NA,Phase 3,3,Actual,"Charles University, Czech Republic",,3,NA,Steering Committee decision in accordance with stopping rule 1: Emergence of new data,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,within 6 months of study completion,NA,http://mendeley.com,Yes,Deidentified record-level data will be shared in a public database,2020-11-10T11:28:47Z,2020-11-10T11:28:47Z
NCT04384380,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-07,NA,NA,2020-07-31,2020-05-10,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-07-31,2020-08-04,Actual,"April 1, 2020",Actual,2020-04-01,March 2020,2020-03-31,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,,Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19,"A Multi-center, Randomized, Open-label, Controlled Trial to Evaluate the Efficacy and Tolerability of Hydroxychloroquine (HCQ) in Adult Patients With Mild to Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment",Completed,NA,N/A,33,Actual,Taoyuan General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,The study outcome will be shared with the experts and persons interested in this field.,2020-11-01T12:01:18Z,2020-11-01T12:01:18Z
NCT04364893,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-07,NA,NA,2020-07-01,2020-04-25,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-07-01,2020-07-02,Actual,"April 9, 2020",Actual,2020-04-09,July 2020,2020-07-31,"December 1, 2020",Anticipated,2020-12-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,BRACE-CORONA,,Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19,Suspension of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Hospitalized Patients With Coronavirus Infection (COVID-19). A Randomized Trial,Recruiting,NA,N/A,700,Anticipated,D'Or Institute for Research and Education,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:03:45Z,2020-11-01T12:03:45Z
NCT04353674,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-07,NA,NA,2020-09-16,2020-04-16,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-09-16,2020-09-18,Actual,"April 28, 2020",Actual,2020-04-28,September 2020,2020-09-30,January 2021,Anticipated,2021-01-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Modulation of Hyperinflammation in COVID-19,Novel Extracorporeal Treatment to Modulate Hyperinflammation in COVID-19 Patients,Recruiting,NA,N/A,40,Anticipated,Lawson Health Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:12Z,2020-11-01T12:05:12Z
NCT04352933,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-07,NA,NA,2020-05-11,2020-04-15,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-13,Actual,"May 11, 2020",Actual,2020-05-11,May 2020,2020-05-31,April 2021,Anticipated,2021-04-30,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,NA,,PROLIFIC ChemoprophylaxisTrial (COVID-19),ChemoPROphyLaxIs For covId-19 Infectious Disease (the PROLIFIC Trial),Recruiting,NA,Phase 3,1000,Anticipated,Cambridge University Hospitals NHS Foundation Trust,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:17Z,2020-11-01T12:05:17Z
NCT04347031,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-07,NA,NA,2020-05-22,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-27,Actual,"April 8, 2020",Actual,2020-04-08,May 2020,2020-05-31,"August 1, 2020",Anticipated,2020-08-01,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,NA,,A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,"An Open Randomized Study of the Effectiveness of the Drug Mefloquine, Tablets 250 mg, Produced by FSUE SPC ""Farmzashita"" of the Federal Medical Biological Agency, FMBA of Russia (Russia) for the Treatment of Patients With COVID19","Active, not recruiting",NA,Phase 2/Phase 3,320,Actual,Burnasyan Federal Medical Biophysical Center,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:06:05Z,2020-11-01T12:06:05Z
NCT04345848,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-07,NA,NA,2020-09-18,2020-04-09,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-09-18,2020-09-22,Actual,"April 28, 2020",Actual,2020-04-28,April 2020,2020-04-30,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,COVID-HEP,,Preventing COVID-19 Complications With Low- and High-dose Anticoagulation,"Preventing COVID-19-associated Thrombosis, Coagulopathy and Mortality With Low- and High-dose Anticoagulation: a Multicentric Randomized, Open-label Clinical Trial",Recruiting,NA,Phase 3,200,Anticipated,"University Hospital, Geneva",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:06:13Z,2020-11-01T12:06:13Z
NCT04345614,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-07,NA,NA,2020-10-13,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-14,Actual,"April 8, 2020",Actual,2020-04-08,July 2020,2020-07-31,April 2021,Anticipated,2021-04-30,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,,A Study of Auxora in Patients With Severe COVID-19 Pneumonia,"A Randomized Double Blind, Placebo-Controlled Study of Auxora for the Treatment of Severe COVID-19 Pneumonia (CARDEA)",Recruiting,NA,Phase 2,400,Anticipated,"CalciMedica, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:15Z,2020-11-01T12:06:15Z
NCT04344210,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-07,NA,NA,2020-10-11,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-11,2020-10-14,Actual,"April 17, 2020",Actual,2020-04-17,October 2020,2020-10-31,"September 20, 2020",Actual,2020-09-20,"September 20, 2020",Actual,2020-09-20,NA,Interventional,NA,,Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus,Impact of Tele-Interventions During the COVID-19 Pandemic on Glycemic Control and Attitude Toward the Disease in Patients With Diabetes Mellitus - A Randomized Clinical Trial,Completed,NA,N/A,149,Actual,Federal University of Rio Grande do Sul,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-11-01T12:06:25Z,2020-11-01T12:06:25Z
NCT04341922,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-07,NA,NA,2020-10-15,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-10-15,2020-10-19,Actual,"May 9, 2020",Actual,2020-05-09,October 2020,2020-10-31,"September 10, 2021",Anticipated,2021-09-10,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,,A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic,Evaluation of a Brief Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic: A Randomized Controlled Trial,"Active, not recruiting",NA,N/A,670,Actual,Karolinska Institutet,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:06:41Z,2020-11-01T12:06:41Z
NCT04341493,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-07,NA,NA,2020-04-22,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"April 6, 2020",Actual,2020-04-06,April 2020,2020-04-30,"December 30, 2020",Anticipated,2020-12-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,NA,,Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19,Treatment With Hydroxychloroquine vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor Outcome,Recruiting,NA,Phase 4,86,Anticipated,Materno-Perinatal Hospital of the State of Mexico,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,After finishing the study.,Requested by the journal or after publication if any researcher in the world express interest if the information of this survey.,NA,Yes,"If the final selected medical journal to send the paper of our research request it, we will add the full database of the studied population.",2020-11-01T12:06:45Z,2020-11-01T12:06:45Z
NCT04341441,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-07,NA,NA,2020-05-05,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-05-05,2020-05-07,Actual,"April 7, 2020",Actual,2020-04-07,May 2020,2020-05-31,"April 30, 2021",Anticipated,2021-04-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,WHIP COVID-19,,Will Hydroxychloroquine Impede or Prevent COVID-19,Will Hydroxychloroquine Impede or Prevent COVID-19: WHIP COVID-19 Study,Recruiting,NA,Phase 3,3000,Anticipated,Henry Ford Health System,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:45Z,2020-11-01T12:06:45Z
NCT04341415,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-07,NA,NA,2020-09-17,2020-04-07,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-09-17,2020-09-18,Actual,"April 9, 2020",Actual,2020-04-09,September 2020,2020-09-30,March 2021,Anticipated,2021-03-31,March 2021,Anticipated,2021-03-31,NA,Interventional,SOS-COVID19,,Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome,Randomized Double Blinded Monocentric Clinical Trial to Assess the Impact of Auricular Vagus Nerve Neuromodulation in COVID-19 Positive Inpatients Outcome.,Recruiting,NA,N/A,60,Anticipated,Fondation Ophtalmologique Adolphe de Rothschild,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:06:45Z,2020-11-01T12:06:45Z
NCT04341389,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-07,NA,NA,2020-05-14,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"April 12, 2020",Actual,2020-04-12,May 2020,2020-05-31,"January 31, 2021",Anticipated,2021-01-31,"January 31, 2021",Anticipated,2021-01-31,NA,Interventional,CTII-nCoV,,A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector),"A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years","Active, not recruiting",NA,Phase 2,508,Actual,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:46Z,2020-11-01T12:06:46Z
NCT04341038,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-07,NA,NA,2020-04-08,2020-04-08,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-08,2020-04-10,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"July 1, 2020",Anticipated,2020-07-01,"June 1, 2020",Anticipated,2020-06-01,NA,Interventional,TACROVID,,Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury,Open Randomized Single Centre Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With Severe Lung Injury Secondary to COVID-19,Recruiting,NA,Phase 3,84,Anticipated,Hospital Universitari de Bellvitge,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:48Z,2020-11-01T12:06:48Z
NCT04339426,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-07,NA,NA,2020-06-04,2020-04-07,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-09,Actual,"April 20, 2020",Actual,2020-04-20,April 2020,2020-04-30,April 2021,Anticipated,2021-04-30,October 2020,Anticipated,2020-10-31,NA,Interventional,NA,,Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection,"Open-Label, Non-Randomized Study to Evaluate Anti-Malarial/Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 Infection",Recruiting,NA,Phase 2,25,Anticipated,HonorHealth Research Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:07:06Z,2020-11-01T12:07:06Z
NCT04338958,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-07,NA,NA,2020-09-09,2020-04-07,2020-04-08,Actual,NA,NA,NA,NA,NA,NA,2020-09-09,2020-09-10,Actual,"April 22, 2020",Actual,2020-04-22,September 2020,2020-09-30,"August 31, 2021",Anticipated,2021-08-31,"January 31, 2021",Anticipated,2021-01-31,NA,Interventional,RuxCoFlam,,Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation,A Phase-II Clinical Trial for First Line Treatment of Stage II/III Covid-19 Patients to Treat Hyperinflammation,Recruiting,NA,Phase 2,200,Anticipated,University of Jena,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:07:10Z,2020-11-01T12:07:10Z
NCT04342169,"ClinicalTrials.gov processed this data on November 13, 2020",2020-04-07,NA,NA,2020-11-10,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-13,Estimate,"April 4, 2020",Actual,2020-04-04,November 2020,2020-11-30,April 2022,Anticipated,2022-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,University of Utah COVID-19 Hydrochloroquine Trial,Hydroxychloroquine for Outpatients With Confirmed COVID-19,Recruiting,NA,Phase 2,400,Anticipated,University of Utah,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-15T10:59:51Z,2020-11-15T10:59:51Z
NCT04340050,"ClinicalTrials.gov processed this data on November 13, 2020",2020-04-07,NA,NA,2020-11-11,2020-04-08,2020-04-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Estimate,"April 10, 2020",Actual,2020-04-10,November 2020,2020-11-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,COVID-19 Convalescent Plasma,Pilot Study for Use of Convalescent Plasma Collected From Patients Recovered From COVID-19 Disease for Transfusion as an Empiric Treatment During the 2020 Pandemic at the University of Chicago Medical Center,"Active, not recruiting",NA,Early Phase 1,10,Actual,University of Chicago,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,Upon publication of the major manuscript to be generated from this study. Data will be deposited in an appropriate major database,NA,NA,Yes,We will share individual participant data that is de-identified available to all qualified investigators,2020-11-15T10:59:52Z,2020-11-15T10:59:52Z
NCT04346147,"ClinicalTrials.gov processed this data on November 13, 2020",2020-04-07,NA,NA,2020-11-05,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-11-05,2020-11-09,Actual,"April 13, 2020",Actual,2020-04-13,November 2020,2020-11-30,May 2021,Anticipated,2021-05-31,March 2021,Anticipated,2021-03-31,NA,Interventional,Covid19COVINIB,,Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19,"Prospective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Baricitinib, Imatinib or Supportive Treatment in Patients With SARS Cov2 Pneumonia",Recruiting,NA,Phase 2,165,Anticipated,Hospital Universitario de Fuenlabrada,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-14T10:43:31Z,2020-11-14T10:43:31Z
NCT04358081,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-08,NA,NA,2020-09-29,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-09-29,2020-10-01,Actual,"May 1, 2020",Actual,2020-05-01,September 2020,2020-09-30,"July 27, 2020",Actual,2020-07-27,"July 27, 2020",Actual,2020-07-27,NA,Interventional,NA,,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,"A Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease",Completed,NA,Phase 3,20,Actual,Novartis,,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2020-11-01T12:04:40Z,2020-11-01T12:04:40Z
NCT04350580,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-08,NA,NA,2020-09-18,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-09-18,2020-09-22,Actual,"April 11, 2020",Actual,2020-04-11,September 2020,2020-09-30,June 2021,Anticipated,2021-06-30,April 2021,Anticipated,2021-04-30,NA,Interventional,ICAR,,Polyvalent Immunoglobulin in COVID-19 Related ARds,Value of Early Treatment With Polyvalent Immunoglobulin in the Management of Acute Respiratory Distress Syndrome Associated With SARS-CoV-2 Infections,Recruiting,NA,Phase 3,138,Anticipated,Centre Hospitalier St Anne,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:05:36Z,2020-11-01T12:05:36Z
NCT04348383,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-08,NA,NA,2020-08-12,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-08-12,2020-08-13,Actual,"April 8, 2020",Actual,2020-04-08,August 2020,2020-08-31,"January 15, 2021",Anticipated,2021-01-15,"January 15, 2021",Anticipated,2021-01-15,NA,Interventional,DEFACOVID,,Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.,"Phase IIb Prospective, Multi-center, Randomized, Parallel, Double Blind, Placebo Controlled Trial to Evaluate Defibrotide Intravenous Infusion in the Prevention and Treatment of COVID-19 Respiratory Distress and Cytokine Release Syndrome",Recruiting,NA,Phase 2,120,Anticipated,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:54Z,2020-11-01T12:05:54Z
NCT04347941,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-08,NA,NA,2020-08-11,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-13,Actual,"July 11, 2020",Actual,2020-07-11,April 2020,2020-04-30,"September 11, 2021",Anticipated,2021-09-11,"June 11, 2021",Anticipated,2021-06-11,NA,Interventional,APPROVE-CARE,,Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE,Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE,Recruiting,NA,N/A,200,Anticipated,University College Hospital Galway,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,up to 15 years post study,NA,NA,Yes,"Electronic Case report form following informed consent, all patient identification removed, and individual patient response to intervention will be shared.",2020-11-01T12:05:58Z,2020-11-01T12:05:58Z
NCT04347681,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-08,NA,NA,2020-08-09,2020-04-12,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-08-09,2020-08-11,Actual,"April 18, 2020",Actual,2020-04-18,August 2020,2020-08-31,"April 11, 2021",Anticipated,2021-04-11,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19,A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19,Recruiting,NA,Phase 2,575,Anticipated,King Fahad Specialist Hospital Dammam,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:00Z,2020-11-01T12:06:00Z
NCT04346693,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-08,NA,NA,2020-05-22,2020-04-10,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-27,Actual,"April 8, 2020",Actual,2020-04-08,May 2020,2020-05-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19,An Open Randomized Study of the Effectiveness of the Drug Dalargin for the Prevention and Treatment of Symptoms of Pulmonary Complications in Patients With Coronavirus Infection (SARS-COVID-19),"Active, not recruiting",NA,Phase 3,320,Actual,Burnasyan Federal Medical Biophysical Center,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:07Z,2020-11-01T12:06:07Z
NCT04346420,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-08,NA,NA,2020-06-05,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"April 9, 2020",Actual,2020-04-09,June 2020,2020-06-30,"May 1, 2020",Actual,2020-05-01,"May 1, 2020",Actual,2020-05-01,NA,Interventional,NA,,Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19,Impact of the Double-Trunk Mask on Oxygenation Titration in Patients With COVID-19,Completed,NA,N/A,12,Actual,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:06:09Z,2020-11-01T12:06:09Z
NCT04345653,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-08,NA,NA,2020-06-05,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"April 14, 2020",Actual,2020-04-14,June 2020,2020-06-30,"April 8, 2021",Anticipated,2021-04-08,"June 5, 2020",Actual,2020-06-05,NA,Interventional,NA,,Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers,"Feasibility, Safety and Early Efficacy Trial of Hydroxychloroquine as Primary Prevention of Corona Virus Disease 2019 in High Risk Health Care Providers","Active, not recruiting",NA,Phase 2,44,Actual,Hackensack Meridian Health,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:06:14Z,2020-11-01T12:06:14Z
NCT04344457,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-08,NA,NA,2020-06-29,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-06-29,2020-07-01,Actual,"April 16, 2020",Actual,2020-04-16,June 2020,2020-06-30,"September 30, 2020",Anticipated,2020-09-30,"June 20, 2020",Anticipated,2020-06-20,NA,Interventional,COVID-19,,"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19","An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects Positive With SARS-CoV-2 With Mild Symptoms",Recruiting,NA,Phase 1/Phase 2,80,Anticipated,"Perseverance Research Center, LLC",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:23Z,2020-11-01T12:06:23Z
NCT04344236,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-08,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 9, 2020",Actual,2020-04-09,April 2020,2020-04-30,"May 9, 2020",Anticipated,2020-05-09,"May 1, 2020",Anticipated,2020-05-01,NA,Interventional,NA,,Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19,"A Phase II, Randomized, Open-label, Single-institution Study of the Effects of Povidone Iodine Oral Gargles and Nasal Rinses on Viral Load in Patients With COVID-19",Recruiting,NA,Phase 2,48,Anticipated,NYU Langone Health,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,"Requests should be directed to scott.rickert@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: [contact information for PI or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2020-11-01T12:06:25Z,2020-11-01T12:06:25Z
NCT04344106,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-08,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,"May 1, 2020",Anticipated,2020-05-01,"April 15, 2020",Anticipated,2020-04-15,NA,Interventional,ProCov,,Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study,Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study (ProCov),Recruiting,NA,N/A,25,Anticipated,Centre Hospitalier Intercommunal Aix-Pertuis,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:26Z,2020-11-01T12:06:26Z
NCT04343768,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-08,NA,NA,2020-05-02,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-02,2020-05-05,Actual,"April 9, 2020",Actual,2020-04-09,May 2020,2020-05-31,"April 27, 2020",Actual,2020-04-27,"April 27, 2020",Actual,2020-04-27,NA,Interventional,COVIFERON,,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial","An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial",Completed,NA,Phase 2,60,Actual,Shahid Beheshti University of Medical Sciences,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,One year after the publication of the results in a journal.,"Qualifying researchers who reach out to Dr. Seyed Sina Naghibi Irvani at ""sina.irvani@sbmu.ac.ir"" or ""sina.irvani@gmail.com"" and submit a proposal with a valuable research question.",NA,Yes,"One year after the publication of the results in a journal, Qualifying researchers who reach out to Dr. Seyed Sina Naghibi Irvani at ""sina.irvani@sbmu.ac.ir"" or ""sina.irvani@gmail.com"" and submit a proposal with a valuable research question can have access to data and supporting information.",2020-11-01T12:06:29Z,2020-11-01T12:06:29Z
NCT04343755,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-08,NA,NA,2020-07-14,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-07-14,2020-07-16,Actual,"April 9, 2020",Actual,2020-04-09,July 2020,2020-07-31,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection,Phase IIa Study Exploring the Safety and Efficacy of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Hospitalized Subjects With COVID-19 Infection,Recruiting,NA,Phase 2,55,Anticipated,Hackensack Meridian Health,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:29Z,2020-11-01T12:06:29Z
NCT04343261,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-08,2020-09-01,NA,2020-09-22,2020-04-08,2020-04-13,Actual,2020-09-15,2020-09-17,Actual,NA,NA,NA,2020-09-22,2020-09-24,Actual,"April 10, 2020",Actual,2020-04-10,September 2020,2020-09-30,"August 13, 2020",Actual,2020-08-13,"July 23, 2020",Actual,2020-07-23,NA,Interventional,NA,,Convalescent Plasma in the Treatment of COVID 19,Convalescent Plasma in the Treatment of COVID 19,Completed,NA,Phase 2,48,Actual,Saint Francis Care,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:32Z,2020-11-01T12:06:32Z
NCT04343248,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-08,NA,NA,2020-09-17,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-09-17,2020-09-18,Actual,"May 12, 2020",Actual,2020-05-12,September 2020,2020-09-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF),"A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)",Recruiting,NA,Phase 3,800,Anticipated,Romark Laboratories L.C.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:06:32Z,2020-11-01T12:06:32Z
NCT04342728,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-08,NA,NA,2020-08-12,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-08-12,2020-08-14,Actual,"April 8, 2020",Actual,2020-04-08,August 2020,2020-08-31,"April 30, 2021",Anticipated,2021-04-30,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,COVIDAtoZ,,Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation,"Coronavirus Disease 2019- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) Research Study A Randomized, Open Label Single Center Study",Enrolling by invitation,NA,N/A,520,Anticipated,The Cleveland Clinic,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:06:36Z,2020-11-01T12:06:36Z
NCT04342689,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-08,NA,NA,2020-06-15,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-06-15,2020-06-17,Actual,"June 3, 2020",Actual,2020-06-03,June 2020,2020-06-30,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,,The Role of Resistant Starch in COVID-19 Infection,The Role of Resistant Starch in COVID-19 Infection,Recruiting,NA,Phase 3,1500,Anticipated,Yale University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"After publication, indefinitely",NA,NA,Yes,Deidentified data underlying results for publication are planned to be made available after publication.,2020-11-01T12:06:37Z,2020-11-01T12:06:37Z
NCT04342663,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-08,NA,NA,2020-08-28,2020-04-08,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-08-28,2020-09-01,Actual,"April 10, 2020",Actual,2020-04-10,August 2020,2020-08-31,"October 1, 2020",Anticipated,2020-10-01,"August 20, 2020",Actual,2020-08-20,NA,Interventional,STOP COVID,,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","Active, not recruiting",NA,Phase 2,152,Actual,Washington University School of Medicine,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:06:37Z,2020-11-01T12:06:37Z
NCT04341207,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-08,NA,NA,2020-04-09,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-10,Actual,"April 3, 2020",Actual,2020-04-03,April 2020,2020-04-30,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,ONCOVID,,Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients,COVID 19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease Upon Hydroxychloroquine and Azithromycin Therapy in French Cancer Patients,Recruiting,NA,Phase 2,1000,Anticipated,"Gustave Roussy, Cancer Campus, Grand Paris",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:06:47Z,2020-11-01T12:06:47Z
NCT04341142,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-08,NA,NA,2020-07-29,2020-04-08,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-07-31,Actual,"April 9, 2020",Actual,2020-04-09,July 2020,2020-07-31,"April 9, 2024",Anticipated,2024-04-09,"April 9, 2023",Anticipated,2023-04-09,NA,Interventional,COVID-SER,,Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER,Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER,Recruiting,NA,N/A,550,Anticipated,Hospices Civils de Lyon,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:47Z,2020-11-01T12:06:47Z
NCT04342221,"ClinicalTrials.gov processed this data on November 09, 2020",2020-04-08,NA,NA,2020-11-05,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-05,2020-11-06,Actual,"March 29, 2020",Actual,2020-03-29,March 2020,2020-03-31,February 2022,Anticipated,2022-02-28,March 2021,Anticipated,2021-03-31,NA,Interventional,COV-HCQ,,Hydroxychloroquine for COVID-19,Randomized Controlled Trial of Hydroxychloroquine Versus Placebo for the Treatment of Adult Patients With Acute Coronavirus Disease 2019 - COVID-19,Recruiting,NA,Phase 3,220,Anticipated,University Hospital Tuebingen,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-10T11:28:44Z,2020-11-10T11:28:44Z
NCT04344587,"ClinicalTrials.gov processed this data on November 13, 2020",2020-04-08,NA,NA,2020-11-09,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-10,Actual,"April 23, 2020",Actual,2020-04-23,November 2020,2020-11-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,APPEX-19,,Awake Prone Position for Early Hypoxemia in COVID-19,Awake Prone Position for Early Hypoxemia in COVID-19,Enrolling by invitation,NA,N/A,560,Anticipated,Boston University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-14T10:43:33Z,2020-11-14T10:43:33Z
NCT04353037,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-09,NA,NA,2020-04-21,2020-04-15,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"April 7, 2020",Actual,2020-04-07,April 2020,2020-04-30,"June 15, 2021",Anticipated,2021-06-15,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine,PATCH 2 & 3: (Prevention and Treatment of COVID-19 With Hydroxychloroquine) An Open Label Multi-arm Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19,Recruiting,NA,Phase 2,850,Anticipated,UnitedHealth Group,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,1 year,NA,NA,Yes,Data will be collected and managed by Optumcare and UnitedHealth Group Research & Development. Redacted/aggregate data will be shared with the University Of Penn using approved data sharing protocols.,2020-11-01T12:05:16Z,2020-11-01T12:05:16Z
NCT04351906,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-09,NA,NA,2020-09-29,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-09-29,2020-09-30,Actual,"May 3, 2020",Actual,2020-05-03,September 2020,2020-09-30,"October 1, 2021",Anticipated,2021-10-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,,Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome,Low-flow Extracorporeal Carbon Dioxide Removal Using a Renal Replacement Therapy Platform for Correction of Hypercapnia in COVID-19-associated Acute Respiratory Distress Syndrome,Recruiting,NA,N/A,20,Anticipated,University of Giessen,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:05:25Z,2020-11-01T12:05:25Z
NCT04348513,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-09,NA,NA,2020-05-29,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"May 29, 2020",Actual,2020-05-29,May 2020,2020-05-31,"May 31, 2021",Anticipated,2021-05-31,"May 2, 2021",Anticipated,2021-05-02,NA,Interventional,Thy-Support,,Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection,Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (Thy-Support),Recruiting,NA,Phase 2,60,Anticipated,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:50Z,2020-11-01T12:05:50Z
NCT04347980,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-09,NA,NA,2020-04-16,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Actual,April 2020,Anticipated,2020-04-30,March 2020,2020-03-31,August 2020,Anticipated,2020-08-31,June 2020,Anticipated,2020-06-30,NA,Interventional,DHYSCO,,Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19,"Dexamethasone Combined With Hydroxychloroquine Compared to Hydroxychloroquine Alone for Treatment of Severe Acute Respiratory Distress Syndrome Induced by Coronavirus Disease 19 (COVID-19): a Multicentre, Randomised Controlled Trial",Recruiting,NA,Phase 3,122,Anticipated,Centre Chirurgical Marie Lannelongue,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,Beginning 3 months and ending 24 months following article publication,Researchers who provide a methodologically sound and proposal. Data are available for 24 months and request should be addressed by email,NA,Yes,"Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices)",2020-11-01T12:05:58Z,2020-11-01T12:05:58Z
NCT04346615,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-09,NA,NA,2020-09-23,2020-04-10,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-25,Actual,"April 25, 2020",Actual,2020-04-25,September 2020,2020-09-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen,"BHV3500-203: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of Zavegepant* (BHV-3500) Intranasal (IN) for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen",Recruiting,NA,Phase 2/Phase 3,120,Anticipated,"Biohaven Pharmaceuticals, Inc.",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:06:08Z,2020-11-01T12:06:08Z
NCT04346589,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-09,NA,NA,2020-06-05,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"April 15, 2020",Actual,2020-04-15,June 2020,2020-06-30,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients,A Pilot Study to Explore the Efficacy and Safety of Rescue Theraphy With Antibodies From Convalescent Patients Obtained With Double -Filtration Plasmapheresis (DFPP) and Infused in Critically Ill Ventilated Patients With Coronavirus Disease 2019 (COVID-19),Recruiting,NA,N/A,10,Anticipated,A.O. Ospedale Papa Giovanni XXIII,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:06:08Z,2020-11-01T12:06:08Z
NCT04346199,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-09,NA,NA,2020-10-14,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"June 12, 2020",Actual,2020-06-12,October 2020,2020-10-31,"November 23, 2020",Anticipated,2020-11-23,"November 23, 2020",Anticipated,2020-11-23,NA,Interventional,CALAVI,,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19","Active, not recruiting",NA,Phase 2,163,Actual,AstraZeneca,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.,2020-11-01T12:06:10Z,2020-11-01T12:06:10Z
NCT04345692,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-09,NA,NA,2020-06-01,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-04,Actual,"March 26, 2020",Actual,2020-03-26,June 2020,2020-06-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,OAHU-COVID19,,A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients,"A Randomized, Controlled Clinical Trial of the Safety and Efficacy of Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients",Recruiting,NA,Phase 3,350,Anticipated,Queen's Medical Centre,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:13Z,2020-11-01T12:06:13Z
NCT04344730,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-09,NA,NA,2020-04-13,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-14,Actual,"April 10, 2020",Actual,2020-04-10,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,COVIDICUS,,Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia,Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 pneumonia_COVIDICUS,Recruiting,NA,N/A,550,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:06:21Z,2020-11-01T12:06:21Z
NCT04344431,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-09,NA,NA,2020-10-24,2020-04-11,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-24,2020-10-27,Actual,"April 14, 2020",Actual,2020-04-14,October 2020,2020-10-31,April 2022,Anticipated,2022-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,OHB10cov,,Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19),Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19),Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Direction Centrale du Service de SantÃ© des ArmÃ©es,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:23Z,2020-11-01T12:06:23Z
NCT04344080,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-09,NA,NA,2020-04-09,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-09,2020-04-14,Actual,"April 1, 2020",Actual,2020-04-01,April 2020,2020-04-30,February 2021,Anticipated,2021-02-28,December 2020,Anticipated,2020-12-31,NA,Interventional,CYTOCOV-19,,Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19,Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19,Recruiting,NA,N/A,24,Anticipated,UniversitÃ¤tsklinikum Hamburg-Eppendorf,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:27Z,2020-11-01T12:06:27Z
NCT04344041,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-09,NA,NA,2020-10-01,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-01,2020-10-05,Actual,"April 15, 2020",Actual,2020-04-15,October 2020,2020-10-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),Recruiting,NA,Phase 3,260,Anticipated,"University Hospital, Angers",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:06:27Z,2020-11-01T12:06:27Z
NCT04344015,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-09,NA,NA,2020-05-08,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-11,Actual,"April 13, 2020",Actual,2020-04-13,May 2020,2020-05-31,"April 12, 2021",Anticipated,2021-04-12,"April 12, 2021",Anticipated,2021-04-12,NA,Interventional,NA,,COVID-19 Plasma Collection,Collection of COVID-19 Convalescent Plasma,Recruiting,NA,N/A,2000,Anticipated,Thomas Jefferson University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:06:27Z,2020-11-01T12:06:27Z
NCT04343989,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-09,NA,NA,2020-05-04,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-04,2020-05-06,Actual,"March 31, 2020",Actual,2020-03-31,May 2020,2020-05-31,"July 1, 2020",Anticipated,2020-07-01,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,NA,,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Recruiting,NA,Phase 2,90,Anticipated,NYU Langone Health,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,Upon reasonable request by an investigator who proposes to use the data.,NA,Yes,The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: [contact information for PI or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2020-11-01T12:06:27Z,2020-11-01T12:06:27Z
NCT04343976,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-09,NA,NA,2020-06-22,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-06-22,2020-06-24,Actual,"June 22, 2020",Actual,2020-06-22,June 2020,2020-06-30,"August 31, 2021",Anticipated,2021-08-31,"March 1, 2021",Anticipated,2021-03-01,NA,Interventional,NA,,Pegylated Interferon Lambda Treatment for COVID-19,A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda vs. Placebo in Subjects Infected With COVID-19,Enrolling by invitation,NA,Phase 2,20,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,"Data is anticiapted to be made available within 3 months of study completion. Safety data, specifically treatment related adverse events, will be shared in real time",researchers accessing IPD must be an approved and have a data use agreement in place with Partners Healthcare to access the data,NA,Yes,Coded data is anticipated to be shared with outside institutions. Safety data will be shared with the drug manufacturer,2020-11-01T12:06:28Z,2020-11-01T12:06:28Z
NCT04343963,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-09,NA,NA,2020-07-06,2020-04-09,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-07-06,2020-07-07,Actual,"April 4, 2020",Actual,2020-04-04,April 2020,2020-04-30,"April 30, 2021",Anticipated,2021-04-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,PISCO,,Pyridostigmine in Severe SARS-CoV-2 Infection,Pyridostigmine in Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2 Infection,Recruiting,NA,Phase 2/Phase 3,436,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:28Z,2020-11-01T12:06:28Z
NCT04343729,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-09,NA,NA,2020-06-29,2020-04-09,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-06-29,2020-07-01,Actual,"April 18, 2020",Actual,2020-04-18,June 2020,2020-06-30,September 2020,Anticipated,2020-09-30,"June 16, 2020",Actual,2020-06-16,NA,Interventional,MetCOVID,,Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19,"Efficacy of Injectable Methylprednisolone Sodium Succinate in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome Under the New Coronavirus (SARS-CoV2): a Phase IIb, Randomized, Double-blind, Placebo-controlled, Clinical Trial.","Active, not recruiting",NA,Phase 2,416,Actual,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,after study publication.,upon formal request.,NA,Yes,all patient data will be shared after study publication,2020-11-01T12:06:29Z,2020-11-01T12:06:29Z
NCT04438850,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-10,NA,NA,2020-10-20,2020-06-18,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-20,2020-10-22,Actual,"July 31, 2020",Actual,2020-07-31,October 2020,2020-10-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,COVER,,COVidIVERmectin: Ivermectin for Treatment of Covid-19,"Randomized, Double-blind, Multi Centre Phase II, Proof of Concept, Dose Finding Clinical Trial on Ivermectin for the Early Treatment of COVID-19",Recruiting,NA,Phase 2,102,Anticipated,IRCCS Sacro Cuore Don Calabria di Negrar,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,The database will be available upon publication of the results,The data will be available in a public repository,NA,Yes,The anonymized database will be uploaded into a public repository,2020-11-01T11:54:11Z,2020-11-01T11:54:11Z
NCT04390178,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-10,NA,NA,2020-05-13,2020-05-13,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-15,Actual,"April 10, 2020",Actual,2020-04-10,May 2020,2020-05-31,December 2020,Anticipated,2020-12-31,June 2020,Anticipated,2020-06-30,NA,Interventional,NA,,Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19),Plasma From Individuals Who Have Recovered From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection as Treatment for Acute COVID-19 Disease,"Active, not recruiting",NA,Phase 1/Phase 2,10,Actual,Karolinska University Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,We will be sharing data but data the management plan is being designed.,2020-11-01T12:00:28Z,2020-11-01T12:00:28Z
NCT04351724,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-10,NA,NA,2020-04-21,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,ACOVACT,,Austrian CoronaVirus Adaptive Clinical Trial (COVID-19),"A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)",Recruiting,NA,Phase 2/Phase 3,500,Anticipated,Medical University of Vienna,,9,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Anonymized and pseudonymized data will be published in peer reviewed journals and may be presented at congresses and conferences,2020-11-01T12:05:26Z,2020-11-01T12:05:26Z
NCT04348929,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-10,NA,NA,2020-10-02,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-10-02,2020-10-05,Actual,"April 16, 2020",Actual,2020-04-16,October 2020,2020-10-31,"October 1, 2021",Anticipated,2021-10-01,"August 16, 2021",Anticipated,2021-08-16,NA,Interventional,CONFINE,,Birth Experience During COVID-19 Confinement,Birth Experience During COVID-19 Confinement (Confinement and Fostering Intrapartum Care),Recruiting,NA,N/A,927,Anticipated,"Central Hospital, Nancy, France",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"All data generated during this study will be made available via CIC-EC, CHRU Nancy, Nancy- FRANCE in accordance with protocol promotor. Data obtained from this study will be deposited at CIC-EC Nancy where they will be maintained for a minimum of 15 years.",2020-11-01T12:05:47Z,2020-11-01T12:05:47Z
NCT04346628,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-10,NA,NA,2020-09-30,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"July 12, 2020",Actual,2020-07-12,September 2020,2020-09-30,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Interventional,NA,,Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19,"A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild or Asymptomatic COVID-19",Enrolling by invitation,NA,Phase 2,120,Anticipated,Stanford University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,No current plan to share individual participant data (IPD).,2020-11-01T12:06:08Z,2020-11-01T12:06:08Z
NCT04345991,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-10,NA,NA,2020-05-19,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-20,Actual,"April 15, 2020",Actual,2020-04-15,May 2020,2020-05-31,"June 1, 2020",Anticipated,2020-06-01,"May 15, 2020",Anticipated,2020-05-15,NA,Interventional,CORIPLASM,,"Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort",Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - CORIMUNO-CORIPLASM : EFFICACY OF CONVALESCENT PLASMA TO TREAT SARS-COV2 INFECTED PATIENTS,Recruiting,NA,Phase 2,120,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:06:11Z,2020-11-01T12:06:11Z
NCT04345549,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-10,NA,NA,2020-04-10,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-10,2020-04-14,Actual,"February 26, 2020",Actual,2020-02-26,April 2020,2020-04-30,"March 30, 2020",Actual,2020-03-30,"March 30, 2020",Actual,2020-03-30,NA,Interventional,NA,,Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak,Ayurveda Self-Management for Flu Like Symptoms in People Self-Isolated for 7 Days During the Coronavirus Disease 2019 (COVID-19) Outbreak,Completed,NA,N/A,18,Actual,Aarogyam UK,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:06:15Z,2020-11-01T12:06:15Z
NCT04345289,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-10,NA,NA,2020-07-29,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-07-31,Actual,"May 1, 2020",Actual,2020-05-01,July 2020,2020-07-31,"June 15, 2021",Anticipated,2021-06-15,"June 15, 2021",Anticipated,2021-06-15,NA,Interventional,CCAP,,Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia,"Efficacy and Safety of Treatment With Convalescent Plasma for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multicenter Placebo-controlled Trial",Recruiting,NA,Phase 3,1100,Anticipated,Hvidovre University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:17Z,2020-11-01T12:06:17Z
NCT04345276,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-10,NA,NA,2020-06-01,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-02,Actual,"March 18, 2020",Actual,2020-03-18,March 2020,2020-03-31,"April 15, 2020",Actual,2020-04-15,"April 15, 2020",Actual,2020-04-15,NA,Interventional,NA,,Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,An Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,NA,Phase 4,10,Actual,Huoshenshan Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:06:17Z,2020-11-01T12:06:17Z
NCT04344600,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-10,NA,NA,2020-08-18,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-20,Actual,"May 29, 2020",Actual,2020-05-29,August 2020,2020-08-31,December 2021,Anticipated,2021-12-31,June 2021,Anticipated,2021-06-30,NA,Interventional,PROTECT,,Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection,Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection,Recruiting,NA,Phase 2,164,Anticipated,Johns Hopkins University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:22Z,2020-11-01T12:06:22Z
NCT04344561,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-10,NA,NA,2020-06-22,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-06-22,2020-06-24,Actual,"May 25, 2020",Actual,2020-05-25,June 2020,2020-06-30,"May 1, 2021",Anticipated,2021-05-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,UPSAT,,Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation,UPright Incline Positioning in COVID-19 Patients for Oxygen SATuration Improvement With Hypoxemic Respiratory Failure (UPSAT),Recruiting,NA,N/A,70,Anticipated,Johns Hopkins University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Access to IPD on reasonable request,2020-11-01T12:06:22Z,2020-11-01T12:06:22Z
NCT04344535,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-10,NA,NA,2020-04-15,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"August 31, 2021",Anticipated,2021-08-31,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,,Convalescent Plasma vs. Standard Plasma for COVID-19,Convalescent Plasma to Reduce Complications Associated With COVID-19 Infection: A Randomized Trial Comparing the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma vs. Standard Plasma in Hospitalized Patients With COVID- 19 Infection,Enrolling by invitation,NA,Phase 1/Phase 2,500,Anticipated,Stony Brook University,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:22Z,2020-11-01T12:06:22Z
NCT04344444,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-10,NA,NA,2020-08-21,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-08-21,2020-08-24,Actual,"April 13, 2020",Actual,2020-04-13,August 2020,2020-08-31,"December 10, 2021",Anticipated,2021-12-10,"April 10, 2021",Anticipated,2021-04-10,NA,Interventional,RCT,,Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease,Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease: A Randomized Clinical Trial,"Active, not recruiting",NA,Phase 3,600,Anticipated,LCMC Health,,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:06:23Z,2020-11-01T12:06:23Z
NCT04344288,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-10,NA,NA,2020-10-23,2020-04-10,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-26,Actual,"April 21, 2020",Actual,2020-04-21,October 2020,2020-10-31,"August 18, 2020",Actual,2020-08-18,"August 18, 2020",Actual,2020-08-18,NA,Interventional,CORTI-Covid,,Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection,Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection,Terminated,NA,Phase 2,11,Actual,Hospices Civils de Lyon,,2,NA,Competent Authority's decision,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:06:25Z,2020-11-01T12:06:25Z
NCT04342897,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-10,NA,NA,2020-10-27,2020-04-10,2020-04-13,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-29,Actual,"April 20, 2020",Actual,2020-04-20,October 2020,2020-10-31,"October 12, 2020",Actual,2020-10-12,"October 12, 2020",Actual,2020-10-12,NA,Interventional,NA,,A Study of LY3127804 in Participants With COVID-19,"A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19",Terminated,NA,Phase 2,95,Actual,Eli Lilly and Company,,2,NA,Trial terminated for futility.,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting","Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting",http://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement,2020-11-02T10:30:26Z,2020-11-02T10:30:26Z
NCT04356495,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-11,NA,NA,2020-10-05,2020-04-19,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-08,Actual,"July 29, 2020",Actual,2020-07-29,October 2020,2020-10-31,"January 28, 2021",Anticipated,2021-01-28,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,COVERAGE,,Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19),"Outpatient Treatment of Elderly People With Symptomatic SARS-CoV-2 Infection (COVID-19): a Multi-arm, Multi-stage (MAMS) Randomized Trial to Assess the Efficacy and Safety of Several Experimental Treatments to Decrease the Risk of Hospitalization or Death (COVERAGE Trial)",Recruiting,NA,Phase 3,338,Anticipated,"University Hospital, Bordeaux",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:04:50Z,2020-11-01T12:04:50Z
NCT04351789,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-11,NA,NA,2020-08-21,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-08-21,2020-08-24,Actual,"May 1, 2020",Actual,2020-05-01,August 2020,2020-08-31,April 2023,Anticipated,2023-04-30,April 2023,Anticipated,2023-04-30,NA,Interventional,PISCA,,Impact of a Minimal Psychoeducational Intervention on Anxiety Among Hospitalized COVID-19 Patients in Denmark,Impact of a Minimal Psychoeducational Intervention Versus Standard of Care on Anxiety Among Hospitalized COVID-19 Patients in Denmark: a Randomized Clinical Trial,Recruiting,NA,N/A,66,Anticipated,"Copenhagen University Hospital, Hvidovre",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Individual participant data will not be shared with other researchers due to regulatory restrictions.,2020-11-01T12:05:26Z,2020-11-01T12:05:26Z
NCT04348305,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-11,NA,NA,2020-09-03,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-09-03,2020-09-07,Actual,"April 17, 2020",Actual,2020-04-17,June 2020,2020-06-30,"June 8, 2021",Anticipated,2021-06-08,"September 10, 2020",Anticipated,2020-09-10,NA,Interventional,COVID STEROID,,Hydrocortisone for COVID-19 and Severe Hypoxia,Low-dose Hydrocortisone in Patients With COVID-19 and Severe Hypoxia - the COVID STEROID Trial,"Active, not recruiting",NA,Phase 3,1000,Anticipated,Scandinavian Critical Care Trials Group,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,"Immediate sharing of protocol, SAP and ICF. CSR will be shared no later than 6 months after last-patient-last-visit",Contact to the trial management committee,http://www.cric.nu/covid-steroid-trial/,Yes,Fully de-identified IPD will be shared after the approval by the the trial management committee,2020-11-01T12:05:56Z,2020-11-01T12:05:56Z
NCT04347538,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-11,NA,NA,2020-08-24,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-08-24,2020-08-26,Actual,"May 1, 2020",Actual,2020-05-01,August 2020,2020-08-31,June 2022,Anticipated,2022-06-30,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,,Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19,Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19,Recruiting,NA,N/A,90,Anticipated,Vanderbilt University Medical Center,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:01Z,2020-11-01T12:06:01Z
NCT04345419,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-11,NA,NA,2020-08-14,2020-04-13,2020-04-14,Actual,NA,NA,NA,NA,NA,NA,2020-08-14,2020-08-18,Actual,"June 16, 2020",Actual,2020-06-16,August 2020,2020-08-31,December 2029,Anticipated,2029-12-31,December 2029,Anticipated,2029-12-31,NA,Interventional,NA,,Remdesivir vs Chloroquine in Covid 19,Remdesivir in COVID 19 Treatment: A Randomised Trial,Recruiting,NA,Phase 2/Phase 3,120,Anticipated,Tanta University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:16Z,2020-11-01T12:06:16Z
NCT04347382,"ClinicalTrials.gov processed this data on November 13, 2020",2020-04-11,NA,NA,2020-11-09,2020-04-11,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"April 30, 2020",Actual,2020-04-30,November 2020,2020-11-30,"August 30, 2020",Actual,2020-08-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,HNS-COVID-PK,,Honey & Nigella Sativa Trial Against COVID-19,"The Role of Honey and Nigella Sativa in the Management of COVID-19; A Randomized Controlled, Open-label, Add-on Trial in Pakistan",Completed,NA,Phase 3,313,Actual,Sheikh Zayed Federal Postgraduate Medical Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-15T10:59:46Z,2020-11-15T10:59:46Z
NCT04349410,"ClinicalTrials.gov processed this data on November 13, 2020",2020-04-11,NA,NA,2020-11-10,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"April 11, 2020",Actual,2020-04-11,October 2020,2020-10-31,"September 14, 2020",Actual,2020-09-14,"September 14, 2020",Actual,2020-09-14,NA,Interventional,FMTVDM,,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,Completed,NA,Phase 2/Phase 3,1800,Actual,The Camelot Foundation,,11,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,This will depend upon the availability of staff given the multi-nation approach to this project.,Expressed request through email as listed.,NA,Yes,Data will be made available through electronic request from approved individuals and institutions.,2020-11-15T10:59:46Z,2020-11-15T10:59:46Z
NCT04463433,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-12,NA,NA,2020-07-08,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2020-07-08,2020-07-09,Actual,"February 1, 2020",Actual,2020-02-01,July 2020,2020-07-31,"January 31, 2022",Anticipated,2022-01-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,,Psychological Intervention for Parent-child Relationship and Couple Relationship Under COVID-19 in China,Psychological Intervention for Parent-child Relationship and Couple Relationship Under COVID-19 in China,Recruiting,NA,N/A,300,Anticipated,Beijing Normal University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:51:11Z,2020-11-01T11:51:11Z
NCT04349592,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-12,NA,NA,2020-07-28,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-30,Actual,"April 14, 2020",Actual,2020-04-14,May 2020,2020-05-31,"August 30, 2020",Anticipated,2020-08-30,"August 14, 2020",Anticipated,2020-08-14,NA,Interventional,NA,,Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19,Randomized Placebo-controlled Trial of Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19,Recruiting,NA,N/A,456,Anticipated,Hamad Medical Corporation,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:43Z,2020-11-01T12:05:43Z
NCT04349371,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-12,NA,NA,2020-04-17,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-21,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,Saved From COVID-19,Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID,Recruiting,NA,Phase 2,350,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:05:45Z,2020-11-01T12:05:45Z
NCT04346355,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-12,NA,NA,2020-06-18,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-18,2020-06-22,Actual,"March 31, 2020",Actual,2020-03-31,June 2020,2020-06-30,"June 6, 2020",Actual,2020-06-06,"June 6, 2020",Actual,2020-06-06,NA,Interventional,NA,,Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,An Open-label Randomized Multicenter Study to Evaluate the Efficacy of Early Administration of Tocilizumab (TCZ) in Patients With COVID-19 Pneumonia,Terminated,NA,Phase 2,126,Actual,Azienda UnitÃ  Sanitaria Locale Reggio Emilia,,2,NA,Based on interim analysis for futility and given an enrolment rate almost nil,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:06:09Z,2020-11-01T12:06:09Z
NCT04360824,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-13,NA,NA,2020-06-18,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-18,2020-06-19,Actual,"May 6, 2020",Actual,2020-05-06,June 2020,2020-06-30,"April 16, 2021",Anticipated,2021-04-16,"April 16, 2021",Anticipated,2021-04-16,NA,Interventional,NA,,Covid-19 Associated Coagulopathy,COVID-19-associated Coagulopathy: Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults With COVID-19,Recruiting,NA,Phase 4,170,Anticipated,University of Iowa,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,No individual participant data will be shared,2020-11-01T12:04:21Z,2020-11-01T12:04:21Z
NCT04359251,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-13,NA,NA,2020-04-21,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"March 5, 2020",Actual,2020-03-05,April 2020,2020-04-30,"March 25, 2020",Actual,2020-03-25,"March 25, 2020",Actual,2020-03-25,NA,Interventional,NA,,Different PEEP Settings of COVID-19 Induced ARDS,Avoiding High PEEP in COVID-19 Induced ARDS: a Multi-center Study,Completed,NA,N/A,20,Actual,"Southeast University, China",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:04:32Z,2020-11-01T12:04:32Z
NCT04357340,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-13,NA,NA,2020-05-30,2020-04-18,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-30,2020-06-02,Actual,"April 2, 2020",Actual,2020-04-02,May 2020,2020-05-31,"May 30, 2020",Actual,2020-05-30,"April 30, 2020",Actual,2020-04-30,NA,Interventional,NA,,The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19,Efficacy of Pulmonary Physiotherapy on Hospitalized Patients With Novel Coronavirus 2019 Pneumonia,Completed,NA,N/A,40,Actual,Tehran University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Beginning 3 months and ending 12 months following article publication,Researchers who provide an approved methodologically proposal in the same purpose,NA,Yes,"Individual participant data that underline the results reported in this article, after de-identification",2020-11-01T12:04:44Z,2020-11-01T12:04:44Z
NCT04354155,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-13,NA,NA,2020-07-23,2020-04-16,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-07-23,2020-07-27,Actual,"June 2, 2020",Actual,2020-06-02,July 2020,2020-07-31,"October 15, 2022",Anticipated,2022-10-15,September 2022,Anticipated,2022-09-30,NA,Interventional,NA,,COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial,COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial,Recruiting,NA,Phase 2,38,Anticipated,Johns Hopkins All Children's Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:08Z,2020-11-01T12:05:08Z
NCT04350281,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-13,NA,NA,2020-07-27,2020-04-13,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-27,2020-07-28,Actual,"April 9, 2020",Actual,2020-04-09,July 2020,2020-07-31,"July 7, 2020",Actual,2020-07-07,"July 1, 2020",Actual,2020-07-01,NA,Interventional,NA,,Double Therapy With IFN-beta 1b and Hydroxychloroquine,"An Open-label Randomized Controlled Trial on Interferon Î²-1b and Hydroxychloroquine Combination Versus Hydroxychloroquine Alone, as Treatment for COVID-19 Infection",Completed,NA,Phase 2,60,Actual,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:38Z,2020-11-01T12:05:38Z
NCT04349241,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-13,NA,NA,2020-06-24,2020-04-15,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-24,2020-06-25,Actual,"April 18, 2020",Actual,2020-04-18,June 2020,2020-06-30,"June 20, 2020",Actual,2020-06-20,"June 1, 2020",Actual,2020-06-01,NA,Interventional,FAV-001,,Efficacy and Safety of Favipiravir in Management of COVID-19,Efficacy and Safety of Favipiravir in Management of COVID-19,Completed,NA,Phase 3,100,Actual,Ain Shams University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:45Z,2020-11-01T12:05:45Z
NCT04348864,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-13,NA,NA,2020-10-25,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-10-25,2020-10-28,Actual,"April 16, 2020",Actual,2020-04-16,October 2020,2020-10-31,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,COVID-19 Diagnostic Self-testing Using Virtual Point-of-care,Assessment of COVID-19 Diagnostic Self-testing Using Virtual Point-of-care,Recruiting,NA,N/A,100,Anticipated,Neuroganics LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:47Z,2020-11-01T12:05:47Z
NCT04348695,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-13,NA,NA,2020-04-15,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"April 12, 2020",Actual,2020-04-12,April 2020,2020-04-30,"May 13, 2020",Anticipated,2020-05-13,"May 13, 2020",Anticipated,2020-05-13,NA,Interventional,Ruxo-Sim-20,,Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.,Randomized Phase II Clinical Trial of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.Ruxo-Sim-20 Clinical Trial.,Recruiting,NA,Phase 2,94,Anticipated,FundaciÃ³n de investigaciÃ³n HM,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:05:49Z,2020-11-01T12:05:49Z
NCT04348500,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-13,NA,NA,2020-09-30,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"April 24, 2020",Actual,2020-04-24,September 2020,2020-09-30,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease,A Phase II Trial to Evaluate the Safety and Tolerability of ClazakizumabÂ® (Anti-IL- 6 Monoclonal) Compared to Placebo for the Treatment of COVID-19 Infection,"Active, not recruiting",NA,Phase 2,17,Actual,Cedars-Sinai Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:05:50Z,2020-11-01T12:05:50Z
NCT04347954,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-13,NA,NA,2020-10-21,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-23,Actual,"August 15, 2020",Actual,2020-08-15,October 2020,2020-10-31,January 2021,Anticipated,2021-01-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19),Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers,Recruiting,NA,Phase 1/Phase 2,45,Anticipated,Stanford University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:58Z,2020-11-01T12:05:58Z
NCT04347239,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-13,NA,NA,2020-10-14,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"April 15, 2020",Actual,2020-04-15,October 2020,2020-10-31,"April 1, 2021",Anticipated,2021-04-01,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19),"A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)",Recruiting,NA,Phase 2,390,Anticipated,"CytoDyn, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:06:03Z,2020-11-01T12:06:03Z
NCT04346667,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-13,NA,NA,2020-04-30,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-01,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"June 30, 2021",Anticipated,2021-06-30,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,PEACE,,Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds,Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate,Recruiting,NA,Phase 4,400,Anticipated,"Government of Punjab, Specialized Healthcare and Medical Education Department",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:07Z,2020-11-01T12:06:07Z
NCT04346017,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-13,NA,NA,2020-04-13,2020-04-13,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-04-13,2020-04-15,Actual,"March 20, 2020",Actual,2020-03-20,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome,Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in SARS-Cov-2 Infected Patients With a Systemic Inflammatory Response Syndrome,Recruiting,NA,N/A,200,Anticipated,Brugmann University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:06:11Z,2020-11-01T12:06:11Z
NCT04348656,"ClinicalTrials.gov processed this data on November 06, 2020",2020-04-13,NA,NA,2020-11-04,2020-04-13,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-05,Actual,"May 14, 2020",Actual,2020-05-14,September 2020,2020-09-30,"December 31, 2020",Anticipated,2020-12-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,CONCOR-1,,CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1),A Randomized Open-Label Trial of CONvalenscent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1),Recruiting,NA,Phase 3,1200,Anticipated,McMaster University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-09T10:54:05Z,2020-11-09T10:54:05Z
NCT04355728,"ClinicalTrials.gov processed this data on November 13, 2020",2020-04-13,NA,NA,2020-11-09,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"April 25, 2020",Actual,2020-04-25,November 2020,2020-11-30,"October 31, 2020",Actual,2020-10-31,"October 31, 2020",Actual,2020-10-31,NA,Interventional,NA,,Use of UC-MSCs for COVID-19 Patients,Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS),Completed,NA,Phase 1/Phase 2,24,Actual,University of Miami,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-15T10:59:42Z,2020-11-15T10:59:42Z
NCT04382391,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-14,NA,NA,2020-10-20,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-10-20,2020-10-22,Actual,"May 8, 2020",Actual,2020-05-08,May 2020,2020-05-31,"December 30, 2021",Anticipated,2021-12-30,"March 1, 2021",Anticipated,2021-03-01,NA,Interventional,SAVIORII,,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,"A Prospective, Randomized, Controlled Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms (SAVIORII)",Recruiting,NA,N/A,20,Anticipated,Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute),,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:32Z,2020-11-01T12:01:32Z
NCT04361916,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-14,NA,NA,2020-09-10,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-09-10,2020-09-14,Actual,"April 21, 2020",Actual,2020-04-21,August 2020,2020-08-31,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Interventional,Mon-Covid,,Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units (Casale Monferrato and Torino),Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units (Casale Monferrato and Torino),Terminated,NA,N/A,37,Actual,Mario Negri Institute for Pharmacological Research,,1,NA,interrupted early due to the drastic reduction in the number of cases,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,data will be available from the study sponsor upon legitimate request,2020-11-01T12:04:08Z,2020-11-01T12:04:08Z
NCT04357106,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-14,NA,NA,2020-04-21,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-22,Actual,"April 13, 2020",Actual,2020-04-13,April 2020,2020-04-30,August 2020,Anticipated,2020-08-31,July 2020,Anticipated,2020-07-31,NA,Interventional,COPLA,,COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma,COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma,Recruiting,NA,Phase 2,10,Anticipated,Centro de HematologÃ­a y Medicina Interna,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:04:46Z,2020-11-01T12:04:46Z
NCT04356833,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-14,NA,NA,2020-04-28,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-30,Actual,"April 22, 2020",Actual,2020-04-22,April 2020,2020-04-30,"January 14, 2021",Anticipated,2021-01-14,"January 14, 2021",Anticipated,2021-01-14,NA,Interventional,PACA,,Nebulised Rt-PA for ARDS Due to COVID-19,"A Pilot, Open Label, Phase II Clinical Trial of Nebulised Recombinant Tissue-Plasminogen Activator (Rt-PA)",Recruiting,NA,Phase 2,24,Anticipated,"University College, London",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:04:48Z,2020-11-01T12:04:48Z
NCT04355143,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-14,NA,NA,2020-05-19,2020-04-20,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-21,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"April 25, 2021",Anticipated,2021-04-25,"April 25, 2021",Anticipated,2021-04-25,NA,Interventional,COLHEART-19,,Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19),"Randomized, Open-Label, Controlled Trial of Colchicine to Reduce Cardiac Injury in Hospitalized COVID-19 Patients (COLHEART-19)",Recruiting,NA,Phase 2,150,Anticipated,"University of California, Los Angeles",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:02Z,2020-11-01T12:05:02Z
NCT04354831,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-14,NA,NA,2020-05-11,2020-04-16,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-13,Actual,"May 11, 2020",Actual,2020-05-11,May 2020,2020-05-31,"May 1, 2023",Anticipated,2023-05-01,"May 1, 2022",Anticipated,2022-05-01,NA,Interventional,NA,,A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection,"An Open Label, Phase 2 Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection",Recruiting,NA,Phase 2,131,Anticipated,Medical College of Wisconsin,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:05:04Z,2020-11-01T12:05:04Z
NCT04354610,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-14,NA,NA,2020-05-05,2020-04-16,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-05,2020-05-06,Actual,"April 27, 2020",Actual,2020-04-27,April 2020,2020-04-30,"October 18, 2020",Anticipated,2020-10-18,"July 18, 2020",Anticipated,2020-07-18,NA,Interventional,Nancy-CovH-AKI,,Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe Covid-19 Infection,Prediction of Acute Heart or Kidney Injury With Cardiovascular-renal Biomarkers in Patients Hospitalised for Severe or Critical Covid-19 Infection,Recruiting,NA,N/A,57,Anticipated,"Central Hospital, Nancy, France",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:05:06Z,2020-11-01T12:05:06Z
NCT04353596,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-14,NA,NA,2020-06-08,2020-04-16,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-11,Actual,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,"May 15, 2022",Anticipated,2022-05-15,"May 15, 2021",Anticipated,2021-05-15,NA,Interventional,ACEI-COVID,,Stopping ACE-inhibitors in COVID-19,Stopping ACE-inhibitors in COVID-19: A Randomized Controlled Trial,Recruiting,NA,Phase 4,208,Anticipated,Medical University Innsbruck,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:05:13Z,2020-11-01T12:05:13Z
NCT04352608,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-14,NA,NA,2020-08-02,2020-04-16,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-08-02,2020-08-04,Actual,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,"December 13, 2020",Anticipated,2020-12-13,"July 10, 2020",Actual,2020-07-10,NA,Interventional,NA,,Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19),"A Randomized, Double-Blinded, Placebo-Controlled, Phase â… /â…¡ Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18~59 Years","Active, not recruiting",NA,Phase 1/Phase 2,744,Actual,"Sinovac Biotech Co., Ltd",,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:05:19Z,2020-11-01T12:05:19Z
NCT04351542,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-14,NA,NA,2020-04-15,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-15,2020-04-17,Actual,"March 6, 2020",Actual,2020-03-06,April 2020,2020-04-30,"April 12, 2020",Actual,2020-04-12,"April 6, 2020",Actual,2020-04-06,NA,Interventional,NA,,Ayurveda for Flu Like Illness During Covid-19 Outbreak,Ayurveda for Flu-like Illness During the Covid 19 Outbreak: Non Randomised Single-blind Controlled Trial,Completed,NA,N/A,32,Actual,Aarogyam UK,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:05:28Z,2020-11-01T12:05:28Z
NCT04351763,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-14,NA,NA,2020-04-16,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-17,Actual,"April 27, 2020",Anticipated,2020-04-27,April 2020,2020-04-30,"April 10, 2021",Anticipated,2021-04-10,"March 2, 2021",Anticipated,2021-03-02,NA,Interventional,ReCOVery-SIRIO,,Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms,Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms,Recruiting,NA,Phase 2/Phase 3,804,Anticipated,Nicolaus Copernicus University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:05:26Z,2020-11-01T12:05:26Z
NCT04351620,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-14,NA,NA,2020-04-14,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-14,2020-04-17,Actual,April 2020,Anticipated,2020-04-30,April 2020,2020-04-30,June 2020,Anticipated,2020-06-30,June 2020,Anticipated,2020-06-30,NA,Interventional,NA,,High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19,High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19,Recruiting,NA,Phase 1,20,Anticipated,University of Chicago,,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:05:27Z,2020-11-01T12:05:27Z
NCT04351581,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-14,NA,NA,2020-06-04,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-05,Actual,"May 18, 2020",Actual,2020-05-18,June 2020,2020-06-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,RASCOVID-19,,Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19,Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19,Recruiting,NA,N/A,215,Anticipated,"University Hospital, Gentofte, Copenhagen",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:27Z,2020-11-01T12:05:27Z
NCT04351191,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-14,NA,NA,2020-04-29,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-05-01,Actual,"April 15, 2020",Actual,2020-04-15,April 2020,2020-04-30,"June 30, 2020",Anticipated,2020-06-30,"May 30, 2020",Anticipated,2020-05-30,NA,Interventional,PRECISE,,PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds,Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate,Recruiting,NA,Phase 4,400,Anticipated,"Government of Punjab, Specialized Healthcare and Medical Education Department",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:30Z,2020-11-01T12:05:30Z
NCT04350736,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-14,NA,NA,2020-08-31,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-02,Actual,"April 23, 2020",Actual,2020-04-23,August 2020,2020-08-31,"June 24, 2020",Actual,2020-06-24,"June 24, 2020",Actual,2020-06-24,NA,Interventional,NA,,"First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19","A Phase 1, Double-blind, Randomized, Placebo-controlled, Sponsor-open, SAD and MAD Study in Healthy Subjects to Evaluate the Safety, Tolerability, and PK of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19",Completed,NA,Phase 1,54,Actual,Theravance Biopharma,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.",2020-11-01T12:05:34Z,2020-11-01T12:05:34Z
NCT04350723,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-14,NA,NA,2020-10-19,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-22,Actual,"June 10, 2020",Actual,2020-06-10,October 2020,2020-10-31,"August 30, 2021",Anticipated,2021-08-30,"July 30, 2021",Anticipated,2021-07-30,NA,Interventional,COVI-PRONE,,Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 (COVI-PRONE): A Randomized Clinical Trial,Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 (COVI-PRONE): A Randomized Clinical Trial,Recruiting,NA,N/A,350,Anticipated,St. Joseph's Healthcare Hamilton,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:35Z,2020-11-01T12:05:35Z
NCT04350684,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-14,NA,NA,2020-04-16,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-20,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"April 24, 2020",Anticipated,2020-04-24,"April 22, 2020",Anticipated,2020-04-22,NA,Interventional,UAIIC,,Umifenovir in Hospitalized COVID-19 Patients,"Efficacy and Safety of Umifenovir as an Adjuvant Therapy Compared to the Control Therapeutic Regiment of Interferon Beta 1a, Lopinavir / Ritonavir and a Single Dose of Hydroxychloroquine in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial",Enrolling by invitation,NA,Phase 4,40,Anticipated,Shahid Beheshti University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,There is no further information.,2020-11-01T12:05:35Z,2020-11-01T12:05:35Z
NCT04350671,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-14,NA,NA,2020-04-16,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-04-16,2020-04-20,Actual,"April 15, 2020",Anticipated,2020-04-15,April 2020,2020-04-30,"April 24, 2020",Anticipated,2020-04-24,"April 20, 2020",Anticipated,2020-04-20,NA,Interventional,IB1aIC,,Interferon Beta 1a in Hospitalized COVID-19 Patients,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial",Enrolling by invitation,NA,Phase 4,40,Anticipated,Shahid Beheshti University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,There is no further information.,2020-11-01T12:05:35Z,2020-11-01T12:05:35Z
NCT04350593,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-14,NA,NA,2020-08-26,2020-04-14,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-08-26,2020-08-27,Actual,"April 22, 2020",Actual,2020-04-22,August 2020,2020-08-31,December 2020,Anticipated,2020-12-31,October 2020,Anticipated,2020-10-31,NA,Interventional,DARE-19,,Dapagliflozin in Respiratory Failure in Patients With COVID-19,"An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients With COVID-19",Recruiting,NA,Phase 3,900,Anticipated,Saint Luke's Health System,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:35Z,2020-11-01T12:05:35Z
NCT04350320,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-14,NA,NA,2020-05-02,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-05-02,2020-05-05,Actual,"April 30, 2020",Actual,2020-04-30,April 2020,2020-04-30,"November 20, 2020",Anticipated,2020-11-20,"October 20, 2020",Anticipated,2020-10-20,NA,Interventional,COL-COVID,,Trial to Study the Benefit of Colchicine in Patients With COVID-19,"Administration of Colchicine Plus Standard Treatment vs. Standard Therapy, in Hospitalized Patients With COVID-19, Within the First 48 Hours, and no Severity Criteria.",Recruiting,NA,Phase 3,102,Anticipated,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:37Z,2020-11-01T12:05:37Z
NCT04349098,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-14,NA,NA,2020-05-06,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-08,Actual,"April 17, 2020",Actual,2020-04-17,May 2020,2020-05-31,"August 31, 2020",Anticipated,2020-08-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,Coronavirus,,Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection,A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection,Recruiting,NA,Phase 2,230,Anticipated,Karyopharm Therapeutics Inc,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:05:46Z,2020-11-01T12:05:46Z
NCT04348435,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-14,NA,NA,2020-07-10,2020-04-14,2020-04-16,Actual,NA,NA,NA,NA,NA,NA,2020-07-10,2020-07-14,Actual,"May 14, 2020",Actual,2020-05-14,July 2020,2020-07-31,"April 30, 2021",Anticipated,2021-04-30,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19","A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19",Enrolling by invitation,NA,Phase 2,100,Anticipated,Hope Biosciences,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:53Z,2020-11-01T12:05:53Z
NCT04347915,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-14,NA,NA,2020-06-26,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-26,2020-06-30,Actual,"May 6, 2020",Actual,2020-05-06,June 2020,2020-06-30,"December 31, 2020",Anticipated,2020-12-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19,"A Single Blind, Randomized, Placebo-controlled, Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients Diagnosed With Moderate COVID-19",Recruiting,NA,Phase 2,60,Anticipated,Bukwang Pharmaceutical,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:05:58Z,2020-11-01T12:05:58Z
NCT04346446,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-14,NA,NA,2020-06-11,2020-04-14,2020-04-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-11,2020-06-12,Actual,"April 20, 2020",Actual,2020-04-20,June 2020,2020-06-30,"May 30, 2020",Actual,2020-05-30,"May 30, 2020",Actual,2020-05-30,NA,Interventional,NA,,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients: A Pilot Randomized Controlled Trial,Completed,NA,Phase 2,29,Actual,"Institute of Liver and Biliary Sciences, India",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:06:09Z,2020-11-01T12:06:09Z
NCT04357808,"ClinicalTrials.gov processed this data on November 13, 2020",2020-04-14,NA,NA,2020-11-08,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-11-08,2020-11-10,Actual,"April 13, 2020",Actual,2020-04-13,November 2020,2020-11-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,SARCOVID,,Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID),Randomized Open Pilot Study to Evaluate the Efficacy of Subcutaneous Sarilumab in Patients With Moderate-severe COVID-19 Infection,"Active, not recruiting",NA,Phase 2,30,Actual,FundaciÃ³n de InvestigaciÃ³n BiomÃ©dica - Hospital Universitario de La Princesa,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-14T10:43:13Z,2020-11-14T10:43:13Z
NCT04498936,"ClinicalTrials.gov processed this data on November 13, 2020",2020-04-14,NA,NA,2020-11-10,2020-08-03,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"July 15, 2020",Actual,2020-07-15,November 2020,2020-11-30,"October 30, 2020",Actual,2020-10-30,"October 30, 2020",Actual,2020-10-30,NA,Interventional,NA,,Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19,"Efficacy of Adding Sofosbuvir/Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19: A Randomized Controlled Trial",Completed,NA,Phase 4,240,Actual,Assiut University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-15T10:57:49Z,2020-11-15T10:57:49Z
NCT04359095,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-15,NA,NA,2020-09-27,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-09-27,2020-09-30,Actual,"August 18, 2020",Actual,2020-08-18,September 2020,2020-09-30,"February 28, 2021",Anticipated,2021-02-28,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,NA,,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia: A Pragmatic Randomized Controlled Trial,Recruiting,NA,Phase 2/Phase 3,1200,Anticipated,Universidad Nacional de Colombia,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,As soon we have checked the quality of data of recruited participants,Approved by the monitor committee of the study,NA,Yes,Communicating trial results and data to be able to combine data from multiple studies (live SR),2020-11-01T12:04:33Z,2020-11-01T12:04:33Z
NCT04356534,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-15,NA,NA,2020-07-27,2020-04-17,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-07-27,2020-07-28,Actual,"April 19, 2020",Actual,2020-04-19,July 2020,2020-07-31,"July 9, 2020",Actual,2020-07-09,"June 15, 2020",Actual,2020-06-15,NA,Interventional,NA,,Convalescent Plasma Trial in COVID -19 Patients,Use of Convalescent Plasma Therapy for COVID-19 Patients With Hypoxia: a Prospective Randomized Trial,Completed,NA,N/A,40,Actual,Royal College of Surgeons in Ireland - Medical University of Bahrain,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,"Dr Manaf will act as the data custodian and is responsible for the storage, handling and quality of the study data.
Data will be collected in the case report form to allow for cross referencing to check validity.
Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished. All essential documents including source documents will be retained for a period of 5 years after study completion (last patient, last study point). A label stating the date after which the documents can be destroyed will be placed on the inside front cover of the case notes of trial participants.",Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished.,NA,Yes,"Monitoring, audits, and REC review will be permitted and provide direct access to source data and documents. The Lead PI and the researchers assigned by him will have access to the stored data/specimens. Only the Lead PI and the researchers assigned working on this study will be eligible to obtain the data/specimens from the participants during data collection.",2020-11-01T12:04:50Z,2020-11-01T12:04:50Z
NCT04355897,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-15,NA,NA,2020-05-18,2020-04-20,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-20,Actual,"April 28, 2020",Actual,2020-04-28,May 2020,2020-05-31,August 2020,Anticipated,2020-08-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,CoVID-19 Plasma in Treatment of COVID-19 Patients,Convalescent CoVID-19 Plasma in the Treatment of High Risk CoVID-19 Disease,Recruiting,NA,Early Phase 1,100,Anticipated,The Christ Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:04:56Z,2020-11-01T12:04:56Z
NCT04355637,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-15,NA,NA,2020-07-22,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-07-22,2020-07-23,Actual,"April 21, 2020",Actual,2020-04-21,July 2020,2020-07-31,"October 18, 2020",Anticipated,2020-10-18,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,NA,,Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia,Treatment With Inhaled Corticosteroids in Patients Hospitalized Because of COVID19 Pneumonia,Recruiting,NA,Phase 4,300,Anticipated,Fundacion Clinic per a la Recerca BiomÃ©dica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:04:58Z,2020-11-01T12:04:58Z
NCT04355364,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-15,NA,NA,2020-10-15,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-10-15,2020-10-19,Actual,"April 21, 2020",Actual,2020-04-21,October 2020,2020-10-31,"April 21, 2021",Anticipated,2021-04-21,"November 21, 2020",Anticipated,2020-11-21,NA,Interventional,COVIDORNASE,,Efficacy and Safety of Aerosolized Intra-tracheal Dornase Alfa Administration in Patients With COVID19-induced ARDS (COVIDORNASE),Efficacy and Safety of Aerosolized Intra-tracheal Dornase Alfa Administration in Patients With COVID19-induced Acute Respiratory Distress Syndrome (ARDS),Recruiting,NA,Phase 3,100,Anticipated,Fondation Ophtalmologique Adolphe de Rothschild,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:01Z,2020-11-01T12:05:01Z
NCT04355026,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-15,NA,NA,2020-04-18,2020-04-18,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-18,2020-04-21,Actual,"April 10, 2020",Anticipated,2020-04-10,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia,Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia,Recruiting,NA,Phase 4,90,Anticipated,General and Teaching Hospital Celje,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:05:03Z,2020-11-01T12:05:03Z
NCT04353336,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-15,NA,NA,2020-08-03,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-08-03,2020-08-05,Actual,"March 23, 2020",Actual,2020-03-23,August 2020,2020-08-31,"December 23, 2020",Anticipated,2020-12-23,"September 23, 2020",Anticipated,2020-09-23,NA,Interventional,NA,,Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment,Clinical Study Evaluating the Efficacy of Chloroquine or Hydroxychloroquine in COVID-19 Treatment,Recruiting,NA,Phase 2/Phase 3,200,Anticipated,Tanta University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:14Z,2020-11-01T12:05:14Z
NCT04352959,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-15,NA,NA,2020-09-21,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-23,Actual,"April 27, 2020",Actual,2020-04-27,September 2020,2020-09-30,"December 20, 2020",Anticipated,2020-12-20,"November 20, 2020",Anticipated,2020-11-20,NA,Interventional,BBCovid,,COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses,"COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses: Double-blind, Randomized, Placebo-controlled Clinical Study",Recruiting,NA,N/A,206,Anticipated,Claude Bernard University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:05:17Z,2020-11-01T12:05:17Z
NCT04351347,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-15,NA,NA,2020-08-01,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-08-01,2020-08-04,Actual,"June 16, 2020",Actual,2020-06-16,August 2020,2020-08-31,"December 1, 2030",Anticipated,2030-12-01,"December 1, 2030",Anticipated,2030-12-01,NA,Interventional,NA,,The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment,Clinical Study Evaluating the Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment,Recruiting,NA,Phase 2/Phase 3,300,Anticipated,Tanta University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:29Z,2020-11-01T12:05:29Z
NCT04351295,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-15,NA,NA,2020-09-25,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-09-25,2020-09-29,Actual,"April 20, 2020",Actual,2020-04-20,September 2020,2020-09-30,"December 1, 2020",Anticipated,2020-12-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,NA,,Efficacy of Faviprevir in COVID-19 Treatment,Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 Treatment,Recruiting,NA,Phase 2/Phase 3,90,Anticipated,Tanta University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:29Z,2020-11-01T12:05:29Z
NCT04351152,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-15,NA,NA,2020-08-03,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-08-03,2020-08-05,Actual,"April 30, 2020",Actual,2020-04-30,August 2020,2020-08-31,September 2020,Anticipated,2020-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19,"A Phase 3 Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients With Severe and Critical COVID-19 Pneumonia",Recruiting,NA,Phase 3,300,Anticipated,"Humanigen, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-11-01T12:05:31Z,2020-11-01T12:05:31Z
NCT04359290,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-15,NA,NA,2020-10-28,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-10-28,2020-10-29,Actual,"July 1, 2020",Actual,2020-07-01,August 2020,2020-08-31,July 2021,Anticipated,2021-07-31,December 2020,Anticipated,2020-12-31,NA,Interventional,RuXoCoil,,Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS,"Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS A Single-arm, Open-label, Proof of Concept Study","Active, not recruiting",NA,Phase 2,15,Actual,Philipps University Marburg Medical Center,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,3 Months after publication,Central server,NA,Yes,Study protocol will be provided after publication,2020-11-02T10:30:19Z,2020-11-02T10:30:19Z
NCT04351243,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-15,NA,NA,2020-10-28,2020-04-15,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-10-28,2020-10-29,Actual,"April 12, 2020",Actual,2020-04-12,October 2020,2020-10-31,March 2021,Anticipated,2021-03-31,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,,A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE),"A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)","Active, not recruiting",NA,Phase 2,227,Actual,Kinevant Sciences GmbH,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-02T10:30:22Z,2020-11-02T10:30:22Z
NCT04357327,"ClinicalTrials.gov processed this data on November 06, 2020",2020-04-15,NA,NA,2020-11-02,2020-04-18,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-04,Actual,"April 16, 2020",Actual,2020-04-16,November 2020,2020-11-30,"July 31, 2020",Actual,2020-07-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,,Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19),Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19): a Diagnostic Accuracy Study,Completed,NA,N/A,122,Actual,UniversitÃ  degli Studi dell'Insubria,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"Data will be available at the end of the study, once statistical analyses is conducted",Contact Principal Investigator,NA,Yes,"We could provide anamnestic, clinical and serological data of each participant at the end of the study, or at least at the end of the first phase.",2020-11-08T11:36:05Z,2020-11-08T11:36:05Z
NCT04351516,"ClinicalTrials.gov processed this data on November 06, 2020",2020-04-15,NA,NA,2020-11-04,2020-04-16,2020-04-17,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-05,Actual,"April 21, 2020",Actual,2020-04-21,April 2020,2020-04-30,"May 1, 2021",Anticipated,2021-05-01,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,COVID65plus,,Test and Treat COVID 65plus+,Randomized Controlled Trial of Hydroxychloroquine Versus Placebo in Early Ambulatory Diagnosis and Treatment of Elderly COVID19 Patients,"Active, not recruiting",NA,Phase 2/Phase 3,350,Anticipated,University Hospital Tuebingen,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-09T10:54:03Z,2020-11-09T10:54:03Z
NCT04419610,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-16,NA,NA,2020-10-12,2020-06-04,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2020-10-12,2020-10-14,Actual,"October 9, 2020",Actual,2020-10-09,October 2020,2020-10-31,May 2021,Anticipated,2021-05-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,RAS and Coagulopathy in COVID19,Investigating the Relationship Between the Renin Angiotensin System and the Coagulopathy Associated With COVID-19,Recruiting,NA,Early Phase 1,60,Anticipated,Imperial College London,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:56:32Z,2020-11-01T11:56:32Z
NCT04367662,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-16,NA,NA,2020-06-05,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"April 9, 2020",Actual,2020-04-09,June 2020,2020-06-30,"May 14, 2020",Actual,2020-05-14,"May 14, 2020",Actual,2020-05-14,NA,Interventional,COVID'HEMOS,,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,Completed,NA,N/A,99,Actual,"University Hospital, Rouen",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:25Z,2020-11-01T12:03:25Z
NCT04361838,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-16,NA,NA,2020-06-02,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"June 1, 2020",Anticipated,2020-06-01,June 2020,2020-06-30,"August 31, 2020",Anticipated,2020-08-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,NA,,The COVID-19 ICU PRAYER Study,Impact of Multi-Denominational Prayer on Morbidity and Mortality of Patients Admitted to the Intensive Care Unite With Corona Virus Infection,Recruiting,NA,N/A,1000,Anticipated,Kansas City Heart Rhythm Institute,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:04:09Z,2020-11-01T12:04:09Z
NCT04361344,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-16,NA,NA,2020-05-19,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-21,Actual,"May 19, 2020",Actual,2020-05-19,May 2020,2020-05-31,"January 19, 2021",Anticipated,2021-01-19,"January 19, 2021",Anticipated,2021-01-19,NA,Interventional,MARNEVO-Covid,,Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection,Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection - MARNEVO-Covid,Recruiting,NA,N/A,30,Anticipated,Centre Hospitalier de PAU,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:04:16Z,2020-11-01T12:04:16Z
NCT04359264,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-16,NA,NA,2020-07-06,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-06,2020-07-07,Actual,"April 20, 2020",Actual,2020-04-20,July 2020,2020-07-31,"December 30, 2020",Anticipated,2020-12-30,"May 29, 2020",Actual,2020-05-29,NA,Interventional,DISTANSE COVID,,Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial,Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial (DISTANSE COVID-19 RCT),"Active, not recruiting",NA,N/A,392,Actual,"St. Michael's Hospital, Toronto",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:04:32Z,2020-11-01T12:04:32Z
NCT04358406,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-16,NA,NA,2020-07-30,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-30,2020-07-31,Actual,"July 30, 2020",Actual,2020-07-30,July 2020,2020-07-31,"October 30, 2020",Anticipated,2020-10-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,NA,,Rhu-pGSN for Severe Covid-19 Pneumonia,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Study To Evaluate Efficacy And Safety Of Recombinant Human Plasma Gelsolin (Rhu-pGSN) Added To Standard Of Care In Subjects With Severe Covid-19 Pneumonia",Recruiting,NA,Phase 2,60,Anticipated,BioAegis Therapeutics Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:04:38Z,2020-11-01T12:04:38Z
NCT04354870,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-16,NA,NA,2020-10-01,2020-04-16,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-10-01,2020-10-05,Actual,"April 3, 2020",Actual,2020-04-03,October 2020,2020-10-31,"October 1, 2020",Actual,2020-10-01,"September 15, 2020",Actual,2020-09-15,NA,Interventional,NA,,COVID-19 PrEP HCW HCQ Study,Off Label Study to Evaluate the Efficacy of HCQ for Pre-exposure Prophylaxis (PrEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers (HCWs) Who Are at High Risk of Occupational Exposure to SARS-CoV-2,Completed,NA,Phase 2,130,Actual,NYU Langone Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,Study internal to NYU at this time,2020-11-01T12:05:04Z,2020-11-01T12:05:04Z
NCT04354259,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-16,NA,NA,2020-05-13,2020-04-20,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-18,Actual,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,"November 30, 2020",Anticipated,2020-11-30,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,ILIAD,,Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19,"Interferon Lambda for Immediate Antiviral Therapy at Diagnosis (ILIAD): A Phase II Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19",Recruiting,NA,Phase 2,140,Anticipated,"University Health Network, Toronto",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:08Z,2020-11-01T12:05:08Z
NCT04353284,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-16,NA,NA,2020-09-04,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-09-04,2020-09-07,Actual,"June 19, 2020",Actual,2020-06-19,September 2020,2020-09-30,"May 31, 2021",Anticipated,2021-05-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,NA,,Camostat Mesylate in COVID-19 Outpatients,"The Effect of Camostat Mesylate on COVID-19 Infection in Ambulatory Patients: An Investigator-Initiated Randomized, Placebo-Controlled, Phase IIa Trial",Recruiting,NA,Phase 2,114,Anticipated,Yale University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:15Z,2020-11-01T12:05:15Z
NCT04353206,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-16,NA,NA,2020-07-13,2020-04-16,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-07-13,2020-07-15,Actual,"June 27, 2020",Actual,2020-06-27,July 2020,2020-07-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure,A Feasibility Study Assessing the Safety of Multiple Doses of Anti-SARS-CoV-2 Plasma in Mechanically Ventilated Intubated Patients With Respiratory Failure Due to COVID-19,Recruiting,NA,Early Phase 1,60,Anticipated,Cedars-Sinai Medical Center,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:05:15Z,2020-11-01T12:05:15Z
NCT04353128,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-16,NA,NA,2020-06-11,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-06-11,2020-06-16,Actual,"April 20, 2020",Actual,2020-04-20,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,October 2020,Anticipated,2020-10-31,NA,Interventional,MeCOVID,,Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.,Multicenter Randomized Controlled Trial of the Efficacy of Melatonin in the Prophylaxis of SARS-coronavirus-2 Infection Among High Risk Contacts.,Recruiting,NA,Phase 2/Phase 3,450,Anticipated,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:16Z,2020-11-01T12:05:16Z
NCT04352751,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-16,NA,NA,2020-09-28,2020-04-17,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-29,Actual,"May 1, 2020",Actual,2020-05-01,April 2020,2020-04-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020,Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020,Recruiting,NA,N/A,2000,Anticipated,Hilton Pharma,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:18Z,2020-11-01T12:05:18Z
NCT04358549,"ClinicalTrials.gov processed this data on November 09, 2020",2020-04-16,NA,NA,2020-11-05,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-11-05,2020-11-06,Actual,"April 17, 2020",Actual,2020-04-17,November 2020,2020-11-30,"November 1, 2020",Anticipated,2020-11-01,"November 1, 2020",Anticipated,2020-11-01,NA,Interventional,NA,,Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19,"Open Label, Randomized, Controlled Phase 2 Proof-of-Concept Study of the Use of Favipiravir Compared to Standard of Care in Hospitalized Subjects With COVID-19","Active, not recruiting",NA,Phase 2,50,Actual,"Fujifilm Pharmaceuticals U.S.A., Inc.",,2,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-10T11:28:38Z,2020-11-10T11:28:38Z
NCT04358939,"ClinicalTrials.gov processed this data on November 13, 2020",2020-04-16,NA,NA,2020-11-12,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-13,Estimate,"April 27, 2020",Actual,2020-04-27,November 2020,2020-11-30,"November 24, 2021",Anticipated,2021-11-24,"November 10, 2021",Anticipated,2021-11-10,NA,Interventional,NA,,Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 (HIGH-PRONE-COVID-19),Evaluation of Prone Position in Conscious Patients on Nasal High-flow Oxygen Therapy for COVID-19 Disease Induced Acute Respiratory Distress Syndrome,Recruiting,NA,N/A,404,Anticipated,"University Hospital, Tours",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Data will be available immediately following publication and ending in 5 years.,Contact with the corresponding author.,NA,Yes,Individual participant data after de-identification can be obtained by contacting the corresponding author.,2020-11-15T10:59:40Z,2020-11-15T10:59:40Z
NCT04354428,"ClinicalTrials.gov processed this data on November 13, 2020",2020-04-16,NA,NA,2020-11-09,2020-04-16,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"April 16, 2020",Actual,2020-04-16,November 2020,2020-11-30,January 2021,Anticipated,2021-01-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Treatment for COVID-19 in High-Risk Adult Outpatients,Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults: An Adaptive Randomized Platform Trial,"Active, not recruiting",NA,Phase 2/Phase 3,300,Anticipated,University of Washington,,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,Within 3 months of publication of primary results.,De-identified data from the study will be made available in accordance with the funder's open access policy.,https://www.gatesfoundation.org/how-we-work/general-information/open-access-policy,Yes,De-identified data from the study will be made available in accordance with the funder's open access policy.,2020-11-15T10:59:43Z,2020-11-15T10:59:43Z
NCT04375774,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-17,NA,NA,2020-05-04,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-04,2020-05-05,Actual,May 2020,Anticipated,2020-05-31,May 2020,2020-05-31,May 2020,Anticipated,2020-05-31,May 2020,Anticipated,2020-05-31,NA,Interventional,VADER,,Verification of Alternative Do-it-yourself Equipment Respirators for the COVID-19 Personal Protective Equipment (PPE),Verification of Alternative Do-it-yourself Equipment Respirators,Recruiting,NA,N/A,10,Anticipated,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,All data will be presented in the future manuscript,2020-11-01T12:02:21Z,2020-11-01T12:02:21Z
NCT04373044,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-17,NA,NA,2020-05-30,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-05-30,2020-06-02,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"May 1, 2022",Anticipated,2022-05-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,NA,,"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19",A Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19,Recruiting,NA,Phase 2,144,Anticipated,University of Southern California,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:02:41Z,2020-11-01T12:02:41Z
NCT04363853,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-17,NA,NA,2020-06-15,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-06-15,2020-06-17,Actual,"June 1, 2020",Actual,2020-06-01,June 2020,2020-06-30,"August 1, 2021",Anticipated,2021-08-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,,Tocilizumab Treatment in Patients With COVID-19,Treatment of Serious and Critical Patients With COVID-19 With Tocilizumab,Recruiting,NA,Phase 2,200,Anticipated,Instituto Nacional de Cancerologia de Mexico,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,Data wil be avaible in july 2020,NA,NA,Yes,NA,2020-11-01T12:03:52Z,2020-11-01T12:03:52Z
NCT04361942,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-17,NA,NA,2020-10-11,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-10-11,2020-10-14,Actual,"May 1, 2020",Actual,2020-05-01,October 2020,2020-10-31,"December 31, 2020",Anticipated,2020-12-31,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,COVID_MSV,,Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV),"Double Blind, Placebo-controlled, Phase II Trial to Evaluate Safety and Efficacy of Allogenic Mesenchymal Stromal Cells MSV_allo for Treatment of Acute Respiratory Failure in Patients With COVID-19 Pneumonia (COVID_MSV)",Recruiting,NA,Phase 2,24,Anticipated,Red de Terapia Celular,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:04:08Z,2020-11-01T12:04:08Z
NCT04359953,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-17,NA,NA,2020-07-24,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-24,2020-07-27,Actual,"April 25, 2020",Actual,2020-04-25,April 2020,2020-04-30,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,COVID-Aging,,"Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19","Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19: a Randomized, Multicenter, Adaptative Study",Recruiting,NA,Phase 3,1600,Anticipated,"University Hospital, Strasbourg, France",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:04:26Z,2020-11-01T12:04:26Z
NCT04357782,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-17,NA,NA,2020-09-17,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-09-17,2020-09-18,Actual,"April 16, 2020",Actual,2020-04-16,September 2020,2020-09-30,"October 15, 2020",Anticipated,2020-10-15,"September 18, 2020",Anticipated,2020-09-18,NA,Interventional,AVoCaDO,,Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation,"Administration of Intravenous Vitamin C in Novel Coronavirus Infection and Decreased Oxygenation (AVoCaDO): A Phase I/II Safety, Tolerability, and Efficacy Clinical Trial","Active, not recruiting",NA,Phase 1/Phase 2,20,Actual,Hunter Holmes Mcguire Veteran Affairs Medical Center,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:04:42Z,2020-11-01T12:04:42Z
NCT04356690,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-17,NA,NA,2020-09-03,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-09-03,2020-09-04,Actual,"May 8, 2020",Actual,2020-05-08,September 2020,2020-09-30,December 2021,Anticipated,2021-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Etoposide in Patients With COVID-19 Infection,"A Phase II Single-Center, Randomized, Open-Label, Safety and Efficacy Study of Etoposide in Patients With COVID-19 Infection",Recruiting,NA,Phase 2,64,Anticipated,Boston Medical Center,,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:04:49Z,2020-11-01T12:04:49Z
NCT04356482,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-17,NA,NA,2020-06-03,2020-04-17,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-05,Actual,"May 20, 2020",Actual,2020-05-20,June 2020,2020-06-30,December 2020,Anticipated,2020-12-31,November 2020,Anticipated,2020-11-30,NA,Interventional,COPLASCOV19,,CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19,DETERMINATION OF THE DOSE AND EFFECTIVENESS OF CONVALESCENT PLASMA IN SEVERELY AND VERY SEVERELY ILL PATIENTS BY COVID-19,Recruiting,NA,Phase 1/Phase 2,90,Anticipated,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:04:50Z,2020-11-01T12:04:50Z
NCT04355936,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-17,NA,NA,2020-08-04,2020-04-20,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-08-04,2020-08-06,Actual,"May 19, 2020",Actual,2020-05-19,August 2020,2020-08-31,"October 1, 2020",Anticipated,2020-10-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,NA,,Telmisartan for Treatment of COVID-19 Patients,Telmisartan for Treatment of COVID-19 Patients: an Open Label Randomized Trial,Recruiting,NA,Phase 4,400,Anticipated,Laboratorio Elea Phoenix S.A.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:04:56Z,2020-11-01T12:04:56Z
NCT04355767,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-17,NA,NA,2020-09-25,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-09-25,2020-09-29,Actual,"August 11, 2020",Actual,2020-08-11,September 2020,2020-09-30,December 2022,Anticipated,2022-12-31,December 2022,Anticipated,2022-12-31,NA,Interventional,C3PO,,Convalescent Plasma in Outpatients With COVID-19,Clinical-trial of COVID-19 Convalescent Plasma in Outpatients,Enrolling by invitation,NA,Phase 3,600,Anticipated,Stanford University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,There is no current plan to share individual participant data (IPD).,2020-11-01T12:04:57Z,2020-11-01T12:04:57Z
NCT04355533,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-17,NA,NA,2020-08-19,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-08-19,2020-08-21,Actual,"July 29, 2020",Actual,2020-07-29,August 2020,2020-08-31,December 2022,Anticipated,2022-12-31,July 2022,Anticipated,2022-07-31,NA,Interventional,PED-COVID,,Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19,Seroprevalence and Antibody Profiling Against SARS-CoV2 in Children and Their Parents,Recruiting,NA,N/A,1920,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:04:59Z,2020-11-01T12:04:59Z
NCT04355351,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-17,NA,NA,2020-06-10,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-06-10,2020-06-12,Actual,"May 5, 2020",Actual,2020-05-05,April 2020,2020-04-30,"October 22, 2020",Anticipated,2020-10-22,"October 22, 2020",Anticipated,2020-10-22,NA,Interventional,CovImmune,,Study of Immune Response During SARS-CoV-2 Infection - (COVID-19),Study of Immune Response During SARS-CoV-2 Infection,Recruiting,NA,N/A,400,Anticipated,Centre Hospitalier Universitaire de Nice,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:05:01Z,2020-11-01T12:05:01Z
NCT04355247,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-17,NA,NA,2020-04-17,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-04-17,2020-04-21,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"April 30, 2021",Anticipated,2021-04-30,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,NA,,Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm,Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm,Recruiting,NA,Phase 2,20,Anticipated,Auxilio Mutuo Cancer Center,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:05:02Z,2020-11-01T12:05:02Z
NCT04355234,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-17,NA,NA,2020-09-07,2020-04-17,2020-04-21,Actual,NA,NA,NA,NA,NA,NA,2020-09-07,2020-09-09,Actual,"May 4, 2020",Actual,2020-05-04,April 2020,2020-04-30,"August 31, 2021",Anticipated,2021-08-31,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,COVIPREG,,"Prevalence and Impact of COVID-19 Infection in Pregnant Women, Fetuses and Newborns","Prevalence and Impact of SARS-COV-2 Infection in Pregnant Women, Fetuses and Newborns",Recruiting,NA,N/A,2200,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:05:02Z,2020-11-01T12:05:02Z
NCT04377308,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-18,NA,NA,2020-05-04,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-04,2020-05-06,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"October 20, 2021",Anticipated,2021-10-20,"April 20, 2021",Anticipated,2021-04-20,NA,Interventional,NA,,Fluoxetine to Reduce Intubation and Death After COVID19 Infection,Fluoxetine to Reduce Intubation and Death After COVID19 Infection,Recruiting,NA,Phase 4,2000,Anticipated,University of Toledo Health Science Campus,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:02:10Z,2020-11-01T12:02:10Z
NCT04357730,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-18,NA,NA,2020-10-13,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-19,Actual,"May 14, 2020",Actual,2020-05-14,October 2020,2020-10-31,November 2021,Anticipated,2021-11-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,,Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection,Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection: A Phase 2a Clinical Trial,Recruiting,NA,Phase 2,60,Anticipated,Denver Health and Hospital Authority,,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,A de-identified dataset will be made available to other investigators who may submit proposals to the PI for additional analyses or validation.,2020-11-01T12:04:42Z,2020-11-01T12:04:42Z
NCT04376034,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-19,NA,NA,2020-05-01,2020-05-01,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-01,2020-05-06,Actual,"April 16, 2020",Actual,2020-04-16,May 2020,2020-05-31,"March 30, 2021",Anticipated,2021-03-30,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,NA,,Convalescent Plasma Collection and Treatment in Pediatrics and Adults,Convalescent Plasma Collection From Individuals That Recovered From COVID19 and Treatment of Critically Ill Individuals With Donor Convalescent Plasma,Recruiting,NA,Phase 3,240,Anticipated,West Virginia University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:02:19Z,2020-11-01T12:02:19Z
NCT04363814,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-19,NA,NA,2020-06-26,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-06-26,2020-06-30,Actual,"June 10, 2020",Actual,2020-06-10,June 2020,2020-06-30,"July 31, 2021",Anticipated,2021-07-31,"July 1, 2021",Anticipated,2021-07-01,NA,Interventional,NA,,Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection,"A Prospective, Open-label, Randomized Pilot Study (Including a Control Group) of BACTEK-R (MV130), Administered Sublingually to Assess the Clinical Impact in Subjects With Mild Pneumonia Due to COVID-19",Recruiting,NA,Phase 3,100,Anticipated,Inmunotek S.L.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:53Z,2020-11-01T12:03:53Z
NCT04358614,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-19,NA,NA,2020-04-21,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-21,2020-04-24,Actual,"March 16, 2020",Actual,2020-03-16,April 2020,2020-04-30,"April 7, 2020",Actual,2020-04-07,"April 5, 2020",Actual,2020-04-05,NA,Interventional,NA,,Baricitinib Therapy in COVID-19,Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact,Completed,NA,Phase 2/Phase 3,12,Actual,Hospital of Prato,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:04:36Z,2020-11-01T12:04:36Z
NCT04357028,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-19,NA,NA,2020-07-15,2020-04-19,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-16,Actual,"July 13, 2020",Anticipated,2020-07-13,July 2020,2020-07-31,"November 1, 2020",Anticipated,2020-11-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,MV-COVID19,,Measles Vaccine in HCW,Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial),Recruiting,NA,Phase 3,200,Anticipated,Kasr El Aini Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:04:46Z,2020-11-01T12:04:46Z
NCT04356937,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-19,NA,NA,2020-08-19,2020-04-19,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-08-19,2020-08-24,Actual,"April 20, 2020",Actual,2020-04-20,August 2020,2020-08-31,"October 1, 2020",Anticipated,2020-10-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,NA,,Efficacy of Tocilizumab on Patients With COVID-19,Tocilizumab to Prevent the Progression of Hypoxemic Respiratory Failure in Hospitalized Non-Critically Ill Patients With COVID-19,"Active, not recruiting",NA,Phase 3,243,Actual,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,Request for IPD can be submitted to PI for review,2020-11-01T12:04:46Z,2020-11-01T12:04:46Z
NCT04385771,"ClinicalTrials.gov processed this data on November 06, 2020",2020-04-19,NA,NA,2020-11-02,2020-05-11,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-04,Actual,"September 1, 2020",Actual,2020-09-01,November 2020,2020-11-30,"October 31, 2021",Anticipated,2021-10-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,CYCOV-II,,Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,"Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation - Randomized, Controlled, Open-label Intervention, Multi-center Trial (CYCOV-II-study)",Recruiting,NA,N/A,80,Anticipated,University Hospital Freiburg,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-08T11:35:35Z,2020-11-08T11:35:35Z
NCT04534673,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-20,NA,NA,2020-08-30,2020-08-30,2020-09-01,Actual,NA,NA,NA,NA,NA,NA,2020-08-30,2020-09-01,Actual,"August 5, 2020",Actual,2020-08-05,August 2020,2020-08-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,,Pegylated Interferon Lambda for Treatment of COVID-19 Infection,Pegylated Interferon Lambda for Treatment of COVID-19 Infection- A Randomized Open Label Pilot Trial,Recruiting,NA,Phase 2,40,Anticipated,Soroka University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:42:42Z,2020-11-01T11:42:42Z
NCT04358003,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-20,NA,NA,2020-08-13,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-08-13,2020-08-17,Actual,"May 20, 2020",Actual,2020-05-20,August 2020,2020-08-31,"December 1, 2021",Anticipated,2021-12-01,"August 1, 2021",Anticipated,2021-08-01,NA,Interventional,NA,,Plasma Adsorption in Patients With Confirmed COVID-19,Plasma Adsorption in Patients With Confirmed COVID-19 Infection,Recruiting,NA,N/A,2000,Anticipated,Marker Therapeutics AG,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,TRUE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:04:40Z,2020-11-01T12:04:40Z
NCT04374149,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-20,NA,NA,2020-09-15,2020-05-02,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-09-15,2020-09-16,Actual,"April 30, 2020",Actual,2020-04-30,September 2020,2020-09-30,"December 1, 2020",Anticipated,2020-12-01,"September 25, 2020",Anticipated,2020-09-25,NA,Interventional,NA,,Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS,"Interventional Study to Evaluate the Efficacy of Therapeutic Plasma Exchange (TPE) Alone or in Combination With Ruxolitinib in COVID-19 Positive Patients With PENN Grade 2, 3, 4 Cytokine Released Syndrome (CRS)","Active, not recruiting",NA,Phase 2,20,Actual,Prisma Health-Upstate,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:02:33Z,2020-11-01T12:02:33Z
NCT04374084,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-20,NA,NA,2020-06-03,2020-05-02,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-05,Actual,"May 10, 2020",Actual,2020-05-10,June 2020,2020-06-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,,Moxibustion Plus Cupping in Convalescent Patients With COVID-19,Moxibustion Plus Cupping in Convalescent Patients With COVID-19: A Randomized Clinical Trial,Recruiting,NA,N/A,60,Anticipated,Guang'anmen Hospital of China Academy of Chinese Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,It depends.,It depends.,NA,Yes,Individual participant data are available on reasonable request. You can send e-mail to us if you have any question.,2020-11-01T12:02:34Z,2020-11-01T12:02:34Z
NCT04368845,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-20,NA,NA,2020-05-19,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-21,Actual,"May 11, 2020",Actual,2020-05-11,April 2020,2020-04-30,March 2021,Anticipated,2021-03-31,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,ATHLOS,,Telerehabilitation in Patients With COVID-19 After Hospitalization. The ATHLOS Study,"A Telerehabilitation Approach to Improve Long-term Physical Ability and Quality of Life in Patients With Severe Acute Respiratory Syndrome Coronavirus (SARSCoV-2, COVID-19) Immediately After Hospitalization. The ATHLOS Study",Recruiting,NA,N/A,100,Anticipated,Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:17Z,2020-11-01T12:03:17Z
NCT04368156,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-20,NA,NA,2020-04-28,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-29,Actual,"April 20, 2020",Actual,2020-04-20,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,SAVIOR,,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,"A Prospective, Randomized, Controlled Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms (SAVIOR)",Recruiting,NA,N/A,90,Anticipated,Hospital ClÃ­nico Universitario de Valencia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:03:22Z,2020-11-01T12:03:22Z
NCT04366063,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-20,NA,NA,2020-04-29,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-04-30,Actual,"April 5, 2020",Actual,2020-04-05,April 2020,2020-04-30,"December 10, 2020",Anticipated,2020-12-10,"June 6, 2020",Anticipated,2020-06-06,NA,Interventional,NA,,Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome,Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection: A Phase 2-3 Clinical Trial,Recruiting,NA,Phase 2/Phase 3,60,Anticipated,Royan Institute,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,6 months after publication,Researchers and clinicians,NA,Yes,NA,2020-11-01T12:03:36Z,2020-11-01T12:03:36Z
NCT04364763,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-20,NA,NA,2020-09-25,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-09-25,2020-09-28,Actual,"August 5, 2020",Actual,2020-08-05,September 2020,2020-09-30,"December 31, 2021",Anticipated,2021-12-31,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,,A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study),"A Phase 2, Randomized, Placebo-Controlled Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)",Recruiting,NA,Phase 2,252,Anticipated,"Renibus Therapeutics, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:46Z,2020-11-01T12:03:46Z
NCT04362332,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-20,NA,NA,2020-06-17,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-17,2020-06-19,Actual,"April 14, 2020",Actual,2020-04-14,June 2020,2020-06-30,"June 8, 2020",Actual,2020-06-08,"June 8, 2020",Actual,2020-06-08,NA,Interventional,ARCHAIC,,"Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19","An Open Label Cluster Randomized Controlled Trial of Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19",Terminated,NA,Phase 4,25,Actual,UMC Utrecht,,3,NA,"Currently, almost no patients admitted to Dutch hospitals. If any effect of HCQ is to be
    expected we need more than 1000 inclusions",FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,12 months,NA,NA,Yes,NA,2020-11-01T12:04:05Z,2020-11-01T12:04:05Z
NCT04362085,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-20,NA,NA,2020-09-02,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-09-02,2020-09-04,Actual,"May 11, 2020",Actual,2020-05-11,September 2020,2020-09-30,December 2020,Anticipated,2020-12-31,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG),Recruiting,NA,Phase 3,462,Anticipated,"St. Michael's Hospital, Toronto",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:04:06Z,2020-11-01T12:04:06Z
NCT04362059,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-20,NA,NA,2020-09-08,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-09-08,2020-09-09,Actual,"June 18, 2020",Actual,2020-06-18,September 2020,2020-09-30,"November 16, 2021",Anticipated,2021-11-16,"July 27, 2021",Anticipated,2021-07-27,NA,Interventional,COVSurf,,A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19,A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19,Recruiting,NA,N/A,24,Anticipated,University Hospital Southampton NHS Foundation Trust,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:04:07Z,2020-11-01T12:04:07Z
NCT04359901,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-20,NA,NA,2020-09-10,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-09-10,2020-09-11,Actual,"April 10, 2020",Actual,2020-04-10,September 2020,2020-09-30,April 2023,Anticipated,2023-04-30,April 2022,Anticipated,2022-04-30,NA,Interventional,NA,,Sarilumab for Patients With Moderate COVID-19 Disease,Sarilumab for Patients With Moderate COVID-19 Disease: A Randomized Controlled Trial With a Play-The-Winner Design,Recruiting,NA,Phase 2,120,Anticipated,VA Boston Healthcare System,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,Within one year of primary publication.,"Consistent with VA Privacy, Regulatory and IT requirements and VHA Handbook 1200.12",NA,Yes,"Digital data underlying primary scientific publications will be held as part of a data sharing resource. Study data held for this purpose may include data, data content, format, and organization. The data may contain but are not limited to individually identifiable information, other PHI, and study codes. The data may be available to the public and other VA and non-VA researchers under certain conditions and consistent with the informed consent and CSP policy that prioritize protecting participants' privacy and confidentiality to the fullest extent possible. A detailed plan will be developed in accordance with current technology, infrastructure, best practices, and policies and procedures in place at the time of oversight committee reviews (e.g., Privacy Board, Information Security, and Information Technology standards). The plan will include how data will be discovered, retrieved, analyzed, and managed and will note the materials that are available in machine-readable formats.",2020-11-01T12:04:28Z,2020-11-01T12:04:28Z
NCT04359537,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-20,NA,NA,2020-05-16,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-05-16,2020-05-19,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"September 25, 2020",Anticipated,2020-09-25,"August 25, 2020",Anticipated,2020-08-25,NA,Interventional,CHEER,,Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19,Comparative Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19 in Healthcare Personnel,Recruiting,NA,Phase 2,200,Anticipated,Shaheed Zulfiqar Ali Bhutto Medical University,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:04:30Z,2020-11-01T12:04:30Z
NCT04359277,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-20,NA,NA,2020-10-05,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-08,Actual,"April 21, 2020",Actual,2020-04-21,October 2020,2020-10-31,"September 20, 2020",Actual,2020-09-20,"September 20, 2020",Actual,2020-09-20,NA,Interventional,NA,,A Randomized Trial of Anticoagulation Strategies in COVID-19,A Randomized Trial of Anticoagulation Strategies in COVID-19,Terminated,NA,Phase 3,77,Actual,NYU Langone Health,,2,NA,the PROTECT study is being transitioned to ACTIV4 ACUTE anticoagulation inpatient study,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,"Requests may be directed to: jeffrey.berger@nyumc.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: jeffrey.berger@nyumc.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2020-11-01T12:04:32Z,2020-11-01T12:04:32Z
NCT04358068,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-20,NA,NA,2020-07-30,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-07-30,2020-08-03,Actual,"May 1, 2020",Actual,2020-05-01,July 2020,2020-07-31,"July 7, 2020",Actual,2020-07-07,"July 7, 2020",Actual,2020-07-07,NA,Interventional,NA,,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,"A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19",Completed,NA,Phase 2,20,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.,"With whom?
Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.
For what types of analyses?
To achieve aims in the proposal approved by the AIDS Clinical Trials Group.
By what mechanism will data be made available?
Researchers may submit a request for access to data using the AIDS Clinical Trials Group ""Data Request"" form at: https://actgnetwork.org/about-actg/templates-and-forms. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.",NA,Yes,"Individual participant data that underlie results in the publication, after deidentification.",2020-11-01T12:04:40Z,2020-11-01T12:04:40Z
NCT04357990,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-20,NA,NA,2020-09-15,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-09-15,2020-09-17,Actual,"September 4, 2020",Actual,2020-09-04,September 2020,2020-09-30,March 2021,Anticipated,2021-03-31,March 2021,Anticipated,2021-03-31,NA,Interventional,KONS-COVID19,,Viruxal Oral and Nasal Spray for Treating the Symptoms of COVID-19,"Use of a Medical Device, Viruxal Oral and Nasal Spray, for Treating the Symptoms of COVID-19 Via Application to the Naso- and Oropharyngeal Mucosa",Recruiting,NA,N/A,128,Anticipated,Kerecis Ltd.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:04:40Z,2020-11-01T12:04:40Z
NCT04357457,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-20,NA,NA,2020-09-21,2020-04-20,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-23,Actual,"September 3, 2020",Actual,2020-09-03,September 2020,2020-09-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,AIRVM-COVID,,Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia,Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia: a Randomized Controlled Double-blind Study From the Skip-icu Consortium,Recruiting,NA,Phase 3,212,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Yes, upon request, after approval by the primary investigator and clinical research platform of East Paris. For the purpose of IPD meta-analysis, or secondary analysis. Unidentifying data will be shared.",2020-11-01T12:04:44Z,2020-11-01T12:04:44Z
NCT04359680,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-20,NA,NA,2020-10-28,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-10-28,2020-10-29,Actual,"May 13, 2020",Actual,2020-05-13,October 2020,2020-10-31,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,,Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection,"A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection",Recruiting,NA,Phase 3,4000,Anticipated,Romark Laboratories L.C.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-02T10:30:19Z,2020-11-02T10:30:19Z
NCT04357366,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-20,NA,NA,2020-10-27,2020-04-21,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-29,Actual,"April 15, 2020",Actual,2020-04-15,October 2020,2020-10-31,"April 15, 2022",Anticipated,2022-04-15,"April 15, 2022",Anticipated,2022-04-15,NA,Interventional,SAVE,,suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE),"suPAR-guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE Open-label, Non-randomized Single-arm Trial",Recruiting,NA,Phase 2,500,Anticipated,Hellenic Institute for the Study of Sepsis,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-02T10:30:20Z,2020-11-02T10:30:20Z
NCT04359797,"ClinicalTrials.gov processed this data on November 13, 2020",2020-04-20,NA,NA,2020-11-06,2020-04-20,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-10,Actual,"April 27, 2020",Actual,2020-04-27,November 2020,2020-11-30,June 2021,Anticipated,2021-06-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,COVID-19 Patient Positioning Pragmatic Trial,Pragmatic Trial Exploring Impact of Patient Positioning in the Management of Patients Infected With COVID-19: Supine vs. Prone,Enrolling by invitation,NA,N/A,500,Anticipated,Vanderbilt University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,The data will become available 3 months following publication of outcomes and will remain available for at least 5 years.,Data will be made available to researchers who provide a methodologically sound proposal that has been approved by the Vanderbilt Institutional Review Board and the study executive committee.,NA,Yes,Individual participant data that underlie the results reported will be made available (including data dictionaries) after de-identification.,2020-11-14T10:43:10Z,2020-11-14T10:43:10Z
NCT04413864,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-21,NA,NA,2020-06-02,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"April 24, 2020",Actual,2020-04-24,May 2020,2020-05-31,"February 28, 2021",Anticipated,2021-02-28,"February 28, 2021",Anticipated,2021-02-28,NA,Interventional,DEXDO-COVID,,Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19,Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19,Recruiting,NA,N/A,50,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:57:20Z,2020-11-01T11:57:20Z
NCT04363736,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-21,NA,NA,2020-09-09,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-09-09,2020-09-11,Actual,"May 5, 2020",Actual,2020-05-05,September 2020,2020-09-30,"August 12, 2020",Actual,2020-08-12,"August 12, 2020",Actual,2020-08-12,NA,Interventional,MARIPOSA,,A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,"A Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg/kg or 4mg/kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 Pneumonia",Completed,NA,Phase 2,100,Actual,Hoffmann-La Roche,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2020-11-01T12:03:53Z,2020-11-01T12:03:53Z
NCT04363385,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-21,NA,NA,2020-07-23,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-07-23,2020-07-24,Actual,"May 31, 2020",Actual,2020-05-31,July 2020,2020-07-31,"May 31, 2021",Anticipated,2021-05-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,NA,,Collection of Biological Samples With Clinical Characterization of Covid-19 Patients,Cohort of Patients With Covid19: Constitution of Blood Samples Collections With Clinical Characterization,Recruiting,NA,N/A,500,Anticipated,Centre Hospitalier Intercommunal Creteil,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:55Z,2020-11-01T12:03:55Z
NCT04362189,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-21,NA,NA,2020-10-21,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-23,Actual,"June 30, 2020",Actual,2020-06-30,October 2020,2020-10-31,"October 31, 2020",Anticipated,2020-10-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,NA,,Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19,"A Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19","Active, not recruiting",NA,Phase 2,100,Anticipated,Hope Biosciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:04:05Z,2020-11-01T12:04:05Z
NCT04362111,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-21,NA,NA,2020-09-08,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-09-08,2020-09-11,Actual,"July 29, 2020",Actual,2020-07-29,September 2020,2020-09-30,March 2021,Anticipated,2021-03-31,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,Early Treatment of Cytokine Storm Syndrome in Covid-19,Early Treatment of Cytokine Storm Syndrome in Covid-19,Recruiting,NA,Phase 3,30,Anticipated,University of Alabama at Birmingham,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,During study enrollment,wchatham@uabmc.edu,NA,Yes,Contact PI by e-mail for protocol specifics Submission of results for peer reviewed publication,2020-11-01T12:04:06Z,2020-11-01T12:04:06Z
NCT04361526,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-21,NA,NA,2020-04-23,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-23,2020-04-24,Actual,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,CytokCOVID19,,Pilot Study on Cytokine Filtration in COVID-19 ARDS,Pilot Study on Cytokine Filtration in COVID-19 ARDS (CytokCOVID19),Recruiting,NA,N/A,40,Anticipated,Hospital Clinic of Barcelona,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:04:13Z,2020-11-01T12:04:13Z
NCT04360551,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-21,NA,NA,2020-07-30,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-30,2020-08-03,Actual,"July 1, 2020",Actual,2020-07-01,July 2020,2020-07-31,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,,Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients,"Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients",Recruiting,NA,Phase 2,40,Anticipated,University of Hawaii,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:04:23Z,2020-11-01T12:04:23Z
NCT04359862,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-21,NA,NA,2020-10-13,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-14,Actual,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,"April 30, 2021",Anticipated,2021-04-30,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,SEVO-COVID19,,Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection,Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection,Recruiting,NA,Phase 4,50,Anticipated,FundaciÃ³n para la InvestigaciÃ³n del Hospital ClÃ­nico de Valencia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:04:28Z,2020-11-01T12:04:28Z
NCT04359654,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-21,NA,NA,2020-10-15,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-10-15,2020-10-19,Actual,"June 16, 2020",Actual,2020-06-16,October 2020,2020-10-31,"November 1, 2021",Anticipated,2021-11-01,"August 1, 2021",Anticipated,2021-08-01,NA,Interventional,COVASE,,Nebulised Dornase Alfa for Treatment of COVID-19,"A Single-site, Randomised, Controlled, Parallel Design, Open-label Investigation of an Approved Nebulised Recombinant Human DNase Enzyme (Dornase Alfa) to Reduce Hyperinflammation in Hospitalised Participants With COVID-19",Recruiting,NA,Phase 2,50,Anticipated,"University College, London",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Anonymised results will be published in a scientific journal (TBC) and posted on the Breathing Matters website www.breathingatters@ucl.ac.uk,2020-11-01T12:04:30Z,2020-11-01T12:04:30Z
NCT04359329,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-21,NA,NA,2020-04-22,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"April 20, 2020",Actual,2020-04-20,April 2020,2020-04-30,"November 15, 2020",Anticipated,2020-11-15,"November 15, 2020",Anticipated,2020-11-15,NA,Interventional,NA,,Estrogen Patch for COVID-19 Symptoms,Phase II Clinical Trial of Estradiol to Reduce Severity of COVID19 Infection in COVID19+ and Presumptive COVID19+ Patients,Recruiting,NA,Phase 2,110,Anticipated,Stony Brook University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:04:31Z,2020-11-01T12:04:31Z
NCT04358783,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-21,NA,NA,2020-05-15,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-05-15,2020-05-19,Actual,"April 27, 2020",Actual,2020-04-27,April 2020,2020-04-30,"May 30, 2021",Anticipated,2021-05-30,"February 1, 2021",Anticipated,2021-02-01,NA,Interventional,COP-COVID-19,,Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia,"Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Plasma From Patients Cured of COVID-19 Compared to the Best Available Therapy in Subjects With SARS-CoV-2 Pneumonia",Recruiting,NA,Phase 2,30,Anticipated,Hospital Universitario Dr. Jose E. Gonzalez,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:04:35Z,2020-11-01T12:04:35Z
NCT04358926,"ClinicalTrials.gov processed this data on November 06, 2020",2020-04-21,NA,NA,2020-11-01,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-11-01,2020-11-03,Actual,"April 30, 2020",Actual,2020-04-30,November 2020,2020-11-30,"November 1, 2020",Actual,2020-11-01,"October 15, 2020",Actual,2020-10-15,NA,Interventional,HBOTCOVID19,,Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19),Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19),Completed,NA,N/A,30,Actual,Assaf-Harofeh Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,Within 1 month of request,Specific requests,NA,Yes,Sharing upon specific requests will be considered,2020-11-07T11:25:00Z,2020-11-07T11:25:00Z
NCT04362176,"ClinicalTrials.gov processed this data on November 13, 2020",2020-04-21,NA,NA,2020-11-08,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-11-08,2020-11-10,Actual,"April 24, 2020",Actual,2020-04-24,November 2020,2020-11-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,PassItOn,,Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults,Passive Immunity Trial for Our Nation (PassItOn),Recruiting,NA,Phase 3,1000,Anticipated,Vanderbilt University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-14T10:43:06Z,2020-11-14T10:43:06Z
NCT04359810,"ClinicalTrials.gov processed this data on November 13, 2020",2020-04-21,NA,NA,2020-11-12,2020-04-21,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-13,Estimate,"April 21, 2020",Actual,2020-04-21,November 2020,2020-11-30,April 2021,Anticipated,2021-04-30,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Plasma Therapy of COVID-19 in Severely Ill Patients,"A Phase 2, Multi-Center, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Convalescent Plasma in Severely Ill Adults With COVID-19",Recruiting,NA,Phase 2,219,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,The data-sharing plans for this study will be made available at a later date.,2020-11-15T10:59:39Z,2020-11-15T10:59:39Z
NCT04373200,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-22,NA,NA,2020-05-27,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-28,Actual,"May 25, 2020",Actual,2020-05-25,May 2020,2020-05-31,"November 25, 2020",Anticipated,2020-11-25,"November 25, 2020",Anticipated,2020-11-25,NA,Interventional,HARMONICOV,,Human Ab Response & immunoMONItoring of COVID-19 Patients,Human Ab Response & immunoMONItoring of COVID-19 Patients,Recruiting,NA,N/A,75,Anticipated,Rennes University Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:02:40Z,2020-11-01T12:02:40Z
NCT04366882,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-22,NA,NA,2020-04-28,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-29,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,MIA-COVID-19,,Minimal Invasive Autopsies to Investigate Changes in Deceased COVID-19 Patients,"Increasing Our Understanding of COVID-19: Minimal Invasive Autopsies to Investigate Clinical, Radiological, Microbiological and Histopathological Changes in Deceased COVID-19 Patients",Recruiting,NA,N/A,45,Anticipated,Jessa Hospital,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:03:31Z,2020-11-01T12:03:31Z
NCT04366323,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-22,NA,NA,2020-06-04,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-05,Actual,"April 27, 2020",Actual,2020-04-27,June 2020,2020-06-30,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,,Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19,"Phase I / II Clinical Trial, Multicenter, Randomized and Controlled, to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19",Recruiting,NA,Phase 1/Phase 2,26,Anticipated,Andalusian Network for Design and Translation of Advanced Therapies,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:35Z,2020-11-01T12:03:35Z
NCT04366245,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-22,NA,NA,2020-06-08,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-11,Actual,"April 23, 2020",Actual,2020-04-23,June 2020,2020-06-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,,Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,"Phase I / II Multicentre, Randomized and Controlled Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection",Recruiting,NA,Phase 1/Phase 2,72,Anticipated,Andalusian Network for Design and Translation of Advanced Therapies,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:03:35Z,2020-11-01T12:03:35Z
NCT04366089,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-22,NA,NA,2020-04-27,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-28,Actual,"March 26, 2020",Actual,2020-03-26,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,PROBIOZOVID,,Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,Oxygen-Ozone as Adjuvant Treatment in Early Control of Disease Progression in Patients With COVID-19 Associated With Modulation of the Gut Microbial Flora,Recruiting,NA,Phase 2,152,Anticipated,Azienda Policlinico Umberto I,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:36Z,2020-11-01T12:03:36Z
NCT04365101,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-22,NA,NA,2020-10-16,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-19,Actual,"May 13, 2020",Actual,2020-05-13,September 2020,2020-09-30,"June 30, 2021",Anticipated,2021-06-30,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,CYNK001COVID,,Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 (CYNK-001-COVID-19),A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19,Recruiting,NA,Phase 1/Phase 2,86,Anticipated,Celularity Incorporated,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:44Z,2020-11-01T12:03:44Z
NCT04364737,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-22,NA,NA,2020-08-27,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-08-27,2020-08-28,Actual,"April 17, 2020",Actual,2020-04-17,August 2020,2020-08-31,"April 30, 2023",Anticipated,2023-04-30,"January 31, 2023",Anticipated,2023-01-31,NA,Interventional,NA,,CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients,CONTAIN COVID-19: Convalescent Plasma to Limit Coronavirus Associated Complications: a Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV2 Plasma to Placebo in COVID-19 Hospitalized Patients,Recruiting,NA,Phase 2,300,Anticipated,NYU Langone Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,"The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to Mila.Ortigoza@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"IPD that underlie the results reported in this article, after deidenficiation (text, tables, figures, and appendices) will be shared.",2020-11-01T12:03:46Z,2020-11-01T12:03:46Z
NCT04364594,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-22,NA,NA,2020-07-22,2020-04-25,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-07-22,2020-07-23,Actual,"March 26, 2020",Actual,2020-03-26,July 2020,2020-07-31,"May 30, 2020",Actual,2020-05-30,"April 24, 2020",Actual,2020-04-24,NA,Interventional,COVID-T,,COVID-19 Search in Conjunctival Cells,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Diagnostic Targets for Customized Medicine.,Completed,NA,N/A,50,Actual,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,The data will be available immediately after the statistical analysis of the results and will remain available for at least 1 year,On request by e-mail,NA,Yes,"Study Protocol approved by Ethical Committee, informed consent, clinical study report, will be available",2020-11-01T12:03:47Z,2020-11-01T12:03:47Z
NCT04361474,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-22,NA,NA,2020-06-08,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-09,Actual,"May 18, 2020",Actual,2020-05-18,May 2020,2020-05-31,"May 25, 2021",Anticipated,2021-05-25,"May 18, 2020",Actual,2020-05-18,NA,Interventional,COVIDORL,,Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,A Randomized Controlled Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,Recruiting,NA,Phase 3,120,Anticipated,Fondation Ophtalmologique Adolphe de Rothschild,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:04:14Z,2020-11-01T12:04:14Z
NCT04361396,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-22,NA,NA,2020-07-01,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-01,2020-07-02,Actual,October 2020,Anticipated,2020-10-31,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,October 2020,Anticipated,2020-10-31,NA,Interventional,LAPTRANSCOV,,Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum of COVID-19 Patients,Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum During an Emergency Laparoscopy Conducted on Confirmed or Suspected COVID-19 Patients,Recruiting,NA,N/A,40,Anticipated,Centre Hospitalier RenÃ© Dubos,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:04:15Z,2020-11-01T12:04:15Z
NCT04360980,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-22,NA,NA,2020-07-27,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-27,2020-07-28,Actual,"March 20, 2020",Actual,2020-03-20,July 2020,2020-07-31,"September 30, 2020",Anticipated,2020-09-30,"September 1, 2020",Anticipated,2020-09-01,NA,Interventional,NA,,The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection,Effects of Standard Protocol Therapy With or Without Colchicine in Covid-19 Infection: A Randomized Double Blind Clinical Trial,Recruiting,NA,Phase 2,80,Anticipated,Shahid Beheshti University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:04:19Z,2020-11-01T12:04:19Z
NCT04360837,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-22,NA,NA,2020-05-19,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-05-19,2020-05-21,Actual,"May 6, 2020",Actual,2020-05-06,May 2020,2020-05-31,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,,PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill Corona Virus Disease-19 (COVID-19) Patients,PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill COVID-19 Patients Under Electric Impedance Tomography (EIT),Recruiting,NA,N/A,10,Anticipated,Szeged University,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:04:21Z,2020-11-01T12:04:21Z
NCT04360811,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-22,NA,NA,2020-04-22,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-04-22,2020-04-24,Actual,"April 17, 2020",Actual,2020-04-17,April 2020,2020-04-30,April 2022,Anticipated,2022-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,COroFet,,"Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic","Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic by Creation and Analysis of a Biological and Tissue Collection of Pregnancy Outcomes",Recruiting,NA,N/A,3600,Anticipated,"University Hospital, Toulouse",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:04:21Z,2020-11-01T12:04:21Z
NCT04361214,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-22,NA,NA,2020-10-27,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-29,Actual,"May 5, 2020",Actual,2020-05-05,October 2020,2020-10-31,February 2021,Anticipated,2021-02-28,February 2021,Anticipated,2021-02-28,NA,Interventional,NA,,Leflunomide in Mild COVID-19 Patients,Leflunomide for the Treatment of Ambulatory Patients With Mild COVID-19,Recruiting,NA,Phase 1,20,Anticipated,University of Chicago,,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-02T10:30:17Z,2020-11-02T10:30:17Z
NCT04363463,"ClinicalTrials.gov processed this data on November 09, 2020",2020-04-22,NA,NA,2020-11-04,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-06,Actual,"August 28, 2020",Actual,2020-08-28,November 2020,2020-11-30,"August 28, 2022",Anticipated,2022-08-28,"August 28, 2022",Anticipated,2022-08-28,NA,Interventional,PROVID-19,,Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress,Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress,Recruiting,NA,N/A,400,Anticipated,Centre Hospitalier RÃ©gional d'OrlÃ©ans,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-10T11:28:35Z,2020-11-10T11:28:35Z
NCT04362137,"ClinicalTrials.gov processed this data on November 13, 2020",2020-04-22,NA,NA,2020-11-10,2020-04-22,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"May 2, 2020",Actual,2020-05-02,November 2020,2020-11-30,"October 17, 2020",Actual,2020-10-17,"October 17, 2020",Actual,2020-10-17,NA,Interventional,RUXCOVID,,"Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)","Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)",Completed,NA,Phase 3,432,Actual,Novartis,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com",2020-11-15T10:59:38Z,2020-11-15T10:59:38Z
NCT04377750,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-23,NA,NA,2020-05-05,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-05,2020-05-06,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"May 8, 2021",Anticipated,2021-05-08,"April 29, 2020",Actual,2020-04-29,NA,Interventional,NA,,The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,Recruiting,NA,Phase 4,500,Anticipated,Hadassah Medical Organization,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,No plan,2020-11-01T12:02:07Z,2020-11-01T12:02:07Z
NCT04368377,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-23,NA,NA,2020-04-28,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-29,Actual,"April 6, 2020",Actual,2020-04-06,April 2020,2020-04-30,"April 23, 2020",Actual,2020-04-23,"April 23, 2020",Actual,2020-04-23,NA,Interventional,PIC-19,,Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19,Platelet Inhibition With GP IIb/IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use Protocol,Completed,NA,Phase 2,5,Actual,University of Milan,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:21Z,2020-11-01T12:03:21Z
NCT04366947,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-23,NA,NA,2020-04-28,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-29,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"May 20, 2020",Anticipated,2020-05-20,"May 20, 2020",Anticipated,2020-05-20,NA,Interventional,NA,,Intravascular Access in Suspected/Confirmed COVID-19 Patient,Comparison of Intraosseous Versus Intravenous Access in Suspected/Confirmed COVID-19 Patient in Prehospital Setting,"Active, not recruiting",NA,N/A,60,Anticipated,Lazarski University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,the investigators will decide after study finishing,2020-11-01T12:03:30Z,2020-11-01T12:03:30Z
NCT04366297,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-23,NA,NA,2020-04-27,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-28,Actual,"January 12, 2020",Actual,2020-01-12,April 2020,2020-04-30,"February 25, 2020",Actual,2020-02-25,"February 25, 2020",Actual,2020-02-25,NA,Interventional,NA,,Intravascular Access of COVID-19 Patient Under Personal Protective Equipment,Intraosseous Versus Intravenous Access During COVID-19 Patients Performed by Paramedics Wearing Level C Personal Protective Equipment. A Multi-center Prospective Randomized Crossover Single-blinded Simulation Trial,Completed,NA,N/A,41,Actual,Lazarski University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,the investigators will add data into manuscript,2020-11-01T12:03:35Z,2020-11-01T12:03:35Z
NCT04366271,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-23,NA,NA,2020-05-07,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-11,Actual,"May 7, 2020",Actual,2020-05-07,May 2020,2020-05-31,"May 31, 2021",Anticipated,2021-05-31,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,MESCEL-COVID19,,Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19,Phase II Clinical Trial to Explore the Efficacy of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With Severe Pulmonary Involvement by COVID-19,Recruiting,NA,Phase 2,106,Anticipated,"Hospital Infantil Universitario NiÃ±o JesÃºs, Madrid, Spain",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:03:35Z,2020-11-01T12:03:35Z
NCT04364022,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-23,NA,NA,2020-08-31,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-02,Actual,"April 23, 2020",Actual,2020-04-23,August 2020,2020-08-31,March 2021,Anticipated,2021-03-31,March 2021,Anticipated,2021-03-31,NA,Interventional,COPEP,,Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland,Efficacy of Pragmatic Same-day Ring COVID-19 Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland: an Open-label Cluster Randomized Trial,Recruiting,NA,Phase 3,300,Anticipated,"University Hospital, Geneva",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:03:51Z,2020-11-01T12:03:51Z
NCT04363528,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-23,NA,NA,2020-07-31,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-07-31,2020-08-04,Actual,"April 24, 2020",Actual,2020-04-24,July 2020,2020-07-31,"October 30, 2020",Anticipated,2020-10-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,COVIDOP-DVT,,Incidence of Deep Vein Thrombosis at Doppler Echo in Covid-19 Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU,Incidence of Deep Vein Thrombosis at Doppler Echo in Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU,Recruiting,NA,N/A,50,Anticipated,Versailles Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:03:54Z,2020-11-01T12:03:54Z
NCT04363502,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-23,NA,NA,2020-10-27,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-28,Actual,"May 7, 2020",Actual,2020-05-07,October 2020,2020-10-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Recruiting,NA,Phase 2,30,Anticipated,Johns Hopkins University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:55Z,2020-11-01T12:03:55Z
NCT04363450,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-23,NA,NA,2020-08-31,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-02,Actual,"April 27, 2020",Actual,2020-04-27,August 2020,2020-08-31,"June 1, 2021",Anticipated,2021-06-01,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,HCQPreP,,Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP),Hydroxychloroquine as Primary Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP),Recruiting,NA,Phase 3,1700,Anticipated,Louisiana State University Health Sciences Center in New Orleans,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:55Z,2020-11-01T12:03:55Z
NCT04363437,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-23,NA,NA,2020-05-06,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-08,Actual,"April 26, 2020",Actual,2020-04-26,May 2020,2020-05-31,"June 14, 2020",Anticipated,2020-06-14,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,COMBATCOVID19,,COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19,COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19 (the COMBAT-COVID-19 Pilot Study),Recruiting,NA,Phase 2,70,Anticipated,Maimonides Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:55Z,2020-11-01T12:03:55Z
NCT04363346,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-23,NA,NA,2020-05-14,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"May 14, 2020",Actual,2020-05-14,May 2020,2020-05-31,January 2022,Anticipated,2022-01-31,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,,Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia,Study of FT516 Safety and Feasibility for the Treatment of Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients With Hypoxia,Recruiting,NA,Phase 1,12,Anticipated,"Masonic Cancer Center, University of Minnesota",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:03:56Z,2020-11-01T12:03:56Z
NCT04361253,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-23,NA,NA,2020-05-14,2020-04-23,2020-04-24,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"April 30, 2020",Actual,2020-04-30,May 2020,2020-05-31,December 2021,Anticipated,2021-12-31,June 2021,Anticipated,2021-06-30,NA,Interventional,(ESCAPE),,Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy,"A Prospective, Randomized, Double-Masked, Placebo-Controlled Trial of High-Titer COVID-19 Convalescent Plasma (HT-CCP) for the Treatment of Hospitalized Patients With COVID-19 of Moderate Severity",Recruiting,NA,Phase 3,220,Anticipated,Brigham and Women's Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,Beginning 3 months after study publication. No end date.,Proposals should be submitted to rmkaufman@bwh.harvard.edu.,NA,Yes,Deidentified data will be made available upon request to the principal investigator following the publication of the primary manuscript.,2020-11-01T12:04:16Z,2020-11-01T12:04:16Z
NCT04363541,"ClinicalTrials.gov processed this data on November 06, 2020",2020-04-23,NA,NA,2020-11-03,2020-04-23,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-05,Actual,"August 27, 2020",Actual,2020-08-27,November 2020,2020-11-30,June 2022,Anticipated,2022-06-30,April 2022,Anticipated,2022-04-30,NA,Interventional,TherMoCoV,,Local Thermotherapy for Patients With Mild-to-moderate COVID-19,"A Multicenter, Open-label, Parallel-group, Randomized, Adaptive Trial to Evaluate Local Thermotherapy in Patients With Mild-to-moderate COVID-19, to Prevent Disease Progression",Recruiting,NA,N/A,274,Anticipated,Instituto Nacional de Perinatologia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,NA,2020-11-09T10:53:55Z,2020-11-09T10:53:55Z
NCT04393961,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-24,NA,NA,2020-05-16,2020-05-16,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-05-16,2020-05-19,Actual,"April 5, 2020",Actual,2020-04-05,April 2020,2020-04-30,"August 29, 2020",Anticipated,2020-08-29,"July 29, 2020",Anticipated,2020-07-29,NA,Interventional,NA,,At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study,At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study,Recruiting,NA,N/A,600,Anticipated,ProofPilot,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,FALSE,NA,,As soon reasonably sized data sets are available.,No personally identifiable information will be provided. Those who wish to access must have a ProofPilot account. All access must be approved by study investigators.,http://go.proofpilot.com,Yes,"Given the enormous policy and health implications, we will be making results available as soon as there are sufficient data sets to analyze. We will also provide our study design for replication in other environments and via other tests.",2020-11-01T11:59:46Z,2020-11-01T11:59:46Z
NCT04385095,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-24,NA,NA,2020-08-25,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-08-25,2020-08-27,Actual,"March 16, 2020",Actual,2020-03-16,May 2020,2020-05-31,"May 31, 2021",Anticipated,2021-05-31,"February 1, 2021",Anticipated,2021-02-01,NA,Interventional,NA,,Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection,A Randomised Double-blind Placebo-controlled Trial to Determine the Safety and Efficacy of Inhaled SNG001 (IFN-Î²1a for Nebulisation) for the Treatment of Patients With Confirmed SARS-CoV-2 Infection,Recruiting,NA,Phase 2,820,Anticipated,Synairgen Research Ltd.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No plan to share data,2020-11-01T12:01:14Z,2020-11-01T12:01:14Z
NCT04372979,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-24,NA,NA,2020-10-23,2020-04-29,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-26,Actual,"September 14, 2020",Actual,2020-09-14,October 2020,2020-10-31,June 2021,Anticipated,2021-06-30,May 2021,Anticipated,2021-05-31,NA,Interventional,PLASCOSSA,,Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.,Evaluation Of Efficacy Of COVID-19 Convalescent Plasma Versus Standard Plasma In The Early Care Of COVID-19 Patients Hospitalized Outside Intensive Care Units.,Recruiting,NA,Phase 3,80,Anticipated,Direction Centrale du Service de SantÃ© des ArmÃ©es,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:02:41Z,2020-11-01T12:02:41Z
NCT04372589,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-24,NA,NA,2020-06-01,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-04,Actual,"May 20, 2020",Actual,2020-05-20,April 2020,2020-04-30,January 2021,Anticipated,2021-01-31,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,Antithrombotic Therapy to Ameliorate Complications of COVID-19 ( ATTACC ),Antithrombotic Therapy to Ameliorate Complications of COVID-19,Recruiting,NA,Phase 2/Phase 3,3000,Anticipated,University of Manitoba,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:02:45Z,2020-11-01T12:02:45Z
NCT04368988,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-24,NA,NA,2020-10-08,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-10-08,2020-10-09,Actual,"May 25, 2020",Actual,2020-05-25,May 2020,2020-05-31,"November 18, 2021",Anticipated,2021-11-18,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,NA,,Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant,"A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-Mâ„¢ Adjuvant In Healthy Subjects","Active, not recruiting",NA,Phase 1/Phase 2,1419,Actual,Novavax,,10,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:16Z,2020-11-01T12:03:16Z
NCT04368923,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-24,NA,NA,2020-06-19,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-06-19,2020-06-23,Actual,"March 15, 2020",Actual,2020-03-15,June 2020,2020-06-30,"June 23, 2020",Anticipated,2020-06-23,"June 21, 2020",Anticipated,2020-06-21,NA,Interventional,NA,,Management of Covid-19 Patients During Home Isolation,Management of Covid-19 Patients During Home Isolation,"Active, not recruiting",NA,N/A,60,Actual,Cairo University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:03:16Z,2020-11-01T12:03:16Z
NCT04368260,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-24,NA,NA,2020-04-27,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-29,Actual,"April 24, 2020",Actual,2020-04-24,April 2020,2020-04-30,"July 31, 2020",Anticipated,2020-07-31,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,NA,,Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic,Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic,Recruiting,NA,N/A,40,Anticipated,University of Virginia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,,Starting 6 months after publication,Requests to made to Principal Investigator,NA,Yes,All individual participant data (IPD) that underlie results in a publication will be shared.,2020-11-01T12:03:22Z,2020-11-01T12:03:22Z
NCT04368000,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-24,NA,NA,2020-08-24,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-08-24,2020-08-26,Actual,"April 29, 2020",Actual,2020-04-29,August 2020,2020-08-31,January 2021,Anticipated,2021-01-31,December 2020,Anticipated,2020-12-31,NA,Interventional,PAPR,,Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization,Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization,"Active, not recruiting",NA,N/A,30,Actual,University of Utah,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:23Z,2020-11-01T12:03:23Z
NCT04367168,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-24,NA,NA,2020-05-26,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-28,Actual,"May 27, 2020",Actual,2020-05-27,April 2020,2020-04-30,"April 27, 2021",Anticipated,2021-04-27,"April 27, 2021",Anticipated,2021-04-27,NA,Interventional,ColchiVID,,Colchicine Twice Daily During 10 Days as an Option for the Treatment of Symptoms Induced by Inflammation in Patients With Mild and Severe Coronavirus Disease,"Double-blind, Placebo-controlled Clinical Trial of the Use of Colchicine for the Management of Patients With Mild and Severe SARS-Cov2 Infection",Recruiting,NA,Phase 2,174,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,6 months after publication of the clinical trial,Reviewers of scientific journals and researchers who contact the principal researcher by e-mail,NA,Yes,All IPD that underlie results in a publication,2020-11-01T12:03:28Z,2020-11-01T12:03:28Z
NCT04366960,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-24,NA,NA,2020-05-14,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-15,Actual,"May 14, 2020",Actual,2020-05-14,May 2020,2020-05-31,November 2020,Anticipated,2020-11-30,August 2020,Anticipated,2020-08-31,NA,Interventional,X-Covid 19,,Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients,Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients: Comparison of 40 mg o.d. Versus 40 mg b.i.d. A Randomized Clinical Trial,Recruiting,NA,Phase 3,2712,Anticipated,Niguarda Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:03:30Z,2020-11-01T12:03:30Z
NCT04366791,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-24,NA,NA,2020-06-15,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-06-15,2020-06-17,Actual,"April 23, 2020",Actual,2020-04-23,June 2020,2020-06-30,"October 23, 2020",Anticipated,2020-10-23,"October 23, 2020",Anticipated,2020-10-23,NA,Interventional,RESCUE 1-19,,Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19,The RESCUE 1-19 Trial: Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19,Recruiting,NA,Phase 1/Phase 2,10,Anticipated,Emory University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,NA,NA,,NA,NA,NA,No,"No
Results of the trial and not individual patient data will be shared. The study protocol, consent, and investigator's brochure will be available. The statistical plan is incorporated into the protocol, along with inclusion and exclusion criteria.",2020-11-01T12:03:32Z,2020-11-01T12:03:32Z
NCT04366141,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-24,NA,NA,2020-05-26,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-28,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"January 1, 2021",Anticipated,2021-01-01,"January 1, 2021",Anticipated,2021-01-01,NA,Interventional,NA,,COVID-19 (Coronavirus Disease 2019) Intubation Barrier Box,The Impact of a Barrier Enclosure on Endotracheal Intubation Duration and First Pass Attempt - A Randomized Controlled Trial,Recruiting,NA,N/A,120,Anticipated,University of British Columbia,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:36Z,2020-11-01T12:03:36Z
NCT04366050,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-24,NA,NA,2020-07-07,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-07-07,2020-07-08,Actual,"May 11, 2020",Actual,2020-05-11,July 2020,2020-07-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,RAMIC,,Ramipril for the Treatment of COVID-19,"A Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy of Ramipril to Prevent ICU Admission, Need for Mechanical Ventilation or Death in Persons With COVID-19",Enrolling by invitation,NA,Phase 2,560,Anticipated,"University of California, San Diego",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:03:36Z,2020-11-01T12:03:36Z
NCT04365972,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-24,NA,NA,2020-05-06,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-08,Actual,"April 23, 2020",Actual,2020-04-23,May 2020,2020-05-31,"April 30, 2020",Actual,2020-04-30,"April 30, 2020",Actual,2020-04-30,NA,Interventional,NA,,Attention Bias Modification for Reducing Health Anxiety During the Coronavirus Pandemic,Attention Bias Modification for Reducing Health Anxiety During the Coronavirus Pandemic: An Open Pilot Trial,Completed,NA,N/A,20,Actual,Tel Aviv University,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:37Z,2020-11-01T12:03:37Z
NCT04365608,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-24,NA,NA,2020-04-27,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-29,Actual,"March 20, 2020",Actual,2020-03-20,April 2020,2020-04-30,"May 20, 2020",Anticipated,2020-05-20,"May 20, 2020",Anticipated,2020-05-20,NA,Interventional,NA,,Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment,Safety and Efficacy of Endotracheal Intubation by Paramedics in Suspected/Confirmed COVID-19 Patients Under Cardiac Arrest Using Vie Scope Laryngoscope,Recruiting,NA,N/A,90,Anticipated,Lazarski University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,after manuscript publishing,NA,NA,Yes,NA,2020-11-01T12:03:40Z,2020-11-01T12:03:40Z
NCT04365309,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-24,NA,NA,2020-04-27,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-27,2020-04-28,Actual,"February 10, 2020",Actual,2020-02-10,March 2020,2020-03-31,June 2020,Anticipated,2020-06-30,April 2020,Anticipated,2020-04-30,NA,Interventional,PEAC,,Protective Effect of Aspirin on COVID-19 Patients,Protective Effect of Aspirin on COVID-19 Patients,Enrolling by invitation,NA,Phase 2/Phase 3,128,Anticipated,Xijing Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:03:42Z,2020-11-01T12:03:42Z
NCT04365257,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-24,NA,NA,2020-05-13,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-15,Actual,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,PREVENT,,Prazosin to Prevent COVID-19 (PREVENT-COVID Trial),Alpha-1 Adrenergic Receptor Antagonism to Prevent COVID-19 Cytokine Storm Syndrome and Acute Respiratory Distress Syndrome: A Randomized Study Comparing the Efficacy of Prazosin vs. Standard of Care for SARS-CoV-2 Infection,Recruiting,NA,Phase 2,220,Anticipated,Johns Hopkins University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:43Z,2020-11-01T12:03:43Z
NCT04365153,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-24,NA,NA,2020-09-02,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-09-02,2020-09-03,Actual,"April 24, 2020",Actual,2020-04-24,September 2020,2020-09-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Canakinumab in Covid-19 Cardiac Injury (The Three C Study),Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function in SARSCoV2 Associated Acute Myocardial Injury With Heightened Inflammation,"Active, not recruiting",NA,Phase 2,45,Actual,The Cleveland Clinic,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:43Z,2020-11-01T12:03:43Z
NCT04365127,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-24,NA,NA,2020-09-11,2020-04-24,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-09-11,2020-09-16,Actual,"April 27, 2020",Actual,2020-04-27,September 2020,2020-09-30,"April 17, 2021",Anticipated,2021-04-17,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,,Progesterone for the Treatment of COVID-19 in Hospitalized Men,"A Single Center, Randomized, Controlled Trial of the Safety and Efficacy of Progesterone for the Treatment of COVID-19 in Hospitalized Men","Active, not recruiting",NA,Phase 1,40,Actual,Cedars-Sinai Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:03:44Z,2020-11-01T12:03:44Z
NCT04363827,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-24,NA,NA,2020-05-29,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"May 14, 2020",Actual,2020-05-14,May 2020,2020-05-31,March 2021,Anticipated,2021-03-31,September 2020,Anticipated,2020-09-30,NA,Interventional,PROTECT,,Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19),PROTECT: A Randomized Study With Hydroxychloroquine Versus Observational Support for Prevention or Early Phase Treatment of Coronavirus Disease (COVID-19),Recruiting,NA,Phase 2,2300,Anticipated,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:03:53Z,2020-11-01T12:03:53Z
NCT04363606,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-24,NA,NA,2020-10-06,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"May 27, 2020",Actual,2020-05-27,June 2020,2020-06-30,December 2021,Anticipated,2021-12-31,April 2021,Anticipated,2021-04-30,NA,Interventional,FatCovid-19,,Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability,Chronic Fatigue Etiology and Recovery in Covid-19 Patients : the Role of Fatigability and Stay in Intensive Care,Recruiting,NA,N/A,82,Anticipated,Centre Hospitalier Universitaire de Saint Etienne,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:54Z,2020-11-01T12:03:54Z
NCT04363593,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-24,NA,NA,2020-05-04,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-04,2020-05-06,Actual,"May 4, 2020",Actual,2020-05-04,May 2020,2020-05-31,"November 4, 2020",Anticipated,2020-11-04,"November 4, 2020",Anticipated,2020-11-04,NA,Interventional,ROCOCO,,Serology COVID-19 From the Cornwall Hospital Union,Serology COVID-19 From the Cornwall Hospital Union,Recruiting,NA,N/A,3200,Anticipated,Centre Hospitalier de Cornouaille,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:03:54Z,2020-11-01T12:03:54Z
NCT04363372,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-24,NA,NA,2020-06-30,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,June 2020,Anticipated,2020-06-30,June 2020,2020-06-30,September 2020,Anticipated,2020-09-30,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19,"A Pilot, Multiple Dose Study to Evaluate the Efficacy and Safety of MRx-4DP0004 in Hospitalised Patients With Symptoms of COVID-19 (SARS-CoV-2 Infection)",Recruiting,NA,Phase 2,90,Anticipated,4D pharma plc,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:55Z,2020-11-01T12:03:55Z
NCT04362813,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-24,NA,NA,2020-10-08,2020-04-24,2020-04-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-08,2020-10-09,Actual,"April 30, 2020",Actual,2020-04-30,October 2020,2020-10-31,"December 22, 2020",Anticipated,2020-12-22,"September 16, 2020",Actual,2020-09-16,NA,Interventional,CAN-COVID,,Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia,"Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Canakinumab on Cytokine Release Syndrome in Patients With COVID-19-induced Pneumonia (CAN-COVID)","Active, not recruiting",NA,Phase 3,451,Actual,Novartis,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.",2020-11-01T12:04:02Z,2020-11-01T12:04:02Z
NCT04369378,"ClinicalTrials.gov processed this data on November 13, 2020",2020-04-24,NA,NA,2020-11-10,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-13,Estimate,"August 19, 2020",Actual,2020-08-19,November 2020,2020-11-30,"April 30, 2021",Anticipated,2021-04-30,"February 28, 2021",Anticipated,2021-02-28,NA,Interventional,NA,,Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic,Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic,Recruiting,NA,N/A,200,Anticipated,Lake Erie College of Osteopathic Medicine,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,Upon publication of findings,Upon written request to corresponding author on publication,NA,Yes,"De-identified participant data will be reported as individual data points, as well as means +/- SD or medians with quartiles.",2020-11-15T10:59:34Z,2020-11-15T10:59:34Z
NCT04518969,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-25,NA,NA,2020-08-18,2020-08-18,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"May 3, 2020",Actual,2020-05-03,August 2020,2020-08-31,"December 1, 2020",Anticipated,2020-12-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,NA,,Determination of the Hemoadsorption Impact as Adjunctive Treatment Upon the Support Therapy of COVID-19,"Comparing the Cytokine Clearances of Pro-, and Anti-inflammatory Mediators, Chemokines and Complement in the COVID-19 Patients Treated With CytoSorb as Compared to the Same Patient Population Who do Not Receive Blood Purification Treatment",Recruiting,NA,N/A,24,Anticipated,Brugmann University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:44:38Z,2020-11-01T11:44:38Z
NCT04392778,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-25,NA,NA,2020-05-17,2020-05-17,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-05-17,2020-05-19,Actual,"April 1, 2020",Actual,2020-04-01,May 2020,2020-05-31,September 2020,Anticipated,2020-09-30,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Clinical Use of Stem Cells for the Treatment of Covid-19,What is the Effect of Mesenchymal Stem Cell Therapy on Seriously Ill Patients With Covid 19 in Intensive Care? (Prospective Double Controlled Study),Recruiting,NA,Phase 1/Phase 2,30,Anticipated,SBÃœ Dr. Sadi Konuk EÄŸitim ve AraÅŸtÄ±rma Hastanesi,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:59:58Z,2020-11-01T11:59:58Z
NCT04372017,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-25,NA,NA,2020-06-05,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"May 14, 2020",Actual,2020-05-14,June 2020,2020-06-30,"June 4, 2021",Anticipated,2021-06-04,"June 4, 2020",Actual,2020-06-04,NA,Interventional,NA,,Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection,"Randomized, Double-Blind, Controlled Trial of Hydroxychloroquine vs Placebo as Post-Exposure Prophylaxis Against COVID-19 Infection","Active, not recruiting",NA,Phase 3,1,Actual,Sanford Health,,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:02:48Z,2020-11-01T12:02:48Z
NCT04368299,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-25,NA,NA,2020-07-13,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-07-13,2020-07-15,Actual,"May 1, 2020",Actual,2020-05-01,July 2020,2020-07-31,"December 31, 2021",Anticipated,2021-12-31,"October 31, 2021",Anticipated,2021-10-31,NA,Interventional,NA,,Telemedicine for Follow-up of Systemic Lupus Erythematosus,"Use of Telemedicine for Follow-up of Systemic Lupus Erythematosus (""TeleSLE"") in the COVID-19 Outbreak: a Pragmatic Randomised Controlled Trial",Recruiting,NA,N/A,150,Anticipated,Chinese University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:03:22Z,2020-11-01T12:03:22Z
NCT04365699,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-25,NA,NA,2020-04-25,2020-04-25,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-25,2020-04-28,Actual,"April 8, 2020",Actual,2020-04-08,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Cardiovascular Effects of COVID-19,A Single-center Registry and Embedded Interventional Study of the Effects of COVID-19 With and Without Treatment With AT-001 on Cardiac Structure and Function in Patients Hospitalized for Management of COVID-19 Infection,Recruiting,NA,Phase 2,500,Anticipated,NYU Langone Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Beginning 9 months and ending 36 months following article publication,Requests may be directed to Stuart.Katz@nyulangone.org.,NA,Yes,The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to Stuart.Katz@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.,2020-11-01T12:03:40Z,2020-11-01T12:03:40Z
NCT04364802,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-25,NA,NA,2020-05-12,2020-04-25,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-14,Actual,"April 29, 2020",Actual,2020-04-29,May 2020,2020-05-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,PIIPPI,,COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients,Povidone-Iodine Intranasal for Prophylaxis in Front-line Health-care Personnel and Inpatients During the Sars-CoV-2 Pandemic,Recruiting,NA,Phase 2,250,Anticipated,University of Kentucky,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:45Z,2020-11-01T12:03:45Z
NCT04428268,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-26,NA,NA,2020-06-13,2020-06-10,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-13,2020-06-16,Actual,"March 10, 2020",Actual,2020-03-10,June 2020,2020-06-30,"August 30, 2020",Anticipated,2020-08-30,"June 10, 2020",Actual,2020-06-10,NA,Interventional,NA,,Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia,"Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Chloroquine + Low Dose Losartan Compared to Chloroquine Monotherapy in Subjects With SARS-CoV-2 Pneumonia",Recruiting,NA,Phase 2,20,Anticipated,Hospital Universitario Dr. Jose E. Gonzalez,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T11:55:28Z,2020-11-01T11:55:28Z
NCT04373824,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-26,NA,NA,2020-05-01,2020-05-01,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-05-01,2020-05-04,Actual,"April 25, 2020",Actual,2020-04-25,May 2020,2020-05-31,"July 25, 2020",Anticipated,2020-07-25,"July 25, 2020",Anticipated,2020-07-25,NA,Interventional,NA,,Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study,To Study the Effectiveness of Ivermectin With Standard of Care Treatment Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study,Recruiting,NA,N/A,50,Anticipated,Max Healthcare Insititute Limited,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:02:35Z,2020-11-01T12:02:35Z
NCT04370782,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-26,NA,NA,2020-05-14,2020-04-29,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"April 28, 2020",Actual,2020-04-28,May 2020,2020-05-31,"December 31, 2020",Anticipated,2020-12-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting,A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting,Recruiting,NA,Phase 4,750,Anticipated,"St. Francis Hospital, New York",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:04Z,2020-11-01T12:03:04Z
NCT04368676,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-26,NA,NA,2020-09-01,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-09-01,2020-09-03,Actual,"June 25, 2020",Actual,2020-06-25,September 2020,2020-09-30,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,BREATH,,Breath Regulation and Yogic Exercise An Online Therapy for Calm and Happiness,Breath Regulation and Yogic Exercise An Online Therapy for Calm and Happiness (BREATH): an RCT for Frontline Hospital and Long-term Care Home Staff Managing the COVID-19 Pandemic,Recruiting,NA,Early Phase 1,60,Anticipated,Lawson Health Research Institute,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:18Z,2020-11-01T12:03:18Z
NCT04366856,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-26,NA,NA,2020-08-17,2020-04-28,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-08-17,2020-08-19,Actual,"June 26, 2020",Actual,2020-06-26,July 2020,2020-07-31,January 2021,Anticipated,2021-01-31,December 2020,Anticipated,2020-12-31,NA,Interventional,PROVID,,PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study),PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study),Recruiting,NA,N/A,500,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:03:31Z,2020-11-01T12:03:31Z
NCT04365985,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-26,NA,NA,2020-06-30,2020-04-26,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-02,Actual,"April 29, 2020",Actual,2020-04-29,June 2020,2020-06-30,August 2021,Anticipated,2021-08-31,May 2021,Anticipated,2021-05-31,NA,Interventional,SINK COVID-19,,Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19,Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19,Recruiting,NA,Phase 2,500,Anticipated,William Beaumont Hospitals,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:37Z,2020-11-01T12:03:37Z
NCT04365738,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-26,NA,NA,2020-04-26,2020-04-26,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-26,2020-04-28,Actual,"March 11, 2020",Actual,2020-03-11,April 2020,2020-04-30,"April 26, 2020",Actual,2020-04-26,"April 10, 2020",Actual,2020-04-10,NA,Interventional,NA,,Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection,Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection: Prospective Randomized Controlled Trial,Completed,NA,N/A,270,Actual,Istanbul Bilgi University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:03:38Z,2020-11-01T12:03:38Z
NCT04400032,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-27,NA,NA,2020-09-10,2020-05-20,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-09-10,2020-09-14,Actual,"May 15, 2020",Actual,2020-05-15,September 2020,2020-09-30,June 2021,Anticipated,2021-06-30,January 2021,Anticipated,2021-01-31,NA,Interventional,CIRCA-19,,Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome - Vanguard,Cellular Immuno-Therapy for COVID-19 ARDS (CIRCA-19) the Vanguard Study,Recruiting,NA,Phase 1,9,Anticipated,Ottawa Hospital Research Institute,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:59:02Z,2020-11-01T11:59:02Z
NCT04389710,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-27,NA,NA,2020-06-23,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-23,2020-06-25,Actual,"April 15, 2020",Actual,2020-04-15,June 2020,2020-06-30,"April 14, 2021",Anticipated,2021-04-14,"April 14, 2021",Anticipated,2021-04-14,NA,Interventional,NA,,Convalescent Plasma for the Treatment of COVID-19,Convalescent Plasma for the Treatment of Patients With COVID-19,Recruiting,NA,Phase 2,100,Anticipated,Thomas Jefferson University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:00:31Z,2020-11-01T12:00:31Z
NCT04379453,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-27,NA,NA,2020-05-07,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-08,Actual,"April 27, 2020",Anticipated,2020-04-27,April 2020,2020-04-30,"April 27, 2020",Anticipated,2020-04-27,"April 27, 2020",Anticipated,2020-04-27,NA,Interventional,NA,,Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses,Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses,Recruiting,NA,N/A,10,Anticipated,Hospital Israelita Albert Einstein,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:55Z,2020-11-01T12:01:55Z
NCT04374565,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-27,NA,NA,2020-08-20,2020-05-01,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-08-20,2020-08-21,Actual,"May 5, 2020",Actual,2020-05-05,August 2020,2020-08-31,"April 5, 2021",Anticipated,2021-04-05,"April 5, 2021",Anticipated,2021-04-05,NA,Interventional,NA,,Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia,Efficacy and Safety of High-Titer Anti-SARS-CoV-2 (COVID19) Convalescent Plasma for Hospitalized Patients With Infection Due to COVID-19 to Decrease Complications: A Phase II Trial,"Active, not recruiting",NA,Phase 2,29,Anticipated,University of Virginia,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:02:29Z,2020-11-01T12:02:29Z
NCT04370262,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-27,NA,NA,2020-06-11,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-06-11,2020-06-16,Actual,"April 7, 2020",Actual,2020-04-07,June 2020,2020-06-30,"April 7, 2021",Anticipated,2021-04-07,"September 7, 2020",Anticipated,2020-09-07,NA,Interventional,NA,,Multi-site Adaptive Trials for COVID-19,"A Multi-site, Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Standard of Care (SOC) Plus Famotidine vs SOC Plus Placebo for the Treatment of COVID-19 in Hospitalized Adults",Recruiting,NA,Phase 3,942,Anticipated,Northwell Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:03:07Z,2020-11-01T12:03:07Z
NCT04369794,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-27,NA,NA,2020-08-05,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-08-05,2020-08-07,Actual,"August 10, 2020",Anticipated,2020-08-10,August 2020,2020-08-31,August 2023,Anticipated,2023-08-31,June 2021,Anticipated,2021-06-30,NA,Interventional,BATTLE,,"COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement","COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement",Recruiting,NA,Phase 4,1000,Anticipated,"University of Campinas, Brazil",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:10Z,2020-11-01T12:03:10Z
NCT04369456,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-27,NA,NA,2020-04-30,2020-04-27,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-01,Actual,"April 22, 2020",Actual,2020-04-22,April 2020,2020-04-30,"October 22, 2020",Anticipated,2020-10-22,"October 22, 2020",Anticipated,2020-10-22,NA,Interventional,PredictCovidT,,Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients,Blood Innate Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients,Recruiting,NA,N/A,115,Anticipated,Centre Hospitalier Universitaire de Nice,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:13Z,2020-11-01T12:03:13Z
NCT04369365,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-27,NA,NA,2020-04-29,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-05-01,Actual,"April 27, 2020",Actual,2020-04-27,April 2020,2020-04-30,"December 27, 2020",Anticipated,2020-12-27,"August 27, 2020",Anticipated,2020-08-27,NA,Interventional,NA,,"A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic","A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic",Recruiting,NA,Phase 2,200,Anticipated,Medical University of Vienna,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:03:13Z,2020-11-01T12:03:13Z
NCT04369066,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-27,NA,NA,2020-07-29,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-07-30,Actual,"April 28, 2020",Actual,2020-04-28,July 2020,2020-07-31,"April 28, 2021",Anticipated,2021-04-28,"October 28, 2020",Anticipated,2020-10-28,NA,Interventional,Curie-O-SA,,"COVID-19 Study of the Serological Response Against the Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV-2) Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur","COVID-19 Study of the Serological Response Against the SARS-CoV-2 Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur",Recruiting,NA,N/A,2800,Anticipated,Institut Curie,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:03:15Z,2020-11-01T12:03:15Z
NCT04367831,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-27,NA,NA,2020-05-17,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-17,2020-05-19,Actual,"May 2, 2020",Actual,2020-05-02,May 2020,2020-05-31,April 2021,Anticipated,2021-04-30,November 2020,Anticipated,2020-11-30,NA,Interventional,IMPROVE,,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19: A Cluster Based Randomized Selection Trial (IMPROVE-COVID),Recruiting,NA,Phase 4,100,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:24Z,2020-11-01T12:03:24Z
NCT04367077,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-27,NA,NA,2020-09-28,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-29,Actual,"April 28, 2020",Actual,2020-04-28,September 2020,2020-09-30,August 2022,Anticipated,2022-08-31,September 2021,Anticipated,2021-09-30,NA,Interventional,MACoVIA,,MultiStem Administration for COVID-19 Induced ARDS (MACoVIA),A Phase 2/3 Study to Assess the Safety and Efficacy of MultiStemÂ® Therapy in Subjects With Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease (COVID-19),Recruiting,NA,Phase 2/Phase 3,400,Anticipated,"Athersys, Inc",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:29Z,2020-11-01T12:03:29Z
NCT04366180,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-27,NA,NA,2020-04-28,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-04-28,2020-04-30,Actual,"April 24, 2020",Actual,2020-04-24,April 2020,2020-04-30,October 2020,Anticipated,2020-10-31,June 2020,Anticipated,2020-06-30,NA,Interventional,NA,,Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers,Multicentric Study to Assess the Effect of Consumption of Lactobacillus Coryniformis K8 on Healthcare Personnel Exposed to COVID-19,Recruiting,NA,N/A,314,Anticipated,Biosearch S.A.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:36Z,2020-11-01T12:03:36Z
NCT04372693,"ClinicalTrials.gov processed this data on November 06, 2020",2020-04-27,NA,NA,2020-10-30,2020-04-29,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-10-30,2020-11-03,Actual,"September 1, 2020",Actual,2020-09-01,October 2020,2020-10-31,"February 28, 2021",Anticipated,2021-02-28,"January 30, 2021",Anticipated,2021-01-30,NA,Interventional,(COVID-19),,Unplanned Shifting to Online Distance Learning: Nursing Students' Perception and Achievement,Unplanned Shifting the Traditional Classroom-Based to Online Distance Learning as a Result of (COVID-19) Social Distancing Measures: Nursing Students' Perception and Achievement,Enrolling by invitation,NA,N/A,180,Anticipated,Cairo University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,the study will be available to interested researchers by Publication in the indexed journal at the end of the study completion,2020-11-07T11:24:32Z,2020-11-07T11:24:32Z
NCT04367545,"ClinicalTrials.gov processed this data on November 06, 2020",2020-04-27,NA,NA,2020-11-04,2020-04-27,2020-04-29,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-05,Actual,"April 16, 2020",Actual,2020-04-16,November 2020,2020-11-30,"May 17, 2020",Actual,2020-05-17,"May 17, 2020",Actual,2020-05-17,NA,Interventional,MolCOVID,,Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic,Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic,Completed,NA,N/A,130,Actual,"University Hospital, Rouen",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-09T10:53:51Z,2020-11-09T10:53:51Z
NCT04368728,"ClinicalTrials.gov processed this data on November 13, 2020",2020-04-27,NA,NA,2020-11-11,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Estimate,"April 29, 2020",Actual,2020-04-29,November 2020,2020-11-30,"December 11, 2022",Anticipated,2022-12-11,"June 13, 2021",Anticipated,2021-06-13,NA,Interventional,NA,,"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS",Recruiting,NA,Phase 2/Phase 3,43998,Anticipated,BioNTech SE,,11,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2020-11-15T10:59:35Z,2020-11-15T10:59:35Z
NCT04366232,"ClinicalTrials.gov processed this data on November 13, 2020",2020-04-27,NA,NA,2020-11-09,2020-04-27,2020-04-28,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"August 19, 2020",Actual,2020-08-19,April 2020,2020-04-30,"October 2, 2020",Actual,2020-10-02,"October 2, 2020",Actual,2020-10-02,NA,Interventional,JAKINKOV,,Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation (JAKINCOV),"Interleukin-1 (IL-1) and Interferon Gamma (IFNg) Inhibition During COVID 19 Inflammation: Randomized, Controlled Study Assessing Efficacy and Safety of Anakinra and Ruxolitinib",Terminated,NA,Phase 2,2,Actual,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,,2,NA,investigator decision,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-15T10:59:36Z,2020-11-15T10:59:36Z
NCT04406181,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-28,NA,NA,2020-05-28,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"May 18, 2020",Actual,2020-05-18,May 2020,2020-05-31,"January 1, 2021",Anticipated,2021-01-01,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Psychological Well-being of Patients Awaiting for Cardiac Surgery During the COVID-19 Pandemic,Effect on the COVID-19 Pandemic-induced Reduction in Elective Surgery on Medical Events and Psychological Well-being of Patients Waiting for Cardiac Surgery,Recruiting,NA,N/A,200,Anticipated,Universitair Ziekenhuis Brussel,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:58:20Z,2020-11-01T11:58:20Z
NCT04379154,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-28,NA,NA,2020-07-10,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-10,2020-07-14,Actual,"April 14, 2020",Actual,2020-04-14,April 2020,2020-04-30,"November 16, 2020",Anticipated,2020-11-16,October 2020,Anticipated,2020-10-31,NA,Interventional,VOC-COVID,,Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-COV-2 (COVID-19),Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by (SARS-CoV-2): Predictive Interest in Short-term Evolution,Recruiting,NA,N/A,60,Anticipated,Hopital Foch,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:01:57Z,2020-11-01T12:01:57Z
NCT04376476,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-28,NA,NA,2020-05-07,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-08,Actual,"May 5, 2020",Actual,2020-05-05,May 2020,2020-05-31,"June 5, 2021",Anticipated,2021-06-05,"June 5, 2021",Anticipated,2021-06-05,NA,Interventional,HPI-COVID-19,,Host-pathogen Interactions During SARS-CoV-2 Infection,Host-pathogen Interactions During Paediatric and Adult SARS-CoV-2 Infection (COVID-19),Recruiting,NA,N/A,450,Anticipated,Hospices Civils de Lyon,,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:02:16Z,2020-11-01T12:02:16Z
NCT04371640,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-28,NA,NA,2020-05-05,2020-04-28,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-05,2020-05-07,Actual,May 2020,Anticipated,2020-05-31,May 2020,2020-05-31,August 2020,Anticipated,2020-08-31,July 2020,Anticipated,2020-07-31,NA,Interventional,SirCO-1,,Sirolimus in COVID-19 Phase 1,"A Randomized, Double-Blinded, Placebo-Controlled Trial Evaluating the Virological Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sirolimus Adjuvant Therapy in Patients With Coronavirus Disease (COVID-19)",Recruiting,NA,Phase 1,40,Anticipated,Thomas Jefferson University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T12:02:50Z,2020-11-01T12:02:50Z
NCT04371510,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-28,NA,NA,2020-04-30,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-01,Actual,"April 22, 2020",Actual,2020-04-22,April 2020,2020-04-30,"February 22, 2021",Anticipated,2021-02-22,"October 22, 2020",Anticipated,2020-10-22,NA,Interventional,PredictCovid-D,,Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients,Blood Innate Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients,Recruiting,NA,N/A,115,Anticipated,Centre Hospitalier Universitaire de Nice,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:02:51Z,2020-11-01T12:02:51Z
NCT04371419,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-28,NA,NA,2020-06-17,2020-04-28,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-17,2020-06-19,Actual,"May 13, 2020",Actual,2020-05-13,June 2020,2020-06-30,"May 24, 2020",Actual,2020-05-24,"May 24, 2020",Actual,2020-05-24,NA,Interventional,NA,,COVID-19 Health Messaging to Underserved Communities,COVID-19 Health Messaging to Underserved Communities,Completed,NA,N/A,15475,Actual,"National Bureau of Economic Research, Inc.",,17,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"Generally, social scientists post code and de-identified data when the findings are published","To be determined, if published alongside the paper data and code may be gated.",NA,Yes,"Generally, economists will post code and de-identified data when the findings are published",2020-11-01T12:02:52Z,2020-11-01T12:02:52Z
NCT04370886,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-28,NA,NA,2020-05-28,2020-04-28,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"April 30, 2020",Actual,2020-04-30,April 2020,2020-04-30,"May 10, 2020",Actual,2020-05-10,"April 30, 2020",Actual,2020-04-30,NA,Interventional,NA,,Recruit Blood Donors Via SMS During Epidemic of COVID-19,Recruit Blood Donors Via SMS With Different Contents During Epidemic of COVID-19,Completed,NA,N/A,456517,Actual,Guangzhou Blood Center,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:03:03Z,2020-11-01T12:03:03Z
NCT04371029,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-28,NA,NA,2020-06-11,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-11,2020-06-12,Actual,"April 28, 2020",Actual,2020-04-28,June 2020,2020-06-30,"December 28, 2020",Anticipated,2020-12-28,"September 28, 2020",Anticipated,2020-09-28,NA,Interventional,COVISLEEP,,Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS,Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS,Recruiting,NA,N/A,25,Anticipated,"University Hospital, Bordeaux",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:02Z,2020-11-01T12:03:02Z
NCT04369599,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-28,NA,NA,2020-09-11,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-09-11,2020-09-16,Actual,"August 11, 2020",Actual,2020-08-11,September 2020,2020-09-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,Trans Thoracic Manipulation of Ventilation/Perfusion: the V/Q Vest for COVID-19,Trans Thoracic Manipulation of Ventilation/Perfusion: the V/Q Vest,Enrolling by invitation,NA,N/A,24,Anticipated,Emory University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,NA,NA,,Sharing of data will begin 9 months and end 36 months following article publication.,"Data will be made available for sharing with researchers who provide a methodologically sound proposal, in order to achieve aims stated in the approved proposal. Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata. Information regarding submitting proposals and accessing data may be found at (link to be provided).",NA,Yes,"All of the individual participant data collected during the trial will be made available for sharing, after deidentification.",2020-11-01T12:03:12Z,2020-11-01T12:03:12Z
NCT04369469,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-28,NA,NA,2020-10-06,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"May 11, 2020",Actual,2020-05-11,October 2020,2020-10-31,July 2021,Anticipated,2021-07-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia,"A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome",Recruiting,NA,Phase 3,270,Anticipated,Alexion Pharmaceuticals,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:03:12Z,2020-11-01T12:03:12Z
NCT04410354,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-28,NA,NA,2020-10-28,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-10-28,2020-10-29,Actual,"June 16, 2020",Actual,2020-06-16,October 2020,2020-10-31,December 2020,Anticipated,2020-12-31,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,,Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Oral Merimepodib in Combination With Intravenous Remdesivir in Adult Patients With Advanced Coronavirus Disease 2019 (COVID-19)","Active, not recruiting",NA,Phase 2,80,Anticipated,"ViralClear Pharmaceuticals, Inc.",,2,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-02T10:29:50Z,2020-11-02T10:29:50Z
NCT04371393,"ClinicalTrials.gov processed this data on November 09, 2020",2020-04-28,NA,NA,2020-11-04,2020-04-28,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-06,Actual,"April 30, 2020",Actual,2020-04-30,November 2020,2020-11-30,April 2022,Anticipated,2022-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,MSCs in COVID-19 ARDS,Mesenchymal Stromal Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress Syndrome,Recruiting,NA,Phase 3,300,Anticipated,Icahn School of Medicine at Mount Sinai,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"De-identified study data sets must be submitted to the designated NHLBI Program Official no later than 3 years after the end of the clinical activity (final patient follow-up, etc.) or 2 years after the main paper of the trial has been published, whichever comes first. Data are prepared by the study coordinating center and sent to the designated PO for review prior to release.",Anyone who wishes to access the data.,NA,Yes,"All of the individual participant data collected during the trial, after deidentification.",2020-11-10T11:28:29Z,2020-11-10T11:28:29Z
NCT04392219,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-29,NA,NA,2020-08-14,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-14,2020-08-17,Actual,"April 10, 2020",Actual,2020-04-10,August 2020,2020-08-31,"August 11, 2020",Actual,2020-08-11,"August 11, 2020",Actual,2020-08-11,NA,Interventional,NA,,"COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers","A Randomized, Double-Blind, Placebo-Controlled, First-in-Human Study Designed to Evaluate the Safety, Tolerability, and Pharmacokinetics of EIDD-2801 Following Oral Administration to Healthy Volunteers",Completed,NA,Phase 1,130,Actual,"Ridgeback Biotherapeutics, LP",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:00:06Z,2020-11-01T12:00:06Z
NCT04385810,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-29,NA,NA,2020-05-12,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-13,Actual,"April 27, 2020",Actual,2020-04-27,May 2020,2020-05-31,October 2020,Anticipated,2020-10-31,October 2020,Anticipated,2020-10-31,NA,Interventional,DOCOV,,Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19,Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19,Recruiting,NA,N/A,100,Anticipated,Fondation Ophtalmologique Adolphe de Rothschild,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:01:08Z,2020-11-01T12:01:08Z
NCT04384588,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-29,NA,NA,2020-05-09,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-09,2020-05-12,Actual,"April 7, 2020",Actual,2020-04-07,May 2020,2020-05-31,"April 6, 2021",Anticipated,2021-04-06,"April 6, 2021",Anticipated,2021-04-06,NA,Interventional,FALP-COVID,,COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID),Investigational- Compassionate Use of Convalescent Plasma From COVID-19 Donors in Oncological and Non-Oncological Patients With Severity Criteria: FALP 001-2020 Trial (FALP-COVID),Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Fundacion Arturo Lopez Perez,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:17Z,2020-11-01T12:01:17Z
NCT04380532,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-29,NA,NA,2020-05-22,2020-05-06,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-27,Actual,"May 15, 2020",Actual,2020-05-15,May 2020,2020-05-31,"June 15, 2021",Anticipated,2021-06-15,"May 15, 2021",Anticipated,2021-05-15,NA,Interventional,COVID-19,,Tableted COVID-19 Therapeutic Vaccine,Clinical Trial of COVID-19 Therapeutic Vaccine Formulated as an Oral Pill,"Active, not recruiting",NA,Phase 1/Phase 2,20,Anticipated,Immunitor LLC,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,when become public,non-confidential data,http://immunitor.com,Yes,Free dissemination of published data,2020-11-01T12:01:46Z,2020-11-01T12:01:46Z
NCT04378712,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-29,NA,NA,2020-05-13,2020-05-05,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-15,Actual,"January 21, 2020",Actual,2020-01-21,May 2020,2020-05-31,"March 23, 2020",Actual,2020-03-23,"March 23, 2020",Actual,2020-03-23,NA,Interventional,NA,,Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19),"Effects of Hydrogen/Oxygen Mixed Gas Inhalation for Patients With Coronavirus Disease 2019 (COVID-19) Who Had Dyspnea: A Multicenter, Open-label Clinical Trial",Completed,NA,N/A,90,Actual,Guangzhou Institute of Respiratory Disease,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:02:00Z,2020-11-01T12:02:00Z
NCT04374487,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-29,NA,NA,2020-07-20,2020-05-01,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-07-20,2020-07-22,Actual,"May 9, 2020",Actual,2020-05-09,July 2020,2020-07-31,"August 9, 2021",Anticipated,2021-08-09,"August 9, 2021",Anticipated,2021-08-09,NA,Interventional,NA,,Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications,"A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications","Active, not recruiting",NA,Phase 2,100,Actual,Max Healthcare Insititute Limited,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:02:30Z,2020-11-01T12:02:30Z
NCT04372004,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-29,NA,NA,2020-08-07,2020-04-29,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-08-07,2020-08-11,Actual,"May 8, 2020",Actual,2020-05-08,May 2020,2020-05-31,June 2021,Anticipated,2021-06-30,May 2021,Anticipated,2021-05-31,NA,Interventional,CATCH COVID-19,,Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19),Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19),Recruiting,NA,Phase 1,100,Anticipated,Texas Cardiac Arrhythmia Research Foundation,,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:02:48Z,2020-11-01T12:02:48Z
NCT04371965,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-29,NA,NA,2020-10-23,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-26,Actual,"September 1, 2020",Actual,2020-09-01,July 2020,2020-07-31,"October 23, 2020",Actual,2020-10-23,"October 23, 2020",Actual,2020-10-23,NA,Interventional,KILLER,,"Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19","Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With SARS-CoV-2",Completed,NA,Phase 2,24,Actual,Poitiers University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:02:49Z,2020-11-01T12:02:49Z
NCT04371367,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-29,NA,NA,2020-10-21,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-23,Actual,"April 27, 2020",Actual,2020-04-27,October 2020,2020-10-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,FORCE,,"Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )","A Double-blind, Randomized Study Versus Placebo of Avdoralimab (IPH5401), an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia",Recruiting,NA,Phase 2,168,Anticipated,Assistance Publique Hopitaux De Marseille,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:02:53Z,2020-11-01T12:02:53Z
NCT04370938,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-29,NA,NA,2020-04-29,2020-04-29,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-04-29,2020-05-01,Actual,"April 29, 2020",Actual,2020-04-29,April 2020,2020-04-30,"October 29, 2020",Anticipated,2020-10-29,"October 29, 2020",Anticipated,2020-10-29,NA,Interventional,NA,,Provider Burnout During COVID-19,Exploring Provider Burnout During the COVID-19 Pandemic,Recruiting,NA,N/A,250,Anticipated,University of Pittsburgh,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:03:03Z,2020-11-01T12:03:03Z
NCT04370288,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-29,NA,NA,2020-04-30,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-04,Actual,"April 19, 2020",Actual,2020-04-19,April 2020,2020-04-30,"September 21, 2020",Anticipated,2020-09-21,"September 20, 2020",Anticipated,2020-09-20,NA,Interventional,Covid-19,,Clinical Application of Methylene Blue for Treatment of Covid-19 Patients,The Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 Patients,Recruiting,NA,Phase 1,20,Anticipated,Mashhad University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-11-01T12:03:07Z,2020-11-01T12:03:07Z
NCT04370236,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-29,NA,NA,2020-10-22,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-10-22,2020-10-26,Actual,"October 21, 2020",Actual,2020-10-21,October 2020,2020-10-31,February 2021,Anticipated,2021-02-28,February 2021,Anticipated,2021-02-28,NA,Interventional,NA,,INB03 for the Treatment of Pulmonary Complications From COVID-19,"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of INB03 in the Treatment of Participants With Pulmonary Complications From Coronavirus Disease (COVID-19)",Recruiting,NA,Phase 2/Phase 3,366,Anticipated,"Inmune Bio, Inc.",,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:03:07Z,2020-11-01T12:03:07Z
NCT04369820,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-29,NA,NA,2020-04-30,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-04,Actual,"March 31, 2020",Actual,2020-03-31,April 2020,2020-04-30,November 2020,Anticipated,2020-11-30,September 2020,Anticipated,2020-09-30,NA,Interventional,C5-COV,,C5a Receptor Expression - COVID-19 (C5-COV),C5a Receptor Expression in Circulating Myeloid Cells in ARDS Secondary to COVID-19,Recruiting,NA,N/A,100,Anticipated,Assistance Publique Hopitaux De Marseille,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:03:10Z,2020-11-01T12:03:10Z
NCT04372186,"ClinicalTrials.gov processed this data on November 06, 2020",2020-04-29,NA,NA,2020-11-02,2020-04-29,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-04,Actual,"May 14, 2020",Actual,2020-05-14,November 2020,2020-11-30,"December 1, 2021",Anticipated,2021-12-01,"August 18, 2020",Actual,2020-08-18,NA,Interventional,EMPACTA,,A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia","Active, not recruiting",NA,Phase 3,379,Anticipated,"Genentech, Inc.",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2020-11-08T11:35:48Z,2020-11-08T11:35:48Z
NCT04375202,"ClinicalTrials.gov processed this data on November 06, 2020",2020-04-29,NA,NA,2020-11-03,2020-05-03,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-05,Actual,"April 18, 2020",Actual,2020-04-18,November 2020,2020-11-30,"October 31, 2021",Anticipated,2021-10-31,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,COLVID-19,,Colchicine in COVID-19: a Pilot Study,Treatment With COLchicine of Patients Affected by COVID-19: a Pilot Study,Recruiting,NA,Phase 2,308,Anticipated,University Of Perugia,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-09T10:53:46Z,2020-11-09T10:53:46Z
NCT04408066,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-30,NA,NA,2020-06-02,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"April 30, 2020",Actual,2020-04-30,June 2020,2020-06-30,"April 30, 2022",Anticipated,2022-04-30,"April 30, 2022",Anticipated,2022-04-30,NA,Interventional,CAPTURE,,COVID-19: A POC Test Under Research & Evaluation,Specimen Collection for Development and Performance Evaluation of the LumiraDx Platform Point of Care Tests for Sars-Cov-2 IgG/IgM & Antigen to be Used as an Aid in Diagnosis of COVID-19,Recruiting,NA,N/A,2000,Anticipated,LumiraDx UK Limited,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:58:07Z,2020-11-01T11:58:07Z
NCT04379531,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-30,NA,NA,2020-06-10,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-06-10,2020-06-12,Actual,"April 25, 2020",Actual,2020-04-25,May 2020,2020-05-31,"May 22, 2020",Actual,2020-05-22,"May 22, 2020",Actual,2020-05-22,NA,Interventional,LDCTiP,,LDCT in COVID-19 Pneumonia: a Prospective Moscow Study,Low-dose Computed Tomography in COVID-19 Pneumonia: a Prospective Moscow Study,Completed,NA,N/A,230,Actual,Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:55Z,2020-11-01T12:01:55Z
NCT04377568,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-30,NA,NA,2020-10-07,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-10-07,2020-10-08,Actual,"October 7, 2020",Actual,2020-10-07,October 2020,2020-10-31,"May 1, 2022",Anticipated,2022-05-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,CONCOR-KIDS,,Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children,"A Randomized, Multicentered, Open-label Phase 2 Clinical Trial of the Safety and Efficacy of Human Coronavirus- Immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children",Recruiting,NA,Phase 2,100,Anticipated,The Hospital for Sick Children,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:02:08Z,2020-11-01T12:02:08Z
NCT04374942,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-30,NA,NA,2020-05-06,2020-04-30,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-08,Actual,"April 30, 2020",Actual,2020-04-30,May 2020,2020-05-31,"January 30, 2022",Anticipated,2022-01-30,"August 27, 2020",Anticipated,2020-08-27,NA,Interventional,HEROs,,Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?,"Protecting Frontline Health Care Workers From COVID-19 With Hydroxychloroquine Pre-exposure Prophylaxis: A Randomized, Placebo-controlled Multi-Site Trial in Toronto, Canada",Enrolling by invitation,NA,Phase 3,988,Anticipated,"University Health Network, Toronto",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,"At the time of completion of the analysis of primary and secondary outcomes, the HEROS Steering Committee will review all applications for use of participant level data and make recommendations.",2020-11-01T12:02:27Z,2020-11-01T12:02:27Z
NCT04374032,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-30,NA,NA,2020-10-01,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-10-01,2020-10-05,Actual,"May 1, 2020",Actual,2020-05-01,October 2020,2020-10-31,"December 31, 2020",Anticipated,2020-12-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,NA,,Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection,"An Open-label, Prospective, Randomized, Comparative Clinical Trial to Evaluate the Efficacy and Safety of ENKORTENÂ® as an Immunomodulatory Therapy, Within the Usual Therapeutically Established Protocol, for the Treatment of Patients With Moderate to Severe COVID-19 Infection","Active, not recruiting",NA,Phase 2/Phase 3,120,Actual,Bosnalijek D.D,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:02:34Z,2020-11-01T12:02:34Z
NCT04373161,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-30,NA,NA,2020-05-05,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-05-05,2020-05-06,Actual,"March 20, 2020",Actual,2020-03-20,May 2020,2020-05-31,"April 22, 2020",Actual,2020-04-22,"April 22, 2020",Actual,2020-04-22,NA,Interventional,NA,,Home Pulse Oximeter Use in Patients With COVID-19,Utilizing Home Pulse Oximetry for Patients With COVID-19 To Monitor Disease Progression,Completed,NA,N/A,209,Actual,Swedish Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T12:02:40Z,2020-11-01T12:02:40Z
NCT04373135,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-30,NA,NA,2020-10-11,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-10-11,2020-10-14,Actual,"May 8, 2020",Actual,2020-05-08,October 2020,2020-10-31,March 2021,Anticipated,2021-03-31,February 2021,Anticipated,2021-02-28,NA,Interventional,UC-COVID,,"Understanding Community Considerations, Opinions, Values, Impacts, and Decisions for COVID-19",A Study to Evaluate Health Behavior and Access Impacts Due to COVID-19 and for Community Engagement of Stakeholders Surrounding Scarce Resource Allocation Policy.,"Active, not recruiting",NA,N/A,2500,Actual,"University of California, Los Angeles",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Within 4 months of study closure,Reasonable request to investigators,NA,Yes,Data requests for analysis may be approved by the investigators upon reasonable request.,2020-11-01T12:02:40Z,2020-11-01T12:02:40Z
NCT04372680,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-30,NA,NA,2020-04-30,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-04-30,2020-05-04,Actual,"April 22, 2020",Actual,2020-04-22,April 2020,2020-04-30,"September 22, 2020",Anticipated,2020-09-22,"September 22, 2020",Anticipated,2020-09-22,NA,Interventional,INVICTUS,,WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound,"WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound: a Prospective, Multicenter, Randomized, Open-label, Parallel-group Clinical Trial",Recruiting,NA,N/A,200,Anticipated,"University Hospital, Toulouse",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:02:44Z,2020-11-01T12:02:44Z
NCT04372628,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-30,NA,NA,2020-09-04,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-09-04,2020-09-09,Actual,"June 1, 2020",Actual,2020-06-01,September 2020,2020-09-30,"May 1, 2021",Anticipated,2021-05-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,TREATNOW,,Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19,Trial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19,Recruiting,NA,Phase 2,600,Anticipated,Vanderbilt University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:02:45Z,2020-11-01T12:02:45Z
NCT04371978,"ClinicalTrials.gov processed this data on October 30, 2020",2020-04-30,NA,NA,2020-10-01,2020-04-30,2020-05-01,Actual,NA,NA,NA,NA,NA,NA,2020-10-01,2020-10-05,Actual,"October 1, 2020",Actual,2020-10-01,October 2020,2020-10-31,"September 30, 2021",Anticipated,2021-09-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,,Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19,Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19,Recruiting,NA,Phase 3,100,Anticipated,Rabin Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:02:49Z,2020-11-01T12:02:49Z
NCT04373382,"ClinicalTrials.gov processed this data on November 06, 2020",2020-04-30,NA,NA,2020-11-03,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-05,Actual,"July 27, 2020",Actual,2020-07-27,November 2020,2020-11-30,February 2022,Anticipated,2022-02-28,February 2022,Anticipated,2022-02-28,NA,Interventional,NA,,Peer Champion Support for Hospital Staff During and After the COVID-19 Pandemic,Peer Champion Support for Hospital Staff During and After the COVID-19 Pandemic,"Active, not recruiting",NA,N/A,882,Actual,"Mount Sinai Hospital, Canada",,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-09T10:53:47Z,2020-11-09T10:53:47Z
NCT04373460,"ClinicalTrials.gov processed this data on November 13, 2020",2020-04-30,NA,NA,2020-11-06,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"June 3, 2020",Actual,2020-06-03,October 2020,2020-10-31,"January 31, 2023",Anticipated,2023-01-31,"December 21, 2022",Anticipated,2022-12-21,NA,Interventional,CSSC-004,,Convalescent Plasma to Limit SARS-CoV-2 Associated Complications,Comparison of the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune) Plasma Among Outpatients With Symptomatic COVID-19,Recruiting,NA,Phase 2,1344,Anticipated,Johns Hopkins University,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,After publication of initial study manuscript,Public,NA,Yes,"Anonymized individual participant data (IPD) collected in this study, including data dictionaries, will be made available to other researchers after the end of the study.",2020-11-14T10:42:52Z,2020-11-14T10:42:52Z
NCT04372602,"ClinicalTrials.gov processed this data on November 13, 2020",2020-04-30,NA,NA,2020-11-06,2020-04-30,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"October 12, 2020",Actual,2020-10-12,November 2020,2020-11-30,"April 30, 2022",Anticipated,2022-04-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,NA,,Duvelisib to Combat COVID-19,A Pilot Study of Duvelisib to Combat COVID-19,Recruiting,NA,Phase 2,28,Anticipated,Washington University School of Medicine,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-14T10:42:53Z,2020-11-14T10:42:53Z
NCT04383002,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-01,NA,NA,2020-09-09,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-09-09,2020-09-11,Actual,"September 2, 2020",Actual,2020-09-02,September 2020,2020-09-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,High Dose Inhaled Nitric Oxide for COVID-19 (ICU Patients),Use of High Dose Inhaled Nitric Oxide in Intubated Patients Admitted With COVID-19,Recruiting,NA,Phase 1,20,Anticipated,"University Health Network, Toronto",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:01:28Z,2020-11-01T12:01:28Z
NCT04379271,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-01,NA,NA,2020-06-29,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-06-29,2020-07-01,Actual,"June 11, 2020",Actual,2020-06-11,June 2020,2020-06-30,October 2020,Anticipated,2020-10-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,"A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)","A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19",Recruiting,NA,Phase 2/Phase 3,230,Anticipated,Immunic AG,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:01:56Z,2020-11-01T12:01:56Z
NCT04378738,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-01,NA,NA,2020-05-06,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-07,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"May 8, 2020",Anticipated,2020-05-08,"May 7, 2020",Anticipated,2020-05-07,NA,Interventional,NA,,Social Media and Covid19 Pandemic,The Role of Social Media as an Information Source in Covid19 Pandemic,Enrolling by invitation,NA,N/A,212,Anticipated,Acibadem University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,if requested to.,2020-11-01T12:01:59Z,2020-11-01T12:01:59Z
NCT04377789,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-01,NA,NA,2020-05-14,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-15,Actual,"March 20, 2020",Actual,2020-03-20,May 2020,2020-05-31,"August 31, 2020",Anticipated,2020-08-31,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,NA,,Effect of Quercetin on Prophylaxis and Treatment of COVID-19,The Possible Effect of Quercetin on Prophylaxis and Treatment of COVID-19,Recruiting,NA,N/A,50,Anticipated,Kanuni Sultan Suleyman Training and Research Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:02:07Z,2020-11-01T12:02:07Z
NCT04376788,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-01,NA,NA,2020-07-07,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-07-07,2020-07-09,Actual,"May 20, 2020",Actual,2020-05-20,July 2020,2020-07-31,"September 1, 2020",Anticipated,2020-09-01,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,COVID-19,,Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19,Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19,Recruiting,NA,Phase 2,15,Anticipated,Ain Shams University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:02:13Z,2020-11-01T12:02:13Z
NCT04375124,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-01,NA,NA,2020-05-14,2020-05-01,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-15,Actual,"April 25, 2020",Actual,2020-04-25,May 2020,2020-05-31,"September 30, 2020",Anticipated,2020-09-30,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,NA,,Treatment of Angiotensin Peptide (1-7) for COVID-19,Evaluation of the Possible Role of Angiotensin Peptide (1-7) on Treatment of COVID-19,Recruiting,NA,N/A,20,Anticipated,Kanuni Sultan Suleyman Training and Research Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:02:26Z,2020-11-01T12:02:26Z
NCT04374786,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-01,NA,NA,2020-06-01,2020-05-01,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-04,Actual,"May 15, 2020",Actual,2020-05-15,June 2020,2020-06-30,"October 1, 2020",Anticipated,2020-10-01,"September 1, 2020",Anticipated,2020-09-01,NA,Interventional,NA,,Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic,Effects of a Mobile App on Health and Well-being During COVID-19 Pandemic in House Staff at Banner University Medical Center Phoenix,Enrolling by invitation,NA,N/A,328,Anticipated,University of Arizona,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:02:28Z,2020-11-01T12:02:28Z
NCT04373733,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-01,NA,NA,2020-07-02,2020-05-01,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-07-02,2020-07-07,Actual,"May 1, 2020",Actual,2020-05-01,July 2020,2020-07-31,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,PIONEER,,Early Intervention in COVID-19: Favipiravir Verses Standard Care,A Randomised Controlled Trial of Early Intervention in Patients HospItalised With COVID-19: Favipiravir and StaNdard Care vErsEs Standard CaRe,Recruiting,NA,Phase 3,450,Anticipated,Chelsea and Westminster NHS Foundation Trust,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Research team wishes to enable any meta-analyses of COVID-19 trials making appropriate requests. No plan to share IPD has been made at this time.,2020-11-01T12:02:36Z,2020-11-01T12:02:36Z
NCT04374461,"ClinicalTrials.gov processed this data on November 02, 2020",2020-05-01,NA,NA,2020-10-29,2020-05-01,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-10-30,Actual,"May 1, 2020",Actual,2020-05-01,October 2020,2020-10-31,May 2022,Anticipated,2022-05-31,May 2022,Anticipated,2022-05-31,NA,Interventional,NA,,A Study of N-acetylcysteine in Patients With COVID-19 Infection,Phase II Study of N-acetylcysteine in Severe or Critically Ill Patients With Refractory COVID-19 Infection,Recruiting,NA,Phase 2,84,Anticipated,Memorial Sloan Kettering Cancer Center,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,"Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.",2020-11-03T10:52:08Z,2020-11-03T10:52:08Z
NCT04373291,"ClinicalTrials.gov processed this data on November 06, 2020",2020-05-01,NA,NA,2020-11-04,2020-05-01,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-05,Actual,"May 18, 2020",Actual,2020-05-18,November 2020,2020-11-30,January 2021,Anticipated,2021-01-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic,Using BCG Vaccine to Enhance Non-specific Protection of Health Care Workers During the COVID-19 Pandemic. A Randomized Controlled Multi-center Trial,Recruiting,NA,Phase 3,1500,Anticipated,Bandim Health Project,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,When follow-up has been completed and the dataset have been closed,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to cbenn@health.sdu.dk,NA,Yes,Non-identifiable individual data can be shared on the basis of a data sharing proposal sent to cbenn@health.sdu.dk,2020-11-09T10:53:47Z,2020-11-09T10:53:47Z
NCT04374019,"ClinicalTrials.gov processed this data on November 09, 2020",2020-05-01,NA,NA,2020-11-04,2020-05-01,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-06,Actual,"May 1, 2020",Actual,2020-05-01,November 2020,2020-11-30,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,Novel Agents for Treatment of High-risk COVID-19 Positive Patients,"Randomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive Patients",Recruiting,NA,Phase 2,240,Anticipated,University of Kentucky,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-10T11:28:26Z,2020-11-10T11:28:26Z
NCT04373707,"ClinicalTrials.gov processed this data on November 13, 2020",2020-05-01,NA,NA,2020-11-10,2020-05-01,2020-05-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"May 13, 2020",Actual,2020-05-13,November 2020,2020-11-30,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,COVI-DOSE,,Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19,Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE,Recruiting,NA,Phase 4,602,Anticipated,"Central Hospital, Nancy, France",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-15T10:59:30Z,2020-11-15T10:59:30Z
NCT04374591,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-02,NA,NA,2020-10-02,2020-05-02,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-10-02,2020-10-06,Actual,"August 1, 2020",Actual,2020-08-01,July 2020,2020-07-31,"November 1, 2020",Anticipated,2020-11-01,"November 1, 2020",Anticipated,2020-11-01,NA,Interventional,NA,,The Role of Sodium Bicarbonate as Adjuvant Treatment of Computed Tomography Identified COVID-19 Pneumonia,The Role of Sodium Bicarbonate as Adjuvant Treatment of Computed Tomography Identified COVID-19 Pneumonia: A Preliminary Report of Short Term Follow up,"Active, not recruiting",NA,N/A,180,Anticipated,Mansoura University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:02:29Z,2020-11-01T12:02:29Z
NCT04374539,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-02,NA,NA,2020-07-01,2020-05-02,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-07-01,2020-07-07,Actual,"April 29, 2020",Actual,2020-04-29,May 2020,2020-05-31,"August 29, 2021",Anticipated,2021-08-29,"May 5, 2021",Anticipated,2021-05-05,NA,Interventional,REP-COVID,,Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial,Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial,Recruiting,NA,Phase 2,116,Anticipated,Fundacion Clinic per a la Recerca BiomÃ©dica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:02:29Z,2020-11-01T12:02:29Z
NCT04374526,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-02,NA,NA,2020-10-05,2020-05-02,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-06,Actual,"May 27, 2020",Actual,2020-05-27,May 2020,2020-05-31,"June 30, 2021",Anticipated,2021-06-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,LIFESAVER,,Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.,Early transfusIon of COVID-19 Convalescent Plasma in Elderly COVID-19 Patients to Prevent Disease Progression.,Recruiting,NA,Phase 2/Phase 3,182,Anticipated,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:02:30Z,2020-11-01T12:02:30Z
NCT04394455,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-03,NA,NA,2020-06-30,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-02,Actual,"June 30, 2020",Anticipated,2020-06-30,June 2020,2020-06-30,"December 30, 2020",Anticipated,2020-12-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,NA,,Brief Cognitive Behavioral Therapy Versus Crisis Intervention Therapy Through Telepsychiatry on Psychiatric Symptoms,Effect of Brief Cognitive Behavioral Therapy Versus Crisis Intervention Therapy Through Telepsychiatry in Medical Staff During the COVID-19 Pandemic: A Multicentric Randomized Controlled Trial,Enrolling by invitation,NA,N/A,236,Anticipated,Universidad Nacional Autonoma de Honduras,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:59:42Z,2020-11-01T11:59:42Z
NCT04392531,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-03,NA,NA,2020-08-27,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-08-27,2020-08-28,Actual,"April 16, 2020",Actual,2020-04-16,August 2020,2020-08-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19,"Open, Controlled, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Cyclosporine Plus Standard Treatment vs Standard Treatment Only in Hospitalized Patients With COVID-19 Infection",Recruiting,NA,Phase 4,120,Anticipated,Instituto de InvestigaciÃ³n Sanitaria de la FundaciÃ³n JimÃ©nez DÃ­az,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:00:00Z,2020-11-01T12:00:00Z
NCT04376814,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-03,NA,NA,2020-06-12,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-06-12,2020-06-16,Actual,"March 29, 2020",Actual,2020-03-29,May 2020,2020-05-31,"May 25, 2020",Actual,2020-05-25,"April 5, 2020",Actual,2020-04-05,NA,Interventional,NA,,Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19,"The Regimen of Favipiravir Plus Hydroxychloroquine Can Accelerate Recovery of the COVID-19 Patients With Moderate Severity in Comparison to Lopinavir/Ritonavir Plus Hydroxychloroquine Regimen: an Open-label, Non-randomized Clinical Trial Study",Completed,NA,N/A,40,Actual,Baqiyatallah Medical Sciences University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:02:13Z,2020-11-01T12:02:13Z
NCT04376593,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-03,NA,NA,2020-07-02,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-07-02,2020-07-07,Actual,"May 1, 2020",Actual,2020-05-01,July 2020,2020-07-31,May 2022,Anticipated,2022-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,PET/CT Imaging in COVID-19 Patients,18F-Î±vÎ²6-binding-peptide PET/CT in Patients Post SARS CoV2 Infection,Enrolling by invitation,NA,Early Phase 1,10,Actual,"University of California, Davis",,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:02:16Z,2020-11-01T12:02:16Z
NCT04375098,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-03,NA,NA,2020-09-12,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-09-12,2020-09-16,Actual,"May 4, 2020",Actual,2020-05-04,September 2020,2020-09-30,"August 17, 2020",Actual,2020-08-17,"August 17, 2020",Actual,2020-08-17,NA,Interventional,NA,,Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection,Efficacy and Safety of Early Anti-SARS-COV-2 Convalescent Plasma in Patients Admitted for COVID-19 Infection: a Randomized Phase II Trial,Completed,NA,Phase 2,58,Actual,Pontificia Universidad Catolica de Chile,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:02:26Z,2020-11-01T12:02:26Z
NCT04581031,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-04,NA,NA,2020-10-06,2020-10-06,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-09,Actual,"July 11, 2020",Actual,2020-07-11,October 2020,2020-10-31,"February 1, 2021",Anticipated,2021-02-01,"February 1, 2021",Anticipated,2021-02-01,NA,Interventional,COSMIC-19,,COntinuous Signs Monitoring In Covid-19 Patients,COntinuous Signs Monitoring In Covid-19 Patients,Recruiting,NA,N/A,60,Anticipated,The Christie NHS Foundation Trust,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:37:24Z,2020-11-01T11:37:24Z
NCT04391712,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-04,NA,NA,2020-08-03,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-03,2020-08-05,Actual,"April 30, 2020",Actual,2020-04-30,August 2020,2020-08-31,"July 16, 2020",Actual,2020-07-16,"May 15, 2020",Actual,2020-05-15,NA,Interventional,NA,,Photobiomodulation Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,Multiwave Locked System (MLS) Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,Completed,NA,Phase 2,10,Actual,Lowell General Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:00:16Z,2020-11-01T12:00:16Z
NCT04388527,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-04,NA,NA,2020-09-16,2020-05-12,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2020-09-16,2020-09-17,Actual,"April 30, 2020",Actual,2020-04-30,September 2020,2020-09-30,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,COVID-19 Convalescent Plasma for Mechanically Ventilated Population,"An Open-Label, Single Arm, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill Mechanically Ventilated Participants With COVID-19 Caused by SARS-CoV-2",Recruiting,NA,Phase 1,50,Anticipated,University of Pennsylvania,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:00:39Z,2020-11-01T12:00:39Z
NCT04385043,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-04,NA,NA,2020-05-11,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-12,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"May 15, 2021",Anticipated,2021-05-15,"October 15, 2020",Anticipated,2020-10-15,NA,Interventional,COV2-CP,,Hyperimmune Plasma in Patients With COVID-19 Severe Infection,Efficacy and Safety of Hyperimmune Plasma Treatment in Patients With COVID-19 Severe Infection,Recruiting,NA,Phase 2/Phase 3,400,Anticipated,University of Catanzaro,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:14Z,2020-11-01T12:01:14Z
NCT04380935,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-04,NA,NA,2020-08-16,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-08-16,2020-08-18,Actual,"May 18, 2020",Actual,2020-05-18,August 2020,2020-08-31,"October 31, 2020",Anticipated,2020-10-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,NA,,Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome,Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome in Referral Hospitals in Indonesia,Recruiting,NA,Phase 2/Phase 3,60,Anticipated,Indonesia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:01:42Z,2020-11-01T12:01:42Z
NCT04380818,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-04,NA,NA,2020-06-17,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-06-17,2020-06-18,Actual,"June 5, 2020",Actual,2020-06-05,May 2020,2020-05-31,"July 1, 2021",Anticipated,2021-07-01,"May 4, 2021",Anticipated,2021-05-04,NA,Interventional,NA,,Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19: Multi-central Prospective Study,Recruiting,NA,N/A,106,Anticipated,Grupo de InvestigaciÃ³n ClÃ­nica en OncologÃ­a Radioterapia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Protocol/ICF from approval Individual epidemiological and clinical data after recruitment is complete.,NA,NA,Yes,Individual epidemiological and clinical data will be shared after recruitment is complete.,2020-11-01T12:01:44Z,2020-11-01T12:01:44Z
NCT04379375,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-04,NA,NA,2020-09-30,2020-05-04,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"July 27, 2020",Actual,2020-07-27,September 2020,2020-09-30,"September 30, 2020",Actual,2020-09-30,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,,Nudges to Improve Health Behaviors That Limit COVID-19 Spread,Using Behavioral Nudges to Improve Preventive Health Behaviors That Limit COVID-19 Spread,Terminated,NA,N/A,45,Actual,Medical College of Wisconsin,,2,NA,Slow enrollment rate,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:56Z,2020-11-01T12:01:56Z
NCT04379336,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-04,NA,NA,2020-05-06,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-07,Actual,"May 4, 2020",Actual,2020-05-04,May 2020,2020-05-31,"April 28, 2021",Anticipated,2021-04-28,"April 28, 2021",Anticipated,2021-04-28,NA,Interventional,NA,,BCG Vaccination for Healthcare Workers in COVID-19 Pandemic,"Reducing Morbidity and Mortality in Health Care Workers Exposed to SARS-CoV-2 by Enhancing Non-specific Immune Responses Through Bacillus Calmette-GuÃ©rin Vaccination, a Randomized Controlled Trial",Recruiting,NA,Phase 3,500,Anticipated,TASK Applied Science,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,IPD will only be shared among researchers included in the protocol team at this stage.,2020-11-01T12:01:56Z,2020-11-01T12:01:56Z
NCT04378803,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-04,NA,NA,2020-08-14,2020-05-04,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-08-14,2020-08-17,Actual,"May 13, 2020",Actual,2020-05-13,August 2020,2020-08-31,"August 4, 2020",Actual,2020-08-04,"August 4, 2020",Actual,2020-08-04,NA,Interventional,NA,,Mindfulness Training for Seniors,Mindfulness Training for Older Adults During the COVID-19 Pandemic,Completed,NA,N/A,53,Actual,University of Miami,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:59Z,2020-11-01T12:01:59Z
NCT04377672,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-04,NA,NA,2020-05-31,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-05-31,2020-06-02,Actual,"May 28, 2020",Actual,2020-05-28,May 2020,2020-05-31,"May 28, 2022",Anticipated,2022-05-28,"May 28, 2021",Anticipated,2021-05-28,NA,Interventional,NA,,Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19),Safety and Pharmacokinetics of Human Convalescent Plasma in High Risk Children Exposed or Infected With SARS-CoV-2,Recruiting,NA,Phase 1,30,Anticipated,Johns Hopkins University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:02:08Z,2020-11-01T12:02:08Z
NCT04377659,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-04,NA,NA,2020-10-27,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-28,Actual,"May 1, 2020",Actual,2020-05-01,October 2020,2020-10-31,"May 1, 2021",Anticipated,2021-05-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,NA,,Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection,A Phase II Study of IL-6 Receptor Antagonist Tocilizumab to Prevent Respiratory Failure and Death in Patients With Severe COVID-19 Infection,Recruiting,NA,Phase 2,40,Anticipated,Memorial Sloan Kettering Cancer Center,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.",2020-11-01T12:02:08Z,2020-11-01T12:02:08Z
NCT04377620,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-04,NA,NA,2020-10-16,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-20,Actual,"May 24, 2020",Actual,2020-05-24,October 2020,2020-10-31,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,,Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT),"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)",Recruiting,NA,Phase 3,500,Anticipated,Incyte Corporation,,3,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:02:08Z,2020-11-01T12:02:08Z
NCT04377477,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-04,NA,NA,2020-07-21,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-07-21,2020-07-22,Actual,"May 10, 2020",Actual,2020-05-10,July 2020,2020-07-31,"August 30, 2022",Anticipated,2022-08-30,"August 10, 2021",Anticipated,2021-08-10,NA,Interventional,COLOR-19,,COVID-19 Pneumonitis Low Dose Lung Radiotherapy (COLOR-19),Pilot Study on the Feasibility of Low Dose Radiotherapy for SARS-Cov-2 Pneumonitis (COVID-19 Low Dose Radiotherapy - COLOR 19),Recruiting,NA,N/A,30,Anticipated,Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Data will be available starting six months from the publication and for five years.,"Written request to principal investigator , indicating the details of the data requested, the reasons of the inquiry and the purpose of the data use; data will be released after Local Ethics Committee approval. Data will be released only for no-profit use, in particular for research purposes.",NA,Yes,All Individual Participant Data that underlie results in the publication,2020-11-01T12:02:09Z,2020-11-01T12:02:09Z
NCT04376684,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-04,NA,NA,2020-10-23,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-27,Actual,"May 28, 2020",Actual,2020-05-28,October 2020,2020-10-31,"December 21, 2020",Anticipated,2020-12-21,"December 21, 2020",Anticipated,2020-12-21,NA,Interventional,OSCAR,,Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease,"A Randomized, Double-blind, Placebo-controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients With Severe Pulmonary COVID-19 Related Disease",Recruiting,NA,Phase 2,800,Anticipated,GlaxoSmithKline,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.","Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.",http://clinicalstudydatarequest.com,Yes,IPD for this study will be made available via the Clinical Study Data Request site.,2020-11-01T12:02:14Z,2020-11-01T12:02:14Z
NCT04377165,"ClinicalTrials.gov processed this data on November 09, 2020",2020-05-04,NA,NA,2020-11-04,2020-05-04,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-06,Actual,"May 6, 2020",Actual,2020-05-06,April 2020,2020-04-30,"August 26, 2020",Actual,2020-08-26,"August 26, 2020",Actual,2020-08-26,NA,Interventional,NA,,Innovative Tool to Limit Spread of SARS-CoV-2 (COVID 19) in Residential Aged Care Facilities,Innovative Tool to Limit Spread of SARS-CoV-2(COVID 19) in Residential Aged Care,Terminated,NA,N/A,34,Actual,The University of Queensland,,2,NA,"Engagement issues, poor recruitment to study",FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-10T11:28:23Z,2020-11-10T11:28:23Z
NCT04375397,"ClinicalTrials.gov processed this data on November 13, 2020",2020-05-04,NA,NA,2020-11-06,2020-05-04,2020-05-05,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"June 6, 2020",Actual,2020-06-06,November 2020,2020-11-30,"April 16, 2021",Anticipated,2021-04-16,"March 19, 2021",Anticipated,2021-03-19,NA,Interventional,iNSPIRE,,Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury,IbrutiNib in SARS CoV-2 Induced Pulmonary Injury and Respiratory Failure (iNSPIRE),Recruiting,NA,Phase 2,46,Anticipated,AbbVie,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,"Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.",Requests for access to individual participant data from ibrutinib clinical studies conducted by AbbVie can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu,http://yoda.yale.edu/,Yes,"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.",2020-11-14T10:42:47Z,2020-11-14T10:42:47Z
NCT04392713,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-05,NA,NA,2020-05-17,2020-05-17,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-05-17,2020-05-19,Actual,"April 15, 2020",Actual,2020-04-15,May 2020,2020-05-31,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Efficacy of Ivermectin in COVID-19,Efficacy of Ivermectin in COVID-19 : A Randomized Controlled Trial,Recruiting,NA,N/A,100,Anticipated,"Combined Military Hospital, Pakistan",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:59:58Z,2020-11-01T11:59:58Z
NCT04389372,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-05,NA,NA,2020-05-14,2020-05-11,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"March 15, 2020",Actual,2020-03-15,May 2020,2020-05-31,December 2021,Anticipated,2021-12-31,March 2021,Anticipated,2021-03-31,NA,Interventional,ChroMig-Smart,,"Effectiveness and Acceptability of MINDFULNESS by Smartphone, for Patients With Chronic Migraine and Medication Overuse",Feasibility and Effectiveness of Mindfulness Program by Smartphone for Patients With Chronic Migraine and Medication Overuse During Covid-19 Emergency,Recruiting,NA,N/A,50,Anticipated,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:00:33Z,2020-11-01T12:00:33Z
NCT04385108,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-05,NA,NA,2020-07-29,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-07-31,Actual,"March 4, 2020",Actual,2020-03-04,July 2020,2020-07-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,COVIDBioToul,,Predictive Immune Biomarkers for COVID-19 Pathogenesis,Identification of Predictive Immune Biomarkers Based on the Understanding of COVID-19 Pathogenesis to Influence Therapeutic Management,Recruiting,NA,N/A,170,Anticipated,"University Hospital, Toulouse",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:14Z,2020-11-01T12:01:14Z
NCT04383613,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-05,NA,NA,2020-09-14,2020-05-08,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-09-14,2020-09-16,Actual,"May 15, 2020",Actual,2020-05-15,September 2020,2020-09-30,"December 11, 2020",Anticipated,2020-12-11,"December 11, 2020",Anticipated,2020-12-11,NA,Interventional,COVID-PRONE,,Prone Positioning for Patients on General Medical Wards With COVID19,Prone Positioning for Patients on General Medical Wards With COVID19: A Multicenter Pragmatic Randomized Trial [COVID-PRONE],Recruiting,NA,N/A,350,Anticipated,"St. Michael's Hospital, Toronto",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:25Z,2020-11-01T12:01:25Z
NCT04382560,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-05,NA,NA,2020-09-24,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-25,Actual,"May 2, 2020",Actual,2020-05-02,September 2020,2020-09-30,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,NA,,Coping Strategies and Responsiveness to a Brief Online Intervention During COVID-19 Pandemic,Resting Heart Rate Variability as a Predictor of Coping Strategies and Responsiveness to a Brief Online Intervention During Forced Quarantine,Completed,NA,N/A,69,Actual,University of Parma,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:31Z,2020-11-01T12:01:31Z
NCT04381884,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-05,NA,NA,2020-10-01,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-10-01,2020-10-05,Actual,"May 18, 2020",Actual,2020-05-18,October 2020,2020-10-31,"September 29, 2020",Actual,2020-09-29,"September 29, 2020",Actual,2020-09-29,NA,Interventional,NA,,Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19,"A Pilot, Proof of Concept Trial to Prove Ivermectin Efficacy in the Reduction of SARS-CoV-2 Replication at Early Stages of COVID-19",Completed,NA,Phase 2,45,Actual,Laboratorio Elea Phoenix S.A.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:01:37Z,2020-11-01T12:01:37Z
NCT04379661,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-05,NA,NA,2020-05-06,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-06,2020-05-07,Actual,"April 3, 2020",Actual,2020-04-03,May 2020,2020-05-31,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,SUNLIGHT Study: Online Support Groups for MS to Address COVID-19,SUNLIGHT Study: Online Support Groups for Multiple Sclerosis (MS) to Address COVID-19,Recruiting,NA,N/A,52,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:53Z,2020-11-01T12:01:53Z
NCT04379076,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-05,NA,NA,2020-05-13,2020-05-05,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-15,Actual,"May 14, 2020",Actual,2020-05-14,May 2020,2020-05-31,"December 30, 2020",Anticipated,2020-12-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,ILIAD-7-UK,,InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort,"A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in UK",Recruiting,NA,Phase 2,48,Anticipated,Revimmune,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,publication,2020-11-01T12:01:57Z,2020-11-01T12:01:57Z
NCT04379037,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-05,NA,NA,2020-07-05,2020-05-05,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-05,2020-07-07,Actual,"June 27, 2020",Actual,2020-06-27,July 2020,2020-07-31,"November 1, 2020",Anticipated,2020-11-01,"September 1, 2020",Anticipated,2020-09-01,NA,Interventional,NA,,Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients,Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients,Recruiting,NA,N/A,50,Anticipated,Nemechek Technologies,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:58Z,2020-11-01T12:01:58Z
NCT04377711,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-05,NA,NA,2020-06-09,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-06-09,2020-06-11,Actual,"June 8, 2020",Actual,2020-06-08,June 2020,2020-06-30,"December 1, 2020",Anticipated,2020-12-01,"September 1, 2020",Anticipated,2020-09-01,NA,Interventional,NA,,A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ciclesonide Metered-Dose Inhaler in Non-hospitalized Patients 12 Years of Age and Older With Symptomatic COVID-19 Infection",Recruiting,NA,Phase 3,400,Anticipated,Covis Pharma S.Ã .r.l.,,2,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:02:07Z,2020-11-01T12:02:07Z
NCT04378920,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-05,NA,NA,2020-10-27,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-29,Actual,"April 14, 2020",Actual,2020-04-14,October 2020,2020-10-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,"A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes","A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes",Recruiting,NA,Phase 1/Phase 2,90,Anticipated,Institut de Cancerologie Strasbourg Europe,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-02T10:30:08Z,2020-11-02T10:30:08Z
NCT04377100,"ClinicalTrials.gov processed this data on November 13, 2020",2020-05-05,NA,NA,2020-11-12,2020-05-05,2020-05-06,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-13,Estimate,"November 18, 2020",Anticipated,2020-11-18,"October 28, 2020",2020-10-28,"February 28, 2021",Anticipated,2021-02-28,"February 28, 2021",Anticipated,2021-02-28,NA,Interventional,NA,,Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses,Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses,Recruiting,NA,N/A,3000,Anticipated,National Institutes of Health Clinical Center (CC),,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-15T10:59:27Z,2020-11-15T10:59:27Z
NCT04433910,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-06,NA,NA,2020-06-19,2020-06-15,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-19,2020-06-23,Actual,June 2020,Anticipated,2020-06-30,June 2020,2020-06-30,February 2021,Anticipated,2021-02-28,December 2020,Anticipated,2020-12-31,NA,Interventional,CAPSID,,A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19,"A Randomized, Prospective, Open Label Clinical Trial on the Use of Convalescent Plasma Compared to Best Supportive Care in Patients With Severe COVID-19",Recruiting,NA,Phase 2,106,Anticipated,Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:54:45Z,2020-11-01T11:54:45Z
NCT04385901,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-06,NA,NA,2020-06-03,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-05,Actual,"May 19, 2020",Actual,2020-05-19,June 2020,2020-06-30,"April 19, 2022",Anticipated,2022-04-19,"April 19, 2022",Anticipated,2022-04-19,NA,Interventional,NA,,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,Recruiting,NA,N/A,72,Anticipated,University of Missouri-Columbia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:08Z,2020-11-01T12:01:08Z
NCT04384549,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-06,NA,NA,2020-08-17,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-08-17,2020-08-18,Actual,"May 20, 2020",Actual,2020-05-20,August 2020,2020-08-31,"February 20, 2021",Anticipated,2021-02-20,"February 20, 2021",Anticipated,2021-02-20,NA,Interventional,COVID-BCG,,Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers,Randomized Controlled Trial Evaluating the Efficacy of Vaccination With Bacillus Calmette and GuÃ©rin (BCG) in the Prevention of COVID-19 Via the Strengthening of Innate Immunity in Health Care Workers,Recruiting,NA,Phase 3,1120,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:17Z,2020-11-01T12:01:17Z
NCT04383535,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-06,NA,NA,2020-09-29,2020-05-08,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-09-29,2020-09-30,Actual,"May 15, 2020",Actual,2020-05-15,September 2020,2020-09-30,"September 27, 2020",Actual,2020-09-27,"September 27, 2020",Actual,2020-09-27,NA,Interventional,PLASM-AR,,Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia,"Randomized, Double-blind, Placebo-controlled Clinical Trial of Convalescent Plasma for the Treatment of COVID-19 Pneumonia With Severity Criteria",Completed,NA,N/A,333,Actual,Hospital Italiano de Buenos Aires,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:25Z,2020-11-01T12:01:25Z
NCT04382768,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-06,NA,NA,2020-06-10,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-10,2020-06-11,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,January 2021,Anticipated,2021-01-31,January 2021,Anticipated,2021-01-31,NA,Interventional,CÃ³rdobaTrail,,Inhaled Ibuprofen to Treat COVID-19,"Extended Compassionate Use Program (UCA) With Inhalational Ibuprofen in Patients With Acute Respiratory Pathology, Mediated by COVID-19.",Recruiting,NA,N/A,40,Anticipated,QuÃ­mica Luar SRL,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-11-01T12:01:30Z,2020-11-01T12:01:30Z
NCT04382092,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-06,NA,NA,2020-05-08,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-11,Actual,"March 23, 2020",Actual,2020-03-23,May 2020,2020-05-31,"April 24, 2020",Actual,2020-04-24,"April 24, 2020",Actual,2020-04-24,NA,Interventional,NA,,Co-infection Management in COVID-19 Critically Ill,Co-infections in COVID-19 Critically Ill and Antibiotic Management,Completed,NA,N/A,32,Actual,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:35Z,2020-11-01T12:01:35Z
NCT04381858,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-06,NA,NA,2020-05-08,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-12,Actual,"May 6, 2020",Actual,2020-05-06,May 2020,2020-05-31,"September 30, 2020",Anticipated,2020-09-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,NA,,Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia,Efficacy and Safety of Convalescent Plasma vs Human Immunoglobulin for the Treatment of COVID-19 Pneumonia: A Randomized Controlled Trial,Recruiting,NA,Phase 3,500,Anticipated,Centenario Hospital Miguel Hidalgo,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:37Z,2020-11-01T12:01:37Z
NCT04380701,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-06,NA,NA,2020-09-10,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-09-10,2020-09-11,Actual,"April 23, 2020",Actual,2020-04-23,September 2020,2020-09-30,November 2020,Anticipated,2020-11-30,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,,A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults,"A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-2019 Using Different Dosing Regimens in Healthy Adults",Recruiting,NA,Phase 1/Phase 2,456,Anticipated,BioNTech SE,,7,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:45Z,2020-11-01T12:01:45Z
NCT04380519,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-06,NA,NA,2020-09-28,2020-05-06,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-29,Actual,"April 23, 2020",Actual,2020-04-23,September 2020,2020-09-30,"July 24, 2020",Actual,2020-07-24,"July 10, 2020",Actual,2020-07-10,NA,Interventional,NA,,Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),"An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)",Completed,NA,Phase 2/Phase 3,372,Actual,R-Pharm,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:01:46Z,2020-11-01T12:01:46Z
NCT04380376,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-06,NA,NA,2020-05-10,2020-05-06,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-10,2020-05-12,Actual,"April 30, 2020",Actual,2020-04-30,May 2020,2020-05-31,"October 30, 2020",Anticipated,2020-10-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,MICOV,,Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia,"Single-center, Prospective, Open-label, Comparator Study, Blind for Central Accessor to Access the Efficacy, Safety, and Tolerability of Inhalations of Low-doses of Melphalan in Patients With Pneumonia With Confirmed or Suspected COVID-19",Recruiting,NA,Phase 2,60,Anticipated,"Federal State Budgetary Institution, Pulmonology Scientific Research Institute",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:47Z,2020-11-01T12:01:47Z
NCT04379518,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-06,NA,NA,2020-09-14,2020-05-06,2020-05-07,Actual,NA,NA,NA,NA,NA,NA,2020-09-14,2020-09-17,Actual,"September 4, 2020",Actual,2020-09-04,September 2020,2020-09-30,"September 4, 2021",Anticipated,2021-09-04,"September 4, 2021",Anticipated,2021-09-04,NA,Interventional,NA,,Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients,Phase 1/2A Study of Rintatolimod and IFN-Alpha Regimen in Cancer Patients With Mild or Moderate COVID-19 Infection,Recruiting,NA,Phase 1/Phase 2,44,Anticipated,Roswell Park Cancer Institute,,1,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:01:55Z,2020-11-01T12:01:55Z
NCT04521309,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-07,NA,NA,2020-09-03,2020-08-19,2020-08-20,Actual,NA,NA,NA,NA,NA,NA,2020-09-03,2020-09-04,Actual,"June 19, 2020",Actual,2020-06-19,May 2020,2020-05-31,March 2021,Anticipated,2021-03-31,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients,Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Antibodies Based Intravenous Immunoglobulin (IVIG) Therapy for Severe and Critically Ill COVID-19 Patients,Recruiting,NA,Phase 1/Phase 2,50,Anticipated,Dow University of Health Sciences,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:44:22Z,2020-11-01T11:44:22Z
NCT04390477,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-07,NA,NA,2020-05-14,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-15,Actual,"May 4, 2020",Actual,2020-05-04,May 2020,2020-05-31,May 2021,Anticipated,2021-05-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Study to Evaluate the Effect of a Probiotic in COVID-19,The Intestinal Microbiota as a Therapeutic Target in Hospitalized Patients With COVID-19 Infection,Recruiting,NA,N/A,40,Anticipated,Bioithas SL,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:00:27Z,2020-11-01T12:00:27Z
NCT04390139,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-07,NA,NA,2020-05-13,2020-05-13,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-15,Actual,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,December 2020,Anticipated,2020-12-31,October 2020,Anticipated,2020-10-31,NA,Interventional,COVIDMES,,Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19,"A Prospective, Double-blind, Randomized, Parallel, Placebo-controlled Pilot Clinical Trial for the Evaluation of the Efficacy and Safety of Two Doses of WJ-MSC in Patients With Acute Respiratory Distress Syndrome Secondary to Infection by COVID-19",Recruiting,NA,Phase 1/Phase 2,30,Anticipated,Banc de Sang i Teixits,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:00:29Z,2020-11-01T12:00:29Z
NCT04390022,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-07,NA,NA,2020-09-22,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-23,Actual,"July 31, 2020",Actual,2020-07-31,September 2020,2020-09-30,"December 30, 2020",Anticipated,2020-12-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,SAINT,,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Pilot Study to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission,"Active, not recruiting",NA,Phase 2,24,Anticipated,"Clinica Universidad de Navarra, Universidad de Navarra",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:00:30Z,2020-11-01T12:00:30Z
NCT04384731,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-07,NA,NA,2020-07-24,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-07-24,2020-07-28,Actual,"May 29, 2020",Actual,2020-05-29,July 2020,2020-07-31,"January 30, 2021",Anticipated,2021-01-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,Caards-1,,CurosurfÂ® in Adult Acute Respiratory Distress Syndrome Due to COVID-19,Randomized Controlled Phase II Trial of Poractant Alfa (CurosurfÂ®) by Fiberoptic Bronchoscopy-directed Endobronchial Administration in Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Viral Pneumonia,Recruiting,NA,Phase 2,20,Anticipated,Versailles Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:16Z,2020-11-01T12:01:16Z
NCT04384497,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-07,NA,NA,2020-05-26,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-27,Actual,"May 7, 2020",Actual,2020-05-07,May 2020,2020-05-31,December 2020,Anticipated,2020-12-31,June 2020,Anticipated,2020-06-30,NA,Interventional,NA,,Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study,Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study,Recruiting,NA,Phase 1/Phase 2,50,Anticipated,Karolinska University Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"The investigators will be sharing the data, but the management plan is being designed.",2020-11-01T12:01:18Z,2020-11-01T12:01:18Z
NCT04382755,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-07,NA,NA,2020-07-07,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-07-07,2020-07-09,Actual,"May 22, 2020",Actual,2020-05-22,July 2020,2020-07-31,September 2021,Anticipated,2021-09-30,May 2021,Anticipated,2021-05-31,NA,Interventional,ZILU-COV,,ZilucoplanÂ® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure,"A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Complement C5 Inhibition With ZilucoplanÂ® in Improving Oxygenation and short-and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure",Recruiting,NA,Phase 2,81,Anticipated,"University Hospital, Ghent",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:30Z,2020-11-01T12:01:30Z
NCT04382586,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-07,NA,NA,2020-10-06,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"July 6, 2020",Actual,2020-07-06,October 2020,2020-10-31,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants,"A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID-19 Infection and Pulmonary Distress",Recruiting,NA,Phase 2,52,Anticipated,BeiGene,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,NA,2020-11-01T12:01:31Z,2020-11-01T12:01:31Z
NCT04382040,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-07,NA,NA,2020-09-30,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-01,Actual,"May 8, 2020",Actual,2020-05-08,May 2020,2020-05-31,January 2021,Anticipated,2021-01-31,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,,"A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19","A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19",Recruiting,NA,Phase 2,50,Anticipated,MGC Pharmaceuticals d.o.o,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:36Z,2020-11-01T12:01:36Z
NCT04381962,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-07,NA,NA,2020-06-04,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-09,Actual,"May 29, 2020",Actual,2020-05-29,May 2020,2020-05-31,"October 13, 2020",Anticipated,2020-10-13,"September 13, 2020",Anticipated,2020-09-13,NA,Interventional,ATOMIC2,,A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2),A Multi-centre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID-19 (ATOMIC2),Recruiting,NA,Phase 3,800,Anticipated,University of Oxford,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:01:36Z,2020-11-01T12:01:36Z
NCT04381377,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-07,NA,NA,2020-05-07,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-08,Actual,"April 29, 2020",Actual,2020-04-29,May 2020,2020-05-31,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,Efficacy and Safety of PolyoxidoniumÂ® in Hospitalized Patients With Coronavirus Disease COVID-19,"A Multi-centre, Adaptive, Randomized, Double-blind, Placebo-controlled Comparative Clinical Study of the Safety and Efficacy of PolyoxidoniumÂ®, Lyophilizate for Solution for Injections and Topical Application, 6 mg (NPO Petrovax Pharm LLC, Russia) in Patients With Coronavirus Disease (COVID-19).",Recruiting,NA,Phase 2/Phase 3,394,Anticipated,NPO Petrovax,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:01:40Z,2020-11-01T12:01:40Z
NCT04381364,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-07,NA,NA,2020-08-20,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-08-20,2020-08-24,Actual,"May 29, 2020",Actual,2020-05-29,May 2020,2020-05-31,"December 31, 2020",Anticipated,2020-12-31,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,HALT,,Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19),Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19),Recruiting,NA,Phase 2,446,Anticipated,St Goran's Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:40Z,2020-11-01T12:01:40Z
NCT04381000,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-07,NA,NA,2020-06-30,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"April 1, 2020",Actual,2020-04-01,June 2020,2020-06-30,"June 10, 2020",Actual,2020-06-10,"May 29, 2020",Actual,2020-05-29,NA,Interventional,NA,,Quarantine and Telerehabilitation in Chronic Pain Patients During COVID-19 Pandemic.,The Impact of Quarantine and the Effectiveness of Telerehabilitation in Patients With Chronic Pain During COVID-19 Pandemic.,Completed,NA,N/A,170,Actual,Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:01:42Z,2020-11-01T12:01:42Z
NCT04380961,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-07,NA,NA,2020-10-22,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-10-22,2020-10-26,Actual,"April 24, 2020",Actual,2020-04-24,October 2020,2020-10-31,"September 28, 2021",Anticipated,2021-09-28,"September 28, 2021",Anticipated,2021-09-28,NA,Interventional,NA,,A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19,"Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical COVID-19 Disease",Recruiting,NA,Phase 2,270,Anticipated,"Janssen Pharmaceutica N.V., Belgium",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2020-11-01T12:01:42Z,2020-11-01T12:01:42Z
NCT04380909,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-07,NA,NA,2020-05-07,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-07,2020-05-08,Actual,"May 6, 2020",Actual,2020-05-06,May 2020,2020-05-31,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,ROCO,,ROCO - Self-help for People With Psychological Distress Due to the Covid-19 Situation,Randomized Controlled Trial (RCT) to Evaluate the Efficacy of an Internet-based Self-help Program for People With Psychological Distress Due to Covid-19,Recruiting,NA,N/A,80,Anticipated,University of Bern,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:42Z,2020-11-01T12:01:42Z
NCT04380688,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-07,NA,NA,2020-09-17,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-09-17,2020-09-18,Actual,"June 13, 2020",Actual,2020-06-13,September 2020,2020-09-30,"November 19, 2020",Anticipated,2020-11-19,"November 19, 2020",Anticipated,2020-11-19,NA,Interventional,CALAVI US,,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19","Active, not recruiting",NA,Phase 2,61,Actual,AstraZeneca,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",2020-11-01T12:01:45Z,2020-11-01T12:01:45Z
NCT04382066,"ClinicalTrials.gov processed this data on November 02, 2020",2020-05-07,NA,NA,2020-10-29,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-10-30,Actual,"May 12, 2020",Actual,2020-05-12,October 2020,2020-10-31,November 2020,Anticipated,2020-11-30,November 2020,Anticipated,2020-11-30,NA,Interventional,APLICOV-PC,,Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19,"Multicenter, Randomized, Parallel and Proof of Concept Study to Evaluate the Safety Profile of Three Doses of Plitidepsin in Patients With COVID-19 Requiring Hospitalization","Active, not recruiting",NA,Phase 1,46,Actual,PharmaMar,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,Data of the final publication of the study will be shared upon request.,2020-11-03T10:52:05Z,2020-11-03T10:52:05Z
NCT04381936,"ClinicalTrials.gov processed this data on November 13, 2020",2020-05-07,NA,NA,2020-11-09,2020-05-07,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"March 19, 2020",Actual,2020-03-19,November 2020,2020-11-30,December 2031,Anticipated,2031-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,RECOVERY,,Randomised Evaluation of COVID-19 Therapy,Randomised Evaluation of COVID-19 Therapy,Recruiting,NA,Phase 2/Phase 3,20000,Anticipated,University of Oxford,,10,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,Proposals for substudies must be approved by the Trial Steering Committee. Procedures for accessing the data for this study are available on https://www.ndph.ox.ac.uk/data-access,https://www.ndph.ox.ac.uk/data-access,Yes,The data-sharing plans for this study have been provided in the Data Sharing Statement in RECOVERY publication: N Engl J Med. 2020 Jul 17;NEJMoa2021436. doi: 10.1056/NEJMoa2021436,2020-11-15T10:59:24Z,2020-11-15T10:59:24Z
NCT04405986,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-08,NA,NA,2020-05-28,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"May 19, 2020",Actual,2020-05-19,May 2020,2020-05-31,"December 19, 2020",Anticipated,2020-12-19,"December 19, 2020",Anticipated,2020-12-19,NA,Interventional,BRAINCOV,,Exploring Brain Damages After COVID-19 Infection,Exploring Brain Damages After COVID-19 Infection,Recruiting,NA,N/A,38,Anticipated,"University Hospital, Bordeaux",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:58:21Z,2020-11-01T11:58:21Z
NCT04400929,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-08,NA,NA,2020-07-02,2020-05-21,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-07-02,2020-07-07,Actual,"June 2, 2020",Actual,2020-06-02,July 2020,2020-07-31,June 2022,Anticipated,2022-06-30,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,,Using GM-CSF as a Host Directed Therapeutic Against COVID-19,Using GM-CSF as a Host Directed Therapeutic Against COVID-19 - a Phase 2 Investigator Initiated Trial,Recruiting,NA,Phase 2,30,Anticipated,Singapore General Hospital,,5,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2020-11-01T11:58:56Z,2020-11-01T11:58:56Z
NCT04394416,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-08,NA,NA,2020-06-02,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"June 2, 2020",Actual,2020-06-02,June 2020,2020-06-30,"June 1, 2023",Anticipated,2023-06-01,"June 1, 2022",Anticipated,2022-06-01,NA,Interventional,NA,,Trial of Imatinib for Hospitalized Adults With COVID-19,Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19,Recruiting,NA,Phase 3,204,Anticipated,"University of Maryland, Baltimore",,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:59:42Z,2020-11-01T11:59:42Z
NCT04394377,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-08,NA,NA,2020-10-05,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-06,Actual,"June 21, 2020",Actual,2020-06-21,May 2020,2020-05-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,ACTION,,Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial,Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus (COVID-19) - COALIZAO ACTION Trial,Recruiting,NA,Phase 4,600,Anticipated,Brazilian Clinical Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,All data provided during study is anonymized to respect the privacy of patients who have participated in the trial in line with applicable regulations.,2020-11-01T11:59:42Z,2020-11-01T11:59:42Z
NCT04390464,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-08,NA,NA,2020-05-14,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"May 8, 2020",Actual,2020-05-08,May 2020,2020-05-31,"May 1, 2022",Anticipated,2022-05-01,"May 7, 2021",Anticipated,2021-05-07,NA,Interventional,TACTIC-R,,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R),mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R),Recruiting,NA,Phase 4,1167,Anticipated,Cambridge University Hospitals NHS Foundation Trust,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:00:27Z,2020-11-01T12:00:27Z
NCT04389294,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-08,NA,NA,2020-05-13,2020-05-13,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-15,Actual,"May 5, 2020",Actual,2020-05-05,May 2020,2020-05-31,"October 30, 2020",Anticipated,2020-10-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists,Hospital for Special Surgery COVID-19 Antibody Serology Among Anesthesiologists and Surgeons 2020,Recruiting,NA,N/A,300,Anticipated,"Hospital for Special Surgery, New York",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:00:35Z,2020-11-01T12:00:35Z
NCT04384965,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-08,NA,NA,2020-05-28,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-05-29,Actual,"May 12, 2020",Actual,2020-05-12,May 2020,2020-05-31,"November 1, 2022",Anticipated,2022-11-01,"May 1, 2022",Anticipated,2022-05-01,NA,Interventional,NA,,Accelerated iTBS for Depressed Patients During the COVID-19 Pandemic,A Novel and Practical Accelerated Intermittent Theta Burst Protocol as a Substitute for Depressed Patients Needing Electroconvulsive Therapy During the COVID-19 Pandemic,Recruiting,NA,N/A,200,Anticipated,Centre for Addiction and Mental Health,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:01:15Z,2020-11-01T12:01:15Z
NCT04384458,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-08,NA,NA,2020-10-05,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-06,Actual,"July 20, 2020",Actual,2020-07-20,October 2020,2020-10-31,April 2021,Anticipated,2021-04-30,"September 10, 2020",Actual,2020-09-10,NA,Interventional,NA,,Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis,Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis,Recruiting,NA,N/A,400,Anticipated,Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:01:18Z,2020-11-01T12:01:18Z
NCT04382729,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-08,NA,NA,2020-05-08,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-08,2020-05-11,Actual,"April 17, 2020",Actual,2020-04-17,May 2020,2020-05-31,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Neuromuscular Electrical Stimulation in Patients With COVID19 Associated Pneumonia,Effects of Neuromuscular Electrical Stimulation Therapy on Physical Function in Patients With COVID-19 Associated Pneumonia: Study Protocol of a Randomized Controlled Trial,Recruiting,NA,N/A,80,Anticipated,"University of Turin, Italy",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-11-01T12:01:30Z,2020-11-01T12:01:30Z
NCT04382924,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-08,NA,NA,2020-09-08,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-09-08,2020-09-09,Actual,"August 5, 2020",Actual,2020-08-05,May 2020,2020-05-31,February 2022,Anticipated,2022-02-28,January 2022,Anticipated,2022-01-31,NA,Interventional,NA,,Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease,A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease,Recruiting,NA,Phase 2/Phase 3,682,Anticipated,Algernon Pharmaceuticals,,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:01:29Z,2020-11-01T12:01:29Z
NCT04382547,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-08,NA,NA,2020-05-26,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-26,2020-05-28,Actual,"May 11, 2020",Actual,2020-05-11,May 2020,2020-05-31,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,,Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells,Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells,Enrolling by invitation,NA,Phase 1/Phase 2,40,Anticipated,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:31Z,2020-11-01T12:01:31Z
NCT04382131,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-08,NA,NA,2020-09-01,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-09-01,2020-09-02,Actual,"June 23, 2020",Actual,2020-06-23,July 2020,2020-07-31,"October 31, 2020",Anticipated,2020-10-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,NA,,Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19 (ELVIS COVID-19),Hypertonic Saline Nasal Irrigation and Gargling for Suspected or Confirmed COVID-19: Pragmatic Web-based Bayesian Adaptive Randomised Controlled Trial (ELVIS COVID-19),Recruiting,NA,N/A,405,Anticipated,University of Edinburgh,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:01:35Z,2020-11-01T12:01:35Z
NCT04381988,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-08,NA,NA,2020-05-11,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-13,Actual,"May 7, 2020",Actual,2020-05-07,May 2020,2020-05-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy,A Phase II Randomized Double-Blind Placebo-Controlled Clinical Trial Of Hydroxychloroquine For Prophylaxis Against Covid-19 In Patients Receiving Radiotherapy (COVID),Recruiting,NA,Phase 2,132,Anticipated,Memorial Sloan Kettering Cancer Center,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,"Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.",2020-11-01T12:01:36Z,2020-11-01T12:01:36Z
NCT04386694,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-08,NA,NA,2020-10-28,2020-05-11,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-10-28,2020-10-29,Actual,"May 18, 2020",Actual,2020-05-18,October 2020,2020-10-31,"September 17, 2020",Actual,2020-09-17,"September 17, 2020",Actual,2020-09-17,NA,Interventional,NA,,Photobiomodulation Therapy Combined With Static Magnetic Field in Patients With COVID-19,Is Photobiomodulation Therapy (PBMT) Combined With Static Magnetic Field (sMF) Able to Decrease the Intensive Care Unit (ICU) Length of Stay for Patients With COVID-19?,Completed,NA,N/A,30,Actual,University of Nove de Julho,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2020-11-02T10:30:04Z,2020-11-02T10:30:04Z
NCT04382651,"ClinicalTrials.gov processed this data on November 06, 2020",2020-05-08,NA,NA,2020-11-02,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"June 7, 2020",Actual,2020-06-07,November 2020,2020-11-30,"April 9, 2021",Anticipated,2021-04-09,"December 18, 2020",Anticipated,2020-12-18,NA,Interventional,MAS-COVID,,Study of Efficacy and Safety of MAS825 in Patients With COVID-19,"A Phase 2, Randomized, Placebo-controlled, Participant and Investigator Blinded, Multi-center Study to Assess Efficacy and Safety of MAS825 for the Treatment of SARS-CoV-2 Infected Patients With COVID-19 Pneumonia and Impaired Respiratory Function",Recruiting,NA,Phase 2,120,Anticipated,Novartis,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.",2020-11-07T11:24:18Z,2020-11-07T11:24:18Z
NCT04382053,"ClinicalTrials.gov processed this data on November 13, 2020",2020-05-08,NA,NA,2020-11-06,2020-05-08,2020-05-11,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"May 27, 2020",Actual,2020-05-27,November 2020,2020-11-30,"December 21, 2020",Anticipated,2020-12-21,"December 21, 2020",Anticipated,2020-12-21,NA,Interventional,NA,,Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia,"Phase 2, Randomized, Controlled, Open Label Multi-center Study to Assess Efficacy and Safety of DFV890 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Patients With Coronavirus Disease 2019 (COVID-19) Pneumonia and Impaired Respiratory Function",Recruiting,NA,Phase 2,120,Anticipated,Novartis,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Yes,"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.",2020-11-14T10:42:38Z,2020-11-14T10:42:38Z
NCT04389333,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-09,NA,NA,2020-07-19,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-07-19,2020-07-21,Actual,"March 26, 2020",Actual,2020-03-26,July 2020,2020-07-31,"May 20, 2020",Actual,2020-05-20,"April 26, 2020",Actual,2020-04-26,NA,Interventional,NA,,Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic,"Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic: a Prospective, Open-label, Pilot, Randomized Trial",Completed,NA,N/A,40,Actual,Changhai Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:00:34Z,2020-11-01T12:00:34Z
NCT04387760,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-09,NA,NA,2020-08-16,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2020-08-16,2020-08-18,Actual,"August 11, 2020",Actual,2020-08-11,August 2020,2020-08-31,"May 14, 2021",Anticipated,2021-05-14,"April 14, 2021",Anticipated,2021-04-14,NA,Interventional,NA,,Favipiravir vs Hydroxychloroquine in COVID -19,Treatment of Covid-19 With Favipiravir Versus Hydroxychloroquine: a Randomized Comparator Trial,Recruiting,NA,Phase 2,150,Anticipated,Royal College of Surgeons in Ireland - Medical University of Bahrain,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,"Dr Manaf will act as the data custodian and is responsible for the storage, handling and quality of the study data.
Data will be collected in the case report form to allow for cross referencing to check validity.
Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished. All essential documents including source documents will be retained for a period of 5 years after study completion (last patient, last study point). A label stating the date after which the documents can be destroyed will be placed on the inside front cover of the case notes of trial participants.",Study documents (paper and electronic) will be retained in a secure (kept locked when not in use) location during and after the trial has finished.,NA,Yes,"Monitoring, audits, and REC review will be permitted and provide direct access to source data and documents. The Lead PI and the researchers assigned by him will have access to the stored data/specimens. Only the Lead PI and the researchers assigned working on this study will be eligible to obtain the data/specimens from the participants during data collection.",2020-11-01T12:00:44Z,2020-11-01T12:00:44Z
NCT04385199,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-09,NA,NA,2020-05-11,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-12,Actual,"May 4, 2020",Actual,2020-05-04,May 2020,2020-05-31,"August 1, 2020",Anticipated,2020-08-01,"August 1, 2020",Anticipated,2020-08-01,NA,Interventional,NA,,Convalescent Plasma for Patients With COVID-19,The Use of Convalescent Plasma for Patients Hospitalized With COVID-19 Disease,Recruiting,NA,Phase 2,30,Anticipated,Henry Ford Health System,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:12Z,2020-11-01T12:01:12Z
NCT04384445,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-09,NA,NA,2020-09-27,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-09-27,2020-09-29,Actual,"September 8, 2020",Actual,2020-09-08,September 2020,2020-09-30,"December 31, 2020",Anticipated,2020-12-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,NA,,Zofin (Organicell Flow) for Patients With COVID-19,"A Phase I/II Randomized, Double Blinded, Placebo Trial to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Zofin for the Treatment of Moderate to SARS Related to COVID-19 Infection vs Placebo",Recruiting,NA,Phase 1/Phase 2,20,Anticipated,Organicell Regenerative Medicine,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:18Z,2020-11-01T12:01:18Z
NCT04383574,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-09,NA,NA,2020-09-08,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-09-08,2020-09-10,Actual,"May 22, 2020",Actual,2020-05-22,May 2020,2020-05-31,"May 30, 2021",Anticipated,2021-05-30,"August 28, 2020",Actual,2020-08-28,NA,Interventional,NA,,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19),"A Randomized, Double-Blinded, Placebo-Controlled, Phase â… /â…¡ Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) in Healthy Population Aged â‰¥60 Years","Active, not recruiting",NA,Phase 1/Phase 2,422,Anticipated,"Sinovac Biotech Co., Ltd",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:01:25Z,2020-11-01T12:01:25Z
NCT04392973,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-10,NA,NA,2020-07-26,2020-05-13,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-07-26,2020-07-28,Actual,"May 21, 2020",Actual,2020-05-21,July 2020,2020-07-31,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,FACCT,,FAvipiravir and HydroxyChloroquine Combination Therapy,A Trial of Favipiravir and Hydroxychloroquine Combination in Adults Hospitalized With Moderate and Severe Covid-19,Recruiting,NA,N/A,520,Anticipated,King Abdullah International Medical Research Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:59:55Z,2020-11-01T11:59:55Z
NCT04391140,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-10,NA,NA,2020-08-14,2020-05-14,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-14,2020-08-18,Actual,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,June 2021,Anticipated,2021-06-30,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Prone Positioning and High-flow Nasal Cannula in COVID-19 Induced ARDS,Effectiveness of Prone Positioning Combined With High-flow Nasal Cannula for Patients With COVID-19 Induced ARDS,Recruiting,NA,N/A,248,Anticipated,Hospital Universitari Vall d'Hebron Research Institute,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Data will be shared when first 200 patients (counting the 5 studies participating in the meta-trial) will be included and at the end of inclusion,NA,NA,Yes,"Data will be shared to perform a meta-trial including other studies that assess the effectiveness of prone position in COVID-19 patients supported with nasal high flow.
No patient identifying data will be transferred to the data repository. The data set will use pseudoanonymised data. The consent process for the study will highlight that this is a meta-trial and that both aggregated and individual data without personal identifying features will be used to formulate the results from the study. Local regulation for the management of patient data needs to be adhered to as part of agreement for involvement in the study.
Data will be shared during the study at two points, Time 1 An interim analysis at 200 patients in which aggregated outcome data for the primary outcome and severe adverse effects will be analyzed
Time 2 Final analysis outlining salient clinical feature of patients for each group, outcomes",2020-11-01T12:00:21Z,2020-11-01T12:00:21Z
NCT04385836,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-10,NA,NA,2020-05-12,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-13,Actual,"June 1, 2020",Anticipated,2020-06-01,May 2020,2020-05-31,"September 1, 2020",Anticipated,2020-09-01,"September 1, 2020",Anticipated,2020-09-01,NA,Interventional,NA,,Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Recruiting,NA,Early Phase 1,150,Anticipated,"Ministry of Health, Saudi Arabia",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Yes,NA,2020-11-01T12:01:08Z,2020-11-01T12:01:08Z
NCT04385017,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-10,NA,NA,2020-05-11,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-11,2020-05-12,Actual,"May 11, 2020",Anticipated,2020-05-11,May 2020,2020-05-31,"June 12, 2021",Anticipated,2021-06-12,"June 12, 2021",Anticipated,2021-06-12,NA,Interventional,CoVInnate,,Role of Inflammasomes in COVID-19 Disease,Role of Inflammasomes in COVID-19 Disease,Recruiting,NA,N/A,40,Anticipated,Centre Hospitalier Universitaire de Nice,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:01:14Z,2020-11-01T12:01:14Z
NCT04446104,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-11,NA,NA,2020-10-13,2020-06-23,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-19,Actual,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,"August 31, 2020",Actual,2020-08-31,"August 31, 2020",Actual,2020-08-31,NA,Interventional,NA,,A Preventive Treatment for Migrant Workers at High-risk of COVID-19,A Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of COVID-19 (DORM Trial),Completed,NA,Phase 3,4257,Actual,"National University Hospital, Singapore",,5,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:53:17Z,2020-11-01T11:53:17Z
NCT04442191,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-11,NA,NA,2020-06-19,2020-06-19,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-19,2020-06-22,Actual,"May 5, 2020",Actual,2020-05-05,June 2020,2020-06-30,"May 5, 2021",Anticipated,2021-05-05,"May 5, 2021",Anticipated,2021-05-05,NA,Interventional,NA,,Convalescent Plasma as a Possible Treatment for COVID-19,"Infusion of Convalescent Plasma for the Treatment of Patients Infected With Severe Acute Respiratory Syndrome-Coronavirus-2 (COVID-19): A Double-blinded, Placebo-controlled, Proof-of-concept Study",Recruiting,NA,Phase 2,50,Anticipated,University of Illinois at Chicago,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:53:43Z,2020-11-01T11:53:43Z
NCT04393636,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-11,NA,NA,2020-06-05,2020-05-14,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"June 5, 2020",Actual,2020-06-05,June 2020,2020-06-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2022",Anticipated,2022-12-31,NA,Interventional,DCC,,Digital Cardiac Counseling Trial: DCC Trial,Randomized Controlled Trial of Digital Cardiac Counseling in Patients With Delayed Cardiac Surgical Treatment Due to Covid-19 Pandemic (DCC Trial),Recruiting,NA,N/A,394,Anticipated,Academisch Ziekenhuis Maastricht,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:59:48Z,2020-11-01T11:59:48Z
NCT04388514,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-11,NA,NA,2020-05-13,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-14,Actual,"April 8, 2020",Actual,2020-04-08,May 2020,2020-05-31,"October 8, 2020",Anticipated,2020-10-08,"October 8, 2020",Anticipated,2020-10-08,NA,Interventional,CORMOR,,Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure,Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure,Recruiting,NA,N/A,90,Anticipated,Azienda Sanitaria-Universitaria Integrata di Udine,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,starting 6 months after publication,Contacting the Principal Investigator,NA,Yes,all IPD that underlie results in a publication,2020-11-01T12:00:39Z,2020-11-01T12:00:39Z
NCT04387409,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-11,NA,NA,2020-09-29,2020-05-11,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-09-29,2020-09-30,Actual,"May 25, 2020",Actual,2020-05-25,September 2020,2020-09-30,"May 1, 2021",Anticipated,2021-05-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,NA,,Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic,"A Phase III, Double-blind, Randomized, Placebo-controlled Multicentre Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Healthcare Professionals' Absenteeism in the SARS-CoV-2 Pandemic by Modulating the Immune System","Active, not recruiting",NA,Phase 3,59,Actual,Vakzine Projekt Management GmbH,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,There is uncertainty whether the European Union General Data Protection Regulation allows dissemination of individual participant data to other researchers. Some reasons why the EU Regulation would not allow this are the lack of suitable safeguards when person data are transferred to any researcher asking for it and the impairment of the rights of the subjects for erasure of their data once they are disseminated.,2020-11-01T12:00:50Z,2020-11-01T12:00:50Z
NCT04386850,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-11,NA,NA,2020-06-10,2020-05-11,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-06-10,2020-06-12,Actual,"April 14, 2020",Actual,2020-04-14,May 2020,2020-05-31,"March 15, 2021",Anticipated,2021-03-15,"November 15, 2020",Anticipated,2020-11-15,NA,Interventional,NA,,Oral 25-hydroxyvitamin D3 and COVID-19,Preventive and Therapeutic Effects of Oral 25-hydroxyvitamin D3 on Coronavirus (COVID-19) in Adults,Recruiting,NA,Phase 2/Phase 3,1500,Anticipated,Tehran University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Beginning 9 month and ending 36 months following article publication.,Investigators whose proposed use of the data has been approved by the current study principal investigators.,NA,Yes,The datasets used and analyzed during the current study will be available from the Study Principal Investigators (zhilayas@gmeil.com) on reasonable request .,2020-11-01T12:00:55Z,2020-11-01T12:00:55Z
NCT04386616,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-11,NA,NA,2020-10-16,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-19,Actual,"June 2, 2020",Actual,2020-06-02,October 2020,2020-10-31,"March 3, 2021",Anticipated,2021-03-03,"January 29, 2021",Anticipated,2021-01-29,NA,Interventional,COVASTIL,,A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia,"A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MSTT1041A or UTTR1147A in Patients With Severe COVID-19 Pneumonia",Recruiting,NA,Phase 2,390,Anticipated,"Genentech, Inc.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).
For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2020-11-01T12:00:58Z,2020-11-01T12:00:58Z
NCT04386291,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-11,NA,NA,2020-06-29,2020-05-11,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-06-29,2020-07-01,Actual,"May 25, 2020",Actual,2020-05-25,June 2020,2020-06-30,"January 30, 2022",Anticipated,2022-01-30,"May 19, 2021",Anticipated,2021-05-19,NA,Interventional,NA,,Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19,Meditation and Yoga for Heightened Anxiety Related to COVID-19,Recruiting,NA,N/A,360,Anticipated,"Research Foundation for Mental Hygiene, Inc.",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:01:03Z,2020-11-01T12:01:03Z
NCT04384900,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-11,NA,NA,2020-05-12,2020-05-11,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-05-12,2020-05-14,Actual,"May 11, 2020",Actual,2020-05-11,April 2020,2020-04-30,December 2020,Anticipated,2020-12-31,November 2020,Anticipated,2020-11-30,NA,Interventional,PROVENT-COVID,,Accelerated Prone Position Ventilation of Patients With COVID-19,Accelerated Prone Position Ventilation of Patients With COVID-19,Recruiting,NA,N/A,150,Anticipated,Nordsjaellands Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,9 months after publication of primary results,NA,NA,Yes,De-identified data will be made publicly available 9 months after the publication of the outcome data according to the recent ICMJE recommendations,2020-11-01T12:01:15Z,2020-11-01T12:01:15Z
NCT04522128,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-12,NA,NA,2020-08-20,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2020-08-20,2020-08-21,Actual,"May 22, 2020",Actual,2020-05-22,August 2020,2020-08-31,"December 31, 2022",Anticipated,2022-12-31,"March 31, 2022",Anticipated,2022-03-31,NA,Interventional,NA,,Does Quality of Life Decline During the COVID-19 Pandemic and Can we Change Behaviour to Improve Poor Quality of Life?,Does Quality of Life Decline During the COVID-19 Pandemic and Can we Change Behaviour to Improve Poor Quality of Life?,Recruiting,NA,N/A,969,Anticipated,University of Manchester,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,WHOQOL COMBI data cannot be shared with researchers outside of the research team.,2020-11-01T11:44:16Z,2020-11-01T11:44:16Z
NCT04412330,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-12,NA,NA,2020-06-22,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-22,2020-06-24,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"May 1, 2021",Anticipated,2021-05-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,OPTIMAL,,Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19,Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19 (OPTImAL) - a Single Center Prospective Study,Recruiting,NA,N/A,20,Anticipated,University of Kentucky,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:57:30Z,2020-11-01T11:57:30Z
NCT04402944,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-12,NA,NA,2020-10-23,2020-05-25,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-26,Actual,"July 5, 2020",Actual,2020-07-05,October 2020,2020-10-31,"December 31, 2021",Anticipated,2021-12-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,NA,,Pulmozyme to Improve COVID-19 ARDS Outcomes,Pulmozyme to Improve COVID-19 ARDS Outcomes,Recruiting,NA,Phase 2,60,Anticipated,Boston Children's Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2020-11-01T11:58:42Z,2020-11-01T11:58:42Z
NCT04390191,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-12,NA,NA,2020-05-13,2020-05-13,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-13,2020-05-15,Actual,"May 7, 2020",Actual,2020-05-07,May 2020,2020-05-31,May 2021,Anticipated,2021-05-31,April 2021,Anticipated,2021-04-30,NA,Interventional,PAP-COVID,,Early CPAP in COVID-19 Confirmed or Suspected Patients,Early Continuous Positive Airway Pressure (CPAP) in COVID-19 Confirmed or Suspected Patients,Recruiting,NA,N/A,200,Anticipated,Icahn School of Medicine at Mount Sinai,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:00:28Z,2020-11-01T12:00:28Z
NCT04389944,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-12,NA,NA,2020-08-03,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-08-03,2020-08-04,Actual,"March 31, 2020",Actual,2020-03-31,August 2020,2020-08-31,"June 30, 2020",Actual,2020-06-30,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe Coronavirus Disease 2019 Infectious Disease (COVID-19),Completed,NA,N/A,15,Actual,"University Hospital, Basel, Switzerland",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:00:30Z,2020-11-01T12:00:30Z
NCT04389385,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-12,NA,NA,2020-05-14,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-15,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,"May 31, 2021",Anticipated,2021-05-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo),Aerosol Inhalation of the Exosomes Derived From Allogenic COVID-19 T Cell in the Treatment of Early Stage Novel Coronavirus Pneumonia,"Active, not recruiting",NA,Phase 1,60,Anticipated,TC Erciyes University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:00:33Z,2020-11-01T12:00:33Z
NCT04387253,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-12,NA,NA,2020-06-04,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-09,Actual,"May 23, 2020",Actual,2020-05-23,April 2020,2020-04-30,"July 23, 2021",Anticipated,2021-07-23,"July 23, 2021",Anticipated,2021-07-23,NA,Interventional,NA,,Study of Late Fetal Loss in Poitou-Charentes. GYNE-COVID,Study of Late Fetal Loss in Poitou-Charentes. GYNE-COVID,Recruiting,NA,N/A,80,Anticipated,Poitiers University Hospital,,NA,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:00:52Z,2020-11-01T12:00:52Z
NCT04388410,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-12,NA,NA,2020-08-24,2020-05-12,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2020-08-24,2020-08-26,Actual,"August 25, 2020",Actual,2020-08-25,August 2020,2020-08-31,"December 31, 2020",Anticipated,2020-12-31,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,EPCOvid-1,,Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19,Phase 2b/3 Trial to Evaluate the Safety and Efficacy of Plasma Transfusion From Convalescent Patients With SARS-CoV-2 Infection on Severity and Mortality of COVID-19 in Hospitalized Patients.,Recruiting,NA,Phase 2/Phase 3,410,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Plan to make IPD still not decided and would need approval by regulatory authorities,2020-11-01T12:00:40Z,2020-11-01T12:00:40Z
NCT04387292,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-12,NA,NA,2020-09-11,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-09-11,2020-09-14,Actual,"September 7, 2020",Actual,2020-09-07,September 2020,2020-09-30,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,SOCOVID,,Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic,Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic,Recruiting,NA,N/A,100,Anticipated,Fondation Ophtalmologique Adolphe de Rothschild,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:00:52Z,2020-11-01T12:00:52Z
NCT04386668,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-12,NA,NA,2020-10-06,2020-05-12,2020-05-13,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"May 26, 2020",Actual,2020-05-26,October 2020,2020-10-31,"August 31, 2020",Actual,2020-08-31,"July 12, 2020",Actual,2020-07-12,NA,Interventional,LIO-C,,Let It Out (LIO) and COVID19: Testing an Online Emotional Disclosure-based Intervention During the COVID19 Pandemic,Let It Out (LIO) and COVID19: a Randomised Controlled Trial of an Online Emotional Disclosure-based Intervention for Adults During the COVID19 Pandemic,Terminated,NA,N/A,80,Actual,"University College, London",,2,NA,Interim analysis indicated adaptations to intervention may be required.,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,Open access,NA,Yes,Fully anonymised participant data will be made available open access via ESRC data repository ReShare,2020-11-01T12:00:57Z,2020-11-01T12:00:57Z
NCT04402957,"ClinicalTrials.gov processed this data on November 06, 2020",2020-05-12,NA,NA,2020-11-04,2020-05-25,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-05,Actual,"October 14, 2020",Actual,2020-10-14,November 2020,2020-11-30,"June 30, 2021",Anticipated,2021-06-30,"January 31, 2021",Anticipated,2021-01-31,NA,Interventional,NA,,LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19),"Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of LSALT Peptide as Prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)",Recruiting,NA,Phase 2,60,Anticipated,Arch Biopartners Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-09T10:53:27Z,2020-11-09T10:53:27Z
NCT04391127,"ClinicalTrials.gov processed this data on November 13, 2020",2020-05-12,NA,NA,2020-11-06,2020-05-14,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"May 4, 2020",Actual,2020-05-04,November 2020,2020-11-30,"November 6, 2020",Actual,2020-11-06,"November 6, 2020",Actual,2020-11-06,NA,Interventional,NA,,Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection,Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial,Completed,NA,Phase 3,108,Actual,Centenario Hospital Miguel Hidalgo,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-14T10:42:22Z,2020-11-14T10:42:22Z
NCT04400838,"ClinicalTrials.gov processed this data on November 13, 2020",2020-05-12,NA,NA,2020-11-12,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-13,Estimate,"May 28, 2020",Actual,2020-05-28,May 2020,2020-05-31,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,,Investigating a Vaccine Against COVID-19,"A Phase 2/3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19",Recruiting,NA,Phase 2/Phase 3,12390,Anticipated,University of Oxford,,28,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-15T10:59:03Z,2020-11-15T10:59:03Z
NCT04479202,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-13,NA,NA,2020-07-19,2020-07-19,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-07-19,2020-07-21,Actual,"February 8, 2020",Actual,2020-02-08,May 2020,2020-05-31,"April 23, 2020",Actual,2020-04-23,"April 18, 2020",Actual,2020-04-18,NA,Interventional,BOIFIM,,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,Completed,NA,Phase 4,76,Actual,Chinese Medical Association,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,We have other articles about covid-19 yet to be published,2020-11-01T11:49:18Z,2020-11-01T11:49:18Z
NCT04416919,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-13,NA,NA,2020-06-30,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"July 15, 2020",Anticipated,2020-07-15,June 2020,2020-06-30,May 2025,Anticipated,2025-05-31,May 2025,Anticipated,2025-05-31,NA,Interventional,NA,,Assessment of N-95 Facemask for Use in COVID-19 Pandemic in Case of Shortage of Personal Protective Equipment,A Proposed Alternative to the N-95 Mask Shortage in the COVID-19 Pandemic. A Feasibility Study,Recruiting,NA,N/A,20,Anticipated,University of Oklahoma,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:56:55Z,2020-11-01T11:56:55Z
NCT04405076,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-13,NA,NA,2020-07-08,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-07-08,2020-07-10,Actual,"May 29, 2020",Actual,2020-05-29,July 2020,2020-07-31,August 2021,Anticipated,2021-08-31,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,,"Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older","A Phase 2a, Randomized, Observer-Blind, Placebo Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-COV-2 Vaccine in Adults Aged 18 Years and Older","Active, not recruiting",NA,Phase 2,600,Actual,"ModernaTX, Inc.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:58:28Z,2020-11-01T11:58:28Z
NCT04394403,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-13,NA,NA,2020-10-21,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-22,Actual,"May 14, 2020",Actual,2020-05-14,October 2020,2020-10-31,"June 30, 2021",Anticipated,2021-06-30,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,CoronaStress,,Pilot Internet-based Self-Help Program for Managing Corona (COVID-19) Stress,Pilot Internet-based Self-Help Program for Managing Corona Stress vs. Waitlist Control,Recruiting,NA,N/A,120,Anticipated,Hebrew University of Jerusalem,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:59:42Z,2020-11-01T11:59:42Z
NCT04394169,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-13,NA,NA,2020-07-10,2020-05-16,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-07-10,2020-07-14,Actual,"May 25, 2020",Actual,2020-05-25,July 2020,2020-07-31,"March 25, 2021",Anticipated,2021-03-25,"September 25, 2020",Anticipated,2020-09-25,NA,Interventional,PAIN-COVID,,Early Care Program for the Management of Post-ICU Syndrome and Chronic Pain After COVID-19 Infection.,"Early Care, Therapeutic Education, and Psychological Intervention for the Management of Post-intensive Care Syndrome and Chronic Pain After Coronavirus Disease 2019 Infection. Simple-blind, Controlled, Randomized Trial.",Recruiting,NA,N/A,102,Anticipated,Hospital Clinic of Barcelona,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:59:44Z,2020-11-01T11:59:44Z
NCT04392414,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-13,NA,NA,2020-09-23,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-25,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"September 23, 2020",Actual,2020-09-23,"July 10, 2020",Actual,2020-07-10,NA,Interventional,NA,,Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease,"Randomized, Open Label, Prospective Study of the Safety and Efficacy of Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease",Completed,NA,Phase 2,60,Actual,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,There is no current plan to share individual participant data (IPD).,2020-11-01T12:00:02Z,2020-11-01T12:00:02Z
NCT04391829,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-13,NA,NA,2020-10-26,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-10-26,2020-10-28,Actual,"August 31, 2020",Actual,2020-08-31,May 2020,2020-05-31,"August 31, 2021",Anticipated,2021-08-31,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,COVIDSPERM,,Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males,Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males,Recruiting,NA,N/A,20,Anticipated,Universitair Ziekenhuis Brussel,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:00:15Z,2020-11-01T12:00:15Z
NCT04389840,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-13,NA,NA,2020-09-30,2020-05-13,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"June 3, 2020",Actual,2020-06-03,May 2020,2020-05-31,March 2021,Anticipated,2021-03-31,February 2021,Anticipated,2021-02-28,NA,Interventional,NA,,Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure,A Phase 2/3 Study to Evaluate the Safety and Efficacy of Dociparstat Sodium for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure,Recruiting,NA,Phase 2/Phase 3,524,Anticipated,Chimerix,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:00:31Z,2020-11-01T12:00:31Z
NCT04388683,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-13,NA,NA,2020-05-14,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"May 12, 2020",Actual,2020-05-12,May 2020,2020-05-31,"July 31, 2021",Anticipated,2021-07-31,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NO-COVID-19,,Inhaled Nitric Oxide for Preventing Progression in COVID-19,Prevention of COVID-19 Progression Through Early Administration of Inhaled Nitric Oxide.,Recruiting,NA,Phase 2,42,Anticipated,Tufts Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Data from this pilot study will be used to plan future a larger randomized controlled outcome trial.,2020-11-01T12:00:38Z,2020-11-01T12:00:38Z
NCT04388826,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-13,NA,NA,2020-10-27,2020-05-13,2020-05-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-29,Actual,"June 18, 2020",Actual,2020-06-18,October 2020,2020-10-31,"December 18, 2020",Anticipated,2020-12-18,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,NA,,COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111,"Randomized, Placebo-Controlled, Phase 2 Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)",Recruiting,NA,Phase 2,40,Anticipated,Veru Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-02T10:29:59Z,2020-11-02T10:29:59Z
NCT04390412,"ClinicalTrials.gov processed this data on November 13, 2020",2020-05-13,NA,NA,2020-11-06,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-10,Actual,"May 4, 2020",Actual,2020-05-04,July 2020,2020-07-31,December 2020,Anticipated,2020-12-31,"August 30, 2020",Actual,2020-08-30,NA,Interventional,NA,,Low Dose Radiotherapy in COVID-19 Pneumonia,Assessment of Adding Low Dose Pulmonary Radiotherapy to the National Protocol of COVID-19 Management: A Pilot Trial,"Active, not recruiting",NA,Phase 1/Phase 2,5,Actual,Shahid Beheshti University of Medical Sciences,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,After the completion of trial for one year.,Verified researchers,NA,Yes,IPD will be shared after the completion of study to other researchers.,2020-11-14T10:42:24Z,2020-11-14T10:42:24Z
NCT04420390,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-14,NA,NA,2020-06-04,2020-06-04,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-09,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"September 8, 2020",Anticipated,2020-09-08,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,LOWRAD-Cov19,,Low Dose Radiotherapy for COVID-19 Pneumonitis,Low Dose Radiotherapy as Antinflammatory Treatment for COVID-19 Pneumonitis,Recruiting,NA,N/A,41,Anticipated,"Hospital San Carlos, Madrid",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:56:25Z,2020-11-01T11:56:25Z
NCT04397718,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-14,NA,NA,2020-10-23,2020-05-19,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-26,Actual,"July 6, 2020",Actual,2020-07-06,October 2020,2020-10-31,"December 6, 2020",Anticipated,2020-12-06,"December 6, 2020",Anticipated,2020-12-06,NA,Interventional,HITCH,,Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization,"Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH): A Multicenter, Phase 2 Randomized Controlled Trial of Best Supportive Care (BSC) vs BSC Plus Degarelix",Recruiting,NA,Phase 2,198,Anticipated,VA Office of Research and Development,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T11:59:19Z,2020-11-01T11:59:19Z
NCT04390594,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-14,NA,NA,2020-09-03,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-09-03,2020-09-07,Actual,"August 13, 2020",Actual,2020-08-13,September 2020,2020-09-30,"August 12, 2021",Anticipated,2021-08-12,"February 12, 2021",Anticipated,2021-02-12,NA,Interventional,SEN-CoV-Fadj,,Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal,"Multicentre, Open Label, Randomised, Adaptative Clinical Trial of Efficacy and Safety of Treatment Regimens in Adult COVID-19 Patients in Senegal",Recruiting,NA,Phase 3,186,Anticipated,Institut Pasteur de Dakar,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T12:00:26Z,2020-11-01T12:00:26Z
NCT04390516,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-14,NA,NA,2020-06-10,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-06-10,2020-06-12,Actual,"March 24, 2020",Actual,2020-03-24,June 2020,2020-06-30,"May 30, 2020",Actual,2020-05-30,"May 4, 2020",Actual,2020-05-04,NA,Interventional,READY,,Respiratory Decompensation and Model for the Triage of COVID-19 Patients,Prediction Of Respiratory Decompensation In Covid-19 Patients Using Machine Learning: The READY Trial,Completed,NA,N/A,197,Actual,Dascena,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T12:00:27Z,2020-11-01T12:00:27Z
NCT04390503,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-14,NA,NA,2020-05-14,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-15,Actual,May 2020,Anticipated,2020-05-31,May 2020,2020-05-31,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,Convalescent Plasma for COVID-19 Close Contacts,"A Phase 2 Randomized, Double-blinded Trial to Evaluate the Efficacy and Safety of Human Anti- SARS-CoV-2 Plasma in Close Contacts of COVID-19 Cases",Recruiting,NA,Phase 2,200,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:00:27Z,2020-11-01T12:00:27Z
NCT04389450,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-14,NA,NA,2020-10-28,2020-05-14,2020-05-15,Actual,NA,NA,NA,NA,NA,NA,2020-10-28,2020-10-29,Actual,"October 1, 2020",Actual,2020-10-01,October 2020,2020-10-31,March 2022,Anticipated,2022-03-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,"Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19","A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of Severe COVID-19",Recruiting,NA,Phase 2,140,Anticipated,Pluristem Ltd.,,5,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-02T10:29:58Z,2020-11-02T10:29:58Z
NCT04408040,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-15,NA,NA,2020-07-24,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-07-24,2020-07-28,Actual,"July 14, 2020",Actual,2020-07-14,July 2020,2020-07-31,"July 31, 2022",Anticipated,2022-07-31,"July 31, 2022",Anticipated,2022-07-31,NA,Interventional,NA,,Use of Convalescent Plasma for COVID-19,"Use of Convalescent Plasma Collected From Donors Recovered From COVID-19 Virus Disease for Transfusion, as an Empirical and Preemptive Treatment During Viral Pandemic Outbreak",Recruiting,NA,Phase 2,700,Anticipated,"Northside Hospital, Inc.",,4,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:58:07Z,2020-11-01T11:58:07Z
NCT04400799,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-15,NA,NA,2020-07-14,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-07-14,2020-07-16,Actual,"June 15, 2020",Actual,2020-06-15,July 2020,2020-07-31,"April 14, 2021",Anticipated,2021-04-14,"March 14, 2021",Anticipated,2021-03-14,NA,Interventional,NA,,Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19,Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With Coronavirus: The Multicenter Randomized Controlled Ovid Trial,Recruiting,NA,Phase 3,1000,Anticipated,University of Zurich,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:58:57Z,2020-11-01T11:58:57Z
NCT04395144,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-15,NA,NA,2020-08-09,2020-05-18,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2020-08-09,2020-08-11,Actual,"May 15, 2020",Actual,2020-05-15,August 2020,2020-08-31,"December 31, 2020",Anticipated,2020-12-31,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,COVAYDE,,COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss,Randomized-controlled Trial of HFNC Alone vs HFNC and Awake Self-proning for Treatment of Severe COVID-19,Recruiting,NA,N/A,346,Anticipated,HÃ´pital de Verdun,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:59:38Z,2020-11-01T11:59:38Z
NCT04394208,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-15,NA,NA,2020-08-16,2020-05-16,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-08-16,2020-08-18,Actual,"August 16, 2020",Actual,2020-08-16,August 2020,2020-08-31,"February 28, 2021",Anticipated,2021-02-28,"January 30, 2021",Anticipated,2021-01-30,NA,Interventional,SCOPE,,Silymarin in COVID-19 Pneumonia,Trial of Silymarin in Adults With COVID-19 Pneumonia,Recruiting,NA,Phase 3,50,Anticipated,Cairo University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,NA,2020-11-01T11:59:43Z,2020-11-01T11:59:43Z
NCT04394182,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-15,NA,NA,2020-05-16,2020-05-16,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-05-16,2020-05-19,Actual,"April 21, 2020",Actual,2020-04-21,May 2020,2020-05-31,"April 21, 2021",Anticipated,2021-04-21,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,ULTRA-COVID,,Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,Low Doses of Lung Radiation Therapy in Cases of COVID-19 Pneumonia: Prospective Multicentric Study in Radiation Oncology Centers,Recruiting,NA,N/A,15,Anticipated,Fundacion GenesisCare,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Medical history and biographical and clinical data of each patient will be recorded and shared.
The overall results of any research conducted will be available on study data publication.",2020-11-01T11:59:43Z,2020-11-01T11:59:43Z
NCT04393948,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-15,NA,NA,2020-06-23,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-06-23,2020-06-25,Actual,June 2020,Anticipated,2020-06-30,June 2020,2020-06-30,November 2020,Anticipated,2020-11-30,October 2020,Anticipated,2020-10-31,NA,Interventional,NA,,Lung Irradiation for COVID-19 Pneumonia,Pilot Study of Low-Dose Single or Bilateral Whole Lung Irradiation for SARS-CoV-2 Pneumonia,Recruiting,NA,N/A,48,Anticipated,Brigham and Women's Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:59:46Z,2020-11-01T11:59:46Z
NCT04393415,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-15,NA,NA,2020-07-24,2020-05-15,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-07-24,2020-07-27,Actual,"May 25, 2020",Actual,2020-05-25,July 2020,2020-07-31,"September 1, 2020",Anticipated,2020-09-01,"August 25, 2020",Anticipated,2020-08-25,NA,Interventional,NA,,Using PRP and Cord Blood in Treatment of Covid -19,the Effect of PRP and Cord Blood in Improving the Symptoms of Covid-19,Recruiting,NA,N/A,100,Anticipated,Aljazeera Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:59:50Z,2020-11-01T11:59:50Z
NCT04392232,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-15,NA,NA,2020-05-18,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-20,Actual,"May 5, 2020",Actual,2020-05-05,May 2020,2020-05-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection,A Phase 2 Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection,Recruiting,NA,Phase 2,100,Anticipated,TriHealth Inc.,,1,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:00:06Z,2020-11-01T12:00:06Z
NCT04392323,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-15,NA,NA,2020-05-15,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-05-15,2020-05-18,Actual,"May 13, 2020",Actual,2020-05-13,May 2020,2020-05-31,"July 31, 2020",Anticipated,2020-07-31,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,NA,,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Recruiting,NA,N/A,500,Anticipated,Northwell Health,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:00:03Z,2020-11-01T12:00:03Z
NCT04391179,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-15,NA,NA,2020-07-29,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-07-31,Actual,"May 31, 2020",Actual,2020-05-31,July 2020,2020-07-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,DICER,,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,Recruiting,NA,Phase 2,80,Anticipated,University of Michigan,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:00:20Z,2020-11-01T12:00:20Z
NCT04392141,"ClinicalTrials.gov processed this data on November 06, 2020",2020-05-15,NA,NA,2020-10-31,2020-05-15,2020-05-18,Actual,NA,NA,NA,NA,NA,NA,2020-10-31,2020-11-03,Actual,"April 1, 2020",Actual,2020-04-01,October 2020,2020-10-31,"November 1, 2020",Anticipated,2020-11-01,"November 1, 2020",Anticipated,2020-11-01,NA,Interventional,NA,,Colchicine Plus Phenolic Monoterpenes to Treat COVID-19,Application of Colchicine Plus Herbal Phenolic Monoterpene Fractions to Treat COVID-19,Recruiting,NA,Phase 1/Phase 2,200,Anticipated,Kermanshah University of Medical Sciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-07T11:24:04Z,2020-11-07T11:24:04Z
NCT04474483,"ClinicalTrials.gov processed this data on November 13, 2020",2020-05-15,NA,NA,2020-11-06,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-10,Actual,"November 6, 2020",Actual,2020-11-06,November 2020,2020-11-30,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,COVID-19,,Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19,A Pilot Placebo-controlled Randomized Double-blind Trial of Melatonin in Outpatients With COVID-19 Infection,Recruiting,NA,Phase 2,30,Anticipated,State University of New York at Buffalo,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-14T10:40:28Z,2020-11-14T10:40:28Z
NCT04407208,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-16,NA,NA,2020-06-27,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-06-27,2020-06-30,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"June 22, 2020",Actual,2020-06-22,"June 22, 2020",Actual,2020-06-22,NA,Interventional,NA,,Convalescent Plasma Therapy in Patients With COVID-19,Convalescent Plasma Therapy in Patients With COVID-19,Completed,NA,Phase 1,10,Actual,Biofarma,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:58:13Z,2020-11-01T11:58:13Z
NCT04396106,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-16,NA,NA,2020-10-26,2020-05-19,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2020-10-26,2020-10-27,Actual,"May 26, 2020",Actual,2020-05-26,October 2020,2020-10-31,January 2021,Anticipated,2021-01-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19),"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-527 in Subjects With Moderate COVID-19",Recruiting,NA,Phase 2,190,Anticipated,"Atea Pharmaceuticals, Inc.",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:59:32Z,2020-11-01T11:59:32Z
NCT04395105,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-16,NA,NA,2020-07-16,2020-05-18,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-20,Actual,"May 21, 2020",Actual,2020-05-21,July 2020,2020-07-31,"January 31, 2021",Anticipated,2021-01-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,"Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial",High Versus Low Dose Dexamethasone for the Treatment of COVID-19 Related ARDS: a Multicenter and Randomized Open-label Clinical Trial,Recruiting,NA,Phase 3,284,Anticipated,Centro de EducaciÃ³n Medica e Investigaciones ClÃ­nicas Norberto Quirno,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:59:38Z,2020-11-01T11:59:38Z
NCT04393246,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-16,NA,NA,2020-07-07,2020-05-16,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-07-07,2020-07-08,Actual,"July 3, 2020",Actual,2020-07-03,July 2020,2020-07-31,"June 15, 2021",Anticipated,2021-06-15,"February 15, 2021",Anticipated,2021-02-15,NA,Interventional,NA,,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms (TACTIC-E),Recruiting,NA,Phase 2/Phase 3,1407,Anticipated,Cambridge University Hospitals NHS Foundation Trust,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:59:51Z,2020-11-01T11:59:51Z
NCT04393727,"ClinicalTrials.gov processed this data on November 13, 2020",2020-05-16,NA,NA,2020-11-09,2020-05-16,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"May 1, 2020",Actual,2020-05-01,November 2020,2020-11-30,"September 30, 2020",Actual,2020-09-30,"September 30, 2020",Actual,2020-09-30,NA,Interventional,TSUNAMI,,Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19,Transfusion of Convalescent Plasma for the Early Treatment of pneumonIa Due to SARSCoV2: a Multicenter Open Label Randomized Control Trial,Terminated,NA,Phase 2,1,Actual,"Azienda Ospedaliero, Universitaria Pisana",,2,NA,"Study was stopped because the Promoter was changed and a new study on convalescent plasma
    promoted by AIFA was started in Italy.",FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-15T10:59:13Z,2020-11-15T10:59:13Z
NCT04407130,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-17,NA,NA,2020-10-20,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-10-20,2020-10-22,Actual,"June 16, 2020",Actual,2020-06-16,June 2020,2020-06-30,October 2020,Anticipated,2020-10-31,October 2020,Anticipated,2020-10-31,NA,Interventional,NA,,Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.,"Ivermectin and Doxycycline in Combination or Ivermectin Alone for the Treatment of Adult Bangladeshi Patients Hospitalized for COVID-19: a Randomised, Double-blind, Placebo-controlled Trial.",Enrolling by invitation,NA,Phase 2,72,Anticipated,"International Centre for Diarrhoeal Disease Research, Bangladesh",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:58:14Z,2020-11-01T11:58:14Z
NCT04398004,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-17,NA,NA,2020-10-10,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-10-10,2020-10-14,Actual,"May 6, 2020",Actual,2020-05-06,October 2020,2020-10-31,"May 6, 2022",Anticipated,2022-05-06,"May 6, 2022",Anticipated,2022-05-06,NA,Interventional,ACHIEVE,,Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,Anti-inflammatory Clarithromycin to Improve SARS-CoV-2 (COVID-19) Infection Early: The ACHIEVE Open-label Non-randomized Clinical Trial,"Active, not recruiting",NA,Phase 2,90,Anticipated,Hellenic Institute for the Study of Sepsis,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:59:17Z,2020-11-01T11:59:17Z
NCT04395911,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-17,NA,NA,2020-09-11,2020-05-18,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2020-09-11,2020-09-16,Actual,"September 10, 2020",Actual,2020-09-10,August 2020,2020-08-31,December 2021,Anticipated,2021-12-31,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections,A Multi-Center Pilot Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device (SCD) in Patients Developing Acute Kidney Injury (AKI) or Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 Infection,Recruiting,NA,N/A,35,Anticipated,SeaStar Medical,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,NA,NA,,Data will be collected throughout the study conduct.,Participant data will be accessible to the Investigational Site and CRO through a secured electronic data capture system. CRO personnel will be responsible for data verification. De-identified Participant information will be accessible to the CRO and the Sponsor.,NA,Yes,Unidentified participant data collected for this study will be submitted to a CRO for data analysis. All data will be submitted to the Sponsor.,2020-11-01T11:59:33Z,2020-11-01T11:59:33Z
NCT04394442,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-17,NA,NA,2020-05-18,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-19,Actual,"March 21, 2020",Actual,2020-03-21,May 2020,2020-05-31,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,Hydroxychloroquine in COVID-19 Patients,Use of Hydroxychloroquine in Patients With COVID-19: A Randomized Controlled Clinical Trial,Recruiting,NA,Phase 2,200,Anticipated,Zagazig University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:59:42Z,2020-11-01T11:59:42Z
NCT04394793,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-17,NA,NA,2020-08-30,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-08-30,2020-09-01,Actual,"June 13, 2020",Actual,2020-06-13,August 2020,2020-08-31,September 2020,Anticipated,2020-09-30,"August 27, 2020",Actual,2020-08-27,NA,Interventional,NA,,Low Dose Radiation Therapy for Covid-19 Pneumonia,Low Dose Radiation Therapy for Covid-19 Pneumonia: A Pilot Study,"Active, not recruiting",NA,N/A,10,Actual,"All India Institute of Medical Sciences, New Delhi",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:59:40Z,2020-11-01T11:59:40Z
NCT04421625,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-18,NA,NA,2020-08-05,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-08-05,2020-08-07,Actual,"June 15, 2020",Actual,2020-06-15,May 2020,2020-05-31,"June 15, 2022",Anticipated,2022-06-15,"June 15, 2022",Anticipated,2022-06-15,NA,Interventional,PAPESCO-19,,Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic,"Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic: Constitution of a Biological Collection Linked to a Prospective, Multicenter Cohort Study",Recruiting,NA,N/A,12000,Anticipated,Institut Cancerologie de l'Ouest,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:56:16Z,2020-11-01T11:56:16Z
NCT04405999,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-18,NA,NA,2020-09-02,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-09-02,2020-09-03,Actual,"May 14, 2020",Actual,2020-05-14,September 2020,2020-09-30,"August 31, 2020",Actual,2020-08-31,"August 9, 2020",Actual,2020-08-09,NA,Interventional,NA,,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease: a Randomised Controlled Trial,Completed,NA,Phase 4,50,Actual,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:58:21Z,2020-11-01T11:58:21Z
NCT04403269,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-18,NA,NA,2020-05-22,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-27,Actual,"May 5, 2020",Actual,2020-05-05,May 2020,2020-05-31,"May 5, 2021",Anticipated,2021-05-05,"May 5, 2021",Anticipated,2021-05-05,NA,Interventional,GERONIMO 19,,"NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE","""STUDY OF THE EFFICIENCY OF NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE"" GERONIMO 19",Recruiting,NA,Phase 2,35,Anticipated,Versailles Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:58:40Z,2020-11-01T11:58:40Z
NCT04402918,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-18,NA,NA,2020-05-25,2020-05-25,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-25,2020-05-27,Actual,"May 17, 2020",Actual,2020-05-17,April 2020,2020-04-30,"December 31, 2020",Anticipated,2020-12-31,"May 19, 2020",Anticipated,2020-05-19,NA,Interventional,TRANSCOVID,,Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 (COVID-19) During Pregnancy,Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 During Pregnancy,Recruiting,NA,N/A,160,Anticipated,Centre Hospitalier Universitaire de Besancon,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:58:42Z,2020-11-01T11:58:42Z
NCT04399317,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-18,NA,NA,2020-06-23,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-23,2020-06-25,Actual,"May 28, 2020",Actual,2020-05-28,May 2020,2020-05-31,August 2020,Anticipated,2020-08-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Flow Controlled Ventilation in ARDS Associated With COVID-19,Flow Controlled Ventilation in ARDS Associated With COVID-19,Recruiting,NA,N/A,20,Anticipated,Hamad Medical Corporation,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,A decision regarding sharing information will be taken at later stage.,2020-11-01T11:59:08Z,2020-11-01T11:59:08Z
NCT04397796,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-18,NA,NA,2020-08-05,2020-05-19,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-08-05,2020-08-07,Actual,"August 3, 2020",Actual,2020-08-03,May 2020,2020-05-31,June 2021,Anticipated,2021-06-30,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,,Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation,"Phase 1b Randomized, Double-Blind, Placebo-Controlled Study Of The Safety Of Therapeutic Treatment With Immunomodulatory Mesenchymal Stem Cells In Adults With COVID-19 Infection Requiring Mechanical Ventilation",Recruiting,NA,Phase 1,45,Anticipated,"NantKwest, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:59:18Z,2020-11-01T11:59:18Z
NCT04395807,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-18,NA,NA,2020-06-04,2020-05-19,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-05,Actual,"June 3, 2020",Actual,2020-06-03,June 2020,2020-06-30,May 2021,Anticipated,2021-05-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,COVID HELMET,,Helmet CPAP Versus HFNC in COVID-19,Helmet Continuous Positive Airway Pressure Versus High-Flow Nasal Cannula in COVID-19: A Pragmatic Randomised Clinical Trial,Recruiting,NA,N/A,120,Anticipated,Lund University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:59:33Z,2020-11-01T11:59:33Z
NCT04395768,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-18,NA,NA,2020-09-09,2020-05-19,2020-05-20,Actual,NA,NA,NA,NA,NA,NA,2020-09-09,2020-09-11,Actual,"September 9, 2020",Actual,2020-09-09,September 2020,2020-09-30,"December 31, 2021",Anticipated,2021-12-31,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,NA,,International ALLIANCE Study of Therapies to Prevent Progression of COVID-19,"Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 With or Without Vitamin C, a Multi-centre, International, Randomized Trial: The International ALLIANCE Study",Recruiting,NA,Phase 2,200,Anticipated,"National Institute of Integrative Medicine, Australia",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:59:34Z,2020-11-01T11:59:34Z
NCT04394117,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-18,NA,NA,2020-07-14,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-07-14,2020-07-16,Actual,"June 19, 2020",Actual,2020-06-19,July 2020,2020-07-31,"April 30, 2021",Anticipated,2021-04-30,"January 30, 2021",Anticipated,2021-01-30,NA,Interventional,CLARITY,,Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease,Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease,Recruiting,NA,Phase 4,605,Anticipated,The George Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,To be confirmed,To be determined,NA,Yes,"Trial data will be disseminated in the form of a publication to a relevant clinical journal and presentation at appropriate scientific conferences.
Individual participant data that underlie the results reported, after de-identification (text, tables, figures, and appendices), may be shared with Investigators whose proposed use of the data has been approved by an independent review committee (""learned intermediary"") identified for this purpose.",2020-11-01T11:59:44Z,2020-11-01T11:59:44Z
NCT04394013,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-18,NA,NA,2020-08-31,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-02,Actual,"August 26, 2020",Actual,2020-08-26,August 2020,2020-08-31,December 2020,Anticipated,2020-12-31,October 2020,Anticipated,2020-10-31,NA,Interventional,NA,,A Web-Based Gentle Body Stretching to Alleviate Loneliness and Improve Mental Fitness During COVID-19 Isolation Period,A Web-Based Gentle Body Stretching to Alleviate Loneliness and Improve Mental Fitness During COVID-19 Isolation Period,Recruiting,NA,N/A,70,Anticipated,Monash University Malaysia,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Upon request via direct contact to researcher,2020-11-01T11:59:45Z,2020-11-01T11:59:45Z
NCT04393818,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-18,NA,NA,2020-09-09,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-09-09,2020-09-10,Actual,"May 5, 2020",Actual,2020-05-05,August 2020,2020-08-31,"August 24, 2020",Actual,2020-08-24,"August 24, 2020",Actual,2020-08-24,NA,Interventional,PsyCovid_App,,Mobile Phone Based Intervention to Protect Mental Health in Healthcare Workers at Frontline Against COVID19,A Double-blinded Randomized Controlled Trial to Examine the Effectiveness of a Mobile-based Intervention to Reduce Mental Health Problems in Healthcare Workers at the Frontline Against COVID-19 in Spain: the PsyCovidApp Trial,Completed,NA,Phase 3,560,Actual,FundaciÃ³ d'investigaciÃ³ SanitÃ ria de les Illes Balears,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:59:46Z,2020-11-01T11:59:46Z
NCT04393792,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-18,NA,NA,2020-05-18,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-05-18,2020-05-19,Actual,May 2020,Anticipated,2020-05-31,May 2020,2020-05-31,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,SINUS WASH Pilot Study in Adults Testing Positive for COVID-19,Can a Sinus Rinse and Mouth Wash Reduce Viral Load in COVID-19 Positive Individuals and Their Co-residents?,Recruiting,NA,Phase 1,40,Anticipated,Hampshire Hospitals NHS Foundation Trust,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:59:47Z,2020-11-01T11:59:47Z
NCT04393038,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-18,NA,NA,2020-07-17,2020-05-18,2020-05-19,Actual,NA,NA,NA,NA,NA,NA,2020-07-17,2020-07-20,Actual,"May 1, 2020",Actual,2020-05-01,July 2020,2020-07-31,"April 30, 2021",Anticipated,2021-04-30,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,Mir-Age,,ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19,"A Phase 2/3, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and the Safety of ABX464 in Treating Inflammation and Preventing COVID-19 Associated Acute Respiratory Failure in Patients Aged â‰¥ 65 and Patients Aged â‰¥18 With at Least One Additional Risk Factor Who Are Infected With SARS-CoV-2.",Recruiting,NA,Phase 2/Phase 3,1034,Anticipated,Abivax S.A.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:59:52Z,2020-11-01T11:59:52Z
NCT04418206,"ClinicalTrials.gov processed this data on November 13, 2020",2020-05-18,NA,NA,2020-11-06,2020-06-04,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"June 1, 2020",Actual,2020-06-01,May 2020,2020-05-31,"June 1, 2021",Anticipated,2021-06-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,EliSpot,,Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19,Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19,Recruiting,NA,N/A,300,Anticipated,Centre Hospitalier Universitaire de Nice,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-14T10:41:42Z,2020-11-14T10:41:42Z
NCT04416360,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-19,NA,NA,2020-06-03,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-04,Actual,"May 5, 2020",Actual,2020-05-05,June 2020,2020-06-30,January 2021,Anticipated,2021-01-31,July 2020,Anticipated,2020-07-31,NA,Interventional,CLIECO,,Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder in Covid-19 Outbreak,Clinical Evolution and Parenting in Children and Adolescents With Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder Quarantined Because of Covid-19 Outbreak,Recruiting,NA,N/A,40,Anticipated,"University Hospital, Toulouse",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:57:01Z,2020-11-01T11:57:01Z
NCT04414631,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-19,NA,NA,2020-08-10,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-08-10,2020-08-11,Actual,"August 6, 2020",Actual,2020-08-06,July 2020,2020-07-31,July 2021,Anticipated,2021-07-31,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,,Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,"Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial (PROTECT-COVID-19).",Recruiting,NA,Phase 2,120,Anticipated,"University Hospital, Basel, Switzerland",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:57:15Z,2020-11-01T11:57:15Z
NCT04407286,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-19,NA,NA,2020-09-01,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-01,2020-09-02,Actual,"May 19, 2020",Actual,2020-05-19,September 2020,2020-09-30,"May 18, 2021",Anticipated,2021-05-18,"October 18, 2020",Anticipated,2020-10-18,NA,Interventional,NA,,Vitamin D Testing and Treatment for COVID 19,Vitamin D Testing and Treatment for Adults With COVID 19,Recruiting,NA,Phase 1,100,Anticipated,Arizona State University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,Contact us if you wish to discuss sharing of de-identified data,2020-11-01T11:58:12Z,2020-11-01T11:58:12Z
NCT04402203,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-19,NA,NA,2020-05-22,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-26,Actual,May 2020,Anticipated,2020-05-31,May 2020,2020-05-31,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh,Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh,Recruiting,NA,Phase 2/Phase 3,50,Anticipated,Bangladesh Medical Research Council (BMRC),,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:58:47Z,2020-11-01T11:58:47Z
NCT04399967,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-19,NA,NA,2020-09-28,2020-05-19,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-30,Actual,"June 13, 2020",Actual,2020-06-13,September 2020,2020-09-30,"June 30, 2022",Anticipated,2022-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,QTW2020,,"COVID-19 Brief Advice and Chat-based Support for Smoking Cessation Via ""Quit to Win"" Contest 2020","Building Capacity and Promoting Smoking Cessation in the Community Via ""Quit to Win"" Contest 2020: a Single-blind Randomized Controlled Trial on COVID-19 Related Brief Advice and Personalized Chat-based Intervention for Smoking Cessation",Recruiting,NA,N/A,842,Anticipated,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:59:03Z,2020-11-01T11:59:03Z
NCT04399746,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-19,NA,NA,2020-05-20,2020-05-20,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-20,2020-05-22,Actual,"March 15, 2020",Actual,2020-03-15,May 2020,2020-05-31,"June 10, 2020",Anticipated,2020-06-10,"May 20, 2020",Actual,2020-05-20,NA,Interventional,IvAzCol,,Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19,A Pilot Study for COVID-19 Outpatient Treatment With the Combination of Ivermectin-azithromycin-cholecalciferol,Recruiting,NA,N/A,30,Anticipated,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:59:04Z,2020-11-01T11:59:04Z
NCT04399252,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-19,NA,NA,2020-06-29,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-29,2020-07-01,Actual,"June 24, 2020",Actual,2020-06-24,May 2020,2020-05-31,"May 25, 2022",Anticipated,2022-05-25,"May 25, 2022",Anticipated,2022-05-25,NA,Interventional,NA,,Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19,A Randomized Trial of the Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19,Recruiting,NA,N/A,1000,Anticipated,Duke University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:59:08Z,2020-11-01T11:59:08Z
NCT04399005,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-19,NA,NA,2020-06-23,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-23,2020-06-25,Actual,"May 25, 2020",Actual,2020-05-25,May 2020,2020-05-31,"June 10, 2020",Actual,2020-06-10,"June 5, 2020",Actual,2020-06-05,NA,Interventional,NA,,The Efficacy Comparing Daily and After-each-case Room Disinfection.,The Efficacy Comparing Daily and After-each-case Room Disinfection in the Endoscopy Unit During the COVID-19 Pandemic.,Completed,NA,N/A,240,Actual,The First Affiliated Hospital of Zhejiang Chinese Medical University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,individual participant data sharing will be consider after study,2020-11-01T11:59:10Z,2020-11-01T11:59:10Z
NCT04397757,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-19,NA,NA,2020-09-16,2020-05-19,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-09-16,2020-09-17,Actual,"May 13, 2020",Actual,2020-05-13,September 2020,2020-09-30,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.,"An Open-Label, Controlled, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill, Hospitalized Participants With COVID-19 Pneumonia Caused by SARS-CoV-2.",Recruiting,NA,Phase 1,80,Anticipated,University of Pennsylvania,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:59:19Z,2020-11-01T11:59:19Z
NCT04397692,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-19,NA,NA,2020-07-06,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-07-06,2020-07-08,Actual,"June 13, 2020",Actual,2020-06-13,July 2020,2020-07-31,"September 30, 2020",Anticipated,2020-09-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial),Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial),Recruiting,NA,N/A,20,Anticipated,Beyond Air Inc.,,2,NA,NA,NA,NA,NA,NA,TRUE,FALSE,TRUE,TRUE,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:59:19Z,2020-11-01T11:59:19Z
NCT04397510,"ClinicalTrials.gov processed this data on November 13, 2020",2020-05-19,NA,NA,2020-11-06,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"June 1, 2020",Actual,2020-06-01,November 2020,2020-11-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury,Nebulized Heparin vs. Placebo for the Treatment of COVID-19 Induced Lung Injury,Enrolling by invitation,NA,Phase 4,50,Anticipated,Frederick Health,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-14T10:42:14Z,2020-11-14T10:42:14Z
NCT04399356,"ClinicalTrials.gov processed this data on November 13, 2020",2020-05-19,NA,NA,2020-11-09,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"October 1, 2020",Actual,2020-10-01,November 2020,2020-11-30,"February 12, 2021",Anticipated,2021-02-12,"January 1, 2021",Anticipated,2021-01-01,NA,Interventional,NA,,Niclosamide for Mild to Moderate COVID-19,Niclosamide for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19),Recruiting,NA,Phase 2,100,Anticipated,Tufts Medical Center,,2,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-15T10:59:06Z,2020-11-15T10:59:06Z
NCT04397562,"ClinicalTrials.gov processed this data on November 13, 2020",2020-05-19,NA,NA,2020-11-10,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"April 29, 2020",Actual,2020-04-29,November 2020,2020-11-30,"August 3, 2020",Actual,2020-08-03,"July 3, 2020",Actual,2020-07-03,NA,Interventional,CORONA,,A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Adaptively Designed Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19",Completed,NA,Phase 3,206,Actual,Biocad,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-15T10:59:06Z,2020-11-15T10:59:06Z
NCT04441684,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-20,NA,NA,2020-06-19,2020-06-19,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-19,2020-06-22,Actual,"April 17, 2020",Actual,2020-04-17,June 2020,2020-06-30,August 2021,Anticipated,2021-08-31,"May 7, 2020",Actual,2020-05-07,NA,Interventional,SeroCoV-HUS,,"Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19)","Study of the Seroprevalence of SARS-CoV-2 in Hospital Staff in Strasbourg University Hospital, Strasbourg, France",Recruiting,NA,N/A,1800,Anticipated,"University Hospital, Strasbourg, France",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:53:46Z,2020-11-01T11:53:46Z
NCT04403477,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-20,NA,NA,2020-05-24,2020-05-24,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-05-24,2020-05-27,Actual,"May 20, 2020",Actual,2020-05-20,May 2020,2020-05-31,"October 30, 2020",Anticipated,2020-10-30,"July 20, 2020",Anticipated,2020-07-20,NA,Interventional,NA,,Convalescent Plasma Therapy in Severe COVID-19 Infection,"Convalescent Plasma Transfusion Therapy in Severe COVID-19 Patients- a Tolerability, Efficacy and Dose-response Phase II RCT",Recruiting,NA,Phase 2,20,Anticipated,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,six months,"Available on public domain like figshare, researchgate and others",NA,Yes,Data will be shared with the journal authority and make public as part of the publication,2020-11-01T11:58:39Z,2020-11-01T11:58:39Z
NCT04402970,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-20,NA,NA,2020-06-24,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-06-24,2020-06-26,Actual,"June 19, 2020",Actual,2020-06-19,June 2020,2020-06-30,"May 31, 2022",Anticipated,2022-05-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,DORNASESARS2,,Dornase Alfa for ARDS in Patients With SARS-CoV-2,Inhaled Dornase Alfa for Treatment of ARDS in Patients With SARS-CoV-2,Recruiting,NA,Phase 3,20,Anticipated,University of Missouri-Columbia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T11:58:41Z,2020-11-01T11:58:41Z
NCT04401293,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-20,NA,NA,2020-06-04,2020-05-21,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-09,Actual,"April 26, 2020",Actual,2020-04-26,June 2020,2020-06-30,"April 26, 2021",Anticipated,2021-04-26,"October 22, 2020",Anticipated,2020-10-22,NA,Interventional,NA,,Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients,Systemic Anticoagulation With Full Dose Low Molecular Weight Heparin (LMWH) Vs. Prophylactic or Intermediate Dose LMWH in High Risk COVID-19 Patients (HEP-COVID Trial),Recruiting,NA,Phase 3,308,Anticipated,Northwell Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:58:53Z,2020-11-01T11:58:53Z
NCT04398277,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-20,NA,NA,2020-05-20,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-20,2020-05-21,Actual,"May 1, 2020",Actual,2020-05-01,May 2020,2020-05-31,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,A Daily Coping Toolkit for Medical Personnel and First-Responders During COVID-19 Pandemic,A Daily Coping Toolkit for Medical Personnel and First-Responders During the COVID-19 Pandemic,Recruiting,NA,N/A,1000,Anticipated,Kent State University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,12 months after data collection is complete,Contact the PI,NA,Yes,All data and materials will be made available.,2020-11-01T11:59:14Z,2020-11-01T11:59:14Z
NCT04397666,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-20,NA,NA,2020-08-14,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-08-14,2020-08-18,Actual,"May 15, 2020",Actual,2020-05-15,August 2020,2020-08-31,"November 15, 2020",Anticipated,2020-11-15,"September 15, 2020",Anticipated,2020-09-15,NA,Interventional,P20/09,,RT-PCR on Conjunctival Sample for the Detection of SARS-CoV-2 in Patients With Covid-19,RT-PCR on Conjunctival Sample for the Detection of SARS-Cov-2 in Patients With Covid-19,Recruiting,NA,N/A,68,Anticipated,Versailles Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:59:19Z,2020-11-01T11:59:19Z
NCT04397523,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-20,NA,NA,2020-05-20,2020-05-20,2020-05-21,Actual,NA,NA,NA,NA,NA,NA,2020-05-20,2020-05-22,Actual,"April 30, 2020",Actual,2020-04-30,May 2020,2020-05-31,"April 29, 2021",Anticipated,2021-04-29,"April 29, 2021",Anticipated,2021-04-29,NA,Interventional,NA,,Efficacy and Safety of COVID-19 Convalescent Plasma,Use of COVID-19 Convalescent Plasma in the Patients Infected With COVID-19 (SARS-CoV-2) - Efficacy and Safety,Recruiting,NA,N/A,20,Anticipated,Institute for Transfusion Medicine of RNM,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:59:21Z,2020-11-01T11:59:21Z
NCT04552951,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-21,NA,NA,2020-09-16,2020-09-16,2020-09-17,Actual,NA,NA,NA,NA,NA,NA,2020-09-16,2020-09-17,Actual,"April 4, 2020",Actual,2020-04-04,September 2020,2020-09-30,"December 30, 2020",Anticipated,2020-12-30,"September 14, 2020",Anticipated,2020-09-14,NA,Interventional,COVID-VIT-D,,Effect of Vitamin D on Morbidity and Mortality of the COVID-19,Estudio Destinado a Valorar la Utilidad de Vitamina D Sobre Morbilidad y Mortalidad de la infecciÃ³n Por Virus SARS-COV-2 (COVID-19) en el Hospital Universitario Central de Asturias,Recruiting,NA,Phase 4,80,Anticipated,FundaciÃ³n para la InvestigaciÃ³n Biosanitaria del Principado de Asturias,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:40:31Z,2020-11-01T11:40:31Z
NCT04413006,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-21,NA,NA,2020-06-01,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-02,Actual,"May 25, 2020",Anticipated,2020-05-25,May 2020,2020-05-31,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Self-compassion for Chronic Pain Virtual Group Treatment Program,A Self-compassion Group-based Treatment for Chronic Pain Via Video Conferencing During the COVID-19 Pandemic: Feasibility Study for a Potential New Mode of Treatment Delivery,Recruiting,NA,N/A,28,Anticipated,University of Manitoba,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:57:26Z,2020-11-01T11:57:26Z
NCT04412538,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-21,NA,NA,2020-06-02,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"May 15, 2020",Actual,2020-05-15,June 2020,2020-06-30,September 2021,Anticipated,2021-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19,"A Randomized, Double-blind, Placebo-controlled, Phase Ia/IIa Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged 18 to 59 Years",Recruiting,NA,Phase 1/Phase 2,942,Anticipated,Chinese Academy of Medical Sciences,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:57:29Z,2020-11-01T11:57:29Z
NCT04410549,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-21,NA,NA,2020-07-15,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-16,Actual,"June 1, 2020",Actual,2020-06-01,July 2020,2020-07-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Pulmonary Optical Coherence Tomography in COVID-19 Patients,Optical Coherence Tomography for Microvascular Lung Vessels Obstructive Thromboinflammatory Syndrome Assessment in Patients With COVID-19: an Exploratory Study,Recruiting,NA,N/A,10,Anticipated,IRCCS San Raffaele,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:57:43Z,2020-11-01T11:57:43Z
NCT04401423,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-21,NA,NA,2020-08-18,2020-05-21,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-20,Actual,August 2020,Anticipated,2020-08-31,August 2020,2020-08-31,December 2021,Anticipated,2021-12-31,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,,TXA127 for the Treatment of Severe COVID-19,Randomized Controlled Trial of Angiotensin 1-7 (TXA127) for the Treatment of Severe COVID-19,Recruiting,NA,Phase 2,100,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T11:58:52Z,2020-11-01T11:58:52Z
NCT04401202,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-21,NA,NA,2020-05-22,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-26,Actual,"May 21, 2020",Actual,2020-05-21,May 2020,2020-05-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Nigella Sativa in COVID-19,"Effects of Nigella Sativa as a Treatment of Patients With Upper Respiratory Tract Infection Caused by SARS-coronavirus-2: a Prospective, Randomized, Open-label, Controlled Clinical Study",Recruiting,NA,Phase 2,200,Anticipated,King Abdulaziz University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:58:54Z,2020-11-01T11:58:54Z
NCT04401150,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-21,NA,NA,2020-08-14,2020-05-21,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-08-14,2020-08-18,Actual,"August 14, 2020",Actual,2020-08-14,August 2020,2020-08-31,January 2022,Anticipated,2022-01-31,November 2021,Anticipated,2021-11-30,NA,Interventional,LOVIT-COVID,,Lessening Organ Dysfunction With VITamin C - COVID-19,Lessening Organ Dysfunction With VITamin C - COVID,Recruiting,NA,Phase 3,800,Anticipated,UniversitÃ© de Sherbrooke,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:58:54Z,2020-11-01T11:58:54Z
NCT04400279,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-21,NA,NA,2020-08-18,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-20,Actual,"June 1, 2020",Actual,2020-06-01,August 2020,2020-08-31,November 2020,Anticipated,2020-11-30,September 2020,Anticipated,2020-09-30,NA,Interventional,COPE,,The COVID-19 Pandemic and Exercise Study,COvid-19 Pandemic and Exercise (COPE) Trial: A Randomized Study Examining Physical Activities and Wellbeing in Individuals Mandated to Stay at Home,"Active, not recruiting",NA,N/A,334,Actual,University of British Columbia,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"4 months following trial's end, materials will be made available. following publication, all data will be made available.",Investigators whose proposed use of the data has been approved by an independent review committee identified for the purpose for the purpose of meta-analyses and to achieve aims in the approved proposal. Investigators of the study need to approve the proposals. Proposals should be directed to eli.puterman@Ubc.ca,https://osf.io/g9xqp,Yes,"All of the individual participant data collected during the trial, after de-identification upon request and cleared for approval by principal investigator.
All of the protocols, statistical analysis plan, informed consent form, analytic code.",2020-11-01T11:59:01Z,2020-11-01T11:59:01Z
NCT04400058,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-21,NA,NA,2020-10-16,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-19,Actual,"June 1, 2020",Actual,2020-06-01,October 2020,2020-10-31,"December 30, 2020",Anticipated,2020-12-30,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,NA,,Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression,Efficacy and Safety of Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression,Recruiting,NA,Phase 3,208,Anticipated,Octapharma,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:59:02Z,2020-11-01T11:59:02Z
NCT04399980,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-21,NA,NA,2020-10-03,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-10-03,2020-10-06,Actual,"May 20, 2020",Actual,2020-05-20,October 2020,2020-10-31,"May 31, 2021",Anticipated,2021-05-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,NA,,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation,"Active, not recruiting",NA,Phase 2,30,Actual,The Cleveland Clinic,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:59:03Z,2020-11-01T11:59:03Z
NCT04399889,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-21,NA,NA,2020-06-18,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-18,2020-06-22,Actual,"June 18, 2020",Actual,2020-06-18,June 2020,2020-06-30,"July 31, 2021",Anticipated,2021-07-31,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,NA,,hCT-MSCs for COVID19 ARDS,Pilot Study of Safety and Efficacy of Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC) in COVID-19 Related Acute Respiratory Distress Syndrome (ARDS),Recruiting,NA,Phase 1/Phase 2,30,Anticipated,Duke University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:59:03Z,2020-11-01T11:59:03Z
NCT04399681,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-21,NA,NA,2020-05-21,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-21,2020-05-22,Actual,"May 10, 2020",Actual,2020-05-10,May 2020,2020-05-31,"September 10, 2020",Anticipated,2020-09-10,"August 10, 2020",Anticipated,2020-08-10,NA,Interventional,NA,,The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19,The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19 at Emergency Department,Recruiting,NA,N/A,100,Anticipated,Kanuni Sultan Suleyman Training and Research Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:59:05Z,2020-11-01T11:59:05Z
NCT04399109,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-21,NA,NA,2020-05-21,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-05-21,2020-05-22,Actual,"May 20, 2020",Actual,2020-05-20,May 2020,2020-05-31,"May 19, 2021",Anticipated,2021-05-19,"May 19, 2021",Anticipated,2021-05-19,NA,Interventional,ReCOVER,,Evaluation of a Remote Monitoring Smartphone Application and Care Model of COVID-19 Patients in the Community (ReCOVER),ReCOVER (Remote COVID-19 Evaluation and Response): a Prospective Non-randomised Controlled Trial to Evaluate the Effect of a Novel Smartphone Application-centric Model of Care for the Remote Monitoring of COVID-19 Patients in the Community.,Recruiting,NA,N/A,2000,Anticipated,"Prince of Wales Hospital, Sydney",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:59:09Z,2020-11-01T11:59:09Z
NCT04401410,"ClinicalTrials.gov processed this data on November 13, 2020",2020-05-21,NA,NA,2020-11-05,2020-05-21,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-11-05,2020-11-09,Actual,"November 4, 2020",Actual,2020-11-04,November 2020,2020-11-30,"August 15, 2021",Anticipated,2021-08-15,"August 15, 2021",Anticipated,2021-08-15,NA,Interventional,BATIT,,Anti-SARS Cov-2 T Cell Infusions for COVID 19,BAT IT: Banked Anti-SARS Cov-2 T Cell Infusions for Treatment of COVID 19,Recruiting,NA,Phase 1,58,Anticipated,Baylor College of Medicine,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-14T10:42:07Z,2020-11-14T10:42:07Z
NCT04400305,"ClinicalTrials.gov processed this data on November 13, 2020",2020-05-21,NA,NA,2020-11-10,2020-05-21,2020-05-22,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-13,Estimate,"May 20, 2020",Actual,2020-05-20,May 2020,2020-05-31,January 2021,Anticipated,2021-01-31,January 2021,Anticipated,2021-01-31,NA,Interventional,COVID-19,,"""Increasing Physical Activity in Canadian Adults Affected by COVID-19 Social Distancing Restrictions: A Feasibility Trial of an Online Intervention""","""Increasing Physical Activity in Canadian Adults Who Have Been Affected by COVID-19 Social Distancing Restrictions: A Feasibility Trial of an Online Intervention""",Recruiting,NA,N/A,40,Anticipated,University of Victoria,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-15T10:59:04Z,2020-11-15T10:59:04Z
NCT04411602,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-22,NA,NA,2020-05-29,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"April 7, 2020",Actual,2020-04-07,May 2020,2020-05-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Feasibility Study of Anti-SARS-CoV-2 Plasma Transfusions in COVID-19 Patients With SRD,Convalescent Plasma to Treat Coronavirus - Associated Severe Pulmonary Complications: A Feasibility Study Assessing the Safety of Multiple Doses of Anti-SARS-CoV-2 Plasma in Patients With Severe Respiratory Distress Due to COVID-19,Recruiting,NA,Phase 1,90,Anticipated,Ascension South East Michigan,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:57:36Z,2020-11-01T11:57:36Z
NCT04410016,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-22,NA,NA,2020-06-10,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-10,2020-06-12,Actual,"May 25, 2020",Actual,2020-05-25,June 2020,2020-06-30,"November 30, 2020",Anticipated,2020-11-30,"July 31, 2020",Anticipated,2020-07-31,NA,Interventional,COVID-WELL,,Evaluation of Staff COVID-19 Wellbeing Centres in a Healthcare Workplace: COVID-WELL Study,Evaluation of a Workplace Intervention to Implement Supported COVID-19 Wellbeing Centres in a Healthcare Workplace During and After the Coronavirus Pandemic: The COVID-WELL Study,Recruiting,NA,N/A,45,Anticipated,University of Nottingham,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Interview data will be available on request at study end (after publication of findings).,On request.,NA,Yes,Interview data will be made available on request (after study end).,2020-11-01T11:57:46Z,2020-11-01T11:57:46Z
NCT04408183,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-22,NA,NA,2020-06-02,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"June 1, 2020",Actual,2020-06-01,June 2020,2020-06-30,November 2020,Anticipated,2020-11-30,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,GLS-1200Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel,"Efficacy, Safety, and Tolerability of GLS-1200 Topical Nasal Spray in the Prevention of Incident Confirmed, Symptomatic SARS-CoV-2 Infection in Healthcare Personnel",Recruiting,NA,Phase 2,225,Anticipated,"GeneOne Life Science, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:58:05Z,2020-11-01T11:58:05Z
NCT04407390,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-22,NA,NA,2020-05-29,2020-05-27,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"June 1, 2020",Anticipated,2020-06-01,May 2020,2020-05-31,"May 1, 2022",Anticipated,2022-05-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,NR-COVID19,,Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly,"Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly. A Randomized Double-blind, Placebo-controlled Trial of Nicotinamide Riboside NR-COVID19",Recruiting,NA,Phase 2,100,Anticipated,University of Copenhagen,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:58:12Z,2020-11-01T11:58:12Z
NCT04404361,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-22,NA,NA,2020-08-26,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-08-26,2020-08-28,Actual,"May 22, 2020",Actual,2020-05-22,August 2020,2020-08-31,"October 31, 2021",Anticipated,2021-10-31,"July 31, 2021",Anticipated,2021-07-31,NA,Interventional,NA,,PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer,"A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of Pacritinib Plus Standard of Care Versus Placebo and Standard of Care in Hospitalized Patients With Severe COVID-19 With or Without Cancer",Recruiting,NA,Phase 3,358,Anticipated,CTI BioPharma,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:58:32Z,2020-11-01T11:58:32Z
NCT04402983,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-22,NA,NA,2020-08-23,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-08-23,2020-08-26,Actual,"May 27, 2020",Actual,2020-05-27,May 2020,2020-05-31,"December 1, 2020",Anticipated,2020-12-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,NA,,The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients,The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients,Recruiting,NA,N/A,34,Anticipated,Istanbul Medipol University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:58:41Z,2020-11-01T11:58:41Z
NCT04402866,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-22,NA,NA,2020-10-15,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-15,2020-10-19,Actual,"June 24, 2020",Actual,2020-06-24,October 2020,2020-10-31,February 2021,Anticipated,2021-02-28,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,TD-0903 for ALI Associated With COVID-19,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Multi-center Study of an Inhaled Pan-Janus Kinase Inhibitor, TD-0903, to Treat Symptomatic Acute Lung Injury Associated With COVID-19",Recruiting,NA,Phase 2,222,Anticipated,Theravance Biopharma,,6,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,"Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.",2020-11-01T11:58:42Z,2020-11-01T11:58:42Z
NCT04402060,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-22,NA,NA,2020-10-13,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-19,Actual,"May 28, 2020",Actual,2020-05-28,October 2020,2020-10-31,November 2020,Anticipated,2020-11-30,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,,A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19,"A Randomized, Double-Blinded, Vehicle-Controlled, Multicenter, Parallel-Group Study of APL-9 in Mild to Moderate Acute Respiratory Distress Syndrome Due to COVID-19",Recruiting,NA,Phase 1/Phase 2,66,Anticipated,"Apellis Pharmaceuticals, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:58:48Z,2020-11-01T11:58:48Z
NCT04401579,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-22,NA,NA,2020-08-11,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-13,Actual,"May 8, 2020",Actual,2020-05-08,April 2020,2020-04-30,"August 1, 2023",Anticipated,2023-08-01,"August 1, 2023",Anticipated,2023-08-01,NA,Interventional,NA,,Adaptive COVID-19 Treatment Trial 2 (ACTT-2),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-2)","Active, not recruiting",NA,Phase 3,1034,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T11:58:51Z,2020-11-01T11:58:51Z
NCT04401046,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-22,NA,NA,2020-07-27,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-07-27,2020-07-28,Actual,"May 20, 2020",Actual,2020-05-20,July 2020,2020-07-31,"October 30, 2020",Anticipated,2020-10-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,COVID-TRAUMA,,COVID-19 and Reorganisation of Cancer Patient Care: Self- Evaluation of Potential Post-traumatic Stress Disorder,COVID-19 EPIDEMIC Reorganisation of Cancer Patient Care: Self- Evaluation of Potential Post-traumatic Stress Disorder,Recruiting,NA,N/A,4000,Anticipated,Institut Paoli-Calmettes,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:58:55Z,2020-11-01T11:58:55Z
NCT04400890,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-22,NA,NA,2020-09-22,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-24,Actual,"September 12, 2020",Actual,2020-09-12,September 2020,2020-09-30,January 2021,Anticipated,2021-01-31,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,,Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of a Plant Polyphenol for COVID-19,Randomized Double-Blind Placebo-Controlled Proof-of-Concept Trial of a Plant Polyphenol for the Outpatient Treatment of Mild Coronavirus Disease (COVID-19),Recruiting,NA,Phase 2,200,Anticipated,Mount Carmel Health System,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:58:56Z,2020-11-01T11:58:56Z
NCT04402879,"ClinicalTrials.gov processed this data on November 06, 2020",2020-05-22,NA,NA,2020-11-02,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"November 3, 2020",Anticipated,2020-11-03,May 2020,2020-05-31,"June 1, 2021",Anticipated,2021-06-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,CORONA,,CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals,A Prospective Randomized Trial of Prone Positioning Versus Usual Care for Patients With Do-not-intubate Goals of Care and Hypoxemic Respiratory Failure During the Coronavirus SARS-CoV-2 (COVID-19) Pandemic,Recruiting,NA,N/A,596,Anticipated,University of Calgary,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-07T11:23:38Z,2020-11-07T11:23:38Z
NCT04402840,"ClinicalTrials.gov processed this data on November 06, 2020",2020-05-22,NA,NA,2020-10-29,2020-05-22,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-11-03,Actual,"April 24, 2020",Actual,2020-04-24,July 2020,2020-07-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,,Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS),Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS),Recruiting,NA,N/A,5,Anticipated,West Virginia University,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-07T11:23:38Z,2020-11-07T11:23:38Z
NCT04404426,"ClinicalTrials.gov processed this data on November 09, 2020",2020-05-22,NA,NA,2020-11-04,2020-05-25,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-06,Actual,"November 2, 2020",Actual,2020-11-02,November 2020,2020-11-30,"September 15, 2021",Anticipated,2021-09-15,"September 15, 2021",Anticipated,2021-09-15,NA,Interventional,CACOLAC,,CACOLAC : Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome,CACOLAC : Randomized Trial of Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome,Recruiting,NA,N/A,100,Anticipated,Rennes University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-10T11:28:01Z,2020-11-10T11:28:01Z
NCT04411433,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-23,NA,NA,2020-05-29,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-02,Actual,"May 8, 2020",Actual,2020-05-08,May 2020,2020-05-31,"July 30, 2020",Anticipated,2020-07-30,"July 30, 2020",Anticipated,2020-07-30,NA,Interventional,NA,,Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19,"An Open-Label, Multicenter, Parallel-Group, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19",Recruiting,NA,Phase 3,1000,Anticipated,"Ministry of Health, Turkey",,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:57:37Z,2020-11-01T11:57:37Z
NCT04406493,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-23,NA,NA,2020-05-27,2020-05-27,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-28,Actual,"April 28, 2020",Actual,2020-04-28,May 2020,2020-05-31,"April 28, 2021",Anticipated,2021-04-28,"April 28, 2021",Anticipated,2021-04-28,NA,Interventional,NA,,Monitoring COVID-19 Patients' Lung Fluid Using Impedance Technique,Monitoring of Lung Fluid Status of Hospitalized COVID-19 Patients by Lung Impedance Technique,Recruiting,NA,N/A,50,Anticipated,Hillel Yaffe Medical Center,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:58:18Z,2020-11-01T11:58:18Z
NCT04405843,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-23,NA,NA,2020-10-12,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-10-12,2020-10-14,Actual,"July 14, 2020",Actual,2020-07-14,July 2020,2020-07-31,"December 14, 2020",Anticipated,2020-12-14,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,,Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19,"Randomized, Placebo Controlled, Double Blind Clinical Trial to Evaluate the Efficacy of Molecule D11AX22 in Adults Patients From Valle Del Cauca, Colombia With Early Stages of SARS COV2 / COVID-19",Recruiting,NA,Phase 2/Phase 3,400,Anticipated,Centro de Estudios en InfectogÃ­a Pediatrica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:58:22Z,2020-11-01T11:58:22Z
NCT04403555,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-23,NA,NA,2020-08-01,2020-05-23,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-08-01,2020-08-04,Actual,"June 1, 2020",Actual,2020-06-01,August 2020,2020-08-31,"December 3, 2030",Anticipated,2030-12-03,"December 1, 2030",Anticipated,2030-12-01,NA,Interventional,NA,,Ivermectin and Doxycycine in COVID-19 Treatment,The Efficacy of Ivermectin and Doxycycline in COVID-19 Treatment,Recruiting,NA,Phase 2/Phase 3,200,Anticipated,Tanta University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:58:38Z,2020-11-01T11:58:38Z
NCT04403100,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-23,NA,NA,2020-06-04,2020-05-23,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-06-04,2020-06-09,Actual,"June 3, 2020",Actual,2020-06-03,June 2020,2020-06-30,"November 28, 2020",Anticipated,2020-11-28,"September 3, 2020",Anticipated,2020-09-03,NA,Interventional,NA,,"Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: ""The Hope Coalition - 1""","Hydroxychloroquine and Lopinavir/ Ritonavir for Hospitalization and Mortality Reduction in Patients With COVID-19 and Mild Disease Symptoms: ""The Hope Coalition""",Recruiting,NA,Phase 3,1968,Anticipated,Cardresearch,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:58:41Z,2020-11-01T11:58:41Z
NCT04429711,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-24,NA,NA,2020-06-14,2020-06-11,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2020-06-14,2020-06-16,Actual,"May 12, 2020",Actual,2020-05-12,June 2020,2020-06-30,"October 31, 2020",Anticipated,2020-10-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19,"Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection and to Decrease Viral Shedding - A Double Blind , Randomized Controlled Trial",Recruiting,NA,N/A,100,Anticipated,Sheba Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T11:55:20Z,2020-11-01T11:55:20Z
NCT04412356,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-24,NA,NA,2020-06-05,2020-05-31,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"June 4, 2020",Actual,2020-06-04,June 2020,2020-06-30,"February 1, 2021",Anticipated,2021-02-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,TTCOV19,,Timing of Tracheotomy in Covid-19 Patients,"Timing of Tracheotomy in Covid-19 Positive Patients: a Randomized, Controlled Trial",Recruiting,NA,N/A,180,Anticipated,"Sahlgrenska University Hospital, Sweden",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:57:30Z,2020-11-01T11:57:30Z
NCT04408456,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-24,NA,NA,2020-08-01,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-08-01,2020-08-04,Actual,"March 1, 2020",Actual,2020-03-01,August 2020,2020-08-31,"July 31, 2020",Actual,2020-07-31,"July 31, 2020",Actual,2020-07-31,NA,Interventional,PEP-CQ,,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 in Asymptomatic Individual at Risk for SARS-CoV-2 Infection-A Open Level Control Clinical Trial,Completed,NA,Phase 3,325,Actual,Postgraduate Institute of Medical Education and Research,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Data will be shared with the concerned authority and Institutional Ethics committee as and when required.,2020-11-01T11:58:02Z,2020-11-01T11:58:02Z
NCT04406246,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-24,NA,NA,2020-05-27,2020-05-27,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-05-27,2020-05-28,Actual,"May 21, 2020",Actual,2020-05-21,May 2020,2020-05-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide,Prevention of Coronavirus Disease (COVID-19) Outbreaks by Prophylactic Treatment With Nitazoxanide,Recruiting,NA,Phase 4,150,Anticipated,Materno-Perinatal Hospital of the State of Mexico,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,The Data will be available upon request after a publication is reached.,2020-11-01T11:58:20Z,2020-11-01T11:58:20Z
NCT04404218,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-24,NA,NA,2020-08-05,2020-05-24,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-08-05,2020-08-07,Actual,"August 4, 2020",Actual,2020-08-04,August 2020,2020-08-31,May 2021,Anticipated,2021-05-31,March 2021,Anticipated,2021-03-31,NA,Interventional,ACAI,,The AÃ§aÃ­ Berry COVID-19 Anti-Inflammation Trial,Randomized Clinical Trial of AÃ§aÃ­ Palm Berry Extract as an Intervention in Patients Diagnosed With COVID-19,Recruiting,NA,Phase 2,480,Anticipated,"University Health Network, Toronto",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:58:33Z,2020-11-01T11:58:33Z
NCT04403685,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-24,NA,NA,2020-08-22,2020-05-24,2020-05-27,Actual,NA,NA,NA,NA,NA,NA,2020-08-22,2020-08-26,Actual,"May 8, 2020",Actual,2020-05-08,August 2020,2020-08-31,"July 21, 2020",Actual,2020-07-21,"July 8, 2020",Actual,2020-07-08,NA,Interventional,TOCIBRAS,,Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 and Increased Inflammatory Markers: a Phase III Randomized Clinical Trial (COVID-19 Coalition Brazil VI) (TOCIBRAS),Terminated,NA,Phase 3,129,Actual,BeneficÃªncia Portuguesa de SÃ£o Paulo,,2,NA,Safety,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:58:37Z,2020-11-01T11:58:37Z
NCT04417335,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-25,NA,NA,2020-06-03,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-04,Actual,"April 16, 2020",Actual,2020-04-16,May 2020,2020-05-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination,"Reducing Hospital Admission of Elderly in SARS-CoV-2 Pandemic Via the Induction of Trained Immunity by Bacillus Calmette-GuÃ©rin Vaccination, a Randomized Controlled Trial","Active, not recruiting",NA,Phase 4,2014,Actual,Radboud University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:56:50Z,2020-11-01T11:56:50Z
NCT04410536,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-25,NA,NA,2020-10-08,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-10-08,2020-10-09,Actual,"June 15, 2020",Actual,2020-06-15,October 2020,2020-10-31,July 2022,Anticipated,2022-07-31,December 2021,Anticipated,2021-12-31,NA,Interventional,MOHC,,Home Detox in Medication Overuse Headache (MOH) During Covid-19 Emergency,Home-withdrawal Program Combined With Behavioural Approach in Patients With Medication Overuse Headache During Covid-19 Emergency: Incidence of Relapses in Overuse and Changes in Impact at One Year Follow up,Recruiting,NA,N/A,25,Anticipated,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:57:43Z,2020-11-01T11:57:43Z
NCT04407182,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-25,NA,NA,2020-07-29,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-07-30,Actual,"May 4, 2020",Actual,2020-05-04,May 2020,2020-05-31,"August 7, 2020",Anticipated,2020-08-07,"August 5, 2020",Anticipated,2020-08-05,NA,Interventional,NA,,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients in Teodoro Maldonado Carbo Specialty's Hospital Infected and Diagnosed by SARS-Cov-2 With COVID-19,Recruiting,NA,Phase 2,80,Anticipated,Catalysis SL,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-11-01T11:58:13Z,2020-11-01T11:58:13Z
NCT04405908,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-25,NA,NA,2020-06-22,2020-05-25,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-06-22,2020-06-23,Actual,"June 19, 2020",Actual,2020-06-19,June 2020,2020-06-30,"March 30, 2021",Anticipated,2021-03-30,"October 20, 2020",Anticipated,2020-10-20,NA,Interventional,NA,,SCB-2019 as COVID-19 Vaccine,"A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety and Immunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for COVID-19 in Healthy Volunteers.",Recruiting,NA,Phase 1,150,Anticipated,Clover Biopharmaceuticals AUS Pty Ltd,,15,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:58:22Z,2020-11-01T11:58:22Z
NCT04408209,"ClinicalTrials.gov processed this data on November 06, 2020",2020-05-25,NA,NA,2020-11-03,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-04,Actual,"April 23, 2020",Actual,2020-04-23,November 2020,2020-11-30,"September 15, 2021",Anticipated,2021-09-15,"August 30, 2021",Anticipated,2021-08-30,NA,Interventional,NA,,Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection,Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection - A Multicenter Phase II Trial,Recruiting,NA,N/A,60,Anticipated,National and Kapodistrian University of Athens,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-08T11:34:55Z,2020-11-08T11:34:55Z
NCT04430608,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-26,NA,NA,2020-06-11,2020-06-11,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2020-06-11,2020-06-12,Actual,"May 25, 2020",Actual,2020-05-25,May 2020,2020-05-31,"May 25, 2021",Anticipated,2021-05-25,"April 25, 2021",Anticipated,2021-04-25,NA,Interventional,CGM-ISO,,Remote Continues Glucose Monitoring During the COVID-19 Pandemic in Quarantined Hospitalized Patients,Remote Glucose Monitoring of Patients With Diabetes Quarantined During the COVID-19 Pandemic - a Hospital-Based Randomized Controlled Trial of the Effect of Remote Continuous Glucose Monitoring Compared to Usual Glucose Monitoring,Recruiting,NA,N/A,72,Anticipated,Nordsjaellands Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,No,"Undecided, will be updated",2020-11-01T11:55:13Z,2020-11-01T11:55:13Z
NCT04410562,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-26,NA,NA,2020-05-29,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-01,Actual,"May 13, 2020",Actual,2020-05-13,April 2020,2020-04-30,"August 1, 2021",Anticipated,2021-08-01,"May 13, 2021",Anticipated,2021-05-13,NA,Interventional,COVID-Preg,,Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy,Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy,Recruiting,NA,Phase 3,714,Anticipated,Barcelona Institute for Global Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,By the end of study,NA,NA,Yes,It would be shared at time of publication.,2020-11-01T11:57:43Z,2020-11-01T11:57:43Z
NCT04409496,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-26,NA,NA,2020-08-02,2020-05-26,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-08-02,2020-08-04,Actual,"June 2, 2020",Actual,2020-06-02,August 2020,2020-08-31,"June 30, 2021",Anticipated,2021-06-30,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,NA,,Chat-based Support for Preveting Smoking Relapse,Chat-based Instant Messaging Support for Preventing Smoking Relapse in the Context of COVID-19 Outbreak: a Pilot Randomised Clinical Trial,"Active, not recruiting",NA,N/A,108,Actual,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:57:49Z,2020-11-01T11:57:49Z
NCT04406389,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-26,NA,NA,2020-10-18,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-10-18,2020-10-20,Actual,"October 13, 2020",Actual,2020-10-13,October 2020,2020-10-31,June 2021,Anticipated,2021-06-30,December 2020,Anticipated,2020-12-31,NA,Interventional,IMPACT,,Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial),InterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19: A Prospective Randomized Study (The IMPACT Trial),Recruiting,NA,Phase 4,186,Anticipated,Weill Medical College of Cornell University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:58:19Z,2020-11-01T11:58:19Z
NCT04405739,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-26,NA,NA,2020-10-21,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-22,Actual,"June 16, 2020",Actual,2020-06-16,October 2020,2020-10-31,"November 25, 2020",Anticipated,2020-11-25,"October 28, 2020",Anticipated,2020-10-28,NA,Interventional,NA,,The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID),The Safety of EIDD-2801 and Its Effect on Viral Shedding of SARS-CoV-2,Recruiting,NA,Phase 2,89,Anticipated,"Ridgeback Biotherapeutics, LP",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:58:23Z,2020-11-01T11:58:23Z
NCT04405310,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-26,NA,NA,2020-09-25,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-09-25,2020-09-29,Actual,"May 20, 2020",Actual,2020-05-20,September 2020,2020-09-30,"December 20, 2020",Anticipated,2020-12-20,"November 20, 2020",Anticipated,2020-11-20,NA,Interventional,CPC-SARS,,Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial,"Plasma From Covalescent Donors With Covid-19 for the Management of Patients With SARS-COV-2 Fase II and III, a Doble Center Randomized Doble Blind Trial",Recruiting,NA,Phase 2,80,Anticipated,Grupo Mexicano para el Estudio de la Medicina Intensiva,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,3 months after completion up to five years,"proposal should be directed to gmemiinv@gmails.com, to gain access, requestor will need to sign a data access agreement",NA,Yes,IPD will be shared by petition.,2020-11-01T11:58:25Z,2020-11-01T11:58:25Z
NCT04405102,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-26,NA,NA,2020-09-28,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-30,Actual,"September 16, 2020",Actual,2020-09-16,September 2020,2020-09-30,"January 1, 2024",Anticipated,2024-01-01,"January 1, 2023",Anticipated,2023-01-01,NA,Interventional,COZI,,COVID-19 Ozanimod Intervention Study,A Randomized Trial on Efficacy and Safety of Ozanimod for the Treatment of COVID-19 Patients Requiring Oxygen Support - A Pilot Trial,Recruiting,NA,Phase 2,48,Anticipated,Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:58:26Z,2020-11-01T11:58:26Z
NCT04405544,"ClinicalTrials.gov processed this data on November 02, 2020",2020-05-26,NA,NA,2020-10-29,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-10-30,Actual,"May 22, 2020",Actual,2020-05-22,October 2020,2020-10-31,"October 29, 2020",Actual,2020-10-29,"July 22, 2020",Actual,2020-07-22,NA,Interventional,NA,,Determination of Acute Encephalopathy Predictors in Patients With COVID-19,Determination of Acute Encephalopathy Predictors in Patients With COVID-19,Completed,NA,N/A,51,Actual,"State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-03T10:51:54Z,2020-11-03T10:51:54Z
NCT04414618,"ClinicalTrials.gov processed this data on November 06, 2020",2020-05-26,NA,NA,2020-11-03,2020-05-29,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-05,Actual,"July 2, 2020",Actual,2020-07-02,May 2020,2020-05-31,December 2020,Anticipated,2020-12-31,November 2020,Anticipated,2020-11-30,NA,Interventional,COVID-19,,A Study of Opaganib in Coronavirus Disease 2019 Pneumonia,"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2a Study, in Adult Subjects Hospitalized With SARS-CoV-2 Positive Pneumonia",Recruiting,NA,Phase 2,40,Anticipated,RedHill Biopharma Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-09T10:53:21Z,2020-11-09T10:53:21Z
NCT04405570,"ClinicalTrials.gov processed this data on November 06, 2020",2020-05-26,NA,NA,2020-11-04,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-05,Actual,"June 16, 2020",Actual,2020-06-16,November 2020,2020-11-30,"December 30, 2020",Anticipated,2020-12-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,NA,,"A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19","A Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate Infectious Virus Detection in Persons With COVID-19",Recruiting,NA,Phase 2,108,Anticipated,"Ridgeback Biotherapeutics, LP",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-09T10:53:25Z,2020-11-09T10:53:25Z
NCT04411446,"ClinicalTrials.gov processed this data on November 13, 2020",2020-05-26,NA,NA,2020-11-08,2020-05-31,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-08,2020-11-10,Actual,"August 11, 2020",Actual,2020-08-11,November 2020,2020-11-30,"December 28, 2020",Anticipated,2020-12-28,"December 15, 2020",Anticipated,2020-12-15,NA,Interventional,CARED,,Cholecalciferol to Improve the Outcomes of COVID-19 Patients,Randomized Controlled Trial of High Dose of Vitamin D as Compared With Placebo to Prevent Complications Among COVID-19 Patients,Recruiting,NA,Phase 4,1264,Anticipated,Vitamin D Study Group,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-14T10:41:50Z,2020-11-14T10:41:50Z
NCT04408157,"ClinicalTrials.gov processed this data on November 13, 2020",2020-05-26,NA,NA,2020-11-06,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"May 20, 2020",Actual,2020-05-20,May 2020,2020-05-31,"December 22, 2021",Anticipated,2021-12-22,"August 22, 2021",Anticipated,2021-08-22,NA,Interventional,SWitCh,,A Research Study to Evaluate the Benefits of a Self-management Booklet to Promote Wellbeing During the COVID-19 Pandemic,A Research Study to Evaluate the Efficacy of a Self-management Booklet (Stay Well During COVID-19; SWitCh) to Promote Wellbeing During the COVID-19 Pandemic,Recruiting,NA,N/A,548,Anticipated,King's College London,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Data will be confidentially and securely stored for 7 years as per University policy. Anonymised aggregated data will be made available upon request to the corresponding author.,2020-11-14T10:41:59Z,2020-11-14T10:41:59Z
NCT04457609,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-27,NA,NA,2020-07-02,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-02,2020-07-07,Actual,July 2020,Anticipated,2020-07-31,July 2020,2020-07-31,September 2020,Anticipated,2020-09-30,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients,Application of Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy for Critically-Ill COVID-19 Patients,Recruiting,NA,Phase 1,40,Anticipated,Indonesia University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:51:48Z,2020-11-01T11:51:48Z
NCT04444271,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-27,NA,NA,2020-06-27,2020-06-21,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-06-27,2020-06-30,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"September 30, 2020",Anticipated,2020-09-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,NA,,Mesenchymal Stem Cell Infusion for COVID-19 Infection,"Prospective, Randomized Phase 2 Clinical Trial of Mesenchymal Stem Cells(MSCs) for the Treatment of Coronavirus Disease 2019(COVID-19)",Recruiting,NA,Phase 2,20,Anticipated,"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:53:29Z,2020-11-01T11:53:29Z
NCT04425317,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-27,NA,NA,2020-09-03,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-09-03,2020-09-07,Actual,"June 24, 2020",Actual,2020-06-24,September 2020,2020-09-30,"June 15, 2021",Anticipated,2021-06-15,"June 15, 2021",Anticipated,2021-06-15,NA,Interventional,COVID_OFF,,Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients,Detection of SARS-CoV-2 in Follicular Fluid and Cumu-lus-oocyte-complexes From COVID-19 Patients During Controlled Ovarian Stimulation for ICSI Treatment,Recruiting,NA,N/A,20,Anticipated,CRG UZ Brussel,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:55:49Z,2020-11-01T11:55:49Z
NCT04416308,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-27,NA,NA,2020-07-07,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-07-07,2020-07-08,Actual,"May 29, 2020",Actual,2020-05-29,June 2020,2020-06-30,"October 10, 2020",Anticipated,2020-10-10,"July 10, 2020",Anticipated,2020-07-10,NA,Interventional,AntiCoV-HB,,COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB),COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne,Recruiting,NA,N/A,13000,Anticipated,Rennes University Hospital,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:57:02Z,2020-11-01T11:57:02Z
NCT04410692,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-27,NA,NA,2020-05-30,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-30,2020-06-02,Actual,"May 15, 2020",Actual,2020-05-15,May 2020,2020-05-31,"May 17, 2020",Actual,2020-05-17,"May 16, 2020",Actual,2020-05-16,NA,Interventional,NA,,Can the Prediction Market Improve Predictions of COVID-19?,Can the Prediction Market Improve Predictions of COVID-19?,Completed,NA,N/A,560,Actual,"National University, Singapore",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,After completion of all analysis. It will be made available in the supporting documentation.,It will be made available in the supporting documentation.,NA,Yes,"Investigators will not be storing or sharing any personal identifiers. All individual level data will be anonymized, and only anonymized data will be shared with other researchers, upon request.",2020-11-01T11:57:42Z,2020-11-01T11:57:42Z
NCT04410510,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-27,NA,NA,2020-09-30,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"September 30, 2020",Anticipated,2020-09-30,September 2020,2020-09-30,June 2021,Anticipated,2021-06-30,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19,"Study of the P2Et Extract Obtained From Caesalpinia Spinosa in the Symptomatic Treatment of Subjects With COVID-19 at the Hospital Universitario San Ignacio, Colombia.",Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Hospital Universitario San Ignacio,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:57:43Z,2020-11-01T11:57:43Z
NCT04410159,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-27,2020-07-08,NA,2020-07-17,2020-05-28,2020-06-01,Actual,2020-07-17,2020-07-21,Actual,NA,NA,NA,2020-07-17,2020-07-21,Actual,"June 22, 2020",Actual,2020-06-22,July 2020,2020-07-31,"July 6, 2020",Actual,2020-07-06,"June 29, 2020",Actual,2020-06-29,NA,Interventional,GARGLES,,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,"A Pilot, Open-Labelled, Randomised Controlled Trial Of Povidone-Iodine Vs Essential Oil And Tap Water Gargling For COVID-19 Patients",Completed,NA,Phase 2,20,Actual,Universiti Sains Islam Malaysia,Inadequate budget for laboratory test lead to small numbers of subjects analyzed,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,September to December 2020,email to drnurul@usim.edu.my,NA,Yes,The participant data from the final research dataset used in the published manuscript will be shared upon reasonable request. The protocol and data analysis will be shared in clinicaltrial,2020-11-01T11:57:45Z,2020-11-01T11:57:45Z
NCT04407689,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-27,NA,NA,2020-06-19,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-06-19,2020-06-22,Actual,"June 8, 2020",Actual,2020-06-08,May 2020,2020-05-31,"December 30, 2020",Anticipated,2020-12-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,ILIAD-7-FR,,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort,"A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in France and Belgium",Recruiting,NA,Phase 2,48,Anticipated,Revimmune,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,publication,2020-11-01T11:58:10Z,2020-11-01T11:58:10Z
NCT04417257,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-28,NA,NA,2020-10-15,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-10-15,2020-10-19,Actual,"June 29, 2020",Actual,2020-06-29,October 2020,2020-10-31,"May 30, 2021",Anticipated,2021-05-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,RESOLUTION,,Study of LAU-7b for the Treatment of COVID-19 Disease in Adults,"RESOLUTION: A Double-blind, Randomized, Placebo-controlled, Pilot Phase II Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease",Recruiting,NA,Phase 2,240,Anticipated,Laurent Pharmaceuticals Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T11:56:50Z,2020-11-01T11:56:50Z
NCT04412486,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-28,NA,NA,2020-07-01,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-07-01,2020-07-02,Actual,"June 1, 2020",Actual,2020-06-01,July 2020,2020-07-31,"May 31, 2022",Anticipated,2022-05-31,"May 31, 2022",Anticipated,2022-05-31,NA,Interventional,NA,,COVID-19 Convalescent Plasma (CCP) Transfusion,An Open Label Trial of Transfusion of COVID-19 Convalescent Plasma (CCP) to Patients With Moderate to Severe COVID-19,Recruiting,NA,Early Phase 1,100,Anticipated,University of Mississippi Medical Center,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:57:30Z,2020-11-01T11:57:30Z
NCT04410328,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-28,NA,NA,2020-10-21,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-23,Actual,"October 21, 2020",Actual,2020-10-21,October 2020,2020-10-31,"December 15, 2021",Anticipated,2021-12-15,"March 15, 2021",Anticipated,2021-03-15,NA,Interventional,ATTAC-19,,Aggrenox To Treat Acute Covid-19,A Randomized Controlled Trial to Evaluate the Outcomes With Aggrenox in Patients With SARS-CoV-2 Infection,Recruiting,NA,Phase 3,132,Anticipated,"Rutgers, The State University of New Jersey",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:57:44Z,2020-11-01T11:57:44Z
NCT04409834,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-28,NA,NA,2020-08-16,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-08-16,2020-08-18,Actual,"August 5, 2020",Actual,2020-08-05,August 2020,2020-08-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,COVID-PACT,,Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial,"A Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 Patients",Recruiting,NA,Phase 4,750,Anticipated,The TIMI Study Group,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:57:47Z,2020-11-01T11:57:47Z
NCT04409743,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-28,NA,NA,2020-10-21,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-23,Actual,"June 7, 2020",Actual,2020-06-07,October 2020,2020-10-31,November 2021,Anticipated,2021-11-30,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,Brief Telehealth CBT-I Intervention in the Context of the COVID-19 Pandemic,"Harnessing Telehealth to Mitigate the Impact of the COVID-19 Pandemic on Sleep, Suicidality, and Neuropsychiatric Symptoms",Recruiting,NA,N/A,50,Anticipated,Stanford University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:57:48Z,2020-11-01T11:57:48Z
NCT04409522,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-28,NA,NA,2020-05-28,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-06-01,Actual,"May 12, 2020",Actual,2020-05-12,May 2020,2020-05-31,"September 25, 2020",Anticipated,2020-09-25,"June 5, 2020",Anticipated,2020-06-05,NA,Interventional,NA,,Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients,Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients,Recruiting,NA,N/A,55,Anticipated,Baqiyatallah Medical Sciences University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:57:49Z,2020-11-01T11:57:49Z
NCT04409509,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-28,NA,NA,2020-09-29,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-09-29,2020-09-30,Actual,"July 1, 2020",Actual,2020-07-01,September 2020,2020-09-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19),"A Phase 2, Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID 19)",Recruiting,NA,Phase 2,124,Anticipated,CSL Behring,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.,"Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee.
An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee.
The requesting party must execute an appropriate data sharing agreement before IPD will be made available.",NA,Yes,"CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.
Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.
If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.",2020-11-01T11:57:49Z,2020-11-01T11:57:49Z
NCT04409327,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-28,NA,NA,2020-10-23,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-26,Actual,"July 11, 2020",Actual,2020-07-11,July 2020,2020-07-31,January 2021,Anticipated,2021-01-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Phase 3 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes,Randomized Double Blind Placebo-Controlled Study to Determine if Prophylaxis With RTB101 Compared to Placebo Reduces Severity of Lab Confirmed COVID19 in Adults â‰¥65 Years in a Nursing Home in Which â‰¥1 Person(s) Have Lab Confirmed COVID19,Recruiting,NA,Phase 3,550,Anticipated,Restorbio Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:57:52Z,2020-11-01T11:57:52Z
NCT04409262,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-28,NA,NA,2020-10-22,2020-05-28,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-10-22,2020-10-26,Actual,"June 16, 2020",Actual,2020-06-16,October 2020,2020-10-31,"December 1, 2020",Anticipated,2020-12-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,REMDACTA,,A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,"A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Patients With Severe COVID-19 Pneumonia",Recruiting,NA,Phase 3,500,Anticipated,Hoffmann-La Roche,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).",2020-11-01T11:57:53Z,2020-11-01T11:57:53Z
NCT04408131,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-28,NA,NA,2020-05-28,2020-05-28,2020-05-29,Actual,NA,NA,NA,NA,NA,NA,2020-05-28,2020-05-29,Actual,"May 28, 2020",Actual,2020-05-28,May 2020,2020-05-31,"January 27, 2021",Anticipated,2021-01-27,"January 27, 2021",Anticipated,2021-01-27,NA,Interventional,COVIDHomeless,,Morbi-mortality by COVID-19 Among Homeless People in Marseille: a Cohort Study,Morbi-mortality by COVID-19 Among Homeless People in Marseille: a Cohort Study,Recruiting,NA,N/A,2000,Anticipated,Assistance Publique Hopitaux De Marseille,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:58:06Z,2020-11-01T11:58:06Z
NCT04433546,"ClinicalTrials.gov processed this data on November 13, 2020",2020-05-28,NA,NA,2020-11-11,2020-06-13,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Estimate,"July 15, 2020",Actual,2020-07-15,November 2020,2020-11-30,"December 3, 2020",Anticipated,2020-12-03,"December 3, 2020",Anticipated,2020-12-03,NA,Interventional,VANGARD,,"Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).","A Randomized, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of Once Weekly Subcutaneous Injections of Pemziviptadil (PB1046), a Sustained-Release VIP (Vasoactive Intestinal Peptide) ANalogue, in Hospitalized COVID-19 Patients at HiGh Risk for Rapid Clinical Deterioration and ARDS (PB1046 VANGARD Study)","Active, not recruiting",NA,Phase 2,54,Actual,PhaseBio Pharmaceuticals Inc.,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-15T10:58:36Z,2020-11-15T10:58:36Z
NCT04427098,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-29,NA,NA,2020-06-15,2020-06-10,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-15,2020-06-17,Actual,"May 22, 2020",Actual,2020-05-22,June 2020,2020-06-30,"October 30, 2020",Anticipated,2020-10-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,INHIXACOV19,,Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients,"Intermediate Dose Enoxaparin in Hospitalized Patients With Moderate-severe COVID19: A Pilot Phase II Single-arm Study, INHIXACOVID19",Recruiting,NA,Phase 2,300,Anticipated,Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:55:37Z,2020-11-01T11:55:37Z
NCT04424901,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-29,NA,NA,2020-06-08,2020-06-08,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-11,Actual,"May 3, 2020",Actual,2020-05-03,May 2020,2020-05-31,"May 30, 2021",Anticipated,2021-05-30,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,TOLD,,Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19,"A Randomized, Open-label Study of the Vascular and Microbiologic Efficacy of Dipyridamole Plus Standard Care vs. Standard Care in Hospitalized COVID19 Patients",Recruiting,NA,Phase 2,100,Anticipated,UConn Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:55:54Z,2020-11-01T11:55:54Z
NCT04420182,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-29,NA,NA,2020-09-24,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-28,Actual,"August 17, 2020",Actual,2020-08-17,September 2020,2020-09-30,"December 31, 2021",Anticipated,2021-12-31,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,,COVID-19 Virtual Care at Home,COVID-19 Virtual Care at Home,Recruiting,NA,N/A,2000,Anticipated,Lawson Health Research Institute,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:56:27Z,2020-11-01T11:56:27Z
NCT04418947,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-29,NA,NA,2020-07-29,2020-06-02,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-07-31,Actual,"June 15, 2020",Actual,2020-06-15,July 2020,2020-07-31,"July 17, 2020",Actual,2020-07-17,"July 17, 2020",Actual,2020-07-17,NA,Interventional,NA,,Project Resurgence Communication Trial,Comparison of the Effectiveness of Communication Strategies on the Return to In-Person Visits to a Medical Center After the Emergence of COVID-19: A Randomized Trial,Completed,NA,N/A,11120,Actual,University of Pennsylvania,,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:56:39Z,2020-11-01T11:56:39Z
NCT04412057,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-29,NA,NA,2020-09-30,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-01,Actual,"June 9, 2020",Actual,2020-06-09,September 2020,2020-09-30,November 2020,Anticipated,2020-11-30,October 2020,Anticipated,2020-10-31,NA,Interventional,NA,,Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury,"A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of CERC-002 in Adults With COVID 19 Pneumonia and Acute Lung Injury",Recruiting,NA,Phase 2,82,Anticipated,Cerecor Inc,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:57:33Z,2020-11-01T11:57:33Z
NCT04412018,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-29,NA,NA,2020-09-10,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-09-10,2020-09-11,Actual,"June 4, 2020",Actual,2020-06-04,September 2020,2020-09-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19,An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 (VASCEPA-COVID-19),Recruiting,NA,Phase 2,100,Anticipated,Canadian Medical and Surgical Knowledge Translation Research Group,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T11:57:33Z,2020-11-01T11:57:33Z
NCT04411680,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-29,NA,NA,2020-10-26,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-10-26,2020-10-28,Actual,"August 18, 2020",Actual,2020-08-18,October 2020,2020-10-31,March 2021,Anticipated,2021-03-31,November 2020,Anticipated,2020-11-30,NA,Interventional,iLeukPulm,,Study of Sargramostim in Patients With COVID-19,A Phase 2 Trial Evaluating Sargramostim in Patients With COVID-19 Associated Acute Hypoxemia,Recruiting,NA,Phase 2,60,Anticipated,"Partner Therapeutics, Inc.",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:57:35Z,2020-11-01T11:57:35Z
NCT04410458,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-29,NA,NA,2020-05-29,2020-05-29,2020-06-01,Actual,NA,NA,NA,NA,NA,NA,2020-05-29,2020-06-01,Actual,"May 31, 2020",Anticipated,2020-05-31,May 2020,2020-05-31,"June 12, 2020",Anticipated,2020-06-12,"May 31, 2020",Anticipated,2020-05-31,NA,Interventional,NA,,Recruit Blood Donors Via SMS During Epidemic of COVID-19 ï¼ˆRepeat Trialï¼‰,Recruit Blood Donors Via SMS With Different Contents During Epidemic of COVID-19ï¼ˆRepeat Trialï¼‰,Enrolling by invitation,NA,N/A,506517,Anticipated,Guangzhou Blood Center,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:57:43Z,2020-11-01T11:57:43Z
NCT04411628,"ClinicalTrials.gov processed this data on November 02, 2020",2020-05-29,NA,NA,2020-10-29,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-10-30,Actual,"May 28, 2020",Actual,2020-05-28,October 2020,2020-10-31,"August 26, 2020",Actual,2020-08-26,"August 26, 2020",Actual,2020-08-26,NA,Interventional,NA,,A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19,"A Randomized, Placebo-Controlled, Double-Blind, Sponsor Unblinded, Single Ascending Dose, Phase 1 First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous LY3819253 in Participants Hospitalized for COVID-19",Completed,NA,Phase 1,24,Actual,Eli Lilly and Company,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-03T10:51:52Z,2020-11-03T10:51:52Z
NCT04412343,"ClinicalTrials.gov processed this data on November 06, 2020",2020-05-29,NA,NA,2020-11-02,2020-05-29,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"May 23, 2020",Actual,2020-05-23,November 2020,2020-11-30,"October 5, 2020",Actual,2020-10-05,"October 5, 2020",Actual,2020-10-05,NA,Interventional,SCOPE,,The Seniors COvid-19 Pandemic and Exercise Study,The Seniors COvid-19 Pandemic and Exercise Study: A Randomized Controlled Trial,Completed,NA,N/A,241,Actual,University of British Columbia,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Data will be available from this trial 1 year after completion of the study. The data will remain available indefinitely.,"The nature of the request for sharing access will be reviewed by the PI (Beauchamp, M) and the data management team. Data will be shared via secure platforms (Redcap). Contact for data access can be done through personal communications (e.g., email) with PI Beauchamp.",https://osf.io/xw9gm,Yes,"The protocol for this study will be available on Open Science Framework (after 4 months to allow for study completion). The Statistical Analysis Plan will also be available on Open Science Framework. The Consent form is freely available if requested from the Primary Investigator (PI: Beauchamp, M.).",2020-11-07T11:23:24Z,2020-11-07T11:23:24Z
NCT04411667,"ClinicalTrials.gov processed this data on November 06, 2020",2020-05-29,NA,NA,2020-11-02,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-04,Actual,"April 28, 2020",Actual,2020-04-28,November 2020,2020-11-30,"November 30, 2020",Anticipated,2020-11-30,"November 1, 2020",Anticipated,2020-11-01,NA,Interventional,NA,,Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19,Randomized Open Label Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection,"Active, not recruiting",NA,Phase 4,34,Actual,Sharp HealthCare,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-08T11:34:50Z,2020-11-08T11:34:50Z
NCT04416139,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-30,NA,NA,2020-06-03,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-03,2020-06-04,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"May 1, 2021",Anticipated,2021-05-01,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,COVID-19,,Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19,Mesenchymal Stem Cells for the Treatment of Severe Acute Respiratory Distress Syndrome Due to COVID-19. Pilot Study,Recruiting,NA,Phase 2,10,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:57:03Z,2020-11-01T11:57:03Z
NCT04412239,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-30,NA,NA,2020-05-30,2020-05-30,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-05-30,2020-06-02,Actual,"April 20, 2020",Actual,2020-04-20,May 2020,2020-05-31,"September 20, 2020",Anticipated,2020-09-20,"August 20, 2020",Anticipated,2020-08-20,NA,Interventional,NA,,To Assess the Efficiency and Satisfaction of Pharmacist Giving Patient-centred Advice on Telephone Consultation in TB Patients: Experience of the COVID-19 Pandemic,To Assess the Efficiency and Satisfaction of Pharmacist Giving Patient-centred Advice on Telephone Consultation in TB Patients: Experience of the COVID-19 Pandemic,Recruiting,NA,N/A,200,Anticipated,Health Science Center of Xi'an Jiaotong University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:57:32Z,2020-11-01T11:57:32Z
NCT04414371,"ClinicalTrials.gov processed this data on October 30, 2020",2020-05-31,NA,NA,2020-06-02,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"May 20, 2020",Actual,2020-05-20,June 2020,2020-06-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Tools for Wellbeing COVID-19 National Study of Undergraduate Students,Tools for Wellbeing COVID-19 National Study of Undergraduate Students,Recruiting,NA,N/A,200,Anticipated,"Rutgers, The State University of New Jersey",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:57:17Z,2020-11-01T11:57:17Z
NCT04424953,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-01,NA,NA,2020-09-06,2020-06-05,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-09-06,2020-09-09,Actual,"June 1, 2020",Actual,2020-06-01,September 2020,2020-09-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,To Compare Videolaryngoscope Against Direct Laryngoscope for Intubation When Powered Air Purifying Respirator is Worn,A Randomised Controlled Trial to Compare McGrath Videolaryngoscope Against Direct Laryngoscope for Endotracheal Intubation When Powered Air Purifying Respirator is Worn During the Current Coronavirus Disease 2019 Pandemic,"Active, not recruiting",NA,N/A,28,Actual,Singapore General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T11:55:51Z,2020-11-01T11:55:51Z
NCT04417270,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-01,NA,NA,2020-07-06,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-07-06,2020-07-08,Actual,"June 12, 2020",Actual,2020-06-12,July 2020,2020-07-31,"October 31, 2020",Anticipated,2020-10-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge,Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge,Recruiting,NA,N/A,50,Anticipated,Northwell Health,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,No,The team has not decided whether to share the results with other researchers. The team will consider publishing results after study completion,2020-11-01T11:56:50Z,2020-11-01T11:56:50Z
NCT04414267,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-01,NA,NA,2020-07-10,2020-06-01,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-07-10,2020-07-14,Actual,"May 26, 2020",Actual,2020-05-26,July 2020,2020-07-31,"May 25, 2021",Anticipated,2021-05-25,"May 25, 2021",Anticipated,2021-05-25,NA,Interventional,ACTIVATEII,,Bacillus Calmette-guÃ©rin Vaccination to Prevent COVID-19,A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-GuÃ©rin Vaccination to Prevent Infections by COVID-19: The ACTIVATE II Trial,Recruiting,NA,Phase 4,900,Anticipated,Hellenic Institute for the Study of Sepsis,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:57:18Z,2020-11-01T11:57:18Z
NCT04414124,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-01,NA,NA,2020-08-12,2020-06-01,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-08-12,2020-08-14,Actual,"July 2, 2020",Actual,2020-07-02,August 2020,2020-08-31,December 2020,Anticipated,2020-12-31,October 2020,Anticipated,2020-10-31,NA,Interventional,NA,,A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19,"A Randomized, Open Label, Prospective, Parallel Group Study to Assess the Natural History of COVID-19 and Effects of KB109 in Addition to Supportive Self Care (SSC) Compared to SSC Alone on Measures of Health in Non-hospitalized Patients With Mild-Moderate COVID-19",Recruiting,NA,N/A,400,Anticipated,Kaleido Biosciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:57:18Z,2020-11-01T11:57:18Z
NCT04412785,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-01,NA,NA,2020-10-22,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-10-22,2020-10-23,Actual,"June 30, 2020",Actual,2020-06-30,October 2020,2020-10-31,December 2021,Anticipated,2021-12-31,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,Cyclosporine in Patients With Moderate COVID-19,Phase I Trial for the Prevention of Cytokine Release Syndrome (CRS) With Cyclosporine in Patients With Moderate COVID-19,Recruiting,NA,Phase 1,20,Anticipated,University of Pennsylvania,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2020-11-01T11:57:28Z,2020-11-01T11:57:28Z
NCT04412772,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-01,NA,NA,2020-06-01,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-01,2020-06-02,Actual,"June 1, 2020",Anticipated,2020-06-01,June 2020,2020-06-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,ARCHITECTS,,A RCT - Safety & Efficacy of Tocilizumab - Tx of Severe COVID-19: ARCHITECTS,"A Randomized, Controlled Clinical Trial of the Safety and Efficacy of Tocilizumab for the Treatment of Severe COVID-19",Recruiting,NA,Phase 3,300,Anticipated,Queen's Medical Centre,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T11:57:28Z,2020-11-01T11:57:28Z
NCT04412291,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-01,NA,NA,2020-06-24,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-24,2020-06-26,Actual,"June 11, 2020",Actual,2020-06-11,June 2020,2020-06-30,February 2021,Anticipated,2021-02-28,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,"A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study","A Single-center, Randomized, Open-label Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study",Recruiting,NA,Phase 2,120,Anticipated,Karolinska University Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T11:57:32Z,2020-11-01T11:57:32Z
NCT04415086,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-01,NA,NA,2020-10-27,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-29,Actual,"June 1, 2020",Actual,2020-06-01,June 2020,2020-06-30,"May 22, 2022",Anticipated,2022-05-22,"April 20, 2022",Anticipated,2022-04-20,NA,Interventional,COOPCOVID-19,,Treatment of Patients With COVID-19 With Convalescent Plasma,"Treatment of Patients With COVID-19 With Convalescent Plasma Transfusion: a Multicenter, Open-labeled, Randomized and Controlled Study",Recruiting,NA,Phase 2,120,Anticipated,University of Sao Paulo General Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-02T10:29:47Z,2020-11-02T10:29:47Z
NCT04412668,"ClinicalTrials.gov processed this data on November 02, 2020",2020-06-01,NA,NA,2020-10-29,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-10-30,Actual,"June 12, 2020",Actual,2020-06-12,October 2020,2020-10-31,"October 31, 2020",Anticipated,2020-10-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,NA,,Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19,A Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of ATYR1923 In Adult Patients With Severe Pneumonia Related to SARS-CoV-2 Infection (COVID-19),Recruiting,NA,Phase 2,30,Anticipated,"aTyr Pharma, Inc.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-03T10:51:51Z,2020-11-03T10:51:51Z
NCT04420247,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-02,NA,NA,2020-10-23,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-27,Actual,"April 16, 2020",Actual,2020-04-16,October 2020,2020-10-31,"September 3, 2020",Actual,2020-09-03,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,,Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19,Multicentric Pragmatic Randomized Controled Trial to Evaluate the Efficacy Chloroquine or Hydroxychloroquine for Five Days in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19,Completed,NA,Phase 3,142,Actual,Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T11:56:26Z,2020-11-01T11:56:26Z
NCT04415151,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-02,NA,NA,2020-10-06,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"July 29, 2020",Actual,2020-07-29,October 2020,2020-10-31,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,I-TOMIC,,Tofacitinib for Treatment of Moderate COVID-19,Investigation of Tofacitinib to Mitigate the Impact of COVID-19 (I-TOMIC) in Moderate SARS-CoV-2 (MODERATE I-TOMIC),Recruiting,NA,Phase 2,60,Anticipated,Yale University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:57:11Z,2020-11-01T11:57:11Z
NCT04415060,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-02,NA,NA,2020-08-31,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-02,Actual,"June 15, 2020",Actual,2020-06-15,August 2020,2020-08-31,"June 15, 2023",Anticipated,2023-06-15,"June 15, 2023",Anticipated,2023-06-15,NA,Interventional,SAVE-ICU,,SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival,"SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival. Multicentre Open-label, Pragmatic, Randomized Controlled Trial and a Parallel Prospective (Non-randomized) Cohort Study",Recruiting,NA,Phase 3,752,Anticipated,Sunnybrook Health Sciences Centre,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:57:12Z,2020-11-01T11:57:12Z
NCT04413968,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-02,NA,NA,2020-10-23,2020-06-02,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-26,Actual,"June 2, 2020",Actual,2020-06-02,May 2020,2020-05-31,"October 2, 2020",Actual,2020-10-02,"July 2, 2020",Actual,2020-07-02,NA,Interventional,COVIDOCRECHE,,"COVID-19 Infection and Transmission in Exposed, Confined and Community-based Infants","Contamination and Transmission of the SARS-CoV-2 Virus in Exposed, Confined and Community-based Infants: A Cross-sectional, Multicentre, Interventional Seroprevalence Study",Completed,NA,N/A,600,Actual,Assistance Publique - HÃ´pitaux de Paris,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:57:19Z,2020-11-01T11:57:19Z
NCT04425720,"ClinicalTrials.gov processed this data on November 13, 2020",2020-06-02,NA,NA,2020-11-09,2020-06-08,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"September 1, 2020",Actual,2020-09-01,November 2020,2020-11-30,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,RPM,,Use of Remote Monitoring for COVID-19 Patient,Use of Remote Patient Monitoring (RPM) Platform for COVID-19 Patient,Recruiting,NA,N/A,300,Anticipated,Montefiore Medical Center,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-15T10:58:43Z,2020-11-15T10:58:43Z
NCT04453852,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-03,NA,NA,2020-06-30,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"June 30, 2020",Actual,2020-06-30,June 2020,2020-06-30,"July 1, 2021",Anticipated,2021-07-01,"July 1, 2021",Anticipated,2021-07-01,NA,Interventional,COVAX19,,Monovalent Recombinant COVID19 Vaccine,"A Randomised, Controlled, Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Adjuvanted Recombinant Protein SARS-COV-2 Vaccine in Healthy Adult Subjects",Recruiting,NA,Phase 1,40,Anticipated,Vaxine Pty Ltd,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:52:23Z,2020-11-01T11:52:23Z
NCT04439045,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-03,NA,NA,2020-08-18,2020-06-18,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-20,Actual,"June 24, 2020",Actual,2020-06-24,August 2020,2020-08-31,"July 1, 2021",Anticipated,2021-07-01,"April 1, 2021",Anticipated,2021-04-01,NA,Interventional,COBRA,,Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study: Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 Infection Rate and COVID-19 Severity",Recruiting,NA,Phase 3,3626,Anticipated,"University Health Network, Toronto",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:54:10Z,2020-11-01T11:54:10Z
NCT04426305,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-03,NA,NA,2020-06-09,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-09,2020-06-11,Actual,"May 21, 2020",Actual,2020-05-21,June 2020,2020-06-30,"October 30, 2020",Anticipated,2020-10-30,"June 20, 2020",Anticipated,2020-06-20,NA,Interventional,NA,,Community Health Workers Against COVID19,Community Health Workers Against COVID19 Tackling Psychosocial Suffering Due to Physical Distancing,Enrolling by invitation,NA,N/A,140,Anticipated,University Ghent,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-11-01T11:55:42Z,2020-11-01T11:55:42Z
NCT04425616,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-03,NA,NA,2020-06-05,2020-06-05,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-11,Actual,"May 29, 2020",Actual,2020-05-29,June 2020,2020-06-30,"November 30, 2022",Anticipated,2022-11-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,NA,,SafeFit Trial: Virtual Clinics to Deliver Universal Interventions in People With Cancer,SafeFit Trial: Virtual Clinics to Deliver Universal Interventions to Maintain and Improve Mental and Physical Health in People With Cancer Who Are Following Social Distancing Guidance: A COVID-19 Targeted Trial,Recruiting,NA,N/A,1100,Anticipated,University Hospital Southampton NHS Foundation Trust,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:55:47Z,2020-11-01T11:55:47Z
NCT04422509,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-03,NA,NA,2020-09-10,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-10,2020-09-14,Actual,"October 3, 2020",Anticipated,2020-10-03,September 2020,2020-09-30,"August 3, 2021",Anticipated,2021-08-03,"August 3, 2021",Anticipated,2021-08-03,NA,Interventional,COVID_LAN,,Lanadelumab for Treatment of COVID-19 Disease,Lanadelumab for Treatment of COVID-19 Disease,Recruiting,NA,Phase 1/Phase 2,80,Anticipated,Radboud University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,this has not yet been decided,2020-11-01T11:56:10Z,2020-11-01T11:56:10Z
NCT04421404,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-03,NA,NA,2020-10-20,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-20,2020-10-22,Actual,"June 9, 2020",Actual,2020-06-09,October 2020,2020-10-31,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,CAPRI,,Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients,A Randomized Controlled Adaptive Study Comparing COVID-19 Convalescent Plasma (CCP) to Non-immune Plasma to Limit Coronavirus-associated Complications in Hospitalized Patients,"Active, not recruiting",NA,Phase 2,50,Anticipated,"University of California, San Francisco",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:56:17Z,2020-11-01T11:56:17Z
NCT04420273,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-03,NA,NA,2020-09-02,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-02,2020-09-04,Actual,"July 2, 2020",Actual,2020-07-02,September 2020,2020-09-30,"December 30, 2021",Anticipated,2021-12-30,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,TMD,,Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access,Targeted Melanoma Detection With Skin Self-examination: Leveraging the Mammogram Encounter,"Active, not recruiting",NA,N/A,1000,Actual,Northwestern University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:56:26Z,2020-11-01T11:56:26Z
NCT04419623,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-03,NA,NA,2020-09-23,2020-06-04,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-25,Actual,"July 9, 2020",Actual,2020-07-09,September 2020,2020-09-30,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Interventional,NA,,A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer,"A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer",Recruiting,NA,Phase 1/Phase 2,146,Anticipated,"Telios Pharma, Inc.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:56:32Z,2020-11-01T11:56:32Z
NCT04419025,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-03,NA,NA,2020-09-23,2020-06-03,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-25,Actual,"September 23, 2020",Actual,2020-09-23,September 2020,2020-09-30,"May 31, 2021",Anticipated,2021-05-31,"January 31, 2021",Anticipated,2021-01-31,NA,Interventional,NA,,Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease,Determination of Efficacy of N-Acetylcysteine in Preventing Those With Mild or Moderate COVID-19 From Progressing to Severe Disease,Recruiting,NA,Phase 4,200,Anticipated,Cambridge Health Alliance,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:56:38Z,2020-11-01T11:56:38Z
NCT04418518,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-03,NA,NA,2020-07-06,2020-06-04,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2020-07-06,2020-07-07,Actual,"June 24, 2020",Actual,2020-06-24,July 2020,2020-07-31,December 2021,Anticipated,2021-12-31,June 2021,Anticipated,2021-06-30,NA,Interventional,CONCOR-1,,A Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness,CONCOR-1: A Randomized Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness,Recruiting,NA,Phase 3,1200,Anticipated,Weill Medical College of Cornell University,,2,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:56:41Z,2020-11-01T11:56:41Z
NCT04418505,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-03,NA,NA,2020-09-10,2020-06-03,2020-06-05,Actual,NA,NA,NA,NA,NA,NA,2020-09-10,2020-09-14,Actual,"September 2, 2020",Actual,2020-09-02,September 2020,2020-09-30,"March 1, 2021",Anticipated,2021-03-01,"March 1, 2021",Anticipated,2021-03-01,NA,Interventional,COVIDLight,,Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms,A Randomized Study Evaluating the Efficacy of the Vielight RX Plus in the Treatment of COVID-19 Respiratory Symptoms,Recruiting,NA,N/A,280,Anticipated,Vielight Inc.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:56:41Z,2020-11-01T11:56:41Z
NCT04416399,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-03,NA,NA,2020-07-23,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-07-23,2020-07-24,Actual,"July 16, 2020",Actual,2020-07-16,July 2020,2020-07-31,"December 30, 2020",Anticipated,2020-12-30,"November 15, 2020",Anticipated,2020-11-15,NA,Interventional,STOIC,,STerOids in COVID-19 Study,Use of High Dose Inhaled Corticosteroids as Treatment of Early COVID-19 Infection to Prevent Clinical Deterioration and Hospitalisation,Recruiting,NA,Phase 2,478,Anticipated,University of Oxford,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:57:01Z,2020-11-01T11:57:01Z
NCT04416334,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-03,NA,NA,2020-06-09,2020-06-03,2020-06-04,Actual,NA,NA,NA,NA,NA,NA,2020-06-09,2020-06-11,Actual,"May 25, 2020",Actual,2020-05-25,June 2020,2020-06-30,"December 31, 2020",Anticipated,2020-12-31,"September 25, 2020",Anticipated,2020-09-25,NA,Interventional,COLCHI-COVID,,PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 70 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS,PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 70 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS SARS-CoV2 (COVID-19),Recruiting,NA,Phase 3,1028,Anticipated,Instituto de InvestigaciÃ³n MarquÃ©s de Valdecilla,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:57:01Z,2020-11-01T11:57:01Z
NCT04435808,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-04,NA,NA,2020-06-16,2020-06-16,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2020-06-16,2020-06-17,Actual,"April 14, 2020",Actual,2020-04-14,June 2020,2020-06-30,"April 14, 2025",Anticipated,2025-04-14,"April 14, 2021",Anticipated,2021-04-14,NA,Interventional,NA,,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Off Label Study to Evaluate the Efficacy of Hydroxychloroquine as Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers at High Risk of Occupational Exposure to SARS-CoV-2,Recruiting,NA,Phase 1/Phase 2,350,Anticipated,University of New Mexico,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:54:31Z,2020-11-01T11:54:31Z
NCT04424212,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-04,NA,NA,2020-06-09,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-09,2020-06-11,Actual,"June 10, 2020",Actual,2020-06-10,June 2020,2020-06-30,August 2021,Anticipated,2021-08-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,ICBT for Mental Health Problems Related to the Coronavirus Pandemic,CoronaCope - Internet-based Cognitive Behavioural Therapy for Adults Suffering From Mental Health Problems Related to the Coronavirus Pandemic,Recruiting,NA,N/A,120,Anticipated,Linkoeping University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:55:58Z,2020-11-01T11:55:58Z
NCT04421391,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-04,NA,NA,2020-06-05,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-05,2020-06-09,Actual,"June 8, 2020",Anticipated,2020-06-08,June 2020,2020-06-30,"November 8, 2020",Anticipated,2020-11-08,"November 1, 2020",Anticipated,2020-11-01,NA,Interventional,NA,,QuadraMune(TM) for Prevention of COVID-19,Phase II Study of QuadraMune(TM) for Prevention of COVID-19 in High Risk Populations,Recruiting,NA,N/A,500,Anticipated,Therapeutic Solutions International,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:56:17Z,2020-11-01T11:56:17Z
NCT04420741,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-04,NA,NA,2020-07-10,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-07-10,2020-07-13,Actual,"June 15, 2020",Actual,2020-06-15,July 2020,2020-07-31,"May 31, 2021",Anticipated,2021-05-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,COMBAT-COVID,,Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure,Efficacy and Safety of 72-hour Infusion of Prostacyclin (1 Nanogram(ng)/ Kilo(kg)/Minute(Min)) in Patients With COVID-19 Induced Pulmonary Endotheliopathy,Recruiting,NA,Phase 2,80,Anticipated,"Rigshospitalet, Denmark",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:56:23Z,2020-11-01T11:56:23Z
NCT04420676,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-04,NA,NA,2020-10-20,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-20,2020-10-22,Actual,"September 24, 2020",Actual,2020-09-24,October 2020,2020-10-31,December 2022,Anticipated,2022-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,SynCov,,Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection,"Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection: A Randomized, Double-blind, Placebo Controlled, Telemedicine Study (SynCov Study)",Recruiting,NA,N/A,108,Anticipated,Medical University of Graz,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,1 year after completion,free,NA,Yes,Upload of microbiome sequences and metadata to a repository,2020-11-01T11:56:23Z,2020-11-01T11:56:23Z
NCT04541979,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-05,NA,NA,2020-09-07,2020-09-07,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-07,2020-09-09,Actual,"June 4, 2020",Actual,2020-06-04,September 2020,2020-09-30,"December 1, 2020",Anticipated,2020-12-01,"November 1, 2020",Anticipated,2020-11-01,NA,Interventional,NA,,Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19,"Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19 - a Phase 2, Single-blinded, Randomized Study",Recruiting,NA,Phase 2,100,Anticipated,Region Skane,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,nn,2020-11-01T11:41:47Z,2020-11-01T11:41:47Z
NCT04513990,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-05,NA,NA,2020-08-13,2020-08-13,2020-08-14,Actual,NA,NA,NA,NA,NA,NA,2020-08-13,2020-08-17,Actual,"April 9, 2020",Actual,2020-04-09,August 2020,2020-08-31,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,END CoV-2,,Novel Point-of-Care Diagnostic Test for SARS-CoV-2 (COVID-19),Evaluation of a Novel Point-of-Care Diagnostic Test for SARS-CoV-2,Recruiting,NA,N/A,1500,Anticipated,M.D. Anderson Cancer Center,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:45:12Z,2020-11-01T11:45:12Z
NCT04427566,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-05,NA,NA,2020-09-23,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-25,Actual,"July 23, 2020",Actual,2020-07-23,September 2020,2020-09-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,VENTED,,Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise,Vented COVID: A Phase II Study Of The Use Of Ultra Low-Dose Bilateral Whole Lung Radiation Therapy in the Treatment Of Critically Ill Patients With COVID-19 Respiratory Compromise,Recruiting,NA,Phase 2,24,Anticipated,Ohio State University Comprehensive Cancer Center,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:55:34Z,2020-11-01T11:55:34Z
NCT04424797,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-05,NA,NA,2020-07-15,2020-06-08,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-16,Actual,"July 13, 2020",Actual,2020-07-13,July 2020,2020-07-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Prone Positioning on Admission for Hospitalized COVID-19 Pneumonia Protocol,Prone Positioning on Admission for Hospitalized COVID-19 Pneumonia Protocol,Recruiting,NA,N/A,100,Anticipated,Poudre Valley Health System,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:55:54Z,2020-11-01T11:55:54Z
NCT04425031,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-05,NA,NA,2020-09-11,2020-06-10,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-09-11,2020-09-14,Actual,"August 25, 2020",Actual,2020-08-25,September 2020,2020-09-30,"March 1, 2024",Anticipated,2024-03-01,"December 1, 2022",Anticipated,2022-12-01,NA,Interventional,HOT-COVID,,Handling Oxygenation Targets in COVID-19,Handling Oxygenation Targets in COVID-19 Patients With Acute Hypoxaemic Respiratory Failure in the Intensive Care Unit: A Randomised Clinical Trial of a Lower Versus a Higher Oxygenation Target,Recruiting,NA,Phase 4,780,Anticipated,Aalborg University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,"Access Criteria:
Managed by the Steering Committee of the HOT-COVID trial.",http://cric.nu/hot-covid,Yes,"All original records (incl. consent forms, electronic clinical report forms (eCRFs), and relevant correspondences) will be archived at trial sites for 15 years. The clean electronic trial database file will be delivered to the EudraCT Database and Zenodo data repository (https://zenodo.org/) and maintained for 15 years and anonymised if requested by the authorities.",2020-11-01T11:55:50Z,2020-11-01T11:55:50Z
NCT04421664,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-05,NA,NA,2020-09-18,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-18,2020-09-22,Actual,"March 25, 2020",Actual,2020-03-25,September 2020,2020-09-30,"August 17, 2020",Actual,2020-08-17,"August 17, 2020",Actual,2020-08-17,NA,Interventional,NA,,Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada),Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada),Terminated,NA,Phase 3,70,Actual,McGill University Health Centre/Research Institute of the McGill University Health Centre,,2,NA,Request of Health Canada after publication of https://doi.org/10.7326/M20-4207,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,At time of publication,To be publicly provided,http://www.covid-19research.ca,Yes,De-identified dataset will be included with publication.,2020-11-01T11:56:16Z,2020-11-01T11:56:16Z
NCT04421508,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-05,NA,NA,2020-09-08,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-08,2020-09-09,Actual,"July 12, 2020",Actual,2020-07-12,September 2020,2020-09-30,June 2021,Anticipated,2021-06-30,February 2021,Anticipated,2021-02-28,NA,Interventional,COViNOX,,A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19,"A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo in Subjects With Mild or Moderate Coronavirus (COVID-19)",Recruiting,NA,Phase 3,500,Anticipated,Bellerophon,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:56:17Z,2020-11-01T11:56:17Z
NCT04420338,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-05,NA,NA,2020-06-15,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-15,2020-06-17,Actual,"June 5, 2020",Actual,2020-06-05,June 2020,2020-06-30,"December 15, 2020",Anticipated,2020-12-15,"December 15, 2020",Anticipated,2020-12-15,NA,Interventional,SeroCOVIDial,,"SeroCOVIDial Study: Assessment of COVID-19 Seroconversion in Patients on Chronic Hemodialysis and in Their Caregivers, a Cohort Study","SeroCOVIDial Study: Assessment of SARS-COV2 Seroconversion in Patients on Chronic Hemodialysis and in Their Caregivers, a Cohort Study",Recruiting,NA,N/A,800,Anticipated,Assistance Publique Hopitaux De Marseille,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:56:25Z,2020-11-01T11:56:25Z
NCT04420299,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-05,NA,NA,2020-06-08,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-11,Actual,"June 4, 2020",Actual,2020-06-04,June 2020,2020-06-30,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,NA,,Clinical Trial on the Efficacy and Safety of Bemiparin in Patients Hospitalized Because of COVID-19,"A Randomized, Single-blind Study With a Parallel Control Group on the Efficacy and Safety of Bemiparin at Therapeutic Dose vs. Prophylactic Dose in Patients Hospitalized for COVID-19",Recruiting,NA,Phase 2,120,Anticipated,FundaciÃ³n de investigaciÃ³n HM,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:56:25Z,2020-11-01T11:56:25Z
NCT04422613,"ClinicalTrials.gov processed this data on November 06, 2020",2020-06-05,NA,NA,2020-11-04,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-05,Actual,"May 28, 2020",Actual,2020-05-28,November 2020,2020-11-30,May 2022,Anticipated,2022-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,PULCO-19,,Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia,Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia,"Active, not recruiting",NA,N/A,73,Actual,"University Hospital, Toulouse",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-09T10:53:15Z,2020-11-09T10:53:15Z
NCT04421027,"ClinicalTrials.gov processed this data on November 13, 2020",2020-06-05,NA,NA,2020-11-06,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-10,Actual,"June 12, 2020",Actual,2020-06-12,"November 1, 2020",2020-11-01,"June 20, 2021",Anticipated,2021-06-20,"May 19, 2021",Anticipated,2021-05-19,NA,Interventional,COV-BARRIER,,A Study of Baricitinib (LY3009104) in Participants With COVID-19,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection",Recruiting,NA,Phase 3,1000,Anticipated,Eli Lilly and Company,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting","Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting",http://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement,2020-11-14T10:41:37Z,2020-11-14T10:41:37Z
NCT04420806,"ClinicalTrials.gov processed this data on November 13, 2020",2020-06-05,NA,NA,2020-11-12,2020-06-05,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-13,Estimate,"March 14, 2020",Actual,2020-03-14,November 2020,2020-11-30,"October 30, 2020",Actual,2020-10-30,"July 30, 2020",Actual,2020-07-30,NA,Interventional,NA,,Effects of COVID-19 Lockdown in Exercising Early Postmenopausal Women,Effects of Three Months of COVID-19 Lockdown Induced Deconditioning After 13 Months of High Intensity Exercise Training in Early Postmenopausal Women,Completed,NA,N/A,21,Actual,University of Erlangen-NÃ¼rnberg Medical School,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-15T10:58:47Z,2020-11-15T10:58:47Z
NCT04441918,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-06,NA,NA,2020-06-18,2020-06-18,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-18,2020-06-22,Actual,"June 5, 2020",Actual,2020-06-05,June 2020,2020-06-30,"December 11, 2020",Anticipated,2020-12-11,"December 11, 2020",Anticipated,2020-12-11,NA,Interventional,NA,,"Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects","A Randomized, Double-blind, Placebo-controlled, Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetic Profile and Immunogenicity of JS016 (Anti-SARS-CoV-2 Monoclonal Antibody) Injection in Chinese Healthy Subjects After Intravenous Infusion of Single Dose",Recruiting,NA,Phase 1,40,Anticipated,"Shanghai Junshi Bioscience Co., Ltd.",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:53:45Z,2020-11-01T11:53:45Z
NCT04423289,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-06,NA,NA,2020-06-08,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-09,Actual,"March 31, 2020",Actual,2020-03-31,June 2020,2020-06-30,"May 18, 2020",Actual,2020-05-18,"May 4, 2020",Actual,2020-05-04,NA,Interventional,NA,,Telematic Monitoring Through a Mobile Application of Patients With COVID-19,COVID Follow-App: Telematic Monitoring Through a Mobile Application of Patients With COVID-19: A Randomized Clinical Trial,Completed,NA,N/A,150,Actual,Hospital Universitari Vall d'Hebron Research Institute,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:56:06Z,2020-11-01T11:56:06Z
NCT04422561,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-06,2020-08-23,NA,2020-08-23,2020-06-06,2020-06-09,Actual,2020-08-23,2020-08-27,Actual,NA,NA,NA,2020-08-23,2020-08-27,Actual,"May 31, 2020",Actual,2020-05-31,August 2020,2020-08-31,"July 27, 2020",Actual,2020-07-27,"July 14, 2020",Actual,2020-07-14,NA,Interventional,NA,,Prophylactic Ivermectin in COVID-19 Contacts,Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19,Completed,NA,Phase 2/Phase 3,340,Actual,Zagazig University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:56:10Z,2020-11-01T11:56:10Z
NCT04428021,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-07,NA,NA,2020-10-15,2020-06-10,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-10-15,2020-10-19,Actual,"June 15, 2020",Actual,2020-06-15,October 2020,2020-10-31,"December 15, 2021",Anticipated,2021-12-15,"June 15, 2021",Anticipated,2021-06-15,NA,Interventional,PLACO-COVID,,Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure,"Effectiveness of Adding Standard Plasma or COVID-19 Convalescent Plasma to Standard Treatment, Versus Standard Treatment Alone, in Patients With Recent Onset of COVID-19 Respiratory Failure. A Randomized, Three-arms, Phase 2 Trial",Recruiting,NA,Phase 2,180,Anticipated,Azienda Ospedaliera CittÃ  della Salute e della Scienza di Torino,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Data will be available after 12 months from study ending and for the following 5 years,Data requests should be submitted to the corresponding author for consideration.,NA,Yes,"All Individual Participant Data requests should be submitted to the corresponding author for consideration. Access to deidentified participant data may be granted following review, after the publication of major results",2020-11-01T11:55:31Z,2020-11-01T11:55:31Z
NCT04425915,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-07,NA,NA,2020-09-02,2020-06-10,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-09-02,2020-09-03,Actual,"June 14, 2020",Actual,2020-06-14,June 2020,2020-06-30,"May 30, 2021",Anticipated,2021-05-30,"May 30, 2021",Anticipated,2021-05-30,NA,Interventional,NA,,Efficacy of Convalescent Plasma Therapy in Patients With COVID-19,Efficacy of Convalescent Plasma Therapy in Patients With COVID-19: A Randomized Control Trial,Recruiting,NA,Phase 3,400,Anticipated,"Institute of Liver and Biliary Sciences, India",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:55:44Z,2020-11-01T11:55:44Z
NCT04422353,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-07,NA,NA,2020-06-08,2020-06-07,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-11,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"December 30, 2024",Anticipated,2024-12-30,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,PTT-Online,,Video Dance Class and Unsupervised Physical Activity During Covid-19 Pandemic in People With Parkinson's Disease,The Impact of Video Dance Class and Unsupervised Physical Activity on Parkinson's People During the Covid-19 Pandemic: Interventional,Recruiting,NA,N/A,60,Anticipated,Federal University of Rio Grande do Sul,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:56:12Z,2020-11-01T11:56:12Z
NCT04424082,"ClinicalTrials.gov processed this data on November 13, 2020",2020-06-07,NA,NA,2020-11-10,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"June 9, 2020",Actual,2020-06-09,November 2020,2020-11-30,"November 7, 2020",Anticipated,2020-11-07,"November 7, 2020",Anticipated,2020-11-07,NA,Interventional,NA,,External Dead Space in Ventilated COVID-19 Patients,Influence of External Dead Space on Volumetric Capnography Derived Parameters in Mechanically Ventilated COVID-19 Patients,Recruiting,NA,N/A,40,Anticipated,Karolinska Institutet,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-15T10:58:44Z,2020-11-15T10:58:44Z
NCT04475601,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-08,NA,NA,2020-07-16,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-17,Actual,"July 15, 2020",Actual,2020-07-15,July 2020,2020-07-31,"May 8, 2022",Anticipated,2022-05-08,"July 8, 2021",Anticipated,2021-07-08,NA,Interventional,COVIDENZA,,Enzalutamide Treatment in COVID-19,"A Prospective, Multicenter, Randomized PHASE II Clinical Trial of Enzalutamide Treatment to Decrease the Morbidity in Patients With Corona Virus Disease 2019 (COVID-19)",Recruiting,NA,Phase 2,500,Anticipated,VÃ¤sterbotten County Council,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,The extent of sharing will be regulated during the trial to consider the integrity of the data according GDPR and national laws,2020-11-01T11:49:40Z,2020-11-01T11:49:40Z
NCT04442087,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-08,NA,NA,2020-10-05,2020-06-19,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-06,Actual,"June 19, 2020",Actual,2020-06-19,August 2020,2020-08-31,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,NA,Interventional,FamilyPEDCOVID,,Study of Seroprevalence of Anti-SARS-CoV2 Among Children of Hospital Workers in AP-HP,Seroprevalence of Anti-SARS-CoV2 Among Children According to Parents' SARS-CoV2 Serological Status. Study in a Hospital Population Assistance Publique-HÃ´pitaux Paris,Recruiting,NA,N/A,400,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:53:44Z,2020-11-01T11:53:44Z
NCT04426292,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-08,NA,NA,2020-06-09,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-09,2020-06-11,Actual,"May 12, 2020",Actual,2020-05-12,June 2020,2020-06-30,"May 12, 2021",Anticipated,2021-05-12,"October 23, 2020",Anticipated,2020-10-23,NA,Interventional,COVEMUZ,,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak,Recruiting,NA,N/A,3500,Anticipated,Universitair Ziekenhuis Brussel,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:55:42Z,2020-11-01T11:55:42Z
NCT04425707,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-08,NA,NA,2020-06-08,2020-06-08,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-11,Actual,"June 9, 2020",Actual,2020-06-09,June 2020,2020-06-30,"September 1, 2020",Anticipated,2020-09-01,"July 1, 2020",Anticipated,2020-07-01,NA,Interventional,NA,,Ivermectin In Treatment of COVID 19 Patients,The Use of Ivermectin In the Treatment of COVID 19 Patients,Recruiting,NA,N/A,100,Anticipated,"Ministry of Health and Population, Egypt",,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:55:46Z,2020-11-01T11:55:46Z
NCT04425538,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-08,NA,NA,2020-06-08,2020-06-08,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-11,Actual,"June 1, 2020",Actual,2020-06-01,June 2020,2020-06-30,December 2020,Anticipated,2020-12-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).,A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).,Recruiting,NA,Phase 2,17,Anticipated,Tufts Medical Center,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:55:47Z,2020-11-01T11:55:47Z
NCT04425005,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-08,NA,NA,2020-06-09,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-09,2020-06-11,Actual,"May 10, 2020",Actual,2020-05-10,June 2020,2020-06-30,February 2021,Anticipated,2021-02-28,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,,Home-based Exercise Training During Covid-19 Pandemic in Post-bariatric,Effect of Home-based Exercise Training Program During the Covid-19 Pandemic in Post-bariatric Patients: A Randomized Controlled Trial,Recruiting,NA,N/A,70,Anticipated,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:55:51Z,2020-11-01T11:55:51Z
NCT04423991,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-08,NA,NA,2020-06-08,2020-06-08,2020-06-09,Actual,NA,NA,NA,NA,NA,NA,2020-06-08,2020-06-09,Actual,"March 10, 2020",Actual,2020-03-10,June 2020,2020-06-30,"June 4, 2020",Actual,2020-06-04,"June 4, 2020",Actual,2020-06-04,NA,Interventional,IDENTIFY,,Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning,Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning: the IDENTIFY Trial,Completed,NA,N/A,290,Actual,Dascena,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:55:59Z,2020-11-01T11:55:59Z
NCT04426695,"ClinicalTrials.gov processed this data on November 13, 2020",2020-06-08,NA,NA,2020-11-09,2020-06-10,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-10,Actual,"June 10, 2020",Actual,2020-06-10,November 2020,2020-11-30,"January 25, 2021",Anticipated,2021-01-25,"January 25, 2021",Anticipated,2021-01-25,NA,Interventional,NA,,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19","A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19",Recruiting,NA,Phase 1/Phase 2,2970,Anticipated,Regeneron Pharmaceuticals,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2020-11-14T10:41:32Z,2020-11-14T10:41:32Z
NCT04425629,"ClinicalTrials.gov processed this data on November 13, 2020",2020-06-08,NA,NA,2020-11-09,2020-06-08,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-10,Actual,"June 16, 2020",Actual,2020-06-16,November 2020,2020-11-30,"December 19, 2020",Anticipated,2020-12-19,"December 19, 2020",Anticipated,2020-12-19,NA,Interventional,NA,,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult Patients With COVID-19","A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19",Recruiting,NA,Phase 1/Phase 2,2104,Anticipated,Regeneron Pharmaceuticals,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2020-11-14T10:41:33Z,2020-11-14T10:41:33Z
NCT04431453,"ClinicalTrials.gov processed this data on November 13, 2020",2020-06-08,NA,NA,2020-11-11,2020-06-11,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Estimate,"July 21, 2020",Actual,2020-07-21,November 2020,2020-11-30,February 2021,Anticipated,2021-02-28,February 2021,Anticipated,2021-02-28,NA,Interventional,CARAVAN,,"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734â„¢) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19)","A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734â„¢) in Participants From Birth to < 18 Years of Age With COVID-19",Recruiting,NA,Phase 2/Phase 3,52,Anticipated,Gilead Sciences,,1,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-15T10:58:38Z,2020-11-15T10:58:38Z
NCT04458948,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-09,NA,NA,2020-06-30,2020-06-30,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-07,Actual,"March 24, 2020",Actual,2020-03-24,April 2020,2020-04-30,"March 24, 2025",Anticipated,2025-03-24,"March 24, 2021",Anticipated,2021-03-24,NA,Interventional,NA,,Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients,Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients With Moderate or Severe COVID-19 Infection,"Active, not recruiting",NA,Phase 2,10000,Anticipated,University of New Mexico,,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:51:40Z,2020-11-01T11:51:40Z
NCT04445246,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-09,NA,NA,2020-06-23,2020-06-23,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-23,2020-06-24,Actual,"May 23, 2020",Actual,2020-05-23,May 2020,2020-05-31,"May 31, 2021",Anticipated,2021-05-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,ILOCOVID,,Inhaled Iloprost for Suspected COVID-19 Respiratory Failure,Inhaled Iloprost for the Treatment of Suspected COVID-19 Respiratory Failure,Recruiting,NA,Phase 2,40,Anticipated,Hamad Medical Corporation,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2020-11-01T11:53:23Z,2020-11-01T11:53:23Z
NCT04434131,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-09,NA,NA,2020-06-14,2020-06-14,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-14,2020-06-16,Actual,"April 28, 2020",Actual,2020-04-28,June 2020,2020-06-30,"April 28, 2025",Anticipated,2025-04-28,"April 28, 2021",Anticipated,2021-04-28,NA,Interventional,NA,,Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19,"Open, Non-comparative Pilot Study to Provide Access to Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19",Recruiting,NA,Phase 2,30,Anticipated,University of New Mexico,,1,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:54:43Z,2020-11-01T11:54:43Z
NCT04429854,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-09,NA,NA,2020-06-09,2020-06-09,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2020-06-09,2020-06-12,Actual,"May 2, 2020",Actual,2020-05-02,June 2020,2020-06-30,"November 2, 2021",Anticipated,2021-11-02,"November 2, 2021",Anticipated,2021-11-02,NA,Interventional,DAWN-Plasma,,Donated Antibodies Working Against nCoV,"A Randomized, Open-label, Adaptive, Proof-of-concept Clinical Trial of Donated Antibodies Working Against With COVID-19: DAWN-PLASMA",Recruiting,NA,Phase 2,483,Anticipated,Universitaire Ziekenhuizen Leuven,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:55:18Z,2020-11-01T11:55:18Z
NCT04429529,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-09,NA,NA,2020-09-22,2020-06-10,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-24,Actual,"June 9, 2020",Actual,2020-06-09,September 2020,2020-09-30,February 2021,Anticipated,2021-02-28,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,,"Safety of TY027, a Treatment for COVID-19, in Humans","Phase 1 First-in-Human, Time Lagged, Randomised, Placebo Controlled, Double Blind, Single Ascending Dose Study of TY027 in Healthy Adult Volunteers","Active, not recruiting",NA,Phase 1,32,Anticipated,Tychan Pte Ltd.,,10,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:55:21Z,2020-11-01T11:55:21Z
NCT04428099,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-09,NA,NA,2020-06-10,2020-06-10,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-10,2020-06-11,Actual,"January 13, 2020",Actual,2020-01-13,June 2020,2020-06-30,"July 12, 2022",Anticipated,2022-07-12,"January 12, 2022",Anticipated,2022-01-12,NA,Interventional,NA,,Healthy Lifestyle Promotion as Adjunctive Teletherapy for Treatment-resistant Major Depression,Effectiveness of a Healthy Lifestyle Promotion Program as Adjunctive Teletherapy for Treatment-resistant Major Depression During Covid 19 Pandemic: A Randomized Clinical Trial Protocol,Recruiting,NA,N/A,186,Anticipated,University of the Balearic Islands,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:55:31Z,2020-11-01T11:55:31Z
NCT04426318,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-09,NA,NA,2020-06-29,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-29,2020-07-01,Actual,"June 14, 2020",Actual,2020-06-14,June 2020,2020-06-30,"June 30, 2022",Anticipated,2022-06-30,"January 30, 2021",Anticipated,2021-01-30,NA,Interventional,CAHMP-ED,,COVID-19 and the Healthy Minds Program for Educators,COVID-19 and the Healthy Minds Program for Educators,Recruiting,NA,N/A,400,Anticipated,"University of Wisconsin, Madison",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Data will be de-identified and made publicly available based on the publication of preregistered study hypotheses following peer review.,Researcher consent. Any reasonable request will be granted.,NA,Yes,"Data will be de-identified and listed in public data registries (i.e., osf) based on the publication of preregistered study hypotheses on a manuscript by manuscript basis.",2020-11-01T11:55:42Z,2020-11-01T11:55:42Z
NCT04425252,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-09,NA,NA,2020-10-27,2020-06-09,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-28,Actual,"June 25, 2020",Actual,2020-06-25,October 2020,2020-10-31,April 2021,Anticipated,2021-04-30,March 2021,Anticipated,2021-03-31,NA,Interventional,CRISIS,,Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19,The CRISIS Study: A Randomized Open-label Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Hospitalized Adults With Coronavirus-19 (COVID-19),Recruiting,NA,Phase 1/Phase 2,24,Anticipated,"Clear Creek Bio, Inc.",,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:55:49Z,2020-11-01T11:55:49Z
NCT04497389,"ClinicalTrials.gov processed this data on November 09, 2020",2020-06-09,NA,NA,2020-11-04,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-06,Actual,"October 28, 2020",Actual,2020-10-28,November 2020,2020-11-30,"September 15, 2021",Anticipated,2021-09-15,"September 15, 2021",Anticipated,2021-09-15,NA,Interventional,NA,,Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients,A Phase I/II Randomized Double-blinded Placebo-controlled Clinical Trial to Determine Safety and Feasibility of Using an Acellular Sterile Filtered Amniotic Fluid as a Treatment for COVID-19 Patients,Recruiting,NA,Phase 1/Phase 2,60,Anticipated,University of Utah,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2020-11-10T11:27:04Z,2020-11-10T11:27:04Z
NCT04427501,"ClinicalTrials.gov processed this data on November 13, 2020",2020-06-09,NA,NA,2020-11-11,2020-06-11,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Estimate,"June 17, 2020",Actual,2020-06-17,November 2020,2020-11-30,"March 11, 2021",Anticipated,2021-03-11,"September 20, 2020",Actual,2020-09-20,NA,Interventional,BLAZE-1,,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness,"A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness",Recruiting,NA,Phase 2,1200,Anticipated,Eli Lilly and Company,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting","Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting",http://vivli.org/,Yes,NA,2020-11-15T10:58:42Z,2020-11-15T10:58:42Z
NCT04584541,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-10,NA,NA,2020-10-12,2020-10-12,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-12,2020-10-14,Actual,"June 11, 2020",Actual,2020-06-11,June 2020,2020-06-30,December 2023,Anticipated,2023-12-31,July 2023,Anticipated,2023-07-31,NA,Interventional,COVIRIC,,SarS-Cov-2 Viral Infection (COVID-19) in Patients With Chronic Inflammatory Rheumatism,Study of the Viral Load and Humoral and Cellular B and T Responses in Patients With Rheumatoid Arthritis and Spondyloarthritis Under Immunosuppressive Treatments,Recruiting,NA,N/A,150,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:36:39Z,2020-11-01T11:36:39Z
NCT04433078,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-10,NA,NA,2020-06-22,2020-06-12,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-22,2020-06-24,Actual,"June 22, 2020",Actual,2020-06-22,June 2020,2020-06-30,July 2021,Anticipated,2021-07-31,January 2021,Anticipated,2021-01-31,NA,Interventional,STORM,,RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM,RepurpoSing Old Drugs TO SuppRess a Modern Threat: The STORM Trial,Recruiting,NA,Phase 2,20,Anticipated,Temple University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:54:51Z,2020-11-01T11:54:51Z
NCT04431466,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-10,NA,NA,2020-08-31,2020-06-11,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-02,Actual,"July 1, 2020",Actual,2020-07-01,August 2020,2020-08-31,"July 1, 2021",Anticipated,2021-07-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,IFORS,,A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19,Phase 2 Clinical Trial to Compare the Efficacy and Safety of Different Doses of Ivermectin in Patients Diagnosed With the New Coronavirus Infection (SARS-CoV-2),Recruiting,NA,Phase 2,64,Anticipated,Universidade Federal de Sao Carlos,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:55:07Z,2020-11-01T11:55:07Z
NCT04429867,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-10,NA,NA,2020-06-11,2020-06-11,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2020-06-11,2020-06-16,Actual,"May 7, 2020",Actual,2020-05-07,June 2020,2020-06-30,"December 7, 2020",Anticipated,2020-12-07,"December 7, 2020",Anticipated,2020-12-07,NA,Interventional,NA,,Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease,Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease,"Active, not recruiting",NA,Phase 4,700,Anticipated,WellStar Health System,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:55:18Z,2020-11-01T11:55:18Z
NCT04429724,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-10,NA,NA,2020-07-16,2020-06-11,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-20,Actual,"July 6, 2020",Actual,2020-07-06,July 2020,2020-07-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,SERODRON,,Health Professional Exposure Assessment to Covid-19,Health Professional Exposure Assessment to Covid-19,Recruiting,NA,N/A,6000,Anticipated,Tourcoing Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:55:19Z,2020-11-01T11:55:19Z
NCT04429594,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-10,NA,NA,2020-10-15,2020-06-11,2020-06-12,Actual,NA,NA,NA,NA,NA,NA,2020-10-15,2020-10-19,Actual,"July 28, 2020",Actual,2020-07-28,June 2020,2020-06-30,"December 31, 2025",Anticipated,2025-12-31,"July 15, 2025",Anticipated,2025-07-15,NA,Interventional,CovImmune 2,,Study of the Incidence of SARS-CoV-2 Infection (COVID-19),Study of the Incidence of SARS-CoV-2 Infection in the Alpes-Maritimes Department by Analysis of the Specific Humoral and Cellular Response During Deconfinement,Recruiting,NA,N/A,1000,Anticipated,Centre Hospitalier Universitaire de Nice,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:55:21Z,2020-11-01T11:55:21Z
NCT04427137,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-10,NA,NA,2020-06-20,2020-06-10,2020-06-11,Actual,NA,NA,NA,NA,NA,NA,2020-06-20,2020-06-23,Actual,"June 9, 2020",Actual,2020-06-09,June 2020,2020-06-30,December 2022,Anticipated,2022-12-31,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,,Accelerated LFR for Bipolar Patients During the COVID-19 Pandemic,A Novel and Practical Accelerated Low-frequency Right-sided Stimulation Protocol as a Substitute for Patients With Bipolar Depression Needing Electroconvulsive Therapy During the COVID-19 Pandemic,Recruiting,NA,N/A,50,Anticipated,Centre for Addiction and Mental Health,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:55:36Z,2020-11-01T11:55:36Z
NCT04555005,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-11,NA,NA,2020-09-17,2020-09-17,2020-09-18,Actual,NA,NA,NA,NA,NA,NA,2020-09-17,2020-09-18,Actual,"March 10, 2020",Actual,2020-03-10,March 2020,2020-03-31,"April 26, 2020",Actual,2020-04-26,"April 26, 2020",Actual,2020-04-26,NA,Interventional,NA,,Mindfulness-based Crisis Intervention for COVID-19 Frontline Healthcare Workers During COVID-19,"Implementation of a Mindfulness-based Crisis Intervention for Frontline Healthcare Workers During the COVID-19 Outbreak in a Public General Hospital in Madrid, Spain",Completed,NA,N/A,1000,Actual,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:40:19Z,2020-11-01T11:40:19Z
NCT04435717,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-11,NA,NA,2020-06-16,2020-06-16,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2020-06-16,2020-06-17,Actual,"May 4, 2020",Actual,2020-05-04,June 2020,2020-06-30,"August 4, 2020",Anticipated,2020-08-04,"August 4, 2020",Anticipated,2020-08-04,NA,Interventional,COVITOZ-01,,Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01),"Unicenter, Randomized, Open-label Clinical Trial on the Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19",Recruiting,NA,Phase 2,78,Anticipated,Hospital Universitario Ramon y Cajal,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:54:32Z,2020-11-01T11:54:32Z
NCT04432051,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-11,NA,NA,2020-08-06,2020-06-12,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-08-06,2020-08-07,Actual,"May 26, 2020",Actual,2020-05-26,August 2020,2020-08-31,"August 10, 2020",Anticipated,2020-08-10,"August 8, 2020",Anticipated,2020-08-08,NA,Interventional,NA,,The Use of Lung Ultrasonography in COVID-19 Patients,The Significance of Lung Ultrasonography in the Follow-up and Treatment of COVID-19 Patients With Respiratory Failure,Recruiting,NA,N/A,100,Anticipated,Gaziosmanpasa Taksim Research and Education Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:55:04Z,2020-11-01T11:55:04Z
NCT04623255,"ClinicalTrials.gov processed this data on November 13, 2020",2020-06-11,NA,NA,2020-11-09,2020-11-09,2020-11-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-10,Actual,"October 16, 2020",Actual,2020-10-16,November 2020,2020-11-30,"November 1, 2021",Anticipated,2021-11-01,"October 15, 2021",Anticipated,2021-10-15,NA,Interventional,COVIPLEX,,Randomised Study of Plasma Exchange in Severe COVID-19,A Randomised Controlled Trial of Plasma Exchange With Standard of Care Compared to Standard of Care Alone in the Treatment of Severe COVID-19 Infection (COVIPLEX),Recruiting,NA,Phase 2,20,Anticipated,"University College, London",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-14T10:34:20Z,2020-11-14T10:34:20Z
NCT04441424,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-12,NA,NA,2020-06-20,2020-06-19,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-20,2020-06-23,Actual,"April 3, 2020",Actual,2020-04-03,June 2020,2020-06-30,"June 1, 2020",Actual,2020-06-01,"June 1, 2020",Actual,2020-06-01,NA,Interventional,NA,,Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients,"The Therapeutic Potential of Convalescent Plasma Therapy on Treating Critically-ill COVID-19 Patients Residing in Respiratory Care Units in Hospitals in Baghdad, Iraq",Completed,NA,N/A,49,Actual,Alkarkh Health Directorate-Baghdad,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:53:47Z,2020-11-01T11:53:47Z
NCT04433949,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-12,NA,NA,2020-06-15,2020-06-15,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-15,2020-06-16,Actual,"June 12, 2020",Actual,2020-06-12,June 2020,2020-06-30,"May 30, 2022",Anticipated,2022-05-30,"May 30, 2022",Anticipated,2022-05-30,NA,Interventional,RESCUE1-19,,Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19,Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19 (RESCUE 1-19): A Randomized Phase III of Best Supportive Care +/- Whole Lung Low-Dose Radiation Therapy in Hospitalized Patients,Recruiting,NA,Phase 3,52,Anticipated,Emory University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Results of the trial and not individual patient data will be shared. The study protocol, consent, and investigator's brochure will be available. The statistical plan is incorporated into the protocol, along with inclusion and exclusion criteria.",2020-11-01T11:54:44Z,2020-11-01T11:54:44Z
NCT04432324,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-12,NA,NA,2020-10-08,2020-06-12,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-10-08,2020-10-12,Actual,"June 2, 2020",Actual,2020-06-02,October 2020,2020-10-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19),"A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19",Recruiting,NA,Phase 2,100,Anticipated,Grifols Therapeutics LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T11:55:00Z,2020-11-01T11:55:00Z
NCT04432298,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-12,NA,NA,2020-06-22,2020-06-12,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-22,2020-06-24,Actual,"June 20, 2020",Actual,2020-06-20,June 2020,2020-06-30,January 2021,Anticipated,2021-01-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,"Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Patients With Acute COVID-19 Disease","Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of the Efficacy and Safety of Intravenous Pamrevlumab, a Monoclonal Antibody Against Connective Tissue Growth Factor (CTGF), in Hospitalized Patients With Acute COVID-19 Disease",Recruiting,NA,Phase 2,130,Anticipated,FibroGen,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:55:00Z,2020-11-01T11:55:00Z
NCT04432272,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-12,NA,NA,2020-08-20,2020-06-12,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-08-20,2020-08-21,Actual,"July 16, 2020",Actual,2020-07-16,August 2020,2020-08-31,August 2021,Anticipated,2021-08-31,June 2021,Anticipated,2021-06-30,NA,Interventional,ABACCuS,,ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS),ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS),Recruiting,NA,Phase 2,500,Anticipated,William Beaumont Hospitals,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T11:55:00Z,2020-11-01T11:55:00Z
NCT04431180,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-12,NA,NA,2020-06-12,2020-06-12,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-12,2020-06-16,Actual,"June 13, 2020",Anticipated,2020-06-13,June 2020,2020-06-30,"June 30, 2020",Anticipated,2020-06-30,"June 13, 2020",Anticipated,2020-06-13,NA,Interventional,NA,,Recruit Blood Donors Via SMS During Epidemic of COVID-19 #Second Repeat Trial#,Recruit Blood Donors Via SMS With Different Contents During Epidemic of COVID-19#Second Repeat Trial#,Enrolling by invitation,NA,N/A,403535,Anticipated,Guangzhou Blood Center,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:55:09Z,2020-11-01T11:55:09Z
NCT04431856,"ClinicalTrials.gov processed this data on November 13, 2020",2020-06-12,NA,NA,2020-11-06,2020-06-12,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"May 15, 2020",Actual,2020-05-15,November 2020,2020-11-30,"November 17, 2020",Anticipated,2020-11-17,"November 17, 2020",Anticipated,2020-11-17,NA,Interventional,Co-PARENT,,CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment,CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment,"Active, not recruiting",NA,N/A,68,Anticipated,University of Miami,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-14T10:41:22Z,2020-11-14T10:41:22Z
NCT04445272,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-13,NA,NA,2020-06-23,2020-06-23,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-23,2020-06-24,Actual,"May 22, 2020",Actual,2020-05-22,June 2020,2020-06-30,"August 22, 2020",Anticipated,2020-08-22,"August 22, 2020",Anticipated,2020-08-22,NA,Interventional,NA,,Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia,"A Multicentre, Open-label Clinical Trial to Evaluate the Effectiveness and Safety of Intravenous Tocilizumab for Treating Patients With COVID-19 Pneumonia: the BREATH-19 Study",Recruiting,NA,Phase 2,500,Anticipated,Fundacion SEIMC-GESIDA,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:53:22Z,2020-11-01T11:53:22Z
NCT04434248,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-13,NA,NA,2020-06-15,2020-06-15,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-15,2020-06-16,Actual,"April 23, 2020",Actual,2020-04-23,June 2020,2020-06-30,July 2020,Anticipated,2020-07-31,July 2020,Anticipated,2020-07-31,NA,Interventional,NA,,An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,"An Adaptive, Multicenter, Randomized, Open-label, Comparative Clinical Study to Assess Efficacy and Safety of Favipiravir in Hospitalized Patients With COVID-19","Active, not recruiting",NA,Phase 2/Phase 3,330,Actual,Chromis LLC,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:54:43Z,2020-11-01T11:54:43Z
NCT04435353,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-14,NA,NA,2020-06-16,2020-06-16,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2020-06-16,2020-06-17,Actual,"March 22, 2020",Actual,2020-03-22,June 2020,2020-06-30,"February 1, 2021",Anticipated,2021-02-01,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Assessment of the Effectiveness of Vibroacoustic Therapy for Respiratory Failure Caused by COVID 19,Assessment of the Effectiveness of Vibroacoustic Therapy for Respiratory Failure Caused by COVID 19,Recruiting,NA,N/A,200,Anticipated,Astana Medical University,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:54:36Z,2020-11-01T11:54:36Z
NCT04444674,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-15,NA,NA,2020-08-02,2020-06-22,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-08-02,2020-08-05,Actual,"June 24, 2020",Actual,2020-06-24,August 2020,2020-08-31,December 2021,Anticipated,2021-12-31,October 2020,Anticipated,2020-10-31,NA,Interventional,NA,,COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection,"An Adaptive Phase I/II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARS-CoV-2 Vaccine in South African Adults Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV",Recruiting,NA,Phase 1/Phase 2,2000,Anticipated,"University of Witwatersrand, South Africa",,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,within 1 year of trial completion,Any investigators who wish to use the data to address any specific questions not directly addressed under the study objectives and which the data would lend itself to.,NA,Yes,"The data accumulated from this study will be stored at RMPRU/ Wits. In collaboration with UK collaborators, we aim to make the data available, within one year of completion of the study to any investigators who wish to use the data to address any specific questions not directly addressed under the study objectives and which the data would lend itself to.
De-identified data will be shared. Related trial documents will be available (protocol, ICFs, statistical analysis plan)",2020-11-01T11:53:27Z,2020-11-01T11:53:27Z
NCT04435522,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-15,NA,NA,2020-09-23,2020-06-15,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-25,Actual,"September 21, 2020",Anticipated,2020-09-21,June 2020,2020-06-30,January 2021,Anticipated,2021-01-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Maraviroc in Patients With Moderate and Severe COVID-19,Open-Label Study of Maraviroc in Hospitalized Individuals Diagnosed With SARS-CoV-2,Recruiting,NA,Phase 1,16,Anticipated,Rhode Island Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:54:35Z,2020-11-01T11:54:35Z
NCT04432987,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-15,NA,NA,2020-06-15,2020-06-15,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-15,2020-06-16,Actual,"May 25, 2020",Actual,2020-05-25,May 2020,2020-05-31,"September 25, 2020",Anticipated,2020-09-25,"August 25, 2020",Anticipated,2020-08-25,NA,Interventional,NA,,Dornase Alpha for the Treatment of COVID-19,Determination of Dornase Alpha Effectiveness in COVID-19 Treatment,Recruiting,NA,Phase 2,60,Anticipated,Acibadem University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:54:52Z,2020-11-01T11:54:52Z
NCT04432805,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-15,NA,NA,2020-06-15,2020-06-15,2020-06-16,Actual,NA,NA,NA,NA,NA,NA,2020-06-15,2020-06-16,Actual,"June 15, 2020",Actual,2020-06-15,June 2020,2020-06-30,"June 15, 2021",Anticipated,2021-06-15,"June 15, 2021",Anticipated,2021-06-15,NA,Interventional,LUSCOVIDPREG,,Descriptive and Evaluation Study of the Use of Pulmonary Ultrasound in the Initial Management of Pregnant Women in the Context of COVID-19,Descriptive and Evaluation Study of the Use of Pulmonary Ultrasound in the Initial Management of Pregnant Women in the Context of COVID-19,Recruiting,NA,N/A,160,Anticipated,Assistance Publique Hopitaux De Marseille,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:54:54Z,2020-11-01T11:54:54Z
NCT04436276,"ClinicalTrials.gov processed this data on November 13, 2020",2020-06-15,NA,NA,2020-11-09,2020-06-15,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-10,Actual,"July 15, 2020",Actual,2020-07-15,November 2020,2020-11-30,"January 4, 2024",Anticipated,2024-01-04,"September 15, 2021",Anticipated,2021-09-15,NA,Interventional,NA,,A Study of Ad26.COV2.S in Adults (COVID-19),"A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older",Recruiting,NA,Phase 1/Phase 2,1045,Anticipated,Janssen Vaccines & Prevention B.V.,,5,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2020-11-14T10:41:17Z,2020-11-14T10:41:17Z
NCT04449718,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-16,NA,NA,2020-06-25,2020-06-25,2020-06-29,Actual,NA,NA,NA,NA,NA,NA,2020-06-25,2020-06-29,Actual,"June 1, 2020",Actual,2020-06-01,June 2020,2020-06-30,"November 30, 2020",Anticipated,2020-11-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,NA,,Vitamin D Supplementation in Patients With COVID-19,"Vitamin D Supplementation in Patients With COVID-19: A Randomized, Double-blind, Placebo-controlled Trial",Recruiting,NA,N/A,200,Anticipated,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:52:53Z,2020-11-01T11:52:53Z
NCT04447781,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-16,NA,NA,2020-08-18,2020-06-24,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"July 15, 2020",Actual,2020-07-15,August 2020,2020-08-31,"February 22, 2022",Anticipated,2022-02-22,"February 22, 2022",Anticipated,2022-02-22,NA,Interventional,NA,,"Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19","A Phase I/IIa, Dose-Ranging Trial to Evaluate Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers",Recruiting,NA,Phase 1/Phase 2,160,Anticipated,International Vaccine Institute,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,NA,NA,TRUE,NA,,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 3 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be anonymized and may be made available upon reasonable request.,2020-11-01T11:53:07Z,2020-11-01T11:53:07Z
NCT04445194,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-16,NA,NA,2020-06-30,2020-06-21,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-02,Actual,"June 22, 2020",Actual,2020-06-22,May 2020,2020-05-31,"September 20, 2021",Anticipated,2021-09-20,"July 21, 2021",Anticipated,2021-07-21,NA,Interventional,NA,,Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine,"A Multi-center, Double-blind, Randomized, Placebo Parallel Controlled, Safety and Tolerability Phase I Clinical Trial of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Healthy People Between 18 and 59 Years of Age",Recruiting,NA,Phase 1,50,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:53:24Z,2020-11-01T11:53:24Z
NCT04438694,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-16,NA,NA,2020-09-25,2020-06-17,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2020-09-25,2020-09-29,Actual,"June 1, 2020",Actual,2020-06-01,September 2020,2020-09-30,"December 31, 2021",Anticipated,2021-12-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,CP IN COVID19,,Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection,Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection,Recruiting,NA,Phase 1/Phase 2,67,Anticipated,Cairo University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:54:12Z,2020-11-01T11:54:12Z
NCT04437875,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-16,NA,NA,2020-08-11,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-12,Actual,"June 17, 2020",Actual,2020-06-17,June 2020,2020-06-30,"August 10, 2020",Actual,2020-08-10,"August 3, 2020",Actual,2020-08-03,NA,Interventional,NA,,"An Open Study of the Safety, Tolerability and Immunogenicity of ""Gam-COVID-Vac Lyo"" Vaccine Against COVID-19","An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac Lyo"" Lyophilizate for the Preparation of a Solution for Intramuscular Injection With the Participation of Healthy Volunteers",Completed,NA,Phase 1/Phase 2,38,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:54:17Z,2020-11-01T11:54:17Z
NCT04436471,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-16,NA,NA,2020-08-11,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-12,Actual,"June 17, 2020",Actual,2020-06-17,June 2020,2020-06-30,"August 10, 2020",Actual,2020-08-10,"August 3, 2020",Actual,2020-08-03,NA,Interventional,NA,,"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" Vaccine Against COVID-19","An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" a Solution for Intramuscular Injection With the Participation of Healthy Volunteers",Completed,NA,Phase 1/Phase 2,38,Actual,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:54:26Z,2020-11-01T11:54:26Z
NCT04435795,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-16,NA,NA,2020-10-14,2020-06-16,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"September 14, 2020",Actual,2020-09-14,October 2020,2020-10-31,"March 25, 2021",Anticipated,2021-03-25,"February 25, 2021",Anticipated,2021-02-25,NA,Interventional,CONTAIN,,Inhaled Ciclesonide for Outpatients With COVID19,Ciclesonide Clinical Trial for COVID-19 Treatment,Recruiting,NA,Phase 2/Phase 3,454,Anticipated,McGill University Health Centre/Research Institute of the McGill University Health Centre,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:54:31Z,2020-11-01T11:54:31Z
NCT04435184,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-16,NA,NA,2020-10-16,2020-06-16,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-19,Actual,"July 9, 2020",Actual,2020-07-09,July 2020,2020-07-31,"January 31, 2021",Anticipated,2021-01-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,CRITICAL,,Crizanlizumab for Treating COVID-19 Vasculopathy,Crizanlizumab for Treating COVID-19 Vasculopathy,Recruiting,NA,Phase 2,40,Anticipated,Johns Hopkins University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:54:37Z,2020-11-01T11:54:37Z
NCT04497948,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-16,NA,NA,2020-10-26,2020-07-31,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-10-26,2020-10-28,Actual,"September 21, 2020",Actual,2020-09-21,October 2020,2020-10-31,"December 14, 2020",Anticipated,2020-12-14,"December 14, 2020",Anticipated,2020-12-14,NA,Interventional,NA,,Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19,"An Open-label, Multiple-dose Study of Acalabrutinib, Co Administered With a Proton-pump Inhibitor, in Participants Hospitalized With COVID-19",Recruiting,NA,Phase 1,48,Anticipated,Acerta Pharma BV,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure,2020-11-01T13:35:14Z,2020-11-01T13:35:14Z
NCT04499677,"ClinicalTrials.gov processed this data on November 02, 2020",2020-06-16,NA,NA,2020-10-28,2020-08-03,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2020-10-28,2020-10-30,Actual,"September 24, 2020",Actual,2020-09-24,June 2020,2020-06-30,"March 1, 2021",Anticipated,2021-03-01,"December 11, 2020",Anticipated,2020-12-11,NA,Interventional,FLARE,,FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals,"Favipiravir, Lopinavir/Ritonavir or Combination Therapy: a Randomised, Double Blind, 2x2 Factorial Placebo-controlled Trial of Early Antiviral Therapy in COVID-19",Recruiting,NA,Phase 2,240,Anticipated,"University College, London",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,No plan to share IPD has been made at this time.,2020-11-03T10:51:08Z,2020-11-03T10:51:08Z
NCT04435379,"ClinicalTrials.gov processed this data on November 06, 2020",2020-06-16,NA,NA,2020-11-03,2020-06-16,2020-06-17,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-05,Actual,"June 18, 2020",Actual,2020-06-18,October 2020,2020-10-31,"September 30, 2021",Anticipated,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,NA,,Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic,"A Phase III, Randomized, Double-blind, Placebo-controlled, Multicentre, Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in the SARS-CoV-2 Pandemic by Modulating the Immune System",Recruiting,NA,Phase 3,2038,Anticipated,Vakzine Projekt Management GmbH,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,There is uncertainty whether the European Union General Data Protection Regulation allows dissemination of individual participant data to other researchers. Some reasons why the EU Regulation would not allow this are the lack of suitable safeguards when personal data are transferred to any researcher asking for it and the impairment of the rights of the subjects for erasure of their data once they are disseminated.,2020-11-09T10:53:07Z,2020-11-09T10:53:07Z
NCT04442958,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-17,NA,NA,2020-06-30,2020-06-19,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"May 15, 2020",Actual,2020-05-15,June 2020,2020-06-30,"June 17, 2020",Actual,2020-06-17,"June 15, 2020",Actual,2020-06-15,NA,Interventional,NA,,Effectiveness of Convalescent Immune Plasma Therapy,Effectiveness of Convalescent Immune Plasma Therapy in Severe COVID-19 Patients With Acute Respiratory Distress Syndrome,Completed,NA,N/A,60,Actual,Bagcilar Training and Research Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T11:53:37Z,2020-11-01T11:53:37Z
NCT04442230,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-17,NA,NA,2020-10-06,2020-06-19,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"September 29, 2020",Anticipated,2020-09-29,October 2020,2020-10-31,February 2021,Anticipated,2021-02-28,February 2021,Anticipated,2021-02-28,NA,Interventional,NA,,NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19),"Phase 2, Double-blind, Randomized, Placebo-controlled Study of NasoVAX in the Prevention of Clinical Worsening in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)",Recruiting,NA,Phase 2,96,Anticipated,"Altimmune, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:53:43Z,2020-11-01T11:53:43Z
NCT04440007,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-17,NA,NA,2020-10-12,2020-06-18,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-12,2020-10-14,Actual,"October 9, 2020",Actual,2020-10-09,October 2020,2020-10-31,March 2021,Anticipated,2021-03-31,January 2021,Anticipated,2021-01-31,NA,Interventional,SOC,,Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With SOC Versus SOC in Subjects With COVID-19,"A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With Standard of Care Versus Standard of Care in Subjects Hospitalized With COVID-19",Recruiting,NA,Phase 2,80,Anticipated,"Sorrento Therapeutics, Inc.",,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:54:00Z,2020-11-01T11:54:00Z
NCT04439071,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-17,NA,NA,2020-08-12,2020-06-17,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2020-08-12,2020-08-13,Actual,"July 9, 2020",Actual,2020-07-09,August 2020,2020-08-31,"January 30, 2021",Anticipated,2021-01-30,"January 30, 2021",Anticipated,2021-01-30,NA,Interventional,FITE19,,A Study to Evaluate Efficacy and Safety of PTC299 in Hospitalized Participants With Coronavirus (COVID-19),Evaluation of the Efficacy and Safety of PTC299 in Hospitalized Subjects With COVID-19 (FITE19),Recruiting,NA,Phase 2/Phase 3,380,Anticipated,PTC Therapeutics,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:54:10Z,2020-11-01T11:54:10Z
NCT04439006,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-17,NA,NA,2020-08-17,2020-06-18,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2020-08-17,2020-08-19,Actual,"July 22, 2020",Actual,2020-07-22,August 2020,2020-08-31,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,,Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization,Randomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-In,Recruiting,NA,Phase 2,72,Anticipated,Ohio State University Comprehensive Cancer Center,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:54:10Z,2020-11-01T11:54:10Z
NCT04438070,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-17,NA,NA,2020-06-17,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2020-06-17,2020-06-18,Actual,"April 10, 2020",Actual,2020-04-10,June 2020,2020-06-30,June 2020,Anticipated,2020-06-30,June 2020,Anticipated,2020-06-30,NA,Interventional,NA,,COVID Screening Strategies in Homeless Shelters,COVID Screening Strategies in Homeless Shelters,Recruiting,NA,N/A,400,Anticipated,St. Joseph's Healthcare Hamilton,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:54:16Z,2020-11-01T11:54:16Z
NCT04438057,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-17,NA,NA,2020-08-19,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-19,2020-08-21,Actual,"August 12, 2020",Actual,2020-08-12,August 2020,2020-08-31,"August 12, 2021",Anticipated,2021-08-12,"August 12, 2020",Actual,2020-08-12,NA,Interventional,NA,,Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19,Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19,Recruiting,NA,Phase 2,150,Anticipated,Metro Infectious Disease Consultants,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:54:16Z,2020-11-01T11:54:16Z
NCT04437823,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-17,NA,NA,2020-06-17,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2020-06-17,2020-06-18,Actual,"June 1, 2020",Actual,2020-06-01,June 2020,2020-06-30,"June 30, 2021",Anticipated,2021-06-30,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,NA,,Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients,Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients,Recruiting,NA,Phase 2,20,Anticipated,Jinnah Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,At the end of completion of the study,Available online,NA,Yes,The report will be published and available online.,2020-11-01T11:54:17Z,2020-11-01T11:54:17Z
NCT04437719,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-17,NA,NA,2020-08-12,2020-06-17,2020-06-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-12,2020-08-14,Actual,"June 29, 2020",Actual,2020-06-29,August 2020,2020-08-31,"December 31, 2021",Anticipated,2021-12-31,"December 29, 2021",Anticipated,2021-12-29,NA,Interventional,OBVIONCO,,"Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group for a Period of 6 Months During the COVID-19 Pandemic","Longitudinal Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group, Paris, France for a Period of 6 Months During the COVID-19 Pandemic in 2020",Recruiting,NA,N/A,100,Anticipated,Groupe Hospitalier Paris Saint Joseph,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:54:18Z,2020-11-01T11:54:18Z
NCT04450004,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-18,NA,NA,2020-10-21,2020-06-25,2020-06-29,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-23,Actual,"July 10, 2020",Actual,2020-07-10,October 2020,2020-10-31,"December 31, 2021",Anticipated,2021-12-31,"September 20, 2021",Anticipated,2021-09-20,NA,Interventional,NA,,"Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.","A Randomized, Partially-Blinded, Dose-Ranging Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID 19 Vaccine in Adults 18-55 Years of Age","Active, not recruiting",NA,Phase 1,180,Anticipated,Medicago,,9,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:52:50Z,2020-11-01T11:52:50Z
NCT04449276,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-18,NA,NA,2020-10-19,2020-06-23,2020-06-26,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-20,Actual,"June 18, 2020",Actual,2020-06-18,June 2020,2020-06-30,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,,"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults","COVID-19: A Phase 1, Partially Blind, Placebo-controlled, Dose-escalation, First-in-human, Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity After 1 and 2 Doses of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Healthy Adults",Recruiting,NA,Phase 1,284,Anticipated,CureVac AG,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:52:57Z,2020-11-01T11:52:57Z
NCT04444596,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-18,NA,NA,2020-06-22,2020-06-22,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-06-22,2020-06-23,Actual,"June 17, 2020",Actual,2020-06-17,April 2020,2020-04-30,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,NA,,Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19,Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19,Recruiting,NA,N/A,100,Anticipated,Medical University Innsbruck,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:53:27Z,2020-11-01T11:53:27Z
NCT04443881,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-18,NA,NA,2020-06-20,2020-06-20,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-06-20,2020-06-23,Actual,"May 8, 2020",Actual,2020-05-08,June 2020,2020-06-30,March 2021,Anticipated,2021-03-31,December 2020,Anticipated,2020-12-31,NA,Interventional,ANA-COVID-GEAS,,Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS),"Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19. A Phase 2/3, Randomized, Open-label, Parallel Group, 2-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Added to Standard of Care, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS- CoV-2 Infection",Recruiting,NA,Phase 2/Phase 3,180,Anticipated,Fundacion Miguel Servet,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,"All collected IPD will be available for exploitation in future research projects. This statement also includes the availability of the study protocol, the statistical analysis plan, the informed consent form, the clinical study report and the analytic code.",2020-11-01T11:53:31Z,2020-11-01T11:53:31Z
NCT04443673,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-18,NA,NA,2020-08-20,2020-06-19,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-08-20,2020-08-24,Actual,"August 20, 2020",Actual,2020-08-20,August 2020,2020-08-31,"June 30, 2021",Anticipated,2021-06-30,"February 28, 2021",Anticipated,2021-02-28,NA,Interventional,NA,,Glycine Supplement for Severe COVID-19,Controlled and Randomized Clinical Trial for Evaluating the Effect of a Supplement of Glycine as Adjuvant in the Treatment of COVID-19 Pneumonia in Patients Initiating Mechanical Ventilation,Recruiting,NA,N/A,82,Anticipated,Instituto Nacional de Enfermedades Respiratorias,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,From publication of results in a scientific journal onward.,Reasonable request by E-mail (mhvargasb@yahoo.com.mx),NA,Yes,IPD can be shared on a reasonable basis and after authorization from the Instituto Nacional de Enfermedades Respiratorias' IRB.,2020-11-01T11:53:33Z,2020-11-01T11:53:33Z
NCT04441632,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-18,NA,NA,2020-08-11,2020-06-18,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-12,Actual,"June 15, 2020",Actual,2020-06-15,August 2020,2020-08-31,"July 30, 2020",Actual,2020-07-30,"July 26, 2020",Actual,2020-07-26,NA,Interventional,TEAM-ICU,,Effect of Positive Attitudes on Behavior and Wellness,"The Impact of Positive Reinforcement on Teamwork Climate, Resiliency, and Burnout During the COVID-19 Pandemic: the TEAM-ICU Study (Transforming Employee Attitudes Via Messaging Strengthens Interconnection, Communication, and Unity)",Completed,NA,N/A,24,Actual,Cedars-Sinai Medical Center,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:53:46Z,2020-11-01T11:53:46Z
NCT04441385,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-18,NA,NA,2020-07-07,2020-06-18,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2020-07-07,2020-07-09,Actual,"June 26, 2020",Actual,2020-06-26,July 2020,2020-07-31,"December 20, 2020",Anticipated,2020-12-20,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,MARACOVID,,Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).,"Bicentric, Phase 2, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc Associated With Standard Treatment in Hospitalized Patients With Pulmonary SARS-CoV-2 Infection (COVID-19).",Recruiting,NA,Phase 2,200,Anticipated,Hospital Universitario Infanta Leonor,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T11:53:48Z,2020-11-01T11:53:48Z
NCT04438980,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-18,NA,NA,2020-06-18,2020-06-18,2020-06-19,Actual,NA,NA,NA,NA,NA,NA,2020-06-18,2020-06-22,Actual,"May 15, 2020",Actual,2020-05-15,June 2020,2020-06-30,February 2021,Anticipated,2021-02-28,December 2020,Anticipated,2020-12-31,NA,Interventional,CORTIVID,,Glucocorticoids in COVID-19 (CORTIVID),Treatment of COVID-19 Pneumonia With Glucocorticoids. A Randomized Controlled Trial,Recruiting,NA,Phase 3,72,Anticipated,Fundacion Miguel Servet,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,"All collected IPD will be available for exploitation in future research projects. This statement also includes the availability of the study protocol, the statistical analysis plan, the informed consent form, the clinical study report and the analytic code.",2020-11-01T11:54:10Z,2020-11-01T11:54:10Z
NCT04445454,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-19,NA,NA,2020-06-22,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-22,2020-06-24,Actual,"June 12, 2020",Actual,2020-06-12,June 2020,2020-06-30,"September 30, 2022",Anticipated,2022-09-30,"September 30, 2022",Anticipated,2022-09-30,NA,Interventional,NA,,Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection,Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection,Recruiting,NA,Phase 1/Phase 2,20,Anticipated,University of Liege,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:53:21Z,2020-11-01T11:53:21Z
NCT04445389,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-19,NA,NA,2020-07-24,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-24,2020-07-28,Actual,"June 17, 2020",Actual,2020-06-17,July 2020,2020-07-31,"June 17, 2022",Anticipated,2022-06-17,"March 17, 2021",Anticipated,2021-03-17,NA,Interventional,NA,,"Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults","A Phase 1/2a, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Subjects",Recruiting,NA,Phase 1/Phase 2,210,Anticipated,"Genexine, Inc.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:53:22Z,2020-11-01T11:53:22Z
NCT04445311,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-19,NA,NA,2020-06-19,2020-06-19,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-19,2020-06-24,Actual,"May 31, 2020",Actual,2020-05-31,June 2020,2020-06-30,"August 15, 2020",Anticipated,2020-08-15,"July 30, 2020",Anticipated,2020-07-30,NA,Interventional,NA,,Ivermectin in Treatment of COVID-19,Use of Ivermectin as a Therapeutic Option for Patients With COVID-19,Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Zagazig University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:53:22Z,2020-11-01T11:53:22Z
NCT04442178,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-19,NA,NA,2020-10-08,2020-06-19,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2020-10-08,2020-10-12,Actual,"September 15, 2020",Actual,2020-09-15,June 2020,2020-06-30,"March 31, 2021",Anticipated,2021-03-31,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,ILIAD-7-US-I,,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ),"A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection. US Infectious Cohort",Recruiting,NA,Phase 2,48,Anticipated,Revimmune,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Publication,2020-11-01T11:53:43Z,2020-11-01T11:53:43Z
NCT04442152,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-19,NA,NA,2020-06-19,2020-06-19,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2020-06-19,2020-06-22,Actual,June 2020,Anticipated,2020-06-30,June 2020,2020-06-30,August 2020,Anticipated,2020-08-31,August 2020,Anticipated,2020-08-31,NA,Interventional,NA,,Impact of COVID-19 on Family Dynamics on Bandebereho Study Participants,Phone Survey for Understanding the Impact of COVID-19 on Caregiving and Family Dynamics on Bandebereho Study Participants,Enrolling by invitation,NA,N/A,1000,Anticipated,"Promundo, United States",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:53:43Z,2020-11-01T11:53:43Z
NCT04441996,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-19,NA,NA,2020-07-19,2020-06-19,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2020-07-19,2020-07-22,Actual,"July 17, 2020",Actual,2020-07-17,July 2020,2020-07-31,October 2020,Anticipated,2020-10-31,October 2020,Anticipated,2020-10-31,NA,Interventional,NA,,Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity,Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity,Enrolling by invitation,NA,Phase 4,20,Anticipated,Emory University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:53:44Z,2020-11-01T11:53:44Z
NCT04442048,"ClinicalTrials.gov processed this data on November 13, 2020",2020-06-19,NA,NA,2020-11-09,2020-06-19,2020-06-22,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-10,Actual,"June 25, 2020",Actual,2020-06-25,November 2020,2020-11-30,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,COV-IMMUNO,,Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure,"COV-IMMUNO: A Randomized, Phase III Trial of Immunization With IMM-101 Versus Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure",Recruiting,NA,Phase 3,1500,Anticipated,Canadian Cancer Trials Group,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-14T10:41:11Z,2020-11-14T10:41:11Z
NCT04466683,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-20,NA,NA,2020-09-23,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-25,Actual,"August 28, 2020",Actual,2020-08-28,September 2020,2020-09-30,"December 31, 2022",Anticipated,2022-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,PREVENT,,Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia,Phase II Protocol of Low-Dose Whole Thorax Megavoltage Radiotherapy for Patients With SARS-COV-2 Pneumonia,Recruiting,NA,Phase 2,100,Anticipated,Ohio State University Comprehensive Cancer Center,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T11:50:47Z,2020-11-01T11:50:47Z
NCT04446429,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-22,NA,NA,2020-07-28,2020-06-23,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-29,Actual,"July 2, 2020",Actual,2020-07-02,July 2020,2020-07-31,"January 31, 2021",Anticipated,2021-01-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Anti-Androgen Treatment for COVID-19,Anti-Androgen Treatment for COVID-19,Recruiting,NA,N/A,381,Anticipated,"Applied Biology, Inc.",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:53:15Z,2020-11-01T11:53:15Z
NCT04473274,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-22,NA,NA,2020-07-17,2020-07-14,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-07-17,2020-07-20,Actual,"May 21, 2020",Actual,2020-05-21,July 2020,2020-07-31,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,GOTCHA,,"GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study","GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study",Recruiting,NA,Phase 4,20,Anticipated,Samaritan Health Services,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:50:01Z,2020-11-01T11:50:01Z
NCT04453384,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-22,NA,NA,2020-09-14,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2020-09-14,2020-09-16,Actual,"September 1, 2020",Actual,2020-09-01,June 2020,2020-06-30,December 2021,Anticipated,2021-12-31,November 2020,Anticipated,2020-11-30,NA,Interventional,POLYCOR,,Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia,"A Randomized, Double-blind, Placebo-controlled Phase 2 (2a and 2b) Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia",Recruiting,NA,Phase 2,368,Anticipated,Nantes University Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:52:26Z,2020-11-01T11:52:26Z
NCT04447235,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-22,NA,NA,2020-07-28,2020-06-23,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-29,Actual,"July 23, 2020",Actual,2020-07-23,June 2020,2020-06-30,February 2021,Anticipated,2021-02-28,December 2020,Anticipated,2020-12-31,NA,Interventional,TITAN,,Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection,"Randomized, Doubled-blind Phase II Trial Evaluating the Use of Ivermectin Plus Losartan for Prophylaxis of Severe Events in Cancer Patients With Recent Diagnosis of COVID-19",Recruiting,NA,Phase 2,176,Anticipated,Instituto do Cancer do Estado de SÃ£o Paulo,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,no plan to share individual participant data,2020-11-01T11:53:10Z,2020-11-01T11:53:10Z
NCT04445597,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-22,NA,NA,2020-06-22,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-22,2020-06-24,Actual,"May 7, 2020",Actual,2020-05-07,June 2020,2020-06-30,"June 30, 2020",Anticipated,2020-06-30,"June 30, 2020",Anticipated,2020-06-30,NA,Interventional,NA,,Unraveling the Mechanisms of Olfactory Dysfunction in COVID-19,Unraveling the Mechanisms of Olfactory Dysfunction in COVID-19,Recruiting,NA,N/A,8,Anticipated,Universitaire Ziekenhuizen Leuven,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:53:20Z,2020-11-01T11:53:20Z
NCT04445467,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-22,NA,NA,2020-08-16,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-08-16,2020-08-19,Actual,"August 1, 2020",Actual,2020-08-01,June 2020,2020-06-30,November 2020,Anticipated,2020-11-30,November 2020,Anticipated,2020-11-30,NA,Interventional,VIRCO,,An Adaptive Clinical Trial of Antivirals for COVID-19 Infection,An Adaptive Randomised Placebo Controlled Phase II Trial of Antivirals for COVID-19 Infection,Recruiting,NA,Phase 2,190,Anticipated,Bayside Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:53:21Z,2020-11-01T11:53:21Z
NCT04445428,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-22,NA,NA,2020-07-15,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-16,Actual,"July 15, 2020",Actual,2020-07-15,July 2020,2020-07-31,June 2021,Anticipated,2021-06-30,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,,OPV as Potential Protection Against COVID-19,Oral Polio Vaccine as Potential Protection Against COVID-19: A Cluster-randomised Trial in Guinea-Bissau,Enrolling by invitation,NA,Phase 4,3400,Anticipated,Bandim Health Project,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Provided request, data can be made available",2020-11-01T11:53:22Z,2020-11-01T11:53:22Z
NCT04445376,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-22,NA,NA,2020-10-06,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"July 3, 2020",Actual,2020-07-03,October 2020,2020-10-31,"October 3, 2020",Actual,2020-10-03,"September 10, 2020",Actual,2020-09-10,NA,Interventional,NA,,Effect of Physical Therapy Exercises on Cardiorespiratory Fitness Level in COVID19 Patients After Recovery.,Effect of Aerobic Exercises on Cardio-respiratory Fitness and Quality of Life in Recovered COVID 19 Recovered Patients.,Completed,NA,N/A,20,Actual,Government College University Faisalabad,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:53:22Z,2020-11-01T11:53:22Z
NCT04445324,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-22,NA,NA,2020-10-01,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-10-01,2020-10-05,Actual,"August 25, 2020",Actual,2020-08-25,October 2020,2020-10-31,December 2020,Anticipated,2020-12-31,"August 25, 2020",Actual,2020-08-25,NA,Interventional,NA,,Effects of Online and Recovery-oriented Peer Support Groups Facilitated by Peer Support Workers in Times of COVID-19,Effects of Online and Recovery-oriented Peer Support Groups Facilitated by Peer Support Workers in Times of COVID-19 : A Feasibility Study of a Trial,"Active, not recruiting",NA,N/A,30,Actual,Centre de Recherche de l'Institut Universitaire en santÃ© Mentale de MontrÃ©al,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:53:22Z,2020-11-01T11:53:22Z
NCT04445285,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-22,NA,NA,2020-08-19,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-08-19,2020-08-21,Actual,"April 28, 2020",Actual,2020-04-28,August 2020,2020-08-31,"February 28, 2021",Anticipated,2021-02-28,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,DAMPENCOVID,,Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure,Double Blind Randomized Phase 2 Placebo Controlled Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure,Recruiting,NA,Phase 2,44,Anticipated,University of South Alabama,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:53:22Z,2020-11-01T11:53:22Z
NCT04444700,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-22,NA,NA,2020-08-17,2020-06-22,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-08-17,2020-08-19,Actual,"July 4, 2020",Actual,2020-07-04,June 2020,2020-06-30,"December 31, 2020",Anticipated,2020-12-31,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,RAPID-BRAZIL,,A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic,UtilizaÃ§Ã£o da Enoxaparina em Dose Anticoagulante em Pacientes Hospitalizados Com sÃ­ndrome respiratÃ³ria Aguda Grave Por COVID-19,Recruiting,NA,Phase 3,462,Anticipated,University of Sao Paulo General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:53:27Z,2020-11-01T11:53:27Z
NCT04456361,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-23,NA,NA,2020-08-03,2020-06-30,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2020-08-03,2020-08-04,Actual,"April 16, 2020",Actual,2020-04-16,June 2020,2020-06-30,"December 15, 2020",Anticipated,2020-12-15,"October 15, 2020",Anticipated,2020-10-15,NA,Interventional,NA,,Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19,A Study of Mesenchymal Stem Cells as a Treatment in Patients With Acute Respiratory Distress Syndrome Caused by COVID-19,"Active, not recruiting",NA,Early Phase 1,9,Anticipated,Instituto de Medicina Regenerativa,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:52:01Z,2020-11-01T11:52:01Z
NCT04448769,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-23,NA,NA,2020-08-18,2020-06-25,2020-06-26,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"June 26, 2020",Actual,2020-06-26,August 2020,2020-08-31,"July 24, 2020",Actual,2020-07-24,"July 24, 2020",Actual,2020-07-24,NA,Interventional,COVAL-NANCY,,Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19),Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19) in the Population of the Grand Nancy Metropolitan Area,Completed,NA,N/A,2006,Actual,"Central Hospital, Nancy, France",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-11-01T11:53:00Z,2020-11-01T11:53:00Z
NCT04447534,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-23,NA,NA,2020-08-14,2020-06-23,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2020-08-14,2020-08-17,Actual,"June 23, 2020",Actual,2020-06-23,August 2020,2020-08-31,"October 1, 2020",Anticipated,2020-10-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,NA,,Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19,Does Zinc Supplementation Enhance the Clinical Efficacy of Chloroquine/Hydroxychloroquine in Treatment of COVID-19?,Recruiting,NA,Phase 3,200,Anticipated,Tanta University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:53:08Z,2020-11-01T11:53:08Z
NCT04447469,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-23,NA,NA,2020-10-06,2020-06-24,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"July 27, 2020",Actual,2020-07-27,October 2020,2020-10-31,April 2021,Anticipated,2021-04-30,February 2021,Anticipated,2021-02-28,NA,Interventional,NA,,Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation,"A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Mavrilimumab (KPL-301) Treatment in Adult Subjects Hospitalized With Severe COVID-19 Pneumonia and Hyper-inflammation",Recruiting,NA,Phase 2/Phase 3,573,Anticipated,"Kiniksa Pharmaceuticals, Ltd.",,6,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,IPD requests will be accepted after publication of the primary data manuscript,"IPD access will be provided to qualified academic researchers pending the Sponsor's review of the proposed research, including scientific novelty, review of the analytical and publication plans, funding source of the proposed research, any potential conflicts of interest, and institutional capabilities to perform the planned research.",NA,Yes,The Sponsor will review IPD requests proposals from qualified researchers,2020-11-01T11:53:08Z,2020-11-01T11:53:08Z
NCT04447404,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-23,NA,NA,2020-09-29,2020-06-23,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2020-09-29,2020-09-30,Actual,"September 21, 2020",Actual,2020-09-21,September 2020,2020-09-30,October 2021,Anticipated,2021-10-31,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,,DUR-928 in Subjects With SARS-CoV-2 With Acute Liver or Kidney Injury,"A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Safety and Efficacy of DUR-928 in Subjects Infected With SARS-CoV-2 With Acute Liver or Kidney Injury",Recruiting,NA,Phase 2,80,Anticipated,Durect,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:53:09Z,2020-11-01T11:53:09Z
NCT04445935,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-23,NA,NA,2020-06-23,2020-06-23,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-23,2020-06-24,Actual,"June 28, 2020",Anticipated,2020-06-28,June 2020,2020-06-30,"March 28, 2021",Anticipated,2021-03-28,"September 28, 2020",Anticipated,2020-09-28,NA,Interventional,NA,,Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial,Anticoagulation in Patients Suffering From COVID-19 Disease-The Anti-Co Trial,Recruiting,NA,Phase 4,100,Anticipated,Hamad Medical Corporation,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,this will depend on IRB advice,2020-11-01T11:53:18Z,2020-11-01T11:53:18Z
NCT04446377,"ClinicalTrials.gov processed this data on November 06, 2020",2020-06-23,NA,NA,2020-11-03,2020-06-23,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-04,Actual,"July 15, 2020",Actual,2020-07-15,June 2020,2020-06-30,"April 30, 2021",Anticipated,2021-04-30,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,NA,,A Study of LAM-002A for the Prevention of Progression of COVID-19,"A Phase II Randomized, Double-Blind, Placebo-Controlled Study of LAM-002A for the Prevention of Progression of COVID-19",Recruiting,NA,Phase 2,142,Anticipated,"AI Therapeutics, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-08T11:34:11Z,2020-11-08T11:34:11Z
NCT04449380,"ClinicalTrials.gov processed this data on November 13, 2020",2020-06-23,NA,NA,2020-11-06,2020-06-25,2020-06-26,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-10,Actual,"November 2, 2020",Actual,2020-11-02,November 2020,2020-11-30,June 2021,Anticipated,2021-06-30,April 2021,Anticipated,2021-04-30,NA,Interventional,INTERCOP,,Clinical Study for the Treatment With Interferon-ÃŸ-1a (IFNÃŸ-1a) of COVID-19 Patients,"Randomized, Controlled, Open Label, Phase 2 Clinical Trial of Interferon-Î²-1a (IFNÎ²-1a) in COVID-19 Patients",Recruiting,NA,Phase 2,126,Anticipated,IRCCS San Raffaele,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-14T10:41:02Z,2020-11-14T10:41:02Z
NCT04448119,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-24,NA,NA,2020-10-22,2020-06-24,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2020-10-22,2020-10-23,Actual,"October 16, 2020",Actual,2020-10-16,October 2020,2020-10-31,March 2021,Anticipated,2021-03-31,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,,Control of COVID-19 Outbreaks in Long Term Care,Control of COVID-19 Outbreaks in Long Term Care (CONTROL-COVID),Recruiting,NA,Phase 2,760,Anticipated,Appili Therapeutics Inc.,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:53:05Z,2020-11-01T11:53:05Z
NCT04458363,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-25,NA,NA,2020-07-02,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-02,2020-07-07,Actual,July 2020,Anticipated,2020-07-31,July 2020,2020-07-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,,Convalescent Plasma in Pediatric COVID-19,Convalescent Plasma to Optimize Treatment of COVID-19 Disease in Pediatric Patients: A Feasibility Study,Recruiting,NA,Early Phase 1,50,Anticipated,Emory University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:51:45Z,2020-11-01T11:51:45Z
NCT04455815,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-25,NA,NA,2020-10-02,2020-07-01,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2020-10-02,2020-10-06,Actual,"September 25, 2020",Actual,2020-09-25,October 2020,2020-10-31,"August 31, 2021",Anticipated,2021-08-31,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,NA,,A Trial Looking at the Use of Camostat to Reduce Progression of Symptoms of Coronavirus (COVID-19) in People Who Have Tested Positive But Are Able to Stay at Home,"A Randomised Phase II/III Trial in a Community Setting, Assessing Use of Camostat in Reducing the Clinical Progression of COVID-19 by Blocking SARS-CoV-2 Spike Protein-initiated Membrane Fusion",Recruiting,NA,Phase 2/Phase 3,389,Anticipated,Cancer Research UK,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:52:07Z,2020-11-01T11:52:07Z
NCT04452773,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-25,NA,NA,2020-07-14,2020-06-29,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-14,2020-07-15,Actual,"July 14, 2020",Actual,2020-07-14,July 2020,2020-07-31,December 2021,Anticipated,2021-12-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Clinical Trial to Evaluate the Efficacy of Food Supplement ManremycÂ® Against SARS- COV-2 Infection (COVID-19) in Healthcare Workers,"Double-blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of the ManremycÂ® Food Supplement to Prevent SARS-CoV-2 Infection",Recruiting,NA,N/A,315,Anticipated,Reig Jofre Group,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:52:29Z,2020-11-01T11:52:29Z
NCT04448756,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-25,NA,NA,2020-10-07,2020-06-25,2020-06-26,Actual,NA,NA,NA,NA,NA,NA,2020-10-07,2020-10-08,Actual,"July 29, 2020",Actual,2020-07-29,October 2020,2020-10-31,"November 13, 2020",Anticipated,2020-11-13,"November 13, 2020",Anticipated,2020-11-13,NA,Interventional,ANEMONE,,M5049 Study in Participants With Coronavirus Disease 2019 (COVID-19) Pneumonia,"A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of M5049 in Hospitalized Participants With COVID-19 Pneumonia",Recruiting,NA,Phase 2,150,Anticipated,EMD Serono,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html",2020-11-01T11:53:00Z,2020-11-01T11:53:00Z
NCT04464486,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-26,NA,NA,2020-07-08,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2020-07-08,2020-07-09,Actual,"April 21, 2020",Actual,2020-04-21,July 2020,2020-07-31,"May 31, 2021",Anticipated,2021-05-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,NA,,Remote COVID-19 Symptom Tracking for Cancer Patients at Home During the Pandemic,Remote COVID-19 Symptom Tracking and Improved Cancer Symptom Control for Cancer Patients at Home During the Pandemic,Enrolling by invitation,NA,N/A,300,Anticipated,University of Utah,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,After acceptance of the main findings publications in peer reviewed scientific journals.,"Data will be available to address research questions/hypothesis of the request. Once the Principal Investigator reviews the research question proposed, the data elements that can address the question will be shared.",NA,Yes,Secondary data analysis and use by other investigators is welcomed once the proposed aims have been analyzed and published. PI Mooney will share de-identified data with other investigators for study by proposing aims/hypotheses and identifying the data elements required and receiving agreement from the research team. Data will be shared with investigators working under an institution with a Federal Wide Assurance (FWA). The research team agrees to share data in a manner that is fully consistent with the data sharing policies of NIH and the University of Utah as well as applicable laws and regulations.,2020-11-01T11:51:05Z,2020-11-01T11:51:05Z
NCT04463264,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-26,NA,NA,2020-10-07,2020-07-07,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-07,2020-10-08,Actual,"June 26, 2020",Actual,2020-06-26,June 2020,2020-06-30,"December 26, 2020",Anticipated,2020-12-26,"November 15, 2020",Anticipated,2020-11-15,NA,Interventional,NA,,Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19),"Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoC-2 Virus Infection (COVID-19). A Pilot, Randomized, Simple Blind, Placebo-controlled, Parallel-group Study",Recruiting,NA,Phase 2/Phase 3,135,Anticipated,Laboratorios Roemmers S.A.I.C.F.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:51:12Z,2020-11-01T11:51:12Z
NCT04455360,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-26,NA,NA,2020-10-20,2020-07-01,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2020-10-20,2020-10-22,Actual,"October 1, 2020",Actual,2020-10-01,July 2020,2020-07-31,September 2021,Anticipated,2021-09-30,March 2021,Anticipated,2021-03-31,NA,Interventional,Cov-EMERALD,,Early EMDR Following Covid-19 Critical Illness: A Feasibility Trial,EMERALD: Can a Virtual Eye Movement Desensitisation and Reprocessing Intervention Improve Psychological Outcome Following Covid-19 Related Critical Illness: A Feasibility Trial,Recruiting,NA,N/A,26,Anticipated,University Hospital Southampton NHS Foundation Trust,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:52:13Z,2020-11-01T11:52:13Z
NCT04454606,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-26,NA,NA,2020-06-30,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"May 1, 2020",Actual,2020-05-01,June 2020,2020-06-30,"May 31, 2020",Actual,2020-05-31,"May 15, 2020",Actual,2020-05-15,NA,Interventional,NA,,The New Silicone N99 Half-Piece Respirator,The New Silicone N99 Half-Piece Respirator:VJR-NMU N99:New and Effective Tool to Prevent COVID-19,Completed,NA,N/A,43,Actual,Bangkok Metropolitan Administration Medical College and Vajira Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:52:17Z,2020-11-01T11:52:17Z
NCT04452565,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-26,NA,NA,2020-09-04,2020-06-26,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2020-09-04,2020-09-07,Actual,"October 15, 2020",Anticipated,2020-10-15,July 2020,2020-07-31,"February 15, 2021",Anticipated,2021-02-15,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NATADEX,,"NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection","Randomized Controlled Phase 2/3 Clinical Trial of NA-831 Alone or With Atazanavir, or NA-831 With Dexamethasone, or Atazanavir With Dexamethasone in the Treatment of COVID-19 Infection",Recruiting,NA,Phase 2/Phase 3,525,Anticipated,"NeuroActiva, Inc.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:52:32Z,2020-11-01T11:52:32Z
NCT04451174,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-26,NA,NA,2020-10-16,2020-06-26,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-20,Actual,"June 23, 2020",Actual,2020-06-23,October 2020,2020-10-31,"December 30, 2020",Anticipated,2020-12-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,PREDCOVID,,Early Use of Corticosteroids in Non-critical Patients With COVID-19 Pneumonia,Early Use of Corticosteroids in Non-critical Patients With COVID-19 Pneumonia (PREDCOVID),Recruiting,NA,Phase 3,184,Anticipated,University of Chile,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,starting 6 months after publication,NA,NA,Yes,NA,2020-11-01T11:52:40Z,2020-11-01T11:52:40Z
NCT04449588,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-26,NA,NA,2020-07-24,2020-06-26,2020-06-29,Actual,NA,NA,NA,NA,NA,NA,2020-07-24,2020-07-27,Actual,"July 23, 2020",Actual,2020-07-23,June 2020,2020-06-30,"August 7, 2022",Anticipated,2022-08-07,"August 7, 2021",Anticipated,2021-08-07,NA,Interventional,NA,,Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS,"A Multi-center, Open-label, Randomized Parallel Controlled Evaluation on the Efficacy and Safety of BDB-001 Injection in the Treatment of Progressive Severe COVID-19 in Phase II/III",Recruiting,NA,Phase 2/Phase 3,368,Anticipated,"Staidson (Beijing) Biopharmaceuticals Co., Ltd",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:52:55Z,2020-11-01T11:52:55Z
NCT04453657,"ClinicalTrials.gov processed this data on November 06, 2020",2020-06-26,NA,NA,2020-11-02,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,December 2020,Anticipated,2020-12-31,October 2020,2020-10-31,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,,"Tele-Wellness Supported App for Family Child Care Home Providers and Families to Promote Health, Family Engagement, and School Readiness Amid COVID-19","Adapting and Delivering a Tele-Wellness Supported Digital Toolkit to Baltimore City's Approved Family Child Care Home Providers Caring for Children of Essential Workers: Promoting Health, Early Literacy, and Quality Parent Engagement Amid COVID-19: A Pilot Study",Enrolling by invitation,NA,N/A,270,Anticipated,Johns Hopkins University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-07T11:22:11Z,2020-11-07T11:22:11Z
NCT04452318,"ClinicalTrials.gov processed this data on November 13, 2020",2020-06-26,NA,NA,2020-11-09,2020-06-26,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-10,Actual,"July 13, 2020",Actual,2020-07-13,November 2020,2020-11-30,"August 15, 2021",Anticipated,2021-08-15,"June 15, 2021",Anticipated,2021-06-15,NA,Interventional,NA,,Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2",Recruiting,NA,Phase 3,2000,Anticipated,Regeneron Pharmaceuticals,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency [EMA], Pharmaceuticals and Medical Devices Agency [PMDA], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://vivli.org/,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2020-11-14T10:40:58Z,2020-11-14T10:40:58Z
NCT04464408,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-28,NA,NA,2020-09-08,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-08,2020-09-09,Actual,"July 23, 2020",Actual,2020-07-23,September 2020,2020-09-30,June 2021,Anticipated,2021-06-30,December 2020,Anticipated,2020-12-31,NA,Interventional,Avi-Mild,,Favipiravir Therapy in Adults With Mild COVID-19,A Trial of Favipiravir Therapy in Adults With Mild Coronavirus Disease COVID-19,Recruiting,NA,Phase 2/Phase 3,576,Anticipated,King Abdullah International Medical Research Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:51:05Z,2020-11-01T11:51:05Z
NCT04525742,"ClinicalTrials.gov processed this data on November 06, 2020",2020-06-28,NA,NA,2020-10-31,2020-08-23,2020-08-25,Actual,NA,NA,NA,NA,NA,NA,2020-10-31,2020-11-03,Actual,"July 5, 2020",Actual,2020-07-05,October 2020,2020-10-31,"September 15, 2020",Actual,2020-09-15,"August 30, 2020",Actual,2020-08-30,NA,Interventional,NA,,COVID-19 Pandemic and Parents of Disabled Children,COVID-19 Pandemic From the Perspective of Parents of Disabled Children,Completed,NA,N/A,309,Actual,Gaziosmanpasa Taksim Research and Education Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Research is planned to bu conducted between June 15 th and July 15 th 2020. After 15 th of July in 1 week coming statistical analysis will be finished and than in 3 weeks article will be written,In necessary cases colleced data from the research will be shared with the local ethical committe,NA,Yes,Study protocol was established by Berrin Huner and Ebru Yilmaz YalcÄ±nkaya Statistical analysis (Power analysis) was established by Ozden Ozyemisci Taskiran Informed consent was written by Berrin Huner,2020-11-07T11:19:47Z,2020-11-07T11:19:47Z
NCT04469621,"ClinicalTrials.gov processed this data on November 13, 2020",2020-06-28,NA,NA,2020-11-10,2020-07-12,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-13,Estimate,"July 17, 2020",Actual,2020-07-17,November 2020,2020-11-30,"October 23, 2020",Actual,2020-10-23,"October 23, 2020",Actual,2020-10-23,NA,Interventional,NA,,A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19,"A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Immunomodulatory Effect of the RIPK1 Inhibitor SAR443122 in Hospitalized Patients With Severe COVID-19",Completed,NA,Phase 1,68,Actual,Sanofi,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2020-11-15T10:58:16Z,2020-11-15T10:58:16Z
NCT04479163,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-29,NA,NA,2020-08-03,2020-07-19,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-08-03,2020-08-05,Actual,"June 4, 2020",Actual,2020-06-04,July 2020,2020-07-31,"July 30, 2020",Anticipated,2020-07-30,"July 30, 2020",Anticipated,2020-07-30,NA,Interventional,NA,,Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2,Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2.,Recruiting,NA,N/A,210,Anticipated,Fundacion Infant,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:49:18Z,2020-11-01T11:49:18Z
NCT04459455,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-29,NA,NA,2020-10-19,2020-07-05,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-20,Actual,"August 19, 2020",Actual,2020-08-19,October 2020,2020-10-31,"October 15, 2020",Actual,2020-10-15,"October 15, 2020",Actual,2020-10-15,NA,Interventional,NA,,"Project H-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic","Project HF-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic",Completed,NA,N/A,500,Actual,Stony Brook University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:51:37Z,2020-11-01T11:51:37Z
NCT04458298,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-29,NA,NA,2020-08-28,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-08-28,2020-08-31,Actual,"July 1, 2020",Actual,2020-07-01,August 2020,2020-08-31,"November 10, 2020",Anticipated,2020-11-10,"October 10, 2020",Anticipated,2020-10-10,NA,Interventional,PRANA,,A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients,"A Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of OP-101 (Dendrimer N-acetyl-cysteine) in Patients With Severe COVID-19",Recruiting,NA,Phase 2,24,Anticipated,"Orpheris, Inc.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:51:45Z,2020-11-01T11:51:45Z
NCT04453475,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-29,NA,NA,2020-08-26,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2020-08-26,2020-08-27,Actual,"July 1, 2020",Actual,2020-07-01,August 2020,2020-08-31,"December 31, 2021",Anticipated,2021-12-31,"July 31, 2021",Anticipated,2021-07-31,NA,Interventional,AnhandCOV19,,Feasibility and Benefits of Digital Services During the COVID19 Pandemic,Therapies to Achieve Treatment Goals While Being Exposed to Hygiene and Distance Rules: Feasibility and Benefits of Digital Services During the COVID19 Pandemic (Anhand-COVID19),Recruiting,NA,N/A,1230,Anticipated,Jacobs University Bremen gGmbH,,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Individual participant data (IPD) will not be published. Other researchers are welcome to get in contact with the PI to get access to anonymous data.,2020-11-01T11:52:25Z,2020-11-01T11:52:25Z
NCT04452435,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-29,NA,NA,2020-10-19,2020-06-29,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-20,Actual,"July 21, 2020",Actual,2020-07-21,October 2020,2020-10-31,"October 13, 2020",Actual,2020-10-13,"October 13, 2020",Actual,2020-10-13,NA,Interventional,NA,,Safety and Efficacy of C21 in Subjects With COVID-19,"A Randomised, Double-blind, Placebo-controlled, Phase 2 Trial Investigating the Safety and Efficacy of C21 in Hospitalised Subjects With COVID-19 Infection Not Requiring Mechanical Ventilation",Completed,NA,Phase 2,106,Actual,Vicore Pharma AB,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:52:33Z,2020-11-01T11:52:33Z
NCT04451889,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-29,NA,NA,2020-07-22,2020-06-29,2020-06-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-22,2020-07-24,Actual,"August 1, 2020",Anticipated,2020-08-01,June 2020,2020-06-30,"September 1, 2021",Anticipated,2021-09-01,"July 1, 2021",Anticipated,2021-07-01,NA,Interventional,NA,,Probe-based Confocal Laser Endomicroscopy in Critically Ill COVID-19 Patients,Probe-based Confocal Laser Endomicroscopy in Critically Ill COVID-19 Patients,Recruiting,NA,N/A,15,Anticipated,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,There is no current plan to share individual participant data (IPD).,2020-11-01T11:52:36Z,2020-11-01T11:52:36Z
NCT04456153,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-30,NA,NA,2020-07-28,2020-06-30,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-30,Actual,"July 22, 2020",Actual,2020-07-22,July 2020,2020-07-31,March 2021,Anticipated,2021-03-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Atovaquone for Treatment of COVID-19,Atovaquone for Treatment of COVID-19,Recruiting,NA,Phase 2,60,Anticipated,University of Texas Southwestern Medical Center,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2020-11-01T11:52:03Z,2020-11-01T11:52:03Z
NCT04457388,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-30,NA,NA,2020-07-07,2020-06-30,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-07,2020-07-08,Actual,"March 25, 2020",Actual,2020-03-25,July 2020,2020-07-31,"June 15, 2020",Actual,2020-06-15,"June 15, 2020",Actual,2020-06-15,NA,Interventional,NA,,Tele-Yoga Therapy for Chronic Pain,Tele- Yoga Therapy for Patients With Chronic Pain During Covid-19 Lockdown: A Prospective Non-randomized Single Arm Clinical Trial,Completed,NA,N/A,18,Actual,Aarogyam UK,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:51:50Z,2020-11-01T11:51:50Z
NCT04457349,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-30,NA,NA,2020-09-06,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-09-06,2020-09-09,Actual,"July 25, 2020",Actual,2020-07-25,September 2020,2020-09-30,"December 29, 2020",Anticipated,2020-12-29,"November 29, 2020",Anticipated,2020-11-29,NA,Interventional,NA,,Therapeutic Plasma Exchange in Resistant Cytokine Storm of COVID 19,Does Therapeutic Plasma Exchange Have A Role in Resistant Cytokine Storm State Of COVID-19 Infection?,Recruiting,NA,N/A,10,Anticipated,Alexandria University,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:51:50Z,2020-11-01T11:51:50Z
NCT04456595,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-30,NA,NA,2020-10-19,2020-06-30,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-20,Actual,"July 21, 2020",Actual,2020-07-21,October 2020,2020-10-31,October 2021,Anticipated,2021-10-31,September 2021,Anticipated,2021-09-30,NA,Interventional,PROFISCOV,,Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals,"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy and Safety in Healthcare Professionals of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac",Recruiting,NA,Phase 3,13060,Anticipated,Butantan Institute,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:51:59Z,2020-11-01T11:51:59Z
NCT04456452,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-30,NA,NA,2020-09-28,2020-06-30,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-30,Actual,"July 27, 2020",Actual,2020-07-27,September 2020,2020-09-30,"November 13, 2020",Anticipated,2020-11-13,"September 8, 2020",Actual,2020-09-08,NA,Interventional,NA,,Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation,A Randomized Controlled Trial to Evaluate the Safety of Intravenous Ampionâ„¢ in Adult COVID-19 Patients Requiring Oxygen Supplementation,"Active, not recruiting",NA,Phase 1,10,Actual,Ampio Pharmaceuticals. Inc.,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:52:00Z,2020-11-01T11:52:00Z
NCT04456062,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-30,NA,NA,2020-08-27,2020-06-30,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2020-08-27,2020-08-31,Actual,"August 4, 2020",Actual,2020-08-04,August 2020,2020-08-31,March 2021,Anticipated,2021-03-31,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,,Using Caring Contacts to Reduce Psychiatric Morbidity Following Hospitalization During the COVID-19 Pandemic,Using Caring Contacts to Reduce Psychiatric Morbidity Following Hospitalization During the COVID-19 Pandemic,Recruiting,NA,N/A,150,Anticipated,Sunnybrook Health Sciences Centre,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:52:04Z,2020-11-01T11:52:04Z
NCT04454398,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-30,NA,NA,2020-10-26,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2020-10-26,2020-10-27,Actual,"September 17, 2020",Actual,2020-09-17,October 2020,2020-10-31,February 2021,Anticipated,2021-02-28,February 2021,Anticipated,2021-02-28,NA,Interventional,NA,,Study to Evaluate STI-1499 (COVI-GUARD) in Patients With Moderate COVID-19,"A Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of STI-1499 (COVI-GUARDâ„¢) in Hospitalized Patients With Moderate COVID-19",Recruiting,NA,Phase 1,33,Anticipated,"Sorrento Therapeutics, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:52:19Z,2020-11-01T11:52:19Z
NCT04453514,"ClinicalTrials.gov processed this data on October 30, 2020",2020-06-30,NA,NA,2020-07-22,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2020-07-22,2020-07-24,Actual,"July 21, 2020",Actual,2020-07-21,July 2020,2020-07-31,October 2020,Anticipated,2020-10-31,October 2020,Anticipated,2020-10-31,NA,Interventional,NA,,Feasibility of a Brief Trauma-informed Yoga Intervention for Anxiety During the Coronavirus Disease (COVID-19) Pandemic,Cultivating Calm During COVID-19: A Feasibility Study of Video-based Trauma-informed Yoga,Recruiting,NA,N/A,200,Anticipated,National University of Natural Medicine,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:52:25Z,2020-11-01T11:52:25Z
NCT04455308,"ClinicalTrials.gov processed this data on November 06, 2020",2020-06-30,NA,NA,2020-11-03,2020-07-01,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-04,Actual,"July 21, 2020",Actual,2020-07-21,November 2020,2020-11-30,"October 19, 2020",Actual,2020-10-19,"October 19, 2020",Actual,2020-10-19,NA,Interventional,ECCES,,COVID-19 and Chilblains,"Chilblains, COVID-19 and Lockdown: Epidemiologic Study",Completed,NA,N/A,269,Actual,Rennes University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-08T11:33:59Z,2020-11-08T11:33:59Z
NCT04482673,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-01,NA,NA,2020-07-31,2020-07-21,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2020-07-31,2020-08-04,Actual,"July 31, 2020",Actual,2020-07-31,July 2020,2020-07-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,VitD-COVID19,,Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection,The Role of Vitamin D in Mitigating COVID-19 Infection Severity: Focusing on Reducing Health Disparities in South Carolina,Recruiting,NA,Phase 4,140,Anticipated,Medical University of South Carolina,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:48:56Z,2020-11-01T11:48:56Z
NCT04461925,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-01,NA,NA,2020-07-07,2020-07-07,2020-07-08,Actual,NA,NA,NA,NA,NA,NA,2020-07-07,2020-07-08,Actual,"May 2, 2020",Actual,2020-05-02,June 2020,2020-06-30,December 2021,Anticipated,2021-12-31,"May 2, 2021",Anticipated,2021-05-02,NA,Interventional,NA,,Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs,Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic Multipotent Mesenchymal Stem Cells of the Placenta and Umbilical Cord,Recruiting,NA,Phase 1/Phase 2,30,Anticipated,Institute of Cell Therapy,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:51:21Z,2020-11-01T11:51:21Z
NCT04460027,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-01,NA,NA,2020-08-12,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-08-12,2020-08-17,Actual,"June 22, 2020",Actual,2020-06-22,August 2020,2020-08-31,"August 31, 2020",Anticipated,2020-08-31,"August 31, 2020",Anticipated,2020-08-31,NA,Interventional,NA,,W-SUDs for COVID-19,Woebot for Substance Use Disorders During COVID-19,Recruiting,NA,Phase 1,160,Anticipated,"Woebot Labs, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:51:34Z,2020-11-01T11:51:34Z
NCT04458519,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-01,NA,NA,2020-10-06,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"July 16, 2020",Actual,2020-07-16,July 2020,2020-07-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection,Randomised Single Blinded Clinical Study of Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection,Recruiting,NA,N/A,40,Anticipated,Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM),,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:51:44Z,2020-11-01T11:51:44Z
NCT04458246,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-01,NA,NA,2020-07-02,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-02,2020-07-07,Actual,July 2020,Anticipated,2020-07-31,July 2020,2020-07-31,June 2021,Anticipated,2021-06-30,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Home-based Aerobic Training Among Adolescents With Chronic Diseases During COVID-19 Pandemic,"Online, Home-based, Aerobic Training Program Among Adolescents With Chronic Diseases During COVID-19 Pandemic: A Randomized Controlled Trial",Recruiting,NA,N/A,140,Anticipated,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:51:45Z,2020-11-01T11:51:45Z
NCT04465604,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-02,NA,NA,2020-07-09,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-07-09,2020-07-10,Actual,"July 1, 2020",Anticipated,2020-07-01,July 2020,2020-07-31,May 2021,Anticipated,2021-05-31,"November 1, 2020",Anticipated,2020-11-01,NA,Interventional,NA,,Hypertonic Saline for COVID-19 Symptoms,HYPERTONIC SALINE COATED FACE MASK FOR REDUCING RESPIRATORY SYMPTOM SEVERITY IN PATIENTS WITH COVID-19,Recruiting,NA,N/A,50,Anticipated,King Faisal Specialist Hospital & Research Center,,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:50:57Z,2020-11-01T11:50:57Z
NCT04463849,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-02,NA,NA,2020-07-08,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2020-07-08,2020-07-09,Actual,"June 30, 2020",Actual,2020-06-30,July 2020,2020-07-31,"June 30, 2021",Anticipated,2021-06-30,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,COBETOX,,Effects of COVID-19 Infection on Beta-cell Function in Euglycemic Patients,Effects of SARS-CoV-2 Infection on Beta-cell Function in Euglycemic Patients,Recruiting,NA,N/A,24,Anticipated,University of Milan,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:51:09Z,2020-11-01T11:51:09Z
NCT04460703,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-02,NA,NA,2020-07-18,2020-07-06,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-18,2020-07-21,Actual,"July 3, 2020",Actual,2020-07-03,July 2020,2020-07-31,"July 8, 2020",Actual,2020-07-08,"July 8, 2020",Actual,2020-07-08,NA,Interventional,NA,,"COVID-19 Vaccine Messaging, Part 1","Persuasive Messages for COVID-19 Vaccine Uptake: a Randomized Controlled Trial, Part 1",Completed,NA,N/A,4000,Actual,Yale University,,12,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,After publication,Anonymized data and analysis code will be posted in a public replication archive,NA,Yes,Anonymized data and analysis code will be posted in a public replication archive after publication.,2020-11-01T11:51:29Z,2020-11-01T11:51:29Z
NCT04460534,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-02,NA,NA,2020-07-02,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-02,2020-07-07,Actual,"May 7, 2020",Actual,2020-05-07,July 2020,2020-07-31,"August 31, 2021",Anticipated,2021-08-31,"July 31, 2021",Anticipated,2021-07-31,NA,Interventional,COVISPERM,,Detection of COVID-19 (SARS-CoV-2) in the Semen of COVID+ Patients (Positive RT-PCR on a Nasopharyngeal Swab),Detection of SARS-CoV-2 in the Semen of COVID+ Patients (Positive RT-PCR on a Nasopharyngeal Swab),Recruiting,NA,N/A,100,Anticipated,GCS Ramsay SantÃ© pour l'Enseignement et la Recherche,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:51:30Z,2020-11-01T11:51:30Z
NCT04457726,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-02,NA,NA,2020-07-02,2020-07-02,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-02,2020-07-07,Actual,"July 1, 2020",Anticipated,2020-07-01,June 2020,2020-06-30,December 2022,Anticipated,2022-12-31,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,,Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19,Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19,Recruiting,NA,Phase 1/Phase 2,18,Anticipated,KK Women's and Children's Hospital,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:51:48Z,2020-11-01T11:51:48Z
NCT04461379,"ClinicalTrials.gov processed this data on November 13, 2020",2020-07-02,NA,NA,2020-11-12,2020-07-07,2020-07-08,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-13,Estimate,"July 21, 2020",Actual,2020-07-21,November 2020,2020-11-30,"January 1, 2021",Anticipated,2021-01-01,"January 1, 2021",Anticipated,2021-01-01,NA,Interventional,NA,,"Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers","Prevention, Efficacy and Safety of BCG Vaccine in COVID-19- Randomized Clinical Trial","Active, not recruiting",NA,Phase 3,908,Anticipated,Hospital Universitario Dr. Jose E. Gonzalez,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-15T10:58:22Z,2020-11-15T10:58:22Z
NCT04505761,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-03,NA,NA,2020-08-20,2020-08-07,2020-08-10,Actual,NA,NA,NA,NA,NA,NA,2020-08-20,2020-08-24,Actual,"August 1, 2020",Actual,2020-08-01,June 2020,2020-06-30,"January 1, 2021",Anticipated,2021-01-01,"January 1, 2021",Anticipated,2021-01-01,NA,Interventional,COVRehab,,"The Usability, Feasibility, and Tolerability of Virtual Reality for Rehabilitation From COVID-19","The Usability, Feasibility, and Tolerability of Virtual Reality for Rehabilitation From COVID-19: An Explorative Study",Recruiting,NA,N/A,40,Anticipated,Radboud University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Only upon asking.,2020-11-01T11:46:11Z,2020-11-01T11:46:11Z
NCT04470869,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-03,NA,NA,2020-07-09,2020-07-09,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-07-09,2020-07-14,Actual,"June 12, 2020",Actual,2020-06-12,July 2020,2020-07-31,"October 12, 2021",Anticipated,2021-10-12,"April 12, 2021",Anticipated,2021-04-12,NA,Interventional,OLAF,,Impact on the OLAF Intervention to Prevent Post Traumatic Disorders During the Confinement.,Impact of the Psychiatric Intervention OLAF on the Post Traumatic Disorder in the Relatives of Patients Hospitalized in Intensive Care Unit During the SARS-Cov-2 Pandemic Confinement in France.,Recruiting,NA,N/A,130,Anticipated,"University Hospital, Toulouse",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:50:19Z,2020-11-01T11:50:19Z
NCT04466540,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-03,NA,NA,2020-07-09,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-07-09,2020-07-10,Actual,"May 12, 2020",Actual,2020-05-12,July 2020,2020-07-31,"December 30, 2020",Anticipated,2020-12-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,COALITION-V,,Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19),"Pragmatic, Double-blind, Placebo-controlled Randomized Clinical Trial, Evaluating Hydroxychloroquine for Prevention of Hospitalization and Respiratory Complications in Non-hospitalized Patients With Confirmed or Probable COVID-19",Recruiting,NA,Phase 4,1300,Anticipated,Hospital AlemÃ£o Oswaldo Cruz,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:50:48Z,2020-11-01T11:50:48Z
NCT04460183,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-03,NA,NA,2020-10-09,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-10-09,2020-10-12,Actual,"July 29, 2020",Actual,2020-07-29,October 2020,2020-10-31,"April 23, 2021",Anticipated,2021-04-23,"January 27, 2021",Anticipated,2021-01-27,NA,Interventional,NA,,A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19,"NOCoV2 - An Open-label, Adaptive Randomized, Controlled Multicenter Study to Evaluate the Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19 Requiring Supplemental Oxygen",Recruiting,NA,Phase 2/Phase 3,300,Anticipated,Thirty Respiratory Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:51:32Z,2020-11-01T11:51:32Z
NCT04459962,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-03,NA,NA,2020-07-03,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-03,2020-07-07,Actual,"June 29, 2020",Actual,2020-06-29,July 2020,2020-07-31,"June 14, 2021",Anticipated,2021-06-14,"August 28, 2020",Anticipated,2020-08-28,NA,Interventional,NA,,Covid-19 Breath Test,Breath Test Feasibility Trial for Covid-19 Infection Diagnosis,Recruiting,NA,N/A,250,Anticipated,Ancon Technologies Ltd,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:51:35Z,2020-11-01T11:51:35Z
NCT04459676,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-03,NA,NA,2020-08-03,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-08-03,2020-08-04,Actual,"July 31, 2020",Actual,2020-07-31,August 2020,2020-08-31,October 2020,Anticipated,2020-10-31,October 2020,Anticipated,2020-10-31,NA,Interventional,NA,,Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia,"A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Assess Safety and Efficacy of ANG- 3777 in Patients Hospitalized With Confirmed COVID-19 Pneumonia",Recruiting,NA,Phase 2,100,Anticipated,Angion Biomedica Corp,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2020-11-01T11:51:36Z,2020-11-01T11:51:36Z
NCT04459325,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-03,NA,NA,2020-10-13,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-14,Actual,"June 1, 2020",Actual,2020-06-01,July 2020,2020-07-31,"July 20, 2020",Actual,2020-07-20,"July 20, 2020",Actual,2020-07-20,NA,Interventional,NA,,TigeraseÂ® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19,A Prospective Open-label Study of the TigeraseÂ® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19,Completed,NA,Phase 3,100,Actual,AO GENERIUM,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:51:38Z,2020-11-01T11:51:38Z
NCT04459286,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-03,NA,NA,2020-10-11,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-10-11,2020-10-14,Actual,"October 9, 2020",Actual,2020-10-09,August 2020,2020-08-31,"March 21, 2021",Anticipated,2021-03-21,"January 21, 2021",Anticipated,2021-01-21,NA,Interventional,NACOVID,,The Nitazoxanide Plus Atazanavir for COVID-19 Study,"A Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir/Ritonavir for the Treatment of COVID-19: a Pilot Study",Recruiting,NA,Phase 2,98,Anticipated,Obafemi Awolowo University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:51:38Z,2020-11-01T11:51:38Z
NCT04459247,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-03,NA,NA,2020-08-25,2020-07-03,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-08-25,2020-08-27,Actual,"June 15, 2020",Actual,2020-06-15,August 2020,2020-08-31,"September 10, 2020",Anticipated,2020-09-10,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,SHADE,,"Short Term, High Dose Vitamin D Supplementation for COVID-19","Short Term, High Dose Vitamin D Supplementation for COVID-19 Disease: Double Blind, Controlled, Study","Active, not recruiting",NA,N/A,30,Anticipated,Postgraduate Institute of Medical Education and Research,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:51:38Z,2020-11-01T11:51:38Z
NCT04467918,"ClinicalTrials.gov processed this data on November 06, 2020",2020-07-03,NA,NA,2020-11-02,2020-07-09,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"July 6, 2020",Actual,2020-07-06,November 2020,2020-11-30,"December 16, 2020",Anticipated,2020-12-16,"November 16, 2020",Anticipated,2020-11-16,NA,Interventional,CANDIDATE,,CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms,"Cannabidiol (CBD) in Patients With Mild to Moderate Symptoms of Coronavirus 2019: A Randomized, Double-blind, Placebo-controlled Clinical Trial","Active, not recruiting",NA,Phase 2/Phase 3,100,Anticipated,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Immediately the following publication. No end date.,"Researchers who provide a methodologically sound proposal. Depending on the level of the proposed use of data, approval by an independent review committee will be required for the identified purpose.",NA,Yes,"All of the individual participant data collected during the trial, after deidentification.",2020-11-07T11:21:45Z,2020-11-07T11:21:45Z
NCT04461340,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-04,NA,NA,2020-09-06,2020-07-07,2020-07-08,Actual,NA,NA,NA,NA,NA,NA,2020-09-06,2020-09-09,Actual,"August 15, 2020",Actual,2020-08-15,September 2020,2020-09-30,"November 30, 2020",Anticipated,2020-11-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,NA,,Efficacy and Safety of Sirolimus in COVID-19 Infection,Efficacy and Safety of Sirolimus for Treating COVID-19 Infection,Recruiting,NA,Phase 2,40,Anticipated,Alexandria University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:51:26Z,2020-11-01T11:51:26Z
NCT04460443,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-04,NA,NA,2020-08-01,2020-07-04,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-08-01,2020-08-04,Actual,"August 1, 2020",Actual,2020-08-01,August 2020,2020-08-31,"August 31, 2021",Anticipated,2021-08-31,"August 1, 2021",Anticipated,2021-08-01,NA,Interventional,NA,,Sofosbuvir With and Without Ribavirin in Treatment of COVID 19,Sofosbuvir With and Without Ribavirin in Treatment of COVID 19 Patients,Recruiting,NA,Phase 2/Phase 3,60,Anticipated,Tanta University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:51:31Z,2020-11-01T11:51:31Z
NCT04463420,"ClinicalTrials.gov processed this data on November 06, 2020",2020-07-04,NA,NA,2020-11-03,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-04,Actual,"August 15, 2020",Actual,2020-08-15,November 2020,2020-11-30,"December 15, 2020",Anticipated,2020-12-15,"November 15, 2020",Anticipated,2020-11-15,NA,Interventional,NA,,Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19,Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19 a Multi-center Randomized Blinding Clinical Trial Study,Recruiting,NA,N/A,224,Anticipated,Baqiyatallah Medical Sciences University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-08T11:33:49Z,2020-11-08T11:33:49Z
NCT04468139,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-05,NA,NA,2020-07-09,2020-07-09,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2020-07-09,2020-07-13,Actual,"June 20, 2020",Actual,2020-06-20,July 2020,2020-07-31,"July 30, 2020",Anticipated,2020-07-30,"July 20, 2020",Anticipated,2020-07-20,NA,Interventional,NA,,"The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19","The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19",Recruiting,NA,Phase 4,60,Anticipated,"Ministry of Health, Saudi Arabia",,1,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2020-11-01T11:50:37Z,2020-11-01T11:50:37Z
NCT04459520,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-05,NA,NA,2020-08-19,2020-07-05,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-08-19,2020-08-20,Actual,"July 23, 2020",Actual,2020-07-23,August 2020,2020-08-31,"July 29, 2020",Actual,2020-07-29,"July 28, 2020",Actual,2020-07-28,NA,Interventional,NA,,Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance,Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance,Completed,NA,N/A,1400,Actual,"University of California, Los Angeles",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:51:37Z,2020-11-01T11:51:37Z
NCT04479540,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-06,NA,NA,2020-09-09,2020-07-20,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-09-09,2020-09-10,Actual,"May 26, 2020",Actual,2020-05-26,June 2020,2020-06-30,"August 31, 2021",Anticipated,2021-08-31,"May 26, 2021",Anticipated,2021-05-26,NA,Interventional,COVIDEP,,Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With COVID-19 Lung Disease,Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With SARS Coronavirus (COV-2) Lung Disease,Recruiting,NA,N/A,120,Anticipated,Hopital Foch,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:49:16Z,2020-11-01T11:49:16Z
NCT04472728,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-06,NA,NA,2020-08-31,2020-07-13,2020-07-15,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-02,Actual,"June 16, 2020",Actual,2020-06-16,July 2020,2020-07-31,September 2021,Anticipated,2021-09-30,July 2021,Anticipated,2021-07-31,NA,Interventional,COVA,,Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients,"Adaptive Design Phase 2 to 3, Randomized, Double-blind, to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BIO101 in the Prevention of the Respiratory Deterioration in Hospitalized COVID-19 Patients",Recruiting,NA,Phase 2/Phase 3,310,Anticipated,Biophytis,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:50:07Z,2020-11-01T11:50:07Z
NCT04460690,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-06,NA,NA,2020-09-24,2020-07-06,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-28,Actual,"July 13, 2020",Actual,2020-07-13,September 2020,2020-09-30,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Interventional,NA,,"Rapid, Onsite COVID-19 Detection","Rapid, Onsite COVID-19 Detection",Enrolling by invitation,NA,N/A,10000,Anticipated,"University of Wisconsin, Madison",,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,NA,NA,,Data from this study may be requested from other researchers 7 years after the completion of the primary endpoint by contacting David O'Connor at the University of Wisconsin - Madison.,NA,NA,Yes,"Participants will consent to having their data (not their name) and viral sequences shared with the public via manuscripts, presentations and online databases; the study team will share that with other researchers when needed. Samples can be shared with UW researchers internally and non UW researchers through the Material Transfer Agreement process.",2020-11-01T11:51:29Z,2020-11-01T11:51:29Z
NCT04460677,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-06,NA,NA,2020-09-04,2020-07-06,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-09-04,2020-09-09,Actual,"August 12, 2020",Actual,2020-08-12,September 2020,2020-09-30,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,NA,,ASD (Autism Spectrum Disorder) Telehealth for Distress Related to COVID-19,ASD (Autism Spectrum Disorder) Telehealth for Distress Related to COVID-19 (Coronavirus Disease),Recruiting,NA,N/A,80,Anticipated,"Rutgers, The State University of New Jersey",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,Plan will be decided as study progresses.,2020-11-01T11:51:30Z,2020-11-01T11:51:30Z
NCT04460014,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-06,NA,NA,2020-10-01,2020-07-06,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-10-01,2020-10-05,Actual,"September 30, 2020",Actual,2020-09-30,October 2020,2020-10-31,"August 1, 2021",Anticipated,2021-08-01,"March 1, 2021",Anticipated,2021-03-01,NA,Interventional,NA,,Simple Cognitive Task Intervention After Trauma During COVID-19 In Hospital Staff EKUT-P RCT,"Reducing Intrusive Memories After Trauma Via a Simple Cognitive Intervention During COVID-19 in Hospital Staff: ""EKUT-P"" (Enkel Kognitiv Uppgift Efter Trauma Under COVID-19 - sjukvÃ¥rdspersonal) - A Randomized Controlled Trial (RCT)",Recruiting,NA,N/A,164,Anticipated,Karolinska Institutet,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:51:34Z,2020-11-01T11:51:34Z
NCT04468646,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-07,NA,NA,2020-07-10,2020-07-10,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2020-07-10,2020-07-13,Actual,"June 15, 2020",Actual,2020-06-15,July 2020,2020-07-31,"August 30, 2020",Anticipated,2020-08-30,"July 15, 2020",Anticipated,2020-07-15,NA,Interventional,NA,,To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients,To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients,Recruiting,NA,Phase 3,100,Anticipated,University of Health Sciences Lahore,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:50:34Z,2020-11-01T11:50:34Z
NCT04464395,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-07,NA,NA,2020-10-14,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"July 1, 2020",Actual,2020-07-01,October 2020,2020-10-31,"August 31, 2021",Anticipated,2021-08-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,NA,,Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients,Immunotherapy of COVID-19 With B-Cell Activating CPI-006 Monoclonal Antibody,Recruiting,NA,Phase 1,60,Anticipated,"Corvus Pharmaceuticals, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:51:05Z,2020-11-01T11:51:05Z
NCT04463602,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-07,NA,NA,2020-08-11,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-13,Actual,"July 25, 2020",Actual,2020-07-25,August 2020,2020-08-31,"January 30, 2021",Anticipated,2021-01-30,"December 15, 2020",Anticipated,2020-12-15,NA,Interventional,NA,,Desidustat in the Management of COVID-19 Patients,"A Phase 2b, Multicenter, Open-label, Randomized, Comparator-Controlled, Study to Evaluate the Efficacy and Safety of Desidustat Tablet for the Management of COVID-19 Patients",Recruiting,NA,Phase 2,24,Anticipated,Cadila Healthcare Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:51:10Z,2020-11-01T11:51:10Z
NCT04463004,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-07,NA,NA,2020-09-08,2020-07-07,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-08,2020-09-10,Actual,"September 2, 2020",Actual,2020-09-02,September 2020,2020-09-30,August 2021,Anticipated,2021-08-31,August 2021,Anticipated,2021-08-31,NA,Interventional,NA,,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation,Recruiting,NA,Phase 2,60,Anticipated,Virginia Commonwealth University,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:51:15Z,2020-11-01T11:51:15Z
NCT04462627,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-07,NA,NA,2020-07-07,2020-07-07,2020-07-08,Actual,NA,NA,NA,NA,NA,NA,2020-07-07,2020-07-08,Actual,"April 14, 2020",Actual,2020-04-14,July 2020,2020-07-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Reduction of COVID 19 Transmission to Health Care Professionals,Reduction of COVID 19 Transmission to Health Care Professionals,Recruiting,NA,N/A,500,Anticipated,Brugmann University Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:51:17Z,2020-11-01T11:51:17Z
NCT04514627,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-08,NA,NA,2020-08-17,2020-08-13,2020-08-17,Actual,NA,NA,NA,NA,NA,NA,2020-08-17,2020-08-19,Actual,"July 13, 2020",Actual,2020-07-13,August 2020,2020-08-31,"July 31, 2021",Anticipated,2021-07-31,"July 31, 2021",Anticipated,2021-07-31,NA,Interventional,PENFS COVID-19,,Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19,Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19,Recruiting,NA,N/A,100,Anticipated,Olive View-UCLA Education & Research Institute,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:45:07Z,2020-11-01T11:45:07Z
NCT04469179,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-08,NA,NA,2020-09-04,2020-07-10,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2020-09-04,2020-09-09,Actual,"August 20, 2020",Actual,2020-08-20,July 2020,2020-07-31,December 2020,Anticipated,2020-12-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,"Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19","A Phase 1B, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of SAB-185 in Ambulatory Subjects With COVID-19",Recruiting,NA,Phase 1,21,Anticipated,"SAb Biotherapeutics, Inc.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Starting 6 months after publication and ending 36 months following article publication,Anyone who wishes to access the data.,NA,Yes,"Individual participant data that underlie the results reported in the published article, after deidentification (test, tables, figures, and appendices)",2020-11-01T11:50:29Z,2020-11-01T11:50:29Z
NCT04466670,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-08,NA,NA,2020-07-08,2020-07-08,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-07-08,2020-07-10,Actual,"July 8, 2020",Anticipated,2020-07-08,July 2020,2020-07-31,"April 30, 2021",Anticipated,2021-04-30,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,NA,,Hemostasis in COVID-19: an Adaptive Clinical Trial,Dynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical Trial,Recruiting,NA,Phase 3,310,Anticipated,University of Sao Paulo General Hospital,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:50:47Z,2020-11-01T11:50:47Z
NCT04466098,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-08,NA,NA,2020-08-12,2020-07-08,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-08-12,2020-08-14,Actual,"July 30, 2020",Actual,2020-07-30,August 2020,2020-08-31,"December 1, 2021",Anticipated,2021-12-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,NA,,Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19),"Multi-center, Randomized, Placebo Controlled, Interventional Phase 2A Clinical Trial Evaluating the Safety and Potential Efficacy of Multiple Dosing of Mesenchymal Stromal Cells in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2)",Recruiting,NA,Phase 2,30,Anticipated,"Masonic Cancer Center, University of Minnesota",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:50:52Z,2020-11-01T11:50:52Z
NCT04466085,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-08,NA,NA,2020-07-24,2020-07-08,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-07-24,2020-07-27,Actual,"July 12, 2020",Actual,2020-07-12,July 2020,2020-07-31,"December 15, 2021",Anticipated,2021-12-15,"September 15, 2021",Anticipated,2021-09-15,NA,Interventional,NA,,Clinical Study of Recombinant Novel Coronavirus Vaccine,"A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years",Recruiting,NA,Phase 2,900,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,6,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:50:52Z,2020-11-01T11:50:52Z
NCT04463472,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-08,NA,NA,2020-08-20,2020-07-08,2020-07-09,Actual,NA,NA,NA,NA,NA,NA,2020-08-20,2020-08-24,Actual,"June 29, 2020",Actual,2020-06-29,August 2020,2020-08-31,"July 31, 2021",Anticipated,2021-07-31,"September 26, 2020",Anticipated,2020-09-26,NA,Interventional,NA,,Study of COVID-19 DNA Vaccine (AG0301-COVID19),"A Non-randomized, Open-label, Non-controlled Phase I/II Study to Assess Safety and Immunogenicity of Two Doses of Intramuscular AG0301-COVID19 (1mg/2mg) in Healthy Adults","Active, not recruiting",NA,Phase 1/Phase 2,30,Anticipated,"AnGes, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:51:11Z,2020-11-01T11:51:11Z
NCT04473053,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-09,NA,NA,2020-08-19,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-08-19,2020-08-21,Actual,"July 3, 2020",Actual,2020-07-03,August 2020,2020-08-31,"December 3, 2021",Anticipated,2021-12-03,"July 3, 2021",Anticipated,2021-07-03,NA,Interventional,DEFINE,,Rapid Experimental Medicine for COVID-19,Rapid Experimental Medicine for COVID-19 - DEFINE COVID-19,Recruiting,NA,Phase 2/Phase 3,60,Anticipated,University of Edinburgh,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:50:03Z,2020-11-01T11:50:03Z
NCT04471636,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-09,NA,NA,2020-09-18,2020-07-13,2020-07-15,Actual,NA,NA,NA,NA,NA,NA,2020-09-18,2020-09-22,Actual,"September 18, 2020",Actual,2020-09-18,September 2020,2020-09-30,March 2021,Anticipated,2021-03-31,February 2021,Anticipated,2021-02-28,NA,Interventional,MR SPOC,,Telemedicine in Outpatient Covid-19 Patients,Munich Remote SpO2 and Electrocardiogram Assessment in Covid-19 Patients,Recruiting,NA,N/A,600,Anticipated,Ludwig-Maximilians - University of Munich,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:50:15Z,2020-11-01T11:50:15Z
NCT04470999,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-09,NA,NA,2020-07-16,2020-07-13,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-20,Actual,"April 15, 2020",Actual,2020-04-15,July 2020,2020-07-31,"December 31, 2020",Anticipated,2020-12-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,Changes in Cellular Immune Profile During COVID-19 Infection,Cellular Immune Profile Changes in Individuals With Active or Past COVID-19 Infection,Recruiting,NA,N/A,25,Anticipated,Seraph Research Institute,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:50:18Z,2020-11-01T11:50:18Z
NCT04470544,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-09,NA,NA,2020-09-24,2020-07-13,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-25,Actual,"July 28, 2020",Actual,2020-07-28,September 2020,2020-09-30,"September 15, 2022",Anticipated,2022-09-15,"September 15, 2022",Anticipated,2022-09-15,NA,Interventional,RECOVER,,Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19,"RECOVER: Phase 2 Randomized, Double-Blind Trial TREating Hospitalized Patients With COVID-19 With Camostat MesilatE, a TMPRSS2 Inhibitor",Recruiting,NA,Phase 2,264,Anticipated,Academic and Community Cancer Research United,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:50:22Z,2020-11-01T11:50:22Z
NCT04468009,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-09,NA,NA,2020-08-03,2020-07-09,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2020-08-03,2020-08-05,Actual,"June 25, 2020",Actual,2020-06-25,August 2020,2020-08-31,June 2021,Anticipated,2021-06-30,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,,Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma,Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma,Recruiting,NA,Phase 2,36,Anticipated,Hospital de Infecciosas Francisco Javier Muniz,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:50:38Z,2020-11-01T11:50:38Z
NCT04466605,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-09,NA,NA,2020-07-09,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-07-09,2020-07-10,Actual,"March 30, 2020",Actual,2020-03-30,July 2020,2020-07-31,"July 6, 2020",Actual,2020-07-06,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,,Effect of Tele-Yoga Therapy on Patients With Chronic Musculoskeletal Pain During Covid-19 Lockdown,Effect of Tele-Yoga Therapy on Patients With Chronic Musculoskeletal Pain During Covid-19 Lockdown: Randomized Clinical Trial,Completed,NA,N/A,64,Actual,Aarogyam UK,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:50:47Z,2020-11-01T11:50:47Z
NCT04466280,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-09,NA,NA,2020-07-09,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-07-09,2020-07-10,Actual,"July 15, 2020",Anticipated,2020-07-15,July 2020,2020-07-31,"December 15, 2020",Anticipated,2020-12-15,"November 15, 2020",Anticipated,2020-11-15,NA,Interventional,NA,,"Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19","Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19 Disease in Healthcare Providers at Baqiyatallah Hospital in Tehran",Recruiting,NA,N/A,180,Anticipated,Baqiyatallah Medical Sciences University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:50:50Z,2020-11-01T11:50:50Z
NCT04465695,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-09,NA,NA,2020-07-13,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-07-13,2020-07-15,Actual,"July 14, 2020",Actual,2020-07-14,July 2020,2020-07-31,"September 30, 2021",Anticipated,2021-09-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,,Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19,"An Open-label Randomised Controlled Trial on Dual Therapy With Interferon Beta-1b and Clofazimine Combination, as Treatment for COVID-19 Infection",Recruiting,NA,Phase 2,81,Anticipated,The University of Hong Kong,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Within 12 months of study published,To be approved by the HKU/ IRB clinical trial study panel of valid research purpose,NA,Yes,To share anonymised participant data,2020-11-01T11:50:56Z,2020-11-01T11:50:56Z
NCT04467840,"ClinicalTrials.gov processed this data on November 06, 2020",2020-07-09,NA,NA,2020-11-02,2020-07-09,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"August 21, 2020",Actual,2020-08-21,September 2020,2020-09-30,February 2021,Anticipated,2021-02-28,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia","Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: a Randomized, Double-blind, Placebo-Controlled Phase 2/3 Study, in Adult Subjects Hospitalized With Severe SARS-CoV-2 Positive Pneumonia",Recruiting,NA,Phase 2/Phase 3,270,Anticipated,RedHill Biopharma Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-07T11:21:46Z,2020-11-07T11:21:46Z
NCT04466800,"ClinicalTrials.gov processed this data on November 13, 2020",2020-07-09,NA,NA,2020-11-06,2020-07-09,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"July 30, 2020",Actual,2020-07-30,November 2020,2020-11-30,"November 30, 2021",Anticipated,2021-11-30,"April 2, 2021",Anticipated,2021-04-02,NA,Interventional,RECOVER-19,,Functional and Respiratory Rehabilitation and Nutritional Care of COVID-19 Patients (RECOVER-19),Functional and Respiratory Rehabilitation and Nutritional Care of COVID-19 Patients,Recruiting,NA,N/A,160,Anticipated,Rennes University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-14T10:40:40Z,2020-11-14T10:40:40Z
NCT04469114,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-10,NA,NA,2020-09-21,2020-07-10,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-23,Actual,"September 16, 2020",Actual,2020-09-16,July 2020,2020-07-31,"January 31, 2021",Anticipated,2021-01-31,"December 7, 2020",Anticipated,2020-12-07,NA,Interventional,NA,,Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Trial of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia",Recruiting,NA,Phase 2,260,Anticipated,Hospital Israelita Albert Einstein,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:50:30Z,2020-11-01T11:50:30Z
NCT04468971,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-10,NA,NA,2020-10-11,2020-07-10,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2020-10-11,2020-10-14,Actual,"September 29, 2020",Actual,2020-09-29,September 2020,2020-09-30,"September 30, 2021",Anticipated,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,RESOLVE,,REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia,"Phase 1 Double-Blinded, Randomized, Placebo Controlled Safety and Early Efficacy Trial of Cryopreserved Cord Blood Derived T-Regulatory Cell Infusions (CK0802) In The Treatment Of COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS)",Recruiting,NA,Phase 1,45,Anticipated,"Cellenkos, Inc.",,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:50:32Z,2020-11-01T11:50:32Z
NCT04468893,"ClinicalTrials.gov processed this data on November 06, 2020",2020-07-10,NA,NA,2020-11-03,2020-07-10,2020-07-13,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-04,Actual,"May 20, 2020",Actual,2020-05-20,November 2020,2020-11-30,"January 15, 2021",Anticipated,2021-01-15,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Online Positive Psychology Intervention for Depression and Anxiety Due to COVID-19,"Effectiveness of a Self-applied Positive Psychology Online Intervention Program ""Mental Health COVID-19"" in Mexican Population: A Randomized Controlled Trial.",Recruiting,NA,N/A,128,Anticipated,Universidad Internacional de Valencia,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,This data will be available approximately in december 2020 and it will be permanently available. It will be shared in the databases of the journal where the article(s) will be published,Through the servers of the journal(s) where we will publish the articles.,NA,Yes,"The information will be available in a private server or in a server of the journal(s) that we will publish the articles that will be the result of this study. The protocol of the study is currently in progress to be published, in this article will be included such study protocol, the informed consent is already shared in the register of clinical trials.",2020-11-08T11:33:41Z,2020-11-08T11:33:41Z
NCT04560231,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-11,NA,NA,2020-09-24,2020-09-22,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-25,Actual,"June 1, 2020",Actual,2020-06-01,September 2020,2020-09-30,"November 30, 2020",Anticipated,2020-11-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,RC19LGH,,Remdesivir in COVID-19 Lahore General Hospital,Is Remdesivir a Possible Therapeutic Option for SARS-CoV-2 : An Interventional Study,Recruiting,NA,Early Phase 1,30,Anticipated,Lahore General Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:39:41Z,2020-11-01T11:39:41Z
NCT04560205,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-11,NA,NA,2020-09-22,2020-09-22,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-23,Actual,"May 1, 2020",Actual,2020-05-01,September 2020,2020-09-30,"October 30, 2020",Anticipated,2020-10-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,TC19LGH,,Tocilizumab in COVID-19 Lahore General Hospital,Tocilizumab: A Therapeutic Cache Against the Treatment of Severe Cases of COVID-19,Recruiting,NA,Phase 1,50,Anticipated,Lahore General Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:39:41Z,2020-11-01T11:39:41Z
NCT04471519,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-11,NA,NA,2020-09-29,2020-07-14,2020-07-15,Actual,NA,NA,NA,NA,NA,NA,2020-09-29,2020-10-01,Actual,"July 13, 2020",Actual,2020-07-13,September 2020,2020-09-30,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,BBV152,,Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers,"An Adaptive Phase 1, Followed by Phase 2 Randomized, Double-blind, Multicenter Study to Evaluate the Safety, Reactogenicity, Tolerability, and Immunogenicity of BBV152 in Healthy Volunteers","Active, not recruiting",NA,Phase 1/Phase 2,755,Actual,Bharat Biotech International Limited,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:50:16Z,2020-11-01T11:50:16Z
NCT04470531,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-11,NA,NA,2020-07-15,2020-07-13,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-16,Actual,"July 12, 2020",Actual,2020-07-12,July 2020,2020-07-31,"January 30, 2021",Anticipated,2021-01-30,"October 12, 2020",Anticipated,2020-10-12,NA,Interventional,NA,,Role of Co-trimoxazole in Severe COVID-19 Patients,Role of Co-trimoxazole in Severe COVID-19 Patients,Recruiting,NA,Phase 2,94,Anticipated,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,six months,"Available on public domain like figshare, researchgate and others",NA,Yes,Data will be shared with the journal authority and make public as part of the publication,2020-11-01T11:50:22Z,2020-11-01T11:50:22Z
NCT04470427,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-11,NA,NA,2020-10-27,2020-07-11,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-28,Actual,"July 27, 2020",Actual,2020-07-27,October 2020,2020-10-31,"October 27, 2022",Anticipated,2022-10-27,"October 27, 2022",Anticipated,2022-10-27,NA,Interventional,NA,,"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19","A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older","Active, not recruiting",NA,Phase 3,30000,Anticipated,"ModernaTX, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T13:43:36Z,2020-11-01T13:43:36Z
NCT04480593,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-12,NA,NA,2020-09-28,2020-07-20,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-30,Actual,"June 2, 2020",Actual,2020-06-02,September 2020,2020-09-30,"August 30, 2020",Actual,2020-08-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,Bee-Covid,,The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.,"The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19: a Randomized, Open and Pilot Clinical Study.",Completed,NA,Phase 2/Phase 3,120,Actual,D'Or Institute for Research and Education,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:49:09Z,2020-11-01T11:49:09Z
NCT04470739,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-12,NA,NA,2020-07-13,2020-07-13,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-07-13,2020-07-14,Actual,"May 30, 2020",Actual,2020-05-30,July 2020,2020-07-31,"October 30, 2020",Anticipated,2020-10-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,Is Thymus Size of Infants Who Born to COVID-19 Positive Mothers Associated With Neonatal Morbidities?,Is Thymus Size of Infants Who Born to COVID-19 Positive Mothers Associated With Neonatal Morbidities?,Recruiting,NA,N/A,20,Anticipated,Kanuni Sultan Suleyman Training and Research Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:50:20Z,2020-11-01T11:50:20Z
NCT04560257,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-13,NA,NA,2020-09-24,2020-09-22,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-28,Actual,"May 1, 2020",Actual,2020-05-01,September 2020,2020-09-30,"October 30, 2020",Anticipated,2020-10-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,HFNC19LGH,,High Flow Nasal Cannula HFNC In Covid-19 Patients,Prone Positioning and High Flow Nasal Canula (HFNC) Therapy: A Game Changer in COVID-19 Outcome,Recruiting,NA,N/A,30,Anticipated,Lahore General Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:39:41Z,2020-11-01T11:39:41Z
NCT04495933,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-13,NA,NA,2020-09-02,2020-07-31,2020-08-03,Actual,NA,NA,NA,NA,NA,NA,2020-09-02,2020-09-04,Actual,"July 13, 2020",Actual,2020-07-13,July 2020,2020-07-31,September 2021,Anticipated,2021-09-30,October 2020,Anticipated,2020-10-31,NA,Interventional,NA,,"A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults","A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Dosage-Escalation, Single Centre Study to Evaluate the Safety and Immunogenicity of an Adjuvanted SARS-CoV-2 Sclamp Protein Subunit Vaccine in Healthy Adults Aged 18 to 55 Years Old and Healthy Older Adults, Aged 56 Years and Over",Recruiting,NA,Phase 1,216,Anticipated,The University of Queensland,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,"Immediately following publication, no end date",Available only to achieve the aims in the approved proposal,NA,Yes,individual participant data underlying published results only on a case-by-case basis at the discretion of Primary Sponsor,2020-11-01T11:47:19Z,2020-11-01T11:47:19Z
NCT04479358,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-13,NA,NA,2020-09-21,2020-07-18,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-23,Actual,"September 10, 2020",Actual,2020-09-10,September 2020,2020-09-30,"March 1, 2021",Anticipated,2021-03-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,COVIDOSE-2,,Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19,"COVIDOSE-2: A Multi-center, Randomized, Controlled Phase 2 Trial Comparing Early Administration of Low-dose Tocilizumab to Standard of Care in Hospitalized Patients With COVID-19 Pneumonitis Not Requiring Invasive Ventilation",Recruiting,NA,Phase 2,332,Anticipated,University of Chicago,,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,From 1 month following publication of data. Available indefinitely thereafter.,Proposals will need to be sent to study principal investigators. Requestors will need to sign a data access request form. Link to be determined.,NA,Yes,"Individual participant data that underlie the results of this article, after de-identification. Sharing period will be 1 month after data are published and available indefinitely thereafter. Researchers who provide methodologically sound proposals for the purposes of achieving stated aims in their proposal will be eligible for data-sharing.",2020-11-01T11:49:17Z,2020-11-01T11:49:17Z
NCT04477993,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-13,NA,NA,2020-07-17,2020-07-17,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2020-07-17,2020-07-20,Actual,"July 17, 2020",Anticipated,2020-07-17,July 2020,2020-07-31,"December 31, 2021",Anticipated,2021-12-31,"February 17, 2021",Anticipated,2021-02-17,NA,Interventional,RUXO-COVID,,Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19,"Randomized, Double-Blind Clinical Trial of Ruxolitinib in Patients With Acute Respiratory Disorder Syndrome Due to SARS-CoV-2 Infection",Recruiting,NA,Phase 2/Phase 3,200,Anticipated,University of Sao Paulo General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:49:26Z,2020-11-01T11:49:26Z
NCT04476667,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-13,NA,NA,2020-07-16,2020-07-16,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-20,Actual,"June 15, 2020",Actual,2020-06-15,July 2020,2020-07-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,"Online Delivery of Psychotherapy, Tailored to Patients' Suffering From Mental Health Problems Due to COVID-19","Online Delivery of Psychotherapy, Tailored to Patients' Suffering From Mental Health Problems Due to COVID-19",Recruiting,NA,N/A,80,Anticipated,Queen's University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Ethics and Data Privacy: Only care providers involved in care of participant will have access to charts. Patients will only be identifiable by ID number on OPTT platform and real identity and consent forms will be stored locally in locked file cabinet and destroyed 5 years after study completion date. Only anonymized data will be provided to analysis team members.
OPTT is HIPAA, PIPEDA and SOC-2 compliant and all servers and databases are hosted in AWS Canada cloud infrastructure which is managed by Medstack to assure all provincial and federal privacy and security regulations are met. OPTT will not collect any identifiable personal information or IP addresses for privacy purposes. OPTT will only collect anonymized metadata to improve its service quality and provide advanced analytics to the clinician team. All data is encrypted by OPTT and no employee has direct access to patient data. All encrypted backups are kept in the S3 storage that is dedicated to Queen's University.",2020-11-01T11:49:34Z,2020-11-01T11:49:34Z
NCT04470609,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-13,NA,NA,2020-07-13,2020-07-13,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-07-13,2020-07-14,Actual,"July 10, 2020",Actual,2020-07-10,July 2020,2020-07-31,November 2021,Anticipated,2021-11-30,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged â©¾60 Years,"A Randomized, Double-blind, Placebo-controlled, Phase Ib/IIb Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged â©¾60 Years",Enrolling by invitation,NA,Phase 1/Phase 2,471,Anticipated,Chinese Academy of Medical Sciences,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:50:21Z,2020-11-01T11:50:21Z
NCT04470622,"ClinicalTrials.gov processed this data on November 13, 2020",2020-07-13,NA,NA,2020-11-09,2020-07-13,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"July 20, 2020",Actual,2020-07-20,November 2020,2020-11-30,March 2021,Anticipated,2021-03-31,February 2021,Anticipated,2021-02-28,NA,Interventional,NA,,Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1),"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Aprepitant Injectable Emulsion in Early Hospitalized Adult Patients With COVID-19",Recruiting,NA,Phase 2,100,Anticipated,Heron Therapeutics,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-15T10:58:14Z,2020-11-15T10:58:14Z
NCT04537962,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-14,NA,NA,2020-09-02,2020-09-02,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2020-09-02,2020-09-03,Actual,"June 11, 2020",Actual,2020-06-11,June 2020,2020-06-30,"August 30, 2021",Anticipated,2021-08-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,"Evaluationof the Load of SARS-CoV-2 Virus in Oral Cavity, Oropharinge and Saliva of Patients With Covid-19 After Disinfection With Oral Antimicrobial Solutions: a Pilot Study","AvaliaÃ§Ã£o do Covid-19 na Cavidade Oral, Orofaringe e Saliva apÃ³s desinfecÃ§Ã£o Com soluÃ§Ãµes Antimicrobianas Orais: Estudo Piloto.",Enrolling by invitation,NA,N/A,70,Anticipated,Hospital Israelita Albert Einstein,,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:42:20Z,2020-11-01T11:42:20Z
NCT04488081,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-14,NA,NA,2020-09-25,2020-07-24,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2020-09-25,2020-09-29,Actual,"July 31, 2020",Actual,2020-07-31,July 2020,2020-07-31,"November 1, 2022",Anticipated,2022-11-01,"July 24, 2022",Anticipated,2022-07-24,NA,Interventional,I-SPY_COVID,,I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients,I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients,Recruiting,NA,Phase 2,1500,Anticipated,QuantumLeap Healthcare Collaborative,,5,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Post publication or earlier if warranted.,Sharing criteria are based on the circumstances of the request and whether the data have been published.,NA,Yes,We will share data on a case by case basis with appropriate IRB review and review by our Data Safety Monitoring Comittee.,2020-11-01T11:48:19Z,2020-11-01T11:48:19Z
NCT04478539,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-14,NA,NA,2020-07-17,2020-07-17,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2020-07-17,2020-07-20,Actual,"June 1, 2020",Actual,2020-06-01,July 2020,2020-07-31,"July 1, 2021",Anticipated,2021-07-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,,Extracorporeal Blood Purification as a Treatment Modality for COVID-19,Clinical Efficacy and Safety of Extracorporeal Blood Purification to Control Hyperinflammation and Hypercoagulability in COVID-19 Patients,Recruiting,NA,N/A,35,Anticipated,Zan Mitrev Clinic,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T11:49:22Z,2020-11-01T11:49:22Z
NCT04477083,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-14,NA,NA,2020-07-17,2020-07-17,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2020-07-17,2020-07-20,Actual,"July 15, 2020",Actual,2020-07-15,July 2020,2020-07-31,"August 15, 2020",Anticipated,2020-08-15,"August 15, 2020",Anticipated,2020-08-15,NA,Interventional,NA,,"Development and Validation of ""Ready-to-Use"" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19","Development and Validation of ""Ready-to-Use"" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19","Active, not recruiting",NA,N/A,40,Anticipated,Mansoura University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:49:31Z,2020-11-01T11:49:31Z
NCT04475913,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-14,NA,NA,2020-07-14,2020-07-14,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-14,2020-07-17,Actual,"July 11, 2018",Actual,2018-07-11,July 2020,2020-07-31,August 2020,Anticipated,2020-08-31,"July 11, 2020",Actual,2020-07-11,NA,Interventional,NA,,Digital vs Analog Impression in Cases of All-on-4 - Prosthesis,"In a Post -Covid-19 World, What is the Clinical Influence of Digital vs Analog Impression in Cases of All-on-4 - Prosthesis ?","Active, not recruiting",NA,N/A,56,Actual,October University for Modern Sciences and Arts,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:49:38Z,2020-11-01T11:49:38Z
NCT04475107,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-14,NA,NA,2020-10-11,2020-07-15,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-10-11,2020-10-14,Actual,"July 9, 2020",Actual,2020-07-09,July 2020,2020-07-31,February 2021,Anticipated,2021-02-28,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients,"A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase â…¡ Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients",Recruiting,NA,Phase 2,76,Anticipated,Shin Poong Pharmaceutical Co. Ltd.,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:49:44Z,2020-11-01T11:49:44Z
NCT04473898,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-14,NA,NA,2020-07-23,2020-07-14,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-07-23,2020-07-27,Actual,"June 19, 2020",Actual,2020-06-19,July 2020,2020-07-31,"December 19, 2020",Anticipated,2020-12-19,"October 19, 2020",Anticipated,2020-10-19,NA,Interventional,NA,,Telerehabilitation After Coronavirus,Telerehabilitation After Covid-19: Effectiveness of Respiratory and Aerobic Training,Recruiting,NA,N/A,36,Anticipated,KTO Karatay University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:49:53Z,2020-11-01T11:49:53Z
NCT04473261,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-14,NA,NA,2020-07-14,2020-07-14,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-07-14,2020-07-16,Actual,"July 14, 2020",Actual,2020-07-14,July 2020,2020-07-31,"September 30, 2020",Anticipated,2020-09-30,"September 15, 2020",Anticipated,2020-09-15,NA,Interventional,I-COVID-PK,,Efficacy of Iodine Complex Against COVID-19 Patients,Efficacy of Iodine Complex in Mild to Moderate COVID-19 Patients,Recruiting,NA,Phase 1/Phase 2,30,Anticipated,Sheikh Zayed Federal Postgraduate Medical Institute,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:50:01Z,2020-11-01T11:50:01Z
NCT04473170,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-14,NA,NA,2020-07-15,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-16,Actual,"April 4, 2020",Actual,2020-04-04,July 2020,2020-07-31,"July 14, 2020",Actual,2020-07-14,"May 20, 2020",Actual,2020-05-20,NA,Interventional,SENTAD-COVID,,Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19,"Adaptive Open-label Study Evaluating the Safety and Efficacy of Autologous Non- Hematopoietic Peripheral Blood Stem Cells Therapy in COVID-19 Outbreak in Abu Dhabi, 2020 (SENTAD-COVID Study)",Completed,NA,Phase 1/Phase 2,146,Actual,Abu Dhabi Stem Cells Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:50:03Z,2020-11-01T11:50:03Z
NCT04472585,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-14,NA,NA,2020-07-14,2020-07-14,2020-07-15,Actual,NA,NA,NA,NA,NA,NA,2020-07-14,2020-07-15,Actual,"July 14, 2020",Actual,2020-07-14,July 2020,2020-07-31,"September 30, 2020",Anticipated,2020-09-30,"September 15, 2020",Anticipated,2020-09-15,NA,Interventional,SINZ-COVID-PK,,Efficacy of Subcutaneous Ivermectin With or Without Zinc and Nigella Sativa in COVID-19 Patients,Sub-cutaneous Ivermectin in Combination With and Without Oral Zinc and Nigella Sativa: a Placebo Randomized Control Trial on Mild to Moderate COVID-19 Patients,Recruiting,NA,Phase 1/Phase 2,40,Anticipated,Sheikh Zayed Federal Postgraduate Medical Institute,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:50:09Z,2020-11-01T11:50:09Z
NCT04472494,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-14,NA,NA,2020-10-15,2020-07-14,2020-07-15,Actual,NA,NA,NA,NA,NA,NA,2020-10-15,2020-10-19,Actual,"August 24, 2020",Actual,2020-08-24,October 2020,2020-10-31,"January 14, 2021",Anticipated,2021-01-14,"January 13, 2021",Anticipated,2021-01-13,NA,Interventional,NA,,Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise,"Phase 2, Randomized, Double-Blind Placebo Controlled Study of Intravenous Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise",Recruiting,NA,Phase 2,129,Anticipated,Bristol-Myers Squibb,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:50:09Z,2020-11-01T11:50:09Z
NCT04471766,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-14,NA,NA,2020-07-21,2020-07-14,2020-07-15,Actual,NA,NA,NA,NA,NA,NA,2020-07-21,2020-07-22,Actual,"July 20, 2020",Actual,2020-07-20,July 2020,2020-07-31,November 2020,Anticipated,2020-11-30,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,,Locally Produced Cloth Face Mask and COVID-19 Like Illness Prevention,Evaluation of Locally Produced Cloth Face Mask on COVID-19 and Respiratory Illnesses Prevention at the Community Level - a Cluster-randomized Trial,Enrolling by invitation,NA,N/A,66000,Anticipated,Bandim Health Project,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:50:14Z,2020-11-01T11:50:14Z
NCT04473248,"ClinicalTrials.gov processed this data on November 13, 2020",2020-07-14,NA,NA,2020-11-11,2020-07-14,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Estimate,"June 28, 2020",Actual,2020-06-28,July 2020,2020-07-31,"August 30, 2020",Actual,2020-08-30,"August 30, 2020",Actual,2020-08-30,NA,Interventional,NA,,Spartan COVID-19 System: Evaluation of Clinical Sample Collection,Evaluation of Clinical Sample Collection Project: Spartan COVID-19,Completed,NA,N/A,27,Actual,Spartan Bioscience Inc.,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-15T10:58:12Z,2020-11-15T10:58:12Z
NCT04500067,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-15,NA,NA,2020-10-12,2020-08-04,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2020-10-12,2020-10-14,Actual,"May 7, 2020",Actual,2020-05-07,October 2020,2020-10-31,"September 15, 2020",Actual,2020-09-15,"September 15, 2020",Actual,2020-09-15,NA,Interventional,NA,,"Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment","An Open-label Multicenter Randomized Trial to Evaluate the Efficacy of Bioven, Manufactured by Biopharma Plasma, LLC, in Complex Therapy of Patients With Pneumonia Induced by COVID-19 / SARS-CoV-2",Completed,NA,Phase 3,76,Actual,Biopharma Plasma LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,After trial result publication 3 months later,"For specialists in medicine, pharmacy, scientists",NA,Yes,"After completion of the trial, results will be published. Access to parts CSR planned after the release of scientific publications",2020-11-01T11:46:50Z,2020-11-01T11:46:50Z
NCT04481685,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-15,NA,NA,2020-08-20,2020-07-20,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2020-08-20,2020-08-21,Actual,"July 20, 2020",Actual,2020-07-20,May 2020,2020-05-31,July 2022,Anticipated,2022-07-31,July 2021,Anticipated,2021-07-31,NA,Interventional,NA,,"A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)","A Double-blind, Randomized, Controlled Trial of ATI-450 in Patients With Moderate-severe COVID-19",Recruiting,NA,Phase 2,36,Anticipated,University of Kansas Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:49:02Z,2020-11-01T11:49:02Z
NCT04478071,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-15,NA,NA,2020-09-08,2020-07-15,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2020-09-08,2020-09-10,Actual,"August 22, 2020",Actual,2020-08-22,September 2020,2020-09-30,"August 1, 2022",Anticipated,2022-08-01,"August 1, 2022",Anticipated,2022-08-01,NA,Interventional,NA,,Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19),Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19),Recruiting,NA,Phase 2,300,Anticipated,"The University of Texas Health Science Center, Houston",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:49:25Z,2020-11-01T11:49:25Z
NCT04478019,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-15,NA,NA,2020-07-15,2020-07-15,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-20,Actual,"July 7, 2020",Actual,2020-07-07,May 2020,2020-05-31,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,SHIELD,,SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding,Role of NaSo-oropHaryngeal Antiseptic dEcolonizaiton to Reduce Covid-19 Viral Shedding and Disease Transmission: SHIELD Study,Recruiting,NA,Early Phase 1,94,Anticipated,"University of Wisconsin, Madison",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,Data will be shared after enrollment goals are reached for this study. Data will be shared via this website and publication in peer-reviewed journals.,NA,NA,Yes,De-identified study results will be shared with other researchers.,2020-11-01T11:49:25Z,2020-11-01T11:49:25Z
NCT04477655,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-15,NA,NA,2020-08-02,2020-07-16,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2020-08-02,2020-08-04,Actual,"May 3, 2020",Actual,2020-05-03,August 2020,2020-08-31,"December 30, 2020",Anticipated,2020-12-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,PRO-CARF,,Prone Positioning in Non-intubated Patients With COVID-19 Associated Acute Respiratory Failure,Prone Positioning in Non-intubated Patients With Severe COVID-19: a Randomized Controlled Trial,Recruiting,NA,N/A,200,Anticipated,Hospital Civil de Guadalajara,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:49:28Z,2020-11-01T11:49:28Z
NCT04476953,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-15,NA,NA,2020-08-11,2020-07-16,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-13,Actual,"August 3, 2020",Actual,2020-08-03,August 2020,2020-08-31,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Interventional,NA,,COVID-FISETIN: Pilot in Covid-19 of Fisetin to Alleviate Dysfunction and Inflammation,COVID-FISETIN: A Phase 2 Placebo-Controlled Pilot Study in Covid-19 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Hospitalized Adults,Enrolling by invitation,NA,Phase 2,70,Anticipated,Mayo Clinic,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:49:32Z,2020-11-01T11:49:32Z
NCT04475575,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-15,NA,NA,2020-07-16,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-17,Actual,"April 6, 2020",Actual,2020-04-06,July 2020,2020-07-31,"July 1, 2020",Actual,2020-07-01,"June 30, 2020",Actual,2020-06-30,NA,Interventional,NA,,Can the Electronic Nose Smell COVID-19 Antibodies?,Can the Electronic Nose Smell COVID-19 Antibodies? A Proof-of-principle Study,Completed,NA,N/A,222,Actual,Maastricht University Medical Center,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-11-01T11:49:40Z,2020-11-01T11:49:40Z
NCT04475562,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-15,NA,NA,2020-07-16,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-17,Actual,"April 6, 2020",Actual,2020-04-06,July 2020,2020-07-31,"July 1, 2020",Actual,2020-07-01,"May 6, 2020",Actual,2020-05-06,NA,Interventional,NA,,Can the Electronic Nose Smell COVID-19?,Can the Electronic Nose Smell COVID-19? A Proof-of-principle Study,Completed,NA,N/A,219,Actual,Maastricht University Medical Center,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-11-01T11:49:40Z,2020-11-01T11:49:40Z
NCT04475185,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-15,NA,NA,2020-09-21,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-22,Actual,"July 20, 2020",Actual,2020-07-20,September 2020,2020-09-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,COVRESP,,Safety and Effectiveness Assessment of the MakAir Artificial Ventilator,"Interventional, Open, Non-comparative, Multicenter Study to Assess the Safety and Effectiveness of the Use of the MakAir Artificial Ventilator in the Expected Situation of a Shortage of Technical Devices for Invasive Mechanical Ventilation, Linked to the Coronavirus COVID-19",Recruiting,NA,N/A,117,Anticipated,Nantes University Hospital,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:49:43Z,2020-11-01T11:49:43Z
NCT04474340,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-15,NA,NA,2020-07-17,2020-07-15,2020-07-16,Actual,NA,NA,NA,NA,NA,NA,2020-07-17,2020-07-21,Actual,"May 21, 2020",Actual,2020-05-21,July 2020,2020-07-31,"December 30, 2020",Anticipated,2020-12-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients,COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients: Multicenter Interventional Study,Recruiting,NA,Phase 1,300,Anticipated,"Ministry of Health, Kuwait",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-11-01T11:49:49Z,2020-11-01T11:49:49Z
NCT04477954,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-16,NA,NA,2020-08-18,2020-07-17,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"July 6, 2020",Actual,2020-07-06,August 2020,2020-08-31,"December 30, 2020",Anticipated,2020-12-30,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,,Hyperbaric Oxygen as an Adjuvant Treatment for Patients With Covid-19 Severe Hypoxemia,Hyperbaric Oxygen as an Adjuvant Treatment for Patients With Covid-19 Severe Hypoxemia,Recruiting,NA,Phase 2,80,Anticipated,AsociaciÃ³n Argentina de Medicina HiperbÃ¡rica e InvestigaciÃ³n,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:49:26Z,2020-11-01T11:49:26Z
NCT04476992,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-16,NA,NA,2020-09-14,2020-07-16,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2020-09-14,2020-09-16,Actual,"July 24, 2020",Actual,2020-07-24,September 2020,2020-09-30,"September 17, 2021",Anticipated,2021-09-17,"July 17, 2021",Anticipated,2021-07-17,NA,Interventional,NICOR,,Nitric Oxide Therapy for COVID-19 Patients With Oxygen Requirement,A Safety Study on the Use of Intermittent Versus Continuous Inhalation of NO in Spontaneous Breathing COVID-19 Patients,"Active, not recruiting",NA,Phase 1/Phase 2,20,Anticipated,"Federal State Budgetary Scientific Institution, Research Institute of Cardiology",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T11:49:32Z,2020-11-01T11:49:32Z
NCT04476979,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-16,NA,NA,2020-08-17,2020-07-16,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2020-08-17,2020-08-18,Actual,"July 16, 2020",Actual,2020-07-16,July 2020,2020-07-31,"December 31, 2021",Anticipated,2021-12-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,TOCIDEX,,Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19,Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19,Recruiting,NA,Phase 2,120,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:49:32Z,2020-11-01T11:49:32Z
NCT04476888,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-16,NA,NA,2020-07-20,2020-07-17,2020-07-20,Actual,NA,NA,NA,NA,NA,NA,2020-07-20,2020-07-22,Actual,"April 26, 2020",Actual,2020-04-26,July 2020,2020-07-31,September 2020,Anticipated,2020-09-30,August 2020,Anticipated,2020-08-31,NA,Interventional,COLLATE,,Convalescent Plasma Treatment in COVID-19,Convalescent Plasma Treatment in COVID-19 Patients at a Tertiary Care Center in Pakistan,Recruiting,NA,N/A,100,Anticipated,Aga Khan University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:49:32Z,2020-11-01T11:49:32Z
NCT04475588,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-16,NA,NA,2020-07-16,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-17,Actual,"May 1, 2020",Actual,2020-05-01,July 2020,2020-07-31,"July 8, 2020",Actual,2020-07-08,"July 8, 2020",Actual,2020-07-08,NA,Interventional,NA,,Efficacy and Safety of Itolizumab in COVID-19 Complications,"A Multi-Centre, Open Label, Two Arm Randomized, Pivotal Phase 2 Trial to Study the Efficacy and Safety of Itolizumab in COVID-19 Complications",Completed,NA,Phase 2,30,Actual,Biocon Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:49:40Z,2020-11-01T11:49:40Z
NCT04475302,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-16,NA,NA,2020-07-21,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-21,2020-07-23,Actual,"July 1, 2020",Actual,2020-07-01,July 2020,2020-07-31,May 2021,Anticipated,2021-05-31,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots,Study to Evaluate the Effectiveness of BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots in India,Recruiting,NA,Phase 3,2175,Anticipated,"Tuberculosis Research Centre, India",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:49:42Z,2020-11-01T11:49:42Z
NCT04475120,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-16,NA,NA,2020-07-16,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-17,Actual,"April 15, 2020",Actual,2020-04-15,July 2020,2020-07-31,"July 2, 2020",Actual,2020-07-02,"July 2, 2020",Actual,2020-07-02,NA,Interventional,NA,,Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients,Interventional Pilot Study to Assess the Use of Oral and Intra-nasal Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients,Completed,NA,Phase 2/Phase 3,60,Actual,University of Rome Tor Vergata,,4,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,NA,2020-11-01T11:49:44Z,2020-11-01T11:49:44Z
NCT04483375,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-17,NA,NA,2020-08-04,2020-07-22,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2020-08-04,2020-08-05,Actual,"July 24, 2020",Actual,2020-07-24,July 2020,2020-07-31,"January 15, 2021",Anticipated,2021-01-15,"November 20, 2020",Anticipated,2020-11-20,NA,Interventional,NA,,"Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects","A Randomized, Double-blinded, Placebo-controlled, Single Ascending Dose, Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetics of SCTA01 in Healthy Subjects",Recruiting,NA,Phase 1,33,Anticipated,Sinocelltech Ltd.,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:48:50Z,2020-11-01T11:48:50Z
NCT04480957,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-17,NA,NA,2020-08-13,2020-07-17,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2020-08-13,2020-08-17,Actual,"August 4, 2020",Actual,2020-08-04,August 2020,2020-08-31,January 2021,Anticipated,2021-01-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects,"A Phase 1/2 Randomised, Double Blinded, Placebo Controlled, Ascending Dose Study to Assess the Safety, Tolerability, and Immunogenicity of ARCT-021 in Healthy Adult Subjects",Recruiting,NA,Phase 1/Phase 2,92,Anticipated,"Arcturus Therapeutics, Inc.",,8,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:49:07Z,2020-11-01T11:49:07Z
NCT04480112,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-19,NA,NA,2020-09-03,2020-07-19,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-09-03,2020-09-04,Actual,"June 2, 2020",Actual,2020-06-02,September 2020,2020-09-30,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,Impact of Covid-19 on Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults,Impact of Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults With and Without Cognitive Impairment,Enrolling by invitation,NA,N/A,150,Anticipated,Boston University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:49:12Z,2020-11-01T11:49:12Z
NCT04514900,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-20,NA,NA,2020-10-20,2020-08-12,2020-08-17,Actual,NA,NA,NA,NA,NA,NA,2020-10-20,2020-10-22,Actual,"September 23, 2020",Actual,2020-09-23,October 2020,2020-10-31,"September 15, 2021",Anticipated,2021-09-15,"September 15, 2021",Anticipated,2021-09-15,NA,Interventional,iREACH,,Exploring Optimal Treatment Components for Contactless Online Group-based Behavioral Weight Loss Program,Exploring the Optimal Treatment Components for a Contactless Online Group-based Behavioral Weight Loss Program for the COVID 19 Pandemic,"Active, not recruiting",NA,N/A,120,Anticipated,University of South Carolina,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:45:06Z,2020-11-01T11:45:06Z
NCT04488484,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-20,NA,NA,2020-08-10,2020-07-27,2020-07-28,Actual,NA,NA,NA,NA,NA,NA,2020-08-10,2020-08-12,Actual,"July 1, 2020",Actual,2020-07-01,July 2020,2020-07-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,PERSO-COVID,,Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group Infected With Severe Acute Respiratory Syndrome Coronavirus 2.,Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group,"Active, not recruiting",NA,N/A,450,Anticipated,Groupe Hospitalier Paris Saint Joseph,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:48:17Z,2020-11-01T11:48:17Z
NCT04485429,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-20,NA,NA,2020-07-23,2020-07-23,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-23,2020-07-24,Actual,"July 20, 2020",Anticipated,2020-07-20,July 2020,2020-07-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia,"Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia: A Randomized, Controlled, 2x2 Factorial Study",Recruiting,NA,Phase 3,268,Anticipated,D'Or Institute for Research and Education,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:48:36Z,2020-11-01T11:48:36Z
NCT04480424,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-20,NA,NA,2020-09-21,2020-07-20,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-23,Actual,"September 17, 2020",Actual,2020-09-17,September 2020,2020-09-30,February 2021,Anticipated,2021-02-28,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19),"A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit",Recruiting,NA,Phase 2,100,Anticipated,Grifols Therapeutics LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:49:10Z,2020-11-01T11:49:10Z
NCT04480138,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-20,NA,NA,2020-08-11,2020-07-20,2020-07-21,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-13,Actual,"August 11, 2020",Actual,2020-08-11,August 2020,2020-08-31,"January 30, 2021",Anticipated,2021-01-30,"December 15, 2020",Anticipated,2020-12-15,NA,Interventional,NA,,Pegylated Interferon - Î±2b With SARSCoV- 2 (COVID-19),"A Phase II, Multicenter, Open-label, Randomized, Comparator Controlled Study to Evaluate the Efficacy and Safety of Pegylated Interferon - Î±2b in the Treatment of Adult Patients Diagnosed With SARS-CoV2 (COVID-19)",Recruiting,NA,Phase 2,40,Anticipated,Cadila Healthcare Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:49:12Z,2020-11-01T11:49:12Z
NCT04570462,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-21,NA,NA,2020-09-29,2020-09-29,2020-09-30,Actual,NA,NA,NA,NA,NA,NA,2020-09-29,2020-09-30,Actual,"May 18, 2020",Actual,2020-05-18,September 2020,2020-09-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Mild Hypothermia for COVID-19 ARDS,Application of Mild Hypothermia for COVID-19 Acute Respiratory Distress,Recruiting,NA,N/A,20,Anticipated,Northwell Health,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:38:35Z,2020-11-01T11:38:35Z
NCT04494724,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-21,NA,NA,2020-07-30,2020-07-30,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2020-07-30,2020-07-31,Actual,"July 13, 2020",Actual,2020-07-13,July 2020,2020-07-31,"July 31, 2021",Anticipated,2021-07-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Clazakizumab vs. Placebo - COVID-19 Infection,A Phase 2 Trial to Evaluate the Safety and Tolerability of ClazakizumabÂ® [Anti-Interleukin (IL)-6 Monoclonal] Compared to Placebo for the Treatment of COVID-19 Infection,Recruiting,NA,Phase 2,60,Anticipated,The Methodist Hospital System,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:47:27Z,2020-11-01T11:47:27Z
NCT04487639,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-21,NA,NA,2020-07-23,2020-07-23,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2020-07-23,2020-07-27,Actual,"July 10, 2020",Actual,2020-07-10,July 2020,2020-07-31,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Interventional,FERTICOVID,,Presence of SARS-CoV-2 in Semen: Impact on Fertility Preservation in Male Oncological Patients ?,Presence of SARS-CoV-2 in Semen: Impact on Fertility Preservation in Male Oncological Patients During the COVID-19 Pandemic ?,Recruiting,NA,N/A,250,Anticipated,"University Hospital, Clermont-Ferrand",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:48:22Z,2020-11-01T11:48:22Z
NCT04485169,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-21,NA,NA,2020-09-24,2020-07-22,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-28,Actual,"April 1, 2020",Actual,2020-04-01,September 2020,2020-09-30,"July 31, 2020",Actual,2020-07-31,"July 31, 2020",Actual,2020-07-31,NA,Interventional,Plex,,Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm;,Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm; a Retrospective Propensity Matched Control Study,Completed,NA,N/A,280,Actual,UNICEF,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,Data is available right now and will remain available (6 months),By email,NA,Yes,data can be shared on demand in SPSS sheet,2020-11-01T11:48:38Z,2020-11-01T11:48:38Z
NCT04484207,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-21,NA,NA,2020-10-12,2020-07-21,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2020-10-12,2020-10-14,Actual,"July 6, 2020",Actual,2020-07-06,October 2020,2020-10-31,"October 26, 2020",Anticipated,2020-10-26,"October 20, 2020",Anticipated,2020-10-20,NA,Interventional,NA,,Addressing COVID-19 Mental Health Problems Among US Veterans,Addressing COVID-19 Mental Health Problems Among US Veterans,Recruiting,NA,N/A,200,Anticipated,"Research Foundation for Mental Hygiene, Inc.",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,two months,Co-Is,NA,Yes,"Data will be shared as needed with investigators, IRB etc. A plan will be determined in the short future",2020-11-01T11:48:44Z,2020-11-01T11:48:44Z
NCT04483752,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-21,NA,NA,2020-07-22,2020-07-22,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2020-07-22,2020-07-23,Actual,"June 8, 2020",Actual,2020-06-08,July 2020,2020-07-31,"November 8, 2021",Anticipated,2021-11-08,"February 8, 2021",Anticipated,2021-02-08,NA,Interventional,PREDISCAN,,Predicting the Progression to Chronic Fibrosis of Lung Lesions Related to Covid-19 Infection From Chest CT Images,Predicting the Progression to Chronic Fibrosis of Lung Lesions Related to Covid-19 Infection From Chest CT Images,Recruiting,NA,N/A,100,Anticipated,Centre Chirurgical Marie Lannelongue,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:48:47Z,2020-11-01T11:48:47Z
NCT04482647,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-21,NA,NA,2020-09-21,2020-07-21,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-23,Actual,"June 17, 2020",Actual,2020-06-17,September 2020,2020-09-30,"July 1, 2021",Anticipated,2021-07-01,"July 1, 2021",Anticipated,2021-07-01,NA,Interventional,NA,,Breathing Techniques and Meditation for Health Care Workers During COVID-19 Pandemic,Breathing Techniques and Meditation for Health Care Workers During COVID-19,Recruiting,NA,Phase 1,50,Anticipated,M.D. Anderson Cancer Center,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:48:56Z,2020-11-01T11:48:56Z
NCT04482621,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-21,NA,NA,2020-09-24,2020-07-21,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-25,Actual,"September 14, 2020",Actual,2020-09-14,September 2020,2020-09-30,July 2021,Anticipated,2021-07-31,May 2021,Anticipated,2021-05-31,NA,Interventional,DART,,Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial,Decitabine for COVID-19 Pneumonia-ARDS Treatment: DART Trial,Recruiting,NA,Phase 2,40,Anticipated,Johns Hopkins University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:48:56Z,2020-11-01T11:48:56Z
NCT04482634,"ClinicalTrials.gov processed this data on November 06, 2020",2020-07-21,NA,NA,2020-11-04,2020-07-21,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-05,Actual,"September 1, 2020",Actual,2020-09-01,July 2020,2020-07-31,August 2022,Anticipated,2022-08-31,August 2022,Anticipated,2022-08-31,NA,Interventional,NA,,Tele-rehabilitation Versus Home Exercise Program in COVID-19,Is Tele-rehabilitation Superior to Home Exercise Program in the Pulmonary Rehabilitation of the Patients With COVID-19 With Post-intensive Care Syndrome? A Randomized Controlled Trial,Recruiting,NA,N/A,122,Anticipated,KoÃ§ University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-09T10:52:41Z,2020-11-09T10:52:41Z
NCT04481633,"ClinicalTrials.gov processed this data on November 13, 2020",2020-07-21,NA,NA,2020-11-10,2020-07-21,2020-07-22,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"September 9, 2020",Actual,2020-09-09,November 2020,2020-11-30,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,NA,Interventional,PREPCOV,,Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection,Real-life Evaluation of the Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection in Patients Receiving Long-term Treatment for Systemic Lupus Erythematosus and/or Gougerot's Disease,Recruiting,NA,N/A,800,Anticipated,"University Hospital, Toulouse",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-15T10:58:05Z,2020-11-15T10:58:05Z
NCT04488796,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-22,NA,NA,2020-09-21,2020-07-26,2020-07-28,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-23,Actual,"September 7, 2020",Actual,2020-09-07,September 2020,2020-09-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,STAND UP to SARS-CoV-2 (COVID-19): Using Behavioural Economics to Reduce Sedentary Behaviour in At-home Office Workers,"STAND UP to SARS-CoV-2 (COVID-19): Using Behavioural Economics to Reduce Sedentary Behaviour in At-home Office Workers, a Pilot Randomized Controlled Trial",Recruiting,NA,N/A,145,Anticipated,"Western University, Canada",,6,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:48:15Z,2020-11-01T11:48:15Z
NCT04487444,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-22,NA,NA,2020-09-10,2020-07-24,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2020-09-10,2020-09-14,Actual,"September 10, 2020",Actual,2020-09-10,July 2020,2020-07-31,June 2021,Anticipated,2021-06-30,March 2021,Anticipated,2021-03-31,NA,Interventional,Ta1,,Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection,A Pilot Trial of Thymalfasin (Ta1) to Treat COVID-19 Infection in Patients With Lymphocytopenia,Recruiting,NA,Phase 2,80,Anticipated,Rhode Island Hospital,,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:48:23Z,2020-11-01T11:48:23Z
NCT04487210,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-22,NA,NA,2020-10-26,2020-07-22,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-26,2020-10-27,Actual,"October 7, 2020",Actual,2020-10-07,October 2020,2020-10-31,"June 30, 2021",Anticipated,2021-06-30,"January 30, 2021",Anticipated,2021-01-30,NA,Interventional,NA,,A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19,"A Phase I, Prospective, Open-Labeled Study to Evaluate the Safety and Immunogenicity of MVC-COV1901",Recruiting,NA,Phase 1,45,Anticipated,Medigen Vaccine Biologics Corp.,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:48:25Z,2020-11-01T11:48:25Z
NCT04486508,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-22,NA,NA,2020-10-16,2020-07-22,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-20,Actual,"July 30, 2020",Actual,2020-07-30,October 2020,2020-10-31,"December 6, 2020",Anticipated,2020-12-06,"October 25, 2020",Anticipated,2020-10-25,NA,Interventional,INSPIRATION,,Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19,Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19: An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19,Recruiting,NA,Phase 3,600,Anticipated,Rajaie Cardiovascular Medical and Research Center,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:48:30Z,2020-11-01T11:48:30Z
NCT04483960,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-22,NA,NA,2020-07-22,2020-07-22,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2020-07-22,2020-07-23,Actual,"July 21, 2020",Anticipated,2020-07-21,July 2020,2020-07-31,"June 12, 2022",Anticipated,2022-06-12,"June 12, 2021",Anticipated,2021-06-12,NA,Interventional,ASCOT,,Australasian COVID-19 Trial (ASCOT),"An International Multi-Centre Randomised Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients Diagnosed With SARS-CoV-2 Infection (COVID-19)",Recruiting,NA,Phase 3,2400,Anticipated,University of Melbourne,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T11:48:46Z,2020-11-01T11:48:46Z
NCT04483830,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-22,NA,NA,2020-09-07,2020-07-22,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2020-09-07,2020-09-09,Actual,"June 5, 2020",Actual,2020-06-05,September 2020,2020-09-30,"September 7, 2020",Actual,2020-09-07,"August 6, 2020",Actual,2020-08-06,NA,Interventional,SulES-COVID,,Suloexide in the Treatment of Early Stages of COVID-19,Sulodexide in the Treatment of Early Stages of COVID-19,Completed,NA,Phase 2/Phase 3,243,Actual,Clinedem,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,individual participant data will be confidential,2020-11-01T11:48:47Z,2020-11-01T11:48:47Z
NCT04487574,"ClinicalTrials.gov processed this data on November 13, 2020",2020-07-22,NA,NA,2020-11-11,2020-07-24,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Estimate,"July 25, 2020",Actual,2020-07-25,November 2020,2020-11-30,"October 29, 2020",Actual,2020-10-29,"October 29, 2020",Actual,2020-10-29,NA,Interventional,NA,,A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19,"A Multicenter, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of XC221, Tablets, 100 mg in Patients With COVID-19",Completed,NA,Phase 3,118,Actual,RSV Therapeutics LLC,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-15T10:57:59Z,2020-11-15T10:57:59Z
NCT04484493,"ClinicalTrials.gov processed this data on November 13, 2020",2020-07-22,NA,NA,2020-11-11,2020-07-22,2020-07-23,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Estimate,"August 8, 2020",Actual,2020-08-08,November 2020,2020-11-30,"November 3, 2020",Actual,2020-11-03,"October 25, 2020",Actual,2020-10-25,NA,Interventional,NA,,Corticosteroid Nasal Spray in COVID-19 Anosmia,Role of Corticosteroid Nasal Spray in Recovery of Smell Sensation in COVID-19 Patients,Completed,NA,Phase 3,100,Actual,Benha University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-15T10:58:03Z,2020-11-15T10:58:03Z
NCT04490278,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-23,NA,NA,2020-09-30,2020-07-23,2020-07-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"September 29, 2020",Actual,2020-09-29,September 2020,2020-09-30,"July 30, 2021",Anticipated,2021-07-30,"July 30, 2021",Anticipated,2021-07-30,NA,Interventional,NA,,CoV-PICS: A Virtual Post-ICU Clinic,"COVID-19 Virtual Post Intensive Care Syndrome (CoV-PICS) Clinic: Modern, Convenient and Practical Recovery Care",Recruiting,NA,N/A,80,Anticipated,Washington University School of Medicine,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:48:03Z,2020-11-01T11:48:03Z
NCT04487990,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-23,NA,NA,2020-07-24,2020-07-24,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2020-07-24,2020-07-27,Actual,"June 29, 2020",Actual,2020-06-29,July 2020,2020-07-31,July 2021,Anticipated,2021-07-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19,CoV-Hep Study: Randomized and Paired Clinical Trial Comparing Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19,Recruiting,NA,N/A,90,Anticipated,University of Sao Paulo General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:48:20Z,2020-11-01T11:48:20Z
NCT04486482,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-23,NA,NA,2020-07-23,2020-07-23,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-23,2020-07-24,Actual,July 2020,Anticipated,2020-07-31,July 2020,2020-07-31,March 2021,Anticipated,2021-03-31,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,,A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function,"An Exploratory, Open Label, Clinical Study to Evaluate the Physiologic Effects of KB109 in Adult Patients With Mild-to-Moderate COVID-19 on Gut Microbiota Structure and Function in the Outpatient Setting",Recruiting,NA,N/A,50,Anticipated,Kaleido Biosciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:48:30Z,2020-11-01T11:48:30Z
NCT04486313,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-23,NA,NA,2020-10-28,2020-07-23,2020-07-24,Actual,NA,NA,NA,NA,NA,NA,2020-10-28,2020-10-29,Actual,"August 13, 2020",Actual,2020-08-13,October 2020,2020-10-31,"December 30, 2020",Anticipated,2020-12-30,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,NA,,Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19,"Phase 3, Randomized, Double-Blind, Placebo-Controlled, Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19",Recruiting,NA,Phase 3,800,Anticipated,Romark Laboratories L.C.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-02T10:29:04Z,2020-11-02T10:29:04Z
NCT04488575,"ClinicalTrials.gov processed this data on November 13, 2020",2020-07-23,NA,NA,2020-11-11,2020-07-25,2020-07-28,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Estimate,"August 26, 2020",Actual,2020-08-26,November 2020,2020-11-30,"December 21, 2020",Anticipated,2020-12-21,"December 21, 2020",Anticipated,2020-12-21,NA,Interventional,NA,,Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection,A Phase 2 Double-blind Placebo-controlled Study Investigating the Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With SARS-CoV-2 Infection,Recruiting,NA,Phase 2,60,Anticipated,"Evelo Biosciences, Inc.",,2,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-15T10:57:57Z,2020-11-15T10:57:57Z
NCT04494386,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-24,NA,NA,2020-08-12,2020-07-29,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2020-08-12,2020-08-13,Actual,"July 23, 2020",Actual,2020-07-23,August 2020,2020-08-31,"November 30, 2021",Anticipated,2021-11-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,ULSC,,Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS,Phase 1/2a Study of Umbilical Cord Lining Stem Cells (ULSC) in Patients With ARDS Due to COVID-19,Recruiting,NA,Phase 1/Phase 2,60,Anticipated,"Restem, LLC.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:47:30Z,2020-11-01T11:47:30Z
NCT04487964,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-24,NA,NA,2020-07-25,2020-07-24,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2020-07-25,2020-07-28,Actual,"January 1, 2020",Actual,2020-01-01,July 2020,2020-07-31,January 2021,Anticipated,2021-01-31,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,NA,,Complementary Intervention for COVID-19,Evaluation of The Potential Therapeutic Effects of Licorice and Boswellia Serrata Gum in Egyptian Patients With COVID-19 as a Complementary Medicine,Recruiting,NA,N/A,70,Anticipated,Egyptian Biomedical Research Network,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"A pilot study for evaluation of the potential therapeutic effect of food supplement, licorice extract, and Boswellia Serrata gum",2020-11-01T11:48:20Z,2020-11-01T11:48:20Z
NCT04487171,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-24,NA,NA,2020-07-24,2020-07-24,2020-07-27,Actual,NA,NA,NA,NA,NA,NA,2020-07-24,2020-07-27,Actual,"July 21, 2020",Actual,2020-07-21,July 2020,2020-07-31,August 2021,Anticipated,2021-08-31,July 2021,Anticipated,2021-07-31,NA,Interventional,COVIE-19/20,,Screening for Postpartum Depression and Associated Risk Factors Among Women Who Deliver in Four Hospital in France During the COVID-19 Epidemic,Screening for Postpartum Depression and Associated Risk Factors Among Women Who Deliver in Four Hospital in France During the COVID-19 Epidemic,Recruiting,NA,N/A,248,Anticipated,"Centre Hospitalier Universitaire, Amiens",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:48:25Z,2020-11-01T11:48:25Z
NCT04519437,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-24,NA,NA,2020-10-27,2020-08-18,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-28,Actual,"July 26, 2020",Actual,2020-07-26,October 2020,2020-10-31,"October 25, 2021",Anticipated,2021-10-25,"October 25, 2021",Anticipated,2021-10-25,NA,Interventional,NA,,"Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19","A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers",Recruiting,NA,Phase 1,940,Anticipated,Regeneron Pharmaceuticals,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,"Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.","Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency [EMA], Pharmaceuticals and Medical Devices Agency [PMDA], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).",https://vivli.org,Yes,All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing,2020-11-01T13:28:26Z,2020-11-01T13:28:26Z
NCT04492228,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-25,NA,NA,2020-09-28,2020-07-29,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-30,Actual,"September 1, 2020",Actual,2020-09-01,September 2020,2020-09-30,"May 30, 2021",Anticipated,2021-05-30,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,ketocovidiet,,Eucaloric Ketogenic Diet in COVID-19 Cytokine Storm Syndrome,Randomized Open Controlled Clinical Trial to Evaluate the Effectiveness of a Eucaloric Ketogenic Nutrition in Comparison With a Standard Nutrition in Covid-19 Disease in Reducing Cytokine Storm Syndrome and ARDS,Recruiting,NA,N/A,100,Anticipated,Ospedale Policlinico San Martino,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:47:44Z,2020-11-01T11:47:44Z
NCT04490473,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-25,NA,NA,2020-07-28,2020-07-28,2020-07-29,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-29,Actual,"July 24, 2020",Actual,2020-07-24,July 2020,2020-07-31,"December 24, 2020",Anticipated,2020-12-24,"October 24, 2020",Anticipated,2020-10-24,NA,Interventional,NA,,Turkish of the SARS-CoV-2 Anxiety Scale,Turkish Validity And Reliability of the SARS-CoV-2 Anxiety Scale,Recruiting,NA,N/A,300,Anticipated,Eskisehir Osmangazi University,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,will be shared after the work is finished.,It will be shared with researchers who want to use the anxiety scale.,NA,Yes,It is planned to be published in the journal after the study is completed. The study will be shared with other researchers after it is published in the journal.,2020-11-01T11:47:59Z,2020-11-01T11:47:59Z
NCT04489446,"ClinicalTrials.gov processed this data on November 06, 2020",2020-07-25,NA,NA,2020-11-02,2020-07-25,2020-07-28,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"August 19, 2020",Actual,2020-08-19,November 2020,2020-11-30,March 2021,Anticipated,2021-03-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Sildenafil in COVID-19,Sildenafil for Treating Patients With COVID-19 and Perfusion Mismatch: A Pilot Randomised Trial,Recruiting,NA,Phase 1/Phase 2,40,Anticipated,Universidad Nacional Andres Bello,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-11-07T11:21:03Z,2020-11-07T11:21:03Z
NCT04496245,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-26,NA,NA,2020-09-02,2020-07-31,2020-08-03,Actual,NA,NA,NA,NA,NA,NA,2020-09-02,2020-09-04,Actual,"August 24, 2020",Actual,2020-08-24,July 2020,2020-07-31,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,COVIDRASP,,Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85,Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85,Recruiting,NA,Phase 3,1000,Anticipated,The University of Queensland,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:47:17Z,2020-11-01T11:47:17Z
NCT04501796,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-27,NA,NA,2020-08-05,2020-08-05,2020-08-06,Actual,NA,NA,NA,NA,NA,NA,2020-08-05,2020-08-06,Actual,August 2020,Anticipated,2020-08-31,August 2020,2020-08-31,December 2021,Anticipated,2021-12-31,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,,A Trial of NT-I7 in COVID-19 (SPESELPIS),"A Double-blind, Randomized, Placebo-controlled, Phase 1, Single-dose, Dose-escalating Trial of Long-acting Recombinant Human IL-7 (NT-I7) for COVID-19",Recruiting,NA,Phase 1,30,Anticipated,NeoImmuneTech,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:46:39Z,2020-11-01T11:46:39Z
NCT04499313,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-27,NA,NA,2020-08-17,2020-08-04,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2020-08-17,2020-08-18,Actual,"August 2, 2020",Actual,2020-08-02,August 2020,2020-08-31,"November 30, 2020",Anticipated,2020-11-30,"November 15, 2020",Anticipated,2020-11-15,NA,Interventional,NA,,Dexamethasone Vs Methylprednisolone for the Treatment of Patients With ARDS Caused by COVID-19,The Outcome of Dexamethasone and Methylprednisolone Treatment for Patients With ARDS Caused by COVID-19,Recruiting,NA,Phase 3,60,Anticipated,Chattogram General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:46:57Z,2020-11-01T11:46:57Z
NCT04497623,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-27,NA,NA,2020-09-22,2020-08-01,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-24,Actual,"July 28, 2020",Actual,2020-07-28,September 2020,2020-09-30,"September 20, 2020",Actual,2020-09-20,"August 13, 2020",Actual,2020-08-13,NA,Interventional,SabanaHerons,,"Clinical Evaluation of Ventilador Innovation Product in Colombia in the SARS COVID 19 Pandemic, Unisabana Herons.","Clinical Evaluation of Ventilator Innovation Product in Colombia in the SARS Pandemic Covid 19, Unisabana Herons - A Cohort Study - Phase 1",Completed,NA,N/A,5,Actual,FundaciÃ³n Neumologica Colombiana,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,The clinical and ventilatory data of the patients will be entered into an anonymized database hosted on the RedCap platform with which the University of La Sabana has an agreement.,2020-11-01T11:47:08Z,2020-11-01T11:47:08Z
NCT04490824,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-27,NA,NA,2020-09-16,2020-07-27,2020-07-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-16,2020-09-18,Actual,"October 1, 2020",Anticipated,2020-10-01,September 2020,2020-09-30,"November 30, 2020",Anticipated,2020-11-30,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,NA,,Inhalation of KELEA Excellerated Water in Covid-19 Infected Individuals,Can Inhalation of KELEA Excellerated Water Reduce the Time Required for Covid-19 Infected Individuals to Become Symptom-Free and to Test Negative Using Either the PCR or Antigen Assay,Recruiting,NA,N/A,100,Anticipated,Institute of Progressive Medicine,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:47:56Z,2020-11-01T11:47:56Z
NCT04491240,"ClinicalTrials.gov processed this data on November 06, 2020",2020-07-27,2020-10-21,NA,2020-10-28,2020-07-27,2020-07-29,Actual,2020-10-28,2020-11-04,Actual,NA,NA,NA,2020-10-28,2020-11-04,Actual,"July 20, 2020",Actual,2020-07-20,October 2020,2020-10-31,"October 20, 2020",Actual,2020-10-20,"October 1, 2020",Actual,2020-10-01,NA,Interventional,COVID-19EXO,,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,The Protocol of Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Two-Sided Pneumonia,Completed,NA,Phase 1/Phase 2,30,Actual,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-08T11:33:20Z,2020-11-08T11:33:20Z
NCT04518514,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-28,NA,NA,2020-08-14,2020-08-14,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2020-08-14,2020-08-19,Actual,"April 20, 2020",Actual,2020-04-20,August 2020,2020-08-31,"November 30, 2020",Anticipated,2020-11-30,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,NA,,Telemedical Risk Assessment and Preoperative Evaluation (TAPE),Telemedical Risk Assessment and Preoperative Evaluation for Anesthesia During the COVID-19 Pandemic,Recruiting,NA,N/A,100,Anticipated,RWTH Aachen University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:44:41Z,2020-11-01T11:44:41Z
NCT04495101,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-28,NA,NA,2020-10-08,2020-07-30,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2020-10-08,2020-10-09,Actual,"July 29, 2020",Actual,2020-07-29,September 2020,2020-09-30,April 2021,Anticipated,2021-04-30,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,,Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19,"A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Prolastin Plus Standard Medical Treatment (SMT) Versus SMT Alone in Hospitalized Subjects With COVID-19",Recruiting,NA,Phase 2,100,Anticipated,Grifols Therapeutics LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:47:24Z,2020-11-01T11:47:24Z
NCT04494399,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-28,NA,NA,2020-07-29,2020-07-29,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-07-31,Actual,"July 29, 2020",Actual,2020-07-29,July 2020,2020-07-31,"August 1, 2022",Anticipated,2022-08-01,"July 1, 2022",Anticipated,2022-07-01,NA,Interventional,NA,,IFN Beta-1b and Ribavirin for Covid-19,"An Open-label Randomised Controlled Trial on IFN Beta-1b and Ribavirin Combination, as Treatment for Covid-19 Infection",Recruiting,NA,Phase 2,96,Anticipated,The University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:47:30Z,2020-11-01T11:47:30Z
NCT04494204,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-28,NA,NA,2020-10-17,2020-07-30,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2020-10-17,2020-10-20,Actual,"August 7, 2020",Actual,2020-08-07,October 2020,2020-10-31,"October 30, 2020",Anticipated,2020-10-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,NA,,Effect of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets in the Treatment of Mild to Moderate COVID-19 Patients,"An Open Label, Multicenter, Randomized, Controlled, Clinical Study to Evaluate the Efficacy and Safety of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets Compared With Standard Treatment Protocol in the Treatment of Mild to Moderate COVID-19 Patients.",Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Nutrin GmbH,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"The trial is meant for pandemic, and any data is fruitful to the society will be shared with researchers only, without compromising personal data of the participant.",2020-11-01T11:47:31Z,2020-11-01T11:47:31Z
NCT04492527,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-28,NA,NA,2020-07-29,2020-07-28,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-07-31,Actual,"July 28, 2020",Actual,2020-07-28,July 2020,2020-07-31,"July 31, 2021",Anticipated,2021-07-31,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,,Student-delivered Telehealth Program for COVID-19 Education and Health Promotion,A Student-delivered Community Outreach teleheAlth Program for Covid Education and Health Promotion (COACH),Recruiting,NA,N/A,75,Anticipated,University of British Columbia,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:47:42Z,2020-11-01T11:47:42Z
NCT04492514,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-28,NA,NA,2020-07-28,2020-07-28,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-30,Actual,"May 20, 2020",Actual,2020-05-20,July 2020,2020-07-31,"May 31, 2021",Anticipated,2021-05-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,NA,,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,Recruiting,NA,Phase 2,60,Anticipated,University of Cincinnati,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:47:42Z,2020-11-01T11:47:42Z
NCT04492501,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-28,NA,NA,2020-07-28,2020-07-28,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-30,Actual,"April 1, 2020",Actual,2020-04-01,July 2020,2020-07-31,"July 20, 2020",Actual,2020-07-20,"July 20, 2020",Actual,2020-07-20,NA,Interventional,NA,,Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan,"Role of Investigational Therapies Alone or in Combination to Treat Moderate, Severe and Critical COVID-19",Completed,NA,N/A,600,Actual,UNICEF,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,6 months from completion of study,email,NA,Yes,data can be shared on demand in SPSS sheet,2020-11-01T11:47:42Z,2020-11-01T11:47:42Z
NCT04492410,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-28,NA,NA,2020-07-29,2020-07-29,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-07-30,Actual,"July 21, 2020",Actual,2020-07-21,July 2020,2020-07-31,March 2021,Anticipated,2021-03-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NEOSCREENCOVID,,COVID-19 Infection Screening in Cancer Patients (NEOSCREENCOVID),COVID-19 Infection Screening in Cancer Patients (NEOSCREENCOVID),Recruiting,NA,N/A,500,Anticipated,Centre Antoine Lacassagne,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:47:43Z,2020-11-01T11:47:43Z
NCT04491994,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-28,2020-07-31,NA,2020-08-18,2020-07-28,2020-07-30,Actual,2020-08-18,2020-08-21,Actual,NA,NA,NA,2020-08-18,2020-08-21,Actual,"April 10, 2020",Actual,2020-04-10,August 2020,2020-08-31,"May 31, 2020",Actual,2020-05-31,"May 31, 2020",Actual,2020-05-31,NA,Interventional,COVID-19,sample size calculation was done and 540 patients enrolled,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Clearing the Fog: Is HCQ Effective in Reducing COVID-19 progression-a Randomized Controlled Trial,Completed,NA,Phase 3,540,Actual,UNICEF,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,any time when asked,by email,NA,Yes,data can be shared on demand in SPSS sheet,2020-11-01T11:47:46Z,2020-11-01T11:47:46Z
NCT04490850,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-28,NA,NA,2020-07-28,2020-07-28,2020-07-29,Actual,NA,NA,NA,NA,NA,NA,2020-07-28,2020-07-29,Actual,"July 15, 2020",Actual,2020-07-15,July 2020,2020-07-31,"July 15, 2021",Anticipated,2021-07-15,"July 15, 2021",Anticipated,2021-07-15,NA,Interventional,EPI-COVID-POP,,COVID-19 Seroprevalence Study in French Guiana,COVID-19 Seroprevalence Study in French Guiana,Recruiting,NA,N/A,1500,Anticipated,Institut Pasteur,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:47:55Z,2020-11-01T11:47:55Z
NCT04492358,"ClinicalTrials.gov processed this data on November 13, 2020",2020-07-28,NA,NA,2020-11-05,2020-07-29,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2020-11-05,2020-11-09,Actual,"October 22, 2020",Actual,2020-10-22,July 2020,2020-07-31,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,,"Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center","Phase 2/3, Randomized, Open Study to Compare the Efficacy and Safety of Colchicine and Glucocorticoids Compared With the Standard of Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center",Recruiting,NA,Phase 2/Phase 3,144,Anticipated,Fundacion Clinic per a la Recerca BiomÃ©dica,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-14T10:40:02Z,2020-11-14T10:40:02Z
NCT04492475,"ClinicalTrials.gov processed this data on November 13, 2020",2020-07-28,NA,NA,2020-11-11,2020-07-28,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Estimate,"August 4, 2020",Actual,2020-08-04,November 2020,2020-11-30,"December 30, 2020",Anticipated,2020-12-30,"December 15, 2020",Anticipated,2020-12-15,NA,Interventional,NA,,Adaptive COVID-19 Treatment Trial 3 (ACTT-3),"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults (ACTT-3)","Active, not recruiting",NA,Phase 3,969,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-15T10:57:55Z,2020-11-15T10:57:55Z
NCT04494867,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-29,NA,NA,2020-09-23,2020-07-29,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-25,Actual,"August 19, 2020",Actual,2020-08-19,September 2020,2020-09-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Core Warming in COVID-19 Patients Undergoing Mechanical Ventilation,"Core Warming of COVID-19 Patients Undergoing Mechanical Ventilation: a Randomized, Single Center Pilot Study",Recruiting,NA,N/A,20,Anticipated,Sharp HealthCare,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2020-11-01T11:47:27Z,2020-11-01T11:47:27Z
NCT04493359,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-29,NA,NA,2020-07-29,2020-07-29,2020-07-30,Actual,NA,NA,NA,NA,NA,NA,2020-07-29,2020-07-31,Actual,"July 25, 2020",Actual,2020-07-25,July 2020,2020-07-31,"February 14, 2022",Anticipated,2022-02-14,"February 14, 2022",Anticipated,2022-02-14,NA,Interventional,SWITCH-COVID,,Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19,Switch or Maintenance of Renin-Angiotensin System Inhibitors in Patients With Covid-19: A Randomized Proof of Concept Trial,Recruiting,NA,Phase 2/Phase 3,240,Anticipated,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,Data may be requested for collaboration projects,2020-11-01T11:47:38Z,2020-11-01T11:47:38Z
NCT04494984,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-29,NA,NA,2020-10-27,2020-07-30,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-28,Actual,"July 27, 2020",Actual,2020-07-27,October 2020,2020-10-31,December 2020,Anticipated,2020-12-31,"November 23, 2020",Anticipated,2020-11-23,NA,Interventional,NA,,"A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.","A Stage 2/3, Adaptive, Randomized, Controlled, Double-blind Study to Investigate the Pharmacokinetics, Efficacy and Safety of the Hyperimmune Equine Serum (INM005) in Adult Patients With Moderate to Severe Confirmed SARS-CoV2 Disease.","Active, not recruiting",NA,Phase 2/Phase 3,242,Actual,Inmunova S.A.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T13:36:15Z,2020-11-01T13:36:15Z
NCT04494646,"ClinicalTrials.gov processed this data on November 06, 2020",2020-07-29,NA,NA,2020-10-30,2020-07-29,2020-07-31,Actual,NA,NA,NA,NA,NA,NA,2020-10-30,2020-11-03,Actual,"September 8, 2020",Actual,2020-09-08,October 2020,2020-10-31,"February 28, 2021",Anticipated,2021-02-28,"January 30, 2021",Anticipated,2021-01-30,NA,Interventional,NA,,BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19),"BARCONA: A Phase II/III, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)",Recruiting,NA,Phase 2/Phase 3,440,Anticipated,NYU Langone Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Data will become available beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,"The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to Sripal.Bangalore@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",NA,Yes,"Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices) will be shared upon reasonable request.",2020-11-07T11:20:54Z,2020-11-07T11:20:54Z
NCT04535791,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-30,NA,NA,2020-08-31,2020-08-31,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-02,Actual,"July 15, 2020",Actual,2020-07-15,August 2020,2020-08-31,July 2021,Anticipated,2021-07-31,May 2021,Anticipated,2021-05-31,NA,Interventional,COVID-19,,Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring COVID-19 in Healthcare Workers,Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring or Evolving Into the Severe Form of COVID-19 in Healthcare Workers Caring for Patients With the Disease. Blinded Randomized Clinical Trial,Recruiting,NA,Phase 3,400,Anticipated,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T11:42:35Z,2020-11-01T11:42:35Z
NCT04495842,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-30,NA,NA,2020-10-15,2020-07-31,2020-08-03,Actual,NA,NA,NA,NA,NA,NA,2020-10-15,2020-10-19,Actual,"October 1, 2020",Actual,2020-10-01,October 2020,2020-10-31,"June 30, 2021",Anticipated,2021-06-30,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,NA,,The Effect of Aromatherapy on COVID-19-induced Anxiety,The Effect of Aromatherapy on COVID-19-induced Anxiety,Recruiting,NA,N/A,65,Anticipated,Franklin School of Integrative Health Sciences,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:47:20Z,2020-11-01T11:47:20Z
NCT04495816,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-30,NA,NA,2020-07-31,2020-07-30,2020-08-03,Actual,NA,NA,NA,NA,NA,NA,2020-07-31,2020-08-04,Actual,"July 15, 2020",Actual,2020-07-15,July 2020,2020-07-31,June 2021,Anticipated,2021-06-30,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,COVID-19 Anosmia Study,COVID-19 Anosmia Study,Recruiting,NA,Phase 2,126,Anticipated,Icahn School of Medicine at Mount Sinai,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:47:20Z,2020-11-01T11:47:20Z
NCT04525378,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-31,NA,NA,2020-08-24,2020-08-22,2020-08-25,Actual,NA,NA,NA,NA,NA,NA,2020-08-24,2020-08-26,Actual,"July 1, 2020",Actual,2020-07-01,August 2020,2020-08-31,"October 31, 2020",Anticipated,2020-10-31,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,MSC-based Therapy in COVID-19-associated Acute Respiratory Distress Syndrome,Mesenchymal Stromal Cell-based Therapy for COVID-19-associated Acute Respiratory Distress Syndrome: a Pilot Clinical Study,Recruiting,NA,Phase 1,20,Anticipated,D'Or Institute for Research and Education,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:43:49Z,2020-11-01T11:43:49Z
NCT04498377,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-31,NA,NA,2020-09-15,2020-07-31,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-09-15,2020-09-16,Actual,"October 9, 2020",Anticipated,2020-10-09,September 2020,2020-09-30,"June 30, 2021",Anticipated,2021-06-30,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,NA,,Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Multicenter Study to Evaluate the Efficacy and Safety of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19",Recruiting,NA,Phase 2,38,Anticipated,Generon (Shanghai) Corporation Ltd.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:47:02Z,2020-11-01T11:47:02Z
NCT04497454,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-31,NA,NA,2020-07-31,2020-07-31,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-07-31,2020-08-04,Actual,"May 8, 2020",Actual,2020-05-08,July 2020,2020-07-31,"December 1, 2021",Anticipated,2021-12-01,"July 1, 2021",Anticipated,2021-07-01,NA,Interventional,COVEN,,Mechanical Ventilation Strategy for Coronavirus Disease 2019 (COVID-19),Mechanical Ventilation Strategy for Coronavirus Disease 2019 (COVID-19) - COVEN Study,Recruiting,NA,N/A,128,Anticipated,University of Sao Paulo General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:47:09Z,2020-11-01T11:47:09Z
NCT04497298,"ClinicalTrials.gov processed this data on October 30, 2020",2020-07-31,NA,NA,2020-09-24,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-28,Actual,"August 10, 2020",Actual,2020-08-10,September 2020,2020-09-30,October 2021,Anticipated,2021-10-31,November 2020,Anticipated,2020-11-30,NA,Interventional,COVID-19-101,,Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine,"A Randomized, Placebo-controlled Trial, to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine, a Measles Vector-based Vaccine Candidate Against COVID-19 in Healthy Volunteers Consisting of an Unblinded Dose Escalation and a Blinded Treatment Phase",Recruiting,NA,Phase 1,90,Anticipated,Institut Pasteur,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:47:10Z,2020-11-01T11:47:10Z
NCT04505722,"ClinicalTrials.gov processed this data on November 13, 2020",2020-07-31,NA,NA,2020-11-06,2020-08-07,2020-08-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"September 7, 2020",Actual,2020-09-07,November 2020,2020-11-30,"March 10, 2023",Anticipated,2023-03-10,"March 10, 2023",Anticipated,2023-03-10,NA,Interventional,ENSEMBLE,,A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants,"A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older",Recruiting,NA,Phase 3,60000,Anticipated,Janssen Vaccines & Prevention B.V.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2020-11-14T10:39:41Z,2020-11-14T10:39:41Z
NCT04500366,"ClinicalTrials.gov processed this data on November 13, 2020",2020-07-31,NA,NA,2020-11-06,2020-08-04,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-10,Actual,"August 26, 2020",Actual,2020-08-26,November 2020,2020-11-30,May 2021,Anticipated,2021-05-31,April 2021,Anticipated,2021-04-30,NA,Interventional,NA,,GERAS Frailty Rehabilitation at Home During COVID-19,GERAS Frailty Rehabilitation at Home: Virtual Bundled Care for Seniors Who Are Frail to Build Strength and Resilience During COVID-19,Recruiting,NA,N/A,70,Anticipated,McMaster University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-14T10:39:48Z,2020-11-14T10:39:48Z
NCT04497987,"ClinicalTrials.gov processed this data on November 13, 2020",2020-07-31,NA,NA,2020-11-06,2020-07-31,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-10,Actual,"August 2, 2020",Actual,2020-08-02,November 2020,2020-11-30,"June 29, 2021",Anticipated,2021-06-29,"March 8, 2021",Anticipated,2021-03-08,NA,Interventional,BLAZE-2,,A Study of LY3819253 (LY-CoV555) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff,"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of LY3819253 in Preventing SARS-CoV-2 Infection and COVID-19 in Skilled Nursing and Assisted Living Facility Residents and Staff; a NIAID and Lilly Collaborative Study",Recruiting,NA,Phase 3,2400,Anticipated,Eli Lilly and Company,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.",A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.,https://vivli.org/,Yes,Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.,2020-11-14T10:39:51Z,2020-11-14T10:39:51Z
NCT04497649,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-01,NA,NA,2020-09-11,2020-08-01,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-09-11,2020-09-16,Actual,"July 1, 2020",Actual,2020-07-01,September 2020,2020-09-30,"October 10, 2020",Anticipated,2020-10-10,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,NA,,Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients,Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients: A Randomized Controlled Trial.,Recruiting,NA,Phase 2/Phase 3,100,Anticipated,Tanta University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:47:08Z,2020-11-01T11:47:08Z
NCT04497415,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-02,NA,NA,2020-10-21,2020-08-02,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-23,Actual,"October 21, 2020",Anticipated,2020-10-21,October 2020,2020-10-31,"January 30, 2021",Anticipated,2021-01-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,NA,,The COVID-19 and Healthcare Workers: An Active Intervention,The COVID-19 and Healthcare Workers: An Active Intervention,Recruiting,NA,N/A,1200,Anticipated,"Research Foundation for Mental Hygiene, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,within one year post data collection,NA,NA,Yes,"Data will be shared as needed with investigators, IRB, etc. A plan will be determined in the short future",2020-11-01T11:47:09Z,2020-11-01T11:47:09Z
NCT04526054,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-03,NA,NA,2020-10-01,2020-08-21,2020-08-25,Actual,NA,NA,NA,NA,NA,NA,2020-10-01,2020-10-05,Actual,"September 3, 2020",Actual,2020-09-03,October 2020,2020-10-31,"September 3, 2021",Anticipated,2021-09-03,"September 3, 2021",Anticipated,2021-09-03,NA,Interventional,NA,,Morphological Abnormalities of the Olfactory Bulb on MRI and Olfactometry in Anosmic Versus Normosmic COVID-19 Patients,Longitudinal and Comparative Study of Morphological Abnormalities of the Olfactory Bulb on MRI and Olfactometry in Anosmic Versus Normosmic COVID-19 Patients,Recruiting,NA,N/A,30,Anticipated,Hopital Foch,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:43:45Z,2020-11-01T11:43:45Z
NCT04501965,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-03,NA,NA,2020-08-05,2020-08-04,2020-08-06,Actual,NA,NA,NA,NA,NA,NA,2020-08-05,2020-08-07,Actual,"June 1, 2020",Actual,2020-06-01,July 2020,2020-07-31,"September 30, 2020",Anticipated,2020-09-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,PHYTCOVID-19,,Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients,"Evaluation de l'efficacitÃ© et de la tolÃ©rance de Quinquina et d'un phytomÃ©dicament "" ACAR "" en Comparaison Avec l'Hydroxychloroquine Chez Des Adultes Malades de Covid-19 Sans symptÃ´mes",Enrolling by invitation,NA,Phase 2,231,Actual,Institute for Research and Development of Medicinal and Food Plants of Guinea,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,The data could be available from september 30th to december 30th,partnership framework established,NA,Yes,"The samples stored in the biobank could be shared with other researchers with a view to in-depth analyzes in order to dig for example a posteriori on the hypotheses relating to the blood levels of the phytomedicine, hydroxychloroquine, etc., cardio-metabolic biological markers infarction, insulin sensitivity, thrombosis, specific antibodies, genetic markers, viral markers ...",2020-11-01T11:46:38Z,2020-11-01T11:46:38Z
NCT04498442,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-03,NA,NA,2020-10-07,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-10-07,2020-10-08,Actual,"May 22, 2020",Actual,2020-05-22,October 2020,2020-10-31,"December 31, 2020",Anticipated,2020-12-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,NA,,"A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls","A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls",Recruiting,NA,N/A,30000,Anticipated,Beth Israel Deaconess Medical Center,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:47:02Z,2020-11-01T11:47:02Z
NCT04498247,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-03,NA,NA,2020-10-21,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-22,Actual,"August 27, 2020",Actual,2020-08-27,October 2020,2020-10-31,"April 26, 2022",Anticipated,2022-04-26,"April 26, 2022",Anticipated,2022-04-26,NA,Interventional,NA,,"A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)","A Phase 1/Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety, Tolerability and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Younger and Older Participants",Recruiting,NA,Phase 1/Phase 2,260,Anticipated,Merck Sharp & Dohme Corp.,,6,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2020-11-01T11:47:03Z,2020-11-01T11:47:03Z
NCT04510207,"ClinicalTrials.gov processed this data on November 02, 2020",2020-08-03,NA,NA,2020-10-29,2020-08-10,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-10-30,Actual,"July 16, 2020",Actual,2020-07-16,October 2020,2020-10-31,"September 16, 2021",Anticipated,2021-09-16,"March 16, 2021",Anticipated,2021-03-16,NA,Interventional,COVID-19,,"A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above","Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above",Recruiting,NA,Phase 3,45000,Anticipated,China National Biotec Group Company Limited,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-03T10:50:59Z,2020-11-03T10:50:59Z
NCT04498273,"ClinicalTrials.gov processed this data on November 06, 2020",2020-08-03,NA,NA,2020-11-03,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-05,Actual,"September 7, 2020",Actual,2020-09-07,November 2020,2020-11-30,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,,COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80,COVID-19 Outpatient Thrombosis Prevention Trial: A Multi-center Adaptive Randomized Placebo-controlled Platform Trial Evaluating the Efficacy and Safety of Anti-thrombotic Strategies in COVID-19 Adults Not Requiring Hospitalization at Time of Diagnosis,Recruiting,NA,Phase 3,7000,Anticipated,University of Pittsburgh,,4,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,Undecided,2020-11-09T10:52:32Z,2020-11-09T10:52:32Z
NCT04501978,"ClinicalTrials.gov processed this data on November 13, 2020",2020-08-03,NA,NA,2020-11-06,2020-08-05,2020-08-06,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"August 4, 2020",Actual,2020-08-04,November 2020,2020-11-30,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Interventional,TICO,,ACTIV-3: Therapeutics for Inpatients With COVID-19,"A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19","Active, not recruiting",NA,Phase 3,10000,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-14T10:39:46Z,2020-11-14T10:39:46Z
NCT04497272,"ClinicalTrials.gov processed this data on November 13, 2020",2020-08-03,NA,NA,2020-11-06,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-10,Actual,"August 7, 2020",Actual,2020-08-07,November 2020,2020-11-30,"October 7, 2021",Anticipated,2021-10-07,"August 7, 2021",Anticipated,2021-08-07,NA,Interventional,SignCov,,Assesment of the Metabolomic Signature in COVID-19 Patients,Assesment of the Metabolomic Signature in COVID-19 Patients (SignCov Study),Recruiting,NA,N/A,150,Anticipated,Centre Hospitalier Universitaire de Nice,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-14T10:39:54Z,2020-11-14T10:39:54Z
NCT04504734,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-04,NA,NA,2020-09-29,2020-08-06,2020-08-07,Actual,NA,NA,NA,NA,NA,NA,2020-09-29,2020-10-01,Actual,"September 30, 2020",Anticipated,2020-09-30,September 2020,2020-09-30,"May 1, 2021",Anticipated,2021-05-01,"February 1, 2021",Anticipated,2021-02-01,NA,Interventional,NA,,Bucillamine in Treatment of Patients With COVID-19,"Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients With Mild-Moderate COVID-19",Enrolling by invitation,NA,Phase 3,1000,Anticipated,"Revive Therapeutics, Ltd.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:46:19Z,2020-11-01T11:46:19Z
NCT04502667,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-04,NA,NA,2020-08-04,2020-08-04,2020-08-06,Actual,NA,NA,NA,NA,NA,NA,2020-08-04,2020-08-06,Actual,"July 15, 2020",Actual,2020-07-15,August 2020,2020-08-31,April 2021,Anticipated,2021-04-30,February 2021,Anticipated,2021-02-28,NA,Interventional,COVID-19,,Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19,Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19: Open Controlled Clinical Trial,Recruiting,NA,Phase 3,40,Anticipated,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:46:32Z,2020-11-01T11:46:32Z
NCT04502472,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-04,NA,NA,2020-08-04,2020-08-04,2020-08-06,Actual,NA,NA,NA,NA,NA,NA,2020-08-04,2020-08-06,Actual,"June 6, 2020",Actual,2020-06-06,July 2020,2020-07-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,Inova-CCP,,Open-label Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma,Open-label Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma Collected From Individuals With Documented Infection and Recovery From COVID-19 (SARS-CoV-2),Recruiting,NA,Phase 2/Phase 3,200,Anticipated,Inova Health Care Services,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T11:46:33Z,2020-11-01T11:46:33Z
NCT04502342,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-04,NA,NA,2020-08-05,2020-08-04,2020-08-06,Actual,NA,NA,NA,NA,NA,NA,2020-08-05,2020-08-07,Actual,"June 1, 2020",Actual,2020-06-01,August 2020,2020-08-31,"September 30, 2020",Anticipated,2020-09-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,CANCOVID-19,,"Add on to Azythromycine, Phytomedicine and/or Antimalarial Drug vs Hydroxychloroquine in Uncomplicated COVID-19 Patients",Ã‰valuationefficacitÃ© et tolÃ©rance d'Une mÃ©dication Ã  Base de CosphÃ©runate et d'un phytomÃ©dicament Antiviral Par Voie Orale en Comparaison Avec un Traitement Ã  Base d'Hydroxychloroquine Chez Des Adultes Malades Covid-19 Sans Complications,Enrolling by invitation,NA,Phase 2,30,Actual,Institute for Research and Development of Medicinal and Food Plants of Guinea,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,The data could be available from september 30th to december 30th,partnership framework established,NA,Yes,"The samples stored in the biobank could be shared with other researchers with a view to in-depth analyzes in order to dig for example a posteriori on the hypotheses relating to the blood levels of the phytomedicine, hydroxychloroquine, etc., cardio-metabolic biological markers infarction, insulin sensitivity, thrombosis, specific antibodies, genetic markers, viral markers ...",2020-11-01T11:46:35Z,2020-11-01T11:46:35Z
NCT04501445,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-04,NA,NA,2020-10-07,2020-08-05,2020-08-06,Actual,NA,NA,NA,NA,NA,NA,2020-10-07,2020-10-08,Actual,"September 14, 2020",Actual,2020-09-14,October 2020,2020-10-31,"September 15, 2021",Anticipated,2021-09-15,"August 1, 2021",Anticipated,2021-08-01,NA,Interventional,NA,,Psychological Symptoms and Families of COVID-19 Patients,Relieving the Burden of Psychological Symptoms Among Families of Critically Ill Patients With COVID-19,Recruiting,NA,N/A,100,Anticipated,Rush University Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:46:41Z,2020-11-01T11:46:41Z
NCT04500418,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-04,NA,NA,2020-08-25,2020-08-04,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2020-08-25,2020-08-26,Actual,"August 25, 2020",Actual,2020-08-25,August 2020,2020-08-31,"September 30, 2021",Anticipated,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,NA,,CharitÃ© Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients,CharitÃ© Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients,Recruiting,NA,Phase 2,183,Anticipated,"Charite University, Berlin, Germany",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,Undecided at this moment. (08/2020),2020-11-01T11:46:48Z,2020-11-01T11:46:48Z
NCT04500132,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-04,NA,NA,2020-08-05,2020-08-04,2020-08-05,Actual,NA,NA,NA,NA,NA,NA,2020-08-05,2020-08-06,Actual,"May 28, 2020",Actual,2020-05-28,August 2020,2020-08-31,May 2022,Anticipated,2022-05-31,August 2021,Anticipated,2021-08-31,NA,Interventional,NA,,To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia,"Phase 2, Multi-center, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia",Recruiting,NA,Phase 2,60,Anticipated,Enzychem Lifesciences Corporation,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:46:50Z,2020-11-01T11:46:50Z
NCT04504877,"ClinicalTrials.gov processed this data on November 06, 2020",2020-08-04,NA,NA,2020-11-02,2020-08-06,2020-08-07,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-04,Actual,"June 16, 2020",Actual,2020-06-16,November 2020,2020-11-30,"December 16, 2020",Anticipated,2020-12-16,"November 16, 2020",Anticipated,2020-11-16,NA,Interventional,BONSAI,,Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling wIth COVID-19,Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling (Bonsai Study) wIth COVID-19: a Randomised Controlled Trial,"Active, not recruiting",NA,Phase 2/Phase 3,120,Actual,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Immediately the following publication. No end date,"Researchers who provide a methodologically sound proposal. Depending on the level of the proposed use of data, approval by an independent review committee will be required for the identified purpose.",NA,Yes,"All of the individual participant data collected during the trial, after deidentification",2020-11-08T11:32:57Z,2020-11-08T11:32:57Z
NCT04534790,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-05,NA,NA,2020-08-30,2020-08-30,2020-09-01,Actual,NA,NA,NA,NA,NA,NA,2020-08-30,2020-09-01,Actual,"July 24, 2020",Actual,2020-07-24,August 2020,2020-08-31,"April 5, 2021",Anticipated,2021-04-05,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia,"Randomized Trial, Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia",Recruiting,NA,N/A,30,Anticipated,Instituto Mexicano del Seguro Social,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:42:42Z,2020-11-01T11:42:42Z
NCT04508439,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-05,NA,NA,2020-08-08,2020-08-08,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2020-08-08,2020-08-11,Actual,"June 20, 2020",Actual,2020-06-20,August 2020,2020-08-31,"December 30, 2020",Anticipated,2020-12-30,"August 30, 2020",Anticipated,2020-08-30,NA,Interventional,NA,,Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection,Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection,Recruiting,NA,N/A,130,Anticipated,Hospital Regional de Alta especialidad de Ixtapaluca,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:45:48Z,2020-11-01T11:45:48Z
NCT04501783,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-05,NA,NA,2020-08-05,2020-08-05,2020-08-06,Actual,NA,NA,NA,NA,NA,NA,2020-08-05,2020-08-06,Actual,"May 20, 2020",Actual,2020-05-20,August 2020,2020-08-31,August 2020,Anticipated,2020-08-31,"July 29, 2020",Actual,2020-07-29,NA,Interventional,NA,,Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19,Randomized Open-label Multicenter Parallel-group Study of Efficacy and Safety of TL-FVP-t vs. Standard of Care Therapy in Patients With Mild to Moderate Coronavirus Disease (SARS-CoV-2/COVID-19),"Active, not recruiting",NA,Phase 3,168,Anticipated,R-Pharm,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:46:39Z,2020-11-01T11:46:39Z
NCT04501458,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-05,NA,NA,2020-10-19,2020-08-05,2020-08-06,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-20,Actual,"May 18, 2020",Actual,2020-05-18,October 2020,2020-10-31,"December 19, 2020",Anticipated,2020-12-19,"December 19, 2020",Anticipated,2020-12-19,NA,Interventional,NA,,Western Kenya Integrated COVID-19 Response,"Western Kenya Integrated COVID-19 Response Leveraging the Community Health Strategy, Youth, and Technology to Flatten the COVID-19 Curve and Improve COVID-19 Case Detection, Isolation and Management in Western Kenya",Recruiting,NA,N/A,200000,Anticipated,Surgical Systems Research Group,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Immediately following publication; indefinitely.,Anyone with an approved proposal who wishes to access the data.,NA,Yes,De-identified participant data will be available when results are reported.,2020-11-01T11:46:41Z,2020-11-01T11:46:41Z
NCT04504032,"ClinicalTrials.gov processed this data on November 06, 2020",2020-08-05,NA,NA,2020-11-03,2020-08-05,2020-08-07,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-04,Actual,"September 2, 2020",Actual,2020-09-02,October 2020,2020-10-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19),"A Randomized, Controlled, Phase 2b Study to Evaluate Safety and Efficacy of Rivaroxaban (XareltoÂ®) for High Risk People With Mild COVID-19",Recruiting,NA,Phase 2,600,Anticipated,Bill & Melinda Gates Medical Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-11-08T11:32:58Z,2020-11-08T11:32:58Z
NCT04501952,"ClinicalTrials.gov processed this data on November 06, 2020",2020-08-05,NA,NA,2020-11-02,2020-08-05,2020-08-06,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-04,Actual,"September 18, 2020",Actual,2020-09-18,November 2020,2020-11-30,January 2021,Anticipated,2021-01-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734â„¢) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting,"A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734â„¢) Treatment of COVID-19 in an Outpatient Setting",Recruiting,NA,Phase 3,1230,Anticipated,Gilead Sciences,,2,NA,NA,TRUE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-08T11:33:01Z,2020-11-08T11:33:01Z
NCT04527471,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-06,NA,NA,2020-08-28,2020-08-24,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2020-08-28,2020-09-01,Actual,"August 28, 2020",Anticipated,2020-08-28,August 2020,2020-08-31,March 2021,Anticipated,2021-03-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19,"A Single-center, Pilot, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ensifentrine in the Recovery of Hospitalized Patients With COVID-19",Recruiting,NA,Phase 2,45,Anticipated,Verona Pharma plc,,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Verona Pharma will not be sharing individual deidentified participant data or other relevant study documents.,2020-11-01T11:43:36Z,2020-11-01T11:43:36Z
NCT04513158,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-06,NA,NA,2020-10-14,2020-08-12,2020-08-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"August 14, 2020",Actual,2020-08-14,October 2020,2020-10-31,"December 31, 2021",Anticipated,2021-12-31,"August 1, 2021",Anticipated,2021-08-01,NA,Interventional,NA,,Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection,Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection,Recruiting,NA,Phase 2,100,Anticipated,Norton Healthcare,,1,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:45:19Z,2020-11-01T11:45:19Z
NCT04505774,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-06,NA,NA,2020-09-29,2020-08-07,2020-08-10,Actual,NA,NA,NA,NA,NA,NA,2020-09-29,2020-10-01,Actual,"September 4, 2020",Actual,2020-09-04,September 2020,2020-09-30,December 2021,Anticipated,2021-12-31,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,,Anti-thrombotics for Adults Hospitalized With COVID-19 (ACTIV-4),"A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults With COVID-19",Recruiting,NA,Phase 4,2000,Anticipated,University of Pittsburgh,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,Data will be shared as per NIH guidelines.,2020-11-01T11:46:11Z,2020-11-01T11:46:11Z
NCT04504240,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-06,NA,NA,2020-08-07,2020-08-06,2020-08-07,Actual,NA,NA,NA,NA,NA,NA,2020-08-07,2020-08-11,Actual,"August 1, 2020",Actual,2020-08-01,August 2020,2020-08-31,"October 30, 2020",Anticipated,2020-10-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,NA,,Role of Famotidine in the Symptomatic Improvement of COVID-19 Patients,Role of Famotidine in the Symptomatic Improvement of Moderate to Severe COVID-19 Patients,Recruiting,NA,Phase 3,200,Anticipated,Chattogram General Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:46:22Z,2020-11-01T11:46:22Z
NCT04505592,"ClinicalTrials.gov processed this data on November 13, 2020",2020-08-06,NA,NA,2020-11-10,2020-08-06,2020-08-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"September 25, 2020",Actual,2020-09-25,November 2020,2020-11-30,April 2021,Anticipated,2021-04-30,February 2021,Anticipated,2021-02-28,NA,Interventional,NA,,Tenecteplase in Patients With COVID-19,Tenecteplase With Concomitant Anticoagulation for Severe Acute Respiratory Failure in Patients With COVID-19,Recruiting,NA,Phase 2,60,Anticipated,Icahn School of Medicine at Mount Sinai,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-15T10:57:44Z,2020-11-15T10:57:44Z
NCT04522492,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-07,NA,NA,2020-08-20,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2020-08-20,2020-08-21,Actual,"August 11, 2020",Actual,2020-08-11,August 2020,2020-08-31,March 2021,Anticipated,2021-03-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Impact of COVID-19 on Mental Health of Patients With Skin Picking,Impact of COVID-19 Pandemia on the Mental Health of Patients With Skin Picking Disorder and Their Treatment With Remote Cognitive Behavioral Therapy: Controlled Clinical Trial,Enrolling by invitation,NA,N/A,20,Anticipated,Hospital de Clinicas de Porto Alegre,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:44:14Z,2020-11-01T11:44:14Z
NCT04509999,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-07,NA,NA,2020-10-26,2020-08-11,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2020-10-26,2020-10-27,Actual,"October 26, 2020",Actual,2020-10-26,October 2020,2020-10-31,September 2022,Anticipated,2022-09-30,September 2022,Anticipated,2022-09-30,NA,Interventional,NA,,Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection,Randomized Trial of Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection,Recruiting,NA,Phase 3,100,Anticipated,University of Florida,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T11:45:38Z,2020-11-01T11:45:38Z
NCT04508075,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-07,NA,NA,2020-08-20,2020-08-08,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2020-08-20,2020-08-21,Actual,"August 10, 2020",Actual,2020-08-10,August 2020,2020-08-31,September 2021,Anticipated,2021-09-30,January 2021,Anticipated,2021-01-31,NA,Interventional,COVID-19,,"Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine","A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years in Indonesia",Recruiting,NA,Phase 3,1620,Anticipated,PT Bio Farma,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:45:50Z,2020-11-01T11:45:50Z
NCT04507256,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-07,NA,NA,2020-10-19,2020-08-07,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-20,Actual,"August 18, 2020",Actual,2020-08-18,October 2020,2020-10-31,"October 1, 2021",Anticipated,2021-10-01,"October 1, 2021",Anticipated,2021-10-01,NA,Interventional,NA,,AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19,"A Phase I Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD7442 in Healthy Adults",Recruiting,NA,Phase 1,60,Anticipated,AstraZeneca,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.","When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,"Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.",2020-11-01T11:45:59Z,2020-11-01T11:45:59Z
NCT04511650,"ClinicalTrials.gov processed this data on November 02, 2020",2020-08-07,NA,NA,2020-10-29,2020-08-11,2020-08-13,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-10-30,Actual,"October 21, 2020",Actual,2020-10-21,October 2020,2020-10-31,February 2021,Anticipated,2021-02-28,February 2021,Anticipated,2021-02-28,NA,Interventional,RESCUE,,"A Study to Evaluate the Safety and Efficacy of Razuprotafib, a Novel Tie 2 Activator, in Hospitalized Subjects With Moderate to Severe Coronavirus Disease 2019 (COVID-19)","A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Dose Escalation and Proof-of-Concept Study to Evaluate the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Moderate to Severe Coronavirus Disease 2019 (COVID-19) (RESCUE Study)",Recruiting,NA,Phase 2,180,Anticipated,Aerpio Therapeutics,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-03T10:50:57Z,2020-11-03T10:50:57Z
NCT04506268,"ClinicalTrials.gov processed this data on November 09, 2020",2020-08-07,NA,NA,2020-11-05,2020-08-07,2020-08-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-05,2020-11-06,Actual,"September 9, 2020",Actual,2020-09-09,November 2020,2020-11-30,November 2020,Anticipated,2020-11-30,"October 13, 2020",Actual,2020-10-13,NA,Interventional,COVID SAFE,,COVID-19 SAFE Enrollment,Opt-In Versus Opt-Out for COVID Screening Assessment for Exposure,"Active, not recruiting",NA,N/A,1200,Anticipated,University of Pennsylvania,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-10T11:26:59Z,2020-11-10T11:26:59Z
NCT04511819,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-08,NA,NA,2020-10-28,2020-08-11,2020-08-13,Actual,NA,NA,NA,NA,NA,NA,2020-10-28,2020-10-29,Actual,"August 28, 2020",Actual,2020-08-28,October 2020,2020-10-31,November 2020,Anticipated,2020-11-30,November 2020,Anticipated,2020-11-30,NA,Interventional,LOSVID,,Losmapimod Safety and Efficacy in COVID-19,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Losmapimod in Adult Subjects With COVID-19 (LOSVID STUDY)",Recruiting,NA,Phase 3,410,Anticipated,Fulcrum Therapeutics,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-02T10:28:44Z,2020-11-02T10:28:44Z
NCT04516915,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-10,NA,NA,2020-08-19,2020-08-17,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-19,2020-08-21,Actual,"June 15, 2020",Actual,2020-06-15,August 2020,2020-08-31,July 2021,Anticipated,2021-07-31,May 2021,Anticipated,2021-05-31,NA,Interventional,IONIC,,IMU-838 and Oseltamivir in the Treatment of COVID-19,"Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination With Oseltamivir, in Adults With COVID-19",Recruiting,NA,Phase 2,120,Anticipated,University Hospitals Coventry and Warwickshire NHS Trust,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:44:51Z,2020-11-01T11:44:51Z
NCT04513470,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-10,NA,NA,2020-10-14,2020-08-13,2020-08-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"August 1, 2020",Actual,2020-08-01,October 2020,2020-10-31,February 2021,Anticipated,2021-02-28,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,Allocetra-OTS in COVID-19,"A Multi-Center, Open-Label Study, Evaluating Safety of Allocetra-OTS for the Prevention of Organ-Failure Deterioration in Severe Patients With COVID-19 and Respiratory Dysfunction","Active, not recruiting",NA,Phase 1,5,Actual,Hadassah Medical Organization,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:45:16Z,2020-11-01T11:45:16Z
NCT04508868,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-10,NA,NA,2020-08-17,2020-08-10,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2020-08-17,2020-08-19,Actual,"August 17, 2020",Anticipated,2020-08-17,August 2020,2020-08-31,July 2021,Anticipated,2021-07-31,December 2020,Anticipated,2020-12-31,NA,Interventional,CoviDep,,Treatment of Depressive Symptoms in Older Individuals in Isolation During Covid-19,Behavioral Activation and Mental Imagery Delivered Via Telephone for the Treatment of Depressive Symptoms in Older Individuals in Isolation During Covid-19: A Randomized Clinical Trial,Recruiting,NA,N/A,154,Anticipated,Uppsala University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"Study protocol to be shared before data collection is completed
Statistical Analysis Plan to be shared before data analysis begin",Data will be shared upon reasonable requests assessed by the investigators.,NA,Yes,De-identified outcome measure IPD will be shared upon reasonable requests from academic researchers.,2020-11-01T11:45:45Z,2020-11-01T11:45:45Z
NCT04508023,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-10,NA,NA,2020-10-16,2020-08-10,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-19,Actual,"August 13, 2020",Actual,2020-08-13,October 2020,2020-10-31,"April 6, 2021",Anticipated,2021-04-06,"March 3, 2021",Anticipated,2021-03-03,NA,Interventional,PREVENT-HD,,"A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection","A Multicenter, Randomized, Placebo-Controlled, Pragmatic Phase 3 Study Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic COVID-19 Infection",Recruiting,NA,Phase 3,4000,Anticipated,"Janssen Research & Development, LLC",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2020-11-01T11:45:51Z,2020-11-01T11:45:51Z
NCT04581018,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-11,NA,NA,2020-10-12,2020-10-06,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-12,2020-10-14,Actual,"August 13, 2020",Actual,2020-08-13,October 2020,2020-10-31,"April 30, 2022",Anticipated,2022-04-30,"October 30, 2021",Anticipated,2021-10-30,NA,Interventional,NA,,An Evaluation of a Synbiotic Formula for Patients With COVID-19 Infection,An Evaluation of a Synbiotic Formula for Symptom Improvement in Hospitalised Patients With COVID-19 Infection,Recruiting,NA,N/A,50,Anticipated,Chinese University of Hong Kong,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:37:25Z,2020-11-01T11:37:25Z
NCT04527575,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-11,NA,NA,2020-09-21,2020-08-25,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-22,Actual,"July 27, 2020",Actual,2020-07-27,August 2020,2020-08-31,"October 4, 2020",Anticipated,2020-10-04,"September 28, 2020",Anticipated,2020-09-28,NA,Interventional,EpiVacCorona,,"Study of the Safety, Reactogenicity and Immunogenicity of ""EpiVacCorona"" Vaccine for the Prevention of COVID-19","Simple, Blind, Placebo-controlled, Randomized Study of the Safety, Reactogenicity and Immunogenicity of Vaccine Based on Peptide Antigens for the Prevention of COVID-19 (EpiVacCorona), in Volunteers Aged 18-60 Years (I-II Phase)","Active, not recruiting",NA,Phase 1/Phase 2,100,Actual,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:43:35Z,2020-11-01T11:43:35Z
NCT04514705,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-11,NA,NA,2020-08-13,2020-08-13,2020-08-17,Actual,NA,NA,NA,NA,NA,NA,2020-08-13,2020-08-17,Actual,"August 11, 2020",Actual,2020-08-11,August 2020,2020-08-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,,Characteristics in Post Covid-19 Patients,Clinical Respiratory Investigation in Post Covid-19 Patients,Recruiting,NA,N/A,20,Anticipated,Universidade Metodista de Piracicaba,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:45:07Z,2020-11-01T11:45:07Z
NCT04512079,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-11,NA,NA,2020-10-12,2020-08-11,2020-08-13,Actual,NA,NA,NA,NA,NA,NA,2020-10-12,2020-10-14,Actual,"September 8, 2020",Actual,2020-09-08,October 2020,2020-10-31,June 2021,Anticipated,2021-06-30,March 2021,Anticipated,2021-03-31,NA,Interventional,FREEDOM COVID,,FREEDOM COVID-19 Anticoagulation Strategy,FREEDOM COVID Anticoagulation Strategy Randomized Trial,Recruiting,NA,Phase 4,3600,Anticipated,Icahn School of Medicine at Mount Sinai,,3,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,Beginning 9 months and ending 36 months following article publication.,"Investigators whose proposed use of the data has been approved by an independent review committee (""learned intermediary"") identified for this purpose. The type of analysis that will be conducted is for individual participant data meta-analysis. Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata.",NA,Yes,"Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).",2020-11-01T11:45:25Z,2020-11-01T11:45:25Z
NCT04512027,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-11,NA,NA,2020-10-16,2020-08-12,2020-08-13,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-19,Actual,"September 15, 2020",Actual,2020-09-15,October 2020,2020-10-31,"October 16, 2020",Actual,2020-10-16,"September 19, 2020",Actual,2020-09-19,NA,Interventional,Prolectin-M,,Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support.,"Effect of Prolectin-M; a (1-6)-Alpha-D-Mannopyranose on SarsCoV2 Viral Copy Numbers: A Proof of Concept, Open Label Randomized Controlled Trial",Completed,NA,N/A,10,Actual,Composite Interceptive Med Science,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:45:25Z,2020-11-01T11:45:25Z
NCT04510662,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-11,NA,NA,2020-08-11,2020-08-11,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2020-08-11,2020-08-12,Actual,August 2020,Anticipated,2020-08-31,August 2020,2020-08-31,April 2021,Anticipated,2021-04-30,March 2021,Anticipated,2021-03-31,NA,Interventional,STAR-COVID,,Telmisartan in Respiratory Failure Due to COVID-19,Effectiveness and Safety of Telmisartan in Acute Respiratory Failure Due to COVID-19,Recruiting,NA,Phase 2,60,Anticipated,Hospital Regional de Alta Especialidad de Zumpango,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,There is no plan to share individual participant data with other researchers to avoid misuse of patient information.,2020-11-01T11:45:34Z,2020-11-01T11:45:34Z
NCT04509973,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-11,NA,NA,2020-08-28,2020-08-11,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2020-08-28,2020-09-01,Actual,"August 27, 2020",Actual,2020-08-27,August 2020,2020-08-31,"February 17, 2022",Anticipated,2022-02-17,"September 17, 2021",Anticipated,2021-09-17,NA,Interventional,COVIDSTEROID2,,Higher vs. Lower Doses of Dexamethasone for COVID-19 and Severe Hypoxia,Higher vs. Lower Doses of Dexamethasone in Patients With COVID-19 and Severe Hypoxia,Recruiting,NA,Phase 3,1000,Anticipated,Scandinavian Critical Care Trials Group,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,"Immediate sharing of protocol, SAP and ICF. CSR will be shared no later than 6 months after last-patient-last-visit",Contact to the trial management committee,http://www.cric.nu/covid-steroid-2/,Yes,Fully de-identified IPD will be shared after the approval by the the trial management committee,2020-11-01T11:45:38Z,2020-11-01T11:45:38Z
NCT04509947,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-11,NA,NA,2020-09-29,2020-08-11,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2020-09-29,2020-09-30,Actual,"August 11, 2020",Actual,2020-08-11,September 2020,2020-09-30,"October 26, 2021",Anticipated,2021-10-26,"January 8, 2021",Anticipated,2021-01-08,NA,Interventional,NA,,A Study of Ad26.COV2.S in Adults (COVID-19),"A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Adults",Recruiting,NA,Phase 1,250,Anticipated,Janssen Pharmaceutical K.K.,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2020-11-01T11:45:39Z,2020-11-01T11:45:39Z
NCT04510493,"ClinicalTrials.gov processed this data on November 06, 2020",2020-08-11,NA,NA,2020-11-03,2020-08-11,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-04,Actual,"October 23, 2020",Actual,2020-10-23,November 2020,2020-11-30,September 2023,Anticipated,2023-09-30,September 2023,Anticipated,2023-09-30,NA,Interventional,CanCovDia,,Canakinumab in Patients With COVID-19 and Type 2 Diabetes,Canakinumab in Patients With COVID-19 and Type 2 Diabetes - CanCovDia Trial,Recruiting,NA,Phase 3,116,Anticipated,"University Hospital, Basel, Switzerland",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-08T11:32:51Z,2020-11-08T11:32:51Z
NCT04522089,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-12,NA,NA,2020-09-22,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-24,Actual,"August 24, 2020",Actual,2020-08-24,August 2020,2020-08-31,"March 20, 2021",Anticipated,2021-03-20,"November 20, 2020",Anticipated,2020-11-20,NA,Interventional,NA,,A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine,"A Randomized, Single Center, Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of Pandemic Virus Vaccine, AdimrSC-2f (SARS-CoV-2), in Healthy Volunteers",Recruiting,NA,Phase 1,70,Anticipated,Adimmune Corporation,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:44:17Z,2020-11-01T11:44:17Z
NCT04519216,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-12,NA,NA,2020-08-18,2020-08-18,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"July 31, 2020",Actual,2020-07-31,August 2020,2020-08-31,"September 30, 2021",Anticipated,2021-09-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,NA,,Breastfeeding Education in the Time of COVID-19,"Breastfeeding Education in the Time of COVID-19. Hybrid Telesimulation With Standardized Patients for Pediatric and Family Medicine Trainees, a Randomized Trial",Recruiting,NA,N/A,39,Anticipated,"University of California, Davis",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:44:36Z,2020-11-01T11:44:36Z
NCT04516811,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-12,NA,NA,2020-09-24,2020-08-17,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-25,Actual,"September 21, 2020",Actual,2020-09-21,September 2020,2020-09-30,"July 31, 2022",Anticipated,2022-07-31,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NA,,Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19,"A Prospective, Randomized, Placebo-controlled, Double-blinded, Phase III Clinical Trial of the Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19",Recruiting,NA,Phase 3,600,Anticipated,South African National Blood Service,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Undecided,undecided,NA,Yes,"Where available and applicable, the results of this study will be reported to the appropriate scientific and management divisions of participating institutions. In addition, interim results may be communicated to lay press if doing so is deemed appropriate and relevant by the Study Management Committee. Interim and final results will be presented at various scientific congresses, meeting and in appropriate peer-reviewed scientific journals. Under no circumstances will personal identifier be revealed to any party not legally entitled to such information.",2020-11-01T11:44:52Z,2020-11-01T11:44:52Z
NCT04511949,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-12,NA,NA,2020-08-13,2020-08-12,2020-08-13,Actual,NA,NA,NA,NA,NA,NA,2020-08-13,2020-08-17,Actual,"July 12, 2020",Actual,2020-07-12,August 2020,2020-08-31,"November 30, 2020",Anticipated,2020-11-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,FAMICOV,,COVID-19: Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease,Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease,Recruiting,NA,N/A,500,Anticipated,Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:45:26Z,2020-11-01T11:45:26Z
NCT04513184,"ClinicalTrials.gov processed this data on November 13, 2020",2020-08-12,NA,NA,2020-11-09,2020-08-12,2020-08-14,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"July 14, 2020",Actual,2020-07-14,November 2020,2020-11-30,"July 31, 2021",Anticipated,2021-07-31,"March 30, 2021",Anticipated,2021-03-30,NA,Interventional,NA,,Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19,Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19,Recruiting,NA,Phase 2,60,Anticipated,Universidad Nacional Autonoma de Mexico,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,"Upon study completion, by request",NA,NA,Yes,Information exchange for research purposes,2020-11-15T10:57:40Z,2020-11-15T10:57:40Z
NCT04516564,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-13,NA,NA,2020-09-18,2020-08-16,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2020-09-18,2020-09-21,Actual,September 2020,Anticipated,2020-09-30,September 2020,2020-09-30,April 2021,Anticipated,2021-04-30,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,,"A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AK119 in Healthy Subjects",Recruiting,NA,Phase 1,32,Anticipated,Akeso,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:44:54Z,2020-11-01T11:44:54Z
NCT04515147,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-13,NA,NA,2020-10-21,2020-08-13,2020-08-17,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-22,Actual,"September 28, 2020",Actual,2020-09-28,August 2020,2020-08-31,"November 9, 2021",Anticipated,2021-11-09,"November 9, 2021",Anticipated,2021-11-09,NA,Interventional,NA,,"A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19","COVID-19: A Phase 2a, Partially Observer-blind, Multicenter, Controlled, Dose-confirmation Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults >60 Years of Age and 18 to 60 Years of Age",Recruiting,NA,Phase 2,691,Anticipated,CureVac AG,,10,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:45:04Z,2020-11-01T11:45:04Z
NCT04540120,"ClinicalTrials.gov processed this data on November 13, 2020",2020-08-13,NA,NA,2020-11-11,2020-09-03,2020-09-07,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Estimate,"September 25, 2020",Actual,2020-09-25,November 2020,2020-11-30,February 2021,Anticipated,2021-02-28,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome,"A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Orally Administered Dapansutrile Capsules for the Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome",Recruiting,NA,Phase 2,80,Anticipated,Olatec Therapeutics LLC,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-15T10:57:12Z,2020-11-15T10:57:12Z
NCT04517123,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-14,NA,NA,2020-10-09,2020-08-14,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2020-10-09,2020-10-12,Actual,"September 1, 2020",Actual,2020-09-01,October 2020,2020-10-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,PRONE,,"Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The ""PRONE"" Study","Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The ""PRONE"" Study",Recruiting,NA,N/A,100,Anticipated,Johns Hopkins University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:44:50Z,2020-11-01T11:44:50Z
NCT04517162,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-14,NA,NA,2020-09-02,2020-08-14,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2020-09-02,2020-09-03,Actual,"August 19, 2020",Actual,2020-08-19,September 2020,2020-09-30,"June 19, 2021",Anticipated,2021-06-19,"February 19, 2021",Anticipated,2021-02-19,NA,Interventional,NA,,Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients,Effect of Collagen-Polyvinylpyrrolidone for the Treatment of Hyperinflammation and the Pulmonary Fibrosis in COVID-19 Patients. Double Blind Placebo-controlled Pilot Trial,Recruiting,NA,Phase 1,90,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Data will be provided based on requirement,2020-11-01T11:44:49Z,2020-11-01T11:44:49Z
NCT04516759,"ClinicalTrials.gov processed this data on November 13, 2020",2020-08-14,NA,NA,2020-11-06,2020-08-16,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"August 12, 2020",Actual,2020-08-12,October 2020,2020-10-31,March 2021,Anticipated,2021-03-31,March 2021,Anticipated,2021-03-31,NA,Interventional,ARCADIA,,AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19,"A Phase II, Randomised, Double-blind, Placebo-controlled Clinical Trial to Assess the Safety and Efficacy of AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19",Recruiting,NA,Phase 2,150,Anticipated,St George Street Capital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-11-14T10:39:28Z,2020-11-14T10:39:28Z
NCT04550351,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-16,NA,NA,2020-09-14,2020-09-14,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2020-09-14,2020-09-16,Actual,"August 19, 2020",Actual,2020-08-19,August 2020,2020-08-31,"December 31, 2021",Anticipated,2021-12-31,"October 31, 2021",Anticipated,2021-10-31,NA,Interventional,NA,,Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (â‰¥60 Years Old),"A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of Recombinant New Coronavirus Vaccines (CHO Cells) in Healthy People Aged 60 Years and Above",Recruiting,NA,Phase 1/Phase 2,50,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:40:48Z,2020-11-01T11:40:48Z
NCT04517422,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-16,NA,NA,2020-09-01,2020-08-16,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2020-09-01,2020-09-03,Actual,"August 19, 2020",Actual,2020-08-19,September 2020,2020-09-30,"January 31, 2021",Anticipated,2021-01-31,"November 20, 2020",Anticipated,2020-11-20,NA,Interventional,NA,,Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19,Efficacy and Safety of Lactobacillus Plantarum and Pediococcus Acidilactici as Co-adjuvant Therapy for Reducing the Risk of Severe Disease in Adults With SARS-CoV-2 and Its Modulation of the Fecal Microbiota: A Randomized Clinical Trial,Recruiting,NA,N/A,300,Anticipated,"AB Biotics, SA",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:44:48Z,2020-11-01T11:44:48Z
NCT04516837,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-16,NA,NA,2020-08-31,2020-08-16,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-01,Actual,"August 31, 2020",Actual,2020-08-31,August 2020,2020-08-31,August 2022,Anticipated,2022-08-31,August 2021,Anticipated,2021-08-31,NA,Interventional,NA,,Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19),The Combination of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) Versus Eltrombopag Monotherapy as Subsequent Treatment for Immune Thrombocytopenia During the COVID-19 Pandemic,Recruiting,NA,Phase 2,120,Anticipated,Peking University People's Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:44:52Z,2020-11-01T11:44:52Z
NCT04547634,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-17,NA,NA,2020-09-07,2020-09-07,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2020-09-07,2020-09-14,Actual,"July 1, 2020",Actual,2020-07-01,September 2020,2020-09-30,December 2020,Anticipated,2020-12-31,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,,Telerehabilitation in Oncology Patients,Effect of a Telerehabilitation-exercise Intervention in Oncology Patients in the Covid-19 Pandemic,Enrolling by invitation,NA,N/A,30,Actual,University of Malaga,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:41:09Z,2020-11-01T11:41:09Z
NCT04530578,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-17,NA,NA,2020-08-27,2020-08-26,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-08-27,2020-08-31,Actual,"June 1, 2020",Actual,2020-06-01,August 2020,2020-08-31,"June 1, 2021",Anticipated,2021-06-01,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,NEBUHEPA,,Nebulized Heparin in Severe Acute Respiratory Syndrome COVID-19,Efficacy and Safety Study to Evaluate the Use of Nebulized Heparin in Patients With Severe Acute Respiratory Syndrome Covid-19 (SARS-CoV-2),Recruiting,NA,Phase 4,200,Anticipated,"Clinica San Camilo, Argentina",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:43:16Z,2020-11-01T11:43:16Z
NCT04519385,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-17,NA,NA,2020-08-21,2020-08-17,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2020-08-21,2020-08-25,Actual,"March 1, 2020",Actual,2020-03-01,August 2020,2020-08-31,"August 5, 2020",Actual,2020-08-05,"July 1, 2020",Actual,2020-07-01,NA,Interventional,NA,,Toclizumam Versus Dexamethasone in Severe Covid-19 Cases,Toclizumam Versus Dexamethasone in Severe Covid-19 Cases,Completed,NA,N/A,69,Actual,South Valley University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:44:35Z,2020-11-01T11:44:35Z
NCT04517396,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-17,NA,NA,2020-08-25,2020-08-17,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-25,2020-08-27,Actual,"August 18, 2020",Actual,2020-08-18,August 2020,2020-08-31,"August 31, 2021",Anticipated,2021-08-31,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,FERMIN,,FEnofibRate as a Metabolic INtervention for COVID-19,FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019,Enrolling by invitation,NA,N/A,300,Anticipated,University of Pennsylvania,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,Not making it available,2020-11-01T11:44:48Z,2020-11-01T11:44:48Z
NCT04516954,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-17,NA,NA,2020-08-18,2020-08-17,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-20,Actual,"August 1, 2020",Actual,2020-08-01,August 2020,2020-08-31,"December 30, 2020",Anticipated,2020-12-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,CPCP,,Convalescent Plasma for COVID-19 Patients,Assessment of the Safety of Convalescent Plasma to Treat COVID-19 Patients With Moderate and Above Illness,Enrolling by invitation,NA,Early Phase 1,10,Anticipated,Vinmec Research Institute of Stem Cell and Gene Technology,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:44:51Z,2020-11-01T11:44:51Z
NCT04540419,"ClinicalTrials.gov processed this data on November 13, 2020",2020-08-17,NA,NA,2020-11-12,2020-09-04,2020-09-07,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-13,Estimate,"September 11, 2020",Actual,2020-09-11,November 2020,2020-11-30,"July 31, 2021",Anticipated,2021-07-31,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,NA,,Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19,"Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group Study Evaluating Efficacy, Reactogenicity and Safety of Recombinant Vaccine Ad5-nCoV Against Novel Coronavirus Infection in Adult Volunteers","Active, not recruiting",NA,Phase 3,500,Actual,NPO Petrovax,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-15T10:57:12Z,2020-11-15T10:57:12Z
NCT04518410,"ClinicalTrials.gov processed this data on November 13, 2020",2020-08-17,NA,NA,2020-11-10,2020-08-18,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"August 19, 2020",Actual,2020-08-19,November 2020,2020-11-30,February 2021,Anticipated,2021-02-28,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,,ACTIV-2: A Study for Outpatients With COVID-19,Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID),Recruiting,NA,Phase 2/Phase 3,2000,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-15T10:57:36Z,2020-11-15T10:57:36Z
NCT04516746,"ClinicalTrials.gov processed this data on November 13, 2020",2020-08-17,NA,NA,2020-11-11,2020-08-17,2020-08-18,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Estimate,"August 28, 2020",Actual,2020-08-28,November 2020,2020-11-30,"October 25, 2022",Anticipated,2022-10-25,"December 22, 2020",Anticipated,2020-12-22,NA,Interventional,NA,,"Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults","A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19",Recruiting,NA,Phase 3,40051,Anticipated,AstraZeneca,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure,2020-11-15T10:57:37Z,2020-11-15T10:57:37Z
NCT04587921,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-18,NA,NA,2020-10-13,2020-10-13,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-14,Actual,"June 22, 2020",Actual,2020-06-22,October 2020,2020-10-31,"June 22, 2021",Anticipated,2021-06-22,"January 22, 2021",Anticipated,2021-01-22,NA,Interventional,MoxiCov,,Feasibility and Impact of Remote Oximetry in Patients Hospitalized With Covid-19,Feasibility and Impact of Remote Oximetry and Cardiac Frequency Monitoring in Patients Hospitalized and Isolated With Covid-19,Recruiting,NA,N/A,90,Anticipated,University of Sao Paulo General Hospital,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:36:13Z,2020-11-01T11:36:13Z
NCT04527614,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-18,NA,NA,2020-10-13,2020-08-25,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-19,Actual,"September 24, 2020",Actual,2020-09-24,October 2020,2020-10-31,"May 30, 2021",Anticipated,2021-05-30,"May 30, 2021",Anticipated,2021-05-30,NA,Interventional,PICOV,,Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection,Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection (PICOV) A Multicentre Academic Prospective Cohort Study in Nursing Home During the Winter Season 2020-2021,Enrolling by invitation,NA,N/A,2000,Anticipated,Sciensano,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:43:35Z,2020-11-01T11:43:35Z
NCT04523571,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-18,NA,NA,2020-10-23,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-26,Actual,"July 28, 2020",Actual,2020-07-28,August 2020,2020-08-31,August 2021,Anticipated,2021-08-31,October 2020,Anticipated,2020-10-31,NA,Interventional,NA,,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects,"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects: A Phase I, Randomized, Placebo-controlled, Observer-blind Study",Recruiting,NA,Phase 1,144,Anticipated,BioNTech SE,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:44:08Z,2020-11-01T11:44:08Z
NCT04519411,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-18,NA,NA,2020-08-18,2020-08-18,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"May 21, 2020",Actual,2020-05-21,August 2020,2020-08-31,"January 31, 2021",Anticipated,2021-01-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure,Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure,Recruiting,NA,N/A,10,Anticipated,Mayo Clinic,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:44:35Z,2020-11-01T11:44:35Z
NCT04519320,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-18,NA,NA,2020-08-20,2020-08-18,2020-08-19,Actual,NA,NA,NA,NA,NA,NA,2020-08-20,2020-08-24,Actual,"May 18, 2020",Actual,2020-05-18,May 2020,2020-05-31,"August 18, 2025",Anticipated,2025-08-18,"August 18, 2021",Anticipated,2021-08-18,NA,Interventional,COV-RECUP,,Medium and Long Term Follow-up of COVID-19 Infected Patients: Research and Characterization of Pulmonary Sequelae,Medium and Long Term Follow-up of SARS-COV-2 Infected Patients Treated at BesanÃ§on and Dijon Hospitals: Research and Characterization of Pulmonary Sequelae,Recruiting,NA,N/A,140,Anticipated,Centre Hospitalier Universitaire de Besancon,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:44:35Z,2020-11-01T11:44:35Z
NCT04612972,"ClinicalTrials.gov processed this data on November 06, 2020",2020-08-18,NA,NA,2020-10-29,2020-10-29,2020-11-03,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-11-03,Actual,"September 10, 2020",Actual,2020-09-10,October 2020,2020-10-31,"September 1, 2021",Anticipated,2021-09-01,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,Cov-Peru,,"Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Adult Population In Peru","Ensayo ClÃ­nico de Fase III, Aleatorio, Doble Ciego y Controlado Con Placebo Paralelo, Para Evaluar la Seguridad y la Eficacia Protectora de la Vacuna Inactivada Contra el SARS-CoV-2 en la PoblaciÃ³n Sana de 18 aÃ±os o mÃ¡s, en PerÃº",Recruiting,NA,Phase 3,6000,Anticipated,Universidad Peruana Cayetano Heredia,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-07T11:16:07Z,2020-11-07T11:16:07Z
NCT04522830,"ClinicalTrials.gov processed this data on November 13, 2020",2020-08-18,NA,NA,2020-11-06,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"July 30, 2020",Actual,2020-07-30,November 2020,2020-11-30,"February 1, 2021",Anticipated,2021-02-01,"January 31, 2021",Anticipated,2021-01-31,NA,Interventional,BTL-TML-COVID,,A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19,"A Double-blind, Placebo-controlled, Phase 2 Trial of Sublingual Low-Dose Thimerosal in Adults With Symptomatic SARS-CoV-2 Infection",Recruiting,NA,Phase 2,40,Anticipated,"Beech Tree Labs, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-14T10:39:19Z,2020-11-14T10:39:19Z
NCT04581161,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-19,NA,NA,2020-10-06,2020-10-06,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-09,Actual,"August 28, 2020",Actual,2020-08-28,October 2020,2020-10-31,October 2020,Anticipated,2020-10-31,October 2020,Anticipated,2020-10-31,NA,Interventional,NA,,Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients,A Novel Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients,Recruiting,NA,N/A,10,Anticipated,Hill-Rom,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T11:37:24Z,2020-11-01T11:37:24Z
NCT04531618,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-19,NA,NA,2020-08-28,2020-08-26,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-08-28,2020-08-31,Actual,"August 13, 2020",Actual,2020-08-13,August 2020,2020-08-31,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,,Mother-infant Bonding During COVID-19,Promoting Mother-Infant Emotional Connection During the COVID-19 Pandemic: an Randomized Controlled Trial (RCT) of Virtual Family Nurture Intervention,Recruiting,NA,N/A,280,Anticipated,Columbia University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:43:08Z,2020-11-01T11:43:08Z
NCT04529499,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-19,NA,NA,2020-09-16,2020-08-26,2020-08-27,Actual,NA,NA,NA,NA,NA,NA,2020-09-16,2020-09-18,Actual,"August 20, 2020",Actual,2020-08-20,September 2020,2020-09-30,"January 31, 2021",Anticipated,2021-01-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients,"A Multi-center, Randomized, Double Blind, Placebo Controlled Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients",Recruiting,NA,Phase 3,780,Anticipated,Dr. Reddy's Laboratories Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:43:22Z,2020-11-01T11:43:22Z
NCT04528641,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-19,NA,NA,2020-08-27,2020-08-25,2020-08-27,Actual,NA,NA,NA,NA,NA,NA,2020-08-27,2020-08-31,Actual,"August 10, 2020",Actual,2020-08-10,August 2020,2020-08-31,"July 31, 2021",Anticipated,2021-07-31,"July 31, 2021",Anticipated,2021-07-31,NA,Interventional,NA,,GRAd-COV2 Vaccine Against COVID-19,"A Phase 1, Dosage-Escalation Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine GRAd-COV2 in Healthy Adults and Elderly Subjects",Recruiting,NA,Phase 1,90,Anticipated,ReiThera Srl,,6,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:43:28Z,2020-11-01T11:43:28Z
NCT04528368,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-19,NA,NA,2020-08-25,2020-08-25,2020-08-27,Actual,NA,NA,NA,NA,NA,NA,2020-08-25,2020-08-27,Actual,"August 18, 2020",Anticipated,2020-08-18,August 2020,2020-08-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support,Efficacy and Safety of Using Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support,Recruiting,NA,Phase 2,60,Anticipated,D'Or Institute for Research and Education,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:43:30Z,2020-11-01T11:43:30Z
NCT04524715,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-19,NA,NA,2020-08-23,2020-08-20,2020-08-24,Actual,NA,NA,NA,NA,NA,NA,2020-08-23,2020-08-25,Actual,"July 26, 2020",Actual,2020-07-26,August 2020,2020-08-31,"January 31, 2021",Anticipated,2021-01-31,"December 10, 2020",Anticipated,2020-12-10,NA,Interventional,NA,,LLLT Treatment of Lung Inflammation in COVID-19,Low-Level Laser Therapy Treatment of Lung Inflammation in COVID-19 Patients,Recruiting,NA,N/A,64,Anticipated,Ward Photonics LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,FALSE,NA,,NA,NA,NA,No,"This investigational study is exploratory in nature. The primary endpoint is most descriptive in statistical terms of whether the active patient group had significantly better outcomes than the control group. Individual patient data may be explored at a later date to determine related factors such as patient demographics, comorbidities, or other evidence of compounding variables.",2020-11-01T11:43:56Z,2020-11-01T11:43:56Z
NCT04523831,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-19,2020-09-30,NA,2020-10-07,2020-08-20,2020-08-24,Actual,2020-10-07,2020-10-09,Actual,NA,NA,NA,2020-10-07,2020-10-09,Actual,"June 1, 2020",Actual,2020-06-01,October 2020,2020-10-31,"September 10, 2020",Actual,2020-09-10,"August 22, 2020",Actual,2020-08-22,NA,Interventional,NA,We followed intention to treat analysis; SPSS (Statistical Package for Social Sciences) version 20 was used to analyze data. To compare mean of the two group chi square test was done.,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,A Phase III Trial to Promote Recovery From Covid 19 With Combined Doxycycline and Ivermectin Along Standard Care,Completed,NA,Phase 3,400,Actual,Dhaka Medical College,"We followed up the patients by telephonic (video) interview, which has some inherent drawback for the study. we could not assess viral clearance directly. Only single dose regimen was used. Efficacy might higher if the different regimen would use.",2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,September 2020 to December 2020,Person who are investigating covid-19 in various aspects,NA,Yes,"Patients age, sex, Date of covid positive report, Symtoms,Date of covid negative report, post covid symptoms, time to recover.",2020-11-01T11:44:05Z,2020-11-01T11:44:05Z
NCT04523181,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-19,NA,NA,2020-10-14,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"October 8, 2020",Actual,2020-10-08,October 2020,2020-10-31,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients,"A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Safety and Efficacy of Antroquinonol in Hospitalized Patients With Mild to Moderate Pneumonia Due to COVID-19",Recruiting,NA,Phase 2,174,Anticipated,Golden Biotechnology Corporation,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:44:10Z,2020-11-01T11:44:10Z
NCT04522466,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-19,NA,NA,2020-09-04,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2020-09-04,2020-09-07,Actual,"April 3, 2020",Actual,2020-04-03,September 2020,2020-09-30,"May 28, 2020",Actual,2020-05-28,"May 28, 2020",Actual,2020-05-28,NA,Interventional,PREAVIS,,Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients,Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients,Terminated,NA,Phase 3,7,Actual,Centre Hospitalier Universitaire de Saint Etienne,,1,NA,Stop of the study by competent authority (ANSM),FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:44:14Z,2020-11-01T11:44:14Z
NCT04521322,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-19,NA,NA,2020-08-19,2020-08-19,2020-08-20,Actual,NA,NA,NA,NA,NA,NA,2020-08-19,2020-08-21,Actual,"July 24, 2020",Actual,2020-07-24,August 2020,2020-08-31,"November 30, 2020",Anticipated,2020-11-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,CARR-COV-02,,Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19 Disease,"Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19. Multicenter, Randomized, Double-blind, Placebo-controlled Trial (CARR-COV-02)",Recruiting,NA,Phase 4,400,Anticipated,Centro de EducaciÃ³n Medica e Investigaciones ClÃ­nicas Norberto Quirno,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:44:22Z,2020-11-01T11:44:22Z
NCT04530448,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-20,NA,NA,2020-10-13,2020-08-26,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-19,Actual,"October 5, 2020",Actual,2020-10-05,October 2020,2020-10-31,March 2021,Anticipated,2021-03-31,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization,Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization,Recruiting,NA,Phase 4,40,Anticipated,West Virginia University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T11:43:16Z,2020-11-01T11:43:16Z
NCT04524598,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-20,NA,NA,2020-09-16,2020-08-20,2020-08-24,Actual,NA,NA,NA,NA,NA,NA,2020-09-16,2020-09-18,Actual,"July 20, 2020",Actual,2020-07-20,September 2020,2020-09-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19,Limbix Spark: A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19,Recruiting,NA,N/A,410,Anticipated,"Limbix Health, Inc.",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T11:43:59Z,2020-11-01T11:43:59Z
NCT04523090,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-20,NA,NA,2020-08-30,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2020-08-30,2020-09-01,Actual,"August 27, 2020",Actual,2020-08-27,August 2020,2020-08-31,August 2021,Anticipated,2021-08-31,April 2021,Anticipated,2021-04-30,NA,Interventional,C3-RCT,,Catalysing the Containment of COVID-19,"The C3 Nitazoxanide for Mild to Moderate COVID-19 in HIV-infected and HIV-uninfected Adults With Enhanced Risk: a Double-blind, Randomised, Placebo-controlled Trial in a Resource-poor Setting",Recruiting,NA,Phase 2/Phase 3,960,Anticipated,University of Cape Town,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:44:11Z,2020-11-01T11:44:11Z
NCT04522817,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-20,NA,NA,2020-10-07,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2020-10-07,2020-10-09,Actual,"October 5, 2020",Actual,2020-10-05,October 2020,2020-10-31,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,CLBS119 for Repair of COVID-19 Induced Pulmonary Damage,CLBS119 (Autologous Peripheral Blood Derived CD34+ Cells) for Repair of COVID-19 Induced Pulmonary Damage,Recruiting,NA,Phase 1,12,Anticipated,"Caladrius Biosciences, Inc.",,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:44:12Z,2020-11-01T11:44:12Z
NCT04523246,"ClinicalTrials.gov processed this data on November 13, 2020",2020-08-20,NA,NA,2020-11-07,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2020-11-07,2020-11-10,Actual,"September 1, 2020",Actual,2020-09-01,November 2020,2020-11-30,"September 1, 2021",Anticipated,2021-09-01,"July 1, 2021",Anticipated,2021-07-01,NA,Interventional,NH-Shingrix,,Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents,"Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents: A Randomized, Doubled-Blinded, Comparative Group Observational Study",Recruiting,NA,Early Phase 1,250,Anticipated,University of Oklahoma,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-14T10:39:18Z,2020-11-14T10:39:18Z
NCT04529525,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-21,NA,NA,2020-09-12,2020-08-26,2020-08-27,Actual,NA,NA,NA,NA,NA,NA,2020-09-12,2020-09-16,Actual,"August 19, 2020",Actual,2020-08-19,September 2020,2020-09-30,"January 31, 2021",Anticipated,2021-01-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,IVERCORCOVID19,,Ivermectin to Prevent Hospitalizations in COVID-19,"Ivermectin to Prevent Hospitalizations in COVID-19: Randomized, Double-blind, Placebo-controlled",Recruiting,NA,Phase 2/Phase 3,500,Anticipated,Instituto de CardiologÃ­a de Corrientes,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:43:22Z,2020-11-01T11:43:22Z
NCT04526912,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-21,NA,NA,2020-09-01,2020-08-21,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2020-09-01,2020-09-02,Actual,"August 28, 2020",Actual,2020-08-28,September 2020,2020-09-30,March 2021,Anticipated,2021-03-31,January 2021,Anticipated,2021-01-31,NA,Interventional,ALI,,Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection,A Proof of Concept Study of the Safety and Efficacy of VIB7734 for the Treatment and Prevention of Acute Lung Injury (ALI) in Patients With SARS-CoV-2 Infection,Recruiting,NA,Phase 1,48,Anticipated,Viela Bio,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:43:39Z,2020-11-01T11:43:39Z
NCT04525417,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-21,NA,NA,2020-08-22,2020-08-22,2020-08-25,Actual,NA,NA,NA,NA,NA,NA,2020-08-22,2020-08-25,Actual,"April 25, 2020",Actual,2020-04-25,August 2020,2020-08-31,"October 25, 2020",Anticipated,2020-10-25,"September 25, 2020",Anticipated,2020-09-25,NA,Interventional,NA,,Rapid Screening Test for Covid-19 Antibodies in Healthcare Workers,Use of Rapid Covid-19 Antibody Test Marketed by AAZ Laboratories in Healthcare Workers Presumably Being Infected by SARS-CoV-2,Recruiting,NA,N/A,100,Anticipated,Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:43:49Z,2020-11-01T11:43:49Z
NCT04524507,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-21,NA,NA,2020-09-30,2020-08-21,2020-08-24,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"August 27, 2020",Actual,2020-08-27,September 2020,2020-09-30,May 2021,Anticipated,2021-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,UNC CCP RCT,,COVID-19 Antibody Plasma Research Study in Hospitalized Patients,"IGHID 12021 - A Randomized, Phase II Study Comparing the Efficacy and Safety of Standard Versus High-Titer Anti-SARS-CoV2 Neutralizing Antibody Plasma in Hospitalized Patients With COVID-19",Recruiting,NA,Phase 2,56,Anticipated,"University of North Carolina, Chapel Hill",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,12-24 months after publication,"Investigators/researchers who propose to use study data will need to have IRB, IEC, or REB approval and an executed data use/sharing agreement with UNC.",NA,Yes,"De-identified individual data that supports the results will be shared beginning 12 to 24 months following publication provided the investigator/researcher who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.",2020-11-01T11:44:00Z,2020-11-01T11:44:00Z
NCT04535167,"ClinicalTrials.gov processed this data on November 02, 2020",2020-08-21,NA,NA,2020-10-28,2020-08-31,2020-09-01,Actual,NA,NA,NA,NA,NA,NA,2020-10-28,2020-10-30,Actual,"September 9, 2020",Actual,2020-09-09,October 2020,2020-10-31,"April 20, 2021",Anticipated,2021-04-20,"April 20, 2021",Anticipated,2021-04-20,NA,Interventional,NA,,"First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending Dose And Extended Infusion of PF 07304814 In Hospitalized Participants With COVID-19.","A PHASE 1B, 2-PART, DOUBLE-BLIND, PLACEBO-CONTROLLED, SPONSOR-OPEN STUDY, TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING (24-HOUR, PART 1) AND EXTENDED (120-HOUR, PART 2) INTRAVENOUS INFUSIONS OF PF-07304814 IN HOSPITALIZED PARTICIPANTS WITH COVID-19",Recruiting,NA,Phase 1,56,Anticipated,Pfizer,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2020-11-03T10:50:36Z,2020-11-03T10:50:36Z
NCT04568031,"ClinicalTrials.gov processed this data on November 13, 2020",2020-08-21,NA,NA,2020-11-12,2020-09-25,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-13,Estimate,"August 23, 2020",Actual,2020-08-23,November 2020,2020-11-30,"November 10, 2021",Anticipated,2021-11-10,"November 10, 2021",Anticipated,2021-11-10,NA,Interventional,NA,,Study of AZD1222 for the Prevention of COVID-19 in Japan,"A Phase I/II Randomized, Double-blind, Placebo-controlled Multicentre Study in Participants Aged 18 Years or Older to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19",Recruiting,NA,Phase 1/Phase 2,256,Anticipated,AstraZeneca,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure,2020-11-15T10:56:44Z,2020-11-15T10:56:44Z
NCT04526990,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-22,NA,NA,2020-09-15,2020-08-22,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2020-09-15,2020-09-16,Actual,"September 15, 2020",Actual,2020-09-15,August 2020,2020-08-31,"January 30, 2022",Anticipated,2022-01-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,NA,,Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above,"A Global Multicenter, Randomized, Double-blind, Placebo -Controlled, Adaptive Designed Phase â…¢ Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Ad5-nCoV in Adults 18 Years of Age and Older",Recruiting,NA,Phase 3,40000,Anticipated,CanSino Biologics Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:43:39Z,2020-11-01T11:43:39Z
NCT04527354,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-24,NA,NA,2020-09-30,2020-08-24,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-01,Actual,"September 8, 2020",Actual,2020-09-08,September 2020,2020-09-30,November 2020,Anticipated,2020-11-30,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,,Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia,"Multicenter, Randomized, Double-blind, Placebo-controlled Pilot Study of Treamid Efficacy and Safety in the Rehabilitation of Patients After COVID-19 Pneumonia",Recruiting,NA,Phase 2,60,Anticipated,PHARMENTERPRISES LLC,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:43:37Z,2020-11-01T11:43:37Z
NCT04527133,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-24,NA,NA,2020-08-25,2020-08-25,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2020-08-25,2020-08-26,Actual,"June 11, 2020",Actual,2020-06-11,August 2020,2020-08-31,"August 31, 2020",Anticipated,2020-08-31,"August 11, 2020",Actual,2020-08-11,NA,Interventional,NA,,An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19,An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19,"Active, not recruiting",NA,N/A,30,Actual,Aviron LLC,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,not planned,2020-11-01T11:43:38Z,2020-11-01T11:43:38Z
NCT04527081,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-24,NA,NA,2020-09-23,2020-08-24,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-25,Actual,"August 31, 2020",Actual,2020-08-31,August 2020,2020-08-31,"September 30, 2021",Anticipated,2021-09-30,"November 26, 2020",Anticipated,2020-11-26,NA,Interventional,NA,,Study of COVID-19 DNA Vaccine (AG0302-COVID19),"A Randomized, Open-label, Non-controlled Phase I/II Study to Assess Safety and Immunogenicity of Twice or Three Times Dosing of Intramuscular AG0302-COVID19 (2mg) in Healthy Adults","Active, not recruiting",NA,Phase 1/Phase 2,30,Anticipated,"AnGes, Inc.",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:43:38Z,2020-11-01T11:43:38Z
NCT04530409,"ClinicalTrials.gov processed this data on November 13, 2020",2020-08-24,NA,NA,2020-11-07,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-11-07,2020-11-10,Actual,"August 26, 2020",Actual,2020-08-26,November 2020,2020-11-30,"January 1, 2021",Anticipated,2021-01-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,NA,,Timing of Corticosteroids in COVID-19,Timing of Corticosteroids in COVID-19,Recruiting,NA,Phase 4,450,Anticipated,ClinAmygate,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-14T10:39:08Z,2020-11-14T10:39:08Z
NCT04537351,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-25,NA,NA,2020-09-23,2020-09-01,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-25,Actual,"August 24, 2020",Actual,2020-08-24,September 2020,2020-09-30,"March 31, 2021",Anticipated,2021-03-31,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,MEND,,The MEseNchymal coviD-19 Trial: a Pilot Study to Investigate Early Efficacy of MSCs in Adults With COVID-19,"A Pilot, Open-label, Randomised Controlled Clinical Trial to Investigate Early Efficacy of CYP-001 in Adults Admitted to Intensive Care With COVID-19",Recruiting,NA,Phase 1/Phase 2,24,Anticipated,Cynata Therapeutics Limited,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T11:42:24Z,2020-11-01T11:42:24Z
NCT04530604,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-25,NA,NA,2020-10-12,2020-08-26,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-10-12,2020-10-14,Actual,"October 1, 2020",Actual,2020-10-01,October 2020,2020-10-31,"October 1, 2021",Anticipated,2021-10-01,"October 1, 2021",Anticipated,2021-10-01,NA,Interventional,NA,,Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS),Defibrotide Therapy for SARS-CoV2 Acute Respiratory Distress Syndrome (ARDS),Recruiting,NA,Phase 1,12,Anticipated,University of Michigan,,1,NA,NA,NA,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:43:16Z,2020-11-01T11:43:16Z
NCT04530435,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-25,NA,NA,2020-10-07,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-10-07,2020-10-08,Actual,"October 6, 2020",Actual,2020-10-06,October 2020,2020-10-31,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,PEP-CoV,,PEP Flute-selfcare in COVID-19,PEP Flute-selfcare to Prevent Respiratory Deterioration and Hospitalization Among COVID-19 Patients: a Randomized Trial,Recruiting,NA,N/A,400,Anticipated,Bispebjerg Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:43:17Z,2020-11-01T11:43:17Z
NCT04530396,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-25,NA,NA,2020-10-23,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-27,Actual,"September 7, 2020",Actual,2020-09-07,August 2020,2020-08-31,"May 1, 2021",Anticipated,2021-05-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,RESIST,,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19","Randomized Double-blind Placebo-controlled Multi-center Clinical Trial in Parallel Assignment of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine in SARS-Ð¡oV-2 Infection Prophylactic Treatment",Recruiting,NA,Phase 3,40000,Anticipated,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:43:17Z,2020-11-01T11:43:17Z
NCT04527562,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-25,NA,NA,2020-08-26,2020-08-25,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2020-08-26,2020-08-28,Actual,"July 14, 2020",Actual,2020-07-14,August 2020,2020-08-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,COLCOVIDBD,,Colchicine in Moderate Symptomatic COVID-19 Patients,"Colchicine in Moderate Symptomatic COVID-19 Patients: Double Blind, Randomized, Placebo Controlled Trial to Observe the Efficacy",Recruiting,NA,N/A,300,Anticipated,Dhaka Medical College,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:43:35Z,2020-11-01T11:43:35Z
NCT04539262,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-26,NA,NA,2020-10-07,2020-09-03,2020-09-04,Actual,NA,NA,NA,NA,NA,NA,2020-10-07,2020-10-08,Actual,"September 14, 2020",Actual,2020-09-14,October 2020,2020-10-31,December 2020,Anticipated,2020-12-31,October 2020,Anticipated,2020-10-31,NA,Interventional,NA,,"Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation","A Phase 1b/2a Study in Participants With Early Stage COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation",Recruiting,NA,Phase 1/Phase 2,282,Anticipated,Gilead Sciences,,8,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:42:11Z,2020-11-01T11:42:11Z
NCT04536441,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-26,NA,NA,2020-09-01,2020-09-01,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2020-09-01,2020-09-02,Actual,"April 1, 2020",Actual,2020-04-01,September 2020,2020-09-30,"June 30, 2020",Actual,2020-06-30,"May 30, 2020",Actual,2020-05-30,NA,Interventional,NA,,Ultra-brief Online Mindfulness-based Intervention During COVID-19 Movement Control Order,Effects of an Ultra-brief Online Mindfulness-based Intervention on Mental Health During the Coronavirus Disease (COVID-19) Outbreak in Malaysia: A Randomised Controlled Trial,Completed,NA,N/A,161,Actual,Universiti Tunku Abdul Rahman,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"The data will be become available once the study is being published, for 5 years.",The data will be made available upon request to the corresponding author.,NA,Yes,NA,2020-11-01T11:42:31Z,2020-11-01T11:42:31Z
NCT04532931,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-26,NA,NA,2020-10-07,2020-08-28,2020-08-31,Actual,NA,NA,NA,NA,NA,NA,2020-10-07,2020-10-08,Actual,"September 3, 2020",Actual,2020-09-03,September 2020,2020-09-30,January 2021,Anticipated,2021-01-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,COVID-19 Treatment in South Africa,"Phase 2, Exploratory, Single Center, Randomized, Open Label, Adaptive Clinical Trial to Compare Safety and Efficacy of Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19",Recruiting,NA,Phase 2,250,Anticipated,Shin Poong Pharmaceutical Co. Ltd.,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:42:58Z,2020-11-01T11:42:58Z
NCT04531774,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-26,NA,NA,2020-10-14,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"August 28, 2020",Actual,2020-08-28,October 2020,2020-10-31,"June 1, 2021",Anticipated,2021-06-01,"June 1, 2021",Anticipated,2021-06-01,NA,Interventional,NA,,RECHARGE: A Brief Psychological Intervention to Build Resilience in Healthcare Workers During COVID-19,RECHARGE: A Brief Psychological Intervention to Build Resilience in Healthcare Workers During COVID-19,Recruiting,NA,N/A,160,Anticipated,University of Zurich,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,One year after conclusion of the study.,NA,NA,Yes,"We follow open science practices and will use open access journals and repositories to publish results, anonymized original data, and meta-data describing the data and procedures (e.g., study protocol, statistical codes, instructions concerning the use of the data) to ensure full transparency and reproducibility.",2020-11-01T11:43:08Z,2020-11-01T11:43:08Z
NCT04530617,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-26,NA,NA,2020-10-20,2020-08-26,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-10-20,2020-10-22,Actual,"October 5, 2020",Actual,2020-10-05,August 2020,2020-08-31,February 2021,Anticipated,2021-02-28,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients,"Randomized, Double-blind, Placebo-controlled, Multicenter, Multi-arm, Phase II Trial of Novel Agents for the Treatment of Mild to Moderate COVID-19 Positive Outpatients",Recruiting,NA,Phase 2,360,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,All IPD results in the publication,2020-11-01T11:43:15Z,2020-11-01T11:43:15Z
NCT04530422,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-26,NA,NA,2020-08-27,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-08-27,2020-08-28,Actual,"April 15, 2020",Actual,2020-04-15,August 2020,2020-08-31,"July 23, 2020",Actual,2020-07-23,"July 8, 2020",Actual,2020-07-08,NA,Interventional,NA,,Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment,Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment,Completed,NA,Phase 3,250,Actual,Almaza Military Fever Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:43:17Z,2020-11-01T11:43:17Z
NCT04530370,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-26,NA,NA,2020-08-27,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-08-27,2020-08-28,Actual,"May 29, 2020",Actual,2020-05-29,August 2020,2020-08-31,"September 1, 2020",Anticipated,2020-09-01,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Efficacy and Safety of Recovered Covid 19 Plasma Transfusion to Covid 19 Severly Ill Patients,Efficacy and Safety of Recovered Covid 19 Plasma Transfusion to Covid 19 Severly Ill Patients,Recruiting,NA,Early Phase 1,30,Anticipated,South Valley University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-11-01T11:43:17Z,2020-11-01T11:43:17Z
NCT04530357,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-26,NA,NA,2020-10-20,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-10-20,2020-10-22,Actual,"September 19, 2020",Actual,2020-09-19,October 2020,2020-10-31,"December 7, 2020",Anticipated,2020-12-07,"November 25, 2020",Anticipated,2020-11-25,NA,Interventional,NA,,"Reactogenicity, Safety and Immunogenicity of QazCovid-inÂ® COVID-19 Vaccine","Randomized, Blind, Placebo-controlled Phase- i Study and Randomized, Open Phase Phase-ii Study of QAZCOVID-INÂ®- COVID-19 Inactivated Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder","Active, not recruiting",NA,Phase 1/Phase 2,244,Anticipated,Research Institute for Biological Safety Problems,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:43:17Z,2020-11-01T11:43:17Z
NCT04554992,"ClinicalTrials.gov processed this data on November 05, 2020",2020-08-26,NA,NA,2020-10-29,2020-09-16,2020-09-18,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-11-02,Actual,"March 20, 2020",Actual,2020-03-20,October 2020,2020-10-31,June 2022,Anticipated,2022-06-30,June 2022,Anticipated,2022-06-30,NA,Interventional,NA,,Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019),Convalescent Plasma for the Treatment of Coronavirus Disease 2019,"Active, not recruiting",NA,Phase 1,350,Actual,The Methodist Hospital System,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-06T12:40:34Z,2020-11-06T12:40:34Z
NCT04559074,"ClinicalTrials.gov processed this data on November 13, 2020",2020-08-26,NA,NA,2020-11-11,2020-09-21,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Estimate,"October 23, 2020",Actual,2020-10-23,August 2020,2020-08-31,"July 31, 2021",Anticipated,2021-07-31,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,,Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension- Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic,Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension- Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic,Recruiting,NA,Phase 4,1000,Anticipated,Queen Mary University of London,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Fully anonymised data will be shared with fellow researchers via conference presentation and via publication of the results in scientific journals. Pseudonymised data will be shared between the research teams named in the application.,2020-11-15T10:56:53Z,2020-11-15T10:56:53Z
NCT04535453,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-27,NA,NA,2020-10-13,2020-08-27,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-14,Actual,"August 28, 2020",Actual,2020-08-28,October 2020,2020-10-31,"December 15, 2021",Anticipated,2021-12-15,"December 15, 2021",Anticipated,2021-12-15,NA,Interventional,NA,,A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults,"A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older",Recruiting,NA,Phase 2,550,Anticipated,Janssen Vaccines & Prevention B.V.,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.janssen.com/clinical-trials/transparency,Yes,"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",2020-11-01T11:42:38Z,2020-11-01T11:42:38Z
NCT04532294,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-27,NA,NA,2020-09-13,2020-08-27,2020-08-31,Actual,NA,NA,NA,NA,NA,NA,2020-09-13,2020-09-16,Actual,"September 8, 2020",Actual,2020-09-08,September 2020,2020-09-30,"December 31, 2020",Anticipated,2020-12-31,"October 15, 2020",Anticipated,2020-10-15,NA,Interventional,NA,,"Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants","A First-in-Human, Randomized, Double-Blind, Placebo Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SARS-CoV-2 Neutralizing Antibody BGB-DXP593 in Healthy Subjects",Recruiting,NA,Phase 1,30,Anticipated,BeiGene,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,NA,2020-11-01T11:43:05Z,2020-11-01T11:43:05Z
NCT04537663,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-28,NA,NA,2020-09-02,2020-09-02,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2020-09-02,2020-09-03,Actual,"August 25, 2020",Actual,2020-08-25,September 2020,2020-09-30,April 2021,Anticipated,2021-04-30,November 2020,Anticipated,2020-11-30,NA,Interventional,BCG-PRIME,,Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults,Bacillus Calmette-GuÃ©rin Vaccination To Prevent Serious Respiratory Tract Infection And Covid-19 In Vulnerable Elderly - An Adaptive Randomized Controlled Trial,Recruiting,NA,Phase 4,5200,Anticipated,UMC Utrecht,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:42:23Z,2020-11-01T11:42:23Z
NCT04533399,"ClinicalTrials.gov processed this data on November 05, 2020",2020-08-28,NA,NA,2020-10-30,2020-08-28,2020-08-31,Actual,NA,NA,NA,NA,NA,NA,2020-10-30,2020-11-02,Actual,"August 17, 2020",Actual,2020-08-17,October 2020,2020-10-31,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,,A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults,"A Phase 2A/B, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1â„¢ Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV",Recruiting,NA,Phase 2,4400,Anticipated,Novavax,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-06T12:41:27Z,2020-11-06T12:41:27Z
NCT04537858,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-29,NA,NA,2020-09-01,2020-09-01,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2020-09-01,2020-09-03,Actual,"June 18, 2020",Actual,2020-06-18,September 2020,2020-09-30,"December 1, 2020",Anticipated,2020-12-01,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,,Virtual Reality Therapy Influence on Heart Rate Variability of Inpatients With COVID-19,Analysis of the Influence of Rehabilitation With Virtual Reality on the Heart Rate Variability of Individuals Under Treatment of COVID-19 in a Hospital Unit.,"Active, not recruiting",NA,N/A,50,Actual,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:42:22Z,2020-11-01T11:42:22Z
NCT04535063,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-29,NA,NA,2020-08-31,2020-08-29,2020-09-01,Actual,NA,NA,NA,NA,NA,NA,2020-08-31,2020-09-02,Actual,"April 18, 2020",Actual,2020-04-18,August 2020,2020-08-31,"February 25, 2021",Anticipated,2021-02-25,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,NA,,Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia,Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia,Recruiting,NA,Phase 3,200,Anticipated,Centro de EducaciÃ³n Medica e Investigaciones ClÃ­nicas Norberto Quirno,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,we will to share results to compare data with other studies with convalescent plasma infusion in COVID 19 patients after finishing our study,2020-11-01T11:42:40Z,2020-11-01T11:42:40Z
NCT04542941,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-31,NA,NA,2020-09-07,2020-09-07,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-07,2020-09-09,Actual,"June 16, 2020",Actual,2020-06-16,September 2020,2020-09-30,"October 31, 2020",Anticipated,2020-10-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,COVIDIT,,Assessment of Safety and Efficacy of CCP,Assessment of Safety and Efficacy of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Adults in Uganda; A Randomised Controlled Trial,"Active, not recruiting",NA,N/A,136,Actual,Makerere University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Arrangments to enable sharing of de-identified data will be instituted by the research team.,2020-11-01T11:41:40Z,2020-11-01T11:41:40Z
NCT04535674,"ClinicalTrials.gov processed this data on October 30, 2020",2020-08-31,NA,NA,2020-10-21,2020-09-01,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-22,Actual,"October 9, 2020",Actual,2020-10-09,October 2020,2020-10-31,May 2021,Anticipated,2021-05-31,February 2021,Anticipated,2021-02-28,NA,Interventional,ASUNCTIS,,Asunercept in Patients With Severe COVID-19,"A Multicenter, Randomised, Controlled, Open Label Trial on the Efficacy and Safety of Asunercept for Patients With Severe COVID-19 Disease",Recruiting,NA,Phase 2,400,Anticipated,Apogenix AG,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:42:35Z,2020-11-01T11:42:35Z
NCT04536051,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-01,NA,NA,2020-09-10,2020-09-01,2020-09-02,Actual,NA,NA,NA,NA,NA,NA,2020-09-10,2020-09-14,Actual,"June 2, 2020",Actual,2020-06-02,September 2020,2020-09-30,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,,A Study of a Candidate COVID-19 Vaccine (COV003),"A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine",Recruiting,NA,Phase 3,5000,Anticipated,University of Oxford,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:42:33Z,2020-11-01T11:42:33Z
NCT04554264,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-02,NA,NA,2020-09-17,2020-09-17,2020-09-18,Actual,NA,NA,NA,NA,NA,NA,2020-09-17,2020-09-18,Actual,"September 1, 2020",Actual,2020-09-01,September 2020,2020-09-30,September 2022,Anticipated,2022-09-30,September 2021,Anticipated,2021-09-30,NA,Interventional,DEPARTS,,Complicated Grief in ICU in the Aftermath of COVID-19,Complicated Grief in ICU in the Aftermath of COVID-19,Recruiting,NA,N/A,160,Anticipated,"Centre Hospitalier Universitaire, Amiens",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:40:23Z,2020-11-01T11:40:23Z
NCT04545749,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-02,NA,NA,2020-09-28,2020-09-10,2020-09-11,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-29,Actual,"September 25, 2020",Actual,2020-09-25,September 2020,2020-09-30,"August 31, 2021",Anticipated,2021-08-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","A Phase I, Open-label Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 Vaccine in Healthy Adult Volunteers",Recruiting,NA,Phase 1,60,Anticipated,"United Biomedical Inc., Asia",,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:41:23Z,2020-11-01T11:41:23Z
NCT04537949,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-02,NA,NA,2020-09-14,2020-09-02,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2020-09-14,2020-09-16,Actual,"September 9, 2020",Actual,2020-09-09,September 2020,2020-09-30,December 2021,Anticipated,2021-12-31,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,,A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults,"A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of a Prophylactic SARS-CoV-2 RNA Vaccine (BNT162b3) Against COVID-19 Using Different Dosing Regimens in Healthy Adults",Recruiting,NA,Phase 1/Phase 2,120,Anticipated,BioNTech SE,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:42:21Z,2020-11-01T11:42:21Z
NCT04537208,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-02,NA,NA,2020-10-21,2020-09-02,2020-09-03,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-22,Actual,"September 3, 2020",Actual,2020-09-03,October 2020,2020-10-31,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,,Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older,Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine Formulations (With or Without Adjuvant) in Healthy Adults 18 Years of Age and Older,Recruiting,NA,Phase 1/Phase 2,440,Anticipated,Sanofi,,21,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2020-11-01T11:42:25Z,2020-11-01T11:42:25Z
NCT04577534,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-03,NA,NA,2020-10-06,2020-10-05,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2020-10-06,2020-10-08,Actual,"August 14, 2020",Actual,2020-08-14,September 2020,2020-09-30,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,COVIDSTORM,,COVID-19: Salvage TOcilizumab as a Rescue Measure,COVID-19: Salvage TOcilizumab as a Rescue Measure. Use of Tocilizumab in the Inflammatory Phase of COVID-19 / New Coronavirus Disease,Recruiting,NA,Phase 3,90,Anticipated,Turku University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Undecided,plan to investigate if it is possible by law,2020-11-01T11:37:48Z,2020-11-01T11:37:48Z
NCT04558463,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-03,NA,NA,2020-09-21,2020-09-21,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-22,Actual,"April 16, 2020",Actual,2020-04-16,September 2020,2020-09-30,"October 30, 2020",Anticipated,2020-10-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19,The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19: An Open Label Trial,Recruiting,NA,Phase 3,100,Anticipated,Indonesia University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:39:53Z,2020-11-01T11:39:53Z
NCT04542213,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-03,NA,NA,2020-09-04,2020-09-04,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-04,2020-09-09,Actual,"August 1, 2020",Actual,2020-08-01,September 2020,2020-09-30,"September 30, 2020",Anticipated,2020-09-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,Covid19DPP4i,,Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19,Effect of the Combination of Dipeptidyl Peptidase-4 Inhibitor (DPP4i) and Insulin in Comparison to Insulin on Metabolic Control and Prognosis in Hospitalized Patients With COVID-19,Recruiting,NA,Phase 3,28,Anticipated,Hospital Regional de Alta Especialidad del Bajio,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,"Data will be available once the main results of the study are published, and in accordance with the journal",Direct contact with the principal investigator,NA,Yes,"Sharing of the data can be done, depending on the requested purposes",2020-11-01T11:41:46Z,2020-11-01T11:41:46Z
NCT04539795,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-03,NA,NA,2020-10-14,2020-09-03,2020-09-07,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"November 1, 2020",Anticipated,2020-11-01,October 2020,2020-10-31,"September 30, 2021",Anticipated,2021-09-30,"September 30, 2021",Anticipated,2021-09-30,NA,Interventional,COSTA,,COVID-19 Study of Safety and Tolerability of Alvelestat,"A Phase Ib/II, Single Center, Placebo-Controlled, Randomized, Blinded Study in Adult Patients (> 18 Years) With COVID-19 Respiratory Disease, to Evaluate, Safety, Tolerability and Mechanistic Effect of Alvelestat on Top of Standard of Care (COSTA)",Recruiting,NA,Phase 1/Phase 2,15,Anticipated,University of Alabama at Birmingham,,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:42:08Z,2020-11-01T11:42:08Z
NCT04539821,"ClinicalTrials.gov processed this data on November 05, 2020",2020-09-03,NA,NA,2020-10-29,2020-09-03,2020-09-07,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-11-02,Actual,"October 1, 2020",Actual,2020-10-01,October 2020,2020-10-31,"June 30, 2021",Anticipated,2021-06-30,"March 31, 2021",Anticipated,2021-03-31,NA,Interventional,VCPM,,Virtual Pain Care Management (COVID-19),Virtual Pain Care for High Risk Veterans on Opioids During COVID19 (and Beyond),Recruiting,NA,N/A,60,Anticipated,VA Office of Research and Development,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-06T12:41:08Z,2020-11-06T12:41:08Z
NCT04569188,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-04,NA,NA,2020-09-30,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"May 15, 2020",Actual,2020-05-15,September 2020,2020-09-30,"September 3, 2020",Actual,2020-09-03,"August 15, 2020",Actual,2020-08-15,NA,Interventional,RESCUE,,Convalescent Plasma in COVID-19 Elderly Patients,Real-time Evaluation of Safety and Efficacy of Convalescent Plasma Units Transfused to Elderly Patients With COVID-19,Completed,NA,Phase 2,21,Actual,Azienda Socio Sanitaria Territoriale di Mantova,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:38:43Z,2020-11-01T11:38:43Z
NCT04542967,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-04,NA,NA,2020-09-08,2020-09-08,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-08,2020-09-10,Actual,"June 23, 2020",Actual,2020-06-23,September 2020,2020-09-30,"September 30, 2020",Anticipated,2020-09-30,"September 2, 2020",Actual,2020-09-02,NA,Interventional,PC-COVID-HCM,,Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease,Convalescent Plasma as a Treatment for Patients With Severe COVID-19 Disease,Recruiting,NA,Phase 2,150,Anticipated,Hospital Central Militar,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,From 6 months after publication,PRIOR APPLICATION,NA,Yes,Plan to make IPD still not decided and would need approval by regulatory authorities,2020-11-01T11:41:40Z,2020-11-01T11:41:40Z
NCT04542421,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-04,NA,NA,2020-09-24,2020-09-06,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-28,Actual,"July 1, 2020",Actual,2020-07-01,September 2020,2020-09-30,"December 1, 2021",Anticipated,2021-12-01,"July 1, 2021",Anticipated,2021-07-01,NA,Interventional,NA,,Lung Ultrasound Implementation in the Management of Patients Hospitalized With COVID-19,Lung Ultrasound Implementation in the Management of Patients Hospitalized With COVID-19,Recruiting,NA,N/A,90,Anticipated,"University of Colorado, Denver",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:41:45Z,2020-11-01T11:41:45Z
NCT04540185,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-04,NA,NA,2020-09-05,2020-09-04,2020-09-07,Actual,NA,NA,NA,NA,NA,NA,2020-09-05,2020-09-09,Actual,"November 1, 2020",Anticipated,2020-11-01,September 2020,2020-09-30,"December 31, 2022",Anticipated,2022-12-31,"November 1, 2022",Anticipated,2022-11-01,NA,Interventional,OPV-NA831,,A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19,"A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Polio Vaccine and NA-831 for Prophylaxis and Treatment of Early Onset of Covid-19",Enrolling by invitation,NA,Phase 3,3600,Anticipated,"NeuroActiva, Inc.",,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,90 days after completion of the study,To be verified and determined at a later date,NA,Yes,We plan to share the Study Protocol and other information if needed,2020-11-01T11:42:05Z,2020-11-01T11:42:05Z
NCT04540939,"ClinicalTrials.gov processed this data on November 05, 2020",2020-09-04,NA,NA,2020-10-29,2020-09-04,2020-09-07,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-11-02,Actual,"October 19, 2020",Actual,2020-10-19,September 2020,2020-09-30,December 2021,Anticipated,2021-12-31,December 2021,Anticipated,2021-12-31,NA,Interventional,NA,,Neural Mechanisms of Mindfulness-based Cognitive Therapy (MBCT) for Posttraumatic Stress Disorder (PTSD) - COVID Related Substudy,Neural Mechanisms of Mindfulness-based Cognitive Therapy (MBCT) for Posttraumatic Stress Disorder (PTSD) - COVID Related Substudy,Recruiting,NA,N/A,60,Anticipated,University of Michigan,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,Within 36 months of completion of the project.,"Access to data generated by the project will be available for educational, research and non-profit purposes to researchers who provide a methodologically sound proposal. Data generated under this project will be administered in accordance with NIH Sharing policies, including NIH Policy on Dissemination of NIH-Funded Clinical Trial Information (8/2016), and the NIH Grants Policy Statement (Availability of Research Results) (11/2015). Depending on such NIH policies, Data generated by this project may be available for educational, research or non-commercial purposes under the terms of a data use agreement. Data will be stored in an established data repository (e.g. Inter-university Consortium for Political and Social Research (ICPSR): icpsr.umich.edu) with appropriate provisions for curation and longterm preservation.",NA,Yes,We plan to make available data from human subjects initially to collaborators for independent replication / data pooling. Completely de-identified research data (redacted according to NIH practice to prevent disclosure of personal identifiers) which documents the research findings will be made available after the main findings from the finalized research dataset have been accepted for publication.,2020-11-06T12:41:06Z,2020-11-06T12:41:06Z
NCT04542694,"ClinicalTrials.gov processed this data on November 06, 2020",2020-09-04,2020-10-11,NA,2020-11-03,2020-09-04,2020-09-09,Actual,2020-11-03,2020-11-05,Actual,NA,NA,NA,2020-11-03,2020-11-05,Actual,"May 21, 2020",Actual,2020-05-21,November 2020,2020-11-30,"August 20, 2020",Actual,2020-08-20,"August 10, 2020",Actual,2020-08-10,NA,Interventional,NA,,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,"Open-label Randomized Multicenter Comparative Study on the Efficacy and Safety of Areplivir Film-coated Tablets (PROMOMED RUS LLC, Russia) in Patients Hospitalized With COVID-19",Completed,NA,Phase 3,200,Actual,"Promomed, LLC",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-09T10:51:55Z,2020-11-09T10:51:55Z
NCT04545060,"ClinicalTrials.gov processed this data on November 13, 2020",2020-09-04,NA,NA,2020-11-12,2020-09-09,2020-09-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-13,Estimate,"August 27, 2020",Actual,2020-08-27,November 2020,2020-11-30,July 2021,Anticipated,2021-07-31,January 2021,Anticipated,2021-01-31,NA,Interventional,COMET-ICE,,VIR-7831 for the Early Treatment of COVID-19 in Outpatients,"A Randomized, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Monoclonal Antibody VIR-7831 for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Non-hospitalized Patients",Recruiting,NA,Phase 2/Phase 3,1360,Anticipated,"Vir Biotechnology, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-15T10:57:07Z,2020-11-15T10:57:07Z
NCT04542447,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-06,NA,NA,2020-09-08,2020-09-06,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-08,2020-09-10,Actual,"September 1, 2020",Actual,2020-09-01,September 2020,2020-09-30,"September 30, 2020",Anticipated,2020-09-30,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,To Evaluate Safety and Efficacy of Nuvastatic as an Immunomodulator Adjuvant Therapy in COVID-19 Patients.,An Open Label Proof of Concept Study to Assess Aspects of Safety and Efficacy of Nuvastaticâ„¢ (C5OSEW5050ESA) as an Immunomodulator Adjuvant Therapy to the Standard Care of Treatment in Covid 19 Patients.,Recruiting,NA,Phase 1,10,Anticipated,Natureceuticals Sdn Bhd,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Institutional sharing,2020-11-01T11:41:45Z,2020-11-01T11:41:45Z
NCT04587414,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-08,NA,NA,2020-10-13,2020-10-13,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-14,Actual,"March 6, 2019",Actual,2019-03-06,October 2020,2020-10-31,"October 31, 2020",Anticipated,2020-10-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,MySteps-CoV,,eHealth Intervention on Physical Activity for Type 2 Diabetics - Frustrated by COVID-19,Personalized eHealth Intervention in Patients With Type 2 Diabetes to Promote Daily Physical Activity Utilizing 24h Self-monitoring - Implementation Frustrated by COVID-19 Epidemic,"Active, not recruiting",NA,N/A,122,Actual,UKK Institute,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:36:16Z,2020-11-01T11:36:16Z
NCT04543760,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-08,NA,NA,2020-10-05,2020-09-09,2020-09-10,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-08,Actual,"October 1, 2020",Actual,2020-10-01,October 2020,2020-10-31,May 2021,Anticipated,2021-05-31,March 2021,Anticipated,2021-03-31,NA,Interventional,DeCOPO,,Effect of Prone Positioning Combined With High Flow Oxygen Therapy on Oxygenation During Acute Respiratory Failure Due to COVID-19,Effect of Prone Positioning Combined With High Flow Oxygen Therapy on Oxygenation During Acute Respiratory Failure Due to Sars-covid-2: a Randomized Crossover Trial.,Recruiting,NA,N/A,18,Anticipated,"Hospital St. Joseph, Marseille, France",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:41:36Z,2020-11-01T11:41:36Z
NCT04542993,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-08,NA,NA,2020-10-14,2020-09-08,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"September 8, 2020",Actual,2020-09-08,October 2020,2020-10-31,June 2022,Anticipated,2022-06-30,September 2021,Anticipated,2021-09-30,NA,Interventional,Reszinate,,Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy,"Can SARS-CoV-2 Viral Shedding in COVID-19 Disease be Reduced by Resveratrol-assisted Zinc Ingestion, a Direct Inhibitor of SARS-CoV-2-RNA Polymerase? A Single Blinded Phase II Protocol (Reszinate Trial)",Recruiting,NA,Phase 2,60,Anticipated,Swedish Medical Center,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,Currently no plan to make IPD available,2020-11-01T11:41:40Z,2020-11-01T11:41:40Z
NCT04542876,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-08,NA,NA,2020-09-08,2020-09-08,2020-09-09,Actual,NA,NA,NA,NA,NA,NA,2020-09-08,2020-09-09,Actual,"May 1, 2020",Actual,2020-05-01,September 2020,2020-09-30,"August 18, 2020",Actual,2020-08-18,"July 31, 2020",Actual,2020-07-31,NA,Interventional,NA,,Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection,Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection: An Open Label Feasibility Study,Completed,NA,N/A,46,Actual,Aarogyam UK,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:41:42Z,2020-11-01T11:41:42Z
NCT04546581,"ClinicalTrials.gov processed this data on November 13, 2020",2020-09-08,NA,NA,2020-11-12,2020-09-08,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-13,Estimate,"October 8, 2020",Actual,2020-10-08,November 2020,2020-11-30,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Interventional,NA,,Inpatient Treatment With Anti-Coronavirus Immunoglobulin (ITAC),"An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19",Recruiting,NA,Phase 3,500,Anticipated,University of Minnesota,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,Yes,A public data set will be made available at the end of the trial,2020-11-15T10:57:05Z,2020-11-15T10:57:05Z
NCT04561154,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-09,NA,NA,2020-09-22,2020-09-22,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-23,Actual,"June 11, 2020",Actual,2020-06-11,September 2020,2020-09-30,"June 11, 2022",Anticipated,2022-06-11,"June 11, 2021",Anticipated,2021-06-11,NA,Interventional,REPERCOV,,Identifying Functional and Psycho-social Complaints After Hospitalization for SARS-CoV-2 Infection( COVID 19)- REPERCOV,Identifying Functional and Psycho-social Complaints After Hospitalization for Severe SARS-CoV-2 Infection (COVID19)- REPERCOV,Recruiting,NA,N/A,134,Anticipated,Centre Hospitalier le Mans,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:39:36Z,2020-11-01T11:39:36Z
NCT04557605,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-09,NA,NA,2020-10-16,2020-09-15,2020-09-21,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-20,Actual,"September 14, 2020",Actual,2020-09-14,October 2020,2020-10-31,"October 15, 2020",Actual,2020-10-15,"October 15, 2020",Actual,2020-10-15,NA,Interventional,NA,,Effects of a Face Mask on Oxygenation During Exercise,The Effects of Wearing a Face Mask During COVID-19 on Blood and Muscle Oxygenation While Performing Exercise,Completed,NA,N/A,14,Actual,University of Saskatchewan,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:40:01Z,2020-11-01T11:40:01Z
NCT04551339,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-09,NA,NA,2020-09-28,2020-09-15,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-29,Actual,"September 28, 2020",Actual,2020-09-28,September 2020,2020-09-30,"May 14, 2021",Anticipated,2021-05-14,"March 14, 2021",Anticipated,2021-03-14,NA,Interventional,ZnCOVID-19,,Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19,Zinc Versus Multivitamin Micronutrient Supplementation to Support Immune Health in the Setting of COVID-19 Pandemic: A Randomized Study,Enrolling by invitation,NA,N/A,4500,Anticipated,Mayo Clinic,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:40:41Z,2020-11-01T11:40:41Z
NCT04549922,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-09,NA,NA,2020-10-23,2020-09-11,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-27,Actual,"October 21, 2020",Anticipated,2020-10-21,October 2020,2020-10-31,December 2021,Anticipated,2021-12-31,February 2021,Anticipated,2021-02-28,NA,Interventional,ASKCOV,,Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19,Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19: A Phase II Randomized Controlled Trial,Recruiting,NA,Phase 2,110,Anticipated,Hospital do Coracao,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,"Protocol will be available in December, together with analysis plan",Protocol and analysis plan will be uploaded to Clinicaltrials.gov,NA,Yes,Data will be available under reasonable request after approval by the steering committee.,2020-11-01T11:40:50Z,2020-11-01T11:40:50Z
NCT04548531,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-09,NA,NA,2020-09-29,2020-09-11,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2020-09-29,2020-09-30,Actual,"September 10, 2020",Actual,2020-09-10,September 2020,2020-09-30,"May 30, 2021",Anticipated,2021-05-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,,Engaging Patients in Colon Cancer Screening Decisions During COVID-19,Engaging Patients in Colon Cancer Screening Decisions During COVID-19,Enrolling by invitation,NA,N/A,800,Anticipated,Massachusetts General Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"Three months after the end of the funded grant period, the study materials and de-identified data will be available, by request, from the PI. Once data are placed on an open access service such as ICPSR they will be available indefinitely.","The PI will share a de-identified data set with outside investigators at no cost, according to approved Partners and Massachusetts General Hospital policies for data sharing. Investigators from other sites will be able to request the data and will be required to complete a data use agreement that ensures that all local Institutional Review Board requirements are met before using the data, that they will not attempt to identify any data in the dataset, and that they will not share the data set with anyone outside their project team.
On ICPSR, individuals must register and agree to ICPSR's Responsible Use statement prior to accessing datasets.",NA,Yes,"Yes To promote research replicability, transparency and future use of the data, de-identified data sets of the patient survey data will be created and will be available, by request, to outside researchers.
After the main manuscripts have been published, de-identified data sets will also be deposited in an open access service such as, ICPSR (https://www.icpsr.umich.edu/icpsrweb/). Before a dataset is made available for access, ICPSR completes a detailed review of all datasets to assess disclosure risk. If necessary, ICPSR modifies data to reduce disclosure risk or limits access to datasets for which modifying the data would substantially limit their utility or the risk of disclosure remains high. No information that contains identifiers or that could be used to link an individual to the data will be included in the de-identified data set.",2020-11-01T11:41:04Z,2020-11-01T11:41:04Z
NCT04547660,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-09,NA,NA,2020-09-11,2020-09-11,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2020-09-11,2020-09-14,Actual,"July 16, 2020",Actual,2020-07-16,September 2020,2020-09-30,October 2021,Anticipated,2021-10-31,July 2021,Anticipated,2021-07-31,NA,Interventional,PLACOVID,,Convalescent Plasma for Severe COVID-19 Patients,"Convalescent Plasma for Severe COVID-19 Patients: a Randomized, Open-label, Phase 3 Trial",Recruiting,NA,Phase 3,160,Anticipated,Hospital de Clinicas de Porto Alegre,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:41:09Z,2020-11-01T11:41:09Z
NCT04547283,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-09,NA,NA,2020-09-11,2020-09-11,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2020-09-11,2020-09-14,Actual,"June 14, 2020",Actual,2020-06-14,September 2020,2020-09-30,"September 30, 2020",Anticipated,2020-09-30,"September 20, 2020",Anticipated,2020-09-20,NA,Interventional,NA,,Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19,Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19: A Pilot Randomized Controlled Trial,Recruiting,NA,N/A,40,Anticipated,Atrium Health,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,The data will become available 3 months following publication of outcomes and will remain available for at least 5 years.,Data will be accessible to researchers who provide a methodologically sound proposal After approval by the AtriumHealth Institutional Review Board and the study investigators.,NA,Yes,Individual patient data underlying reported results will be made available with data dictionaries after de-identification.,2020-11-01T11:41:11Z,2020-11-01T11:41:11Z
NCT04552483,"ClinicalTrials.gov processed this data on November 06, 2020",2020-09-09,NA,NA,2020-11-01,2020-09-15,2020-09-17,Actual,NA,NA,NA,NA,NA,NA,2020-11-01,2020-11-03,Actual,"June 8, 2020",Actual,2020-06-08,November 2020,2020-11-30,"September 5, 2020",Actual,2020-09-05,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,,Effects of Early Use of Nitazoxanide in Patients With COVID-19,Effects of Nitazoxanide Administration to Patients in the Initial Phase of COVID-19,Completed,NA,Phase 2,392,Actual,Universidade Federal do Rio de Janeiro,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,Available as soon as the editorial board of the journal accepting the manuscript requires.,Editorial board of the Journal accepting the manuscript.,NA,Yes,"The investigators plan on sharing all IPD that underlie results in a publication for editorial board, with cautious of not sharing confidential data.",2020-11-07T11:18:56Z,2020-11-07T11:18:56Z
NCT04569266,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-10,NA,NA,2020-09-28,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-29,Actual,"August 7, 2020",Actual,2020-08-07,September 2020,2020-09-30,"May 7, 2022",Anticipated,2022-05-07,"November 7, 2021",Anticipated,2021-11-07,NA,Interventional,RECOVER,,Effectiveness of an Exercise Re-training Program on Dyspnea in Patients After Acute Respiratory Distress Syndrome Secondary to Severe COVID-19 Pneumonia in Post-ICU,Effectiveness of an Exercise Re-training Program on Dyspnea in Patients After Acute Respiratory Distress Syndrome Secondary to Severe COVID-19 Pneumonia in Post-ICU,Recruiting,NA,N/A,200,Anticipated,Groupe Hospitalier Paris Saint Joseph,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:38:43Z,2020-11-01T11:38:43Z
NCT04550325,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-10,NA,NA,2020-09-13,2020-09-13,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2020-09-13,2020-09-16,Actual,"August 5, 2020",Actual,2020-08-05,September 2020,2020-09-30,February 2021,Anticipated,2021-02-28,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,"Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19","A Phase 1/2 Open Label, Multicenter, Single Arm Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose Kamada Anti-SARS-CoV-2 in COVID-19 Hospitalized Patients With Pneumonia",Recruiting,NA,Phase 1/Phase 2,12,Anticipated,"Kamada, Ltd.",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:40:48Z,2020-11-01T11:40:48Z
NCT04547127,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-10,NA,NA,2020-09-10,2020-09-10,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2020-09-10,2020-09-14,Actual,"April 29, 2020",Actual,2020-04-29,September 2020,2020-09-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19),"A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19) With Standard Medical Treatment (SMT) Versus SMT Alone in Subjects With COVID-19 Requiring Admission to the Intensive Care Unit (ICU)",Recruiting,NA,Phase 2,100,Anticipated,Grifols Therapeutics LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:41:13Z,2020-11-01T11:41:13Z
NCT04546737,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-10,NA,NA,2020-09-16,2020-09-10,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2020-09-16,2020-09-17,Actual,"September 8, 2020",Actual,2020-09-08,September 2020,2020-09-30,May 2022,Anticipated,2022-05-31,July 2021,Anticipated,2021-07-31,NA,Interventional,NSpectroCovid,,"Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients","Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients",Recruiting,NA,N/A,20,Anticipated,"Centre Hospitalier Universitaire, Amiens",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:41:15Z,2020-11-01T11:41:15Z
NCT04549376,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-11,NA,NA,2020-09-12,2020-09-12,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2020-09-12,2020-09-16,Actual,"July 1, 2020",Actual,2020-07-01,September 2020,2020-09-30,"October 30, 2020",Anticipated,2020-10-30,"October 20, 2020",Anticipated,2020-10-20,NA,Interventional,VEP-COV,,Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo,Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo: an Open Label Randomized Clinical Trial,Recruiting,NA,Phase 2,200,Anticipated,"Pi Research Consultancy Center, Bangladesh",,7,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,6 months,"Available on public domain like figshare, researchgate and others",NA,Yes,"After completion of the project, a manuscript will be prepared and will be shared to the journal authority for publication. Data will be shared with the journal authority and make public as part of the publication.",2020-11-01T11:40:57Z,2020-11-01T11:40:57Z
NCT04548544,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-11,NA,NA,2020-09-11,2020-09-11,2020-09-14,Actual,NA,NA,NA,NA,NA,NA,2020-09-11,2020-09-14,Actual,"October 18, 2019",Actual,2019-10-18,September 2020,2020-09-30,"May 20, 2020",Actual,2020-05-20,"May 20, 2020",Actual,2020-05-20,NA,Interventional,NA,,A Randomized Controlled Feasibility Study of Emotional Well-being of Adolescents Undergoing a Mindfulness Training During COVID-19,A Randomized Controlled Feasibility Study of Emotional Well-being of Adolescents Undergoing a Mindfulness Training During the COVID-19 Pandemic,Completed,NA,N/A,21,Actual,"University of California, San Francisco",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:41:04Z,2020-11-01T11:41:04Z
NCT04551781,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-13,NA,NA,2020-09-14,2020-09-14,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2020-09-14,2020-09-16,Actual,"April 1, 2020",Actual,2020-04-01,September 2020,2020-09-30,"July 30, 2020",Actual,2020-07-30,"July 30, 2020",Actual,2020-07-30,NA,Interventional,NA,,Short Term Low Dose Corticosteroids for Management of Post covid19 Pulmonary Fibrosis,Short Term Low Dose Corticosteroids for Management of Post Covid-19 Pulmonary Fibrosis,Completed,NA,N/A,450,Actual,South Valley University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:40:39Z,2020-11-01T11:40:39Z
NCT04558476,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-14,NA,NA,2020-09-21,2020-09-21,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-22,Actual,"September 1, 2020",Actual,2020-09-01,September 2020,2020-09-30,"September 1, 2022",Anticipated,2022-09-01,"September 1, 2022",Anticipated,2022-09-01,NA,Interventional,CONFIDENT,,Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation,A Multicenter Randomized Trial to Assess the Efficacy of CONvalescent Plasma Therapy in Patients With Invasive COVID-19 and Acute Respiratory Failure Treated With Mechanical Ventilation: the CONFIDENT Trial,Recruiting,NA,Phase 2,500,Anticipated,University of Liege,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:39:53Z,2020-11-01T11:39:53Z
NCT04591158,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-15,NA,NA,2020-10-15,2020-10-15,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-15,2020-10-19,Actual,"September 15, 2020",Actual,2020-09-15,October 2020,2020-10-31,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,,COVID-19 and Lung Ultrasound Utility,The Utility of Self-administered Lung Ultrasound in Patients With COVID-19,Recruiting,NA,N/A,100,Anticipated,Bridge to Health Medical and Dental USA,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,No,"Notes pertaining to performance characterization of the device, as well as imaging data for additional quantitative evaluation of the image quality will be collected. This date is recorded for future device development. No IPD will be made available to other researchers.",2020-11-01T11:35:48Z,2020-11-01T11:35:48Z
NCT04559113,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-15,NA,NA,2020-09-21,2020-09-21,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-22,Actual,"May 1, 2020",Actual,2020-05-01,September 2020,2020-09-30,"October 30, 2020",Anticipated,2020-10-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,Methyl19LGH,,Methylprednisolone in COVID-19 Patients (Methyl19LGH),Perks of Methylprednisolone for Hospitalized COVID-19 Patients: A Clinical Trial,Recruiting,NA,N/A,200,Anticipated,Lahore General Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:39:48Z,2020-11-01T11:39:48Z
NCT04553705,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-15,NA,NA,2020-09-16,2020-09-16,2020-09-17,Actual,NA,NA,NA,NA,NA,NA,2020-09-16,2020-09-18,Actual,"September 20, 2020",Anticipated,2020-09-20,September 2020,2020-09-30,"December 4, 2020",Anticipated,2020-12-04,"November 4, 2020",Anticipated,2020-11-04,NA,Interventional,NA,,"Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19)",Impact of Different Treatment Modalities on Immunity Against COVID-19,Recruiting,NA,Phase 2/Phase 3,200,Anticipated,Beni-Suef University,,6,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:40:26Z,2020-11-01T11:40:26Z
NCT04552366,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-15,NA,NA,2020-09-20,2020-09-16,2020-09-17,Actual,NA,NA,NA,NA,NA,NA,2020-09-20,2020-09-23,Actual,"September 29, 2020",Anticipated,2020-09-29,September 2020,2020-09-30,"June 30, 2021",Anticipated,2021-06-30,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults,A Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults Aged 18 Years and Older,Recruiting,NA,Phase 1,144,Anticipated,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:40:34Z,2020-11-01T11:40:34Z
NCT04565249,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-15,NA,NA,2020-10-28,2020-09-24,2020-09-25,Actual,NA,NA,NA,NA,NA,NA,2020-10-28,2020-10-29,Actual,"October 22, 2020",Actual,2020-10-22,September 2020,2020-09-30,"October 31, 2021",Anticipated,2021-10-31,"August 31, 2021",Anticipated,2021-08-31,NA,Interventional,NA,,"Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19","A Randomized, Double-blind, Dose-ranging, Placebo Controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19 (INTEGRIS-ARDS)",Recruiting,NA,Phase 2,36,Anticipated,"Pliant Therapeutics, Inc.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-02T10:28:10Z,2020-11-02T10:28:10Z
NCT04551911,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-15,NA,NA,2020-10-27,2020-09-15,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-29,Actual,"October 26, 2020",Actual,2020-10-26,October 2020,2020-10-31,April 2021,Anticipated,2021-04-30,February 2021,Anticipated,2021-02-28,NA,Interventional,NA,,Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19,"A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (Calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected With SARS-CoV-2 (REsCue)",Recruiting,NA,Phase 2,160,Anticipated,"OPKO Health, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-02T10:28:20Z,2020-11-02T10:28:20Z
NCT04610502,"ClinicalTrials.gov processed this data on November 02, 2020",2020-09-15,NA,NA,2020-10-29,2020-10-29,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-10-30,Actual,"September 6, 2020",Actual,2020-09-06,October 2020,2020-10-31,"December 6, 2020",Anticipated,2020-12-06,"October 6, 2020",Actual,2020-10-06,NA,Interventional,SECR-01,,Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 in COVID-19 Patients,"Randomized, Controlled, Double-blind, Multicenter Clinical Study to Compare the Efficacy and Safety of the Administration of Two Hyperimmune Equine Anti-Sars-CoV-2 (""S"" and ""M"") Serum Formulations in Hospitalized Patients With COVID-19",Recruiting,NA,Phase 2,26,Anticipated,Caja Costarricense de Seguro Social,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-03T10:48:17Z,2020-11-03T10:48:17Z
NCT04551547,"ClinicalTrials.gov processed this data on November 13, 2020",2020-09-15,NA,NA,2020-11-05,2020-09-15,2020-09-16,Actual,NA,NA,NA,NA,NA,NA,2020-11-05,2020-11-09,Actual,"October 31, 2020",Actual,2020-10-31,November 2020,2020-11-30,September 2021,Anticipated,2021-09-30,February 2021,Anticipated,2021-02-28,NA,Interventional,NA,,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19,"A Randomized, Double-Blinded, Placebo-Controlled, Phase â… /â…¡ Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) in Healthy Population Aged 3-17 Years",Recruiting,NA,Phase 1/Phase 2,552,Anticipated,"Sinovac Biotech Co., Ltd",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-14T10:38:31Z,2020-11-14T10:38:31Z
NCT04581915,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-16,NA,NA,2020-10-09,2020-10-07,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-09,2020-10-14,Actual,"September 8, 2020",Actual,2020-09-08,October 2020,2020-10-31,"December 31, 2021",Anticipated,2021-12-31,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,PHRUCov01,,PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19,"A Pragmatic, Individually Randomised, Double-blind, Placebo-controlled Trial of Triazavirin (TZV) for the Treatment of Mild-moderate SARS-CoV-2 Infection A Phase II and III Clinical Trial",Recruiting,NA,Phase 2/Phase 3,420,Anticipated,Wits Health Consortium (Pty) Ltd,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:37:19Z,2020-11-01T11:37:19Z
NCT04560881,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-16,NA,NA,2020-09-30,2020-09-21,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"September 16, 2020",Actual,2020-09-16,September 2020,2020-09-30,"December 1, 2021",Anticipated,2021-12-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,NA,,"Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)","Randomized, Double Blind, Placebo Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Argentine Healthy Population Aged Between 18 and 85 Years",Recruiting,NA,Phase 3,3000,Anticipated,Laboratorio Elea Phoenix S.A.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:39:38Z,2020-11-01T11:39:38Z
NCT04555213,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-16,NA,NA,2020-10-11,2020-09-16,2020-09-18,Actual,NA,NA,NA,NA,NA,NA,2020-10-11,2020-10-14,Actual,"September 30, 2020",Actual,2020-09-30,October 2020,2020-10-31,June 2021,Anticipated,2021-06-30,March 2021,Anticipated,2021-03-31,NA,Interventional,NOXCOVID,,A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19,A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19 Infection (NOXCOVID),Recruiting,NA,Phase 1,40,Anticipated,Noxopharm Limited,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:40:17Z,2020-11-01T11:40:17Z
NCT04555148,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-16,NA,NA,2020-09-16,2020-09-16,2020-09-18,Actual,NA,NA,NA,NA,NA,NA,2020-09-16,2020-09-18,Actual,"September 20, 2020",Anticipated,2020-09-20,September 2020,2020-09-30,August 2021,Anticipated,2021-08-31,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,NA,,COVIDIG (COVID-19 Hyper-ImmunoGlobulin),"A Prospective, Open-label, Randomized, Multi-center, Phase 2a Study to Evaluation the Dose Response, Efficacy and Safety of Hyper-Ig (Hyper-immunoglobulin) GC5131 in Patients With COVID-19",Recruiting,NA,Phase 2,60,Anticipated,Green Cross Corporation,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:40:17Z,2020-11-01T11:40:17Z
NCT04555096,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-16,NA,NA,2020-09-19,2020-09-16,2020-09-18,Actual,NA,NA,NA,NA,NA,NA,2020-09-19,2020-09-22,Actual,"September 9, 2020",Actual,2020-09-09,September 2020,2020-09-30,December 2021,Anticipated,2021-12-31,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,,A Trial of GC4419 in Patients With Critical Illness Due to COVID-19,"A Pilot, Randomized, Placebo-Controlled Trial of GC4419 (Avasopasem Manganese) in Patients With Critical Illness Due to SARS-CoV-2 Infection (COVID-19)",Recruiting,NA,Phase 2,50,Anticipated,"Galera Therapeutics, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:40:18Z,2020-11-01T11:40:18Z
NCT04557046,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-17,NA,NA,2020-10-21,2020-09-17,2020-09-21,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-22,Actual,"June 26, 2020",Actual,2020-06-26,October 2020,2020-10-31,"December 31, 2020",Anticipated,2020-12-31,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,ASPIRE,,Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test,A Multicenter COVID-19 Study Conducted to Evaluate the Performance of the LumiraDx SARS-CoV-2 Ag Test at Point of Care Testing Sites,Recruiting,NA,N/A,400,Anticipated,LumiraDx UK Limited,,5,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:40:05Z,2020-11-01T11:40:05Z
NCT04570384,"ClinicalTrials.gov processed this data on November 13, 2020",2020-09-17,NA,NA,2020-11-09,2020-09-29,2020-09-30,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"October 15, 2020",Actual,2020-10-15,October 2020,2020-10-31,"December 28, 2021",Anticipated,2021-12-28,"May 28, 2021",Anticipated,2021-05-28,NA,Interventional,NA,,Intravenous L-Citrulline to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) Illness,"Prospective, Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Intravenous L-Citrulline to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) Illness",Recruiting,NA,Phase 2,60,Anticipated,"Asklepion Pharmaceuticals, LLC",,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-15T10:56:42Z,2020-11-15T10:56:42Z
NCT04568564,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-18,NA,NA,2020-09-30,2020-09-25,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-01,Actual,"October 1, 2020",Actual,2020-10-01,September 2020,2020-09-30,"May 1, 2021",Anticipated,2021-05-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,NA,,Telerehabilitation in Lung Surgery Patients,Telerehabilitation of Reduced Physiotherapy Service in SARS-CoV-2 Pandemic Process in Lung Surgery Patients,Recruiting,NA,N/A,40,Anticipated,Istanbul Medipol University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:38:47Z,2020-11-01T11:38:47Z
NCT04567810,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-18,NA,NA,2020-09-28,2020-09-25,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-30,Actual,"September 18, 2020",Actual,2020-09-18,September 2020,2020-09-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,"Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19)","A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single -Ascending and Multiple Doses of an Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY)",Recruiting,NA,Phase 1,48,Anticipated,Stanford University,,8,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T11:38:54Z,2020-11-01T11:38:54Z
NCT04563650,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-18,NA,NA,2020-09-23,2020-09-23,2020-09-24,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-24,Actual,"September 18, 2020",Actual,2020-09-18,September 2020,2020-09-30,November 2021,Anticipated,2021-11-30,May 2021,Anticipated,2021-05-31,NA,Interventional,SERO-CoV-OLD,,COVID-19 Serology and Immunosenescence,Kinetics of COVID-19-neutralising Antibodies in Patients Residing in EHPAD / USLD: Influence of Immunosenescence,Recruiting,NA,N/A,330,Anticipated,"Centre Hospitalier Universitaire, Amiens",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:39:20Z,2020-11-01T11:39:20Z
NCT04558021,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-18,NA,NA,2020-10-09,2020-09-19,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2020-10-09,2020-10-12,Actual,"October 8, 2020",Actual,2020-10-08,October 2020,2020-10-31,"February 14, 2021",Anticipated,2021-02-14,"January 30, 2021",Anticipated,2021-01-30,NA,Interventional,NICLONEX,,A Study To Evaluate The Efficacy And Safety Of a Novel Niclosamide Suspension Formulation For COVID-19,"A Phase III, Randomized, Placebo-controlled, Clinical Trial to Evaluate the Efficacy and Safety of Co-administered Niclosamide in Patients Treated With an Established Regimen for Novel Coronavirus Infectious Disease (COVID-19)",Recruiting,NA,Phase 3,200,Anticipated,Imuneks Farma ilac San. Tic. A.S.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:39:59Z,2020-11-01T11:39:59Z
NCT04563065,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-19,NA,NA,2020-09-24,2020-09-23,2020-09-24,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-28,Actual,"August 1, 2020",Actual,2020-08-01,September 2020,2020-09-30,"December 31, 2023",Anticipated,2023-12-31,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,ACPREGCOV,,Active Pregnancy Against COVID-19,"Active Pregnancy, Prevention Against the Effects of COVID-19",Recruiting,NA,N/A,280,Anticipated,Universidad Politecnica de Madrid,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:39:23Z,2020-11-01T11:39:23Z
NCT04558125,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-19,NA,NA,2020-10-23,2020-09-21,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-27,Actual,"September 8, 2020",Actual,2020-09-08,September 2020,2020-09-30,"June 30, 2022",Anticipated,2022-06-30,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,NA,,Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism,"Low-Dose Tenecteplase in Covid-19 Patients With Acture Pulmonary Embolism: A Randomized, Double-Blind, Placebo-Controlled Trial","Active, not recruiting",NA,Phase 4,45,Anticipated,Cedars-Sinai Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T11:39:58Z,2020-11-01T11:39:58Z
NCT04558411,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-20,NA,NA,2020-09-20,2020-09-20,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2020-09-20,2020-09-22,Actual,"September 12, 2020",Actual,2020-09-12,September 2020,2020-09-30,"December 15, 2020",Anticipated,2020-12-15,"December 15, 2020",Anticipated,2020-12-15,NA,Interventional,NA,,"Pilot Study of a Brief, Scaleable Intervention for Coronavirus (COVID-19) Mental Health Sequelae in College Students","Pilot Study of a Brief, Scaleable Intervention for COVID-19 Mental Health Sequelae in College Students",Recruiting,NA,N/A,150,Anticipated,"Rutgers, The State University of New Jersey",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,We will share data after the publication of primary manuscripts.,NA,NA,Yes,We will share data after the publication of primary manuscripts.,2020-11-01T11:39:54Z,2020-11-01T11:39:54Z
NCT04558372,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-20,NA,NA,2020-09-23,2020-09-21,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-25,Actual,"April 1, 2020",Actual,2020-04-01,September 2020,2020-09-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Genosvid Diagnostic Test for Early Detection of COVID-19,Genosvid Diagnostic Test for Early Detection of COVID-19: UGM Electronic-Nose Innovation for Indonesia,Recruiting,NA,N/A,1543,Anticipated,Gadjah Mada University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:39:55Z,2020-11-01T11:39:55Z
NCT04563702,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-21,NA,NA,2020-09-24,2020-09-23,2020-09-24,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-28,Actual,September 2020,Anticipated,2020-09-30,September 2020,2020-09-30,October 2021,Anticipated,2021-10-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults,"A Phase 1 Open-Label, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Vaccine (VXA-CoV2-1) Expressing a SARS-CoV-2 Antigen and dsRNA Adjuvant Administered Orally to Healthy Adult Volunteers",Recruiting,NA,Phase 1,48,Anticipated,Vaxart,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,A plan on how to share individual subject's outcomes will be defined within the next few months.,2020-11-01T11:39:20Z,2020-11-01T11:39:20Z
NCT04559035,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-21,NA,NA,2020-09-21,2020-09-21,2020-09-22,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-22,Actual,"September 24, 2020",Anticipated,2020-09-24,September 2020,2020-09-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Nasal Irrigation to Reduce COVID-19 Morbidity,Nasal Irrigation to Reduce COVID-19 Morbidity,Enrolling by invitation,NA,N/A,200,Anticipated,Augusta University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:39:49Z,2020-11-01T11:39:49Z
NCT04566770,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-22,NA,NA,2020-09-24,2020-09-24,2020-09-28,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-28,Actual,"September 24, 2020",Actual,2020-09-24,September 2020,2020-09-30,"October 20, 2022",Anticipated,2022-10-20,"August 21, 2021",Anticipated,2021-08-21,NA,Interventional,NA,,Phase IIb Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector),"A Randomized, Double-blind, Placebo -Controlled Phase IIb Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV in Person 6 Years of Age and Older and Those Who Have Previously Been Vaccinated With Ad5-EBOV",Recruiting,NA,Phase 2,481,Anticipated,CanSino Biologics Inc.,,9,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:39:01Z,2020-11-01T11:39:01Z
NCT04565665,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-22,NA,NA,2020-10-21,2020-09-24,2020-09-25,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-23,Actual,"July 29, 2020",Actual,2020-07-29,October 2020,2020-10-31,"April 30, 2021",Anticipated,2021-04-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,NA,,Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome,Emergency Use Pilot Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of COVID-19 Related Acute Respiratory Distress Syndrome,Recruiting,NA,Phase 1,70,Anticipated,M.D. Anderson Cancer Center,,3,NA,NA,NA,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:39:08Z,2020-11-01T11:39:08Z
NCT04563689,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-22,NA,NA,2020-09-23,2020-09-23,2020-09-24,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-24,Actual,"June 18, 2020",Actual,2020-06-18,September 2020,2020-09-30,December 2020,Anticipated,2020-12-31,October 2020,Anticipated,2020-10-31,NA,Interventional,NA,,Pilot Study to Evaluate Effect of CHX0.12/CPC 0.05 of SARS-CoV-2 Viral Load in COVID-19 Patients,Efecto de un Enjuague Bucal Con Clorhexidina al 0.12% y Cloruro de Cetil Piridinio al 0.05% en la Carga Viral en Saliva en Pacientes COVID-19 + Hospitalizados o Que Esten Recibiendo Cuidado mÃ©dico en Casa en Cali - 2020.,Recruiting,NA,N/A,24,Anticipated,Dentaid SL,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:39:20Z,2020-11-01T11:39:20Z
NCT04561219,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-22,NA,NA,2020-10-26,2020-09-22,2020-09-23,Actual,NA,NA,NA,NA,NA,NA,2020-10-26,2020-10-28,Actual,"April 19, 2020",Actual,2020-04-19,October 2020,2020-10-31,"October 2, 2020",Actual,2020-10-02,"October 2, 2020",Actual,2020-10-02,NA,Interventional,NA,,Nitazoxanide Therapy for Patients With COVID-19 Pneumonia,"Nitazoxanide for Moderate to Severe COVID-19 Pneumonia: a Multicenter, Randomized, Placebo-controlled, Double-Blind Clinical Trial",Completed,NA,Phase 2,500,Actual,Universidade Federal do Rio de Janeiro,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Available as soon as the editorial board of the journal accepting the manuscript requires.,Editorial board of the Journal accepting the manuscript.,NA,Yes,"The investigators plan on sharing all IPD that underlie results in a publication for editorial board, with cautious of not sharing confidential data.",2020-11-01T13:18:21Z,2020-11-01T13:18:21Z
NCT04573270,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-23,NA,NA,2020-09-30,2020-09-30,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"April 24, 2020",Actual,2020-04-24,September 2020,2020-09-30,"September 1, 2020",Actual,2020-09-01,"August 20, 2020",Actual,2020-08-20,NA,Interventional,NA,,Mesenchymal Stem Cells for the Treatment of COVID-19,A Pilot Phase Study Evaluating the Effects of a Single Mesenchymal Stem Cell Injection in Patients With Suspected or Confirmed COVID-19 Infection and Healthcare Providers Exposed to Coronavirus Patients,Completed,NA,Phase 1,40,Actual,Thomas Advanced Medical LLC,,4,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,Data will be blinded and password protected. Research publications will be produced for medical journals. Participating Investigators will have password protected access only.,2020-11-01T11:38:17Z,2020-11-01T11:38:17Z
NCT04568525,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-23,NA,NA,2020-09-28,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-29,Actual,"July 1, 2020",Actual,2020-07-01,September 2020,2020-09-30,"August 1, 2020",Actual,2020-08-01,"July 25, 2020",Actual,2020-07-25,NA,Interventional,NA,,Passive Microwave Radiometry (MWR) and AI for COVID-19 Complications Early Diagnostics of Lungs,Microwave Radiation for Early Diagnostics of Pneumonia in Patients With COVID-19,Completed,NA,N/A,195,Actual,Kyrgyz State Medical Academy,,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:38:47Z,2020-11-01T11:38:47Z
NCT04565379,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-23,NA,NA,2020-09-27,2020-09-23,2020-09-25,Actual,NA,NA,NA,NA,NA,NA,2020-09-27,2020-09-30,Actual,"September 25, 2020",Actual,2020-09-25,September 2020,2020-09-30,"November 30, 2020",Anticipated,2020-11-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,NA,,Clinical Trial to Investigate the Efficacy and Safety of NuSepinÂ® in COVID-19 Pneumonia Patients,"A Randomized, Double Blind, Placebo-controlled, Phase 2 Clinical Trial to Investigate the Efficacy and Safety of 2 Doses of NuSepinÂ® Intravenous Infusion in COVID-19 Pneumonia Patients",Recruiting,NA,Phase 2,60,Anticipated,Shaperon,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:39:09Z,2020-11-01T11:39:09Z
NCT04563676,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-23,NA,NA,2020-09-23,2020-09-23,2020-09-24,Actual,NA,NA,NA,NA,NA,NA,2020-09-23,2020-09-24,Actual,"September 22, 2020",Actual,2020-09-22,September 2020,2020-09-30,March 2021,Anticipated,2021-03-31,March 2021,Anticipated,2021-03-31,NA,Interventional,SEQ-COV-PHYSIO,,Physiopathology and Sequelae of COVID-19 Infection,Physiopathology and Sequelae of COVID-19 Infection,Recruiting,NA,N/A,400,Anticipated,"Centre Hospitalier Universitaire, Amiens",,NA,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:39:20Z,2020-11-01T11:39:20Z
NCT04593940,"ClinicalTrials.gov processed this data on November 06, 2020",2020-09-23,NA,NA,2020-11-02,2020-10-19,2020-10-20,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"October 15, 2020",Actual,2020-10-15,November 2020,2020-11-30,September 2021,Anticipated,2021-09-30,February 2021,Anticipated,2021-02-28,NA,Interventional,ACTIV-1 IM,,Immune Modulators for Treating COVID-19,Randomized Master Protocol for Immune Modulators for Treating COVID-19,Recruiting,NA,Phase 3,2160,Anticipated,Duke University,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-07T11:17:36Z,2020-11-07T11:17:36Z
NCT04567173,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-24,NA,NA,2020-09-26,2020-09-24,2020-09-28,Actual,NA,NA,NA,NA,NA,NA,2020-09-26,2020-09-29,Actual,"September 21, 2020",Actual,2020-09-21,September 2020,2020-09-30,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,Co-CLARITY,,Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19,"A Randomized, Open-Label, Single Center Clinical Trial to Assess the Efficacy and Safety of Convalescent Plasma to Hospitalized Adult COVID-19 Patients as Adjunctive Therapy to Reduce the Need for ICU Admission: Co-CLARITY Trial",Recruiting,NA,Phase 2/Phase 3,136,Anticipated,University of the Philippines,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:38:59Z,2020-11-01T11:38:59Z
NCT04565197,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-24,NA,NA,2020-09-24,2020-09-24,2020-09-25,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-25,Actual,"May 1, 2020",Actual,2020-05-01,September 2020,2020-09-30,"October 30, 2020",Anticipated,2020-10-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,NA,,Convalescent Plasma Therapy for COVID-19 Patients,Convalescent Plasma for Passive Immunization in COVID-19 ICU Patients: An Interventional Study,"Active, not recruiting",NA,Early Phase 1,20,Anticipated,Lahore General Hospital,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:39:10Z,2020-11-01T11:39:10Z
NCT04564716,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-24,NA,NA,2020-09-29,2020-09-24,2020-09-25,Actual,NA,NA,NA,NA,NA,NA,2020-09-29,2020-10-01,Actual,"September 28, 2020",Actual,2020-09-28,September 2020,2020-09-30,"April 10, 2021",Anticipated,2021-04-10,"March 28, 2021",Anticipated,2021-03-28,NA,Interventional,NA,,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus","Ð¡linical Trial of Efficacy, Safety and Immunogenicity of Combined Vector Vaccine Gam-COVID-Vac in SARS-Ð¡oV-2 Infection Prophylactic Treatment in Republic of Belarus",Recruiting,NA,Phase 3,100,Anticipated,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:39:13Z,2020-11-01T11:39:13Z
NCT04568876,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-24,NA,NA,2020-10-27,2020-09-25,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-28,Actual,"October 23, 2020",Actual,2020-10-23,October 2020,2020-10-31,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,,Micronized and Ultramicronized Palmitoylethanolamide in COVID-19 Patients,"Efficacy of Palmitoylethanolamide, in add-on to Standard Therapy, on Inflammatory Markers of Patients With Interstitial Pneumonia Due to COVID-19. A Pilot Controlled, Randomized, Open Lable Clinical Study",Recruiting,NA,Phase 4,40,Anticipated,Epitech Group SpA,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T13:15:16Z,2020-11-01T13:15:16Z
NCT04609462,"ClinicalTrials.gov processed this data on November 05, 2020",2020-09-24,NA,NA,2020-10-29,2020-10-28,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-11-02,Actual,"August 11, 2020",Actual,2020-08-11,October 2020,2020-10-31,"July 28, 2021",Anticipated,2021-07-28,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,HiFlo-COVID,,High-Flow Nasal Cannula in Severe COVID-19 With Acute Hypoxemic Respiratory Failure.,A Trial of High-Flow Nasal Cannula vs. Conventional Oxygen Therapy in Patients With SARS-CoV-2-Related Acute Respiratory Failure: the HiFlo-COVID Trial.,Recruiting,NA,N/A,196,Anticipated,Fundacion Clinica Valle del Lili,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-06T12:38:26Z,2020-11-06T12:38:26Z
NCT04576728,"ClinicalTrials.gov processed this data on November 06, 2020",2020-09-24,NA,NA,2020-11-02,2020-10-05,2020-10-06,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"October 6, 2020",Actual,2020-10-06,November 2020,2020-11-30,March 2021,Anticipated,2021-03-31,March 2021,Anticipated,2021-03-31,NA,Interventional,ESsCOVID,,Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19,"A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase II Trial Investigating the Efficacy and Safety of Trimodulin (BT588) as add-on Therapy to Standard of Care in Adult Subjects With Severe COVID-19",Recruiting,NA,Phase 2,164,Anticipated,Biotest,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-07T11:18:12Z,2020-11-07T11:18:12Z
NCT04569786,"ClinicalTrials.gov processed this data on November 13, 2020",2020-09-24,NA,NA,2020-11-12,2020-09-24,2020-09-30,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-13,Estimate,"October 30, 2020",Actual,2020-10-30,November 2020,2020-11-30,"December 13, 2021",Anticipated,2021-12-13,"December 13, 2021",Anticipated,2021-12-13,NA,Interventional,NA,,Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001),"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of V590 in Healthy Adults",Recruiting,NA,Phase 1,252,Anticipated,Merck Sharp & Dohme Corp.,,9,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2020-11-15T10:56:42Z,2020-11-15T10:56:42Z
NCT04570488,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-25,NA,NA,2020-10-12,2020-09-29,2020-09-30,Actual,NA,NA,NA,NA,NA,NA,2020-10-12,2020-10-14,Actual,"May 15, 2020",Actual,2020-05-15,October 2020,2020-10-31,"May 15, 2021",Anticipated,2021-05-15,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,NA,,Predicting Favorable Outcomes in Hospitalized Covid-19 Patients,Predicting Favorable Outcomes in Hospitalized Covid-19 Patients,Recruiting,NA,N/A,1200,Anticipated,NYU Langone Health,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:38:35Z,2020-11-01T11:38:35Z
NCT04569877,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-25,NA,NA,2020-09-30,2020-09-29,2020-09-30,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"September 24, 2020",Actual,2020-09-24,September 2020,2020-09-30,"December 25, 2022",Anticipated,2022-12-25,"December 25, 2022",Anticipated,2022-12-25,NA,Interventional,GI-COVID,,GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia,Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to Prevent ARDS in COVID-19 Pneumonia (GI-COVID),Recruiting,NA,Phase 2,238,Anticipated,University of Giessen,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,3 Months after publication,Central server,NA,Yes,Study protocol will be provided after publication,2020-11-01T11:38:38Z,2020-11-01T11:38:38Z
NCT04567953,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-25,NA,NA,2020-09-25,2020-09-25,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-25,2020-09-29,Actual,"July 28, 2020",Actual,2020-07-28,September 2020,2020-09-30,"June 27, 2021",Anticipated,2021-06-27,"January 30, 2021",Anticipated,2021-01-30,NA,Interventional,NA,,COVID-19 Tests With Saliva Specimens,COVID-19 Tests With Saliva Specimens,"Active, not recruiting",NA,N/A,2000,Anticipated,Paradigm Laboratories LLC,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:38:50Z,2020-11-01T11:38:50Z
NCT04570254,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-26,NA,NA,2020-09-30,2020-09-28,2020-09-30,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"August 19, 2020",Actual,2020-08-19,September 2020,2020-09-30,"November 15, 2020",Anticipated,2020-11-15,"October 15, 2020",Anticipated,2020-10-15,NA,Interventional,ANTIOX-COVID,,Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19,Open Clinical Trial of the Use of Antioxidants and Pentoxifylline as Adjuvant Therapy to Standard Therapy in Patients With and Without Septic Shock Secondary to COVID-19 Severe Pneumonia,"Active, not recruiting",NA,N/A,11,Anticipated,Unidad Temporal COVID-19 en Centro Citibanamex,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:38:36Z,2020-11-01T11:38:36Z
NCT04568356,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-27,NA,NA,2020-10-16,2020-09-27,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-19,Actual,"April 24, 2020",Actual,2020-04-24,October 2020,2020-10-31,"September 24, 2020",Actual,2020-09-24,"June 12, 2020",Actual,2020-06-12,NA,Interventional,NA,,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,"A Clinical Performance Evaluation of the SARS-COV-2 Direct Antigen Rapid Test ""DART""",Completed,NA,N/A,200,Actual,"E25Bio, Inc.",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,TRUE,NA,FALSE,NA,,One month after the USA-FDA approval date and for the duration of one year after the date of approval,"via email to: Irene Bosch, PhD at ibosch@e25bio.com",http://www.e25bio.com,Yes,"The sponsor E25Bio, Inc. is in agreement to share the outcome of this Clinical Trial. Because the device product has not been previously approved or cleared by FDA, we will be publicly posting not earlier than the date of FDA approval or clearance.",2020-11-01T11:38:48Z,2020-11-01T11:38:48Z
NCT04576312,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-28,NA,NA,2020-10-05,2020-10-05,2020-10-06,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-06,Actual,"June 29, 2020",Actual,2020-06-29,October 2020,2020-10-31,"December 31, 2020",Anticipated,2020-12-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,NA,,Study to Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in Preparation for Evaluation in Adults With COVID-19,"Phase 1 Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in Preparation for Evaluation in Adults With COVID-19",Recruiting,NA,Phase 1,44,Anticipated,UNION therapeutics,,5,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:37:58Z,2020-11-01T11:37:58Z
NCT04568863,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-28,NA,NA,2020-09-28,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-29,Actual,"June 20, 2020",Actual,2020-06-20,September 2020,2020-09-30,"November 30, 2020",Anticipated,2020-11-30,"October 30, 2020",Anticipated,2020-10-30,NA,Interventional,MELCOVID,,Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19,"A Phase II, Single-center, Double-blind, Randomized Placebo-controlled Trial to Explore the Efficacy and Safety of Intravenous Melatonin in Patients With COVID-19 Admitted to the Intensive Care Unit (MelCOVID Study)",Recruiting,NA,Phase 2,18,Anticipated,Pharmamel S.L.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:38:45Z,2020-11-01T11:38:45Z
NCT04568811,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-28,NA,NA,2020-09-28,2020-09-28,2020-09-29,Actual,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-29,Actual,"September 26, 2020",Actual,2020-09-26,September 2020,2020-09-30,"September 27, 2021",Anticipated,2021-09-27,"October 25, 2020",Anticipated,2020-10-25,NA,Interventional,NA,,The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine,"The Single-center, Open-label Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine in Healthy Adults Aged 18-60 Years","Active, not recruiting",NA,Phase 1,89,Actual,Jiangsu Province Centers for Disease Control and Prevention,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:38:46Z,2020-11-01T11:38:46Z
NCT04583410,"ClinicalTrials.gov processed this data on November 13, 2020",2020-09-28,NA,NA,2020-11-10,2020-10-09,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-13,Estimate,"October 22, 2020",Actual,2020-10-22,November 2020,2020-11-30,October 2021,Anticipated,2021-10-31,August 2021,Anticipated,2021-08-31,NA,Interventional,NICOVID-PREV,,Efficacy of Nicotine in Preventing COVID-19 Infection in Caregivers,Efficacy of Nicotine in Preventing COVID-19 Infection in Caregivers,Recruiting,NA,Phase 3,1633,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-15T10:56:27Z,2020-11-15T10:56:27Z
NCT04572399,"ClinicalTrials.gov processed this data on November 13, 2020",2020-09-28,NA,NA,2020-11-12,2020-09-29,2020-10-01,Actual,NA,NA,NA,NA,NA,NA,2020-11-12,2020-11-13,Estimate,"October 30, 2020",Actual,2020-10-30,November 2020,2020-11-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,UVA Light Device to Treat COVID-19,Respiratory Application of a Novel Ultraviolet Light Delivery Device for Patients Infected With COVID-19: A Pilot Study,Recruiting,NA,N/A,5,Anticipated,Cedars-Sinai Medical Center,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,TRUE,TRUE,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-15T10:56:38Z,2020-11-15T10:56:38Z
NCT04577235,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-29,NA,NA,2020-10-05,2020-10-05,2020-10-06,Actual,NA,NA,NA,NA,NA,NA,2020-10-05,2020-10-06,Actual,"June 5, 2020",Actual,2020-06-05,October 2020,2020-10-31,"September 5, 2020",Actual,2020-09-05,"August 5, 2020",Actual,2020-08-05,NA,Interventional,NA,,Correlation Between Thoracic Ultrasound and Thorax Computed Tomography Scores.,Evaluation of the Correlation Between Thoracic Ultrasound and Thorax Computed Tomography Scores of Patients With Severe COVID 19 Pneumonia in Intensive Care.,Completed,NA,N/A,29,Actual,Gaziosmanpasa Taksim Research and Education Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:37:50Z,2020-11-01T11:37:50Z
NCT04573361,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-29,NA,NA,2020-09-30,2020-09-30,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"May 2, 2020",Actual,2020-05-02,September 2020,2020-09-30,"May 27, 2020",Actual,2020-05-27,"May 27, 2020",Actual,2020-05-27,NA,Interventional,NA,,Access to Chiropractic Care During the COVID-19 Healthcare Emergency in Spain,Access to Chiropractic Care During the State of Emergency Generated by the COVID-19 Pandemic in Spain: a Pragmatic Controlled Trial,Completed,NA,N/A,723,Actual,Real Centro Universitario Maria Cristina,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,"All collected IPD will be shared, though a next phase of the study is being debated, which is why we are still undecided.",2020-11-01T11:38:17Z,2020-11-01T11:38:17Z
NCT04573322,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-29,NA,NA,2020-09-30,2020-09-30,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-05,Actual,"September 10, 2020",Actual,2020-09-10,September 2020,2020-09-30,"December 14, 2021",Anticipated,2021-12-14,"November 14, 2021",Anticipated,2021-11-14,NA,Interventional,NA,,Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects,"Open-label, Pharmacokinetic, Pharmacodynamic, Ascending Dose Safety lead-in Followed by a Single-center, Placebo-controlled, Double-blind, Adaptive, Safety and Efficacy, Pilot Study of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 Infected Subjects",Recruiting,NA,Phase 1/Phase 2,224,Anticipated,Diffusion Pharmaceuticals Inc,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,NA,NA,2020-11-01T11:38:17Z,2020-11-01T11:38:17Z
NCT04569825,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-29,NA,NA,2020-09-29,2020-09-29,2020-09-30,Actual,NA,NA,NA,NA,NA,NA,2020-09-29,2020-09-30,Actual,"August 1, 2020",Actual,2020-08-01,August 2020,2020-08-31,"October 15, 2020",Anticipated,2020-10-15,"September 30, 2020",Anticipated,2020-09-30,NA,Interventional,NA,,Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease,Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease,Recruiting,NA,Early Phase 1,250,Anticipated,University Of Anbar,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:38:39Z,2020-11-01T11:38:39Z
NCT04575064,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-30,NA,NA,2020-10-02,2020-10-02,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2020-10-02,2020-10-05,Actual,"June 29, 2020",Actual,2020-06-29,October 2020,2020-10-31,November 2022,Anticipated,2022-11-30,March 2022,Anticipated,2022-03-31,NA,Interventional,NA,,An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY,An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY,"Active, not recruiting",NA,Phase 2/Phase 3,400,Anticipated,"Klinikum Bremen-Mitte, gGmbH",,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:38:06Z,2020-11-01T11:38:06Z
NCT04573153,"ClinicalTrials.gov processed this data on October 30, 2020",2020-09-30,NA,NA,2020-10-04,2020-09-30,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2020-10-04,2020-10-06,Actual,"September 21, 2020",Actual,2020-09-21,September 2020,2020-09-30,"March 31, 2021",Anticipated,2021-03-31,"January 31, 2021",Anticipated,2021-01-31,NA,Interventional,NA,,Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients,"A Multi Centre, Randomised, Controlled, Open-Label Phase 2/3 Study to Evaluate The Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients",Recruiting,NA,Phase 2/Phase 3,400,Anticipated,ScandiBio Therapeutics AB,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:38:18Z,2020-11-01T11:38:18Z
NCT04575597,"ClinicalTrials.gov processed this data on November 13, 2020",2020-09-30,NA,NA,2020-11-10,2020-10-02,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"October 19, 2020",Actual,2020-10-19,November 2020,2020-11-30,"October 14, 2021",Anticipated,2021-10-14,"April 11, 2021",Anticipated,2021-04-11,NA,Interventional,NA,,Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002),"A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults With COVID-19.",Recruiting,NA,Phase 2/Phase 3,1450,Anticipated,Merck Sharp & Dohme Corp.,,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2020-11-15T10:56:34Z,2020-11-15T10:56:34Z
NCT04575584,"ClinicalTrials.gov processed this data on November 13, 2020",2020-09-30,NA,NA,2020-11-10,2020-10-02,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"October 19, 2020",Actual,2020-10-19,November 2020,2020-11-30,"October 18, 2021",Anticipated,2021-10-18,"April 15, 2021",Anticipated,2021-04-15,NA,Interventional,NA,,Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001),"A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults With COVID-19",Recruiting,NA,Phase 2/Phase 3,1300,Anticipated,Merck Sharp & Dohme Corp.,,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2020-11-15T10:56:35Z,2020-11-15T10:56:35Z
NCT04583189,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-01,NA,NA,2020-10-15,2020-10-09,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2020-10-15,2020-10-19,Actual,"October 1, 2020",Actual,2020-10-01,October 2020,2020-10-31,"January 1, 2021",Anticipated,2021-01-01,"January 1, 2021",Anticipated,2021-01-01,NA,Interventional,NA,,Evaluation of the Performance of the Covid-19 Ag BSS Rapid Antigenic Test in Symptomatic Children in a Pediatric Emergency Department,Evaluation Des Performances du Test Rapide antigÃ©nique Covid-19 Ag BSS Chez l'Enfant Symptomatique Dans un Service d'Urgences pÃ©diatriques,Recruiting,NA,N/A,500,Anticipated,Centre Hospitalier Intercommunal Creteil,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:37:03Z,2020-11-01T11:37:03Z
NCT04582344,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-01,NA,NA,2020-10-08,2020-10-08,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-08,2020-10-09,Actual,"September 14, 2020",Actual,2020-09-14,October 2020,2020-10-31,"April 15, 2021",Anticipated,2021-04-15,"February 15, 2021",Anticipated,2021-02-15,NA,Interventional,NA,,Clinical Trial For SARS-CoV-2 Vaccine (COVID-19),"Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated",Recruiting,NA,Phase 3,13000,Anticipated,Health Institutes of Turkey,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:37:15Z,2020-11-01T11:37:15Z
NCT04578210,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-01,NA,NA,2020-10-14,2020-10-06,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"September 4, 2020",Actual,2020-09-04,October 2020,2020-10-31,March 2021,Anticipated,2021-03-31,January 2021,Anticipated,2021-01-31,NA,Interventional,RELEASE,,Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia,A Phase I/II Dose-escalation Multi Center Study to Evaluate the Safety of Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in coronaviruS pnEumonia and/or Lymphopenia,Recruiting,NA,Phase 1/Phase 2,58,Anticipated,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:37:44Z,2020-11-01T11:37:44Z
NCT04575038,"ClinicalTrials.gov processed this data on November 13, 2020",2020-10-01,NA,NA,2020-11-06,2020-10-01,2020-10-05,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"November 12, 2020",Anticipated,2020-11-12,November 2020,2020-11-30,"February 28, 2021",Anticipated,2021-02-28,"January 31, 2021",Anticipated,2021-01-31,NA,Interventional,CRISIS2,,CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19,"The CRISIS2 Study: A Phase 2, Randomized, Double Blind, Placebo-controlled, Multi-center Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Out-patient Adults With SARS-CoV-2",Recruiting,NA,Phase 2,100,Anticipated,"Clear Creek Bio, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-14T10:37:54Z,2020-11-14T10:37:54Z
NCT04583449,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-02,NA,NA,2020-10-09,2020-10-09,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2020-10-09,2020-10-12,Actual,"August 19, 2020",Actual,2020-08-19,October 2020,2020-10-31,"December 1, 2020",Anticipated,2020-12-01,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,NA,,Mental Imagery to Increase Face Covering Use in UK-based Public Places During the COVID-19 Pandemic,Mental Imagery to Increase Face Covering Use in UK-based Public Places During the COVID-19 Pandemic,Recruiting,NA,N/A,250,Anticipated,University of East London,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Data will be made available on completion of article publication. Data will be made permanently available.,NA,NA,Yes,We will share the anonymised data as a Supplementary file when submitting a research write-up as an article to a suitable academic journal.,2020-11-01T11:36:59Z,2020-11-01T11:36:59Z
NCT04597034,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-03,NA,NA,2020-10-20,2020-10-20,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2020-10-20,2020-10-22,Actual,"October 2, 2020",Actual,2020-10-02,September 2020,2020-09-30,"March 30, 2022",Anticipated,2022-03-30,"December 30, 2021",Anticipated,2021-12-30,NA,Interventional,oXAKI-COV,,Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) vs (Standard AN-69) in COVID-19,"A Randomized, Controlled Trial to Evaluate Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) in Comparison With a Semi Selective Semipermeable Membrane (Standard AN-69) in COVID-19 Associated Acute Kidney Injury: oXAKI-COV Study.",Recruiting,NA,N/A,35,Anticipated,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:35:09Z,2020-11-01T11:35:09Z
NCT04581291,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-04,NA,NA,2020-10-07,2020-10-07,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-07,2020-10-09,Actual,"January 1, 2020",Actual,2020-01-01,October 2020,2020-10-31,"October 1, 2020",Actual,2020-10-01,"June 1, 2020",Actual,2020-06-01,NA,Interventional,NA,,The Effect of Aerobic Exercise on Immune Biomarkers and Symptoms Severity and Progression in Patients With COVID-19: A Pilot Randomized Control Trial,The Effect of Aerobic Exercise on Immune Biomarkers and Symptoms Severity and Progression in Patients With COVID-19: A Pilot Randomized Control Trial,Completed,NA,N/A,30,Actual,Istanbul Gelisim University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:37:23Z,2020-11-01T11:37:23Z
NCT04594330,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-05,NA,NA,2020-10-19,2020-10-19,2020-10-20,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-20,Actual,"June 1, 2020",Actual,2020-06-01,October 2020,2020-10-31,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,Virgin Coconut Oil (VCO) as a Potential Adjuvant Therapy in COVID-19 Patients,Pilot Trial for the Benefit of Virgin Coconut Oil (VCO) as a Potential Adjuvant Therapy in COVID-19 Patients,Recruiting,NA,Phase 2,60,Anticipated,Gadjah Mada University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:35:27Z,2020-11-01T11:35:27Z
NCT04593641,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-05,NA,NA,2020-10-18,2020-10-18,2020-10-20,Actual,NA,NA,NA,NA,NA,NA,2020-10-18,2020-10-20,Actual,"September 4, 2020",Actual,2020-09-04,October 2020,2020-10-31,"December 23, 2020",Anticipated,2020-12-23,"October 22, 2020",Anticipated,2020-10-22,NA,Interventional,NA,,"This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)","A Pilot Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Virology of CT-P59 in Patient With Mild Symptoms of SARS-CoV-2 Infection","Active, not recruiting",NA,Phase 1,18,Actual,Celltrion,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:35:31Z,2020-11-01T11:35:31Z
NCT04581954,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-05,NA,NA,2020-10-08,2020-10-08,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-08,2020-10-09,Actual,"October 2, 2020",Actual,2020-10-02,October 2020,2020-10-31,"July 31, 2021",Anticipated,2021-07-31,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,MATIS,,Inflammatory Signal Inhibitors for COVID-19 (MATIS),Randomised Multi-arm Trial of Ruxolitinib (RUX) and Fostamatinib (FOS) for COVID-19 Pneumonia,Recruiting,NA,Phase 1/Phase 2,456,Anticipated,Imperial College London,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,Yes,To be determined,2020-11-01T11:37:18Z,2020-11-01T11:37:18Z
NCT04589936,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-06,NA,NA,2020-10-15,2020-10-15,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-15,2020-10-19,Actual,"September 3, 2020",Actual,2020-09-03,October 2020,2020-10-31,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,PRONE-COVID,,Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care,Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care (PRONE-COVID Study),Recruiting,NA,N/A,56,Anticipated,Cambridge University Hospitals NHS Foundation Trust,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:35:58Z,2020-11-01T11:35:58Z
NCT04584580,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-06,NA,NA,2020-10-10,2020-10-10,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-10,2020-10-14,Actual,"August 1, 2020",Actual,2020-08-01,October 2020,2020-10-31,"December 31, 2020",Anticipated,2020-12-31,"October 31, 2020",Anticipated,2020-10-31,NA,Interventional,NA,,D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia,D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia,Recruiting,NA,Phase 4,50,Anticipated,Ain Shams University,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:36:39Z,2020-11-01T11:36:39Z
NCT04582214,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-06,NA,NA,2020-10-08,2020-10-08,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-08,2020-10-09,Actual,"September 28, 2020",Actual,2020-09-28,October 2020,2020-10-31,"January 1, 2021",Anticipated,2021-01-01,"January 1, 2021",Anticipated,2021-01-01,NA,Interventional,NA,,Oscillation and Lung Expansion Therapy in Patients With COVID-19,A Pilot Study of the Use of Oscillation and Lung Expansion (OLE) Therapy in Patients Hospitalized With COVID-19,Recruiting,NA,N/A,30,Anticipated,Hill-Rom,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T11:37:17Z,2020-11-01T11:37:17Z
NCT04579549,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-06,NA,NA,2020-10-09,2020-10-06,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2020-10-09,2020-10-14,Actual,"September 29, 2020",Actual,2020-09-29,October 2020,2020-10-31,September 2021,Anticipated,2021-09-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,,Repeat Testing for SARS-CoV-2,Repeat Saliva Testing for SARS-CoV-2 Using RT-LAMP Assay,Enrolling by invitation,NA,N/A,10000,Anticipated,"University of Wisconsin, Madison",,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,TRUE,TRUE,NA,FALSE,NA,,Data from this study may be requested from other researchers 7 years after the completion of the primary endpoint by contacting David O'Connor at the University of Wisconsin -Madison.,NA,NA,Yes,"Participants will consent to having their data (not their name) and viral sequences shared with the public via manuscripts, presentations and online databases; the study team will share that with other researchers when needed. Samples can be shared with UW researchers internally and non UW researchers through the Material Transfer Agreement process.",2020-11-01T11:37:34Z,2020-11-01T11:37:34Z
NCT04582201,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-06,NA,NA,2020-10-27,2020-10-08,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-29,Actual,"September 21, 2020",Actual,2020-09-21,October 2020,2020-10-31,"October 15, 2021",Anticipated,2021-10-15,"April 24, 2021",Anticipated,2021-04-24,NA,Interventional,NA,,An Experiment to Evaluate the Safety of agenT-797 in COVID-19 Patients With Severe Difficulty Breathing.,A Phase 1 Study of agenT-797 to Treat Moderate to Severe Acute Respiratory Syndrome in COVID-19 Patients,Recruiting,NA,Phase 1,55,Anticipated,Agenus Inc.,,1,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-02T10:27:51Z,2020-11-02T10:27:51Z
NCT04579640,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-06,NA,NA,2020-10-27,2020-10-06,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-29,Actual,"October 27, 2020",Actual,2020-10-27,October 2020,2020-10-31,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,CORONAVIT,,Trial of Vitamin D to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections,Phase 3 Randomised Controlled Trial of Vitamin D Supplementation to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections in the UK Population,Recruiting,NA,Phase 3,5440,Anticipated,Queen Mary University of London,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,De-identified IPD will be shared with other researchers subject to terms of Data Transfer Agreement and IRB approval,2020-11-02T10:27:53Z,2020-11-02T10:27:53Z
NCT04578158,"ClinicalTrials.gov processed this data on November 02, 2020",2020-10-06,NA,NA,2020-10-29,2020-10-06,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-10-30,Actual,"October 29, 2020",Anticipated,2020-10-29,October 2020,2020-10-31,"June 28, 2021",Anticipated,2021-06-28,"April 28, 2021",Anticipated,2021-04-28,NA,Interventional,NA,,Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19,"A Prospective, Randomized, Open-labelled, Controlled Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With Diagnosis of COVID-19.",Recruiting,NA,Phase 2,200,Anticipated,Liaquat University of Medical & Health Sciences,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-03T10:50:04Z,2020-11-03T10:50:04Z
NCT04579393,"ClinicalTrials.gov processed this data on November 13, 2020",2020-10-06,NA,NA,2020-11-07,2020-10-06,2020-10-08,Actual,NA,NA,NA,NA,NA,NA,2020-11-07,2020-11-10,Actual,"October 8, 2020",Actual,2020-10-08,"November 6, 2020",2020-11-06,"December 15, 2020",Anticipated,2020-12-15,"December 15, 2020",Anticipated,2020-12-15,NA,Interventional,NA,,Fostamatinib for Hospitalized Adults With COVID-19,A Phase II Study Evaluating Fostamatinib for Hospitalized Adults With COVID-19,Recruiting,NA,Phase 2,80,Anticipated,National Institutes of Health Clinical Center (CC),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-14T10:37:47Z,2020-11-14T10:37:47Z
NCT04594668,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-07,NA,NA,2020-10-19,2020-10-19,2020-10-20,Actual,NA,NA,NA,NA,NA,NA,2020-10-19,2020-10-20,Actual,"April 24, 2020",Actual,2020-04-24,April 2020,2020-04-30,"December 31, 2021",Anticipated,2021-12-31,"April 24, 2021",Anticipated,2021-04-24,NA,Interventional,COVIPOC,,Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency,"Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency - A Randomized, Open-Label, Phase II Trial",Recruiting,NA,Phase 2,46,Anticipated,University of Aarhus,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Data will become available following publication with no planned end date.,Access to the data sharing will be given to researchers who provide a methodologically sound proposal for any type of analysis and requires IRB/Ethics approval (if applicable). Proposal should be addressed to us@biomed.au.dk,NA,Yes,"Data sharing plan: Individual de-identified participant data (including data dictionaries) will be shared following the publication of the primary and secondary endpoints as outlined in this protocol. Data to be shared included de-identified data points in published, peer-reviewed articles. Additional, related documents will also be available (study protocol, informed consent form, statistical analysis plan).",2020-11-01T11:35:24Z,2020-11-01T11:35:24Z
NCT04623671,"ClinicalTrials.gov processed this data on November 13, 2020",2020-10-07,NA,NA,2020-11-09,2020-11-09,2020-11-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-10,Actual,"November 20, 2020",Anticipated,2020-11-20,November 2020,2020-11-30,"June 30, 2021",Anticipated,2021-06-30,"April 30, 2021",Anticipated,2021-04-30,NA,Interventional,INSPIRE,,Intravenous Infusion of CAP-1002 in Patients With COVID-19,"A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 in Patients With COVID-19 (INSPIRE)",Recruiting,NA,Phase 2,60,Anticipated,Capricor Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-14T10:34:07Z,2020-11-14T10:34:07Z
NCT04583592,"ClinicalTrials.gov processed this data on November 13, 2020",2020-10-07,NA,NA,2020-11-10,2020-10-08,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,November 2020,Anticipated,2020-11-30,November 2020,2020-11-30,January 2021,Anticipated,2021-01-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT),"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy of Camostat Mesilate for Treatment of COVID-19 in Outpatients",Recruiting,NA,Phase 2,300,Anticipated,Sagent Pharmaceuticals Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-15T10:56:25Z,2020-11-15T10:56:25Z
NCT04581811,"ClinicalTrials.gov processed this data on November 13, 2020",2020-10-07,NA,NA,2020-11-10,2020-10-07,2020-10-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-13,Estimate,"November 10, 2020",Actual,2020-11-10,November 2020,2020-11-30,June 2021,Anticipated,2021-06-30,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS),Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS): A Pilot Study,Recruiting,NA,N/A,52,Anticipated,University of Alabama at Birmingham,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-15T10:56:29Z,2020-11-15T10:56:29Z
NCT04600999,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-08,NA,NA,2020-10-22,2020-10-22,2020-10-23,Actual,NA,NA,NA,NA,NA,NA,2020-10-22,2020-10-23,Actual,"October 7, 2020",Actual,2020-10-07,October 2020,2020-10-31,June 2021,Anticipated,2021-06-30,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,,Clinical Trial of Favipiravir Treatment of Patients With COVID-19,An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients With Mild Pneumonia - An Open-label Randomized Controlled Study -,Recruiting,NA,Phase 3,150,Anticipated,University of Pecs,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:34:41Z,2020-11-01T11:34:41Z
NCT04590430,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-08,NA,NA,2020-10-14,2020-10-14,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,October 2020,Anticipated,2020-10-31,October 2020,2020-10-31,July 2021,Anticipated,2021-07-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,"Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults","A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose First-in-Human Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenously Administered HFB30132A, a Monoclonal Antibody Directed Against SARS-CoV-2, in Healthy Adult Subjects",Recruiting,NA,Phase 1,24,Anticipated,HiFiBiO Therapeutics,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:35:54Z,2020-11-01T11:35:54Z
NCT04584710,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-08,NA,NA,2020-10-23,2020-10-09,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-26,Actual,"October 13, 2020",Actual,2020-10-13,October 2020,2020-10-31,February 2021,Anticipated,2021-02-28,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults,"A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Adults Age â‰¥65 Years",Recruiting,NA,Phase 2,60,Anticipated,Restorbio Inc.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:36:37Z,2020-11-01T11:36:37Z
NCT04583995,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-09,NA,NA,2020-10-13,2020-10-09,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2020-10-13,2020-10-14,Actual,"September 28, 2020",Actual,2020-09-28,October 2020,2020-10-31,"January 14, 2022",Anticipated,2022-01-14,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom","A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1â„¢ Adjuvant in Adult Participants 18-84 Years of Age in the United Kingdom",Recruiting,NA,Phase 3,9000,Anticipated,Novavax,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-11-01T11:36:48Z,2020-11-01T11:36:48Z
NCT04583969,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-09,NA,NA,2020-10-23,2020-10-09,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-26,Actual,"October 19, 2020",Actual,2020-10-19,October 2020,2020-10-31,"July 1, 2021",Anticipated,2021-07-01,"January 8, 2021",Anticipated,2021-01-08,NA,Interventional,NA,,ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19,A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults,Recruiting,NA,Phase 2,200,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T11:36:48Z,2020-11-01T11:36:48Z
NCT04583956,"ClinicalTrials.gov processed this data on November 02, 2020",2020-10-09,NA,NA,2020-10-29,2020-10-09,2020-10-12,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-10-30,Actual,"October 14, 2020",Actual,2020-10-14,October 2020,2020-10-31,"July 1, 2021",Anticipated,2021-07-01,"January 8, 2021",Anticipated,2021-01-08,NA,Interventional,NA,,ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19,A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults,Recruiting,NA,Phase 2,200,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),,2,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-03T10:49:58Z,2020-11-03T10:49:58Z
NCT04610541,"ClinicalTrials.gov processed this data on November 02, 2020",2020-10-11,NA,NA,2020-10-29,2020-10-29,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2020-10-29,2020-10-30,Actual,"October 12, 2020",Actual,2020-10-12,October 2020,2020-10-31,"November 30, 2021",Anticipated,2021-11-30,"October 30, 2021",Anticipated,2021-10-30,NA,Interventional,NA,,REMdesivir-HU Clinical Study and Severe Covid-19 Patients,Open-label Study to Assess the Safety of REMdesivir-HU as Eligible Novel therapY for Moderate and Severe Covid-19 Patients,Recruiting,NA,Phase 3,2000,Anticipated,University of Pecs,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-03T10:48:14Z,2020-11-03T10:48:14Z
NCT04593069,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-12,NA,NA,2020-10-20,2020-10-12,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-20,2020-10-22,Actual,"October 7, 2020",Actual,2020-10-07,October 2020,2020-10-31,"February 28, 2021",Anticipated,2021-02-28,"February 28, 2021",Anticipated,2021-02-28,NA,Interventional,COGCOV,,The COGCOV Study in ICU Patients,"Long-term Cognitive Impairment in ICU Patients, Admitted for COVID-19 Pneumonia: a Single Centre, Prospective Cohort Study",Recruiting,NA,N/A,60,Anticipated,Ziekenhuis Oost-Limburg,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:35:35Z,2020-11-01T11:35:35Z
NCT04589949,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-12,NA,NA,2020-10-15,2020-10-15,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-15,2020-10-19,Actual,"October 12, 2020",Actual,2020-10-12,October 2020,2020-10-31,"November 1, 2023",Anticipated,2023-11-01,"November 1, 2022",Anticipated,2022-11-01,NA,Interventional,CoV-Early,,Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study),Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study),Recruiting,NA,Phase 3,690,Anticipated,Erasmus Medical Center,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:35:58Z,2020-11-01T11:35:58Z
NCT04589117,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-12,NA,NA,2020-10-14,2020-10-14,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"May 27, 2020",Actual,2020-05-27,October 2020,2020-10-31,"August 2, 2020",Actual,2020-08-02,"August 2, 2020",Actual,2020-08-02,NA,Interventional,NA,,Expressive Writing for COVID-19 Resilience for Parents,Expressive Writing for COVID-19 Resilience for Parents,Completed,NA,N/A,11,Actual,Duke University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:36:04Z,2020-11-01T11:36:04Z
NCT04589104,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-12,NA,NA,2020-10-14,2020-10-14,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-14,2020-10-19,Actual,"May 26, 2020",Actual,2020-05-26,October 2020,2020-10-31,"August 17, 2020",Actual,2020-08-17,"August 17, 2020",Actual,2020-08-17,NA,Interventional,NA,,Expressive Writing for COVID-19 Resilience,Expressive Writing for COVID-19 Resilience,Completed,NA,N/A,63,Actual,Duke University,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:36:04Z,2020-11-01T11:36:04Z
NCT04584593,"ClinicalTrials.gov processed this data on November 06, 2020",2020-10-12,NA,NA,2020-11-02,2020-10-12,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"October 2, 2020",Actual,2020-10-02,November 2020,2020-11-30,February 2022,Anticipated,2022-02-28,February 2022,Anticipated,2022-02-28,NA,Interventional,COVSPERM,,Pilot Study to Detect SARS-CoV-2 Virus in Sperm,Pilot Study to Detect SARS-CoV-2 Virus in Sperm : a COVID-19 Study.,Recruiting,NA,N/A,50,Anticipated,"University Hospital, Toulouse",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-07T11:17:55Z,2020-11-07T11:17:55Z
NCT04591717,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-13,NA,NA,2020-10-21,2020-10-15,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-22,Actual,"October 19, 2020",Actual,2020-10-19,October 2020,2020-10-31,"November 19, 2021",Anticipated,2021-11-19,"November 19, 2021",Anticipated,2021-11-19,NA,Interventional,NA,,Study of the Safety of Prophylactic Vaccination With 2nd Generation E1/E2B/E3-Deleted Adenoviral-COVID-19 in Normal Healthy Volunteers,"Phase 1b Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of Prophylactic Vaccination With 2nd Generation E1/E2B/E3-Deleted Adenoviral-COVID-19 in Normal Healthy Volunteers",Recruiting,NA,Phase 1,35,Anticipated,"ImmunityBio, Inc.",,3,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:35:44Z,2020-11-01T11:35:44Z
NCT04587219,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-13,NA,NA,2020-10-26,2020-10-13,2020-10-14,Actual,NA,NA,NA,NA,NA,NA,2020-10-26,2020-10-27,Actual,"October 22, 2020",Actual,2020-10-22,October 2020,2020-10-31,"December 31, 2020",Anticipated,2020-12-31,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,NA,,"The Study of ""Gam-COVID-Vac"" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older","An Open Study of the Safety, Tolerability and Immunogenicity of the ""Gam-COVID-Vac""Vaccine Against COVID-19 (Solution for Intramuscular Injection) With the Participation of Volunteers in the Age Group Over 60 Years",Recruiting,NA,Phase 2,110,Anticipated,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:36:17Z,2020-11-01T11:36:17Z
NCT04588480,"ClinicalTrials.gov processed this data on November 13, 2020",2020-10-14,NA,NA,2020-11-11,2020-10-14,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Estimate,"October 29, 2020",Actual,2020-10-29,November 2020,2020-11-30,"November 30, 2021",Anticipated,2021-11-30,"November 30, 2021",Anticipated,2021-11-30,NA,Interventional,NA,,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults","A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, AND OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY JAPANESE ADULTS",Recruiting,NA,Phase 1/Phase 2,160,Anticipated,BioNTech SE,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2020-11-15T10:56:19Z,2020-11-15T10:56:19Z
NCT04592354,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-15,NA,NA,2020-10-16,2020-10-16,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-19,Actual,"October 15, 2020",Actual,2020-10-15,October 2020,2020-10-31,"June 15, 2021",Anticipated,2021-06-15,"April 15, 2021",Anticipated,2021-04-15,NA,Interventional,AEO,,Anhydrous Enol-Oxaloacetate (AEO) on Improving Fatigue in Post-COVID-19 Survivors,Anhydrous Enol-Oxaloacetate (AEO) on Improving Fatigue in Post-COVID-19 Survivors,Recruiting,NA,N/A,40,Anticipated,Terra Biological LLC,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Data will become available after the conclusion of the study,Unknown at this point.,NA,Yes,The plan is to publish the data so that it is available to other researchers.,2020-11-01T11:35:41Z,2020-11-01T11:35:41Z
NCT04591600,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-15,NA,NA,2020-10-16,2020-10-16,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-16,2020-10-19,Actual,"July 1, 2020",Actual,2020-07-01,October 2020,2020-10-31,"October 14, 2020",Actual,2020-10-14,"September 30, 2020",Actual,2020-09-30,NA,Interventional,NA,,Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients,"Controlled Randomized Clinical Trial on Using Ivermectin With Doxycycline for Treating COVID-19 Patients in Baghdad, Iraq",Completed,NA,Phase 1/Phase 2,140,Actual,Alkarkh Health Directorate-Baghdad,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:35:45Z,2020-11-01T11:35:45Z
NCT04590053,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-15,NA,NA,2020-10-21,2020-10-15,2020-10-19,Actual,NA,NA,NA,NA,NA,NA,2020-10-21,2020-10-22,Actual,"October 20, 2020",Actual,2020-10-20,October 2020,2020-10-31,March 2021,Anticipated,2021-03-31,February 2021,Anticipated,2021-02-28,NA,Interventional,NA,,"Allocetra-OTS in COVID-19, Phase II","A Multi-Center Open-Label Study, Evaluating Safety and Preliminary Efficacy of Allocetra-OTS for the Treatment and Prevention of Organ-Failure Deterioration in Severe and Critical Patients With COVID-19 and Respiratory Dysfunction",Recruiting,NA,Phase 2,24,Anticipated,Hadassah Medical Organization,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:35:57Z,2020-11-01T11:35:57Z
NCT04598594,"ClinicalTrials.gov processed this data on November 13, 2020",2020-10-15,NA,NA,2020-11-10,2020-10-21,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-13,Estimate,November 2020,Anticipated,2020-11-30,November 2020,2020-11-30,November 2021,Anticipated,2021-11-30,September 2021,Anticipated,2021-09-30,NA,Interventional,NICOVID-REA,,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients,Recruiting,NA,Phase 3,220,Anticipated,Assistance Publique - HÃ´pitaux de Paris,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-15T10:56:07Z,2020-11-15T10:56:07Z
NCT04602000,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-18,NA,NA,2020-10-23,2020-10-23,2020-10-26,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-26,Actual,"September 25, 2020",Actual,2020-09-25,October 2020,2020-10-31,September 2021,Anticipated,2021-09-30,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,To Evaluate the Safety and Efficacy of CT-P59 in Patients With Mild to Moderate Syptoms of Severe Acute Respiratory Syndrome COVID-19,"A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination With Standard of Care in Outpatients With Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection",Recruiting,NA,Phase 2/Phase 3,1020,Anticipated,Celltrion,,3,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T11:34:36Z,2020-11-01T11:34:36Z
NCT04597047,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-19,NA,NA,2020-10-20,2020-10-20,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2020-10-20,2020-10-22,Actual,"August 20, 2020",Actual,2020-08-20,October 2020,2020-10-31,"December 31, 2022",Anticipated,2022-12-31,"October 31, 2022",Anticipated,2022-10-31,NA,Interventional,CAPTURE-2,,Research & Evaluation of LumiraDx SARS-CoV-2 (COVID-19) Point of Care Ab Test,"A Multicenter Covid-19 Study Conducted to Evaluate the Agreement Between Fingerstick Whole Blood, Venous Whole Blood, Plasma & Serum as Determined on the LumiraDx POC SARS-CoV-2 Ab Test & to Evaluate the Ease of Use at Point of Care Sites",Recruiting,NA,N/A,200,Anticipated,LumiraDx UK Limited,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,TRUE,TRUE,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-01T11:35:09Z,2020-11-01T11:35:09Z
NCT04596085,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-19,NA,NA,2020-10-28,2020-10-20,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2020-10-28,2020-10-29,Actual,"September 16, 2020",Actual,2020-09-16,October 2020,2020-10-31,"January 30, 2021",Anticipated,2021-01-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,NA,,"Study to Evaluate Efficacy and Safety of ""VIRACIDE"" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)","A Double Blind, Randomized, Placebo Controlled Study to Evaluate Efficacy and Safety of ""VIRACIDE"" in the Management of Corona Virus Disease 2019 (COVID-19)",Recruiting,NA,N/A,124,Anticipated,"The Herb, Inc",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-02T10:27:36Z,2020-11-02T10:27:36Z
NCT04602312,"ClinicalTrials.gov processed this data on November 13, 2020",2020-10-19,NA,NA,2020-11-09,2020-10-22,2020-10-26,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"October 28, 2020",Actual,2020-10-28,October 2020,2020-10-31,March 2021,Anticipated,2021-03-31,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,,How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Healthy Sample),"Online RCT Comparing the Effects of Mindfulness, Sham Mindfulness and Book Listening Control on Coronavirus-related Catastrophizing in Adults",Recruiting,NA,N/A,624,Anticipated,The University of Queensland,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Immediately following publication up and for a further 10 years .,"Investigators whose proposed use of the data has been approved by an independent review committee. Initial contact should be directed to the contact person for scientific enquiries (Mr Jonathan Davies, jonathan.davies@uq.edu.au).
Note: Requestors will need to sign a data access agreement.",https://sites.google.com/view/uqcovidmeditation,Yes,"All of the individual trial-related participant data collected during the trial, after de-identification.",2020-11-15T10:56:04Z,2020-11-15T10:56:04Z
NCT04602286,"ClinicalTrials.gov processed this data on November 13, 2020",2020-10-19,NA,NA,2020-11-09,2020-10-22,2020-10-26,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"October 28, 2020",Actual,2020-10-28,October 2020,2020-10-31,March 2021,Anticipated,2021-03-31,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,,How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Pain Sample),"An Online Randomized Controlled Trial Comparing the Effects of Mindfulness, Sham Mindfulness and Book Listening Control on Pain Experience in Adults With Recurrent and Chronic Pain",Recruiting,NA,N/A,292,Anticipated,The University of Queensland,,4,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,Immediately following publication up and for a further 10 years .,"Investigators whose proposed use of the data has been approved by an independent review committee. Initial contact should be directed to the contact person for scientific enquiries (Mr Jonathan Davies, jonathan.davies@uq.edu.au).
Note: Requestors will need to sign a data access agreement.",https://sites.google.com/view/uqcovidmeditation,Yes,"All of the individual trial-related participant data collected during the trial, after de-identification.",2020-11-15T10:56:04Z,2020-11-15T10:56:04Z
NCT04604977,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-20,NA,NA,2020-10-25,2020-10-25,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-25,2020-10-27,Actual,"September 15, 2020",Actual,2020-09-15,October 2020,2020-10-31,December 2021,Anticipated,2021-12-31,October 2021,Anticipated,2021-10-31,NA,Interventional,Be-Home-Kids,,Feasibility and Effectiveness of Home-behavioral Program for Adolescents With Migraine,Feasibility and Effectiveness of Home-behavioral Program for Adolescents With Chronic Migraine and High Frequency Migraine Without Aura After the Covid-19 Emergency,Recruiting,NA,N/A,25,Anticipated,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-01T11:34:18Z,2020-11-01T11:34:18Z
NCT04600440,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-20,NA,NA,2020-10-22,2020-10-22,2020-10-23,Actual,NA,NA,NA,NA,NA,NA,2020-10-22,2020-10-23,Actual,"April 25, 2020",Actual,2020-04-25,October 2020,2020-10-31,"February 28, 2022",Anticipated,2022-02-28,"December 31, 2021",Anticipated,2021-12-31,NA,Interventional,COP20,,Convalescent Plasma in the Treatment of Covid-19,Convalescent Plasma in the Treatment of Covid-19,Recruiting,NA,N/A,100,Anticipated,Skane University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:34:45Z,2020-11-01T11:34:45Z
NCT04596839,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-20,NA,NA,2020-10-27,2020-10-20,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-28,Actual,"September 4, 2020",Actual,2020-09-04,October 2020,2020-10-31,"January 31, 2021",Anticipated,2021-01-31,"November 15, 2020",Anticipated,2020-11-15,NA,Interventional,NA,,Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19),"Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19): An Open Label, Multi-Center, Randomized Controlled Trial",Recruiting,NA,N/A,60,Anticipated,Beximco Pharmaceuticals Ltd.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T13:03:36Z,2020-11-01T13:03:36Z
NCT04603924,"ClinicalTrials.gov processed this data on November 06, 2020",2020-10-20,NA,NA,2020-11-02,2020-10-23,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-04,Actual,"October 7, 2020",Actual,2020-10-07,November 2020,2020-11-30,June 2022,Anticipated,2022-06-30,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,,Study of Niclosamide in Moderate Hospitalized Coronavirus-19 (COVID-19) Patients,A Phase 2/3 Randomized and Placebo-Controlled Study of ANA001 in Moderate COVID-19 Patients,Recruiting,NA,Phase 2/Phase 3,436,Anticipated,ANA Therapeutics,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-08T11:30:41Z,2020-11-08T11:30:41Z
NCT04598581,"ClinicalTrials.gov processed this data on November 06, 2020",2020-10-20,NA,NA,2020-11-03,2020-10-20,2020-10-22,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-04,Actual,"November 2, 2020",Actual,2020-11-02,November 2020,2020-11-30,November 2021,Anticipated,2021-11-30,October 2021,Anticipated,2021-10-31,NA,Interventional,COVID-RT-01,,"Low Dose Radiation Therapy for Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2), COVID-19",Low Dose Radiation Therapy for Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2),Recruiting,NA,N/A,22,Anticipated,"University Hospital, Basel, Switzerland",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-08T11:30:49Z,2020-11-08T11:30:49Z
NCT04603794,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-21,NA,NA,2020-10-23,2020-10-23,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-27,Actual,"October 1, 2020",Actual,2020-10-01,October 2020,2020-10-31,November 2020,Anticipated,2020-11-30,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,,Efficacy of Mouthwash in Reducing Salivary Carriage of COVID-19,"Comparison of Normal Saline, Hydrogen Peroxide, Chlorhexidine and Povidone-Iodine Mouth Rinses in COVID-19 Patients",Recruiting,NA,Phase 4,60,Anticipated,Ohio State University,,4,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,As per The Ohio State University Office for Responsible Research Practices (Human Studies IRB),2020-11-01T11:34:25Z,2020-11-01T11:34:25Z
NCT04603729,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-21,NA,NA,2020-10-24,2020-10-24,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-24,2020-10-27,Actual,"May 30, 2020",Actual,2020-05-30,October 2020,2020-10-31,"July 1, 2020",Actual,2020-07-01,"June 30, 2020",Actual,2020-06-30,NA,Interventional,covid19,,Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease,Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease,Completed,NA,Phase 3,100,Actual,Fatima Memorial Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,"patient name and medical record will be confidential, onle the principal investigator will have access to data. Results of study will be shared with other researchers",2020-11-01T11:34:26Z,2020-11-01T11:34:26Z
NCT04602871,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-21,NA,NA,2020-10-23,2020-10-23,2020-10-26,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-26,Actual,"July 3, 2020",Actual,2020-07-03,October 2020,2020-10-31,"January 30, 2021",Anticipated,2021-01-30,"January 30, 2021",Anticipated,2021-01-30,NA,Interventional,COVID-19,,Early Detection of COVID-19 Using Breath Analysis - Feasibility Study,Early Detection of the 2019 Novel Coronavirus (SARS-CoV-2) Using Breath Analysis - Feasibility Study,Recruiting,NA,N/A,108,Anticipated,Scentech Medical Technologies Ltd,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,No IPDs are to be shared with other researchers.,2020-11-01T11:34:30Z,2020-11-01T11:34:30Z
NCT04602442,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-21,NA,NA,2020-10-23,2020-10-23,2020-10-26,Actual,NA,NA,NA,NA,NA,NA,2020-10-23,2020-10-26,Actual,"October 1, 2020",Actual,2020-10-01,October 2020,2020-10-31,"December 30, 2021",Anticipated,2021-12-30,"August 1, 2021",Anticipated,2021-08-01,NA,Interventional,COVID-19EXO2,,Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Pneumonia,The Extended Protocol of Evaluation of Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Two-Sided Pneumonia,Enrolling by invitation,NA,Phase 2,90,Anticipated,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:34:33Z,2020-11-01T11:34:33Z
NCT04609423,"ClinicalTrials.gov processed this data on November 13, 2020",2020-10-22,NA,NA,2020-11-09,2020-10-28,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"November 10, 2020",Actual,2020-11-10,November 2020,2020-11-30,May 2023,Anticipated,2023-05-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,Cod Liver Oil for Covid-19 Prevention Study,"A Randomized, Parallel-group Treatment, Quadruple Masked, Two-arm Study, to Assess the Effectiveness of Cod Liver Oil Compared to Placebo in the Prevention of Covid-19 and Airway Infections in Healthy Adults",Recruiting,NA,Phase 4,80000,Anticipated,Oslo University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,"IPD is complicated to share under the European General Data Protection Regulative, however, it is an aim of the study to make such data available within these regulations.",2020-11-15T10:55:58Z,2020-11-15T10:55:58Z
NCT04604327,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-23,NA,NA,2020-10-26,2020-10-26,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-26,2020-10-27,Actual,"October 26, 2020",Anticipated,2020-10-26,October 2020,2020-10-31,"July 31, 2021",Anticipated,2021-07-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,BEMICOP,,Comparison of Two Different Doses of Bemiparin in COVID-19,"Ensayo clÃ­nico Aleatorizado, Abierto, Para Evaluar el Efecto de Dosis profilÃ¡cticas o terapÃ©uticas de Bemiparina en Pacientes Con COVID-19",Recruiting,NA,Phase 3,164,Anticipated,"Clinica Universidad de Navarra, Universidad de Navarra",,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-01T11:34:23Z,2020-11-01T11:34:23Z
NCT04602832,"ClinicalTrials.gov processed this data on November 06, 2020",2020-10-23,NA,NA,2020-11-02,2020-10-23,2020-10-26,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-04,Actual,"October 14, 2020",Actual,2020-10-14,October 2020,2020-10-31,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,EN-COVID-19,,Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19,A Randomized Controlled Trial of an Online Well-Being Intervention (The ENHANCE Program) for Improving Individuals Health and Well-Being During the COVID-19 Pandemic,Enrolling by invitation,NA,N/A,350,Anticipated,University of British Columbia,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,We are currently consulting with others on the grant team regarding our long-term data plan and will update with our final data sharing plan in January 2021,2020-11-08T11:30:43Z,2020-11-08T11:30:43Z
NCT04625985,"ClinicalTrials.gov processed this data on November 13, 2020",2020-10-23,NA,NA,2020-11-10,2020-11-10,2020-11-12,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"July 14, 2020",Actual,2020-07-14,November 2020,2020-11-30,"March 31, 2021",Anticipated,2021-03-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,DMMETCOV19-2,,"Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.","Adaptive Study to Demonstrate Efficacy and Safety of Metformin Glycinate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb",Recruiting,NA,Phase 2,20,Anticipated,Laboratorios Silanes S.A. de C.V.,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-15T10:54:40Z,2020-11-15T10:54:40Z
NCT04610567,"ClinicalTrials.gov processed this data on November 06, 2020",2020-10-24,NA,NA,2020-11-02,2020-10-29,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-04,Actual,"October 27, 2020",Actual,2020-10-27,November 2020,2020-11-30,"July 15, 2021",Anticipated,2021-07-15,"March 15, 2021",Anticipated,2021-03-15,NA,Interventional,Nano-COVID19,,Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19),Two Phases Clinical Trial to Evaluate Safety and Efficacy of Methotrexate Associated to LDL Like Nanoparticles (LDE-MTX) in the Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease.,Recruiting,NA,Phase 1/Phase 2,100,Anticipated,University of Sao Paulo General Hospital,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-08T11:30:24Z,2020-11-08T11:30:24Z
NCT04603963,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-25,NA,NA,2020-10-26,2020-10-26,2020-10-27,Actual,NA,NA,NA,NA,NA,NA,2020-10-26,2020-10-28,Actual,"June 1, 2020",Actual,2020-06-01,October 2020,2020-10-31,"October 23, 2020",Actual,2020-10-23,"October 10, 2020",Actual,2020-10-10,NA,Interventional,NA,,Inspiratory Muscle Training in Patients With COVID-19,Efects of Inspiratory Muscle Training in Patients With COVID-19 After Acute Phase. Prospective Study,Terminated,NA,N/A,55,Actual,Hospital Israelita Albert Einstein,,2,NA,There was a change in the institutional flow reducing the cases of covid 19,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-01T12:56:03Z,2020-11-01T12:56:03Z
NCT04613271,"ClinicalTrials.gov processed this data on November 06, 2020",2020-10-25,NA,NA,2020-11-01,2020-11-01,2020-11-03,Actual,NA,NA,NA,NA,NA,NA,2020-11-01,2020-11-03,Actual,"October 15, 2020",Actual,2020-10-15,November 2020,2020-11-30,"December 31, 2020",Anticipated,2020-12-31,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,FVR,,Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia,"Phase III, Random-Open, Clinical Trials on the Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia",Recruiting,NA,Phase 3,210,Anticipated,Ina-Respond,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-07T11:15:56Z,2020-11-07T11:15:56Z
NCT04615429,"ClinicalTrials.gov processed this data on November 09, 2020",2020-10-25,NA,NA,2020-11-04,2020-11-02,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-06,Actual,"September 15, 2020",Actual,2020-09-15,November 2020,2020-11-30,January 2022,Anticipated,2022-01-31,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19,"Double-blind, Randomized, Controlled, Clinical Trial to Assess the Efficacy of Allogenic Mesenchymal Stromal Cells in Patients With Acute Respiratory Distress Syndrome Due to COVID-19",Recruiting,NA,Phase 2,20,Anticipated,Puerta de Hierro University Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-10T11:25:39Z,2020-11-10T11:25:39Z
NCT04608305,"ClinicalTrials.gov processed this data on November 06, 2020",2020-10-26,NA,NA,2020-11-01,2020-10-27,2020-10-29,Actual,NA,NA,NA,NA,NA,NA,2020-11-01,2020-11-03,Actual,"October 28, 2020",Actual,2020-10-28,November 2020,2020-11-30,"June 1, 2022",Anticipated,2022-06-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,NA,,"Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine","A Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults",Recruiting,NA,Phase 1/Phase 2,1040,Anticipated,Israel Institute for Biological Research (IIBR),,12,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-07T11:16:57Z,2020-11-07T11:16:57Z
NCT04615416,"ClinicalTrials.gov processed this data on November 06, 2020",2020-10-26,NA,NA,2020-11-02,2020-11-02,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-04,Actual,"May 1, 2020",Actual,2020-05-01,November 2020,2020-11-30,January 2023,Anticipated,2023-01-31,January 2021,Anticipated,2021-01-31,NA,Interventional,ERT-P,,Emotion Regulation Training Via Telehealth During the COVID-19 Pandemic,Open Trial of Emotion Regulation Training Via Telehealth for Distressed Adults During the COVID-19 Pandemic,Recruiting,NA,N/A,100,Anticipated,"Teachers College, Columbia University",,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-08T11:29:25Z,2020-11-08T11:29:25Z
NCT04609722,"ClinicalTrials.gov processed this data on November 06, 2020",2020-10-26,NA,NA,2020-11-03,2020-10-26,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-04,Actual,"July 1, 2020",Actual,2020-07-01,November 2020,2020-11-30,"December 30, 2020",Anticipated,2020-12-30,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,NA,,Effect of Solution-Focused Support Program on Anxiety Levels of Parents During the COVID-19 Pandemic,Effect of Solution-Focused Support Program on Anxiety Levels of Parents With Children Aged 3-6 Years During the COVID-19 Pandemic,Recruiting,NA,N/A,60,Anticipated,Adiyaman University Research Hospital,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-08T11:30:27Z,2020-11-08T11:30:27Z
NCT04605588,"ClinicalTrials.gov processed this data on November 06, 2020",2020-10-26,NA,NA,2020-11-04,2020-10-26,2020-10-28,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-05,Actual,November 2020,Anticipated,2020-11-30,November 2020,2020-11-30,April 2021,Anticipated,2021-04-30,April 2021,Anticipated,2021-04-30,NA,Interventional,TriACT,,A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19,"A Triple Combination Antiviral Coronavirus Therapy (TriACT) RCT Comparing Nitazoxanide, Ribavirin and Hydroxychloroquine vs. Placebo",Recruiting,NA,Phase 2,70,Anticipated,"Rutgers, The State University of New Jersey",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-09T10:51:06Z,2020-11-09T10:51:06Z
NCT04610801,"ClinicalTrials.gov processed this data on November 13, 2020",2020-10-26,NA,NA,2020-11-06,2020-10-26,2020-11-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-10,Actual,"August 8, 2020",Actual,2020-08-08,November 2020,2020-11-30,"August 8, 2021",Anticipated,2021-08-08,"August 8, 2021",Anticipated,2021-08-08,NA,Interventional,NA,,Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2,A Randomized Placebo Control Trial to Evaluate the Efficacy of Xylitol Nasal Spray vs. Placebo for Acute COVID-19 Infection,Recruiting,NA,Phase 3,200,Anticipated,Larkin Community Hospital,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-14T10:36:49Z,2020-11-14T10:36:49Z
NCT04613310,"ClinicalTrials.gov processed this data on November 13, 2020",2020-10-26,NA,NA,2020-11-10,2020-11-01,2020-11-03,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"September 25, 2020",Actual,2020-09-25,November 2020,2020-11-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,RaDiCo,,PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19),PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2: a Comparative Clinical Trial,Recruiting,NA,N/A,1250,Anticipated,"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland",,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-15T10:55:53Z,2020-11-15T10:55:53Z
NCT04606563,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-27,NA,NA,2020-10-27,2020-10-27,2020-10-28,Actual,NA,NA,NA,NA,NA,NA,2020-10-27,2020-10-28,Actual,"October 9, 2020",Actual,2020-10-09,October 2020,2020-10-31,"June 30, 2021",Anticipated,2021-06-30,"June 30, 2021",Anticipated,2021-06-30,NA,Interventional,ARBs CORONA II,,Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan on Outcomes of Coronavirus Infection?,Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan on Outcomes of Coronavirus Infection?,Recruiting,NA,Phase 3,1372,Anticipated,University of British Columbia,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-01T12:41:11Z,2020-11-01T12:41:11Z
NCT04608097,"ClinicalTrials.gov processed this data on October 30, 2020",2020-10-28,NA,NA,2020-10-28,2020-10-28,2020-10-29,Actual,NA,NA,NA,NA,NA,NA,2020-10-28,2020-10-29,Actual,"October 28, 2020",Actual,2020-10-28,October 2020,2020-10-31,"January 15, 2021",Anticipated,2021-01-15,"January 15, 2021",Anticipated,2021-01-15,NA,Interventional,NA,,Understanding Reactions to Emotional Material in the Media During COVID-19,Understanding Reactions to Emotional Material in the Media During COVID-19 and the Connections to Cognitive Activities,Recruiting,NA,N/A,66,Anticipated,Uppsala University,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-02T10:26:42Z,2020-11-02T10:26:42Z
NCT04609969,"ClinicalTrials.gov processed this data on November 06, 2020",2020-10-28,NA,NA,2020-11-03,2020-10-28,2020-10-30,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-04,Actual,"October 13, 2020",Actual,2020-10-13,November 2020,2020-11-30,"November 13, 2020",Anticipated,2020-11-13,"November 13, 2020",Anticipated,2020-11-13,NA,Interventional,COVID-VIRO,,Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test,Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test on Nasopharyngeal Specimens i,Recruiting,NA,N/A,200,Anticipated,Centre Hospitalier RÃ©gional d'OrlÃ©ans,,1,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-08T11:30:26Z,2020-11-08T11:30:26Z
NCT04607928,"ClinicalTrials.gov processed this data on November 06, 2020",2020-10-28,NA,NA,2020-11-04,2020-10-28,2020-10-29,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-05,Actual,"August 1, 2020",Actual,2020-08-01,November 2020,2020-11-30,"August 1, 2021",Anticipated,2021-08-01,"August 1, 2021",Anticipated,2021-08-01,NA,Interventional,FIBRO-COVID,,Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19,Phase-II Randomized Clinical Trial to Evaluate the Effect of Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis,Recruiting,NA,Phase 2,148,Anticipated,Institut d'InvestigaciÃ³ BiomÃ¨dica de Bellvitge,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-09T10:51:03Z,2020-11-09T10:51:03Z
NCT04615052,"ClinicalTrials.gov processed this data on November 06, 2020",2020-10-29,NA,NA,2020-11-02,2020-11-02,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-04,Actual,"September 26, 2020",Actual,2020-09-26,November 2020,2020-11-30,"December 21, 2021",Anticipated,2021-12-21,"October 31, 2021",Anticipated,2021-10-31,NA,Interventional,NA,,Home-based Exercise in COVID-19 Survivors,Home-based Exercise Training in COVID-19 Survivors: a Randomized Controlled Trial,Recruiting,NA,N/A,60,Anticipated,University of Sao Paulo,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-08T11:29:38Z,2020-11-08T11:29:38Z
NCT04615741,"ClinicalTrials.gov processed this data on November 13, 2020",2020-10-29,NA,NA,2020-11-06,2020-10-29,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-10,Actual,"November 1, 2020",Anticipated,2020-11-01,November 2020,2020-11-30,"April 30, 2021",Anticipated,2021-04-30,"February 28, 2021",Anticipated,2021-02-28,NA,Interventional,NA,,Finding Wellness in the Pandemic,Improving Health and Wellness During COVID-19,Recruiting,NA,N/A,200,Anticipated,University of Lethbridge,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"After April 2021, for up to 10 years",Researchers must make a reasonable request to the PI,NA,Yes,De-identified data relevant to the researcher's research question may be shared upon a reasonable request,2020-11-14T10:36:36Z,2020-11-14T10:36:36Z
NCT04611256,"ClinicalTrials.gov processed this data on November 13, 2020",2020-10-29,NA,NA,2020-11-09,2020-10-29,2020-11-02,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"August 1, 2020",Actual,2020-08-01,November 2020,2020-11-30,"December 30, 2020",Anticipated,2020-12-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,NA,,Mesenchymal Stem Cells in Patients Diagnosed With COVID-19,Adjuvant Therapy With Mesenchymal Stem Cells in Patients Diagnosed With COVID-19 in Critical Condition,Recruiting,NA,Phase 1,20,Anticipated,Hospital Reg. Lic. Adolfo Lopez Mateos,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-15T10:55:55Z,2020-11-15T10:55:55Z
NCT04613050,"ClinicalTrials.gov processed this data on November 06, 2020",2020-10-30,NA,NA,2020-11-02,2020-11-02,2020-11-03,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"July 2, 2020",Actual,2020-07-02,November 2020,2020-11-30,"January 20, 2021",Anticipated,2021-01-20,"January 4, 2021",Anticipated,2021-01-04,NA,Interventional,NA,,Effect of Respiratory Versus Aerobic Training on Respiratory and Immunity Efficiency in Recovered COVID- 19 Patients,Effect of Respiratory Versus Aerobic Training on Respiratory and Immunity Efficiency in Recovered COVID- 19 Patients,Recruiting,NA,N/A,80,Anticipated,Cairo University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-07T11:16:04Z,2020-11-07T11:16:04Z
NCT04627467,"ClinicalTrials.gov processed this data on November 13, 2020",2020-10-30,NA,NA,2020-11-11,2020-11-11,2020-11-13,Estimate,NA,NA,NA,NA,NA,NA,2020-11-11,2020-11-13,Estimate,"March 28, 2020",Actual,2020-03-28,September 2020,2020-09-30,"February 14, 2021",Anticipated,2021-02-14,"July 9, 2020",Actual,2020-07-09,NA,Interventional,TS-COVID,,Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID),Prophylaxis With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19),"Active, not recruiting",NA,Phase 2,3217,Actual,Fundacion Clinica Valle del Lili,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"We do not plan to share IPD, since we are not allowed to share information concerning medical history of our patients or health workers.",2020-11-15T10:53:51Z,2020-11-15T10:53:51Z
NCT04615975,"ClinicalTrials.gov processed this data on November 06, 2020",2020-10-31,NA,NA,2020-11-03,2020-11-03,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-04,Actual,"November 1, 2020",Actual,2020-11-01,November 2020,2020-11-30,"August 30, 2021",Anticipated,2021-08-30,"July 30, 2021",Anticipated,2021-07-30,NA,Interventional,NA,,Ketogenic Diet as Protective Factor During COVID-19,Pilot Study: Ketogenic Diet as Protective Factor During SARS-CoV-2 Infection,Recruiting,NA,N/A,28,Anticipated,University of Padova,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-08T11:29:04Z,2020-11-08T11:29:04Z
NCT04614025,"ClinicalTrials.gov processed this data on November 06, 2020",2020-11-02,NA,NA,2020-11-02,2020-11-02,2020-11-03,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,November 2020,Anticipated,2020-11-30,November 2020,2020-11-30,March 2022,Anticipated,2022-03-31,May 2021,Anticipated,2021-05-31,NA,Interventional,NA,,Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19,"A Randomized, Controlled, Multicenter, Parallel-Group Phase IIa Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX-PAD for the Treatment of Severe COVID-19",Recruiting,NA,Phase 2,40,Anticipated,Pluristem Ltd.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-07T11:15:28Z,2020-11-07T11:15:28Z
NCT04614012,"ClinicalTrials.gov processed this data on November 06, 2020",2020-11-02,NA,NA,2020-11-02,2020-11-02,2020-11-03,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"July 2, 2020",Actual,2020-07-02,November 2020,2020-11-30,"July 2, 2022",Anticipated,2022-07-02,"July 2, 2022",Anticipated,2022-07-02,NA,Interventional,IMMUNO-COVID19,,Hyperimmune Plasma for Patients With COVID-19,The Use of Hyperimmune Plasma for the Treatment of COVID-19 Infection,Recruiting,NA,N/A,100,Anticipated,A.O. Ospedale Papa Giovanni XXIII,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-07T11:15:29Z,2020-11-07T11:15:29Z
NCT04613297,"ClinicalTrials.gov processed this data on November 06, 2020",2020-11-02,NA,NA,2020-11-02,2020-11-02,2020-11-03,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-03,Actual,"October 19, 2020",Actual,2020-10-19,November 2020,2020-11-30,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Interventional,HLA-G-COVID,,HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment,HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment,Recruiting,NA,N/A,120,Anticipated,Hopital Foch,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-07T11:15:55Z,2020-11-07T11:15:55Z
NCT04615936,"ClinicalTrials.gov processed this data on November 06, 2020",2020-11-02,NA,NA,2020-11-02,2020-11-02,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-02,2020-11-04,Actual,"July 10, 2020",Actual,2020-07-10,November 2020,2020-11-30,"May 31, 2021",Anticipated,2021-05-31,"May 31, 2021",Anticipated,2021-05-31,NA,Interventional,NA,,Nasal Photodisinfection COVID Proof of Concept Study,Methylene Blue-mediated Photodisinfection for SARS-CoV-2 in the Upper Respiratory Tract,Recruiting,NA,N/A,100,Anticipated,Sunnybrook Health Sciences Centre,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-08T11:29:06Z,2020-11-08T11:29:06Z
NCT04614883,"ClinicalTrials.gov processed this data on November 06, 2020",2020-11-02,NA,NA,2020-11-03,2020-11-03,2020-11-04,Actual,NA,NA,NA,NA,NA,NA,2020-11-03,2020-11-04,Actual,"October 21, 2020",Actual,2020-10-21,November 2020,2020-11-30,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Interventional,VOC-COVID-Diag,,Analysis of Volatile Organic Compounds in Exhaled Air and in Sweat in the Context of Suspicion of COVID-19 Infection,Analysis of Volatile Organic Compounds in Exhaled Air and in Sweat in Patients Referred to the Emergency Reception Service for Suspected COVID-19 Infection: Diagnostic Value and for Rapid Screening,Recruiting,NA,N/A,100,Anticipated,Hopital Foch,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-08T11:29:44Z,2020-11-08T11:29:44Z
NCT04616846,"ClinicalTrials.gov processed this data on November 06, 2020",2020-11-02,NA,NA,2020-11-04,2020-11-04,2020-11-05,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-05,Actual,"August 4, 2020",Actual,2020-08-04,November 2020,2020-11-30,"September 15, 2021",Anticipated,2021-09-15,"September 15, 2021",Anticipated,2021-09-15,NA,Interventional,NEOTHROCOVID,,Thromboembolic Risk Screening in Patients With Cancer and COVID-19,Thromboembolic Risk Screening in Patients With Cancer and COVID-19,Recruiting,NA,N/A,120,Anticipated,Centre Antoine Lacassagne,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-09T10:50:27Z,2020-11-09T10:50:27Z
NCT04617483,"ClinicalTrials.gov processed this data on November 06, 2020",2020-11-04,NA,NA,2020-11-04,2020-11-04,2020-11-05,Actual,NA,NA,NA,NA,NA,NA,2020-11-04,2020-11-05,Actual,"October 31, 2020",Actual,2020-10-31,November 2020,2020-11-30,"May 31, 2021",Anticipated,2021-05-31,"November 28, 2020",Anticipated,2020-11-28,NA,Interventional,NA,,"Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults","A Randomized, Double-Blinded Clinical Trial, to Evaluate the Non-inferiority of the Commercial Scale Inactivated SARS-CoV-2 Vaccine Against That of the Pilot Scale Among Adults Aged 26-45 Years, and the Open-labelled, Bridging Non-inferiority of the Vaccine Induced Immunogenicity in Elderly Against That in Adults",Recruiting,NA,Phase 3,1040,Anticipated,"Sinovac Biotech Co., Ltd",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-09T10:50:06Z,2020-11-09T10:50:06Z
NCT04622826,"ClinicalTrials.gov processed this data on November 13, 2020",2020-11-04,NA,NA,2020-11-07,2020-11-07,2020-11-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-07,2020-11-10,Actual,"May 15, 2020",Actual,2020-05-15,November 2020,2020-11-30,"December 31, 2020",Anticipated,2020-12-31,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU Patients,"Studio in Aperto Sulla Somministrazione di Plasma di Paziente Convalescente da COVID- 19 a Paziente Con Polmonite COVID-19 Ospedalizzato, Non in Terapia Intensiva",Recruiting,NA,Phase 2,50,Anticipated,Azienda USL Toscana Nord Ovest,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-11-14T10:34:35Z,2020-11-14T10:34:35Z
NCT04621123,"ClinicalTrials.gov processed this data on November 13, 2020",2020-11-04,NA,NA,2020-11-06,2020-11-06,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"October 30, 2020",Actual,2020-10-30,November 2020,2020-11-30,October 2021,Anticipated,2021-10-31,February 2021,Anticipated,2021-02-28,NA,Interventional,NA,,Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients,Convalescent Methylene Blue Treated (MBT) Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients: a Randomized Double Blind Study (COnV-ert),Recruiting,NA,Phase 2,474,Anticipated,Fundacio Lluita Contra la SIDA,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-11-14T10:35:40Z,2020-11-14T10:35:40Z
NCT04620798,"ClinicalTrials.gov processed this data on November 13, 2020",2020-11-04,NA,NA,2020-11-05,2020-11-05,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-05,2020-11-09,Actual,"September 14, 2020",Actual,2020-09-14,November 2020,2020-11-30,December 2020,Anticipated,2020-12-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students,Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students,"Active, not recruiting",NA,N/A,1700,Anticipated,Indiana University,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,"These study protocol documents will be made available upon completion of the study and the analyses. A de-identified, limited data set and analytic code will be available from the Principal Investigator upon request.","Protocol will be available on clinicaltrials.gov while the other documents, data, and analytic code from the Principal Investigator upon request.",NA,Yes,"The study team will make the following documents available to the public upon completion of the study: (1) Study Protocol, (2) Statistical Analysis Plan (SAP), (3) Informed Consent Form (ICF), and (4) Clinical Study Report (CSR). The individual participant data as well as the analytic code will not be made available to the public due to privacy concerns and in order to protect participants' private health information but will be available from the Principal Investigator upon request.",2020-11-14T10:35:51Z,2020-11-14T10:35:51Z
NCT04619290,"ClinicalTrials.gov processed this data on November 13, 2020",2020-11-04,NA,NA,2020-11-09,2020-11-04,2020-11-06,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"October 12, 2020",Actual,2020-10-12,November 2020,2020-11-30,"December 30, 2020",Anticipated,2020-12-30,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,NA,,Outpatient Treatment With CoVid-19 With Prexablu,Treatment in Outpatient Patients With Covid-19 With Methylene Blue and Photodynamic,Recruiting,NA,Phase 1,46,Anticipated,Hospital Reg. Lic. Adolfo Lopez Mateos,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-15T10:55:45Z,2020-11-15T10:55:45Z
NCT04623021,"ClinicalTrials.gov processed this data on November 13, 2020",2020-11-05,NA,NA,2020-11-09,2020-11-09,2020-11-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-10,Actual,"September 25, 2020",Actual,2020-09-25,November 2020,2020-11-30,March 2021,Anticipated,2021-03-31,February 2021,Anticipated,2021-02-28,NA,Interventional,NA,,A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia,"An Open-label, Randomized, Multicenter, Controlled Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia",Recruiting,NA,Phase 2,100,Anticipated,Chong Kun Dang Pharmaceutical,,2,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-14T10:34:28Z,2020-11-14T10:34:28Z
NCT04619680,"ClinicalTrials.gov processed this data on November 13, 2020",2020-11-05,NA,NA,2020-11-05,2020-11-05,2020-11-06,Actual,NA,NA,NA,NA,NA,NA,2020-11-05,2020-11-09,Actual,November 2020,Anticipated,2020-11-30,November 2020,2020-11-30,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Interventional,ENDCOV-I,,The Study Will Evaluate the Use of Nintedanib in Slowing Lung Fibrosis in Patients With Pulmonary Infiltrates Related to COVID-19,Early Nintedanib Deployment in COVID-19 Interstitial Fibrosis,Recruiting,NA,Phase 4,120,Anticipated,Icahn School of Medicine at Mount Sinai,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,Beginning 3 months and ending 5 years following article publication.,"Investigators whose proposed use of the data has been approved by an independent review committee (""learned intermediary"") identified for this purpose. Proposals should be directed to Maria.Padilla@mssm.edu. To gain access, data requestors will need to sign a data access agreement. Data are available for 5 years at a third party website",NA,Yes,"All of the individual participant data collected during the trial, after deidentification.",2020-11-14T10:36:13Z,2020-11-14T10:36:13Z
NCT04625114,"ClinicalTrials.gov processed this data on November 13, 2020",2020-11-05,NA,NA,2020-11-10,2020-11-10,2020-11-12,Actual,NA,NA,NA,NA,NA,NA,2020-11-10,2020-11-12,Actual,"November 4, 2020",Actual,2020-11-04,November 2020,2020-11-30,"January 1, 2023",Anticipated,2023-01-01,"October 1, 2022",Anticipated,2022-10-01,NA,Interventional,NA,,The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden,The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden,Recruiting,NA,Phase 2,150,Anticipated,"University Hospital, Ghent",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-15T10:55:08Z,2020-11-15T10:55:08Z
NCT04622891,"ClinicalTrials.gov processed this data on November 13, 2020",2020-11-06,NA,NA,2020-11-07,2020-11-07,2020-11-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-07,2020-11-10,Actual,"April 1, 2020",Actual,2020-04-01,November 2020,2020-11-30,"July 30, 2020",Actual,2020-07-30,"July 30, 2020",Actual,2020-07-30,NA,Interventional,NA,,Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection,"Efficacy of Clarithromycin in Comparison to Azithromycin in Treatment of Mild COVID-19 Infection, Randomized Controlled Trial",Completed,NA,N/A,300,Actual,South Valley University,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-11-14T10:34:32Z,2020-11-14T10:34:32Z
NCT04621903,"ClinicalTrials.gov processed this data on November 13, 2020",2020-11-06,NA,NA,2020-11-06,2020-11-06,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-06,2020-11-09,Actual,"October 8, 2020",Actual,2020-10-08,November 2020,2020-11-30,"November 3, 2020",Actual,2020-11-03,"October 27, 2020",Actual,2020-10-27,NA,Interventional,NA,,A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19,A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19: Community Based Participatory Research,Completed,NA,N/A,26,Actual,Aarogyam UK,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-14T10:35:11Z,2020-11-14T10:35:11Z
NCT04621058,"ClinicalTrials.gov processed this data on November 13, 2020",2020-11-06,NA,NA,2020-11-09,2020-11-06,2020-11-09,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-12,Actual,"November 9, 2020",Actual,2020-11-09,November 2020,2020-11-30,"November 9, 2021",Anticipated,2021-11-09,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,NA,,Efficacy of Vitamin D Treatment in Mortality Reduction Due to COVID-19.,Efficacy of Treatment With Vitamin D in Patients Diagnosed With COVID-19 Who Presenting Vitamin D Deficiency and Pneumonia.,Recruiting,NA,Phase 3,108,Anticipated,Bioaraba Health Research Institute,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-11-15T10:55:39Z,2020-11-15T10:55:39Z
NCT04622865,"ClinicalTrials.gov processed this data on November 13, 2020",2020-11-09,NA,NA,2020-11-09,2020-11-09,2020-11-10,Actual,NA,NA,NA,NA,NA,NA,2020-11-09,2020-11-10,Actual,"June 1, 2020",Actual,2020-06-01,November 2020,2020-11-30,June 2021,Anticipated,2021-06-30,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,,Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19,"Randomized, Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Masitinib Combined With Isoquercetin, and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19",Recruiting,NA,Phase 2,200,Anticipated,AB Science,,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-11-14T10:34:33Z,2020-11-14T10:34:33Z
